METHODS AND COMPOSITIONS FOR DETECTING AND MODULATING AN IMMUNOTHERAPY RESISTANCE GENE SIGNATURE IN CANCER

CROSS-REFERENCE TO RELATED APPLICATIONS

[0001] This application claims the benefit of U.S. Provisional Application Nos. 62/567, 153, filed October 2, 2017, 62/573, 117, filed October 16, 2017, 62/588,025, filed November 17, 2017, 62/595,327, filed December 6, 2017, 62/630, 158, filed February 13, 2018, and 62/680,545, filed June 4, 2018. The entire contents of the above-identified applications are hereby fully incorporated herein by reference.

STATEMENT REGARDING FEDERALLY SPONSORED RESEARCH

[0002] This invention was made with government support under grant Nos. CA222663, CAl 80922, CA202820 and CA14051 awarded by the National Institutes of Health. The government has certain rights in the invention.

REFERENCE TO AN ELECTRONIC SEQUENCE LISTING

[0003] The contents of the electronic sequence listing (BROD_2630WP_ST25.txt"; Size is 4 Kilobytes and it was created on September 28, 2018) is herein incorporated by reference in its entirety.

TECHNICAL FIELD

[0004] The subject matter disclosed herein is generally directed to detecting and modulating novel gene signatures for the treatment and prognosis of cancer.

BACKGROUND

[0005] One reason that cancer cells thrive is because they are able to hide from the immune system. Certain cancer cells avoid the immune system better than others and could be a factor in determining survival. Immunotherapies have been developed to enhance immune responses against cancer and lead to prolonged survival. Immune checkpoint inhibitors (ICI) have transformed the therapeutic landscape of several cancer types (Sharma and Allison, 2015). In particular, immune checkpoint inhibitors (ICI) lead to durable responses in -35% of patients with metastatic melanoma by unleashing T cells from oncogenic suppression (Sharma, et al., 2015; and Hodi, et al., 2016). Nonetheless, many patients manifest ICI resistance (ICR), which is often intrinsic (Sharma et al., 2017). ICR is often unpredictable and poorly understood (Sharma, et al., 2017), hampering appropriate selection of patients for therapies, rational enrollment to clinical trials and the development of new therapeutic strategies that could overcome ICR (Sharma, et al., 2015).

[0006] Because ICI targets cell-cell interactions, resistance can stem from different cells and their interactions in the tumor ecosystem. Recent studies illuminated ICI resistance with Whole Exome Sequencing (WES) and transcriptional profiles of bulk tumors (Hugo et al., 2016; Riaz et al., 2017; Van Allen et al., 2015), but had limited ability to dissect the cancer- immune interplay and generate reliable response biomarkers. These studies demonstrated that tumors with a high mutational load (Van Allen et al., 2015) or high immune cell infiltration (Tumeh et al., 2014; and Riaz et al., 2017) are more likely to respond, and linked ICR in patients to functional immune evasion phenotypes, including defects in the JAK/STAT pathway (Zaretsky et al., 2016) and interferon gamma (IFN-γ) response (Zaretsky et al., 2016; and Gao et al., 2016), impaired antigen presentation (Hugo et al., 2016; and Zaretsky et al., 2016), PTEN loss Peng et al., 2016, and increased WNT-B-catenin signaling (Spranger, et al., 2015). However, thus far, the predictive power of these and other (Gibney, et al., 2016) approaches has been limited, either because they report on only some facets of the causes of resistance (WES) and/or because they are highly confounded by tumor composition (RNA and copy-number variations). Indeed, because ICI targets the interactions between different cells in the tumor, its impact depends on multicellular circuits of malignant and non- malignant cells (Tirosh et al., 2016), which are challenging to study in bulk tumor specimens. Single-cell RNA-seq (scRNA-seq) of patient tumors (Tirosh et al., 2016) can alleviate this limitation. Single-cell genomics, especially single cell RNA-Seq (scRNA-Seq), provides a unique tool to comprehensively map the tumor ecosystem (Tirosh et al., 2016a; Patel et al., 2014; Tirosh et al., 2016b; Venteicher et al., 2017; and Li et al., 2017), but has thus far not been used to study ICR.

[0007] Infiltration of the tumor with T cells has been associated with patient survival and improved immunotherapy responses (Fridman et al., 2012), but the determinants that dictate if a tumor will have high ("hot") or low ("cold") levels of T cell infiltration are only partially understood. Among multiple factors, malignant cells may play an important role in determining this phenotype. However, while current methods use bulk genomics to deconvolve the tumor's composition (Newman et al., 2015), they cannot recover the salient intracellular programs of malignant cells. Hence linking malignant cell states to T cell infiltration levels has been challenging.

[0008] Thus, there is a need to better understand tumor immunity and resistance to immunotherapy.

[0009] Citation or identification of any document in this application is not an admission that such document is available as prior art to the present invention.

SUMMARY

[0010] Immune checkpoint inhibitors (ICI) produce durable responses in some melanoma patients, but many patients derive no clinical benefit, and the molecular underpinnings of such resistance remain elusive.

[0011] It is an objective of the present invention to identify molecular signatures for diagnosis, prognosis and treatment of subjects suffering from cancer. It is a further objective to understand tumor immunity and to leverage this knowledge for treating subjects suffering from cancer. It is another objective for identifying gene signatures for predicting response to checkpoint blockade therapy. It is another objective, for modulating the molecular signatures in order to increase efficacy of immunotherapy (e.g., checkpoint blockade therapy).

[0012] Here, Applicants leveraged single-cell RNA-seq (scRNA-seq) from 33 melanoma tumors and computational analyses to interrogate malignant cell states that promote immune evasion. Applicants identified a resistance program expressed by malignant cells that is associated with T cell exclusion and immune evasion. The program is expressed prior to immunotherapy, characterizes cold niches in situ, and predicts clinical responses to anti-PD-1 therapy in an independent cohort of 112 melanoma patients. CDK4/6-inhibition represses this program in individual malignant cells, induces senescence (Senescence Associated Secretory Phenotype (SASP)), and reduces melanoma tumor outgrowth in mouse models in vivo when given in combination with immunotherapy. The disclosed study provides a high-resolution landscape of ICI resistant cell states, identifies clinically predictive signatures, and suggests new therapeutic strategies to overcome immunotherapy resistance. Applicants additionally applied single-nuclei RNA-seq (sNuc-seq) to characterize thousands of cells from estrogen- receptor-positive metastatic breast cancer (MBC). ER+ MBC is currently treated with CDK4/6-inhibitors (see, e.g., Vasan et al., State-of-the-Art Update: CDK4/6 Inhibitors in ER+ Metastatic Breast Cancer, AJHO. 2017; 13(4): 16-22). Finally, Applicants applied single- cell RNA-seq (scRNA-seq) to characterize thousands of cells from colon cancer. [0013] In one aspect, the present invention provides for a method of treating a cancer in a subject in need thereof comprising detecting the expression or activity of an ICR and/or exclusion signature according to any embodiment herein in a tumor obtained from the subject and administering a treatment, wherein if an ICR and/or exclusion signature is detected the treatment comprises administering a checkpoint inhibitor and a CDK4/6 inhibitor.

[0014] In another aspect, the present invention provides for a method of treating a cancer in a subject in need thereof comprising administering a checkpoint inhibitor and a CDK4/6 inhibitor.

[0015] In certain embodiments, the CDK4/6 inhibitor comprises abemaciclib. In certain embodiments, the immunotherapy comprises a check point inhibitor. The checkpoint inhibitor may comprise anti-CTLA4, anti-PD-Ll, anti-PDl, anti-TIM3, anti-TIGIT, anti- LAG3 or a combination thereof. In certain embodiments, the cancer is melanoma or breast cancer.

[0016] In another aspect, the present invention provides for a method of detecting an immune checkpoint inhibitor resistance (ICR) gene signature in a tumor comprising, detecting in tumor cells obtained from a subject in need thereof the expression or activity of a malignant cell gene signature comprising: one or more genes or polypeptides selected from the group consisting of PPIA, RPL31, RPL37A, RPL41, RPS21, RPS27A, SAEl, UBA52,

C19orf48, CHCHD2, FARSA, NONO, RPL27, RPL36, RPS13, RPS14, RPS15, RPS28,

ARMC6, BOLA2, BOLA2B, CDC123, CKS1B, CMSS1, DDX39A, DNAJC9, FAM60A,

UNI, MRPL47, NDUFA13, PET100, PFDN4, PSMA7, RNASEH2A, ROMOl, RPL35A,

SLIRP, SLM02, SNRPF, SNRPG, TPRKB, TXNDC17, UBL5, USMG5, AHNAK, APOD,

ATP1A1, B2M, CD44, CD63, CTSB, CTSD, FOS, GRN, HLA-A, HLA-B, HLA-C, HLA-E,

HLA-H, LAMP2, LGALS3, LGALS3BP, NPC2, PSAP, SERPINE2, TAPBP, TIMP2,

CTSO, KLF4, LEF1-AS1, STOM, TAPBPL, VAT1, ACTA2, C6orf226, CCR10, CITEDl,

COROIA, CXCR4, DDX17, FLJ39051, FMN1, FRZB, FSTL3, FTH1, HLA-DRB5, IDI2-

AS1, JMJD7, LCP1, LINC00518, LOC100506714, LOC100507463, LY96, NMRK1,

P2RX4, PIK3IP1, PYGB, RAB27A, RBP7, RNF213, RTP4, SDCBP, SLC22A18,

SLC7A5P1, SP100, SPESP1, SPINT1, ST3GAL6-AS1, ST6GALNAC2, TFAP2A, TRIM22,

TTLL1 and UCN2; or one or more genes or polypeptides selected from the group consisting of BZW2, CCT3, CDK4, GPATCH4, ISYNA1, MDH2, PPIA, RPL31, RPL37A, RPL41,

RPS21, RPS27A, RUVBL2, SAEl, UBA52, AHCY, C17orf76-ASl, C19orf48, CIQBP,

CCT6A, CHCHD2, CTPS1, EEF1G, EIF2S3, EIF3K, EIF4A1, FARSA, FBL, FKBP4, GAS 5, G B2L1, GPI, HNRNPA1, HNRNPC, IDH2, ILF2, NACA, NCL, ME1, NOLC1,

NONO, PABPCl, PAICS, PFN1, POLD2, PPA1, PTMA, PUF60, RPL10A, RPL11, RPL12,

RPL13, RPL13A, RPL13AP5, RPL17, RPL18, RPL18A, RPL21, RPL26, RPL27, RPL28,

RPL29, RPL3, RPL36, RPL36A, RPL37, RPL4, RPL5, RPL6, RPL8, RPLPO, RPLP1,

RPS10, RPS11, RPS13, RPS14, RPS15, RPS15A, RPS16, RPS17, RPS17L, RPS18, RPS19,

RPS23, RPS24, RPS27, RPS28, RPS3, RPS4X, RPS5, RPS6, RPS7, RPS8, RPS9, RPSA,

RRS1, SERPINF1, SET, SHMT2, SLC19A1, SLC25A13, S HG6, S RPE, SOX4, SSR2,

TIMM50, TOP1MT, TUBB, UQCRFS1, UQCRH, VDAC2, ACTB, AEN, ANP32E, APP,

ARMC6, ATP5A1, ATP5D, ATP5G2, ATP5G3, BOLA2, BOLA2B, BOP1, BTF3,

C20orfl l2, C6orf48, CA14, CACYBP, CBX5, CCT2, CCT4, CCT7, CDC123, CDCA7,

CFL1, CKS1B, CMSS1, C RIPl, CS, DARS, DCAF13, DCT, DCTPP1, DDX21, DDX39A,

DDX39B, DLL3, DNAJC9, EEF1B2, EEF1D, EEF2, EIF3E, EIF3F, EIF3G, EIF3M,

EIF4EBP2, ENOl, EXOSC5, FAM174B, FAM60A, FAM92A1, FBLN1, FOXRED2, FTL,

FUS, GABARAP, GGH, G L3, GRWDl, H3F3A, H3F3AP4, HMGAl, HMGBl, HNl,

HNRNPAIPIO, HNRNPHl, HNRNPM, HSP90AB1, HSPA8, HSPDl, IFRD2, ILF3,

IMPDH2, ITM2C, KIAA0101, LDHB, LSM4, LSM7, LYPLA1, MAGEA4, MAGEC1,

MCM7, METAP2, MIDI, MIR4461, MKI67IP, MLLT11, MPZL1, MRPL15, MRPL37,

MRPL4, MRPL47, MRPS12, MRPS21, NDUFAl l, NDUFA13, NDUFS2, NME2, NOP16,

NPMl, NREP, PA2G4, PAFAH1B3, PETIOO, PFDN2, PFDN4, PGAMl, PIHIDI,

PLEKHJ1, POLR1D, POLR2E, PPP2R1A, PRMT1, PSMA7, PSMD4, RAN, RBM34,

RNASEH2A, RNF2, ROMOl, RPAIN, RPL10, RPL14, RPL15, RPL19, RPL22, RPL27A,

RPL30, RPL32, RPL35, RPL35A, RPL39, RPL7, RPL7A, RPL9, RPLP2, RPS12, RPS2,

RPS20, RPS25, RPS3A, RQCD1, RSL1D1, RTKN, SCD, SCNM1, SERBP1, SF3B4, SKP2,

SLC25A3, SLC25A6, SLIRP, SLM02, SMARCA4, SMIM15, SMS, SNAI2, SNHG15,

SNRPB, SNRPC, SNRPD1, SNRPD2, SNRPF, SNRPG, SRM, SRP14, SSB, TIMM13,

TIMM44, TMC6, TP53, TPI1, TPRKB, TRAPl, TRIM28, TRPM1, TSR1, TUBAIB,

TULP4, TXNDC17, TYMS, UBL5, UCK2, UHRFl, USMG5, USP22, VCY1B, VPS72,

XIST, YWHAE, ZFAS1, ZNF286A, AHNAK, APOD, ATP1A1, B2M, CD44, CD63, CTSB,

CTSD, FOS, GRN, HLA-A, HLA-B, HLA-C, HLA-E, HLA-H, LAMP2, LGALS3,

LGALS3BP, NPC2, PSAP, SERPINE2, TAPBP, TIMP2, A2M, ACSL3, AEBPl, AGA,

APOC2, APOE, ATP1B1, CD151, CD47, CD58, CD59, CDH19, CSPG4, CST3, CTSA,

CTSL1, CTSO, CYP27A1, DAG1, DDR1, EEA1, EMP1, EVA1A, FBX032, FGFR1, GAA,

GPNMB, GSN, HLA-F, HSPA1A, IRF4, ITGA3, KCNN4, KLF4, LEF1-AS1, LRPAPl, MFGE8, MIA, MT2A, EAT1, PC1, NSG1, PROS1, S100A6, S100B, SAT1, SCARB2,

SDC3, SEC11C, SERPINA3, SGK1, SLC26A2, SLC5A3, STOM, STX7, TAPBPL, TIMP1,

TIMP3, TM4SF1, TMEDIO, TPP1, TSC22D3, TYR, UBC, VAT1, WBP2, XAGE1D,

ACSL4, ACTA2, ADM, ANGPTL4, ANXA1, ANXA2, APLP2, APOL1, ARL6IP5, ARSA,

ATF3, ATP1B3, ATP6V0C, BACE2, BBX, BCL6, C4A, C6or£226, CALU, CARD 16,

CASP1, CAST, CAV1, CAV2, CC D3, CCR10, CD9, CDH1, CHI3L1, CITEDl, CLIC4,

COROIA, CRELD1, CRYAB, CSGALNACTl, CXCR4, CYP4V2, DCBLD2, DDX17,

DDX5, DPYSL2, DUSP4, DUSP6, ECM1, EGR1, EPHX2, ERBB3, EZH1, FAM3C,

FCGR2C, FCRLA, FLJ39051, FLJ43663, FLNA, FMN1, FRZB, FSTL3, FTH1, GADD45B,

GATSL3, GEM, GJB1, GOLGB1, GPR155, GPR56, HLA-DRB5, HLA-G, HPCALl,

HTATIP2, IDI2-AS1, IFI27, IFI27L2, IFI35, IFI6, IGFIR, IGFBP7, IGSF8, ILIRAP,

IL6ST, ITGA6, ITGA7, ITGB1, ITGB3, ITM2B, JMJD7, JUN, KLF6, LAMB2, LCP1,

LEPROT, LGALSl, LGMN, LINC00518, LOC100126784, LOC100506190,

LOC100506714, LOC100507463, LPL, LY6E, LY96, LYRM9, MAGEC2, MALATl,

MATN2, MCAM, MFI2, MMP14, MPZ, MT1E, MT1M, MT1X, MTR R2L1,

MTRNR2L10, MTR R2L2, MTR R2L3, MTR R2L4, MTR R2L5, MTR R2L6,

MTR R2L7, MTR R2L8, MYOID, NAV2, FE2L1, FKBIA, FKBIZ, MRK1,

NNMT, NR4A1, P2RX4, PAGE5, PDE4DIP, PDK4, PERP, PIK3IP1, PLP2, PRKCDBP,

PRNP, PRSS23, PSMB9, PTRF, PYGB, QPCT, RAB27A, RBP7, RDH5, RNF145, RNF213,

RPS4Y1, RTP4, S100A1, S100A13, SCCPDH, SDCBP, SEL1L, SEMA3B, SERINC1,

SERPINA1, SGCE, SHC4, SLC20A1, SLC22A18, SLC39A14, SLC7A5P1, SLC7A8,

SNX9, SOD1, SORT1, SP100, SPESP1, SPINT1, SPON2, SPP1, SPRY2, SQSTM1, SRPX,

ST3GAL6-AS1, ST6GALNAC2, STRIP2, SYNE2, SYNGR2, SYPLl, TF, TFAP2A,

TGOLN2, THBD, TMBIM6, TMED9, TMEM255A, TMEM66, TMX4, TNC, TNFSF4,

TRIM22, TRIML2, TSPYL2, TTLLl, TXNIP, UCN2, UPPl, WDFYl, ZBTB20 and

ZBTB38; or one or more genes or polypeptides selected from Table 27B.1.

[0017] In certain embodiments, the ICR signature comprises a ICR-down signature, said signature comprising one or more genes selected from the group consisting of: AHNAK,

APOD, ATP1A1, B2M, CD44, CD63, CTSB, CTSD, FOS, GRN, HLA-A, HLA-B, HLA-C,

HLA-E, HLA-H, LAMP2, LGALS3, LGALS3BP, NPC2, PSAP, SERPINE2, TAPBP,

TIMP2, CTSO, KLF4, LEF1-AS1, STOM, TAPBPL, VAT1, ACTA2, C6orf226, CCR10,

CITEDl, COROIA, CXCR4, DDX17, FLJ39051, FMN1, FRZB, FSTL3, FTH1, HLA-

DRB5, IDI2-AS1, JMJD7, LCP1, LINC00518, LOC100506714, LOC100507463, LY96, NMRKl, P2RX4, PIK3IP1, PYGB, RAB27A, RBP7, RNF213, RTP4, SDCBP, SLC22A18,

SLC7A5P1, SP100, SPESP1, SPINT1, ST3GAL6-AS1, ST6GALNAC2, TFAP2A, TRIM22,

TTLL1 and UCN2; or AHNAK, APOD, ATP1A1, B2M, CD44, CD63, CTSB, CTSD, FOS,

GRN, HLA-A, HLA-B, HLA-C, HLA-E, HLA-H, LAMP2, LGALS3, LGALS3BP, NPC2,

PSAP, SERPINE2, TAPBP, TIMP2, A2M, ACSL3, AEBPl, AGA, APOC2, APOE,

ATP1B1, CD151, CD47, CD58, CD59, CDH19, CSPG4, CST3, CTSA, CTSL1, CTSO,

CYP27A1, DAG1, DDR1, EEA1, EMP1, EVA1A, FBX032, FGFR1, GAA, GPNMB, GSN,

HLA-F, HSPA1A, IRF4, ITGA3, KCNN4, KLF4, LEF1-AS1, LRPAPl, MFGE8, MIA,

MT2A, NEATl, NPCl, NSG1, PROS1, S100A6, S100B, SAT1, SCARB2, SDC3, SEC11C,

SERPINA3, SGK1, SLC26A2, SLC5A3, STOM, STX7, TAPBPL, TIMP1, TIMP3,

TM4SF1, TMED10, TPP1, TSC22D3, TYR, UBC, VAT1, WBP2, X AGE ID, ACSL4,

ACTA2, ADM, ANGPTL4, ANXA1, ANXA2, APLP2, APOLl, ARL6IP5, ARSA, ATF3,

ATP1B3, ATP6V0C, BACE2, BBX, BCL6, C4A, C6orf226, CALU, CARD 16, CASP1,

CAST, CAV1, CAV2, CCND3, CCR10, CD9, CDH1, CHI3L1, CITEDl, CLIC4, COROIA,

CRELD1, CRYAB, CSGALNACTl, CXCR4, CYP4V2, DCBLD2, DDX17, DDX5,

DPYSL2, DUSP4, DUSP6, ECM1, EGR1, EPHX2, ERBB3, EZH1, FAM3C, FCGR2C,

FCRLA, FLJ39051, FLJ43663, FLNA, FMNl, FRZB, FSTL3, FTHl, GADD45B, GATSL3,

GEM, GJB1, GOLGB1, GPR155, GPR56, HLA-DRB5, HLA-G, HPCALl, HTATIP2, IDI2-

AS1, IFI27, IFI27L2, IFI35, IFI6, IGF1R, IGFBP7, IGSF8, ILIRAP, IL6ST, ITGA6,

ITGA7, ITGB1, ITGB3, ITM2B, JMJD7, JUN, KLF6, LAMB2, LCP1, LEPROT, LGALSl,

LGMN, LINC00518, LOC100126784, LOC100506190, LOC100506714, LOC100507463,

LPL, LY6E, LY96, LYRM9, MAGEC2, MALATl, MATN2, MCAM, MFI2, MMP14,

MPZ, MT1E, MT1M, MT1X, MTRNR2L1, MTRNR2L10, MTRNR2L2, MTRNR2L3,

MTRNR2L4, MTRNR2L5, MTRNR2L6, MTRNR2L7, MTRNR2L8, MYOID, NAV2,

NFE2L1, NFKBIA, NFKBIZ, NMRKl, NNMT, NR4A1, P2RX4, PAGE5, PDE4DIP,

PDK4, PERP, PIK3IP1, PLP2, PRKCDBP, PRNP, PRSS23, PSMB9, PTRF, PYGB, QPCT,

RAB27A, RBP7, RDH5, RNF145, RNF213, RPS4Y1, RTP4, S100A1, S100A13, SCCPDH,

SDCBP, SEL1L, SEMA3B, SERINC1, SERPINA1, SGCE, SHC4, SLC20A1, SLC22A18,

SLC39A14, SLC7A5P1, SLC7A8, SNX9, SOD1, SORT1, SP100, SPESP1, SPINT1,

SPON2, SPP1, SPRY2, SQSTM1, SRPX, ST3GAL6-AS1, ST6GALNAC2, STRIP2,

SYNE2, SYNGR2, SYPLl, TF, TFAP2A, TGOLN2, THBD, TMBIM6, TMED9,

TMEM255A, TMEM66, TMX4, TNC, TNFSF4, TRIM22, TRIML2, TSPYL2, TTLL1,

TXNIP, UCN2, UPP1, WDFY1, ZBTB20 and ZBTB38, wherein said ICR-down signature is downregulated in a tumor with a high ICR score and upregulated in a tumor with a low ICR score.

[0018] In certain embodiments, the ICR signature comprises a ICR-up signature, said signature comprising one or more genes selected from the group consisting of: PPIA, RPL31,

RPL37A, RPL41, RPS21, RPS27A, SAE1, UBA52, C19orf48, CHCHD2, FARSA, NONO,

RPL27, RPL36, RPS13, RPS14, RPS15, RPS28, ARMC6, BOLA2, BOLA2B, CDC123,

CKS1B, CMSS1, DDX39A, DNAJC9, FAM60A, UNI, MRPL47, NDUFA13, PET100,

PFDN4, PSMA7, RNASEH2A, ROMOl, RPL35A, SLIRP, SLM02, SNRPF, SNRPG,

TPRKB, TXNDC17, UBL5 and USMG5; or BZW2, CCT3, CDK4, GPATCH4, ISYNA1,

MDH2, PPIA, RPL31, RPL37A, RPL41, RPS21, RPS27A, RUVBL2, SAEl, UBA52,

AHCY, C17orf76-ASl, C19orf48, C1QBP, CCT6A, CHCHD2, CTPS1, EEF1G, EIF2S3,

EIF3K, EIF4A1, FARSA, FBL, FKBP4, GAS5, GNB2L1, GPI, HNRNPA1, HNRNPC,

IDH2, ILF2, NACA, NCL, NME1, NOLC1, NONO, PABPCl, PAICS, PFN1, POLD2,

PPA1, PTMA, PUF60, RPL10A, RPL11, RPL12, RPL13, RPL13A, RPL13AP5, RPL17,

RPL18, RPL18A, RPL21, RPL26, RPL27, RPL28, RPL29, RPL3, RPL36, RPL36A, RPL37,

RPL4, RPL5, RPL6, RPL8, RPLP0, RPLP1, RPS10, RPS11, RPS13, RPS14, RPS15,

RPS15A, RPS16, RPS17, RPS17L, RPS18, RPS19, RPS23, RPS24, RPS27, RPS28, RPS3,

RPS4X, RPS5, RPS6, RPS7, RPS8, RPS9, RPSA, RRS1, SERPINFl, SET, SHMT2,

SLC19A1, SLC25A13, SNHG6, SNRPE, SOX4, SSR2, TIMM50, TOP1MT, TUBB,

UQCRFS1, UQCRH, VDAC2, ACTB, AEN, ANP32E, APP, ARMC6, ATP5A1, ATP5D,

ATP5G2, ATP5G3, BOLA2, BOLA2B, BOP1, BTF3, C20orfl l2, C6orf48, CA14,

CACYBP, CBX5, CCT2, CCT4, CCT7, CDC123, CDCA7, CFL1, CKS1B, CMSS1,

CNRIPl, CS, DARS, DCAF13, DCT, DCTPP1, DDX21, DDX39A, DDX39B, DLL3,

DNAJC9, EEF1B2, EEF1D, EEF2, EIF3E, EIF3F, EIF3G, EIF3M, EIF4EBP2, ENOl,

EXOSC5, FAM174B, FAM60A, FAM92A1, FBLN1, FOXRED2, FTL, FUS, GABARAP,

GGH, GNL3, GRWD1, H3F3A, H3F3AP4, HMGA1, HMGB1, UNI, HNRNPAIPIO,

HNRNPHl, HNRNPM, HSP90AB1, HSPA8, HSPD1, IFRD2, ILF3, IMPDH2, ITM2C,

KIAAOlOl, LDHB, LSM4, LSM7, LYPLAl, MAGEA4, MAGECl, MCM7, METAP2,

MIDI, MIR4461, MKI67IP, MLLT11, MPZL1, MRPL15, MRPL37, MRPL4, MRPL47,

MRPS12, MRPS21, NDUFAl l, NDUFA13, NDUFS2, NME2, NOP16, NPMl, NREP,

PA2G4, PAFAH1B3, PET100, PFDN2, PFDN4, PGAM1, PIH1D1, PLEKHJ1, POLR1D,

POLR2E, PPP2R1A, PRMT1, PSMA7, PSMD4, RAN, RBM34, RNASEH2A, RNF2,

ROMOl, RPAIN, RPL10, RPL14, RPL15, RPL19, RPL22, RPL27A, RPL30, RPL32, RPL35, RPL35A, RPL39, RPL7, RPL7A, RPL9, RPLP2, RPS12, RPS2, RPS20, RPS25,

RPS3A, RQCD1, RSL1D1, RTKN, SCD, SC M1, SERBP1, SF3B4, SKP2, SLC25A3,

SLC25A6, SLIRP, SLM02, SMARCA4, SMFM15, SMS, SNAI2, S HG15, S RPB,

S RPC, S RPD1, S RPD2, S RPF, S RPG, SRM, SRP14, SSB, TIMM13, TIMM44,

TMC6, TP53, TPI1, TPRKB, TRAPl, TRIM28, TRPM1, TSR1, TUBA1B, TULP4,

TXNDC17, TYMS, UBL5, UCK2, UHRF1, USMG5, USP22, VCY1B, VPS72, XIST,

YWHAE, ZFASl and Z F286A, wherein said ICR-up signature is upregulated in a tumor with a high ICR score and downregulated in a tumor with a low ICR score.

[0019] In another aspect, the present invention provides for a method of detecting an immune checkpoint inhibitor resistance (ICR) gene signature in a tumor comprising, detecting in tumor cells obtained from a subject in need thereof the expression or activity of a malignant cell gene signature comprising one or more genes or polypeptides selected from the group consisting of BZW2, CCT3, CDK4, GPATCH4, ISYNA1, MDH2, PPIA, RPL31,

RPL37A, RPL41, RPS21, RPS27A, RUVBL2, SAEl, UBA52, C17orf76-ASl, C1QBP,

CTPS1, EEF1G, EIF2S3, EIF3K, EIF4A1, FBL, GAS 5, G B2L1, GPI, HNR PA1,

HNR PC, IDH2, ILF2, NACA, NCL, NOLC1, NONO, PABPCl, PFN1, PPA1, PTMA,

RPL10A, RPL11, RPL12, RPL13, RPL13A, RPL13AP5, RPL17, RPL18, RPL18A, RPL21,

RPL26, RPL28, RPL29, RPL3, RPL36A, RPL37, RPL4, RPL5, RPL6, RPL8, RPLP0,

RPLP1, RPS10, RPS11, RPS15A, RPS16, RPS17, RPS17L, RPS18, RPS19, RPS23, RPS24,

RPS27, RPS3, RPS4X, RPS5, RPS6, RPS7, RPS8, RPS9, RPSA, SERPINF1, SET, SHMT2,

S HG6, S RPE, SOX4, SSR2, TIMM50, TUBB, UQCRFS1, UQCRH, VDAC2, ACTB,

AEN, ANP32E, ATP5A1, ATP5G2, C20orfl l2, CA14, CBX5, CCT2, CFL1, C RIP1, CS,

DCAF13, DCT, DDX39B, DLL3, EIF4EBP2, FAM174B, FBLNl, FOXRED2, FTL, FUS,

GABARAP, GRWD1, H3F3A, H3F3AP4, HMGA1, HNRNPAIPIO, HSPA8, ITM2C,

KIAA0101, MAGEA4, METAP2, MIDI, MIR4461, MLLT11, MPZL1, MRPS21, NDUFS2,

PA2G4, PAFAH1B3, PFDN2, PGAM1, PIH1D1, PPP2R1A, PSMD4, RAN, RBM34, RNF2,

RPAIN, RPS12, SCD, SCNM1, SF3B4, SKP2, SLC25A3, SMS, SNAI2, SRP14, TMC6,

TP53, TRPM1, TSR1, TUBA1B, TULP4, USP22, VCY1B, VPS72, YWHAE, ZNF286A,

AHNAK, APOD, ATP1A1, B2M, CD44, CD63, CTSB, CTSD, FOS, GRN, HLA-A, HLA-

B, HLA-C, HLA-E, HLA-H, LAMP2, LGALS3, LGALS3BP, NPC2, PSAP, SERPINE2,

TAPBP, TIMP2, A2M, ACSL3, AEBPl, AGA, APOE, ATP1B1, CD151, CD47, CD58,

CD59, CDH19, CSPG4, CST3, CTSA, CTSL1, DAG1, DDR1, EEA1, EMP1, EVA1A,

FBX032, FGFR1, GAA, GPNMB, GSN, HLA-F, HSPA1A, ITGA3, KCNN4, KLF4, LRPAP1, MFGE8, MIA, MT2A, EAT1, PC1, NSG1, PROS1, S100A6, S100B, SAT1, SCARB2, SDC3, SERPINA3, SGK1, SLC26A2, SLC5A3, STOM, TAPBPL, TIMP1, TIMP3, TM4SF1, TMEDIO, TPP1, TSC22D3, TYR, UBC, ACSL4, ADM, ANGPTL4, ANXA1, ANXA2, APLP2, ARL6IP5, ATF3, ATP1B3, BACE2, BBX, BCL6, CALU, CASP1, CAST, CAV1, CC D3, CD9, CHI3L1, CLIC4, CRELD1, CRYAB, CSGALNACTl, DCBLD2, DDX5, DPYSL2, DUSP4, DUSP6, ECM1, EGR1, EPHX2, ERBB3, EZH1, FAM3C, FCGR2C, FCRLA, FLJ43663, GADD45B, GEM, GOLGB1, HPCALl, HTATIP2, IFI35, IGFIR, ILIRAP, IL6ST, ITGA6, ITGB1, ITGB3, ITM2B, JUN, KLF6, LEPROT, LGALSl, LPL, MAGEC2, MFI2, MTIE, MTIM, MTIX, NFKBIA, NFKBIZ, NNMT, NR4A1, PDK4, PLP2, PRKCDBP, PRNP, PRSS23, PSMB9, PTRF, RNF145, RPS4Y1, SCCPDH, SEL1L, SEMA3B, SGCE, SLC20A1, SLC39A14, SOD1, SPRY2, SQSTM1, SRPX, SYNGR2, SYPLl, TF, TGOLN2, TMED9, TMEM66, TMX4, TNC, UPP1, ZBTB20 and ZBTB38.

[0020] In certain embodiments, the ICR signature comprises an ICR-down signature, said signature comprising one or more genes selected from the group consisting of: AHNAK,

APOD, ATP1A1, B2M, CD44, CD63, CTSB, CTSD, FOS, GRN, HLA-A, HLA-B, HLA-C,

HLA-E, HLA-H, LAMP2, LGALS3, LGALS3BP, NPC2, PSAP, SERPINE2, TAPBP,

TIMP2, A2M, ACSL3, AEBP1, AGA, APOE, ATP1B1, CD151, CD47, CD58, CD59,

CDH19, CSPG4, CST3, CTSA, CTSL1, DAG1, DDR1, EEA1, EMP1, EVA1A, FBX032,

FGFR1, GAA, GPNMB, GSN, HLA-F, HSPA1A, ITGA3, KCNN4, KLF4, LRPAPl,

MFGE8, MIA, MT2A, NEATl, NPCl, NSG1, PROS1, S100A6, S100B, SAT1, SCARB2,

SDC3, SERPINA3, SGK1, SLC26A2, SLC5A3, STOM, TAPBPL, TIMP1, TIMP3,

TM4SF1, TMEDIO, TPP1, TSC22D3, TYR, UBC, ACSL4, ADM, ANGPTL4, ANXA1,

ANXA2, APLP2, ARL6IP5, ATF3, ATP1B3, BACE2, BBX, BCL6, CALU, CASP1, CAST,

CAV1, CCND3, CD9, CHI3L1, CLIC4, CRELD1, CRYAB, CSGALNACTl, DCBLD2,

DDX5, DPYSL2, DUSP4, DUSP6, ECM1, EGR1, EPHX2, ERBB3, EZH1, FAM3C,

FCGR2C, FCRLA, FLJ43663, GADD45B, GEM, GOLGB1, HPCALl, HTATIP2, IFI35,

IGFIR, ILIRAP, IL6ST, ITGA6, ITGB1, ITGB3, ITM2B, JUN, KLF6, LEPROT, LGALSl,

LPL, MAGEC2, MFI2, MTIE, MTIM, MTIX, NFKBIA, NFKBIZ, NNMT, NR4A1, PDK4,

PLP2, PRKCDBP, PRNP, PRSS23, PSMB9, PTRF, RNF145, RPS4Y1, SCCPDH, SEL1L,

SEMA3B, SGCE, SLC20A1, SLC39A14, SOD1, SPRY2, SQSTM1, SRPX, SYNGR2,

SYPLl, TF, TGOLN2, TMED9, TMEM66, TMX4, TNC, UPPl, ZBTB20 and ZBTB38, wherein said ICR-down signature is downregulated in a tumor with a high ICR score and upregulated in a tumor with a low ICR score.

[0021] In certain embodiments, the ICR signature comprises an ICR-up signature, said signature comprising one or more genes selected from the group consisting of: BZW2, CCT3, CDK4, GPATCH4, ISYNA1, MDH2, PPIA, RPL31, RPL37A, RPL41, RPS21, RPS27A, RUVBL2, SAE1, UBA52, C17orf76-ASl, C1QBP, CTPS1, EEF1G, EIF2S3, EIF3K, EIF4A1, FBL, GAS5, G B2L1, GPI, HNR PA1, HNR PC, IDH2, ILF2, NACA, NCL, NOLC1, NONO, PABPCl, PFN1, PPA1, PTMA, RPL10A, RPL11, RPL12, RPL13, RPL13A, RPL13AP5, RPL17, RPL18, RPL18A, RPL21, RPL26, RPL28, RPL29, RPL3, RPL36A, RPL37, RPL4, RPL5, RPL6, RPL8, RPLP0, RPLP1, RPS10, RPS11, RPS15A, RPS16, RPS17, RPS17L, RPS18, RPS19, RPS23, RPS24, RPS27, RPS3, RPS4X, RPS5, RPS6, RPS7, RPS8, RPS9, RPSA, SERPINF1, SET, SHMT2, S HG6, S RPE, SOX4, SSR2, TIMM50, TUBB, UQCRFS1, UQCRH, VDAC2, ACTB, AEN, ANP32E, ATP5A1, ATP5G2, C20orfl l2, CA14, CBX5, CCT2, CFL1, C RIP1, CS, DCAF13, DCT, DDX39B, DLL3, EIF4EBP2, FAM174B, FBLN1, FOXRED2, FTL, FUS, GABARAP, GRWD1, H3F3A, H3F3AP4, HMGA1, HNR PA1P10, HSPA8, ITM2C, KIAA0101, MAGEA4, METAP2, MIDI, MIR4461, MLLT11, MPZL1, MRPS21, DUFS2, PA2G4, PAFAH1B3, PFDN2, PGAM1, PIH1D1, PPP2R1A, PSMD4, RAN, RBM34, RNF2, RPAIN, RPS12, SCD, SCNM1, SF3B4, SKP2, SLC25A3, SMS, SNAI2, SRP14, TMC6, TP53, TRPM1, TSR1, TUBA1B, TULP4, USP22, VCY1B, VPS72, YWHAE and ZNF286A, wherein said ICR-up signature is upregulated in a tumor with a high ICR score and downregulated in a tumor with a low ICR score.

[0022] In certain embodiments, the ICR signature according to any embodiment herein is detected in cycling cells and/or expanded cells.

[0023] In another aspect, the present invention provides for a method of detecting an immune cell exclusion gene signature in a tumor comprising, detecting in tumor cells obtained from a subject in need thereof the expression or activity of a malignant cell gene signature comprising: one or more genes or polypeptides selected from the group consisting of BZW2, CCT3, CDK4, GPATCH4, ISYNA1, MDH2, RUVBL2, AHCY, CCT6A, FKBP4,

NMEl, PAICS, POLD2, PUF60, RRSl, SLC19A1, SLC25A13, TOPIMT, HSP90AB1,

RTKN, APOC2, CYP27A1, IRF4, SEC11C, STX7, WBP2, XAGE1D, PAGE5 and WDFY1; or one or more genes or polypeptides selected from the group consisting of BZW2, CCT3,

CDK4, GPATCH4, ISYNA1, MDH2, PPIA, RPL31, RPL37A, RPL41, RPS21, RPS27A,

RUVBL2, SAEl, UBA52, AHCY, C17orf76-ASl, C19orf48, C1QBP, CCT6A, CHCHD2, CTPS1, EEF1G, EIF2S3, EIF3K, EIF4A1, FARSA, FBL, FKBP4, GAS 5, G B2L1, GPL

HNRNPA1, HNRNPC, IDH2, ILF2, NACA, NCL, ME1, NOLC1, PABPCl, PAICS

PFNl, POLD2, PPAl, PTMA, PUF60, RPLIOA, RPLl l, RPL12, RPL13, RPL13A

RPL13AP5, RPL17, RPL18, RPL18A, RPL21, RPL26, RPL27, RPL28, RPL29, RPL3

RPL36, RPL36A, RPL37, RPL4, RPL5, RPL6, RPL8, RPLPO, RPLP1, RPS10, RPS1 L

RPS13, RPS14, RPS15, RPS15A, RPS16, RPS17, RPS17L, RPS18, RPS19, RPS23, RPS24,

RPS27, RPS28, RPS3, RPS4X, RPS5, RPS6, RPS7, RPS8, RPS9, RPSA, RRS1, SERPINF1.

SET, SHMT2, SLC19A1, SLC25A13, SNHG6, SNRPE, SOX4, SSR2, TIMM50, ΤΟΡ1Μ

TUBB, UQCRFS1, UQCRH, VDAC2, APP, ATP5D, ATP5G3, BOP1, BTF3, C6orf48

CACYBP, CCT4, CCT7, CDCA7, DARS, DCTPP1, DDX21, EEF1B2, EEF1D, EEF2.

EIF3E, EIF3F, EIF3G, EIF3M, ENOl, EXOSC5, FAM92A1, GGH, GNL3, HMGBL

HNRNPH1, HNRNPM, HSPD1, IFRD2, ILF3, LMPDH2, LDHB, LSM4, LSM7, LYPLA1,

MAGECl, MCM7, MKI67IP, MRPL15, MRPL37, MRPL4, MRPS12, NDUFAl l, NME2,

NOP16, NPMl, NREP, PLEKHJ1, POLR1D, POLR2E, PRMT1, RPL10, RPL14, RPL15

RPL19, RPL22, RPL27A, RPL30, RPL32, RPL35, RPL39, RPL7, RPL7A, RPL9, RPLP2,

RPS2, RPS20, RPS25, RPS3A, RQCD1, RSL1D1, SERBP1, SLC25A6, SMARCA4,

SMIM15, SNHG15, SNRPB, SNRPC, SNRPD1, SNRPD2, SRM, SSB, TIMM13, TIMM44

TPI1, TRAPl, TRIM28, TYMS, UCK2, UHRF1, XIST, ZFAS1, AHNAK, APOD, ATP1A1.

B2M, CD44, CD63, CTSB, CTSD, FOS, GRN, HLA-A, HLA-B, HLA-C, HLA-E, HLA-H,

LAMP2, LGALS3, LGALS3BP, NPC2, PSAP, SERPINE2, TAPBP, TIMP2, A2M, ACSL3,

AEBPl, AGA, APOC2, APOE, ATP1B1, CD151, CD47, CD58, CD59, CDH19, CSPG4

CST3, CTSA, CTSL1, CTSO, CYP27A1, DAG1, DDR1, EEA1, EMP1, EVA1A, FBX032

FGFR1, GAA, GPNMB, GSN, HLA-F, HSPA1A, IRF4, ITGA3, KCNN4, LEF1-AS1.

LRPAPl, MFGE8, MIA, MT2A, NEAT1, NPCl, NSG1, PROS1, S100A6, S100B, SAT1,

SCARB2, SDC3, SEC11C, SERPINA3, SGK1, SLC26A2, SLC5A3, STX7, TIMP1, TIMP3

TM4SF1, TMED10, TPP1, TSC22D3, TYR, UBC, VAT1, WBP2, XAGE1D, APOLl,

ARSA, ATP6V0C, C4A, CARD 16, CAV2, CDH1, CYP4V2, FLNA, GATSL3, GJB1,

GPR155, GPR56, HLA-G, IFI27, IFI27L2, IFI6, IGFBP7, IGSF8, ITGA7, LAMB2, LGMN

LOC100126784, LOC100506190, LY6E, LYRM9, MALATl, MATN2, MCAM, MMP14,

MPZ, MTRNR2L1, MTRNR2L10, MTRNR2L2, MTRNR2L3, MTRNR2L4, MTRNR2L5,

MTRNR2L6, MTRNR2L7, MTRNR2L8, MYOID, NAV2, NFE2L1, PDE4DLP, PEPJ\

QPCT, RDH5, S100A1, S100A13, SERINC1, SERPINA1, SHC4, SLC7A8, SNX9, SORT1.

SPON2, SPP1, STRLP2, SYNE2, THBD, TMBIM6, TMEM255A, TNFSF4, TRIML2. TSPYL2 and TXNIP.

[0024] In certain embodiments, the exclusion signature comprises an exclusion-down signature, said signature comprising one or more genes selected from the group consisting of: APOC2, CYP27A1, IRF4, SECl lC, STX7, WBP2, XAGEID, PAGE5 and WDFYl; or AHNAK, APOD, ATP1A1, B2M, CD44, CD63, CTSB, CTSD, FOS, GRN, HLA-A, HLA- B, HLA-C, HLA-E, HLA-H, LAMP2, LGALS3, LGALS3BP, PC2, PSAP, SERPINE2, TAPBP, TIMP2, A2M, ACSL3, AEBPl, AGA, APOC2, APOE, ATP1B1, CD151, CD47, CD58, CD59, CDH19, CSPG4, CST3, CTSA, CTSL1, CTSO, CYP27A1, DAG1, DDR1, EEA1, EMP1, EVA1A, FBX032, FGFR1, GAA, GP MB, GSN, HLA-F, HSPA1A, IRF4, ITGA3, KCNN4, LEF1-AS1, LRPAPl, MFGE8, MIA, MT2A, EAT1, PC1, NSG1, PROS1, S100A6, S100B, SAT1, SCARB2, SDC3, SECl lC, SERPINA3, SGK1, SLC26A2, SLC5A3, STX7, TIMP1, TIMP3, TM4SF1, TMEDIO, TPP1, TSC22D3, TYR, UBC, VAT1, WBP2, XAGEID, APOLl, ARSA, ATP6V0C, C4A, CARD 16, CAV2, CDH1, CYP4V2, FLNA, GATSL3, GJB1, GPR155, GPR56, HLA-G, IFI27, IFI27L2, IFI6, IGFBP7, IGSF8, ITGA7, LAMB2, LGMN, LOC100126784, LOC100506190, LY6E, LYRM9, MALATl, MATN2, MCAM, MMP14, MPZ, MTR R2L1, MTR R2L10, MTR R2L2, MTR R2L3, MTR R2L4, MTR R2L5, MTR R2L6, MTR R2L7, MTR R2L8, MYOID, NAV2, FE2L1, PDE4DIP, PERP, QPCT, RDH5, SlOOAl, S100A13, SERINCl, SERPINAl, SHC4, SLC7A8, SNX9, SORT1, SPON2, SPP1, STRIP2, SYNE2, THBD, TMBIM6, TMEM255A, TNFSF4, TRIML2, TSPYL2 and TXNIP, wherein said exclusion-down signature is downregulated in a tumor with T cell exclusion and is upregulated in a tumor with T cell infiltration.

[0025] In certain embodiments, the exclusion signature comprises an exclusion-up signature, said signature comprising one or more genes selected from the group consisting of:

BZW2, CCT3, CDK4, GPATCH4, ISYNA1, MDH2, RUVBL2, AHCY, CCT6A, FKBP4,

NMEl, PAICS, POLD2, PUF60, RRSl, SLC19A1, SLC25A13, TOPIMT, HSP90AB1 and

RTKN; or BZW2, CCT3, CDK4, GPATCH4, ISYNA1, MDH2, PPIA, RPL31, RPL37A,

RPL41, RPS21, RPS27A, RUVBL2, SAE1, UBA52, AHCY, C17orf76-ASl, C19orf48,

C1QBP, CCT6A, CHCHD2, CTPS1, EEF1G, EIF2S3, EIF3K, EIF4A1, FARSA, FBL,

FKBP4, GAS5, GNB2L1, GPI, HNRNPAl, HNRNPC, IDH2, ILF2, NACA, NCL, NMEl,

NOLC1, PABPCl, PAICS, PFN1, POLD2, PPA1, PTMA, PUF60, RPL10A, RPL11,

RPL12, RPL13, RPL13A, RPL13AP5, RPL17, RPL18, RPL18A, RPL21, RPL26, RPL27,

RPL28, RPL29, RPL3, RPL36, RPL36A, RPL37, RPL4, RPL5, RPL6, RPL8, RPLP0, RPLP1, RPS10, RPS11, RPS13, RPS14, RPS15, RPS15A, RPS16, RPS17, RPS17L, RPS18, RPS19, RPS23, RPS24, RPS27, RPS28, RPS3, RPS4X, RPS5, RPS6, RPS7, RPS8, RPS9, RPSA, RRS1, SERPINF1, SET, SHMT2, SLC19A1, SLC25A13, S HG6, S RPE, SOX4, SSR2, TIMM50, TOP1MT, TUBB, UQCRFS1, UQCRH, VDAC2, APP, ATP5D, ATP5G3, BOP1, BTF3, C6orf48, CACYBP, CCT4, CCT7, CDCA7, DARS, DCTPP1, DDX21, EEF1B2, EEF1D, EEF2, EIF3E, EIF3F, EIF3G, EIF3M, ENOl, EXOSC5, FAM92A1, GGH, G L3, HMGB1, HNRNPH1, HNRNPM, HSPD1, IFRD2, ILF3, IMPDH2, LDHB, LSM4, LSM7, LYPLA1, MAGEC1, MCM7, MKI67IP, MRPL15, MRPL37, MRPL4, MRPS12, DUFA11, ME2, NOP16, PM1, REP, PLEKHJ1, POLR1D, POLR2E, PRMT1, RPL10, RPL14, RPL15, RPL19, RPL22, RPL27A, RPL30, RPL32, RPL35, RPL39, RPL7, RPL7A, RPL9, RPLP2, RPS2, RPS20, RPS25, RPS3A, RQCD1, RSL1D1, SERBP1, SLC25A6, SMARCA4, SMIM15, S HG15, S RPB, S RPC, S RPD1, S RPD2, SRM, SSB, TIMM13, TIMM44, TPI1, TRAP1, TRDVI28, TYMS, UCK2, UHRF1, XIST and ZFAS1, wherein said exclusion-up signature is upregulated in a tumor with T cell exclusion and is downregulated in a tumor with T cell infiltration.

[0026] In certain embodiments, the method according to any embodiment herein further comprises detecting the abundance of tumor infiltrating lymphocytes (TIL). In certain embodiments, the gene signature is detected in a bulk tumor sample, whereby the gene signature is detected by deconvolution of bulk expression data such that gene expression is assigned to malignant cells and non-malignant cells in said tumor sample. In certain embodiments, detecting the gene signature comprises detecting downregulation of the down signature and/or upregulation of the up signature, and wherein not detecting the gene signature comprises detecting upregulation of the down signature and/or downregulation of the up signature. In certain embodiments, detecting the signature and/or TILs indicates lower progression free survival and/or resistance to checkpoint blockade therapy, and wherein not detecting the signature and/or TILs indicates higher progression free survival and/or sensitivity to checkpoint blockade therapy. In certain embodiments, detecting the gene signature indicates a 10-year survival rate less than 40% and wherein not detecting the signature indicates a 10-year survival rate greater than 60%.

[0027] In certain embodiments, detecting an ICR signature in a tumor further comprises detecting in tumor infiltrating lymphocytes (TIL) obtained from the subject in need thereof the expression or activity of a CD8 T cell gene signature, said signature comprising one or more genes or polypeptides selected from Table 27B.2. [0028] In certain embodiments, detecting an ICR signature in a tumor further comprises detecting in macrophages obtained from the subject in need thereof the expression or activity of a macrophage gene signature, said signature comprising one or more genes or polypeptides selected from Table 27C.

[0029] In another aspect, the present invention provides for a method of stratifying cancer patients into a high survival group and a low survival group comprising detecting the expression or activity of an ICR and/or exclusion signature in a tumor according to any embodiment herein, wherein if the signature is detected the patient is in the low survival group and if the signature is not detected the patient is in the high survival group. In certain embodiments, patients in the high survival group are immunotherapy responders and patients in the low survival group are immunotherapy non-responders.

[0030] In another aspect, the present invention provides for a method of treating a cancer in a subject in need thereof comprising detecting the expression or activity of an ICR and/or exclusion signature according to any embodiment herein in a tumor obtained from the subject and administering a treatment, wherein if an ICR and/or exclusion signature is detected the treatment comprises administering a treatment regimen comprising an immunotherapy followed by a CDK4/6 inhibitor and an immunotherapy.

[0031] In another aspect, the present invention provides for a method of treating a cancer in a subject in need thereof comprising administering a treatment regimen comprising an immunotherapy followed by a CDK4/6 inhibitor and an immunotherapy.

[0032] In certain embodiments, the CDK4/6 inhibitor comprises abemaciclib. In certain embodiments, the CDK4/6 inhibitor inhibits the expression or activity of one or more CDK7 targets selected from the group consisting of GPATCH4, RPL31, RPL41, C19orf48, EIF4A1, ME1, PABPC1, PTMA, RPL10A, RPL13, RPL28, RPL29, RPL3, RPL36, RPL5, RPLP0,

RPLP1, RPS11, RPS15, RPS15A, RPS27, RPS28, RPS3, RPS5, RPS6, RPS7, RPS8, RPS9,

S RPE, SOX4, ACTB, ANP32E, C6orf48, CCT4, DDX39B, EIF3G, FTL, HNR PH1,

HSP90AB1, HSPA8, IMPDH2, LSM7, MRPL15, MRPL47, DUFS2, PM1, RPL10,

RPL7A, RPS12, RPS2, RPS20, RPS3A, RSL1D1, SC M1, S RPC, TPI1, TRIM28,

TUBAIB and YWHAE. In certain embodiments, the immunotherapy comprises a check point inhibitor. In certain embodiments, the checkpoint inhibitor comprises anti-CTLA4, anti-PD-Ll, anti-PDl, anti-TIM3, anti-TIGIT, anti-LAG3 or a combination thereof. In certain embodiments, the cancer is melanoma or breast cancer. In certain embodiments, the checkpoint inhibitors are administered and the CDK4/6 inhibitor and checkpoint inhibitor are administered between 14 days and 6 months after the first checkpoint inhibitors are administered.

[0033] In another aspect, the present invention provides for a method of treating a cancer in a subject in need thereof comprising administering a combination treatment regimen comprising an immunotherapy and one or more drugs selected from Table 16.

[0034] In another aspect, the present invention provides for a method of detecting an immune checkpoint inhibitor resistance (ICR) gene signature in a tumor comprising, detecting in tumor cells obtained from a subject in need thereof the expression or activity of a malignant cell gene signature comprising: one or more genes or polypeptides selected from the group consisting of C1QBP, CCT2, CCT6A, DCAF13, EIF4A1, ILF2, MAGEA4,

NONO, PA2G4, PGAMl, PPAl, PPIA, RPL18A, RPL26, RPL31, RPSl l, RPS15, RPS21,

RPS5, RUVBL2, SAEl, SNRPE, UBA52, UQCRH, VDAC2, AEBPl, AHNAK, APOC2,

APOD, APOE, B2M, C10orf54, CD63, CTSD, EEA1, EMP1, FBX032, FYB, GATSL3,

HCP5, HLA-A, HLA-B, HLA-C, HLA-E, HLA-F, HLA-H, ITGA3, LAMP2, LYRM9,

MFGE8, MIA, NPC2, NSGl, PROSl, RDH5, SERPINAl, TAPBP, TIMP2, TNFSF4 and

TRIML2 (refined uICR, see table 5); or one or more genes or polypeptides selected from the group consisting of ACAT1, ACP5, ACTB, ACTG1, ADSL, AEN, AK2, ANP32E, APP,

ASAPl, ATP5A1, ATP5D, ATP5G2, BANCR, BCAN, BZW2, C17orf76-ASl, C1QBP,

C20orfl l2, C6orf48, CA14, CBX5, CCT2, CCT3, CCT6A, CDK4, CEP170, CFL1, CHP1,

CNRIPl, CRABP2, CS, CTPS1, CYC1, DAP3, DCAF13, DCT, DDX21, DDX39B, DLL3,

EDNRB, EEF1D, EEF1G, EEF2, EIF1AX, EIF2S3, EIF3E, EIF3K, EIF3L, EIF4A1,

EIF4EBP2, ESRP1, FAM174B, FAM178B, FAM92A1, FBL, FBLN1, FOXRED2, FTL,

FUS, GABARAP, GAS 5, GNB2L1, GPATCH4, GPI, GRWD1, GSTOl, H3F3A, H3F3AP4,

HMGA1, HNRNPAl, HNRNPAIPIO, HNRNPC, HSPA8, IDH2, IFI16, ILF2, IMPDH2,

ISYNA1, ITM2C, KIAA0101, LHFPL3-AS1, LOC100190986, LYPLA1, MAGEA4,

MARCKS, MDH2, METAP2, MIDI, MIR4461, MLLT11, MPZL1, MRPL37, MRPS12,

MRPS21, MYC, NACA, NCL, NDUFS2, NF2, NIDI, NOLC1, NONO, NPMl, NUCKS1,

OAT, PA2G4, PABPCl, PAFAH1B3, PAICS, PFDN2, PFN1, PGAMl, PIH1D1, PLTP,

PPAl, PPIA, PPP2R1A, PSAT1, PSMD4, PTMA, PYCARD, RAN, RASA3, RBM34,

RNF2, RPAIN, RPL10, RPL10A, RPL11, RPL12, RPL13, RPL13A, RPL13AP5, RPL14,

RPL17, RPL18, RPL18A, RPL21, RPL26, RPL28, RPL29, RPL3, RPL30, RPL31, RPL35,

RPL36A, RPL37, RPL37A, RPL39, RPL4, RPL41, RPL5, RPL6, RPL7, RPL7A, RPL8,

RPLP0, RPLP1, RPS10, RPSl l, RPS12, RPS15, RPS15A, RPS16, RPS17, RPS17L, RPS18, RPS19, RPS2, RPS21, RPS23, RPS24, RPS26, RPS27, RPS27A, RPS3, RPS3A, RPS4X,

RPS5, RPS6, RPS7, RPS8, RPS9, RPSA, RSL1D1, RUVBL2, SAE1, SCD, SC M1,

SERBP1, SERPINF1, SET, SF3B4, SHMT2, SKP2, SLC19A1, SLC25A3, SLC25A5,

SLC25A6, SMS, SNAI2, S HG16, S HG6, S RPE, SORD, SOX4, SRP14, SSR2,

TIMM13, TIMM50, TMC6, TOP1MT, TP53, TRAPl, TRPM1, TSR1, TUBAIB, TUBB,

TUBB4A, TULP4, TXLNA, TYRP1, UBA52, UCK2, UQCRFS1, UQCRH, USP22,

VCY1B, VDAC2, VPS72, YWHAE, ZFAS1, Z F286A, A2M, ACSL3, ACSL4, ADM,

AEBPl, AGA, AHNAK, ANGPTL4, ANXA1, ANXA2, APLP2, APOC2, APOD, APOE,

ARF5, ARL6IP5, ATF3, ATP1A1, ATP1B1, ATP1B3, ATRAID, B2M, BACE2, BBX,

BCL6, C10orf54, C4A, CALU, CASP1, CAST, CAV1, CBLB, CC D3, CD151, CD44,

CD47, CD58, CD59, CD63, CD9, CDH19, CHI3L1, CHN1, CLIC4, CLU, CPVL, CRELDl,

CRYAB, CSGALNACTl, CSPG4, CST3, CTSA, CTSB, CTSD, CTSLl, DAG1, DCBLD2,

DDR1, DDX5, DPYSL2, DSCR8, DUSP4, DUSP6, DYNLRBl, ECM1, EEA1, EGR1,

EMP1, EPHX2, ERBB3, EVA1A, EZH1, EZR, FAM3C, FBX032, FCGR2C, FCRLA,

FGFR1, FLJ43663, FOS, FYB, GAA, GADD45B, GATSL3, GEM, GOLGB1, GP MB,

GRN, GSN, HCP5, HLA-A, HLA-B, HLA-C, HLA-E, HLA-F, HLA-H, HPCALl,

HSPAIA, HSPAIB, HTATIP2, ID2, IFI27L2, IFI35, IGFIR, ILIRAP, IL6ST, ISCU,

ITGA3, ITGA6, ITGA7, ITGB1, ITGB3, ITM2B, JUN, KCNN4, KLF4, KLF6, KRT10,

LAMP2, LEPROT, LGALSl, LGALS3, LGALS3BP, LOC100506190, LPL, LRPAPl,

LTBP3, LYRM9, MAEL, MAGEC2, MAP IB, MATN2, MFGE8, MFI2, MIA, MRPS6,

MT1E, MT1M, MT1X, MT2A, NDRG1, NEAT1, NFKBIA, NFKBIZ, NNMT, NPC1,

NPC2, NR4A1, NSG1, OCIAD2, PAGE5, PDK4, PERP, PKM, PLP2, PRKCDBP, PRNP,

PROS1, PRSS23, PSAP, PSMB9, PTRF, RDH5, RNF145, RPS4Y1, S100A13, S100A6,

S100B, SAT1, SCARB2, SCCPDH, SDC3, SEL1L, SEMA3B, SERPINA1, SERPINA3,

SERPINE2, SGCE, SGK1, SLC20A1, SLC26A2, SLC39A14, SLC5A3, SNX9, SOD1,

SPON2, SPRY2, SQSTM1, SRPX, STOM, SYNGR2, SYPLl, TAPBP, TAPBPL, TF,

TGOLN2, THBD, TIMP1, TIMP2, TIMP3, TIPARP, TM4SF1, TMBIM6, TMED10,

TMED9, TMEM66, TMX4, TNC, TNFSF4, TPP1, TRIML2, TSC22D3, TSPYL2, TXNIP,

TYR, UBC, UPPl, XAGEIA, XAGEIB, XAGEIC, XAGEID, XAGEIE, ZBTB20 and

ZBTB38 (uICR, see table 5); or one or more genes or polypeptides selected from the group consisting of ANP32E, CTPS1, DDX39B, EIF4A1, ESRP1, FBL, FUS, HNRNPA1, ILF2,

KIAAOlOl, NUCKSl, PTMA, RPL21, RUVBL2, SET, SLC25A5, TP53, TUBAIB, UCK2,

YWHAE, APLP2, ARL6IP5, CD63, CLU, CRELDl, CTSD, CTSLl, FOS, GAA, GRN, HLA-F, ITM2B, LAMP2, MAPIB, PC2, PSAP, SCARB2, SDC3, SELIL, TMEDIO and TSC22D3 (uICR, see Fig. 3C); or one or more genes or polypeptides selected from the group consisting of MT1E, MT1M, MT1X and MT2A.

[0035] In certain embodiments, the ICR signature may comprises a ICR-down signature, said signature comprising one or more genes selected from the group consisting of: AEBPl,

AHNAK, APOC2, APOD, APOE, B2M, C10orf54, CD63, CTSD, EEA1, EMP1, FBX032,

FYB, GATSL3, HCP5, HLA-A, HLA-B, HLA-C, HLA-E, HLA-F, HLA-H, ITGA3,

LAMP2, LYRM9, MFGE8, MIA, PC2, NSGl, PROSl, RDH5, SERPINA1, TAPBP,

TIMP2, TNFSF4 and TRIML2 (refined uICR-down, see table 5); or A2M, ACSL3, ACSL4,

ADM, AEBPl, AGA, AHNAK, ANGPTL4, ANXA1, ANXA2, APLP2, APOC2, APOD,

APOE, ARF5, ARL6IP5, ATF3, ATP1A1, ATP1B1, ATP1B3, ATRAID, B2M, BACE2,

BBX, BCL6, C10orf54, C4A, CALU, CASP1, CAST, CAV1, CBLB, CCND3, CD151,

CD44, CD47, CD58, CD59, CD63, CD9, CDH19, CHI3L1, CHN1, CLIC4, CLU, CPVL,

CRELD1, CRYAB, CSGALNACT1, CSPG4, CST3, CTSA, CTSB, CTSD, CTSL1, DAG1,

DCBLD2, DDR1, DDX5, DPYSL2, DSCR8, DUSP4, DUSP6, DYNLRBl, ECM1, EEA1,

EGR1, EMP1, EPHX2, ERBB3, EVA1A, EZH1, EZR, FAM3C, FBX032, FCGR2C,

FCRLA, FGFR1, FLJ43663, FOS, FYB, GAA, GADD45B, GATSL3, GEM, GOLGB1,

GPNMB, GRN, GSN, HCP5, HLA-A, HLA-B, HLA-C, HLA-E, HLA-F, HLA-H, HPCALl,

HSPA1A, HSPA1B, HTATIP2, ID2, IFI27L2, IFI35, IGF1R, ILIRAP, IL6ST, ISCU,

ITGA3, ITGA6, ITGA7, ITGB1, ITGB3, ITM2B, JUN, KCNN4, KLF4, KLF6, KRT10,

LAMP2, LEPROT, LGALSl, LGALS3, LGALS3BP, LOC100506190, LPL, LRPAPl,

LTBP3, LYRM9, MAEL, MAGEC2, MAPIB, MATN2, MFGE8, MFI2, MIA, MRPS6,

MT1E, MT1M, MT1X, MT2A, NDRGl, NEATl, NFKBIA, NFKBIZ, NNMT, NPCl,

NPC2, NR4A1, NSGl, OCIAD2, PAGE5, PDK4, PERP, PKM, PLP2, PRKCDBP, PRNP,

PROSl, PRSS23, PSAP, PSMB9, PTRF, RDH5, RNF145, RPS4Y1, S100A13, S100A6,

S100B, SAT1, SCARB2, SCCPDH, SDC3, SELIL, SEMA3B, SERPINA1, SERPINA3,

SERPINE2, SGCE, SGK1, SLC20A1, SLC26A2, SLC39A14, SLC5A3, SNX9, SOD1,

SPON2, SPRY2, SQSTM1, SRPX, STOM, SYNGR2, SYPLl, TAPBP, TAPBPL, TF,

TGOLN2, THBD, TIMP1, TIMP2, TIMP3, TIPARP, TM4SF1, TMBIM6, TMEDIO,

TMED9, TMEM66, TMX4, TNC, TNFSF4, TPP1, TRIML2, TSC22D3, TSPYL2, TXNIP,

TYR, UBC, UPPl, XAGEIA, XAGEIB, XAGEIC, XAGEID, XAGEIE, ZBTB20 and

ZBTB38 (uICR-down, see table 5); or APLP2, ARL6IP5, CD63, CLU, CRELD1, CTSD,

CTSL1, FOS, GAA, GRN, HLA-F, ITM2B, LAMP2, MAPIB, NPC2, PSAP, SCARB2, SDC3, SEL1L, TMED10 and TSC22D3 (uICR-down, see Fig. 3C), wherein said ICR-down signature is downregulated in a tumor with a high ICR score and upregulated in a tumor with a low ICR score.

[0036] In certain embodiments, the ICR signature comprises a ICR-up signature, said signature comprising one or more genes selected from the group consisting of: CIQBP,

CCT2, CCT6A, DCAF13, EIF4A1, ILF2, MAGEA4, NONO, PA2G4, PGAMl, PPAl,

PPIA, RPL18A, RPL26, RPL31, RPS11, RPS15, RPS21, RPS5, RUVBL2, SAE1, SNRPE,

UBA52, UQCRH and VDAC2 (refined uICR-up, see table 5); or ACAT1, ACP5, ACTB,

ACTG1, ADSL, AEN, AK2, ANP32E, APP, ASAP1, ATP5A1, ATP5D, ATP5G2, BANCR,

BCAN, BZW2, C17orf76-ASl, CIQBP, C20orfl l2, C6orf48, CA14, CBX5, CCT2, CCT3,

CCT6A, CDK4, CEP170, CFL1, CHP1, CNRIPl, CRABP2, CS, CTPS1, CYC1, DAP3,

DCAF13, DCT, DDX21, DDX39B, DLL3, EDNRB, EEF1D, EEF1G, EEF2, EIF1AX,

EIF2S3, EIF3E, EIF3K, EIF3L, EIF4A1, EIF4EBP2, ESRPl, FAM174B, FAM178B,

FAM92A1, FBL, FBLN1, FOXRED2, FTL, FUS, GABARAP, GAS 5, GNB2L1,

GPATCH4, GPI, GRWD1, GSTOl, H3F3A, H3F3AP4, HMGA1, HNRNPAl,

HNRNPAIPIO, HNRNPC, HSPA8, IDH2, IFI16, ILF2, IMPDH2, ISYNA1, ITM2C,

KIAA0101, LHFPL3-AS1, LOC100190986, LYPLA1, MAGEA4, MARCKS, MDH2,

METAP2, MIDI, MIR4461, MLLT11, MPZL1, MRPL37, MRPS12, MRPS21, MYC,

NACA, NCL, NDUFS2, NF2, NIDI, NOLCl, NONO, NPMl, NUCKSl, OAT, PA2G4,

PABPCl, PAFAH1B3, PAICS, PFDN2, PFNl, PGAMl, PIHIDI, PLTP, PPAl, PPIA,

PPP2R1A, PSAT1, PSMD4, PTMA, PYCARD, RAN, RASA3, RBM34, RNF2, RPAIN,

RPL10, RPL10A, RPL11, RPL12, RPL13, RPL13A, RPL13AP5, RPL14, RPL17, RPL18,

RPL18A, RPL21, RPL26, RPL28, RPL29, RPL3, RPL30, RPL31, RPL35, RPL36A, RPL37,

RPL37A, RPL39, RPL4, RPL41, RPL5, RPL6, RPL7, RPL7A, RPL8, RPLP0, RPLP1,

RPS10, RPS11, RPS12, RPS15, RPS15A, RPS16, RPS17, RPS17L, RPS18, RPS19, RPS2,

RPS21, RPS23, RPS24, RPS26, RPS27, RPS27A, RPS3, RPS3A, RPS4X, RPS5, RPS6,

RPS7, RPS8, RPS9, RPSA, RSL1D1, RUVBL2, SAEl, SCD, SCNM1, SERBP1,

SERPINFl, SET, SF3B4, SHMT2, SKP2, SLC19A1, SLC25A3, SLC25A5, SLC25A6,

SMS, SNAI2, SNHG16, SNHG6, SNRPE, SORD, SOX4, SRP14, SSR2, TIMM13,

TIMM50, TMC6, TOP1MT, TP53, TRAPl, TRPM1, TSR1, TUBA1B, TUBB, TUBB4A,

TULP4, TXLNA, TYRP1, UBA52, UCK2, UQCRFS1, UQCRH, USP22, VCY1B, VDAC2,

VPS72, YWHAE, ZFAS1 and ZNF286A (uICR-up, see table 5); or ANP32E, CTPS1,

DDX39B, EIF4A1, ESRPl, FBL, FUS, HNRNPAl, ILF2, KIAA0101, NUCKSl, PTMA, RPL21, RUVBL2, SET, SLC25A5, TP53, TUBAIB, UCK2 and YWHAE (uICR-up, see Fig. 3C), wherein said ICR-up signature is upregulated in a tumor with a high ICR score and downregulated in a tumor with a low ICR score.

[0037] In another aspect, the present invention provides for a method of detecting an immune checkpoint inhibitor resistance (ICR) gene signature in a tumor comprising, detecting in tumor cells obtained from a subject in need thereof the expression or activity of a malignant cell gene signature comprising: one or more genes or polypeptides selected from the group consisting of ACTB, AEN, ANP32E, ATP5A1, ATP5G2, BZW2, C17orf76-ASl,

C1QBP, C20orfl l2, CA14, CBX5, CCT2, CCT3, CDK4, CFL1, C RIP1, CRABP2, CS,

CTPS1, DCAF13, DCT, DDX39B, DLL3, EEF1G, EIF2S3, EIF3K, EIF4A1, EIF4EBP2,

FAM174B, FBL, FBLN1, FOXRED2, FTL, FUS, GABARAP, GAS 5, G B2L1,

GPATCH4, GPI, GRWD1, H3F3A, H3F3AP4, HMGA1, HNR PA1, HNR PA1P10,

HNR PC, HSPA8, IDH2, ILF2, ISYNA1, ITM2C, KIAA0101, MAGEA4, MDH2,

METAP2, MIDI, MIR4461, MLLT11, MPZL1, MRPS21, NACA, NCL, DUFS2, NOLC1,

NONO, PA2G4, PABPCl, PAFAH1B3, PFDN2, PFNl, PGAMl, PIHIDI, PPAl, PPIA,

PPP2R1A, PSMD4, PTMA, RAN, RBM34, RNF2, RPAIN, RPL10A, RPL11, RPL12,

RPL13, RPL13A, RPL13AP5, RPL17, RPL18, RPL18A, RPL21, RPL26, RPL28, RPL29,

RPL3, RPL31, RPL36A, RPL37, RPL37A, RPL39, RPL4, RPL41, RPL5, RPL6, RPL8,

RPLP0, RPLP1, RPS10, RPS11, RPS12, RPS15A, RPS16, RPS17, RPS17L, RPS18, RPS19,

RPS21, RPS23, RPS24, RPS26, RPS27, RPS27A, RPS3, RPS4X, RPS5, RPS6, RPS7, RPS8,

RPS9, RPSA, RUVBL2, SAEl, SCD, SCNM1, SERPINFl, SET, SF3B4, SHMT2, SKP2,

SLC25A3, SMS, SNAI2, SNHG6, SNRPE, SOX4, SRP14, SSR2, TIMM50, TMC6, TP53,

TRPM1, TSR1, TUBAIB, TUBB, TULP4, UBA52, UQCRFS1, UQCRH, USP22, VCY1B,

VDAC2, VPS72, YWHAE, ZNF286A, A2M, ACSL3, ACSL4, ADM, AEBP1, AGA,

AHNAK, ANGPTL4, ANXA1, ANXA2, APLP2, APOD, APOE, ARL6IP5, ATF3,

ATP1A1, ATP1B1, ATP1B3, B2M, BACE2, BBX, BCL6, CALU, CASP1, CAST, CAV1,

CCND3, CD151, CD44, CD47, CD58, CD59, CD63, CD9, CDH19, CHI3L1, CLIC4,

CRELD1, CRYAB, CSGALNACT1, CSPG4, CST3, CTSA, CTSB, CTSD, CTSL1, DAG1,

DCBLD2, DDR1, DDX5, DPYSL2, DUSP4, DUSP6, ECM1, EEA1, EGR1, EMP1, EPHX2,

ERBB3, EVA1A, EZH1, FAM3C, FBX032, FCGR2C, FCRLA, FGFR1, FLJ43663, FOS,

GAA, GADD45B, GEM, GOLGB1, GPNMB, GRN, GSN, HLA-A, HLA-B, HLA-C, HLA-

E, HLA-F, HLA-H, HPCALl, HSPA1A, HTATIP2, IFI35, IGF1R, ILIRAP, IL6ST, ITGA3,

ITGA6, ITGB1, ITGB3, ITM2B, JTJN, KCNN4, KLF4, KLF6, LAMP2, LEPROT, LGALSl, LGALS3, LGALS3BP, LPL, LRPAPl, MAGEC2, MFGE8, MFI2, MIA, MTIE, MTIM,

MTIX, MT2A, NEATl, NFKBIA, NFKBIZ, NNMT, NPCl, NPC2, NR4A1, NSGl, PDK4,

PLP2, PRKCDBP, PRNP, PROS1, PRSS23, PSAP, PSMB9, PTRF, RNF145, RPS4Y1,

S100A6, S100B, SAT1, SCARB2, SCCPDH, SDC3, SEL1L, SEMA3B, SERPINA3,

SERPINE2, SGCE, SGK1, SLC20A1, SLC26A2, SLC39A14, SLC5A3, SOD1, SPRY2,

SQSTM1, SRPX, STOM, SYNGR2, SYPL1, TAPBP, TAPBPL, TF, TGOLN2, TIMP1,

TIMP2, TIMP3, TIPARP, TM4SF1, TMED10, TMED9, TMEM66, TMX4, TNC, TPP1,

TSC22D3, TYR, UBC, UPP1, ZBTB20 and ZBTB38 (oncogenic ICR, see table 5); or one or more genes or polypeptides selected from the group consisting of AEN, ATP5A1,

C20orfl l2, CCT2, DCAF13, DDX39B, ISYNA1, NDUFS2, NOLC1, PA2G4, PPP2R1A,

RBM34, RNF2, RPL6, RPL21, SERPINFl, SF3B4, SMS, TMC6, VPS72, ANXAl, ATF3,

BCL6, CD58, CD9, CTSB, DCBLD2, EMP1, HLA-F, HTATIP2, IL1RAP, ITGA6, KCNN4,

KLF4, MTIE, MTIM, MTIX, MT2A, NNMT, PRKCDBP, S100A6 and TSC22D3

(oncogenic ICR, see Fig. 2B); or one or more genes or polypeptides selected from the group consisting of ACTB, ANP32E, CBX5, FUS, HNRNPA1, IDH2, KIAA0101, NCL, PFN1,

PPIA, PTMA, RAN, RPLPO, TUBA1B, TUBB, VCY1B, A2M, APOD, BCL6, CD44,

CD59, CD63, CDH19, CHI3L1, CTSA, CTSB, CTSD, FOS, GPNMB, GRN, HLA-A, HLA-

B, HLA-H, ITM2B, LGALS3BP, NEATl, PDK4, PSAP, SCARB2, SERPINA3, SLC26A2,

TAPBPL, TMEM66 and TYR (oncogenic ICR, see Fig. 10B); or one or more genes or polypeptides selected from the group consisting of MTIE, MTIM, MTIX and MT2A.

[0038] In certain embodiments, the ICR signature comprises an ICR-down signature, said signature comprising one or more genes selected from the group consisting of: A2M,

ACSL3, ACSL4, ADM, AEBPl, AGA, AHNAK, ANGPTL4, ANXAl, ANXA2, APLP2,

APOD, APOE, ARL6IP5, ATF3, ATP1A1, ATP1B1, ATP1B3, B2M, BACE2, BBX, BCL6,

CALU, CASP1, CAST, CAV1, CCND3, CD151, CD44, CD47, CD58, CD59, CD63, CD9,

CDH19, CHI3L1, CLIC4, CRELD1, CRYAB, CSGALNACTl, CSPG4, CST3, CTSA,

CTSB, CTSD, CTSL1, DAG1, DCBLD2, DDR1, DDX5, DPYSL2, DUSP4, DUSP6, ECM1,

EEA1, EGR1, EMP1, EPHX2, ERBB3, EVA1A, EZH1, FAM3C, FBX032, FCGR2C,

FCRLA, FGFRl, FLJ43663, FOS, GAA, GADD45B, GEM, GOLGBl, GPNMB, GRN,

GSN, HLA-A, HLA-B, HLA-C, HLA-E, HLA-F, HLA-H, HPCALl, HSPA1A, HTATIP2,

IFI35, IGF1R, IL1RAP, IL6ST, ITGA3, ITGA6, ITGB1, ITGB3, ITM2B, JUN, KCNN4,

KLF4, KLF6, LAMP2, LEPROT, LGALSl, LGALS3, LGALS3BP, LPL, LRPAPl,

MAGEC2, MFGE8, MFI2, MIA, MTIE, MTIM, MTIX, MT2A, NEATl, NFKBIA, NFKBIZ, NNMT, NPCl, NPC2, NR4A1, NSGl, PDK4, PLP2, PRKCDBP, PRNP, PROSl, PRSS23, PSAP, PSMB9, PTRF, RNF145, RPS4Y1, S100A6, S100B, SAT1, SCARB2, SCCPDH, SDC3, SEL1L, SEMA3B, SERPINA3, SERPINE2, SGCE, SGK1, SLC20A1, SLC26A2, SLC39A14, SLC5A3, SOD1, SPRY2, SQSTM1, SRPX, STOM, SYNGR2, SYPL1, TAPBP, TAPBPL, TF, TGOLN2, TIMP1, TIMP2, TIMP3, TIPARP, TM4SF1, TMEDIO, TMED9, TMEM66, TMX4, TNC, TPP1, TSC22D3, TYR, UBC, UPP1, ZBTB20 and ZBTB38 (oncogenic ICR down, see table 5); or ANXA1, ATF3, BCL6, CD58, CD9, CTSB, DCBLD2, EMP1, HLA-F, HTATIP2, IL1RAP, ITGA6, KCNN4, KLF4, MT1E, MT1M, MT1X, MT2A, NNMT, PRKCDBP, S100A6 and TSC22D3 (oncogenic ICR down, see Fig. 2B); or A2M, APOD, BCL6, CD44, CD59, CD63, CDH19, CHI3L1, CTSA, CTSB, CTSD, FOS, GPNMB, GRN, HLA-A, HLA-B, HLA-H, ITM2B, LGALS3BP, NEATl, PDK4, PSAP, SCARB2, SERPINA3, SLC26A2, TAPBPL, TMEM66 and TYR (oncogenic ICR down, see Fig. 10B), wherein said ICR-down signature is downregulated in a tumor with a high ICR score and upregulated in a tumor with a low ICR score.

[0039] In certain embodiments, the ICR signature comprises an ICR-up signature, said signature comprising one or more genes selected from the group consisting of: ACTB, AEN,

ANP32E, ATP5A1, ATP5G2, BZW2, C17orf76-ASl, C1QBP, C20orfl l2, CA14, CBX5,

CCT2, CCT3, CDK4, CFL1, CNRIPl, CRABP2, CS, CTPS1, DCAF13, DCT, DDX39B,

DLL3, EEF1G, EIF2S3, EIF3K, EIF4A1, EIF4EBP2, FAM174B, FBL, FBLN1, FOXRED2,

FTL, FUS, GABARAP, GAS5, GNB2L1, GPATCH4, GPI, GRWD1, H3F3A, H3F3AP4,

HMGA1, HNRNPAl, HNRNPAIPIO, HNRNPC, HSPA8, IDH2, ILF2, ISYNA1, ITM2C,

KIAA0101, MAGEA4, MDH2, METAP2, MIDI, MIR4461, MLLT11, MPZL1, MRPS21,

NACA, NCL, NDUFS2, NOLCl, NONO, PA2G4, PABPCl, PAFAH1B3, PFDN2, PFNl,

PGAM1, PIH1D1, PPA1, PPIA, PPP2R1A, PSMD4, PTMA, RAN, RBM34, RNF2, RPAIN,

RPL10A, RPL11, RPL12, RPL13, RPL13A, RPL13AP5, RPL17, RPL18, RPL18A, RPL21,

RPL26, RPL28, RPL29, RPL3, RPL31, RPL36A, RPL37, RPL37A, RPL39, RPL4, RPL41,

RPL5, RPL6, RPL8, RPLP0, RPLP1, RPS10, RPS11, RPS12, RPS15A, RPS16, RPS17,

RPS17L, RPS18, RPS19, RPS21, RPS23, RPS24, RPS26, RPS27, RPS27A, RPS3, RPS4X,

RPS5, RPS6, RPS7, RPS8, RPS9, RPSA, RUVBL2, SAEl, SCD, SCNM1, SERPINFl, SET,

SF3B4, SHMT2, SKP2, SLC25A3, SMS, SNAI2, SNHG6, SNRPE, SOX4, SRP14, SSR2,

TIMM50, TMC6, TP53, TRPM1, TSR1, TUBA1B, TUBB, TULP4, UBA52, UQCRFS1,

UQCRH, USP22, VCYIB, VDAC2, VPS72, YWHAE and ZNF286A (oncogenic ICR up, see table 5); or AEN, ATP5A1, C20orfl l2, CCT2, DCAF13, DDX39B, ISYNA1, NDUFS2, NOLCl, PA2G4, PPP2R1A, RBM34, RNF2, RPL6, RPL21, SERPINFl, SF3B4, SMS, TMC6, VPS72 (oncogenic ICR up, see Fig. 2B); or ACTB, ANP32E, CBX5, FUS, HNRNPAl, IDH2, KIAA0101, NCL, PFN1, PPIA, PTMA, RAN, RPLPO, TUBA1B, TUBB and VCY1B (oncogenic ICR up, see Fig. 10B), wherein said ICR-up signature is upregulated in a tumor with a high ICR score and downregulated in a tumor with a low ICR score. In certain embodiments, the ICR signature is detected in cycling cells.

[0040] In another aspect, the present invention provides for a method of detecting an immune cell exclusion gene signature in a tumor comprising, detecting in tumor cells obtained from a subject in need thereof the expression or activity of a malignant cell gene signature comprising: one or more genes or polypeptides selected from the group consisting of ACAT1, ACP5, ACTG1, ADSL, AK2, APP, ASAPl, ATP5D, BANCR, BCAN, BZW2,

C17orf76-ASl, C1QBP, C6orf48, CA14, CCT3, CCT6A, CEP170, CHP1, CTPS1, CYC1,

DAP3, DCT, DDX21, EDNRB, EEF1D, EEF1G, EEF2, EIF1AX, EIF2S3, EIF3E, EIF3K,

EIF3L, EIF4A1, ESRP1, FAM178B, FAM92A1, FTL, GAS 5, GNB2L1, GPI, GSTOl,

IFI16, ILF2, IMPDH2, LHFPL3-AS1, LOC100190986, LYPLA1, MARCKS, MDH2,

MRPL37, MRPS12, MYC, NCL, NF2, NIDI, NOLCl, NPMl, NUCKS1, OAT, PABPCl,

PAICS, PLTP, PSAT1, PYCARD, RASA3, RPL10, RPL10A, RPL11, RPL12, RPL13,

RPL13A, RPL13AP5, RPL14, RPL17, RPL18, RPL18A, RPL28, RPL29, RPL3, RPL30,

RPL35, RPL37A, RPL39, RPL4, RPL5, RPL6, RPL7, RPL7A, RPL8, RPLPO, RPLP1,

RPS10, RPS11, RPS15, RPS15A, RPS16, RPS17, RPS17L, RPS18, RPS19, RPS2, RPS24,

RPS27, RPS3, RPS3A, RPS4X, RPS5, RPS7, RPS8, RPS9, RPSA, RSL1D1, SCD, SERBP1,

SERPINFl, SLC19A1, SLC25A5, SLC25A6, SNAI2, SNHG16, SNHG6, SORD, SOX4,

TIMM13, TIMM50, TOP1MT, TRAPl, TUBB4A, TXLNA, TYRP1, UCK2, UQCRFS1,

ZFASl, A2M, AGA, AHNAK, ANXAl, APLP2, APOC2, ARF5, ATPlAl, ATPIBI,

ATRAID, B2M, C10orf54, C4A, CBLB, CCND3, CD151, CD47, CD58, CD59, CDH19,

CHN1, CLU, CPVL, CST3, CTSB, CTSD, CTSL1, DDR1, DPYSL2, DSCR8, DUSP6,

DYNLRBl, EMP1, EZR, FAM3C, FGFR1, FYB, GAA, GATSL3, GRN, GSN, HCP5,

HLA-B, HLA-C, HLA-F, HLA-H, HSPA1A, HSPA1B, ID2, IFI27L2, ISCU, ITGA3,

ITGA7, ITGB3, KCNN4, KRT10, LOC100506190, LTBP3, LYRM9, MAEL, MAP IB,

MATN2, MFGE8, MFI2, MIA, MRPS6, MT2A, NDRGl, NFKBIA, NPC1, OCIAD2,

PAGE5, PERP, PKM, RDH5, S100A13, S100A6, SERPINA1, SERPINA3, SERPINE2,

SGCE, SLC26A2, SLC5A3, SNX9, SPON2, THBD, TIMP1, TM4SF1, TMBIM6, TNFSF4,

TPP1, TRIML2, TSC22D3, TSPYL2, TXNIP, UBC, XAGE1A, XAGE1B, XAGE1C, XAGEID and XAGE1E (exclusion, see table 5); or one or more genes or polypeptides selected from the group consisting of ACTG1, ADSL, C17orf76-ASl, C1QBP, CTPS1, EIF2S3, EIF3E, ILF2, NCL, NF2, NOLCl, PABPCl, PAICS, RPLIOA, RPL18, RPL6, RPS24, RSL1D1, SERPINFl, SOX4, AHNAK, ANXA1, CCND3, CD151, CD47, CD58, CST3, CTSB, CTSD, EMP1, FGFR1, HLA-C, HLA-F, ITGB3, KCNN4, MIA, MT2A, S100A6, SLC5A3, TIMP1 and TSC22D3 (exclusion, see fig. 2H); or one or more genes or polypeptides selected from the group consisting of C17orf76-ASl, C1QBP, CTPS1, EIF2S3, ILF2, NCL, NOLCl, PABPCl, RPLIOA, RPL18, RPL6, RPS24, SERPINFl, SOX4, AHNAK, ANXA1, CCND3, CD151, CD47, CD58, CST3, CTSB, CTSD, EMP1, FGFR1, HLA-C, HLA-F, ITGB3, KCNN4, MIA, MT2A, S100A6, SLC5A3, TIMP1 and TSC22D3 (exclusion, see fig. 2H).

[0041] In certain embodiments, the exclusion signature comprises an exclusion-down signature, said signature comprising one or more genes selected from the group consisting of: A2M, AGA, AHNAK, ANXA1, APLP2, APOC2, ARF5, ATP1A1, ATP1B1, ATRAID, B2M, C10orf54, C4A, CBLB, CCND3, CD151, CD47, CD58, CD59, CDH19, CHN1, CLU, CPVL, CST3, CTSB, CTSD, CTSL1, DDR1, DPYSL2, DSCR8, DUSP6, DYNLRBl, EMP1, EZR, FAM3C, FGFR1, FYB, GAA, GATSL3, GRN, GSN, HCP5, HLA-B, HLA-C, HLA-F, HLA-H, HSPA1A, HSPA1B, ID2, IFI27L2, ISCU, ITGA3, ITGA7, ITGB3, KCNN4, KRT10, LOC100506190, LTBP3, LYRM9, MAEL, MAPIB, MATN2, MFGE8, MFI2, MIA, MRPS6, MT2A, NDRGl, NFKBIA, NPC1, OCIAD2, PAGE5, PERP, PKM, RDH5, S100A13, S100A6, SERPINA1, SERPINA3, SERPINE2, SGCE, SLC26A2, SLC5A3, SNX9, SPON2, THBD, TIMP1, TM4SF1, TMBIM6, TNFSF4, TPP1, TRIML2, TSC22D3, TSPYL2, TXNIP, UBC, XAGEIA, XAGEIB, XAGEIC, XAGEID and X AGE IE (exclusion-down, see table 5); or AHNAK, ANXA1, CCND3, CD151, CD47, CD58, CST3, CTSB, CTSD, EMP1, FGFR1, HLA-C, HLA-F, ITGB3, KCNN4, MIA, MT2A, S100A6, SLC5A3, TIMP1 and TSC22D3 (exclusion-down, see fig. 2H), wherein said exclusion-down signature is downregulated in a tumor with T cell exclusion and is upregulated in a tumor with T cell infiltration.

[0042] In certain embodiments, the exclusion signature comprises an exclusion-up signature, said signature comprising one or more genes selected from the group consisting of:

ACAT1, ACP5, ACTG1, ADSL, AK2, APP, ASAP1, ATP5D, BANCR, BCAN, BZW2,

C17orf76-ASl, C1QBP, C6orf48, CA14, CCT3, CCT6A, CEP170, CHP1, CTPS1, CYC1,

DAP3, DCT, DDX21, EDNRB, EEFID, EEFIG, EEF2, EIFIAX, EIF2S3, EIF3E, EIF3K, EIF3L, EIF4A1, ESRP1, FAM178B, FAM92A1, FTL, GAS 5, G B2L1, GPI, GSTOl, IFI16, ILF2, IMPDH2, LHFPL3-AS1, LOC100190986, LYPLA1, MARCKS, MDH2, MRPL37, MRPS12, MYC, NCL, F2, NIDI, NOLC1, NPM1, NUCKS1, OAT, PABPCl, PAICS, PLTP, PSAT1, PYCARD, RASA3, RPL10, RPL10A, RPL11, RPL12, RPL13, RPL13A, RPL13AP5, RPL14, RPL17, RPL18, RPL18A, RPL28, RPL29, RPL3, RPL30, RPL35, RPL37A, RPL39, RPL4, RPL5, RPL6, RPL7, RPL7A, RPL8, RPLPO, RPLP1, RPS10, RPS11, RPS15, RPS15A, RPS16, RPS17, RPS17L, RPS18, RPS19, RPS2, RPS24, RPS27, RPS3, RPS3A, RPS4X, RPS5, RPS7, RPS8, RPS9, RPSA, RSL1D1, SCD, SERBP1, SERPINF1, SLC19A1, SLC25A5, SLC25A6, SNAI2, SNHG16, SNHG6, SORD, SOX4, TIMM13, TIMM50, TOPIMT, TRAPl, TUBB4A, TXLNA, TYRPl, UCK2, UQCRFSl and ZFAS1 (exclusion-up, see table 5); or ACTG1, ADSL, C17orf76-ASl, C1QBP, CTPS1, EIF2S3, EIF3E, ILF2, NCL, NF2, NOLC1, PABPCl, PAICS, RPL10A, RPL18, RPL6, RPS24, RSL1D1, SERPINFl and SOX4 (exclusion-up, see fig. 2H); or C17orf76-ASl, C1QBP, CTPS1, EIF2S3, ILF2, NCL, NOLC1, PABPCl, RPL10A, RPL18, RPL6, RPS24, SERPINFl and SOX4 (exclusion-up, see fig. 2H), wherein said exclusion-up signature is upregulated in a tumor with T cell exclusion and is downregulated in a tumor with T cell infiltration.

[0043] In certain embodiments, the method according to any embodiment herein further comprises detecting tumor infiltrating lymphocytes (TIL). Not being bound by a theory, detecting tumor infiltration of immune cells is an independent indicator of immunotherapy resistance and progression free survival and combining detection of TILs with any of the above signatures may increase the prognostic value.

[0044] In certain embodiments, the gene signature according to any embodiment herein is detected in a bulk tumor sample, whereby the gene signature is detected by deconvolution of bulk expression data such that gene expression is assigned to malignant cells and non- malignant cells in said tumor sample.

[0045] In certain embodiments, detecting the gene signature comprises detecting downregulation of the down signature and/or upregulation of the up signature. In certain embodiments, not detecting the gene signature comprises detecting upregulation of the down signature and/or downregulation of the up signature. In certain embodiments, detecting the signature and/or TILs indicates lower progression free survival and/or resistance to checkpoint blockade therapy. In certain embodiments, not detecting the signature and/or TILs indicates higher progression free survival and/or sensitivity to checkpoint blockade therapy. In certain embodiments, detecting the gene signature indicates a 10-year survival rate less than 40% and wherein not detecting the signature indicates a 10-year survival rate greater than 60%.

[0046] In certain embodiments, detecting an ICR signature in a tumor further comprises detecting in tumor infiltrating lymphocytes (TIL) obtained from the subject in need thereof the expression or activity of a CD8 T cell gene signature, said signature comprising one or more genes or polypeptides selected from the group consisting of CEP19, EX05, FAM153C,

FCRL6, GBP2, GBP 5, HSPA1B, IER2, IRF1, KLRK1, LDHA, LOC100506083, MBOAT1,

SEMA4D, SIRT3, SPDYE2, SPDYE2L, STAT1, STOM, UBE2Q2P3, ACP5, AKNA,

BTN3A2, CCDC141, CD27, CDC42SE1, DDIT4, FAU, FKBP5, GPR56, HAVCR2, HLA-

B, HLA-C, HLA-F, IL6ST, ITGA4, KIAA1551, KLF12, MIR155HG, MTA2, MTR R2L1,

MTR R2L3, PIK3IP1, RPL26, RPL27, RPL27A, RPL35A, RPS11, RPS16, RPS20, RPS26,

SPOCK2, SYTL3, TOB1, TPT1, TTN, TXNIP, W K1 and ZFP36L2. In certain embodiments, detecting an ICR signature in a tumor further comprises detecting in macrophages obtained from the subject in need thereof the expression or activity of a macrophage gene signature, said signature comprising one or more genes or polypeptides selected from the group consisting of APOLl, CD274, CSTB, DCN, HLA-DPB2, HLA-

DQA1, HLA-G, HSPA8, HSPBl, IL18BP, TMEM176A, UBD, A2M, ADAP2, ADORA3,

ARL4C, ASPH, BCAT1, Cl lorfi l, C3, C3AR1, C6orf62, CAPN2, CD200R1, CD28, CD9,

CD99, COMT, CREM, CRTAP, CYFIP1, DDOST, DHRS3, EGFL7, EIF1AY, ETS2,

FCGR2A, FOLR2, GATM, GBP3, GNG2, GSTT1, GYPC, HIST1H1E, HPGDS, IFI44L,

IGFBP4, ITGA4, KCTD12, LGMN, LOC441081, LTC4S, LYVE1, MERTK, METTL7B,

MS4A4A, MS4A7, MTSS1, LRP3, OLFML3, PLA2G15, PLXDC2, PMP22, POR,

PRDX2, PTGS1, RNASE1, ROCK1, RPS4Y1, S100A9, SCAMP2, SEPP1, SESN1,

SLC18B1, SLC39A1, SLC40A1, SLC7A8, SORL1, SPP1, STABl, TMEM106C,

TMEM86A, TMEM9, T FRSF1B, T FRSF21, TPD52L2, ULK3 and ZFP36L2.

[0047] In another aspect, the present invention provides for a method of stratifying cancer patients into a high survival group and a low survival group comprising detecting the expression or activity of an ICR and/or exclusion signature in a tumor according to any embodiment herein, wherein if the signature is detected the patient is in the low survival group and if the signature is not detected the patient is in the high survival group. The patients in the high survival group may be immunotherapy responders and patients in the low survival group may be immunotherapy non-responders. [0048] In another aspect, the present invention provides for a method of treating a cancer in a subject in need thereof comprising detecting the expression or activity of an ICR and/or exclusion signature according to any embodiment herein in a tumor obtained from the subject and administering a treatment, wherein if an ICR and/or exclusion signature is detected the treatment comprises administering an agent capable of reducing expression or activity of said signature, and wherein if an ICR and/or exclusion signature is not detected the treatment comprises administering an immunotherapy. The agent capable of reducing expression or activity of said signature may comprise a CDK4/6 inhibitor, a drug selected from Table 16, a cell cycle inhibitor, a PKC activator, an inhibitor of the FKB pathway, an IGF 1R inhibitor, or Reserpine. The agent capable of reducing expression or activity of said signature may comprise an agent capable of modulating expression or activity of a gene selected from the group consisting of MAZ, FKBIZ, MYC, ANXA1, SOX4, MT2A, PTP4A3, CD59, DLL3, SERPINE2, SERPINF 1, PERP, EGR1, SERPINA3, SEMA3B, SMARCA4, IFNGR2, B2M, and PDL1. The agent capable of reducing expression or activity of said signature may comprise an agent capable of targeting or binding to one or more up-regulated secreted or cell surface exposed ICR and/or exclusion signature genes or polypeptides. The method may further comprise detecting the expression or activity of an ICR and/or exclusion signature according to any embodiment herein in a tumor obtained from the subject after the treatment and administering an immunotherapy if said signature is reduced or below a reference level. The agent capable of reducing expression or activity of said signature may be a CDK4/6 inhibitor. The method may further comprise detecting the expression or activity of an ICR and/or exclusion signature according to any embodiment herein in a tumor obtained from the subject before the treatment and administering an immunotherapy if said signature is not detected or below a reference level.

[0049] In certain embodiments, the method further comprises administering an immunotherapy to the subject administered an agent capable of reducing the expression or activity of said signature. The immunotherapy may comprise a check point inhibitor or adoptive cell transfer (ACT). The adoptive cell transfer may comprise a CAR T cell or activated autologous T cells. The checkpoint inhibitor may comprise anti-CTLA4, anti-PD- Ll and/or anti-PDl therapy.

[0050] In another aspect, the present invention provides for a method of treating a cancer in a subject in need thereof comprising detecting the expression or activity of an ICR and/or exclusion signature according to any embodiment herein in a tumor obtained from the subject, wherein if an ICR and/or exclusion signature is detected the treatment comprises administering an agent capable of modulating expression or activity of one or more genes or polypeptides in a network of genes disrupted by perturbation of a gene selected from the group consisting of MAZ, FKBIZ, MYC, ANXA1, SOX4, MT2A, PTP4A3, CD59, DLL3, SERPINE2, SERPINF 1, PERP, EGR1, SERPINA3, SEMA3B, SMARCA4, IFNGR2, B2M, and PDL1.

[0051] In another aspect, the present invention provides for a method of treating a cancer in a subject in need thereof comprising administering to the subject a therapeutically effective amount of an agent: capable of modulating the expression or activity of one or more ICR and/or exclusion signature genes or polypeptides according to any embodiment herein; or capable of targeting or binding to one or more cell surface exposed ICR and/or exclusion signature genes or polypeptides, wherein the gene or polypeptide is up-regulated in the ICR and/or exclusion signature; or capable of targeting or binding to one or more receptors or ligands specific for a cell surface exposed ICR and/or exclusion signature gene or polypeptide, wherein the gene or polypeptide is up-regulated in the ICR and/or exclusion signature; or comprising a secreted ICR and/or exclusion signature gene or polypeptide, wherein the gene or polypeptide is down-regulated in the ICR and/or exclusion signature; or capable of targeting or binding to one or more secreted ICR and/or exclusion signature genes or polypeptides, wherein the genes or polypeptides are up-regulated in the ICR and/or exclusion signature; or capable of targeting or binding to one or more receptors specific for a secreted ICR and/or exclusion signature gene or polypeptide, wherein the secreted gene or polypeptide is up-regulated in the ICR and/or exclusion signature; or comprising a CDK4/6 inhibitor, a drug selected from Table 16, a cell cycle inhibitor, a PKC activator, an inhibitor of the FKB pathway, an IGF 1R inhibitor, or Reserpine.

[0052] In certain embodiments, the agent comprises a therapeutic antibody, antibody fragment, antibody-like protein scaffold, aptamer, protein, CRISPR system or small molecule.

[0053] In certain embodiments, the agent capable of targeting or binding to one or more cell surface exposed ICR and/or exclusion signature polypeptides or one or more receptors specific for a secreted ICR and/or exclusion signature gene or polypeptide comprises a CAR

T cell capable of targeting or binding to one or more cell surface exposed ICR and/or exclusion signature genes or polypeptides or one or more receptors specific for a secreted

ICR and/or exclusion signature gene or polypeptide. [0054] In certain embodiments, the agent capable of modulating the expression or activity of one or more ICR and/or exclusion signature genes or polypeptides comprises a CDK4/6 inhibitor. The CDK4/6 inhibitor may comprise Abemaciclib.

[0055] In certain embodiments, the method further comprises administering an immunotherapy to the subject. The immunotherapy may comprise a check point inhibitor. The checkpoint inhibitor may comprise anti-CTLA4, anti-PD-Ll and/or anti-PDl therapy.

[0056] In another aspect, the present invention provides for a method of monitoring a cancer in a subject in need thereof comprising detecting the expression or activity of an ICR and/or exclusion gene signature according to any embodiment herein in tumor samples obtained from the subject for at least two time points. The at least one sample may be obtained before treatment. The at least one sample may be obtained after treatment.

[0057] In certain embodiments, the cancer according to any embodiment herein is melanoma.

[0058] In certain embodiments, the ICR and/or exclusion signature is expressed in response to administration of an immunotherapy.

[0059] In another aspect, the present invention provides for a method of detecting an ICR signature in a tumor comprising, detecting in tumor cells obtained from a subject in need thereof who has been treated with an immunotherapy the expression or activity of a malignant cell gene signature comprising: a) one or more down regulated genes selected from the group con si sting of genes associated with coagulation, apoptosis, TNF-a signaling via NFk'b, Antigen processing and presentation, metallothionein and IFNGR2; and/or b) one or more up regulated genes selected from the group consisting of genes associated with negative regulation of angiogenesis and MYC targets.

[0060] In another aspect, the present invention provides for a kit comprising reagents to detect at least one ICR and/or exclusion signature gene or polypeptide according to any embodiment herein. The kit may comprise at least one antibody, antibody fragment, or aptamer. The kit may comprise primers and/or probes for quantitative RT-PCR or fluorescently bar-coded oligonucleotide probes for hybridization to RNA.

[0061] In another aspect, the present invention provides for a CDS T cell specific cycling signature (see Table 7). In certain embodiments, modulating target genes in this signature can allow boosting T cell proliferation without activating tumor growth. Not being bound by a theory proliferating CD8 T cells express features that are not present in proliferating malignant cells. In certain embodiments, induction of oxidative phosphorylation and/or repression of hematopoietic lineage genes (e.g., CD37, IL11RA, and IL7R) may increase CD8 T cell proliferation without affecting tumor proliferation.

[0062] In another aspect, the present invention provides for a method of detecting an immunotherapy resistance (ITR) gene signature in a tumor comprising, detecting in tumor cells obtained from a subject in need thereof the expression or activity of a malignant cell gene signature comprising:

a) one or more genes or polypeptides selected from the group consisting of

ACOT7, ACSL3, ACTN1, ADAM15, ADI1, AEBP1, AGPAT1, AGRN, AHCY, AIF1L,

AKAP12, AKT3, ANXA5, APOAIBP, APOD, APOE, ARL2, ARNT2, ARPC1A, ASPH,

ATP1A1, ATP1B1, ATP6V0A1, B3GNT1, BACE2, BAIAP2, BCAN, BIRC7, BTBD3,

Cl lorf24, C17orf89, Clorfl98, Clorf21, Clorf85, CALDl, CALU, CAPN3, CAV1, CBR1,

CCND1, CCT3, CD151, CD276, CD59, CD63, CD9, CDC42BPA, CDC42EP4, CDH19,

CDK2, CDK2AP1, CECR7, CELSR2, CERCAM, CERS2, CHCHD6, CHL1, CHPF,

CLDN12, CLIC4, CNIH4, CNN3, CNP, CNPY2, COA3, COL16A1, COMT, CRIP2,

CRNDE, CRTAP, CRYAB, CSAG1, CSAG3, CSPG4, CSRP1, CTDSPL, CTHRC1,

CTNNALl, CTNNB1, CTSF, CTSK, CTTN, CYB5R1, CYP27A1, CYSTM1, CYTH3,

DAAM2, DCBLD2, DCT, DDR1, DDR2, DIP2C, DLC1, DNAH14, DOCK7, DST, DSTN,

DUSP6, ECM1, EDNRB, EFNA5, EIF4EBP1, EMP1, ENTPD6, EPS8, ERBB3, ETV4,

ETV5, EVA1A, EXOSC4, FAM127A, FAM127B, FAM167B, FARP1, FARP2, FASN,

FKBP10, FKBP4, FKBP9, FN1, FNBPIL, FRMD6, FSTL1, FXYD3, G6PC3, GALE,

GCSH, GDF15, GJB1, GLI3, GNG12, GOLM1, GPM6B, GPR143, GPRC5B, GSTA4,

GSTP1, GULP1, GYG2, H1F0, HIBADH, HMCN1, HMG20B, HOXB7, HOXC10, HSBP1,

HSP90AB1, HSPB1, HSPD1, HSPG2, IFI27, IGF1R, IGFBP7, IGSF11, IGSF3, IGSF8,

IMPDH2, ISYNA1, ITFG3, ITGA3, ITGB3, KIRREL, LAMB1, LAMB2, LAMC1,

LAPTM4A, LAPTM4B, LDLRAD3, LGALSl, LGALS3BP, LINC00473, LINC00673,

LMNA, LOC100126784, LOC100130370, LOC645166, LOXL4, LRP6, MAGEA12,

MAGEA2B, MAGE A3, MAGEA6, MAGED1, MAGED2, MAP IB, MARCKSLl, MDK,

MFAP2, MFGE8, MFI2, MGST3, MIA, MIF, MITF, MLANA, MLPH, MMP14,

MORF4L2, MORN2, MPZLl, MRPL24, MT2A, MTUSl, MXIl, MYH10, MYOIO,

MYOID, NAV2, NCKAPl, NDSTl, NENF, NES, NGFRAPl, NGRN, NHSLl, NIDI,

NMEl, NME2, NME4, NRP2, NRSN2, NSGl, OSBPLIA, P4HA2, PACSIN2, PAX3,

PCDHGC3, PEG10, PFDN2, PFKM, PFN2, PGRMCl, PHB, PHLDBl, PIR, PKNOX2,

PLEKHB1, PLK2, PLOD1, PLOD3, PLP1, PLS3, PLXNA1, PLXNB3, PMEL, PMP22, POLR2F, POLR2L, PON2, PPT2, PRAME, PRDX4, PRDX6, PRKCDBP, PROSl, PRSS23, PSMB5, PTGFRN, PTGR1, PTK2, PTPLAD1, PTPRM, PTPRS, PTRH2, PTTG1IP, PYCRl, PYGB, PYGL, QDPR, QPCT, RAB13, RAB17, RAB34, RAB38, RAI14, RBFOX2, RCAN1, RCN1, RCN2, RDX, RGS20, R D3, ROBOl, ROPN1, ROPN1B, RTKN, S100A1, S100A13, S100A16, S100B, SCARB1, SCCPDH, SCD, SDC3, SDC4, SDCBP, SELE BP1, SEMA3B, SEMA3C, SEMA6A, SEPT 10, SERPENT A3, SERPINE2, SERPINH1, SGCD, SGCE, SHC1, SHC4, SLC19A2, SLC24A5, SLC25A13, SLC25A4, SLC35B2, SLC39A1, SLC39A6, SLC45A2, SLC6A15, SLC7A8, SMARCAl, SNAI2, SNCA, S HG16, S RPE, SORT1, SOX10, SOX13, SOX4, SPARC, SPR, SPRY4, SPTBN1, SRPX, SSFA2, ST3GAL4, ST5, ST6GALNAC2, STK32A, STMN1, STXBP1, SYNGR1, TANC1, TBC1D16, TBC1D7, TCEAL4, TEADl, TENC1, TEX2, TFAP2A, TIMP2, TIMP3, TJP1, TMEM147, TMEM14C, TMEM9, TMEM98, T FRSF19, TOM1L1, TRIM2, TRIM63, TSC22D1, TSPAN3, TSPAN4, TSPAN6, TTLL4, TUBB2A, TUBB2B, TUBB3, TYR, UBL3, VAT1, VIM, VKORCl, WASL, WBP5, WIPI1, WLS, XAGE1A, XAGE1B, XAGE1C, XAGE1D, X AGE IE, XYLB, YWHAE and Z F462; or

b) one or more genes or polypeptides selected from Figure 3C; or

c) one or more genes or polypeptides selected from the group consisting of

ABHD2, ACSL4, AHNAK, AHR, AIM2, ANGPTL4, ANXA1, ANXA2, APOD, ATF3,

ATP1A1, ATP1B3, BBX, BCL6, BIRC3, BSG, C16orf45, C8orf40, CALU, CARD 16,

CAV1, CBFB, CCDC109B, CC D3, CD151, CD200, CD44, CD46, CD47, CD58, CD59,

CD9, CD97, CDH19, CERS5, CFB, CHI3L2, CLEC2B, CLIC4, COL16A1, COL5A2,

CREG1, CRELD1, CRYAB, CSPG4, CST3, CTNNALl, CTSA, CTSB, CTSD, DCBLD2,

DCTN6, EGR1, EMP1, EPDR1, FAM114A1, FAM46A, FCRLA, FN1, F DC3B, FXYD3,

G6PD, GAA, GADD45B, GALNS, GBP2, GEM, GRAMD3, GSTM2, HLA-A, HLA-C,

HLA-E, HLA-F, HPCALl, HSP90B1, HTATIP2, IFI27L2, IFI44, IFI6, IFITM3, IGFIR,

IGFBP3, IGFBP7, ILIRAP, ITGA6, ITGB3, ITM2B, JU B, KCNN4, KIAA1551, KLF4,

KLF6, LAMB1, LAMP2, LGALSl, LGALS3BP, LINC00116, LOC100127888, LOXL2,

LOXL3, LPL, LXN, MAGEC2, MFI2, MIA, MT1E, MT1F, MT1G, MT1M, MT1X, MT2A, FE2L1, NFKBIZ, NNMT, NOTCH2, NR4A1, OS9, P4HA2, PDE4B, PELIl, PIGT,

PMAIPl, PNPLA8, PPAPDCIB, PRKCDBP, PRNP, PROSl, PRSS23, PSMB9, PSMEl,

PTPMT1, PTRF, RAMP1, RND3, RNHl, RPN2, S100A10, S100A6, SCCPDH, SERINC1,

SERPINA3, SERPINEl, SERPINE2, SLC20A1, SLC35A5, SLC39A14, SLC5A3, SMIM3,

SPARC, SPRY2, SQRDL, STAT1, SUMF1, TAPl, TAPBP, TEKT4P2, TF, TFAP2C, TMEM43, TMX4, TNC, T FRSF10B, TNFRSF12A, TSC22D3, TSPAN31, UBA7, UBC, UBE2L6, XP07, ZBTB20, ZDHHC5, ZMYM6 B, ACAA2, ADSL, AEN, AHCY, ALDHIBI, ARHGEF1, ARPC5, ATXN10, ATXN2L, B4GALT3, BCCIP, BGN, C10orf32, C16orf88, C17orf76-ASl, C20orfl l2, CDCA7, CECR5, CPSF1, CS, CTCFL, CTPS1, DLL3, DTD2, ECHDC1, ECHS1, EIF4A1, EIF4EBP2, EIF6, EML4, ENY2, ESRG, FAM174B, FAM213A, FBL, FBLN1, FDXR, F0XRED2, FXN, GALT, GEMIN8, GL0D4, GPATCH4, HDAC2, HMGN3, HSD17B14, IDH2, ILF2, ISYNA1, KIAA0020, KLHDC8B, LMCDl, LOC100505876, LYPLAl, LZTS2, MAZ, METAP2, MIDI, MIR4461, MPDUl, MPZL1, MRPS16, MST01, MTG1, MY ADM, MYBBPIA, MYL6B, NARS2, NCBP1, DUFAF6, DUFS2, F2, NHEJl, NME6, NNT, NOLCl, NTHLl, OAZ2, OXAIL, PABPCl, PAICS, PAK1IP1, PFN1, POLR2A, PPA1, PRAME, PRDX3, PSTPIP2, PTGDS, PTP4A3, RBM34, RBM4, RPL10A, RPL17, RPP30, RPS3, RPS7, RPSA, RUVBL2, SAMM50, SBNOl, SERPINFl, SKP2, SLC45A2, SMC3, SMG7, SMS, SNAI2, SORD, SOX4, SRCAP, SRSF7, STARD10, TBXA2R, THOC5, TIMM22, TIMM23, TMC6, TOMM22, TPM1, TSNAX, TSR1, TSTA3, TULP4, UBAP2L, UCHL5, UROS, VPS72, WDR6, XPNPEPl, XRCC5, YDJC, ZFP36L1, and ZNF286A; or

d) one or more genes or polypeptides selected from the group consisting of AHNAK, AHR, ANXA1, ATP1B3, BBX, BCL6, BIN3, C16orf45, CARD 16, CAST, CAV1, CAV2, CD59, CD9, CDH19, CLEC2B, CRYAB, CYSTM1, FAM114A1, FAM46A, FCRLA, FXYD3, G6PD, GBP2, HLA-A, HLA-E, HLA-F, IGFIR, ILIRAP, IL6ST, ITGBl, ITM2B, KCNN4, KLF4, KLF6, LAMP2, LEPROT, LGALSl, LOC100127888, MT1X, MT2A, MVP, NFAT5, NFE2L1, NFKBIZ, PLP2, PROSl, PRSS23, RNF145, SIOOAIO, SEL1L, SERINC1, SERPINA3, SERPINE2, SPRY2, SQRDL, SQSTM1, TAPBP, TF, TMBIM1, TNFRSFIOB, TNFRSF12A, UBE2B, and ZBTB20; or

e) one or more genes or polypeptides selected from the group consisting of

TM4SF1, ANXA1, MT2A, SERPINA3, EMP1, MIA, ITGA3, CDH19, CTSB, SERPINE2,

MFI2, APOC2, ITGB8, S100A6, NNMT, SLC5A3, SEMA3B, TSC22D3, ITGB3, MATN2,

CRYAB, PERP, CSPG4, SGCE, CD9, A2M, FGFR1, CST3, DDR1, CD59, DPYSL2,

KCNN4, SLC26A2, CD151, SLC39A14, AHNAK, ATP1A1, PROSl, TIMP1, TRIML2,

EGR1, TNC, DCBLD2, DUSP4, DUSP6, CD58, FAM3C, ATP1B1, MT1E, TNFRSF12A,

FXYD3, SCCPDH, GAA, TIMP3, LEF1-AS1, CAV1, MFGE8, NR4A1, LGALS3, CCND3,

CALU, RDH5, APOD, LINC00116, ILIRAP, SERPINA1, NFKBIZ, HSPA1A, PRSS23,

MAP IB, ITGA7, PLP2, IGFBP7, GSN, LOXL3, PTRF, LGALSl, IGFIR, SERPINEl, MT1X, ATP1B3, SDC3, ZBTB38, NSG1, FCGR2A, KLF4, EGR3, DAG1, CTSD, CPVL, EEAl, SLC20A1, CLU, GBP2, SPON2, T FSF4, NPCl, PRKCDBP, HTATIP2, C16orf45, SERPINF1, DCT, SNAI2, PTP4A3, RPS19, BCAN, FOXRED2, FAM174B, TRPM1, ESRP1, PABPCl, CA14, TMC6, C17orf76-ASl, RPL13AP5, TP53, BANCR, RPL28, IDH2, LOC100133445, TYRP1, DLL3, LHFPL3-AS1, SCIN, EIF4EBP2, TIMM50, CD68, GPI, MIR4461, RPS27, C1QBP, EGFL8, RPL21, FAM178B, RPS24, SAEl, KLHDC8B, KCNAB2, RPLPO, SCD, TULP4, IL6R, LINC00439, TSTDl, NF2, TUBB4A, SOX4, RPS3, NAPRTl, RPS6, LIMD2, CDKN2A, PTGDS, ISYNAl, ARHGDIB, CNRIPl, H3F3A, TBXA2R, PSTPIP2, SERPINB9, TMEM204, SORD, RPS5, CDH3, RPL18A, RPL8, VPS53, RBM34, FES, ESRG, RPS7, HSD17B14, TTC39A, FBLN1, SLC45A2, AEN, ACP5, BCL11A, CHP1, XIST, MAZ, FAM92A1, CTPS1, ASAP1, RPL6, MARCKS, MAGEA4, NPL, RPS16, NENF, SLC19A1, FTL, RNF2, MYBBP1A, PPAP2C, GRWD1, SKP2, WDR81, DCUN1D2, LAMP2 and MPZL1; or

f) one or more genes or polypeptides selected from the group consisting of TM4SF1, MT2A, SERPINA3, CDH19, SERPINE2, CRYAB, SGCE, A2M, DDR1, CD59, DPYSL2, DUSP6, MFGE8, NFKBIZ, and PRSS23; or

g) one or more genes or polypeptides selected from the group consisting of SERPINA3, MT2A, SERPINFl, SERPINE2, SOX4, DDR1, CD59, DUSP6, PERP, SEMA3B, PTP4A3, BANCR, DLL3, and LAMP2; or

h) one or more genes or polypeptides selected from the group consisting of MT2A, MT1E, MT1X, MT1M, MT1F, MT1G, MTX1 and MTG1.

[0063] In one embodiment, the ITR signature further comprises one or more genes or polypeptides selected from the group consisting of IFNGR2, B2M, and PDL1.

[0064] In one embodiment, said ITR signature comprises a post-immunotherapy signature-down (PIT-down) module, said module comprising one or more genes selected from the group consisting of: ABHD2, ACSL4, AHNAK, AHR, AIM2, ANGPTL4, ANXA1,

ANXA2, APOD, ATF3, ATPlAl, ATP1B3, BBX, BCL6, BIRC3, BSG, C16orf45, C8orf40,

CALU, CARD 16, CAV1, CBFB, CCDC109B, CCND3, CD151, CD200, CD44, CD46,

CD47, CD58, CD59, CD9, CD97, CDH19, CERS5, CFB, CHI3L2, CLEC2B, CLIC4,

COL16A1, COL5A2, CREG1, CRELD1, CRYAB, CSPG4, CST3, CTNNALl, CTSA,

CTSB, CTSD, DCBLD2, DCTN6, EGR1, EMP1, EPDR1, FAM114A1, FAM46A, FCRLA,

FN1, FNDC3B, FXYD3, G6PD, GAA, GADD45B, GALNS, GBP2, GEM, GRAMD3,

GSTM2, HLA-A, HLA-C, HLA-E, HLA-F, HPCALl, HSP90B1, HTATIP2, IFI27L2, IFI44, IFI6, IFITM3, IGFIR, IGFBP3, IGFBP7, IL1RAP, ITGA6, ITGB3, ITM2B, JU B,

KCNN4, KIAA1551, KLF4, KLF6, LAMB1, LAMP2, LGALSl, LGALS3BP, LINC00116,

LOC100127888, LOXL2, LOXL3, LPL, LXN, MAGEC2, MFI2, MIA, MT1E, MT1F,

MTIG, MTIM, MTIX, MT2A, FE2L1, NFKBIZ, NNMT, NOTCH2, NR4A1, OS9,

P4HA2, PDE4B, PELIl, PIGT, PMAIPl, PNPLA8, PPAPDCIB, PRKCDBP, PRNP,

PROS1, PRSS23, PSMB9, PSME1, PTPMT1, PTRF, RAMP1, RND3, RNH1, RPN2,

S100A10, S100A6, SCCPDH, SERINC1, SERPINA3, SERPINEl, SERPINE2, SLC20A1,

SLC35A5, SLC39A14, SLC5A3, SMIM3, SPARC, SPRY2, SQRDL, STAT1, SUMF1,

TAPl, TAPBP, TEKT4P2, TF, TFAP2C, TMEM43, TMX4, TNC, TNFRSFIOB,

TNFRSF12A, TSC22D3, TSPAN31, UBA7, UBC, UBE2L6, XP07, ZBTB20, ZDHHC5 and ZMYM6NB; or TM4SF1, ANXA1, MT2A, SERPINA3, EMP1, MIA, ITGA3, CDH19,

CTSB, SERPINE2, MFI2, APOC2, ITGB8, S100A6, NNMT, SLC5A3, SEMA3B,

TSC22D3, ITGB3, MATN2, CRYAB, PERP, CSPG4, SGCE, CD9, A2M, FGFR1, CST3,

DDR1, CD59, DPYSL2, KCNN4, SLC26A2, CD151, SLC39A14, AHNAK, ATP1A1,

PROS1, TIMP1, TRIML2, EGR1, TNC, DCBLD2, DUSP4, DUSP6, CD58, FAM3C,

ATP1B1, MT1E, TNFRSF12A, FXYD3, SCCPDH, GAA, TIMP3, LEF1-AS1, CAV1,

MFGE8, NR4A1, LGALS3, CCND3, CALU, RDH5, APOD, LINC00116, ILIRAP,

SERPINA1, NFKBIZ, HSPA1A, PRSS23, MAP IB, ITGA7, PLP2, IGFBP7, GSN, LOXL3,

PTRF, LGALSl, IGFIR, SERPINEl, MTIX, ATP1B3, SDC3, ZBTB38, NSGl, FCGR2A,

KLF4, EGR3, DAG1, CTSD, CPVL, EEA1, SLC20A1, CLU, GBP2, SPON2, TNFSF4,

NPCl, PRKCDBP, HTATIP2, and C16orf45; or an mICR down gene in Figure 3C, wherein said PIT-down module is downregulated in a tumor resistant to immunotherapy and upregulated in a tumor sensitive to immunotherapy as compared to a reference level.

[0065] In one embodiment, said ITR signature comprises a post-immunotherapy signature-up (PIT-up) module, said module comprising one or more genes selected from the group consisting of: ACAA2, ADSL, AEN, AHCY, ALDHIBI, ARHGEF1, ARPC5,

ATXN10, ATXN2L, B4GALT3, BCCIP, BGN, C10orf32, C16orf88, C17orf76-ASl,

C20orfl l2, CDCA7, CECR5, CPSF1, CS, CTCFL, CTPS1, DLL3, DTD2, ECHDC1,

ECHS1, EIF4A1, EIF4EBP2, EIF6, EML4, ENY2, ESRG, FAM174B, FAM213A, FBL,

FBLNl, FDXR, FOXRED2, FXN, GALT, GEMIN8, GLOD4, GPATCH4, HDAC2,

HMGN3, HSD17B14, IDH2, ILF2, ISYNA1, KIAA0020, KLHDC8B, LMCD1,

LOC100505876, LYPLAl, LZTS2, MAZ, METAP2, MIDI, MIR4461, MPDU1, MPZL1,

MRPS16, MSTOl, MTG1, MY ADM, MYBBPIA, MYL6B, NARS2, NCBP1, NDUFAF6, DUFS2, F2, NHEJl, NME6, NNT, NOLCl, NTHLl, OAZ2, OXAIL, PABPCl, PAICS, PAK1IP1, PFN1, POLR2A, PPA1, PRAME, PRDX3, PSTPIP2, PTGDS, PTP4A3, RBM34, RBM4, RPLIOA, RPL17, RPP30, RPS3, RPS7, RPSA, RUVBL2, SAMM50, SBNOl, SERPINF1, SKP2, SLC45A2, SMC3, SMG7, SMS, SNAI2, SORD, SOX4, SRCAP, SRSF7, STARDIO, TBXA2R, THOC5, TIMM22, TIMM23, TMC6, TOMM22, TPM1, TSNAX, TSR1, TSTA3, TULP4, UBAP2L, UCHL5, UROS, VPS72, WDR6, XPNPEPl, XRCC5, YDJC, ZFP36L1 and ZNF286A; or SERPINFl, DCT, SNAI2, PTP4A3, RPS19, BCAN, FOXRED2, FAM174B, TRPM1, ESRP1, PABPCl, CA14, TMC6, C17orf76-ASl, RPL13AP5, TP53, BANCR, RPL28, IDH2, LOC100133445, TYRP1, DLL3, LHFPL3-AS1, SCIN, EIF4EBP2, TIMM50, CD68, GPI, MIR4461, RPS27, C1QBP, EGFL8, RPL21, FAM178B, RPS24, SAEl, KLHDC8B, KCNAB2, RPLPO, SCD, TULP4, IL6R, LINC00439, TSTD1, NF2, TUBB4A, SOX4, RPS3, NAPRTl, RPS6, LIMD2, CDKN2A, PTGDS, ISYNA1, ARHGDIB, CNRIPl, H3F3A, TBXA2R, PSTPIP2, SERPINB9, TMEM204, SORD, RPS5, CDH3, RPL18A, RPL8, VPS53, RBM34, FES, ESRG, RPS7, HSD17B14, TTC39A, FBLN1, SLC45A2, AEN, ACP5, BCL11A, CHP1, XIST, MAZ, FAM92A1, CTPS1, ASAPl, RPL6, MARCKS, MAGEA4, NPL, RPS16, NENF, SLC19A1, FTL, RNF2, MYBBPIA, PPAP2C, GRWDl, SKP2, WDR81, DCUN1D2, and MPZLl; or an mICR up gene in Figure 3C, wherein said PIT-up module is upregulated in a tumor resistant to immunotherapy and downregulated in a tumor sensitive to immunotherapy as compared to a reference level.

[0066] Detecting an immunotherapy resistance gene signature in a tumor may further comprise detecting in tumor infiltrating lymphocytes (TIL) obtained from the subject in need thereof the expression or activity of a CD8 T cell gene signature, said signature comprising one or more genes or polypeptides selected from the group consisting of APOBEC3G, CBLB, CCL4, CCL4L1, CCL4L2, CCL5, CD27, CD8A, CD8B, CST7, CTSW, CXCL13, CXCR6, DTHD1, DUSP2, EOMES, FASLG, FCRL3, GBP 5, GZMA, GZMB, GZMH, GZMK, HCST, HLA-A, HLA-B, HLA-H, ID2, IFNG, IL2RB, KLRC3, KLRC4, KLRC4- KLRKl, KLRDl, KLRKl, LAG3, LSPl, LYST, NKG7, PDCDl, PRFl, PSTPIPl, PYHINl, RARRES3, SH2D1A, SH2D2A, TARP, TIGIT, TNFRSF9 and TOX.

[0067] Detecting an immunotherapy resistance gene signature in a tumor may further comprise detecting in tumor infiltrating lymphocytes (TIL) obtained from the subject in need thereof the expression or activity of a CD4 T cell gene signature, said signature comprising one or more genes or polypeptides selected from the group consisting of AIM1, ANK3, AQP3, CAMK4, CCR4, CCR8, CD28, CD40LG, DGKA, EML4, FAAH2, FBLN7, FKBP5, FLT3LG, FOXP3, FXYD5, IL6R, IL7R, ITGB2-AS1, JU B, KLRBl, LEPROTL1, LOC100128420, MAL, OXNAD1, PBXIP1, PIK3IP1, PIM2, PRKCQ-AS1, RORA, RPL35A, RPL4, RPL6, RPS15A, RPS27, RPS28, 6-Sep, SLAMFl, SORLl, SPOCK2, SUSD3, TCF7, TMEM66, T FRSF 18, T FRSF25, T FRSF4, T FSF8, TRABD2A, TSC22D3 and TXK.

[0068] Detecting an immunotherapy resistance gene signature in a tumor may further comprise detecting in macrophages obtained from the subject in need thereof the expression or activity of a macrophage gene signature, said signature comprising one or more genes or polypeptides selected from the group consisting of AIF1, ALDH2, ANPEP, C15orf48, Clorfl62, C1QA, C1QB, C1QC, C3AR1, CCR1, CD14, CD163, CD300A, CD300C, CD300LF, CD33, CD86, CFP, CLECIOA, CLEC12A, CLEC4A, CLEC5A, CMKLR1, CSF1R, CSF2RB, CSF3R, CSTA, CXCL9, CXCR2P1, DSC2, FAM26F, FBP1, FCER1G, FCGR1A, FCGR1B, FCGR1C, FCGR3A, FCGR3B, FCN1, FOLR2, FPR1, FPR2, FPR3, GGTA1P, GNA15, GPR84, HCK, HK3, IGSF6, IL1B, IL1RN, IL4I1, ITGAM, KYNU, LGALS2, LILRAl, LILRA2, LILRA3, LILRA4, LILRB2, LILRB4, LILRB5, LSTl, MAFB, MARCO, MNDA, MRC1, MS4A4A, MS4A6A, MSR1, NCF2, OLR1, P2RY13, PILRA, PLAU, PLBD1, PLXDC2, PRAM1, RAB20, RAB31, RASSF4, RBM47, RGS18, S100A8, S100A9, SECTM1, SIGLECl, SIGLEC7, SIGLEC9, SLAMF8, SLC31A2, SLC43A2, SLC7A7, SLC8A1, SLC02B1, SPI1, STABl, TBXAS1, TFEC, TGFBI, TLR2, TLR4, TLR8, TMEM176A, TMEM176B, T FSF13, TNFSF13B, TREM2, TYROBP, VSIG4 and Z F385A.

[0069] Detecting an immunotherapy resistance gene signature in a tumor may further comprise detecting in B cells obtained from the subject in need thereof the expression or activity of a B cell gene signature, said signature comprising one or more genes or polypeptides selected from the group consisting of ADAM19, AKAP2, BACH2, BANK1, BCL11A, BLK, CD19, CD1C, CD22, CD79A, CD79B, CLEC17A, C R2, COL19A1, COL4A3, CP E5, CR2, CXCR5, EBF1, ELK2AP, FAM129C, FAM177B, FCER2, FCRL1, FCRL2, FCRL5, FCRLA, HLA-DOB, IGJ, IGLL1, IGLL3P, IGLL5, KIAA0125, KIAA0226L, LOC283663, MS4A1, P2RX5, PAX5, PNOC, POU2AF1, POU2F2, RASGRP3, SEL1L3, SNX29P1, ST6GAL1, STAPl, SWAP70, TCLIA, TMEM154 and VPREB3. [0070] The gene signature may be detected in a bulk tumor sample, whereby the gene signature is detected by deconvolution of bulk expression data such that gene expression is assigned to malignant cells and non-malignant cells in said tumor sample.

[0071] Detecting the ITR gene signature may comprise detecting downregulation of the PIT-down module and/or upregulation of the PIT -up module. Not detecting the ITR gene signature may comprise detecting upregulation of the PIT-down module and/or downregulation of the PIT-up module. The detecting an ITR gene signature may indicates a 10-year survival rate less than 40% and wherein not detecting said signature may indicate a 10-year survival rate greater than 60%. The detecting an ITR gene signature may indicate exclusion of T cells from a tumor and wherein not detecting said signature may indicate infiltration of T cells in a tumor.

[0072] In another aspect, the present invention provides for a method of stratifying cancer patients into a high survival group and a low survival group comprising detecting the expression or activity of an immunotherapy resistance gene signature in a tumor, wherein if an immunotherapy resistance gene signature is detected the patient is in the low survival group and if an immunotherapy resistance gene signature is not detected the patient is in the high survival group. The patients in the high survival group may be immunotherapy responders and patients in the low survival group may be immunotherapy non-responders.

[0073] In another aspect, the present invention provides for a method of treating a cancer in a subject in need thereof comprising detecting the expression or activity of an immunotherapy resistance gene signature according to any of claims 1 to 10 in a tumor obtained from the subject and administering a treatment, wherein if an immunotherapy resistance signature is detected the treatment comprises administering an agent capable of reducing expression or activity of said signature, and wherein if an immunotherapy resistance signature is not detected the treatment comprises administering an immunotherapy. The agent capable of reducing expression or activity of said signature may comprise a drug selected from Table 16, a PKC activator, an inhibitor of the NFKB pathway, an IGF IR inhibitor, or

Reserpine. The agent capable of reducing expression or activity of said signature may comprise an agent capable of modulating expression or activity of a gene selected from the group consisting of MAZ, NFKBIZ, MYC, ANXA1, SOX4, MT2A, PTP4A3, CD59, DLL3,

SERPINE2, SERPINF 1, PERP, EGR1, SERPINA3, SEMA3B, SMARCA4, IFNGR2, B2M, and PDL1. The agent capable of reducing expression or activity of said signature may comprise an agent capable of targeting or binding to one or more up-regulated secreted or cell surface exposed immunotherapy resistance signature genes or polypeptides. The method may further comprise detecting the expression or activity of an immunotherapy resistance gene signature in a tumor obtained from the subject after the treatment and administering an immunotherapy if said signature is not detected. The method may further comprise administering an immunotherapy to the subject administered an agent capable of reducing the expression or activity of said signature. The immunotherapy may comprise a check point inhibitor or adoptive cell transfer (ACT). The adoptive cell transfer may comprise a CAR T cell or activated autologous T cells. The checkpoint inhibitor may comprise anti-CTLA4, anti-PD-Ll and/or anti-PDl therapy.

[0074] In another aspect, the present invention provides for a method of treating a cancer in a subject in need thereof comprising detecting the expression or activity of an immunotherapy resistance gene signature according to any embodiment herein in a tumor obtained from the subject, wherein if an immunotherapy resistance signature is detected the treatment comprises administering an agent capable of modulating expression or activity of one or more genes or polypeptides in a network of genes disrupted by perturbation of a gene selected from the group consisting of MAZ, NFKBIZ, MYC, ANXA1, SOX4, MT2A, PTP4A3, CD59, DLL3, SERPINE2, SERPINF1, PERP, EGR1, SERPINA3, SEMA3B, SMARCA4, IFNGR2, B2M, and PDL1.

[0075] In another aspect, the present invention provides for a method of treating a cancer in a subject in need thereof comprising administering to the subject a therapeutically effective amount of an agent: capable of modulating the expression or activity of one or more immunotherapy resistance signature genes or polypeptides; or capable of targeting or binding to one or more cell surface exposed immunotherapy resistance signature genes or polypeptides, wherein the gene or polypeptide is up-regulated in the ITR signature; or capable of targeting or binding to one or more receptors or ligands specific for a cell surface exposed immunotherapy resistance signature gene or polypeptide, wherein the gene or polypeptide is up-regulated in the ITR signature; or comprising a secreted immunotherapy resistance signature gene or polypeptide, wherein the gene or polypeptide is down-regulated in the ITR signature; or capable of targeting or binding to one or more secreted immunotherapy resistance signature genes or polypeptides, wherein the genes or polypeptides are up-regulated in the ITR signature; or capable of targeting or binding to one or more receptors specific for a secreted immunotherapy resistance signature gene or polypeptide, wherein the secreted gene or polypeptide is up-regulated in the ITR signature; or comprising a drug selected from Table 16, a PKC activator, an inhibitor of the FKB pathway, an IGF IR inhibitor, or Reserpine. The agent capable of modulating the expression or activity of one or more immunotherapy resistance signature genes or polypeptides may comprise a CDK4/6 inhibitor. The CDK4/6 inhibitor may comprise Abemaciclib. The method may further comprise administering an immunotherapy to the subject. The immunotherapy may comprise a check point inhibitor. The checkpoint inhibitor may comprise anti-CTLA4, anti-PD-Ll and/or anti-PDl therapy. Not being bound by a theory, the

CDK4/6 inhibitor may sensitize a subject to checkpoint blockade therapy. The agent may comprise a therapeutic antibody, antibody fragment, antibody-like protein scaffold, aptamer, protein, CRISPR system or small molecule. The agent capable of targeting or binding to one or more cell surface exposed immunotherapy resistance signature polypeptides or one or more receptors specific for a secreted immunotherapy resistance signature gene or polypeptide may comprise a CAR T cell capable of targeting or binding to one or more cell surface exposed immunotherapy resistance signature genes or polypeptides or one or more receptors specific for a secreted immunotherapy resistance signature gene or polypeptide.

[0076] In another aspect, the present invention provides for a method of monitoring a cancer in a subject in need thereof comprising detecting the expression or activity of an immunotherapy resistance gene signature according to any embodiment herein in tumor samples obtained from the subject for at least two time points. The at least one sample may be obtained before treatment. The at least one sample may be obtained after treatment.

[0077] The cancer according to any embodiment may be melanoma. The ITR gene signature may be expressed in response to administration of an immunotherapy.

[0078] In another aspect, the present invention provides for a method of detecting T cell infiltration of a tumor comprising detection in malignant cells expression or activity of one or more genes selected from the group consisting of: HLA-C, FGFR1, ITGB3, CD47, AHNAK,

CTSD, TIMP1, SLC5A3, CST3, CD151, CCND3, MIA, CD58, CTSB, S 100A6, EMP1,

HLA-F, TSC22D3, ANXA1, KCNN4 and MT2A; or A2M, AEBP1, AHNAK, ANXA1,

APOC2, APOD, APOE, ATP1A1, ATP 1B 1, C4A, CAPN3, CAV1, CD151, CD59, CD63,

CDH19, CRYAB, CSPG4, CSRPl , CST3, CTSB, CTSD, DAG I , DDR1 , DUSP6, ETV5,

EVA1A, FBX032, FCGR2A, FGFR1, GAA, GATSL3, GJB 1, CRN, GSN, HLA-B, HLA-C,

HLA-F, HLA-H, IF 135, IGFBP7, IGSF8, ITGA3, ITGA7, ITGB3, LAMP2, LGALS3,

LOXL4, LRPAPl, LY6E, LYRM9, MATN2, MFGE8, MIA, MPZ, MT2A, MTRNR2L3,

MTRNR2L6, NPC1, NPC2, NSG1, PERP, PKM, PLEKHB l, PROS 1, PRSS23, PYGB, RDM 5, ROPNl , S lOOAl, S 100A13, S 100A6, S 100B, SCARB2, SCCPDI I, SDC3, SEMA3B, SERPINA 1 , SERPINA3, SERPINE2, SGCE, SGK1, SLC26A2, SLC5A3, SPON2, SPP l , TIMP1, TIMP2, TIMP3, TM4SF1, TMEM255A, TMX4, TNFSF4, TPP1, TRIML2, TSC22D3, TXNIP, TYR, UBC and WBP2; or HLA-A, HLA-B, HLA-C, B2M, TAPBP, IFI27, IFI35, IRF4, IRF9 and STAT2; or B2M, CTSB, CTSL1, HLA-B/C/F, HSPA IA, HSPA1B, NFKBIA and CD58, wherein detection indicates sensitivity to immunotherapy.

[0079] In another aspect, the present invention provides for a method of detecting T cell exclusion of a tumor comprising detection in malignant cells expression or activity of one or more genes selected from the group consisting of: SERPINF 1 , RPL6, NOLO, RSL1 D1, ILF2, SOX4, ACTGl, C17orf76-AS l, PABPCl, RPS24, ADSL, CIQBP, PAICS, CTPS l, NF2, EIF2S3, RPL18 and RPL10A; or AHCY, BZW2, CCNB 1IP 1, CCT6A, EEF2, EIF3B, GGCT, ILF3, IMPDH2, MDH2, MYBBPIA, NT5DC2, PAICS, PFKM, POLD2, PTK7, SLC 19A1, SMARCA4, STRAP, TIMM13, TOP1MT, TRAP l and USP22; or MYC, STRAP and SMARCA4; or MYC, SNA 12 and SOX4, wherein detection indicates resistance to immunotherapy.

[0080] In another aspect, the present invention provides for a method of detecting an immunotherapy resistance gene signature in a tumor comprising, detecting in tumor cells obtained from a subject in need thereof who has been treated with an immunotherapy the expression or activity of a malignant cell gene signature comprising: one or more down regulated genes selected from the group consisting of genes associated with coagulation, apoptosis, TNF-a signaling via NFKb, Antigen processing and presentation, metallothionein and IFNGR2; and/or one or more up regulated genes selected from the group consisting of genes associated with negative regulation of angiogenesis and MYC targets.

[0081] In another aspect, the present invention provides for a kit comprising reagents to detect at least one immunotherapy resistance signature gene or polypeptide according to the present invention. The kit may comprise at least one antibody, antibody fragment, or aptamer. The kit may comprise primers and/or probes for quantitative RT-PCR or fluorescently bar-coded oligonucleotide probes for hybridization to RNA.

[0082] It is noted that in this disclosure and particularly in the claims and/or paragraphs, terms such as "comprises", "comprised", "comprising" and the like can have the meaning attributed to it in U. S. Patent law; e.g., they can mean "includes", "included", "including", and the like; and that terms such as "consisting essentially of and "consists essentially of have the meaning ascribed to them in U.S. Patent law, e.g., they allow for elements not explicitly recited, but exclude elements that are found in the prior art or that affect a basic or novel characteristic of the invention.

[0083] These and other aspects, objects, features, and advantages of the example embodiments will become apparent to those having ordinary skill in the art upon consideration of the following detailed description of illustrated example embodiments.

BRIEF DESCRIPTION OF THE DRAWINGS

[0084] The following detailed description, given by way of example, but not intended to limit the invention solely to the specific embodiments described, may best be understood in conjunction with the accompanying drawings.

[0085] FIG. 1 - Study design and T cell analysis of ICR. (A) Overview. 31 samples from patients with metastatic melanoma (discovery cohort) were profiled by scRNA- sequencing (left), of which 15 were TN, 15 had ICI resistance (ICR) and one had clinical benefit (CB). Signatures were tested in two validation cohorts collected independently

(right), with bulk RNA-seq of melanoma tumors from 112 patients who underwent biopsies prior to receiving pembrolizumab (anti-PD-1; cohort 1) and from 26 patients, 12 with matched pre-treatment and post-progression (ICR) biopsies (cohort 2). (B-C) Distinct profiles of malignant and non-malignant cells. Shown are tSNE plots of single cell profiles

(dots) from malignant (B) or non-malignant (C) cells, shaded by post-hoc annotation

(materials and methods) or by patient. (D) Variation in T cells ICR. Shown is a tSNE plot of CD8 T cells that Applicants generated based on the genes of the tICR signatures, with cells shaded by treatment category (right), overall expression (OE) of the tICR signature

(middle), and clonality (right). Larger dots: cells from large (> 20 cells) clones. (E) Similar relationship between exhaustion and cytotoxicity signatures in TN and ICR CD8 T cells. For each cell (dot), the exhaustion (y axis) and cytotoxicity (x axis) scores are shown (materials and methods). : TN;: ICR;: CB. Cells from the CB patient have lower than expected exhaustion scores. (F) CD8 T cell clones. Shown is the distribution of clone sizes. Tumors with large (>20 cells) clones are marked. (G) Expanded clones have higher tICR expression.

Box plots show the distribution of tICR OE scores (y axis) in CD8 T-cells from patients stratified by clinical context and by overall clonality level. Left: only CD8 T-cells with reconstructed TCRs are shown; Right: only CD8 T-cells that were not from the three ICR patients with major clonal expansion are shown (right). Box-plots: the middle line represents the median; box edges are the 25 ^th and 75 ^th percentiles, and whiskers represent the most extreme points that do not exceed ±IQR* 1.5; points beyond the distance are plotted as single points. (H) CD8 T cell specific cell-cycle program. Shown are the distribution of OE scores for the CD8 specific cell cycle program in malignant cells (left) and CD8 T cells (right). The p-values were computed by comparing the cycling and non-cycling cells in each cell type with a one-sided t-test.

[0086] FIG. 2 - Malignant cell ICR programs. (A) Robust classification by the oncogenic-ICR signature. Left: Box-plot shows the distribution of OE scores for the oncogenic-ICR signature in malignant cells from ICR and TN patients, when obtained in a cross-validation (CV) procedure and tested on withheld data. Middle line: median; box edges: 25 ^th and 75 ^th percentiles, whiskers: most extreme points that do not exceed ±IQR* 1.5; further outliers are marked individually. Right: Receiver Operating Characteristic (ROC) curve of the performances of different signatures in classifying cells as ICR or TN; the CV oncogenic-ICR signature was obtained by leave-one (patient) out CV; the first and second Area under the curve (AUC) values are for classification of cells and samples, respectively. (B) Genes in the oncogenic-ICR program. Heatmap shows the (centered and scaled) expression of the top 40 oncogenic-ICR-up and oncogenic-ICR-down genes (columns) across the malignant cells (rows), sorted by TN or ICR tumors (shaded bar, left) and clustered within each class. Leftmost bar: cycling and non-cycling cells within each group. Right: The OE of the oncogenic-ICR signature for each cell. (C) Differentially expressed gene sets in ICR vs. TN malignant cells. Box-plots (formatted as in (A)) show the distribution of OE scores for each signature in malignant cells from ICR vs. TN tumors. (D-E) Inverse relationship of the oncogenic-ICR-down and -up programs. Shown are the OE scores of the oncogenic-ICR-down (y-axis) and oncogenic-ICR-up (x-axis) programs in (D) the single cell profiles from TN and ICR tumors, and in (E) lesions of cutaneous and uveal melanoma. The Pearson correlation coefficient (r) and p-value are marked. (F) Workflow for identification of the exclusion signatures. (G-H) Congruence between the oncogenic-ICR and exclusion programs. (G) Violin plots of the distribution of OE scores of exclusion signatures across malignant cells from ICR and TN patients. (H) Left: Heat map of the (centered and scaled) expression of the 40 most differentially expressed exclusion-up and exclusion-down (black) genes (columns) in the malignant cells (rows), sorted by ICR and TN tumors (left shaded bar) and clustered within class. Leftmost shaded bar labels cycling and non-cycling (black) cells within each group. Gene names in the oncogenic-ICR-up or oncogenic-ICR-down signatures (table 5) are marked by shading, respectively. Right: OE scores of the exclusion signature in each cell.

[0087] FIG. 3 - The uICR program has immune evasion properties, and can be reversed by CDK4/6 inhibition. (A-C) Reversal of resistance programs by a CDK4/6 inhibitor, abemaciclib. (A) Significance (y axis, -logio(p-value), Wilcoxon rank sum test) of induction (dark green) or repression (light green) of each signatures in tumors from abemaciclib treated mice compared to vehicle (37). (B) Distribution of uICR OE scores in breast cancer cell lines (M361, MCF and M453) treated with abemaciclib ("abe") or with DMSO vehicle ("con"). Box-plots: the middle line represents the median; box edges are the 25 ^th and 75 ^th percentiles, and whiskers represent the most extreme points that do not exceed ±IQR* 1.5; points beyond the distance are plotted as single points. (C) The relative expression of the 40 most differentially expressed uICR genes (rows) in abemaciclib-treated and control (purple) breast cancer cells lines (columns). Expression values are normalized according to the cell-line specific expression in the control state or denote over- or under- expression, respectively. Bottom: OE scores of the uICR signature for each cell line. (D) Higher uICR scores in uveal melanoma. Shown are the distributions of OE scores of the uICR program in cutaneous (black) vs. uveal melanoma tumors from TCGA, scored after filtering TME contributions (materials and methods). -value: t-test. (E) Suppression of cell-cell interactions in ICR. Bar plots show for each malignant signature (x-axis) the number of genes (y-axis, top) in the signature that can engage in a physical interaction with other cell types and the corresponding statistical enrichment (y-axis, -logio(P -value), hypergeometric test, bottom). Values above the dashed line are statistically significant.

[0088] FIG. 4 - The resistance signatures in malignant cells are prognostic and predictive in validation cohorts. (A) Resistance signatures predict melanoma patient survival based in bulk RNA-seq from TCGA (37). Kaplan-Meier (KM) plots are stratified by high (top 25%), low (bottom 25%), or intermediate (neither high nor low) expression of the respective signature. Pc p-values test if the signature further enhances the predictive power of models with T-cell infiltration levels as a covariate. See fig. 11 for additional signatures. (B, C) Resistance signatures distinguish clinical benefit (CB) and non-CB in mouse models and melanoma patients. Box plots show the distribution of the OE score of the uICR in bulk RNA-Seq from a lung cancer mouse model treated with anti-CTLA-4 therapy (35) (B) or from biopsies of melanoma patients prior to treatment with pembrolizumab (5). Middle line: median; box edges: 25th and 75th percentiles, whiskers: most extreme points that do not exceed ±IQR* 1.5; further outliers are marked individually. P-value: one-sided t-test. (D-F) Resistance signatures predict melanoma patient outcomes following pembrolizumab treatment from pre-treatment RNA-Seq in an independent cohort of 112 patients. (D) KM plots of progression-free survival (PFS) for the 104 patients in the cohort with available PFS data, when the patients are stratified by high (top 25%), low (bottom 25%), or intermediate (neither high nor low) expression of the respective signature. Prediction is enhanced when controlling for cell cycle as a confounder (two right plots, materials and methods). See figs. 12 to 13. (E) Bar plot shows predictive value for PFS for the 104 patients as in (D) with a COX regression model that accounts for inferred T-cell infiltration levels (-logio(p-value), x axis). Light bars: enhances PFS; grey bars: reduces PFS. Bars with black border denote the new signatures identified in this study for malignant resistance. Dashed line: p < 0.05. Resistance signatures are significantly more predictive compared to others (P = 3.37* 10 ^"6 , Wilcoxon-ranksum test)). (F) Distribution of OE scores (y axis) of each signature in the pre- treatment bulk RNA-Seq profiles, showing patients with either intrinsic resistance (Non-CB, n=49) or with clinical benefit (CB, n=39), with the latter also further stratified based on duration of response (CB < 6mo, n=5; 6mo < CB < 1 year, n=9; CB > 1 year, n=25). Twenty- four patients with unknown response or stable disease are not shown here (see fig. 14). Distinctions are enhanced when accounting for inferred T-cell infiltration levels (right). PI and P2 are the one-sided t-test p-value obtained when comparing the non-CB patients to the CB or CB > lyr patients, respectively. The AUC at the top was obtained when predicting long-term CB (CB > lyr) in all patients with a recorder response (n =101). Box plots formatted as in (B). (G) Box-plots show the distribution of OE scores (y axis) of each signature in the pre-treatment bulk RNA-Seq profiles, for patients with complete response (CR, n=14), partial response (PR, n=25), or progressive disease (PD, n=49). P is the onesided t-test p-value obtained when comparing the CR patients to the PR and PD patients. The AUC at the top was obtained when predicting CR in all patients with a recorder response (n =101). (H) Bar plot shows predictive value for predicting complete response with the different signatures ( ogio(t-test p-value), x-axis) in 101 patients with a recorded response. Light bars: positive impact; grey bars: negative impact. Bars with black border denote the new signatures identified in this study for malignant resistance. Dashed line: p = 0.05.

Resistance signatures are significantly more predictive compared to other signatures (P = 1.64* 10-8, Wilcoxon ranksum test). AUC values are marked next to the bar for each significant association. (I) Model for ICR based on this study.

[0089] FIG. 5 - Classification of malignant and non-malignant cells. (A) Inferred large-scale CNVs distinguish malignant (right) from nonmalignant (left) cells. Shown are the inferred CNVs (amplification, deletion) along the chromosomes (x axis) for cells (y axis) in two representative tumors. (B-E) Congruence between different assignment methods. (B) Each plot shows the relation between two different scorings, by showing for CD45 ^" cells the distribution of scores (y axis) by one scheme, stratified to two categories by another scheme. CNV: inference of malignant and non-malignant CD45 ^" cells as in (A, materials and methods); signature based: assignment of CD45 ^" cells as malignant or stroma by scoring the corresponding expression signatures (materials and methods); differential similarity to melanoma: assignment of CD45 ^" cells as malignant or non-malignant by similarity to bulk melanoma tumors compared to normal tissue. Middle line: median; box edges: 25th and 75th percentiles; whiskers: most extreme points that do not exceed ±IQR* 1.5; points beyond the distance: single points. (C) Distribution of CNV-R-score for cells identified as malignant and non-malignant. The CNV-R-score of a cell is defined as the Spearman correlation coefficient (r) between the cell's CNV profile and its tumor's inferred CNV profile (materials and methods). (D) The distribution of CNV-R-scores across each identified cell type. (E) The CNV-R-score (y axis) at each overall CNV signal (materials and methods) for malignant and non-malignant cells; Non-malignant cells with values that exceed the dashed lines were considered unresolved and were omitted from further analyses.

[0090] FIG. 6 - Non-malignant cells. Shown are tSNE plots of all non-malignant cells (dots), shaded by (A) OE scores (bar) of well-established cell type markers (table 26C), or (B) detection of CD4 or CD8 (CD8A or CD8B).

[0091] FIG. 7 - Cell type specific ICR signatures. Left panels: Box-plots show the distribution of OE scores for the ICR signature in each cell type in ICR and TN patients. Middle line: median; box edges: 25th and 75th percentiles; whiskers: most extreme points that do not exceed ±IQR* 1.5; points beyond the distance: single points. Middle and right panels: Receiver Operating Characteristic (ROC) curves of the performances of different signatures in classifying cells (middle) or samples (left) as ICR or TN. (A) Malignant cells, (B) CD4 T cells, (C) CD 8 T cells, (D) B cells, (E) macrophages.

[0092] FIG. 8 - Shift in the balance of cytotoxicity and exhaustion states in CD8

T-cells in the patient with CB. (A) The distribution of expression levels of each of five key checkpoint genes in CD8 T cells from ICR, TN, and CB tumors. (B) Distinct relationship between exhaustion and cytotoxicity signatures in CD8 T cells from a CB patient. For each cell (dot) shown are the cytotoxicity (x-axis) and exhaustion (y-axis) scores (materials and methods), using different exhaustion signatures from (7) and (77). TN; ICR; CB. Cells from the CB patient have lower than expected exhaustion scores (p-values, hypergeometric test materials and methods).

[0093] FIG. 9 - Clonal expansion of CD8 T cells. (A) TCR reconstruction Shown is the fraction (y-axis) of T-cells with one (a or β), both or no TCR chain reconstructed at full length (materials and methods). (B) Variation in CD8 T cell expansion across tumors. Violin plots show the distribution of estimated proportions of CD8 T cell clones in each tumor. Tumors are shaded by treatment group. The tumors of ICR patients have higher T-cell clonal expansion (P = 3.2* 10 ^"2 , one-sided Wilcoxon ranksum test). (C,D) Persistence of clones over time in one patient (Mel75). Shown are the number (C) and relative proportions (D) of cells in each clone for two post-ICI lesions collected, a year apart, from patient Mel75.

[0094] FIG. 10 - The relationship between the malignant ICR program and cell cycle. (A, B) Higher ICR in cycling cells. (A) Box plots of the distribution of OE scores of the oncogenic-ICR signatures (y-axis) in cycling and non-cycling cells from ICR and TN tumors (x-axis). The middle line represents the median; box edges are the 25 ^th and 75 ^th percentiles, and whiskers represent the most extreme points that do not exceed ±IQR* 1.5; points beyond the distance are plotted as single points. (B) Heatmap of the expression of ICR-up (bar) and down (black bar) genes (rows) that are also induced (repressed) in cycling vs. non-cycling malignant cells. Cells (columns) are sorted by TN and ICR tumors and clustered within each set (bar on top); the cells' cycling status in each category is marked by the bar on top. Bottom: Oncogenic ICR signature score (y axis) in each cell (x axis). (C) Abemaciclib represses the uICR program in breast cancer cell lines. Heatmap of the relative expression of all the uICR genes (rows) in Abemaciclib- treated and control breast cancer cells lines (columns), based on the data in (24). Gene expression is relative to the basal expression level in each cell line. Bottom: OE scores (y axis) of the uICR signature for each cell line (x axis).

[0095] FIG. 11 - The resistance signatures score in TCGA tumors predict survival of melanoma patients. Kaplan-Meier (KM) plots stratified by high, intermediate or low OE of the respective signature in bulk RNA-Seq of TCGA tumors. Pc p-values test if the signature further enhances the predictive power of models with inferred T-cell infiltration levels as a covariate.

[0096] FIG. 12 - The resistance signature scores in pre-treatment biopsies predict response to anti-PD-1 therapy in an independent cohort. KM plots of progression-free survival (PFS) for the 104 of 112 patients in validation cohort 1 with PFS data, with patients stratified by high, intermediate and low OE score of the respective signature. Pc p-values test if the signature further enhances the predictive power of models with inferred T cell infiltration levels as a covariate.

[0097] FIG. 13 - The predictive performance of resistance signatures is enhanced when controlling for the cell cycle. KM plots of progression-free survival (PFS) for the 104 of 112 patients in validation cohort 1 with PFS data, with patients stratified by high, intermediate and low OE score of the respective, after controlling for cell cycle as a confounding factor (materials and methods).

[0098] FIG. 14 - The expression of the resistance signatures in 101 melanoma patients, stratified according to their clinical response to pembrolizumab.

Distribution of OE scores (y axis) of each signature in the pre-treatment bulk RNA-Seq profiles, showing overall lOlpatients with complete response (CR, n = 14), partial response or stable disease (PR/SD, n = 38), or progressive disease (PD, n = 49). P is the one-sided t-test p-value obtained when comparing the CR patients to the PR, SD and PD patients. AUC is also marked on top. Middle line: median; box edges: 25 ^th and 75 ^th percentiles; whiskers: most extreme points that do not exceed ±IQR* 1.5.

[0099] FIG. 15 - Pan-cancer analysis of the resistance signatures. Box-plots of the distribution of OE scores (x-axis) of the uICR signature in bulk RNA-seq profiles of 9,559 tumors across 33 cancer types (y-axis) from TCGA either scored (A) "as-is" or (B) with a regression-based process to control for TME-related signals (materials and methods). Middle line: median; box edges: 25th and 75th percentiles; whiskers: most extreme points that do not exceed ±IQR* 1.5; points beyond the distance: single points.

[0100] FIG. 16 - An unbiased analysis reveals a malignant cell state linked to ICR.

[0101] FIG. 17 - An overview of the patients analyzed.

[0102] FIG. 18 - Separation of immunotherapy treated and untreated tumors by Principle Component (PC) analysis. [0103] FIG. 19 - Correlation between the resistance signature and patients that are naive or resistant to immunotherapy.

0104] FIG. 20 - A leave-one-out cross validation analysis.

0105] FIG. 21 - Mutual exclusive expression of the ITR up and down genes across malignant cells, and their anti -correlation in TCGA.

0106] FIG. 22 - Correlation between the resistance signature and MHC-I expression. 0107] FIG. 23 - Association of metallothionein expression and treated and untreated subjects.

0108] FIG. 24 - Association of the resistance signature with prognosis.

0109] FIG. 25 - The resistance signature compared to other single-cell based signatures. 0110] FIG. 26 - The ITR signature is predictive of eventual outcome in both mouse and human data.

0111] FIG. 27 - Association of complete responders and non-complete responders to genes up-regulated post-treatment with immunotherapy.

0112] FIG. 28 - Association of complete responders and non-complete responders to genes down-regulated post-treatment with immunotherapy.

0113] FIG. 29 - Malignant cells ITR signatures have higher exclusion signatures and treatment naive malignant cells have higher infiltration signatures.

0114] FIG. 30 - Analysis of CD 8 T cells.

0115] FIG. 31 - Analysis of CD8 T cells.

0116] FIG. 32 Analysis of CD 8 T cells.

0117] FIG. 33 - The CD8 ITR signature is strongly associated with clonal expansion. 0118] FIG. 34 - An interaction map of genes in the ITR signature and immune and stromal genes.

0119] FIG. 35 - The number of interactions between differentially expressed malignant genes and immune and stromal genes.

0120] FIG. 36 - ITR versus T cell scores in different cancers.

0121] FIG. 37 - ITR scores in two melanomas.

0122] FIG. 38 - tS E analysis of ER+ metastatic breast cancer using single nuclei

RNA-seq (snRNA-seq) on fresh and frozen tissue samples.

0123] FIG. 39 - tSNE analysis of 22 colon cancer samples using scRNA-seq.

0124] FIG. 40 - The expanded T cell state is highly correlated with the overall T cell infiltration level of tumors in an independent lung cancer cohort (Table 10). [0125] FIG. 41 - CDK4/6 inhibitors sensitize melanoma cells.

[0126] FIG. 42 - CDK4/6 inhibitors induce markers of differentiation, senescence and immunogenicity in melanoma.

[0127] FIG. 43 - CDK4/6 inhibitors eliminate a resistant subpopulation of melanoma cells.

[0128] FIG. 44 - Identification of a T cell exclusion program in malignant cells. (A)

Study overview. 31 tumors from melanoma patients (discovery cohort) were profiled by scRNA-seq (left, tan) and integrated analytically with bulk RNA-Seq data from TCGA (473 melanoma tumors). The discovered program was tested in two validation cohorts of bulk RNA-Seq collected independently (right). (B) Analysis approach to discover malignant cell programs associated with immune cell infiltration or exclusion. (C-D) Distinct profiles of malignant and nonmalignant cells. tSNE plots of single cell profiles (dots) from malignant (C) or nonmalignant (D) cells, shaded by post-hoc annotation (Methods, D left) or by tumor (C, D right). (E) Exclusion program. Expression (centered and scaled; bar) of the top genes (columns) in the exclusion program across the malignant cells (rows), sorted by untreated or post-treatment tumors (bar, left) and clustered within each class. Leftmost bar: cycling and non-cycling cells within each group. Right: The overall expression (Methods) of the exclusion program in each cell. See also FIG. 51 and Tables 1,2 and 26C.

[0129] FIG. 45 - Exclusion and resistance programs characterizing individual malignant cells from patients who failed immunotherapy. (A) Post-treatment program in malignant cells. Left: The Overall expression (Methods) of the post-treatment program in malignant cells from post-treatment and untreated patients, when obtained in a cross- validation (CV) procedure and tested on withheld data. Middle line: median; box edges: 25 ^th and 75 ^th percentiles, whiskers: most extreme points that do not exceed ±IQR* 1.5; further outliers are marked individually. Right: Receiver Operating Characteristic (ROC) curve of the performances of different programs in classifying cells as post-treatment or untreated; the CV post-treatment signature was obtained by leave-one (patient) out CV; the first and second Area Under the Curve (AUC) values are for classification of cells and samples, respectively. (B) Significant overlap between the exclusion and post-treatment programs. Venn diagram of the number of genes in each program and in their overlap. P-value: hypergeometric test. (C) Program genes. Expression (centered and scaled, bar) of the top genes (columns) in the post- treatment program across the malignant cells (rows), sorted by untreated or post-treatment tumors (bar, left) and clustered within each class. Leftmost bar: cycling and non-cycling cells within each group. Right: overall expression of the post-treatment program in each cell. (D) Repressed and induced processes. The distribution of overall expression scores of differentially expressed gene sets in malignant cells from post-treatment and untreated (gray) tumors (formatted as in (A)). (E) The exclusion program is higher in post-treatment malignant cells. The distribution of overall expression scores of the exclusion program in malignant cells from post-treatment and untreated (gray) tumors. See also Tables 5 and 8.

[0130] FIG. 46 - The resistance program is a coherently regulated module that represses cell-cell interactions. (A) The immune resistance program is higher in uveal vs. cutaneous melanoma. The distribution of overall expression scores of the immune resistance program in cutaneous vs. uveal melanoma tumors from TCGA, scored after filtering tumor microenvironment contributions (Methods). (B) Cell-cell interaction genes are repressed in the immune resistance program. The number of genes (y axis, top) in each part of the program encoding proteins that engage in a physical interaction with other cell types and the significance of the corresponding enrichment (y axis, -logio(P -value), hypergeometric test, bottom). Values above the dashed line are statistically significant. (C-D) Co-regulation of the immune resistance program. (C) The overall expression of the induced (x axis) and repressed (y axis) parts of the immune resistance programs in each malignant cell (top, scRNA-seq data) and in cutaneous melanoma tumors (bottom, TCGA RNA-Seq data, after filtering tumor microenvironment signals). The Pearson correlation coefficient (r) and p-value are marked. (D) Gene-gene Pearson correlation coefficients (bar) between the genes in the resistance program, across individual malignant cells from the same tumor (top, average coefficient) or across cutaneous melanoma tumors from TCGA skin (bottom, after filtering tumor microenvironment effects). See also FIG. 52.

[0131] FIG. 47 - The resistance program is associated with the cold niche in situ. (A-

B) Multiplex imaging relates resistance program genes to hot or cold niches. Malignant cells expressing high or low/moderate protein levels of HLA-A (A) and c-Jun (B) and their proximity to CD3 ⁺ T cells or CD3 ⁺ CD8 ⁺ T cells in three representative tumors. (C) Congruence of multiplex protein and scRNA-seq profiles. Left and middle: tS E plots of co- embedding of cells from the scRNA-seq data and the images of a specific tumor (Mel 112; others shown in FIG. 53), with cells shaded by clusters (top left), data source (bottom left), and source and cell type (right). Right: Log-odds ratio (bar, Methods) assessing for each pair of cell types (rows, columns) if they are assigned to the same cluster significantly more (>0) or less (<0) than expected by chance. See also FIG. 53.

[0132] FIG. 48 - The resistance program is prognostic and predictive in validation cohorts. (A) The program predicts melanoma patient survival based on bulk RNA-Seq from TCGA (Akbani et al., 2015). Kaplan-Meier (KM) plots stratified by high (top 25%), low (bottom 25%)), or intermediate (remainder) expression of the respective program subset. P: COX regression p-value; Pc: COX regression p-value that tests if the program further enhances the predictive power of a model with inferred T cell infiltration levels as a covariate. (B, C) Resistance signatures distinguish responders and non-responders in mouse models and melanoma patients. The distribution of overall expression of the resistance program in bulk RNA-Seq from (B) a lung cancer mouse model treated with anti-CTLA-4 therapy (Lesterhuis et al., 2015) or (C) biopsies of melanoma patients collected prior to treatment with pembrolizumab (Hugo et al., 2016). Middle line: median; box edges: 25 ^th and 75 ^th percentiles, whiskers: most extreme points that do not exceed ±IQR* 1.5; further outliers are marked individually. (D-F) The program predicts melanoma patient outcomes following pembrolizumab treatment from pre-treatment RNA-Seq in an independent cohort of 112 patients. (D) KM plots of progression-free survival (PFS) for the 104 patients in the cohort with available PFS data, stratified by high (top 25%), low (bottom 25%), or intermediate (remainder) expression of the respective program subset. (E) Predictive value for PFS (- logio(p-value), x axis, COX regression model that accounts for inferred T cell infiltration levels) for the 104 patients in (D). Bars: positive/negative correlation between expression and PFS. Black border: subsets of the resistance program. Dashed line: p = 0.05. (F) Overall expression of the resistance program (y axis) in the pre-treatment bulk RNA-Seq profiles of patients with intrinsic resistance (Non-CB, n=49) or clinical benefit (CB, n=39), latter further stratified by response duration (CB < 6mo, n=5; 6mo < CB < 1 year, n=9; CB > 1 year, n=25). Twenty four patients with unknown response or stable disease are not shown here. PI and P2: one-tailed t-test p-value when comparing the non-CB patients to the CB or to CB > lyr patients, respectively. AUC for predicting CB > lyr in all patients with a recorded response (n = 101) is denoted. Box plots formatted as in (B). (G) Overall expression values of the resistance program (y axis) in the pre-treatment bulk RNA-Seq profiles of patients with complete response (CR, n = 14), partial response (PR, n = 25), or progressive disease (PD, n = 49). P: one-tailed t-test p-value comparing CR patients to PR and PD patients. AUC for predicting CR in all patients with a recorded response (n = 101). (H) Predictive value of different signatures for complete response ( ogio(t-test p-value), x axis) in 101 patients with a recorded response. Bars: expression associated with CR/non-CR, respectively. Black border: subsets of the resistance program. Dashed line: p = 0.05. AUC values are marked next to the bar for each significant association. See also FIG. 54, 55, 57 and Table 10.

[0133] FIG. 49 - The resistance program can be reversed by CDK4/6 inhibition. (A- C) Impact on breast cancer tumors and cell lines. (A) Significance (y axis, -logio(p-value), Wilcoxon rank sum test) of induction (dark green) or repression (light green) of the program subsets in breast cancer tumors from abemaciclib treated mice compared to vehicle (Goel et al., 2017). (B) Overall expression of the program in breast cancer cell lines (M361, MCF and M453) treated with abemaciclib ("abe") or with DMSO vehicle ("con"). Middle line: median; box edges: 25 ^th and 75 ^th percentiles, whiskers: most extreme points that do not exceed ±IQR* 1.5; further outliers are marked individually. P-value: paired t-test. (C) Expression of 40 program genes (columns; shaded bar) that were most differentially expressed in abemaciclib-treated vs. control breast cancer cells lines (rows). Expression is normalized to each cell line's control. Right: overall expression values of the program for each cell line. (D- G) CDK4/6 inhibition reverses the program in melanoma cell lines and induces the SASP. (D,E) tS E plots of 4,024 IGR137 (D) and 7,340 UACC257 (E) melanoma cells, shaded by (left to right): treatment, clusters, or the expression of a cell cycle signature, resistance program, MITF signature, SASP signature and DNMTI. (F) Concentration (pg/ml, y axis) of secreted chemokines in the supernatant of melanoma cells treated for 7 days with abemaciclib (500 nM) or with DMSO control. ^** P<0.01, ^*** P<0.001 t-test. (G) Senescence associated alpha-galactosidase activity and morphological alterations in melanoma cells treated for 10 days with abemaciclib (500 nM, right) vs. DMSO control (left). See also FIG. 56 and Table 23.

[0134] FIG. 50 - Immune resistance model. Malignant cells that evade the immune system have a unique transcriptional state, which distinguishes between responders and non- responders to immunotherapy. This state is tightly linked to the exclusion of T cells from the tumor, the repression of SASP and cell-cell communication routes, and the inhibition of cytokine secretion. CDK4/6 inhibition can reverse this state in malignant cells.

[0135] FIG. 51 - Assignment of cells into cell types by scRNA-seq; related to FIG. 44. (A) Inferred large-scale CNVs distinguish malignant from nonmalignant cells. Shown are the inferred CNVs (amplification, deletion) along the chromosomes (x axis) for cells (y axis) in two representative tumors partitioned as malignant (left) or nonmalignant (right) by CD45 sorting and transcriptional features. (B-E) Congruence between different assignment methods. (B) Each plot shows the relation between two different scorings, by showing for CD45 ^" cells the distribution of scores (y axis) by one scheme, stratified to two categories by another scheme. CNV: inference of malignant and nonmalignant CD45 ^" cells (as in A, Methods); signature based: assignment of CD45 ^" cells as malignant or stroma by scoring the corresponding expression signatures (Methods); differential similarity to melanoma: assignment of CD45 ^" cells as malignant or nonmalignant by similarity to bulk melanoma tumors compared to normal tissue. Middle line: median; box edges: 25 ^th and 75 ^th percentiles, whiskers: most extreme points that do not exceed ±IQR* 1.5; further outliers are marked individually. (C) Distribution of CNV-R-scores for cells called as malignant or nonmalignant. The CNV-R-score of a cell is the Spearman correlation coefficient (r) between the cell's CNV profile and its tumor's inferred CNV profile (Methods). (D) The distribution of CNV-R-scores across each identified cell subset. Box plots as in (B). (E) The CNV-R- score (y axis) vs. the overall CNV signal (x axis, Methods) for malignant and nonmalignant cells; Nonmalignant cells with values that exceed the dashed lines were considered unresolved and were omitted from further analyses. (F-G) tSNE plots of all nonmalignant cells (dots), shaded by (F) overall expression (bar) of well-established cell type markers (Table 26C), or (G) detection of CD4 or CD8 (CD8A or CD8B).

[0136] FIG. 52 - Co-variation of the resistance signature genes across single cells within each tumor; related to FIG. 46. Gene-gene Pearson correlation coefficients (bar) between the genes in the resistance program, across individual malignant cells from each specific tumor (as labeled). Genes are sorted in the same order in all heatmaps (and in FIG. 46D). The consistent intra-tumor correlation suggests shared regulation.

[0137] FIG. 53 - Integrative analysis of scRNA-seq and spatial multiplex protein IHC data; related to FIG. 47. (A-D) Integrative analysis of scRNA-seq and CyCIF multiplex protein data from each of four tumors: (A) Mel79, (B) Mel80, (C) Mel74, and (D) Mel89. Left: tSNE plots of co-embedding of cells from scRNA-seq and images of each tumors, with cells shaded by (from left): clusters, data source, or source and cell type. Right: Log-odds ratio (bar, Methods) assessing for each pair of cell types (rows, columns) if they are assigned to the same cluster significantly more (>0) or less (<0) than expected by chance. [0138] FIG. 54 - The immune resistance program predicts survival of TCGA melanoma patients; related to FIG. 48. Kaplan-Meier (KM) plots stratified by high, intermediate or low Over expression of the respective signature in bulk RNA-Seq of TCGA tumors. P: COX regression p-value; Pc: COX regression p-value that tests if the program further enhances the predictive power of a model with inferred T cell infiltration levels as a covariate.

[0139] FIG. 55 - The immune resistance program predicts response to anti-PD-1 therapy in an independent cohort; related to FIG. 48. (A-E) KM plots of progression- free survival (PFS) for the 104 of 112 patients in validation cohort 2 with PFS data, with patients stratified by high, intermediate and low over expression values of the respective signature, after controlling for cell cycle as a confounding factor (Methods). Pc p-values test if the signature further enhances the predictive power of models with inferred T cell infiltration levels as a covariate. (F) Distribution of overall expression values (y axis) of each signature in the pre-treatment bulk RNA-Seq profiles, showing overall 101 patients with either complete response (CR, n = 14), partial response/stable disease (PR/SD, n = 38), or progressive disease (PD, n = 49). P is the one-sided t-test p-value obtained when comparing CR patients vs. PR, SD and PD patients. AUC is also marked on top. Middle line: median; box edges: 25 ^th and 75 ^th percentiles, whiskers: most extreme points that do not exceed ±IQR* 1.5; further outliers are marked individually.

[0140] FIG. 56 Relationship between the resistance program and cell cycle; related to FIG. 49.. (A, B) Higher expression of the resistance program in cycling cells. (A) Distribution of overall expression values of the resistance program (y axis) in cycling and non-cycling cells from either post-treatment or untreated tumors (x axis). Solid line: mean of the respective distribution; dashed line: mean across all malignant cells. (B) Expression of genes from the resistance program (rows) that are also differentially expressed in cycling vs. non-cycling malignant cells. Cells (columns) are sorted by untreated and post-treatment tumors and clustered within each set (bar on top); the cells' cycling status in each category is marked by the bar on top. (C) Abemaciclib represses the resistance program in breast cancer cell lines. The relative expression of all genes in the resistance program (rows) in abemaciclib-treated and control breast cancer cells lines (columns), based on the data in (Goel et al., 2017). Expression levels are relative to the basal expression level in each cell line. Bottom: overall expression (y axis) of the resistance program in each cell line (x axis).

[0141] FIG. 57 - Pan-cancer analysis of the resistance program; related to FIG. 48. (A-B) Overall expression of the resistance program (x axis) in 9,559 tumors from 33 cancer types (y axis) from TCGA. In (B) a regression-based approach controls for tumor microenvironment-related signals (Methods). Middle line: median; box edges: 25 ^th and 75 ^th percentiles, whiskers: most extreme points that do not exceed ±IQR* 1.5; further outliers are marked individually.

[0142] FIG. 58 - B16 Study design. Mouse study using checkpoint inhibitors and CDK4/6 inhibitors.

[0143] FIG. 59 - Growth curves. B16 implanted mice were treated as indicated and tumor growth was measured.

[0144] FIG. 60 - Survival curves. B16 implanted mice were treated as indicated and survival was measured.

[0145] FIG. 61 - Growth curves. (A-C) Additional growth curves at day 4 (B) and day 7 (C). CD8 depletion shows dependence on CD8 T cells.

[0146] FIG. 62 - Identification of a T cell exclusion program in malignant cells. (A)

Study overview. (B) Method to discover malignant cell programs associated with immune cell infiltration or exclusion. (C,D) Distinct profiles of malignant and non-malignant cells. tS E of single cell profiles (dots) from malignant (C) or non-malignant (D) cells, shaded by post-hoc annotation (D left) or by tumor (C, D right). In (C) only tumors with at least 50 malignant cells are shown. (E) Exclusion program. Expression (centered and scaled; bar) of the top genes (columns) in the exclusion program across malignant cells (rows), sorted by untreated or post-treatment tumors (bar, left). Leftmost bar: cycling and non-cycling (black) cells. Right: Overall Expression (OE) (Methods) of the exclusion program. See also Figures 69-70 and Tables 24-27

[0147] FIG. 63 - Exclusion and resistance programs characterizing individual malignant cells from patients with resistance to ICI. (A) Post-treatment program in malignant cells. Left: OE of the post-treatment program in malignant cells from post- treatment and untreated patients, tested on withheld data (Methods). Middle line: median; box edges: 25 ^th and 75 ^th percentiles, whiskers: most extreme points that do not exceed §|IQR* 1.5; further outliers are marked individually. Right: The performances of different programs in classifying cells as post-treatment or untreated; the first and second Area Under the Curve (AUC) values are for classifying cells and samples, respectively. (B) Significant overlap between the exclusion and post-treatment programs. (C) Expression (centered and scaled, bar) of the top genes (columns) in the post-treatment program across malignant cells (rows), sorted by untreated or post-treatment tumors (bar, left). Leftmost bar: cycling and non-cycling cells. Right: OE of the post-treatment program. (D) Distribution of OE scores (as in (A)) of differentially expressed gene sets in malignant cells from post-treatment and untreated tumors. (E) Distribution of OE scores (as in (A)) of the exclusion program in malignant cells from post-treatment and untreated tumors. See also Figure 70 and Tables 27- 28.

[0148] FIG. 64 - The resistance program is a coherently regulated module that represses cell-cell interactions. (A) Distribution of program OE scores in cutaneous vs. uveal melanoma from TCGA, after filtering microenvironment contributions (Methods). (B) Right: Number of genes in each part of the program that mediate physical interactions with other cell types, and the significance of the corresponding enrichment. Dashed line: statistical significance. (C-D) Co-regulation of the program. (C) OE of the induced and repressed parts of the immune resistance programs in malignant cells (left, scRNA-seq data) and cutaneous melanoma tumors (right, TCGA RNA-Seq data, after filtering microenvironment signals). Pearson correlation coefficient (r) and p-value are marked. (D) Pearson correlation coefficients (bar) between the program's genes, across malignant cells from the same tumor (left, average coefficient) or across cutaneous melanoma from TCGA (right, after filtering microenvironment effects). See also Figure 71.

[0149] FIG. 65 - The resistance program is associated with the cold niche in situ. (A,B) Congruence of in situ multiplex protein and scRNA-seq profiles. (A) Co- embedding of profiles from scRNA-seq and multiplex imaging of the Mel 112 tumor (others in Figure 72), with cells shaded by clusters (top left), data source (bottom left), or source and cell type (right). (B) Log-odds ratio (bar, Methods) assessing for each pair of cell types (rows, columns) if they are assigned to the same cluster significantly more (>0) or less (<0) than expected by chance. (C-D) Multiplex imaging relates program genes to hot or cold niches. Malignant cells expressing high or low/moderate levels of the MHC Class I (C) and c-Jun (D) proteins and their proximity to CD3 ⁺ T cells or CD3 ⁺ CD8 ⁺ T cells in three representative tumors. See also Figure 72.

[0150] FIG. 66 - The resistance program is prognostic and predictive in validation cohorts. (A) The program predicts melanoma patient survival in bulk RNA-Seq from TCGA. Kaplan-Meier (KM) curves stratified by high (top 25%), low (bottom 25%), or intermediate

(remainder) OE of the respective program. Number of subjects at risk indicated at the bottom of the KM curves for five time points. P: COX regression p-value; Pc: COX regression p- value that tests if the program enhances the predictive power of a model with inferred T cell infiltration levels as a covariate. (B, C) Distribution of OE of the resistance program in bulk tumors from (B) a lung cancer mouse model treated with anti-CTLA-4 therapy (Lesterhuis et al., 2015) or (C) melanoma patients prior to pembrolizumab treatment (Hugo et al., 2016).

Middle line: median; box edges: 25 ^th and 75 ^th percentiles, whiskers: most extreme points that do not exceed fflQR* 1.5; outliers are marked individually. (D-F) The program predicts ICI responses in Validation cohort 2. (D) KM plots for PFS for the 104 patients in the cohort with available PFS data, stratified by high (top 25%), low (bottom 25%), or intermediate

(remainder) OE of the respective program (Methods). (E) OE of the resistance program (y axis) in the pre-treatment profiles of patients with intrinsic resistance (PD, n = 49) or objective response (OR, n = 39), the latter further stratified by response duration. Patients with unknown response or stable disease are not shown. PI and P2: one-tailed t-test p-value when comparing the PD patients to all the OR patients or to OR > lyr patients, respectively.

AUC for predicting OR > lyr in all patients with a recorded response (n = 101) is denoted.

Formatted as in (B). (F) OE scores of the resistance program (y axis) in the pre-treatment bulk RNA-Seq profiles of patients with complete response (CR, n = 14), partial response

(PR, n = 25), or progressive disease (PD, n = 49). P: one-tailed t-test p-value comparing CR patients to PR and PD patients. AUC for predicting CR in all patients with a recorded response (n = 101). (G,H) Predictive value (y axis) compared to alternative signature-based predictors. Blue/grey bars: signatures positively/negatively associated with response. Black outline of bars: subsets of the resistance program denoted with numbered legends at the bottom. Dashed line: p = 0.05. (G) Predictive value for PFS (P ^c as in (D), STAR Methods).

(H) Predictive value for complete response. See also Figures 73-74 and Table 29.

[0151] FIG. 67 - The resistance program can be reversed by CDK4/6 inhibition. (A)

OE of the resistance program across cancer cell lines which are resistant or sensitive to both abemaciclib and palbociclib. (B-D) Impact of CDK4/6i on breast cancer tumors and cell line profiles. (B) Significance (y axis, -log ¹⁰ (p-value), Wilcoxon rank sum test) of induction

(dark) or repression (light) of the program subsets in tumors from abemaciclib treated mice compared to vehicle (Goel et al., 2017). (C) OE of the program in cell lines (M361, M453, and MCF) treated with abemaciclib ("abe") or with DMSO vehicle ("con"). Middle line: median; box edges: 25 ^th and 75 ^th percentiles, whiskers: most extreme points that do not exceed §jlQR* 1.5; outliers are marked individually. -value: paired t-test. (D) Expression of 40 program genes (columns) that were most differentially expressed in abemaciclib-treated vs. control (purple) cells lines (rows) (Methods). Expression is normalized in each cell line. Right: OE scores for each cell line. (E-H) CDK4/6i reverses the program in RBI -sufficient melanoma cell lines and induces the SASP. (E,F) tS E of 4,024 IGR137 (E) and 7,340 UACC257 (F) melanoma cells, shaded by (1) treatment, (2) clusters, or the expression of (3) cell cycle signature, (4) resistance program, (5) MITF signature, (6) SASP signature and (7) DNMT1. (G) Concentration (pg/ml, y axis) of secreted chemokines in the supernatant of melanoma cells treated for 7 days with abemaciclib (500 nM) or with DMSO control. ^** P<0.01, ^*** P<0.001 t-test (Table 30B). (G) Senescence-associated β -galactosidase activity and morphological alterations in melanoma cells treated for 10 days with abemaciclib (500 nM, right) vs. DMSO control (left). See also Figure 75 and Table 30.

[0152] FIG. 68 - CDK4/6 inhibition combined with immunotherapy improves response and survival in vivo. (A) Study design. n=9-19 per treatment group. (B) Rate of tumor outgrowth (ratio for every graph) is reduced in animals treated with phased combination (ICI followed by ICI plus abemaciclib) and (C) results in higher survival rates compared to other treatments. (D) Immune resistance model. See also Figure 75.

[0153] FIG. 69 - Cell type assignments; related to Figure 62. (A) Inferred large-scale CNVs distinguish malignant from nonmalignant cells. The inferred CNVs (amplification; deletion) of two representative tumors (Mel79 and Mel 102) are shown along the chromosomes (x axis) for cells (y axis) that were classified as malignant (left) or non- malignant (right) according CD45 sorting and transcriptional features. (B-E) Congruence between different assignment methods (Methods). (B) Each plot shows the distribution of scores (y axis) by one scheme, when assigning the CD45 ^" cells to malignant and nonmalignant cells according to anther scheme. Each scheme evaluates the likelihood that a given cell is malignant in a different way: CNV inference (as in A); the overall expression of melanoma and stroma cell signatures; differential similarity to bulk melanoma tumors compared to normal tissue. Middle line: median; box edges: 25 ^th and 75 ^th percentiles, whiskers: most extreme points that do not exceed |lQR* 1.5; further outliers are marked individually. (C) Distribution of CNV-R-scores for cells classified as malignant or nonmalignant. The CNV-R-score of a cell is the Spearman correlation coefficient (r ⁵ ) between the cell's CNV profile and its tumor's inferred CNV profile (Methods). (D) The distribution of CNV-R-scores across each identified cell subset. Box plots as in (B). (E) The CNV-R- score (y axis) vs. the overall CNV signal (x axis, Methods) for malignant and non-malignant cells; Nonmalignant cells with values that exceed the dashed lines were considered unresolved and were omitted from further analyses. (F-G) tSNE plots of all non-malignant cells (dots), shaded by (F) overall expression (bar) of de novo cell type signatures (Table 26B), and (G) detection of T cell markers CD4 or CD8 (CD8A or CD8B), and B cell markers (CD19 and CD22).

[0154] FIG. 70 - The immune resistance program is robust to varying definitions of T cell infiltration and can be decoupled from cell cycle; related to Figures 62-63. (A-C)

Congruence between the transcriptional programs in malignant that are associated with the exclusion of different T cell subsets. (A) The inferred abundance of different T cell subsets is highly correlated across TCGA melanoma tumors. Pearson correlation coefficient (bar) between the inferred proportions of T cells of different subsets. (B,C) Overlap (B, Jaccard similarity coefficient) and correlation in expression across melanoma cells (C, left) or bulk tumors (C, middle and right) between malignant cell programs associated with the exclusion of different T cell subsets (rows, columns). (D) Congruence between exclusion programs derived with and without controlling for the cell cycle. Venn diagrams show the number of genes shared in upregulated (left) and downregulated (right) portions of indicated programs when they are derived with (top) and without (bottom) regressing out cell cycle from the scRNA-seq and bulk RNA-Seq data. (E) Resistance program is stronger in cycling cells even when filtering cell cycle effects. The distribution of Overall Expression scores of the resistance program (y axis) derived with (right) and without (left) filtering out cell cycle effects (Methods). Solid line: mean of the respective distribution; dashed line: mean across all malignant cells. (F-G) Regression of cell cycle effects masks differences between cycling and non-cycling cells, but preserves differences in the resistance program. (F) Expression of cell cycle genes (columns) across the malignant cells (rows), with (left) and without (right) regressing out cell cycle. Cells are sorted as cycling or non-cycling (red/black, respectively; leftmost bar). (G) Expression of genes in the exclusion (right) and post-treatment (left) programs (columns), after regressing out cell cycle from the data. Cells (rows) are sorted by untreated and post-treatment tumors (right bar) and clustered within each set; rightmost bar: cycling status. [0155] FIG. 71 - Co-variation of the immune resistance program genes across single cells within each tumor; related to Figure 64. Gene-gene Pearson correlation coefficients (bar) between the genes in the resistance program, across individual malignant cells from each specific tumor (as labeled). Genes are sorted in the same order in all heatmaps (and in Figure 64D). The consistent intra-tumor correlation suggests shared regulation.

[0156] FIG. 72 - Integrative analysis of scRNA-seq and in situ immunofluorescence data; related to Figure 65. (A-D) Integrative analysis of scRNA-seq and CyCIF multiplex protein data (Methods) from each of four representative tumors: (A) Mel79, (B) Mel80, (C) Mel74, and (D) Mel89. Left: tS E plots of co-embedding of cells from scRNA-seq and images of each tumors, with cells shaded by (from left): clusters, data source, or combined source and cell type. Right: Log-odds ratio (bar, STAR Methods) assessing for each pair of cell types (rows, columns) if they are assigned to the same cluster significantly more (>0) or less (<0) than expected by chance.

[0157] FIG. 73 - The immune resistance program predicts survival of TCGA melanoma patients; related to Figure 66. (A-D) Kaplan-Meier (KM) plots stratified by high, intermediate or low Overall Expression of the respective signature in bulk RNA-Seq of TCGA tumors. P: COX regression p-value; Pc: COX regression p-value that tests if the program further enhances the predictive power of a model with inferred CD8 ⁺ T cell infiltration levels as a covariate compared to its prognostic value alone (E). The number of subjects at risk are indicated for each group at the bottom of the KM curves for five different time points.

[0158] FIG. 74 - The immune resistance program predicts response to anti-PD-1 therapy in an independent cohort; related to Figure 66. (A-E) KM plots of progression- free survival (PFS) for the 104 of 112 patients in validation cohort 2 with PFS data, with patients stratified by high, intermediate and low Overall Expression values of the respective signature (labeled on top, see Tables 24C), after controlling for cell cycle as a confounding factor (Methods). Pc p-values test if the signature further enhances the predictive power of models with inferred CD8 ⁺ T cell infiltration levels as a covariate. The number of subjects at risk are indicated for each group at the bottom of the KM curves for six different time points.

[0159] FIG. 75 - The immune resistance program in cell cultures, mouse cell lines, and various tumor types; related to Figures 67-68. (A) The distribution of the immune resistance scores across three human melanoma cell lines, in control conditions and following abemaciclib treatment. (B) The transcriptional state of patient-derived melanoma cells grown in monoculture or in co-culture with autologous ex vivo expanded TILs, with and without abemaciclib; right: tS E plots; left: the fraction of immune resistant and sensitive cells in each condition. (C,D) Differences in expression of the resistance program are aligned with the different level of resistance of mouse cell line models to ICI. (C) Distribution of Overall Expression of the resistance program (x axis) across single cells of three mouse cell lines (B16, CT26 and MC38) grown in in vitro monocultures. (D) Heatmap (bottom) shows genes (rows) from the immune resistance program that are differentially expressed between MC38 (bar), CT26 (green bar) and B16 (red bar) cells (columns) by the comparisons indicated on the left bar and legend; cells are first sorted by model and then by Overall Expression of the resistance program (top); the corresponding cell cycle score are shown in the middle panel. (E,F) To test the effect of CD8+ T cell depletion on response to phased combination of CDK4/6i and immunotherapy. B16 cells were implanted in C7BL/6 mice and treated with either vehicle control (n=5), phased combination of ICI and abemaciclib (n=10) or phased combination following CD8+ T cell depletion (n=9, STAR Methods). (E) The reduction in tumor outgrowth rate seen with phased therapy is lost in animals without CD8+ T cells. (F) KM survival curves of animals in (E). (G,H) The resistance program across tumor types. Distribution of Overall Expression scores of the resistance program (x axis) in 9,559 tumors from 33 cancer types (y axis) from TCGA, either scored as-is (G) or with a regression-based approach that controls for tumor microenvironment-related signals (H, Methods). Middle line: median; box edges: 25 ^th and 75 ^th percentiles, whiskers: most extreme points that do not exceed j§IQR* 1.5; further outliers are marked individually.

[0160] FIG. 76 - In vivo perturbation of tumor cells. tSNE analysis of B16 cells implanted subcutaneously into B6 animals followed by treatment with either vehicle, abemaciclib alone, immune checkpoint inhibitors (ICI) alone or ICI plus abema.

[0161] FIG. 77 - Ex vivo perturb-seq. Ex vivo melanoma cells obtained from a human patient were perturbed with a CRISPR system including barcoded guide sequences targeting the indicated genes. The barcodes from this experiment were isolated and sequenced. The graph indicates the barcode detection.

DETAILED DESCRIPTION OF THE EXAMPLE EMBODIMENTS

General Definitions

[0162] Unless defined otherwise, technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this disclosure pertains. Definitions of common terms and techniques in molecular biology may be found in Molecular Cloning: A Laboratory Manual, 2 ^nd edition (1989) (Sambrook, Fritsch, and Maniatis); Molecular Cloning: A Laboratory Manual, 4 ^th edition (2012) (Green and Sambrook); Current Protocols in Molecular Biology (1987) (F.M. Ausubel et al. eds.); the series Methods in Enzymology (Academic Press, Inc.): PCR 2: A Practical Approach (1995) (M.J. MacPherson, B.D. Hames, and G.R. Taylor eds.): Antibodies, A Laboraotry Manual (1988) (Harlow and Lane, eds.): Antibodies A Laboraotry Manual, 2 ^nd edition 2013 (E.A. Greenfield ed.); Animal Cell Culture (1987) (R.I. Freshney, ed.); Benjamin Lewin, Genes IX, published by Jones and Bartlet, 2008 (ISBN 0763752223); Kendrew et al. (eds.), The Encyclopedia of Molecular Biology, published by Blackwell Science Ltd., 1994 (ISBN 0632021829); Robert A. Meyers (ed.), Molecular Biology and Biotechnology: a Comprehensive Desk Reference, published by VCH Publishers, Inc., 1995 (ISBN 9780471185710); Singleton et al., Dictionary of Microbiology and Molecular Biology 2nd ed., J. Wiley & Sons (New York, N.Y. 1994), March, Advanced Organic Chemistry Reactions, Mechanisms and Structure 4th ed., John Wiley & Sons (New York, N.Y. 1992); and Marten H. Hofker and Jan van Deursen, Transgenic Mouse Methods and Protocols, 2 ^nd edition (2011) .

[0163] As used herein, the singular forms "a", "an", and "the" include both singular and plural referents unless the context clearly dictates otherwise.

[0164] The term "optional" or "optionally" means that the subsequent described event, circumstance or substituent may or may not occur, and that the description includes instances where the event or circumstance occurs and instances where it does not.

[0165] The recitation of numerical ranges by endpoints includes all numbers and fractions subsumed within the respective ranges, as well as the recited endpoints.

[0166] The terms "about" or "approximately" as used herein when referring to a measurable value such as a parameter, an amount, a temporal duration, and the like, are meant to encompass variations of and from the specified value, such as variations of +/-10% or less, +1-5% or less, +/-1% or less, and +/-0.1% or less of and from the specified value, insofar such variations are appropriate to perform in the disclosed invention. It is to be understood that the value to which the modifier "about" or "approximately" refers is itself also specifically, and preferably, disclosed.

[0167] Reference throughout this specification to "one embodiment", "an embodiment,"

"an example embodiment," means that a particular feature, structure or characteristic described in connection with the embodiment is included in at least one embodiment of the present invention. Thus, appearances of the phrases "in one embodiment," "in an embodiment," or "an example embodiment" in various places throughout this specification are not necessarily all referring to the same embodiment, but may. Furthermore, the particular features, structures or characteristics may be combined in any suitable manner, as would be apparent to a person skilled in the art from this disclosure, in one or more embodiments. Furthermore, while some embodiments described herein include some but not other features included in other embodiments, combinations of features of different embodiments are meant to be within the scope of the invention. For example, in the appended claims, any of the claimed embodiments can be used in any combination.

[0168] Reference is made to international patent application serial number PCT/US 18/25507, filed March 30, 2018.

[0169] All publications, published patent documents, and patent applications cited in this application are indicative of the level of skill in the art(s) to which the application pertains. All publications, published patent documents, and patent applications cited herein are hereby incorporated by reference to the same extent as though each individual publication, published patent document, or patent application was specifically and individually indicated as being incorporated by reference.

Overview

[0170] Embodiments disclosed herein provide methods and compositions for detecting and modulating an immunotherapy resistance gene signature in cancer. Embodiments disclosed herein also provide for diagnosing, prognosing, monitoring and treating tumors based on detection of an immunotherapy resistance gene signature.

[0171] As used herein, the immunotherapy resistance signature is referred to as "ITR",

"immunotherapy resistance signature", "ICR", "immune checkpoint inhibitor resistance",

"mICR", "malignant immune checkpoint inhibitor resistance", "PIT", "post- immunotherapy", oncogenic-ICR", "unified-ICR", "uICR", "uICR-up", "uICR-down",

"refined uICR", "immune resistant", "refined immune resistant", "functional immune resistance", "post treatment", "exclusion-up", or "exclusion-down". All of these terms may be used in reference to a gene signature in malignant cells from a subject that is resistant to immune checkpoint inhibitors (ICI). In regards to the exclusion signatures, these signatures refer to signatures in malignant cells that correlate to immune cell exclusion. In other words, exclusion-up refers to genes that are upregulated in malignant cells and that are correlated with exclusion, while exclusion-down refer to genes downregulated in malignant cells that are correlated with exclusion. In certain embodiments, exclusion-down refers to genes upregulated when there is immune cell infiltration and thus can be referred to as the infiltration signature. In regards to "oncogenic ICR", "mICR", "malignant immune checkpoint inhibitor resistance", "Post-treatment", "PIT", or "post-immunotherapy", these terms all refer to genes differentially expressed in malignant cells after immunotherapy. All of "unified-ICR", "uICR", "uICR-up", "uICR-down", "refined uICR", "refined immune resistant", "functional immune resistance" refer to an immunotherapy resistant signature that includes genes from the post immunotherapy and exclusion signatures. "Immune resistance, "unified-ICR" or "uICR" refers to all genes in the exclusion signature and post treatment signature. The "functional immune resistance", "refined uICR" and "refined immune resistant" signatures are shortened lists from the immune resistance signature that include the best performing genes from the exclusion and post treatment signatures for predicting immunotherapy sensitivity. In regards to CD8 T cells "tICR" refers to T cell immune checkpoint inhibitor resistance signature.

[0172] As used herein the term "cancer-specific survival" refers to the percentage of patients with a specific type and stage of cancer who have not died from their cancer during a certain period of time after diagnosis. The period of time may be 1 year, 2 years, 5 years, etc., with 5 years being the time period most often used. Cancer-specific survival is also called disease-specific survival. In most cases, cancer-specific survival is based on causes of death listed in medical records.

[0173] As used herein the term "relative survival" refers to a method used to estimate cancer-specific survival that does not use information about the cause of death. It is the percentage of cancer patients who have survived for a certain period of time after diagnosis compared to people who do not have cancer.

[0174] As used herein the term "overall survival" refers to the percentage of people with a specific type and stage of cancer who have not died from any cause during a certain period of time after diagnosis.

[0175] As used herein the term "disease-free survival" refers to the percentage of patients who have no signs of cancer during a certain period of time after treatment. Other names for this statistic are recurrence-free or progression-free survival.

[0176] As used herein a "signature" may encompass any gene or genes, protein or proteins, or epigenetic element(s) whose expression profile or whose occurrence is associated with a specific cell type, subtype, or cell state of a specific cell type or subtype within a population of cells (e.g., immune evading tumor cells, immunotherapy resistant tumor cells, tumor infiltrating lymphocytes, macrophages). In certain embodiments, the expression of the immunotherapy resistant, T cell signature and/or macrophage signature is dependent on epigenetic modification of the genes or regulatory elements associated with the genes. Thus, in certain embodiments, use of signature genes includes epigenetic modifications that may be detected or modulated. For ease of discussion, when discussing gene expression, any of gene or genes, protein or proteins, or epigenetic element(s) may be substituted. As used herein, the terms "signature", "expression profile", or "expression program" may be used interchangeably. It is to be understood that also when referring to proteins (e.g. differentially expressed proteins), such may fall within the definition of "gene" signature. Levels of expression or activity may be compared between different cells in order to characterize or identify for instance signatures specific for cell (sub)populations. Increased or decreased expression or activity or prevalence of signature genes may be compared between different cells in order to characterize or identify for instance specific cell (sub)populations. The detection of a signature in single cells may be used to identify and quantitate for instance specific cell (sub)populations. A signature may include a gene or genes, protein or proteins, or epigenetic element(s) whose expression or occurrence is specific to a cell (sub)population, such that expression or occurrence is exclusive to the cell (sub)population. A gene signature as used herein, may thus refer to any set of up- and/or down-regulated genes that are representative of a cell type or subtype. A gene signature as used herein, may also refer to any set of up- and/or down-regulated genes between different cells or cell (sub)populations derived from a gene-expression profile. For example, a gene signature may comprise a list of genes differentially expressed in a distinction of interest.

[0177] The signature as defined herein (being it a gene signature, protein signature or other genetic or epigenetic signature) can be used to indicate the presence of a cell type, a subtype of the cell type, the state of the microenvironment of a population of cells, a particular cell type population or subpopulation, and/or the overall status of the entire cell

(sub)population. Furthermore, the signature may be indicative of cells within a population of cells in vivo. The signature may also be used to suggest for instance particular therapies, or to follow up treatment, or to suggest ways to modulate immune systems. The signatures of the present invention may be discovered by analysis of expression profiles of single-cells within a population of cells from isolated samples (e.g. tumor samples), thus allowing the discovery of novel cell subtypes or cell states that were previously invisible or unrecognized. The presence of subtypes or cell states may be determined by subtype specific or cell state specific signatures. The presence of these specific cell (sub)types or cell states may be determined by applying the signature genes to bulk sequencing data in a sample. Not being bound by a theory the signatures of the present invention may be microenvironment specific, such as their expression in a particular spatio-temporal context. Not being bound by a theory, signatures as discussed herein are specific to a particular pathological context. Not being bound by a theory, a combination of cell subtypes having a particular signature may indicate an outcome. Not being bound by a theory, the signatures can be used to deconvolute the network of cells present in a particular pathological condition. Not being bound by a theory the presence of specific cells and cell subtypes are indicative of a particular response to treatment, such as including increased or decreased susceptibility to treatment. The signature may indicate the presence of one particular cell type. In one embodiment, the novel signatures are used to detect multiple cell states or hierarchies that occur in subpopulations of cells that are linked to particular pathological condition, or linked to a particular outcome or progression of the disease, or linked to a particular response to treatment of the disease (e.g. resistance to immunotherapy).

[0178] The signature according to certain embodiments of the present invention may comprise or consist of one or more genes, proteins and/or epigenetic elements, such as for instance 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 or more. In certain embodiments, the signature may comprise or consist of two or more genes, proteins and/or epigenetic elements, such as for instance 2, 3, 4, 5, 6, 7, 8, 9, 10 or more. In certain embodiments, the signature may comprise or consist of three or more genes, proteins and/or epigenetic elements, such as for instance 3,

4, 5, 6, 7, 8, 9, 10 or more. In certain embodiments, the signature may comprise or consist of four or more genes, proteins and/or epigenetic elements, such as for instance 4, 5, 6, 7, 8, 9,

10 or more. In certain embodiments, the signature may comprise or consist of five or more genes, proteins and/or epigenetic elements, such as for instance 5, 6, 7, 8, 9, 10 or more. In certain embodiments, the signature may comprise or consist of six or more genes, proteins and/or epigenetic elements, such as for instance 6, 7, 8, 9, 10 or more. In certain embodiments, the signature may comprise or consist of seven or more genes, proteins and/or epigenetic elements, such as for instance 7, 8, 9, 10 or more. In certain embodiments, the signature may comprise or consist of eight or more genes, proteins and/or epigenetic elements, such as for instance 8, 9, 10 or more. In certain embodiments, the signature may comprise or consist of nine or more genes, proteins and/or epigenetic elements, such as for instance 9, 10 or more. In certain embodiments, the signature may comprise or consist of ten or more genes, proteins and/or epigenetic elements, such as for instance 10, 11, 12, 13, 14, 15, or more. It is to be understood that a signature according to the invention may for instance also include genes or proteins as well as epigenetic elements combined.

[0179] In certain embodiments, a signature is characterized as being specific for a particular cell or cell (sub)population if it is upregulated or only present, detected or detectable in that particular cell or cell (sub)population, or alternatively is downregulated or only absent, or undetectable in that particular cell or cell (sub)population. In this context, a signature consists of one or more differentially expressed genes/proteins or differential epigenetic elements when comparing different cells or cell (sub)populations, including comparing different immune cells or immune cell (sub)populations (e.g., T cells), as well as comparing immune cells or immune cell (sub)populations with other immune cells or immune cell (sub)populations. It is to be understood that "differentially expressed" genes/proteins include genes/proteins which are up- or down-regulated as well as genes/proteins which are turned on or off. When referring to up-or down-regulation, in certain embodiments, such up- or down-regulation is preferably at least two-fold, such as two-fold, three-fold, four-fold, five-fold, or more, such as for instance at least ten-fold, at least 20-fold, at least 30-fold, at least 40-fold, at least 50-fold, or more. Alternatively, or in addition, differential expression may be determined based on common statistical tests, as is known in the art.

[0180] As discussed herein, differentially expressed genes/proteins, or differential epigenetic elements may be differentially expressed on a single cell level, or may be differentially expressed on a cell population level. Preferably, the differentially expressed genes/ proteins or epigenetic elements as discussed herein, such as constituting the gene signatures as discussed herein, when as to the cell population level, refer to genes that are differentially expressed in all or substantially all cells of the population (such as at least 80%, preferably at least 90%, such as at least 95% of the individual cells). This allows one to define a particular subpopulation of cells. As referred to herein, a "subpopulation" of cells preferably refers to a particular subset of cells of a particular cell type (e.g., resistant) which can be distinguished or are uniquely identifiable and set apart from other cells of this cell type. The cell subpopulation may be phenotypically characterized, and is preferably characterized by the signature as discussed herein. A cell (sub)population as referred to herein may constitute of a (sub)population of cells of a particular cell type characterized by a specific cell state.

[0181] When referring to induction, or alternatively reducing or suppression of a particular signature, preferable is meant induction or alternatively reduction or suppression (or upregulation or downregulation) of at least one gene/protein and/or epigenetic element of the signature, such as for instance at least two, at least three, at least four, at least five, at least six, or all genes/proteins and/or epigenetic elements of the signature.

[0182] Various aspects and embodiments of the invention may involve analyzing gene signatures, protein signature, and/or other genetic or epigenetic signature based on single cell analyses (e.g. single cell RNA sequencing) or alternatively based on cell population analyses, as is defined herein elsewhere.

[0183] The invention further relates to various uses of the gene signatures, protein signature, and/or other genetic or epigenetic signature as defined herein, as well as various uses of the immune cells or immune cell (sub)populations as defined herein. Particular advantageous uses include methods for identifying agents capable of inducing or suppressing particular immune cell (sub)populations based on the gene signatures, protein signature, and/or other genetic or epigenetic signature as defined herein. The invention further relates to agents capable of inducing or suppressing particular immune cell (sub)populations based on the gene signatures, protein signature, and/or other genetic or epigenetic signature as defined herein, as well as their use for modulating, such as inducing or repressing, a particular gene signature, protein signature, and/or other genetic or epigenetic signature. In one embodiment, genes in one population of cells may be activated or suppressed in order to affect the cells of another population. In related aspects, modulating, such as inducing or repressing, a particular gene signature, protein signature, and/or other genetic or epigenetic signature may modify overall immune composition, such as immune cell composition, such as immune cell subpopulation composition or distribution, or functionality.

[0184] The signature genes of the present invention were discovered by analysis of expression profiles of single-cells within a population of tumor cells, thus allowing the discovery of novel cell subtypes that were previously invisible in a population of cells within a tumor. The presence of subtypes may be determined by subtype specific signature genes.

The presence of these specific cell types may be determined by applying the signature genes to bulk sequencing data in a patient. Not being bound by a theory, many cells that make up a microenvironment, whereby the cells communicate and affect each other in specific ways. As such, specific cell types within this microenvironment may express signature genes specific for this microenvironment. Not being bound by a theory the signature genes of the present invention may be microenvironment specific, such as their expression in a tumor. The signature genes may indicate the presence of one particular cell type. In one embodiment, the expression may indicate the presence of immunotherapy resistant cell types. Not being bound by a theory, a combination of cell subtypes in a subject may indicate an outcome (e.g., resistant cells, cytotoxic T cells, Tregs).

[0185] In certain embodiments, the present invention provides for gene signature screening. The concept of signature screening was introduced by Stegmaier et al. (Gene expression-based high-throughput screening (GE-HTS) and application to leukemia differentiation. Nature Genet. 36, 257-263 (2004)), who realized that if a gene-expression signature was the proxy for a phenotype of interest, it could be used to find small molecules that effect that phenotype without knowledge of a validated drug target. The signature of the present may be used to screen for drugs that reduce the signature in cancer cells or cell lines having a resistant signature as described herein. The signature may be used for GE-HTS. In certain embodiments, pharmacological screens may be used to identify drugs that are selectively toxic to cancer cells having an immunotherapy resistant signature. In certain embodiments, drugs selectively toxic to cancer cells having an immunotherapy resistant signature are used for treatment of a cancer patient. In certain embodiments, cells having an immunotherapy resistant signature as described herein are treated with a plurality of drug candidates not toxic to non-tumor cells and toxicity is assayed.

[0186] The Connectivity Map (cmap) is a collection of genome-wide transcriptional expression data from cultured human cells treated with bioactive small molecules and simple pattern-matching algorithms that together enable the discovery of functional connections between drugs, genes and diseases through the transitory feature of common gene-expression changes (see, Lamb et al., The Connectivity Map: Using Gene-Expression Signatures to Connect Small Molecules, Genes, and Disease. Science 29 Sep 2006: Vol. 313, Issue 5795, pp. 1929-1935, DOI: 10.1126/science.1132939; and Lamb, J., The Connectivity Map: a new tool for biomedical research. Nature Reviews Cancer January 2007: Vol. 7, pp. 54-60). Cmap can be used to screen for a signature in silico.

[0187] In one embodiment, the signature genes may be detected by immunofluorescence, immunohistochemistry, fluorescence activated cell sorting (FACS), mass cytometry

(CyTOF), Drop-seq, RNA-seq, scRNA-seq, InDrop, single cell qPCR, MERFISH (multiplex (in situ) RNA FISH) and/or by in situ hybridization. Other methods including absorbance assays and colorimetric assays are known in the art and may be used herein.

[0188] All gene name symbols refer to the gene as commonly known in the art. The examples described herein refer to the human gene names and it is to be understood that the present invention also encompasses genes from other organisms (e.g., mouse genes). Gene symbols may be those referred to by the HUGO Gene Nomenclature Committee (HGNC) or National Center for Biotechnology Information (NCBI). Any reference to the gene symbol is a reference made to the entire gene or variants of the gene. The signature as described herein may encompass any of the genes described herein. In certain embodiments, the gene signature includes surface expressed and secreted proteins. Not being bound by a theory, surface proteins may be targeted for detection and isolation of cell types, or may be targeted therapeutically to modulate an immune response.

[0189] As used herein, "modulating" or "to modulate" generally means either reducing or inhibiting the expression or activity of, or alternatively increasing the expression or activity of a target gene. In particular, "modulating" or "to modulate" can mean either reducing or inhibiting the activity of, or alternatively increasing a (relevant or intended) biological activity of, a target or antigen as measured using a suitable in vitro, cellular or in vivo assay

(which will usually depend on the target involved), by at least 5%, at least 10%, at least 25%, at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, or more, compared to activity of the target in the same assay under the same conditions but without the presence of an agent. An "increase" or "decrease" refers to a statistically significant increase or decrease respectively. For the avoidance of doubt, an increase or decrease will be at least 10% relative to a reference, such as at least 10%, at least 20%, at least 30%, at least 40%, at least 50%, a t least 60%, at least 70%, at least 80%, at least 90%, at least 95%, at least 97%, at least 98%, or more, up to and including at least 100% or more, in the case of an increase, for example, at least 2-fold, at least 3-fold, at least 4-fold, at least 5-fold, at least 6-fold, at least 7-fold, at least 8-fold, at least 9-fold,at least 10-fold, at least 50-fold, at least 100-fold, or more.

"Modulating" can also involve effecting a change (which can either be an increase or a decrease) in affinity, avidity, specificity and/or selectivity of a target or antigen, such as a receptor and ligand. "Modulating" can also mean effecting a change with respect to one or more biological or physiological mechanisms, effects, responses, functions, pathways or activities in which the target or antigen (or in which its substrate(s), ligand(s) or pathway(s) are involved, such as its signaling pathway or metabolic pathway and their associated biological or physiological effects) is involved. Again, as will be clear to the skilled person, such an action as an agonist or an antagonist can be determined in any suitable manner and/or using any suitable assay known or described herein (e.g., in vitro or cellular assay), depending on the target or antigen involved.

[0190] Modulating can, for example, also involve allosteric modulation of the target and/or reducing or inhibiting the binding of the target to one of its substrates or ligands and/or competing with a natural ligand, substrate for binding to the target. Modulating can also involve activating the target or the mechanism or pathway in which it is involved. Modulating can for example also involve effecting a change in respect of the folding or confirmation of the target, or in respect of the ability of the target to fold, to change its conformation (for example, upon binding of a ligand), to associate with other (sub)units, or to disassociate. Modulating can for example also involve effecting a change in the ability of the target to signal, phosphorylate, dephosphorylate, and the like.

Modulating Agents

[0191] As used herein, an "agent" can refer to a protein-binding agent that permits modulation of activity of proteins or disrupts interactions of proteins and other biomolecules, such as but not limited to disrupting protein-protein interaction, ligand-receptor interaction, or protein-nucleic acid interaction. Agents can also refer to DNA targeting or RNA targeting agents. Agents may include a fragment, derivative and analog of an active agent. The terms "fragment," "derivative" and "analog" when referring to polypeptides as used herein refers to polypeptides which either retain substantially the same biological function or activity as such polypeptides. An analog includes a proprotein which can be activated by cleavage of the proprotein portion to produce an active mature polypeptide. Such agents include, but are not limited to, antibodies ("antibodies" includes antigen-binding portions of antibodies such as epitope- or antigen-binding peptides, paratopes, functional CDRs; recombinant antibodies; chimeric antibodies; humanized antibodies; nanobodies; tribodies; midibodies; or antigen- binding derivatives, analogs, variants, portions, or fragments thereof), protein-binding agents, nucleic acid molecules, small molecules, recombinant protein, peptides, aptamers, avimers and protein-binding derivatives, portions or fragments thereof. An "agent" as used herein, may also refer to an agent that inhibits expression of a gene, such as but not limited to a DNA targeting agent (e.g., CRISPR system, TALE, Zinc finger protein) or RNA targeting agent (e.g., inhibitory nucleic acid molecules such as RNAi, miRNA, ribozyme). [0192] The agents of the present invention may be modified, such that they acquire advantageous properties for therapeutic use (e.g., stability and specificity), but maintain their biological activity.

[0193] It is well known that the properties of certain proteins can be modulated by attachment of polyethylene glycol (PEG) polymers, which increases the hydrodynamic volume of the protein and thereby slows its clearance by kidney filtration. (See, e.g., Clark et al., J. Biol. Chem. 271 : 21969-21977 (1996)). Therefore, it is envisioned that certain agents can be PEGylated (e.g., on peptide residues) to provide enhanced therapeutic benefits such as, for example, increased efficacy by extending half-life in vivo. In certain embodiments, PEGylation of the agents may be used to extend the serum half-life of the agents and allow for particular agents to be capable of crossing the blood-brain barrier.

[0194] In regards to peptide PEGylation methods, reference is made to Lu et al., Int. J.

Pept. Protein Res.43 : 127-38 (1994); Lu et al., Pept. Res. 6: 140-6 (1993); Felix et al., Int. J.

Pept. Protein Res. 46: 253-64 (1995); Gaertner et al., Bioconjug. Chem. 7: 38-44 (1996);

Tsutsumi et al., Thromb. Haemost. 77: 168-73 (1997); Francis et al., hit. J. Hematol. 68: 1-18

(1998); Roberts et al., J. Pharm. Sci. 87: 1440-45 (1998); and Tan et al., Protein Expr. Purif.

12: 45-52 (1998). Polyethylene glycol or PEG is meant to encompass any of the forms of

PEG that have been used to derivatize other proteins, including, but not limited to, mono-

(Cl-10) alkoxy or aryloxy -poly ethylene glycol. Suitable PEG moieties include, for example,

40 kDa methoxy poly(ethylene glycol) propionaldehyde (Dow, Midland, Mich.); 60 kDa methoxy poly(ethylene glycol) propionaldehyde (Dow, Midland, Mich.); 40 kDa methoxy poly(ethylene glycol) maleimido-propionamide (Dow, Midland, Mich.); 31 kDa alpha- methyl-w-(3-oxopropoxy), poly oxy ethylene (NOF Corporation, Tokyo); mPEG2- HS-40k

(Nektar); mPEG2-MAL-40k (Nektar), SU BRIGHT GL2-400MA ((PEG)240kDa) (NOF

Corporation, Tokyo), SUNBRIGHT ME-200MA (PEG20kDa) (NOF Corporation, Tokyo).

The PEG groups are generally attached to the peptide (e.g., neuromedin U receptor agonists or antagonists) via acylation or alkylation through a reactive group on the PEG moiety (for example, a maleimide, an aldehyde, amino, thiol, or ester group) to a reactive group on the peptide (for example, an aldehyde, amino, thiol, a maleimide, or ester group).

[0195] The PEG molecule(s) may be covalently attached to any Lys, Cys, or

K(CO(CH2)2SH) residues at any position in a peptide. In certain embodiments, the neuromedin U receptor agonists described herein can be PEGylated directly to any amino acid at the N-terminus by way of the N-terminal amino group. A "linker arm" may be added to a peptide to facilitate PEGylation. PEGylation at the thiol side-chain of cysteine has been widely reported (see, e.g., Caliceti & Veronese, Adv. Drug Deliv. Rev. 55: 1261-77 (2003)). If there is no cysteine residue in the peptide, a cysteine residue can be introduced through substitution or by adding a cysteine to the N-terminal amino acid.

[0196] Substitutions of amino acids may be used to modify an agent of the present invention. The phrase "substitution of amino acids" as used herein encompasses substitution of amino acids that are the result of both conservative and non-conservative substitutions. Conservative substitutions are the replacement of an amino acid residue by another similar residue in a polypeptide. Typical but not limiting conservative substitutions are the replacements, for one another, among the aliphatic amino acids Ala, Val, Leu and He; interchange of Ser and Thr containing hydroxy residues, interchange of the acidic residues Asp and Glu, interchange between the amide-containing residues Asn and Gin, interchange of the basic residues Lys and Arg, interchange of the aromatic residues Phe and Tyr, and interchange of the small-sized amino acids Ala, Ser, Thr, Met, and Gly. Non-conservative substitutions are the replacement, in a polypeptide, of an amino acid residue by another residue which is not biologically similar. For example, the replacement of an amino acid residue with another residue that has a substantially different charge, a substantially different hydrophobicity, or a substantially different spatial configuration.

[0197] The term "antibody" is used interchangeably with the term "immunoglobulin" herein, and includes intact antibodies, fragments of antibodies, e.g., Fab, F(ab')2 fragments, and intact antibodies and fragments that have been mutated either in their constant and/or variable region (e.g., mutations to produce chimeric, partially humanized, or fully humanized antibodies, as well as to produce antibodies with a desired trait, e.g., enhanced binding and/or reduced FcR binding). The term "fragment" refers to a part or portion of an antibody or antibody chain comprising fewer amino acid residues than an intact or complete antibody or antibody chain. Fragments can be obtained via chemical or enzymatic treatment of an intact or complete antibody or antibody chain. Fragments can also be obtained by recombinant means. Exemplary fragments include Fab, Fab', F(ab')2, Fabc, Fd, dAb, VHH and scFv and/or Fv fragments.

[0198] As used herein, a preparation of antibody protein having less than about 50% of non-antibody protein (also referred to herein as a "contaminating protein"), or of chemical precursors, is considered to be "substantially free." 40%, 30%, 20%, 10% and more preferably 5% (by dry weight), of non-antibody protein, or of chemical precursors is considered to be substantially free. When the antibody protein or biologically active portion thereof is recombinantly produced, it is also preferably substantially free of culture medium, i.e., culture medium represents less than about 30%, preferably less than about 20%, more preferably less than about 10%, and most preferably less than about 5% of the volume or mass of the protein preparation.

[0199] The term "antigen-binding fragment" refers to a polypeptide fragment of an immunoglobulin or antibody that binds antigen or competes with intact antibody (i.e., with the intact antibody from which they were derived) for antigen binding (i.e., specific binding). As such these antibodies or fragments thereof are included in the scope of the invention, provided that the antibody or fragment binds specifically to a target molecule.

[0200] It is intended that the term "antibody" encompass any Ig class or any Ig subclass (e.g. the IgGl, IgG2, IgG3, and IgG4 subclassess of IgG) obtained from any source (e.g., humans and non-human primates, and in rodents, lagomorphs, caprines, bovines, equines, ovines, etc.).

[0201] The term "Ig class" or "immunoglobulin class", as used herein, refers to the five classes of immunoglobulin that have been identified in humans and higher mammals, IgG,

IgM, IgA, IgD, and IgE. The term "Ig subclass" refers to the two subclasses of IgM (H and

L), three subclasses of IgA (IgAl, IgA2, and secretory IgA), and four subclasses of IgG

(IgGl, IgG2, IgG3, and IgG4) that have been identified in humans and higher mammals. The antibodies can exist in monomeric or polymeric form; for example, IgM antibodies exist in pentameric form, and IgA antibodies exist in monomeric, dimeric or multimeric form.

[0202] The term "IgG subclass" refers to the four subclasses of immunoglobulin class

IgG - IgGl, IgG2, IgG3, and IgG4 that have been identified in humans and higher mammals by the heavy chains of the immunoglobulins, VI - γ4, respectively. The term "single-chain immunoglobulin" or "single-chain antibody" (used interchangeably herein) refers to a protein having a two-polypeptide chain structure consisting of a heavy and a light chain, said chains being stabilized, for example, by interchain peptide linkers, which has the ability to specifically bind antigen. The term "domain" refers to a globular region of a heavy or light chain polypeptide comprising peptide loops (e.g., comprising 3 to 4 peptide loops) stabilized, for example, by β pleated sheet and/or intrachain disulfide bond. Domains are further referred to herein as "constant" or "variable", based on the relative lack of sequence variation within the domains of various class members in the case of a "constant" domain, or the significant variation within the domains of various class members in the case of a "variable" domain. Antibody or polypeptide "domains" are often referred to interchangeably in the art as antibody or polypeptide "regions". The "constant" domains of an antibody light chain are referred to interchangeably as "light chain constant regions", "light chain constant domains", "CL" regions or "CL" domains. The "constant" domains of an antibody heavy chain are referred to interchangeably as "heavy chain constant regions", "heavy chain constant domains", "CH" regions or "CH" domains). The "variable" domains of an antibody light chain are referred to interchangeably as "light chain variable regions", "light chain variable domains", "VL" regions or "VL" domains). The "variable" domains of an antibody heavy chain are referred to interchangeably as "heavy chain constant regions", "heavy chain constant domains", "VH" regions or "VH" domains).

[0203] The term "region" can also refer to a part or portion of an antibody chain or antibody chain domain (e.g., a part or portion of a heavy or light chain or a part or portion of a constant or variable domain, as defined herein), as well as more discrete parts or portions of said chains or domains. For example, light and heavy chains or light and heavy chain variable domains include "complementarity determining regions" or "CDRs" interspersed among "framework regions" or "FRs", as defined herein.

[0204] The term "conformation" refers to the tertiary structure of a protein or polypeptide (e.g., an antibody, antibody chain, domain or region thereof). For example, the phrase "light (or heavy) chain conformation" refers to the tertiary structure of a light (or heavy) chain variable region, and the phrase "antibody conformation" or "antibody fragment conformation" refers to the tertiary structure of an antibody or fragment thereof.

[0205] The term "antibody-like protein scaffolds" or "engineered protein scaffolds" broadly encompasses proteinaceous non-immunoglobulin specific-binding agents, typically obtained by combinatorial engineering (such as site-directed random mutagenesis in combination with phage display or other molecular selection techniques). Usually, such scaffolds are derived from robust and small soluble monomeric proteins (such as Kunitz inhibitors or lipocalins) or from a stably folded extra-membrane domain of a cell surface receptor (such as protein A, fibronectin or the ankyrin repeat).

[0206] Such scaffolds have been extensively reviewed in Binz et al. (Engineering novel binding proteins from nonimmunoglobulin domains. Nat Biotechnol 2005, 23 : 1257-1268),

Gebauer and Skerra (Engineered protein scaffolds as next-generation antibody therapeutics.

Curr Opin Chem Biol. 2009, 13 :245-55), Gill and Damle (Biopharmaceutical drug discovery using novel protein scaffolds. Curr Opin Biotechnol 2006, 17:653-658), Skerra (Engineered protein scaffolds for molecular recognition. J Mol Recognit 2000, 13 : 167-187), and Skerra (Alternative non-antibody scaffolds for molecular recognition. Curr Opin Biotechnol 2007, 18:295-304), and include without limitation affibodies, based on the Z-domain of staphylococcal protein A, a three-helix bundle of 58 residues providing an interface on two of its alpha-helices (Nygren, Alternative binding proteins: Affibody binding proteins developed from a small three-helix bundle scaffold. FEBS J 2008, 275:2668-2676); engineered Kunitz domains based on a small (ca. 58 residues) and robust, disulphide-crosslinked serine protease inhibitor, typically of human origin (e.g. LACI-D1), which can be engineered for different protease specificities (Nixon and Wood, Engineered protein inhibitors of proteases. Curr Opin Drug Discov Dev 2006, 9:261-268); monobodies or adnectins based on the 10th extracellular domain of human fibronectin III (10Fn3), which adopts an Ig-like beta- sandwich fold (94 residues) with 2-3 exposed loops, but lacks the central disulphide bridge (Koide and Koide, Monobodies: antibody mimics based on the scaffold of the fibronectin type III domain. Methods Mol Biol 2007, 352:95-109); anticalins derived from the lipocalins, a diverse family of eight-stranded beta-barrel proteins (ca. 180 residues) that naturally form binding sites for small ligands by means of four structurally variable loops at the open end, which are abundant in humans, insects, and many other organisms (Skerra, Alternative binding proteins: Anticalins— harnessing the structural plasticity of the lipocalin ligand pocket to engineer novel binding activities. FEBS J 2008, 275:2677-2683); DARPins, designed ankyrin repeat domains (166 residues), which provide a rigid interface arising from typically three repeated beta-turns (Stumpp et al., DARPins: a new generation of protein therapeutics. Drug Discov Today 2008, 13 :695-701); avimers (multimerized LDLR-A module) (Silverman et al., Multivalent avimer proteins evolved by exon shuffling of a family of human receptor domains. Nat Biotechnol 2005, 23 : 1556-1561); and cysteine-rich knottin peptides (Kolmar, Alternative binding proteins: biological activity and therapeutic potential of cystine-knot miniproteins. FEBS J 2008, 275:2684-2690).

[0207] "Specific binding" of an antibody means that the antibody exhibits appreciable affinity for a particular antigen or epitope and, generally, does not exhibit significant cross reactivity. "Appreciable" binding includes binding with an affinity of at least 25 μΜ.

Antibodies with affinities greater than 1 x 10 ⁷ M ^"1 (or a dissociation coefficient of ΙμΜ or less or a dissociation coefficient of lnm or less) typically bind with correspondingly greater specificity. Values intermediate of those set forth herein are also intended to be within the scope of the present invention and antibodies of the invention bind with a range of affinities, for example, lOOnM or less, 75nM or less, 50nM or less, 25nM or less, for example lOnM or less, 5nM or less, InM or less, or in embodiments 500pM or less, lOOpM or less, 50pM or less or 25pM or less. An antibody that "does not exhibit significant crossreactivity" is one that will not appreciably bind to an entity other than its target (e.g., a different epitope or a different molecule). For example, an antibody that specifically binds to a target molecule will appreciably bind the target molecule but will not significantly react with non-target molecules or peptides. An antibody specific for a particular epitope will, for example, not significantly crossreact with remote epitopes on the same protein or peptide. Specific binding can be determined according to any art-recognized means for determining such binding. Preferably, specific binding is determined according to Scatchard analysis and/or competitive binding assays.

[0208] As used herein, the term "affinity" refers to the strength of the binding of a single antigen-combining site with an antigenic determinant. Affinity depends on the closeness of stereochemical fit between antibody combining sites and antigen determinants, on the size of the area of contact between them, on the distribution of charged and hydrophobic groups, etc. Antibody affinity can be measured by equilibrium dialysis or by the kinetic BIACORE™ method. The dissociation constant, Kd, and the association constant, Ka, are quantitative measures of affinity.

[0209] As used herein, the term "monoclonal antibody" refers to an antibody derived from a clonal population of antibody-producing cells (e.g., B lymphocytes or B cells) which is homogeneous in structure and antigen specificity. The term "polyclonal antibody" refers to a plurality of antibodies originating from different clonal populations of antibody-producing cells which are heterogeneous in their structure and epitope specificity but which recognize a common antigen. Monoclonal and polyclonal antibodies may exist within bodily fluids, as crude preparations, or may be purified, as described herein.

[0210] The term "binding portion" of an antibody (or "antibody portion") includes one or more complete domains, e.g., a pair of complete domains, as well as fragments of an antibody that retain the ability to specifically bind to a target molecule. It has been shown that the binding function of an antibody can be performed by fragments of a full-length antibody. Binding fragments are produced by recombinant DNA techniques, or by enzymatic or chemical cleavage of intact immunoglobulins. Binding fragments include Fab, Fab', F(ab')2, Fabc, Fd, dAb, Fv, single chains, single-chain antibodies, e.g., scFv, and single domain antibodies. [0211] "Humanized" forms of non-human (e.g., murine) antibodies are chimeric antibodies that contain minimal sequence derived from non-human immunoglobulin. For the most part, humanized antibodies are human immunoglobulins (recipient antibody) in which residues from a hypervariable region of the recipient are replaced by residues from a hypervariable region of a non-human species (donor antibody) such as mouse, rat, rabbit or nonhuman primate having the desired specificity, affinity, and capacity. In some instances, FR residues of the human immunoglobulin are replaced by corresponding non-human residues. Furthermore, humanized antibodies may comprise residues that are not found in the recipient antibody or in the donor antibody. These modifications are made to further refine antibody performance. In general, the humanized antibody will comprise substantially all of at least one, and typically two, variable domains, in which all or substantially all of the hypervariable regions correspond to those of a non-human immunoglobulin and all or substantially all of the FR regions are those of a human immunoglobulin sequence. The humanized antibody optionally also will comprise at least a portion of an immunoglobulin constant region (Fc), typically that of a human immunoglobulin.

[0212] Examples of portions of antibodies or epitope-binding proteins encompassed by the present definition include: (i) the Fab fragment, having VL, CL, VH and CHI domains; (ii) the Fab' fragment, which is a Fab fragment having one or more cysteine residues at the C- terminus of the CHI domain; (iii) the Fd fragment having VH and CHI domains; (iv) the Fd' fragment having VH and CHI domains and one or more cysteine residues at the C-terminus of the CHI domain; (v) the Fv fragment having the VL and VH domains of a single arm of an antibody; (vi) the dAb fragment (Ward et al., 341 Nature 544 (1989)) which consists of a VH domain or a VL domain that binds antigen; (vii) isolated CDR regions or isolated CDR regions presented in a functional framework; (viii) F(ab') ₂ fragments which are bivalent fragments including two Fab' fragments linked by a disulphide bridge at the hinge region; (ix) single chain antibody molecules (e.g., single chain Fv; scFv) (Bird et al., 242 Science 423 (1988); and Huston et al., 85 PNAS 5879 (1988)); (x) "diabodies" with two antigen binding sites, comprising a heavy chain variable domain (VH) connected to a light chain variable domain (VL) in the same polypeptide chain (see, e.g., EP 404,097; WO 93/11161; Hollinger et al., 90 PNAS 6444 (1993)); (xi) "linear antibodies" comprising a pair of tandem Fd segments (VH-Chl-VH-Chl) which, together with complementary light chain polypeptides, form a pair of antigen binding regions (Zapata et al., Protein Eng. 8(10): 1057-62 (1995); and U.S. Patent No. 5,641,870). [0213] As used herein, a "blocking" antibody or an antibody "antagonist" is one which inhibits or reduces biological activity of the antigen(s) it binds. In certain embodiments, the blocking antibodies or antagonist antibodies or portions thereof described herein completely inhibit the biological activity of the antigen(s).

[0214] Antibodies may act as agonists or antagonists of the recognized polypeptides. For example, the present invention includes antibodies which disrupt receptor/ligand interactions either partially or fully. The invention features both receptor-specific antibodies and ligand- specific antibodies. The invention also features receptor-specific antibodies which do not prevent ligand binding but prevent receptor activation. Receptor activation (i.e., signaling) may be determined by techniques described herein or otherwise known in the art. For example, receptor activation can be determined by detecting the phosphorylation (e.g., tyrosine or serine/threonine) of the receptor or of one of its down-stream substrates by immunoprecipitation followed by western blot analysis. In specific embodiments, antibodies are provided that inhibit ligand activity or receptor activity by at least 95%, at least 90%, at least 85%, at least 80%, at least 75%, at least 70%, at least 60%, or at least 50% of the activity in absence of the antibody.

[0215] The invention also features receptor-specific antibodies which both prevent ligand binding and receptor activation as well as antibodies that recognize the receptor-ligand complex. Likewise, encompassed by the invention are neutralizing antibodies which bind the ligand and prevent binding of the ligand to the receptor, as well as antibodies which bind the ligand, thereby preventing receptor activation, but do not prevent the ligand from binding the receptor. Further included in the invention are antibodies which activate the receptor. These antibodies may act as receptor agonists, i.e., potentiate or activate either all or a subset of the biological activities of the ligand-mediated receptor activation, for example, by inducing dimerization of the receptor. The antibodies may be specified as agonists, antagonists or inverse agonists for biological activities comprising the specific biological activities of the peptides disclosed herein. The antibody agonists and antagonists can be made using methods known in the art. See, e.g., PCT publication WO 96/40281; U.S. Pat. No. 5,811,097; Deng et al., Blood 92(6): 1981-1988 (1998); Chen et al., Cancer Res. 58(16):3668-3678 (1998);

Harrop et al., J. Immunol. 161(4): 1786-1794 (1998); Zhu et al., Cancer Res. 58(15):3209-

3214 (1998); Yoon et al., J. Immunol. 160(7):3170-3179 (1998); Prat et al., J. Cell. Sci. Ill

(Pt2):237-247 (1998); Pitard et al., J. Immunol. Methods 205(2): 177-190 (1997); Liautard et al., Cytokine 9(4):233-241 (1997); Carlson et al., J. Biol. Chem. 272(17): 11295-11301 (1997); Taryman et al., Neuron 14(4):755-762 (1995); Muller et al., Structure 6(9): 1153- 1167 (1998); Bartunek et al., Cytokine 8(1): 14-20 (1996).

[0216] The antibodies as defined for the present invention include derivatives that are modified, i.e., by the covalent attachment of any type of molecule to the antibody such that covalent attachment does not prevent the antibody from generating an anti -idiotypic response. For example, but not by way of limitation, the antibody derivatives include antibodies that have been modified, e.g., by glycosylation, acetylation, pegylation, phosphylation, amidation, derivatization by known protecting/blocking groups, proteolytic cleavage, linkage to a cellular ligand or other protein, etc. Any of numerous chemical modifications may be carried out by known techniques, including, but not limited to specific chemical cleavage, acetylation, formylation, metabolic synthesis of tunicamycin, etc. Additionally, the derivative may contain one or more non-classical amino acids.

[0217] Simple binding assays can be used to screen for or detect agents that bind to a target protein, or disrupt the interaction between proteins (e.g., a receptor and a ligand). Because certain targets of the present invention are transmembrane proteins, assays that use the soluble forms of these proteins rather than full-length protein can be used, in some embodiments. Soluble forms include, for example, those lacking the transmembrane domain and/or those comprising the IgV domain or fragments thereof which retain their ability to bind their cognate binding partners. Further, agents that inhibit or enhance protein interactions for use in the compositions and methods described herein, can include recombinant peptido-mimetics.

[0218] Detection methods useful in screening assays include antibody-based methods, detection of a reporter moiety, detection of cytokines as described herein, and detection of a gene signature as described herein.

[0219] Another variation of assays to determine binding of a receptor protein to a ligand protein is through the use of affinity biosensor methods. Such methods may be based on the piezoelectric effect, electrochemistry, or optical methods, such as ellipsometry, optical wave guidance, and surface plasmon resonance (SPR).

[0220] The disclosure also encompasses nucleic acid molecules, in particular those that inhibit a signature gene. Exemplary nucleic acid molecules include aptamers, siRNA, artificial microRNA, interfering RNA or RNAi, dsRNA, ribozymes, antisense oligonucleotides, and DNA expression cassettes encoding said nucleic acid molecules.

Preferably, the nucleic acid molecule is an antisense oligonucleotide. Antisense oligonucleotides (ASO) generally inhibit their target by binding target mRNA and sterically blocking expression by obstructing the ribosome. ASOs can also inhibit their target by binding target mRNA thus forming a DNA-RNA hybrid that can be a substance for RNase H. Preferred ASOs include Locked Nucleic Acid (LNA), Peptide Nucleic Acid (PNA), and morpholinos Preferably, the nucleic acid molecule is an RNAi molecule, i.e., RNA interference molecule. Preferred RNAi molecules include siRNA, shRNA, and artificial miRNA. The design and production of siRNA molecules is well known to one of skill in the art (e.g., Hajeri PB, Singh SK. Drug Discov Today. 2009 14(17-18):851-8). The nucleic acid molecule inhibitors may be chemically synthesized and provided directly to cells of interest. The nucleic acid compound may be provided to a cell as part of a gene delivery vehicle. Such a vehicle is preferably a liposome or a viral gene delivery vehicle.

[0221] In certain embodiments, the one or more agents is a small molecule. The term "small molecule" refers to compounds, preferably organic compounds, with a size comparable to those organic molecules generally used in pharmaceuticals. The term excludes biological macromolecules (e.g., proteins, peptides, nucleic acids, etc.). Preferred small organic molecules range in size up to about 5000 Da, e.g., up to about 4000, preferably up to 3000 Da, more preferably up to 2000 Da, even more preferably up to about 1000 Da, e.g., up to about 900, 800, 700, 600 or up to about 500 Da. In certain embodiments, the small molecule may act as an antagonist or agonist (e.g., blocking an enzyme active site or activating a receptor by binding to a ligand binding site).

[0222] One type of small molecule applicable to the present invention is a degrader molecule. Proteolysis Targeting Chimera (PROTAC) technology is a rapidly emerging alternative therapeutic strategy with the potential to address many of the challenges currently faced in modern drug development programs. PROTAC technology employs small molecules that recruit target proteins for ubiquitination and removal by the proteasome (see, e.g., Bondeson and Crews, Targeted Protein Degradation by Small Molecules, Annu Rev Pharmacol Toxicol. 2017 Jan 6; 57: 107-123; and Lai et al., Modular PROTAC Design for the Degradation of Oncogenic BCR-ABL Angew Chem Int Ed Engl. 2016 Jan 11; 55(2): 807-810).

Adoptive Cell Therapy

[0223] As used herein, "ACT", "adoptive cell therapy" and "adoptive cell transfer" may be used interchangeably. In certain embodiments, Adoptive cell therapy (ACT) can refer to the transfer of cells to a patient with the goal of transferring the functionality and characteristics into the new host by engraftment of the cells (see, e.g., Mettananda et al., Editing an a-globin enhancer in primary human hematopoietic stem cells as a treatment for β- thalassemia, Nat Commun. 2017 Sep 4;8(1):424). As used herein, the term "engraft" or "engraftment" refers to the process of cell incorporation into a tissue of interest in vivo through contact with existing cells of the tissue. Adoptive cell therapy (ACT) can refer to the transfer of cells, most commonly immune-derived cells, back into the same patient or into a new recipient host with the goal of transferring the immunologic functionality and characteristics into the new host. If possible, use of autologous cells helps the recipient by minimizing GVHD issues. The adoptive transfer of autologous tumor infiltrating lymphocytes (TIL) (Besser et al., (2010) Clin. Cancer Res 16 (9) 2646-55; Dudley et al., (2002) Science 298 (5594): 850-4; and Dudley et al., (2005) Journal of Clinical Oncology 23 (10): 2346-57.) or genetically re-directed peripheral blood mononuclear cells (Johnson et al., (2009) Blood 114 (3): 535-46; and Morgan et al., (2006) Science 314(5796) 126-9) has been used to successfully treat patients with advanced solid tumors, including melanoma and colorectal carcinoma, as well as patients with CD19-expressing hematologic malignancies (Kalos et al., (2011) Science Translational Medicine 3 (95): 95ra73). In certain embodiments, allogenic cells immune cells are transferred (see, e.g., Ren et al., (2017) Clin Cancer Res 23 (9) 2255-2266). As described further herein, allogenic cells can be edited to reduce alloreactivity and prevent graft-versus-host disease. Thus, use of allogenic cells allows for cells to be obtained from healthy donors and prepared for use in patients as opposed to preparing autologous cells from a patient after diagnosis.

[0224] Aspects of the invention involve the adoptive transfer of immune system cells, such as T cells, specific for selected antigens, such as tumor associated antigens or tumor specific neoantigens (see, e.g., Maus et al., 2014, Adoptive Immunotherapy for Cancer or Viruses, Annual Review of Immunology, Vol. 32: 189-225; Rosenberg and Restifo, 2015, Adoptive cell transfer as personalized immunotherapy for human cancer, Science Vol. 348 no. 6230 pp. 62-68; Restifo et al., 2015, Adoptive immunotherapy for cancer: harnessing the T cell response. Nat. Rev. Immunol. 12(4): 269-281; and Jenson and Riddell, 2014, Design and implementation of adoptive therapy with chimeric antigen receptor-modified T cells. Immunol Rev. 257(1): 127-144; and Rajasagi et al., 2014, Systematic identification of personal tumor-specific neoantigens in chronic lymphocytic leukemia. Blood. 2014 Jul 17; 124(3):453-62). [0225] In certain embodiments, an antigen (such as a tumor antigen) to be targeted in adoptive cell therapy (such as particularly CAR or TCR T-cell therapy) of a disease (such as particularly of tumor or cancer) may be selected from a group consisting of: B cell maturation antigen (BCMA) (see, e.g., Friedman et al., Effective Targeting of Multiple BCMA-Expressing Hematological Malignancies by Anti-BCMA CAR T Cells, Hum Gene Ther. 2018 Mar 8; Berdeja JG, et al. Durable clinical responses in heavily pretreated patients with relapsed/refractory multiple myeloma: updated results from a multicenter study of bb2121 anti-Bcma CAR T cell therapy. Blood. 2017; 130:740; and Mouhieddine and Ghobrial, Immunotherapy in Multiple Myeloma: The Era of CAR T Cell Therapy, Hematologist, May-June 2018, Volume 15, issue 3); PSA (prostate-specific antigen); prostate-specific membrane antigen (PSMA); PSCA (Prostate stem cell antigen); Tyrosine- protein kinase transmembrane receptor ROR1; fibroblast activation protein (FAP); Tumor- associated glycoprotein 72 (TAG72); Carcinoembryonic antigen (CEA); Epithelial cell adhesion molecule (EPCAM); Mesothelin; Human Epidermal growth factor Receptor 2 (ERBB2 (Her2/neu)); Prostase; Prostatic acid phosphatase (PAP); elongation factor 2 mutant (ELF2M); Insulin-like growth factor 1 receptor (IGF-1R); gplOO; BCR-ABL (breakpoint cluster region-Abelson); tyrosinase; New York esophageal squamous cell carcinoma 1 (NY- ESO-1); K-light chain, LAGE (L antigen); MAGE (melanoma antigen); Melanoma-associated antigen 1 (MAGE-A1); MAGE A3; MAGE A6; legumain; Human papillomavirus (HPV) E6; HPV E7; prostein; survivin; PCTA1 (Galectin 8); Mel an- A/MART - 1 ; Ras mutant; TRP-1 (tyrosinase related protein 1, or gp75); Tyrosinase-related Protein 2 (TRP2); TRP-2/INT2 (TRP-2/intron 2); RAGE (renal antigen); receptor for advanced glycation end products 1 (RAGEl); Renal ubiquitous 1, 2 (RUl, RU2); intestinal carboxyl esterase (iCE); Heat shock protein 70-2 (HSP70-2) mutant; thyroid stimulating hormone receptor (TSHR); CD123; CD171; CD19; CD20; CD22; CD26; CD30; CD33; CD44v7/8 (cluster of differentiation 44, exons 7/8); CD53; CD92; CD100; CD148; CD150; CD200; CD261; CD262; CD362; CS-1 (CD2 subset 1, CRACC, SLAMF7, CD319, and 19A24); C-type lectin-like molecule-1 (CLL-1); ganglioside GD3 (aNeu5Ac(2-8)aNeu5Ac(2-3)bDGalp(l-4)bDGlcp(l-l)Cer); Tn antigen (Tn Ag); Fms-Like Tyrosine Kinase 3 (FLT3); CD38; CD 138; CD44v6; B7H3 (CD276); KIT (CD117); Interleukin-13 receptor subunit alpha-2 (IL-13Ra2); Interleukin 11 receptor alpha (IL-l lRa); prostate stem cell antigen (PSCA); Protease Serine 21 (PRSS21); vascular endothelial growth factor receptor 2 (VEGFR2); Lewis(Y) antigen; CD24; Platelet- derived growth factor receptor beta (PDGFR-beta); stage-specific embryonic antigen-4 (SSEA-4); Mucin 1, cell surface associated (MUCl); mucin 16 (MUC16); epidermal growth factor receptor (EGFR); epidermal growth factor receptor variant III (EGFRvIII); neural cell adhesion molecule (NCAM); carbonic anhydrase IX (CAIX); Proteasome (Prosome, Macropain) Subunit, Beta Type, 9 (LMP2); ephrin type-A receptor 2 (EphA2); Ephrin B2; Fucosyl GM1; sialyl Lewis adhesion molecule (sLe); ganglioside GM3 (aNeu5Ac(2- 3)bDGalp(l-4)bDGlcp(l-l)Cer); TGS5; high molecular weight-melanoma-associated antigen (HMWMAA); o-acetyl-GD2 ganglioside (OAcGD2); Folate receptor alpha; Folate receptor beta; tumor endothelial marker 1 (TEM1/CD248); tumor endothelial marker 7-related (TEM7R); claudin 6 (CLDN6); G protein-coupled receptor class C group 5, member D (GPRC5D); chromosome X open reading frame 61 (CXORF61); CD97; CD 179a; anaplastic lymphoma kinase (ALK); Poly sialic acid; placenta-specific 1 (PLAC1); hexasaccharide portion of globoH glycoceramide (GloboH); mammary gland differentiation antigen (NY- BR-1); uroplakin 2 (UPK2); Hepatitis A virus cellular receptor 1 (HAVCR1); adrenoceptor beta 3 (ADRB3); pannexin 3 (PANX3); G protein-coupled receptor 20 (GPR20); lymphocyte antigen 6 complex, locus K 9 (LY6K); Olfactory receptor 51E2 (OR51E2); TCR Gamma Alternate Reading Frame Protein (TARP); Wilms tumor protein (WT1); ETS translocation- variant gene 6, located on chromosome 12p (ETV6-AML); sperm protein 17 (SPA17); X Antigen Family, Member 1A (XAGE1); angiopoietin-binding cell surface receptor 2 (Tie 2); CT (cancer/testis (antigen)); melanoma cancer testis antigen-1 (MAD-CT-1); melanoma cancer testis antigen-2 (MAD-CT-2); Fos-related antigen 1; p53; p53 mutant; human Telomerase reverse transcriptase (hTERT); sarcoma translocation breakpoints; melanoma inhibitor of apoptosis (ML-IAP); ERG (transmembrane protease, serine 2 (TMPRSS2) ETS fusion gene); N- Acetyl glucosaminyl-transferase V (NA17); paired box protein Pax-3 (PAX3); Androgen receptor; Cyclin Bl; Cyclin Dl; v-myc avian myelocytomatosis viral oncogene neuroblastoma derived homolog (MYCN); Ras Homolog Family Member C (RhoC); Cytochrome P450 1B1 (CYPIBI); CCCTC-Binding Factor (Zinc Finger Protein- Like (BORIS); Squamous Cell Carcinoma Antigen Recognized By T Cells-1 or 3 (SARTl, SART3); Paired box protein Pax-5 (PAX5); proacrosin binding protein sp32 (OY-TES1); lymphocyte-specific protein tyrosine kinase (LCK); A kinase anchor protein 4 (AKAP-4); synovial sarcoma, X breakpoint- 1, -2, -3 or -4 (SSX1, SSX2, SSX3, SSX4); CD79a; CD79b; CD72; Leukocyte-associated immunoglobulin-like receptor 1 (LAIRl); Fc fragment of IgA receptor (FCAR); Leukocyte immunoglobulin-like receptor subfamily A member 2

(LILRA2); CD300 molecule-like family member f (CD300LF); C-type lectin domain family 12 member A (CLEC12A); bone marrow stromal cell antigen 2 (BST2); EGF-like module- containing mucin-like hormone receptor-like 2 (EMR2); lymphocyte antigen 75 (LY75); Glypican-3 (GPC3); Fc receptor-like 5 (FCRL5); mouse double minute 2 homolog (MDM2); livin; alphafetoprotein (AFP); transmembrane activator and CAML Interactor (TACI); B-cell activating factor receptor (BAFF-R); V-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog (KRAS); immunoglobulin lambda-like polypeptide 1 (IGLL1); 707-AP (707 alanine proline); ART -4 (adenocarcinoma antigen recognized by T4 cells); BAGE (B antigen; b-catenin/m, b- catenin/mutated); CAMEL (CTL-recognized antigen on melanoma); CAPl (carcinoembryonic antigen peptide 1); CASP-8 (caspase-8); CDC27m (cell-division cycle 27 mutated); CDK4/m (cycline-dependent kinase 4 mutated); Cyp-B (cyclophilin B); DAM (differentiation antigen melanoma); EGP-2 (epithelial glycoprotein 2); EGP-40 (epithelial glycoprotein 40); Erbb2, 3, 4 (erythroblastic leukemia viral oncogene homolog-2, -3, 4); FBP (folate binding protein); , fAchR (Fetal acetylcholine receptor); G250 (glycoprotein 250); GAGE (G antigen); GnT-V (N-acetylglucosaminyltransferase V); HAGE (helicose antigen); ULA-A (human leukocyte antigen- A); HST2 (human signet ring tumor 2); KIAA0205; KDR (kinase insert domain receptor); LDLR/FUT (low density lipid receptor/GDP L-fucose: b-D- galactosidase 2-a-L fucosyltransferase); L1CAM (LI cell adhesion molecule); MC1R (melanocortin 1 receptor); Myosin/m (myosin mutated); MUM-1, -2, -3 (melanoma ubiquitous mutated 1, 2, 3); NA88-A (NA cDNA clone of patient M88); KG2D (Natural killer group 2, member D) ligands; oncofetal antigen (h5T4); pi 90 minor bcr-abl (protein of 190KD bcr-abl); Pml/RARa (promyelocytic leukaemia/retinoic acid receptor a); PRAME (preferentially expressed antigen of melanoma); SAGE (sarcoma antigen); TEL/AMLl (translocation Ets-family leukemia/acute myeloid leukemia 1); TPI/m (triosephosphate isomerase mutated); CD70; and any combination thereof.

[0226] In certain embodiments, an antigen to be targeted in adoptive cell therapy (such as particularly CAR or TCR T-cell therapy) of a disease (such as particularly of tumor or cancer) is a tumor-specific antigen (TSA).

[0227] In certain embodiments, an antigen to be targeted in adoptive cell therapy (such as particularly CAR or TCR T-cell therapy) of a disease (such as particularly of tumor or cancer) is a neoantigen.

[0228] In certain embodiments, an antigen to be targeted in adoptive cell therapy (such as particularly CAR or TCR T-cell therapy) of a disease (such as particularly of tumor or cancer) is a tumor-associated antigen (TAA). [0229] In certain embodiments, an antigen to be targeted in adoptive cell therapy (such as particularly CAR or TCR T-cell therapy) of a disease (such as particularly of tumor or cancer) is a universal tumor antigen. In certain preferred embodiments, the universal tumor antigen is selected from the group consisting of: a human telomerase reverse transcriptase (hTERT), survivin, mouse double minute 2 homolog (MDM2), cytochrome P450 IB 1 (CYP1B), HER2/neu, Wilms' tumor gene 1 (WT1), livin, alphafetoprotein (AFP), carcinoembryonic antigen (CEA), mucin 16 (MUC16), MUC1, prostate-specific membrane antigen (PSMA), p53, cyclin (Dl), and any combinations thereof.

[0230] In certain embodiments, an antigen (such as a tumor antigen) to be targeted in adoptive cell therapy (such as particularly CAR or TCR T-cell therapy) of a disease (such as particularly of tumor or cancer) may be selected from a group consisting of: CD19, BCMA,

CD70, CLL-1, MAGE A3, MAGE A6, HPV E6, HPV E7, WT1, CD22, CD171, ROR1,

MUC16, and SSX2. In certain preferred embodiments, the antigen may be CD19. For example, CD 19 may be targeted in hematologic malignancies, such as in lymphomas, more particularly in B-cell lymphomas, such as without limitation in diffuse large B-cell lymphoma, primary mediastinal b-cell lymphoma, transformed follicular lymphoma, marginal zone lymphoma, mantle cell lymphoma, acute lymphoblastic leukemia including adult and pediatric ALL, non-Hodgkin lymphoma, indolent non-Hodgkin lymphoma, or chronic lymphocytic leukemia. For example, BCMA may be targeted in multiple myeloma or plasma cell leukemia (see, e.g., 2018 American Association for Cancer Research (AACR)

Annual meeting Poster: Allogeneic Chimeric Antigen Receptor T Cells Targeting B Cell

Maturation Antigen). For example, CLL1 may be targeted in acute myeloid leukemia. For example, MAGE A3, MAGE A6, SSX2, and/or KRAS may be targeted in solid tumors. For example, HPV E6 and/or HPV E7 may be targeted in cervical cancer or head and neck cancer. For example, WT1 may be targeted in acute myeloid leukemia (AML), myelodysplastic syndromes (MDS), chronic myeloid leukemia (CML), non-small cell lung cancer, breast, pancreatic, ovarian or colorectal cancers, or mesothelioma. For example,

CD22 may be targeted in B cell malignancies, including non-Hodgkin lymphoma, diffuse large B-cell lymphoma, or acute lymphoblastic leukemia. For example, CD171 may be targeted in neuroblastoma, glioblastoma, or lung, pancreatic, or ovarian cancers. For example, ROR1 may be targeted in ROR1+ malignancies, including non-small cell lung cancer, triple negative breast cancer, pancreatic cancer, prostate cancer, ALL, chronic lymphocytic leukemia, or mantle cell lymphoma. For example, MUC16 may be targeted in MUC16ecto+ epithelial ovarian, fallopian tube or primary peritoneal cancer. For example, CD70 may be targeted in both hematologic malignancies as well as in solid cancers such as renal cell carcinoma (RCC), gliomas (e.g., GBM), and head and neck cancers (HNSCC). CD70 is expressed in both hematologic malignancies as well as in solid cancers, while its expression in normal tissues is restricted to a subset of lymphoid cell types (see, e.g., 2018 American Association for Cancer Research (AACR) Annual meeting Poster: Allogeneic CRISPR Engineered Anti-CD70 CAR-T Cells Demonstrate Potent Preclinical Activity Against Both Solid and Hematological Cancer Cells).

[0231] Various strategies may for example be employed to genetically modify T cells by altering the specificity of the T cell receptor (TCR) for example by introducing new TCR a and β chains with selected peptide specificity (see U.S. Patent No. 8,697,854; PCT Patent Publications: WO2003020763, WO2004033685, WO2004044004, WO2005114215, WO2006000830, WO2008038002, WO2008039818, WO2004074322, WO2005113595, WO2006125962, WO2013166321, WO2013039889, WO2014018863, WO2014083173; U.S. Patent No. 8,088,379).

[0232] As an alternative to, or addition to, TCR modifications, chimeric antigen receptors (CARs) may be used in order to generate immunoresponsive cells, such as T cells, specific for selected targets, such as malignant cells, with a wide variety of receptor chimera constructs having been described (see U.S. Patent Nos. 5,843,728; 5,851,828; 5,912, 170; 6,004,811; 6,284,240; 6,392,013; 6,410,014; 6,753, 162; 8,211,422; and, PCT Publication W09215322).

[0233] In general, CARs are comprised of an extracellular domain, a transmembrane domain, and an intracellular domain, wherein the extracellular domain comprises an antigen- binding domain that is specific for a predetermined target. While the antigen-binding domain of a CAR is often an antibody or antibody fragment (e.g., a single chain variable fragment, scFv), the binding domain is not particularly limited so long as it results in specific recognition of a target. For example, in some embodiments, the antigen-binding domain may comprise a receptor, such that the CAR is capable of binding to the ligand of the receptor. Alternatively, the antigen-binding domain may comprise a ligand, such that the CAR is capable of binding the endogenous receptor of that ligand.

[0234] The antigen-binding domain of a CAR is generally separated from the transmembrane domain by a hinge or spacer. The spacer is also not particularly limited, and it is designed to provide the CAR with flexibility. For example, a spacer domain may comprise a portion of a human Fc domain, including a portion of the CH3 domain, or the hinge region of any immunoglobulin, such as IgA, IgD, IgE, IgG, or IgM, or variants thereof. Furthermore, the hinge region may be modified so as to prevent off-target binding by FcRs or other potential interfering objects. For example, the hinge may comprise an IgG4 Fc domain with or without a S228P, L235E, and/or N297Q mutation (according to Kabat numbering) in order to decrease binding to FcRs. Additional spacers/hinges include, but are not limited to, CD4, CD8, and CD28 hinge regions.

[0235] The transmembrane domain of a CAR may be derived either from a natural or from a synthetic source. Where the source is natural, the domain may be derived from any membrane bound or transmembrane protein. Transmembrane regions of particular use in this disclosure may be derived from CD8, CD28, CD3, CD45, CD4, CD5, CDS, CD9, CD 16, CD22, CD33, CD37, CD64, CD80, CD86, CD 134, CD137, CD 154, TCR. Alternatively, the transmembrane domain may be synthetic, in which case it will comprise predominantly hydrophobic residues such as leucine and valine. Preferably a triplet of phenylalanine, tryptophan and valine will be found at each end of a synthetic transmembrane domain. Optionally, a short oligo- or polypeptide linker, preferably between 2 and 10 amino acids in length may form the linkage between the transmembrane domain and the cytoplasmic signaling domain of the CAR. A glycine-serine doublet provides a particularly suitable linker.

[0236] Alternative CAR constructs may be characterized as belonging to successive generations. First-generation CARs typically consist of a single-chain variable fragment of an antibody specific for an antigen, for example comprising a VL linked to a VH of a specific antibody, linked by a flexible linker, for example by a CD8a hinge domain and a CD8a transmembrane domain, to the transmembrane and intracellular signaling domains of either CD3C or FcRy (scFv-CD3C or scFv-FcRy; see U.S. Patent No. 7,741,465; U.S. Patent No. 5,912, 172; U.S. Patent No. 5,906,936). Second-generation CARs incorporate the intracellular domains of one or more costimulatory molecules, such as CD28, OX40 (CD134), or 4-1BB (CD137) within the endodomain (for example scFv-CD28/OX40/4-lBB-CD3 see U.S. Patent Nos. 8,911,993; 8,916,381; 8,975,071; 9, 101,584; 9, 102,760; 9, 102,761). Third- generation CARs include a combination of costimulatory endodomains, such a

CD97, GDI la-CD18, CD2, ICOS, CD27, CD154, CDS, OX40, 4-1BB, CD2, CD7, LIGHT, LFA-1, NKG2C, B7-H3, CD30, CD40, PD-1, or CD28 signaling domains (for example scFv-

CD28-4-lBB-CD3C or scFv-CD28-OX40-CD3 see U.S. Patent No. 8,906,682; U.S. Patent No. 8,399,645; U.S. Pat. No. 5,686,281; PCT Publication No. WO2014134165; PCT

Publication No. WO2012079000). In certain embodiments, the primary signaling domain comprises a functional signaling domain of a protein selected from the group consisting of

CD3 zeta, CD3 gamma, CD3 delta, CD3 epsilon, common FcR gamma (FCERIG), FcR beta

(Fc Epsilon Rib), CD79a, CD79b, Fc gamma Rlla, DAP10, and DAP12. In certain preferred embodiments, the primary signaling domain comprises a functional signaling domain of

CD3ζ or FcRy. In certain embodiments, the one or more costimulatory signaling domains comprise a functional signaling domain of a protein selected, each independently, from the group consisting of: CD27, CD28, 4-1BB (CD137), OX40, CD30, CD40, PD-1, ICOS, lymphocyte function-associated antigen- 1 (LFA-1), CD2, CD7, LIGHT, NKG2C, B7-H3, a ligand that specifically binds with CD83, CDS, ICAM-1, GITR, BAFFR, HVEM (LIGHTR),

SLAMF7, NKp80 (KLRF1), CD 160, CD 19, CD4, CD 8 alpha, CD 8 beta, IL2R beta, IL2R gamma, IL7R alpha, ITGA4, VLAl, CD49a, ITGA4, IA4, CD49D, ITGA6, VLA-6, CD49f,

ITGAD, CDl ld, ITGAE, CD103, ITGAL, CDl la, LFA-1, ITGAM, CDl lb, ITGAX,

CD 11c, ITGB1, CD29, ITGB2, CD 18, ITGB7, TNFR2, TRANCE/RANKL, DNAM1

(CD226), SLAMF4 (CD244, 2B4), CD84, CD96 (Tactile), CEACAM1, CRT AM, Ly9

(CD229), CD 160 (BY55), PSGL1, CD 100 (SEMA4D), CD69, SLAMF6 (NTB-A, Lyl08),

SLAM (SLAMF1, CD 150, IPO-3), BLAME (SLAMF8), SELPLG (CD 162), LTBR, LAT,

GADS, SLP-76, PAG/Cbp, NKp44, NKp30, NKp46, and NKG2D. In certain embodiments, the one or more costimulatory signaling domains comprise a functional signaling domain of a protein selected, each independently, from the group consisting of: 4-1BB, CD27, and CD28.

In certain embodiments, a chimeric antigen receptor may have the design as described in U.S.

Patent No. 7,446, 190, comprising an intracellular domain of CD3ζ chain (such as amino acid residues 52-163 of the human CD3 zeta chain, as shown in SEQ ID NO: 14 of US

7,446, 190), a signaling region from CD28 and an antigen-binding element (or portion or domain; such as scFv). The CD28 portion, when between the zeta chain portion and the antigen-binding element, may suitably include the transmembrane and signaling domains of

CD28 (such as amino acid residues 114-220 of SEQ ID NO: 10, full sequence shown in SEQ

ID NO: 6 of US 7,446, 190; these can include the following portion of CD28 as set forth in

Genbank identifier NM_006139 (sequence version 1, 2 or 3):

IEVMYPPPYLDNEKSNGTIIHVKGKHLCPSPLFPGPSKPFWVLVVVGGVLACYSLLV T

VAFIIFWVRSKRSRLLHSDYMNMTPRRPGPTRKHYQPYAPPRDFAAYRS) (SEQ ID

NO: 1). Alternatively, when the zeta sequence lies between the CD28 sequence and the antigen-binding element, intracellular domain of CD28 can be used alone (such as amino sequence set forth in SEQ ID NO: 9 of US 7,446, 190). Hence, certain embodiments employ a CAR comprising (a) a zeta chain portion comprising the intracellular domain of human Οϋ3ζ chain, (b) a costimulatory signaling region, and (c) an antigen-binding element (or portion or domain), wherein the costimulatory signaling region comprises the amino acid sequence encoded by SEQ ID NO: 6 of US 7,446, 190.

[0237] Alternatively, costimulation may be orchestrated by expressing CARs in antigen- specific T cells, chosen so as to be activated and expanded following engagement of their native αβΤΟΙ, for example by antigen on professional antigen-presenting cells, with attendant costimulation. In addition, additional engineered receptors may be provided on the immunoresponsive cells, for example to improve targeting of a T-cell attack and/or minimize side effects

[0238] By means of an example and without limitation, Kochenderfer et al., (2009) J

Immunother. 32 (7): 689-702 described anti-CD 19 chimeric antigen receptors (CAR).

FMC63-28Z CAR contained a single chain variable region moiety (scFv) recognizing CD 19 derived from the FMC63 mouse hybridoma (described in Nicholson et al., (1997) Molecular

Immunology 34: 1157-1165), a portion of the human CD28 molecule, and the intracellular component of the human TCR-ζ molecule. FMC63 -CD828BBZ CAR contained the FMC63 scFv, the hinge and transmembrane regions of the CD8 molecule, the cytoplasmic portions of

CD28 and 4-1BB, and the cytoplasmic component of the TCR-ζ molecule. The exact sequence of the CD28 molecule included in the FMC63-28Z CAR corresponded to Genbank identifier NM 006139; the sequence included all amino acids starting with the amino acid sequence IEVMYPPPY and continuing all the way to the carboxy-terminus of the protein. To encode the anti-CD 19 scFv component of the vector, the authors designed a DNA sequence which was based on a portion of a previously published CAR (Cooper et al., (2003) Blood

101 : 1637-1644). This sequence encoded the following components in frame from the 5' end to the 3' end: an Xhol site, the human granulocyte-macrophage colony-stimulating factor

(GM-CSF) receptor a-chain signal sequence, the FMC63 light chain variable region (as in

Nicholson et al., supra), a linker peptide (as in Cooper et al., supra), the FMC63 heavy chain variable region (as in Nicholson et al., supra), and a Notl site. A plasmid encoding this sequence was digested with Xhol and Not! To form the MSGV-FMC63-28Z retroviral vector, the Xhol and Notl-digested fragment encoding the FMC63 scFv was ligated into a second Xhol and Notl-digested fragment that encoded the MSGV retroviral backbone (as in Hughes et al., (2005) Human Gene Therapy 16: 457-472) as well as part of the extracellular portion of human CD28, the entire transmembrane and cytoplasmic portion of human CD28, and the cytoplasmic portion of the human TCR-ζ molecule (as in Maher et al., 2002) Nature Biotechnology 20: 70-75). The FMC63-28Z CAR is included in the KTE-C19 (axicabtagene ciloleucel) anti-CD 19 CAR-T therapy product in development by Kite Pharma, Inc. for the treatment of inter alia patients with relapsed/refractory aggressive B-cell non-Hodgkin lymphoma (NHL). Accordingly, in certain embodiments, cells intended for adoptive cell therapies, more particularly immunoresponsive cells such as T cells, may express the FMC63-28Z CAR as described by Kochenderfer et al. {supra). Hence, in certain embodiments, cells intended for adoptive cell therapies, more particularly immunoresponsive cells such as T cells, may comprise a CAR comprising an extracellular antigen-binding element (or portion or domain; such as scFv) that specifically binds to an antigen, an intracellular signaling domain comprising an intracellular domain of a CD3ζ chain, and a costimulatory signaling region comprising a signaling domain of CD28. Preferably, the CD28 amino acid sequence is as set forth in Genbank identifier NM 006139 (sequence version 1, 2 or 3) starting with the amino acid sequence lEVMYPPPY and continuing all the way to the carboxy-terminus of the protein. The sequence is reproduced herein: IEVMYPPPYLDNEKSNGTIIHVKGKHLCPSPLFPGPSKPFWVLVVVGGVLACYSLLVT VAFIIF WVRSKRSRLLHSD YMNMTPRRPGPTRKHYQP YAPPRDF AAYRS . Preferably, the antigen is CD 19, more preferably the antigen-binding element is an anti-CD 19 scFv, even more preferably the anti-CD19 scFv as described by Kochenderfer et al. {supra).

[0239] Additional anti-CD 19 CARs are further described in WO2015187528. More particularly Example 1 and Table 1 of WO2015187528, incorporated by reference herein, demonstrate the generation of anti-CD 19 CARs based on a fully human anti-CD 19 monoclonal antibody (47G4, as described in US20100104509) and murine anti-CD 19 monoclonal antibody (as described in Nicholson et al. and explained above). Various combinations of a signal sequence (human CD8-alpha or GM-CSF receptor), extracellular and transmembrane regions (human CD8-alpha) and intracellular T-cell signalling domains (CD28-CD3 4-lBB-CD3 CD27-CD3 CD28-CD27-CD3C, 4-lBB-CD27-CD3 CD27- 4-1ΒΒ^ϋ3ζ; CD28-CD27-FcsRI gamma chain; or CD28-FcsRI gamma chain) were disclosed. Hence, in certain embodiments, cells intended for adoptive cell therapies, more particularly immunoresponsive cells such as T cells, may comprise a CAR comprising an extracellular antigen-binding element that specifically binds to an antigen, an extracellular and transmembrane region as set forth in Table 1 of WO2015187528 and an intracellular T- cell signalling domain as set forth in Table 1 of WO2015187528. Preferably, the antigen is CD 19, more preferably the antigen-binding element is an anti-CD 19 scFv, even more preferably the mouse or human anti-CD 19 scFv as described in Example 1 of WO2015187528. In certain embodiments, the CAR comprises, consists essentially of or consists of an amino acid sequence of SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO: 10, SEQ ID NO: 11, SEQ ID NO: 12, or SEQ ID NO: 13 as set forth in Table 1 of WO2015187528.

[0240] By means of an example and without limitation, chimeric antigen receptor that recognizes the CD70 antigen is described in WO2012058460 A2 (see also, Park et al., CD70 as a target for chimeric antigen receptor T cells in head and neck squamous cell carcinoma, Oral Oncol. 2018 Mar;78: 145-150; and Jin et al., CD70, a novel target of CAR T-cell therapy for gliomas, Neuro Oncol. 2018 Jan 10;20(l):55-65). CD70 is expressed by diffuse large B- cell and follicular lymphoma and also by the malignant cells of Hodgkins lymphoma, Waldenstrom's macroglobulinemia and multiple myeloma, and by HTLV-1- and EBV- associated malignancies. (Agathanggelou et al. Am. J.Pathol. 1995; 147: 1152-1160; Hunter et al., Blood 2004; 104:4881. 26; Lens et al., J Immunol. 2005; 174:6212-6219; Baba et al., J Virol. 2008;82:3843-3852.) In addition, CD70 is expressed by non-hematological malignancies such as renal cell carcinoma and glioblastoma. (Junker et al., J Urol. 2005; 173 :2150-2153; Chahlavi et al., Cancer Res 2005;65:5428-5438) Physiologically, CD70 expression is transient and restricted to a subset of highly activated T, B, and dendritic cells.

[0241] By means of an example and without limitation, chimeric antigen receptor that recognizes BCMA has been described (see, e.g., US20160046724A1; WO2016014789A2; WO2017211900A1; WO2015158671A1; US20180085444A1; WO2018028647A1; US20170283504A1 ; and WO2013154760A1).

[0242] In certain embodiments, the immune cell may, in addition to a CAR or exogenous

TCR as described herein, further comprise a chimeric inhibitory receptor (inhibitory CAR) that specifically binds to a second target antigen and is capable of inducing an inhibitory or immunosuppressive or repressive signal to the cell upon recognition of the second target antigen. In certain embodiments, the chimeric inhibitory receptor comprises an extracellular antigen-binding element (or portion or domain) configured to specifically bind to a target antigen, a transmembrane domain, and an intracellular immunosuppressive or repressive signaling domain. In certain embodiments, the second target antigen is an antigen that is not expressed on the surface of a cancer cell or infected cell or the expression of which is downregulated on a cancer cell or an infected cell. In certain embodiments, the second target antigen is an MHC-class I molecule. In certain embodiments, the intracellular signaling domain comprises a functional signaling portion of an immune checkpoint molecule, such as for example PD-1 or CTLA4. Advantageously, the inclusion of such inhibitory CAR reduces the chance of the engineered immune cells attacking non-target (e.g., non-cancer) tissues.

[0243] Alternatively, T-cells expressing CARs may be further modified to reduce or eliminate expression of endogenous TCRs in order to reduce off-target effects. Reduction or elimination of endogenous TCRs can reduce off-target effects and increase the effectiveness of the T cells (U.S. 9, 181,527). T cells stably lacking expression of a functional TCR may be produced using a variety of approaches. T cells internalize, sort, and degrade the entire T cell receptor as a complex, with a half-life of about 10 hours in resting T cells and 3 hours in stimulated T cells (von Essen, M. et al. 2004. J. Immunol. 173 :384-393). Proper functioning of the TCR complex requires the proper stoichiometric ratio of the proteins that compose the

TCR complex. TCR function also requires two functioning TCR zeta proteins with ITAM motifs. The activation of the TCR upon engagement of its MHC -peptide ligand requires the engagement of several TCRs on the same T cell, which all must signal properly. Thus, if a

TCR complex is destabilized with proteins that do not associate properly or cannot signal optimally, the T cell will not become activated sufficiently to begin a cellular response.

[0244] Accordingly, in some embodiments, TCR expression may eliminated using RNA interference (e.g., shRNA, siRNA, miRNA, etc.), CRISPR, or other methods that target the nucleic acids encoding specific TCRs (e.g., TCR-a and TCR-β) and/or CD3 chains in primary T cells. By blocking expression of one or more of these proteins, the T cell will no longer produce one or more of the key components of the TCR complex, thereby destabilizing the TCR complex and preventing cell surface expression of a functional TCR.

[0245] In some instances, CAR may also comprise a switch mechanism for controlling expression and/or activation of the CAR. For example, a CAR may comprise an extracellular, transmembrane, and intracellular domain, in which the extracellular domain comprises a target-specific binding element that comprises a label, binding domain, or tag that is specific for a molecule other than the target antigen that is expressed on or by a target cell. In such embodiments, the specificity of the CAR is provided by a second construct that comprises a target antigen binding domain (e.g., an scFv or a bispecific antibody that is specific for both the target antigen and the label or tag on the CAR) and a domain that is recognized by or binds to the label, binding domain, or tag on the CAR. See, e.g., WO 2013/044225, WO 2016/000304, WO 2015/057834, WO 2015/057852, WO 2016/070061, US 9,233, 125, US 2016/0129109. In this way, a T-cell that expresses the CAR can be administered to a subject, but the CAR cannot bind its target antigen until the second composition comprising an antigen-specific binding domain is administered.

[0246] Alternative switch mechanisms include CARs that require multimerization in order to activate their signaling function (see, e.g., US 2015/0368342, US 2016/0175359, US 2015/0368360) and/or an exogenous signal, such as a small molecule drug (US 2016/0166613, Yung et al., Science, 2015), in order to elicit a T-cell response. Some CARs may also comprise a "suicide switch" to induce cell death of the CAR T-cells following treatment (Buddee et al., PLoS One, 2013) or to downregulate expression of the CAR following binding to the target antigen (WO 2016/011210).

[0247] Alternative techniques may be used to transform target immunoresponsive cells, such as protoplast fusion, lipofection, transfection or electroporation. A wide variety of vectors may be used, such as retroviral vectors, lentiviral vectors, adenoviral vectors, adeno- associated viral vectors, plasmids or transposons, such as a Sleeping Beauty transposon (see U.S. Patent Nos. 6,489,458; 7, 148,203; 7, 160,682; 7,985,739; 8,227,432), may be used to introduce CARs, for example using 2nd generation antigen-specific CARs signaling through Οϋ3ζ and either CD28 or CD137. Viral vectors may for example include vectors based on HIV, S V40, EB V, HS V or BPV.

[0248] Cells that are targeted for transformation may for example include T cells, Natural Killer (NK) cells, cytotoxic T lymphocytes (CTL), regulatory T cells, human embryonic stem cells, tumor-infiltrating lymphocytes (TIL) or a pluripotent stem cell from which lymphoid cells may be differentiated. T cells expressing a desired CAR may for example be selected through co-culture with γ-irradiated activating and propagating cells (AaPC), which co- express the cancer antigen and co-stimulatory molecules. The engineered CAR T-cells may be expanded, for example by co-culture on AaPC in presence of soluble factors, such as IL-2 and IL-21. This expansion may for example be carried out so as to provide memory CAR+ T cells (which may for example be assayed by non-enzymatic digital array and/or multi-panel flow cytometry). In this way, CAR T cells may be provided that have specific cytotoxic activity against antigen-bearing tumors (optionally in conjunction with production of desired chemokines such as interferon-γ). CAR T cells of this kind may for example be used in animal models, for example to treat tumor xenografts.

[0249] In certain embodiments, ACT includes co-transferring CD4+ Thl cells and CD8+ CTLs to induce a synergistic antitumour response (see, e.g., Li et al., Adoptive cell therapy with CD4+ T helper 1 cells and CD8+ cytotoxic T cells enhances complete rejection of an established tumour, leading to generation of endogenous memory responses to non-targeted tumour epitopes. Clin Transl Immunology. 2017 Oct; 6(10): el 60).

[0250] In certain embodiments, Thl7 cells are transferred to a subject in need thereof. Thl7 cells have been reported to directly eradicate melanoma tumors in mice to a greater extent than Thl cells (Muranski P, et al., Tumor-specific Thl7-polarized cells eradicate large established melanoma. Blood. 2008 Jul 15; 112(2): 362-73; and Martin-Orozco N, et al., T helper 17 cells promote cytotoxic T cell activation in tumor immunity. Immunity. 2009 Nov 20; 31(5):787-98). Those studies involved an adoptive T cell transfer (ACT) therapy approach, which takes advantage of CD4 ⁺ T cells that express a TCR recognizing tyrosinase tumor antigen. Exploitation of the TCR leads to rapid expansion of Thl7 populations to large numbers ex vivo for reinfusion into the autologous tumor-bearing hosts.

[0251] In certain embodiments, ACT may include autologous iPSC-based vaccines, such as irradiated iPSCs in autologous anti-tumor vaccines (see e.g., Kooreman, Nigel G. et al., Autologous iPSC-Based Vaccines Elicit Anti-tumor Responses In Vivo, Cell Stem Cell 22, 1-13, 2018, doi.org/10.1016/j .stem.2018.01.016).

[0252] Unlike T-cell receptors (TCRs) that are MHC restricted, CARs can potentially bind any cell surface-expressed antigen and can thus be more universally used to treat patients (see Irving et al., Engineering Chimeric Antigen Receptor T-Cells for Racing in Solid Tumors: Don't Forget the Fuel, Front. Immunol., 03 April 2017, doi.org/10.3389/fimmu.2017.00267). In certain embodiments, in the absence of endogenous T-cell infiltrate (e.g., due to aberrant antigen processing and presentation), which precludes the use of TIL therapy and immune checkpoint blockade, the transfer of CAR T-cells may be used to treat patients (see, e.g., Hinrichs CS, Rosenberg SA. Exploiting the curative potential of adoptive T-cell therapy for cancer. Immunol Rev (2014) 257(1):56-71. doi: 10.1111/ imr.12132).

[0253] Approaches such as the foregoing may be adapted to provide methods of treating and/or increasing survival of a subject having a disease, such as a neoplasia, for example by administering an effective amount of an immunoresponsive cell comprising an antigen recognizing receptor that binds a selected antigen, wherein the binding activates the immunoresponsive cell, thereby treating or preventing the disease (such as a neoplasia, a pathogen infection, an autoimmune disorder, or an allogeneic transplant reaction).

[0254] In certain embodiments, the treatment can be administered after lymphodepleting pretreatment in the form of chemotherapy (typically a combination of cyclophosphamide and fludarabine) or radiation therapy. Initial studies in ACT had short lived responses and the transferred cells did not persist in vivo for very long (Houot et al., T-cell-based immunotherapy: adoptive cell transfer and checkpoint inhibition. Cancer Immunol Res (2015) 3(10): 1115-22; and Kamta et al., Advancing Cancer Therapy with Present and Emerging Immuno-Oncology Approaches. Front. Oncol. (2017) 7:64). Immune suppressor cells like Tregs and MDSCs may attenuate the activity of transferred cells by outcompeting them for the necessary cytokines. Not being bound by a theory lymphodepleting pretreatment may eliminate the suppressor cells allowing the TILs to persist.

[0255] In one embodiment, the treatment can be administrated into patients undergoing an immunosuppressive treatment (e.g., glucocorticoid treatment). The cells or population of cells, may be made resistant to at least one immunosuppressive agent due to the inactivation of a gene encoding a receptor for such immunosuppressive agent. In certain embodiments, the immunosuppressive treatment provides for the selection and expansion of the immunoresponsive T cells within the patient.

[0256] In certain embodiments, the treatment can be administered before primary treatment (e.g., surgery or radiation therapy) to shrink a tumor before the primary treatment. In another embodiment, the treatment can be administered after primary treatment to remove any remaining cancer cells.

[0257] In certain embodiments, immunometabolic barriers can be targeted therapeutically prior to and/or during ACT to enhance responses to ACT or CAR T-cell therapy and to support endogenous immunity (see, e.g., Irving et al., Engineering Chimeric Antigen Receptor T-Cells for Racing in Solid Tumors: Don't Forget the Fuel, Front. Immunol., 03 April 2017, doi.org/10.3389/fimmu.2017.00267).

[0258] The administration of cells or population of cells, such as immune system cells or cell populations, such as more particularly immunoresponsive cells or cell populations, as disclosed herein may be carried out in any convenient manner, including by aerosol inhalation, injection, ingestion, transfusion, implantation or transplantation. The cells or population of cells may be administered to a patient subcutaneously, intradermally, intratumorally, intranodally, intramedullary, intramuscularly, intrathecally, by intravenous or intralymphatic injection, or intraperitoneally. In some embodiments, the disclosed CARs may be delivered or administered into a cavity formed by the resection of tumor tissue (i.e. intracavity delivery) or directly into a tumor prior to resection (i.e. intratumoral delivery). In one embodiment, the cell compositions of the present invention are preferably administered by intravenous injection.

[0259] The administration of the cells or population of cells can consist of the administration of 10 ⁴ - 10 ⁹ cells per kg body weight, preferably 10 ⁵ to 10 ⁶ cells/kg body weight including all integer values of cell numbers within those ranges. Dosing in CAR T cell therapies may for example involve administration of from 10 ⁶ to 10 ⁹ cells/kg, with or without a course of lymphodepletion, for example with cyclophosphamide. The cells or population of cells can be administrated in one or more doses. In another embodiment, the effective amount of cells are administrated as a single dose. In another embodiment, the effective amount of cells are administrated as more than one dose over a period time. Timing of administration is within the judgment of managing physician and depends on the clinical condition of the patient. The cells or population of cells may be obtained from any source, such as a blood bank or a donor. While individual needs vary, determination of optimal ranges of effective amounts of a given cell type for a particular disease or conditions are within the skill of one in the art. An effective amount means an amount which provides a therapeutic or prophylactic benefit. The dosage administrated will be dependent upon the age, health and weight of the recipient, kind of concurrent treatment, if any, frequency of treatment and the nature of the effect desired.

[0260] In another embodiment, the effective amount of cells or composition comprising those cells are administrated parenterally. The administration can be an intravenous administration. The administration can be directly done by injection within a tumor.

[0261] To guard against possible adverse reactions, engineered immunoresponsive cells may be equipped with a transgenic safety switch, in the form of a transgene that renders the cells vulnerable to exposure to a specific signal. For example, the herpes simplex viral thymidine kinase (TK) gene may be used in this way, for example by introduction into allogeneic T lymphocytes used as donor lymphocyte infusions following stem cell transplantation (Greco, et al., Improving the safety of cell therapy with the TK-suicide gene.

Front. Pharmacol. 2015; 6: 95). In such cells, administration of a nucleoside prodrug such as ganciclovir or acyclovir causes cell death. Alternative safety switch constructs include inducible caspase 9, for example triggered by administration of a small-molecule dimerizer that brings together two nonfunctional icasp9 molecules to form the active enzyme. A wide variety of alternative approaches to implementing cellular proliferation controls have been described (see U.S. Patent Publication No. 20130071414; PCT Patent Publication

WO2011146862; PCT Patent Publication WO2014011987; PCT Patent Publication

WO2013040371; Zhou et al. BLOOD, 2014, 123/25:3895 - 3905; Di Stasi et al., The New

England Journal of Medicine 2011; 365: 1673-1683; Sadelain M, The New England Journal of Medicine 2011; 365: 1735-173; Ramos et al., Stem Cells 28(6): 1107-15 (2010)).

[0262] In a further refinement of adoptive therapies, genome editing may be used to tailor immunoresponsive cells to alternative implementations, for example providing edited CAR T cells (see Poirot et al., 2015, Multiplex genome edited T-cell manufacturing platform for

"off-the-shelf adoptive T-cell immunotherapies, Cancer Res 75 (18): 3853; Ren et al., 2017,

Multiplex genome editing to generate universal CAR T cells resistant to PD1 inhibition, Clin

Cancer Res. 2017 May l;23(9):2255-2266. doi: 10.1158/1078-0432.CCR-16-1300. Epub

2016 Nov 4; Qasim et al., 2017, Molecular remission of infant B-ALL after infusion of universal TALEN gene-edited CAR T cells, Sci Transl Med. 2017 Jan 25;9(374); Legut, et al., 2018, CRISPR-mediated TCR replacement generates superior anticancer transgenic T cells. Blood, 131(3), 311-322; and Georgiadis et al., Long Terminal Repeat CRISPR-CAR-

Coupled "Universal" T Cells Mediate Potent Anti-leukemic Effects, Molecular Therapy, In

Press, Corrected Proof, Available online 6 March 2018). Cells may be edited using any

CRISPR system and method of use thereof as described herein. CRISPR systems may be delivered to an immune cell by any method described herein. In preferred embodiments, cells are edited ex vivo and transferred to a subject in need thereof. Immunoresponsive cells, CAR

T cells or any cells used for adoptive cell transfer may be edited. Editing may be performed for example to insert or knock-in an exogenous gene, such as an exogenous gene encoding a

CAR or a TCR, at a preselected locus in a cell (e.g. TRAC locus); to eliminate potential alloreactive T-cell receptors (TCR) or to prevent inappropriate pairing between endogenous and exogenous TCR chains, such as to knock-out or knock-down expression of an endogenous TCR in a cell; to disrupt the target of a chemotherapeutic agent in a cell; to block an immune checkpoint, such as to knock-out or knock-down expression of an immune checkpoint protein or receptor in a cell; to knock-out or knock-down expression of other gene or genes in a cell, the reduced expression or lack of expression of which can enhance the efficacy of adoptive therapies using the cell; to knock-out or knock-down expression of an endogenous gene in a cell, said endogenous gene encoding an antigen targeted by an exogenous CAR or TCR; to knock-out or knock-down expression of one or more MHC constituent proteins in a cell; to activate a T cell; to modulate cells such that the cells are resistant to exhaustion or dysfunction; and/or increase the differentiation and/or proliferation of functionally exhausted or dysfunctional CD8+ T-cells (see PCT Patent Publications: WO2013176915, WO2014059173, WO2014172606, WO2014184744, and WO2014191128).

[0263] In certain embodiments, editing may result in inactivation of a gene. By inactivating a gene, it is intended that the gene of interest is not expressed in a functional protein form. In a particular embodiment, the CRISPR system specifically catalyzes cleavage in one targeted gene thereby inactivating said targeted gene. The nucleic acid strand breaks caused are commonly repaired through the distinct mechanisms of homologous recombination or non-homologous end joining ( HEJ). However, HEJ is an imperfect repair process that often results in changes to the DNA sequence at the site of the cleavage. Repair via non-homologous end joining (NHEJ) often results in small insertions or deletions (Indel) and can be used for the creation of specific gene knockouts. Cells in which a cleavage induced mutagenesis event has occurred can be identified and/or selected by well-known methods in the art. In certain embodiments, homology directed repair (HDR) is used to concurrently inactivate a gene (e.g., TRAC) and insert an endogenous TCR or CAR into the inactivated locus.

[0264] Hence, in certain embodiments, editing of cells (such as by CRISPR/Cas), particularly cells intended for adoptive cell therapies, more particularly immunoresponsive cells such as T cells, may be performed to insert or knock-in an exogenous gene, such as an exogenous gene encoding a CAR or a TCR, at a preselected locus in a cell. Conventionally, nucleic acid molecules encoding CARs or TCRs are transfected or transduced to cells using randomly integrating vectors, which, depending on the site of integration, may lead to clonal expansion, oncogenic transformation, variegated transgene expression and/or transcriptional silencing of the transgene. Directing of transgene(s) to a specific locus in a cell can minimize or avoid such risks and advantageously provide for uniform expression of the transgene(s) by the cells. Without limitation, suitable 'safe harbor' loci for directed transgene integration include CCR5 or AAVS1. Homology-directed repair (HDR) strategies are known and described elsewhere in this specification allowing to insert transgenes into desired loci (e.g., TRAC locus).

[0265] Further suitable loci for insertion of transgenes, in particular CAR or exogenous TCR transgenes, include without limitation loci comprising genes coding for constituents of endogenous T-cell receptor, such as T-cell receptor alpha locus (TRA) or T-cell receptor beta locus (TRB), for example T-cell receptor alpha constant (TRAC) locus, T-cell receptor beta constant 1 (TRBCl) locus or T-cell receptor beta constant 2 (TRBCl) locus. Advantageously, insertion of a transgene into such locus can simultaneously achieve expression of the transgene, potentially controlled by the endogenous promoter, and knockout expression of the endogenous TCR. This approach has been exemplified in Eyquem et al., (2017) Nature 543 : 113-117, wherein the authors used CRISPR/Cas9 gene editing to knock-in a DNA molecule encoding a CD19-specific CAR into the TRAC locus downstream of the endogenous promoter; the CAR-T cells obtained by CRISPR were significantly superior in terms of reduced tonic CAR signaling and exhaustion.

[0266] T cell receptors (TCR) are cell surface receptors that participate in the activation of T cells in response to the presentation of antigen. The TCR is generally made from two chains, a and β, which assemble to form a heterodimer and associates with the CD3- transducing subunits to form the T cell receptor complex present on the cell surface. Each a and β chain of the TCR consists of an immunoglobulin-like N-terminal variable (V) and constant (C) region, a hydrophobic transmembrane domain, and a short cytoplasmic region. As for immunoglobulin molecules, the variable region of the a and β chains are generated by V(D)J recombination, creating a large diversity of antigen specificities within the population of T cells. However, in contrast to immunoglobulins that recognize intact antigen, T cells are activated by processed peptide fragments in association with an MHC molecule, introducing an extra dimension to antigen recognition by T cells, known as MHC restriction. Recognition of MHC disparities between the donor and recipient through the T cell receptor leads to T cell proliferation and the potential development of graft versus host disease (GVHD). The inactivation of TCRa or TCRP can result in the elimination of the TCR from the surface of T cells preventing recognition of alloantigen and thus GVHD. However, TCR disruption generally results in the elimination of the CD3 signaling component and alters the means of further T cell expansion.

[0267] Hence, in certain embodiments, editing of cells (such as by CRISPR/Cas), particularly cells intended for adoptive cell therapies, more particularly immunoresponsive cells such as T cells, may be performed to knock-out or knock-down expression of an endogenous TCR in a cell. For example, HEJ-based or HDR-based gene editing approaches can be employed to disrupt the endogenous TCR alpha and/or beta chain genes. For example, gene editing system or systems, such as CRISPR/Cas system or systems, can be designed to target a sequence found within the TCR beta chain conserved between the beta 1 and beta 2 constant region genes (TRBCl and TRBC2) and/or to target the constant region of the TCR alpha chain (TRAC) gene.

[0268] Allogeneic cells are rapidly rejected by the host immune system. It has been demonstrated that, allogeneic leukocytes present in non-irradiated blood products will persist for no more than 5 to 6 days (Boni, Muranski et al. 2008 Blood l; 112(12):4746-54). Thus, to prevent rejection of allogeneic cells, the host's immune system usually has to be suppressed to some extent. However, in the case of adoptive cell transfer the use of immunosuppressive drugs also have a detrimental effect on the introduced therapeutic T cells. Therefore, to effectively use an adoptive immunotherapy approach in these conditions, the introduced cells would need to be resistant to the immunosuppressive treatment. Thus, in a particular embodiment, the present invention further comprises a step of modifying T cells to make them resistant to an immunosuppressive agent, preferably by inactivating at least one gene encoding a target for an immunosuppressive agent. An immunosuppressive agent is an agent that suppresses immune function by one of several mechanisms of action. An immunosuppressive agent can be, but is not limited to a calcineurin inhibitor, a target of rapamycin, an interleukin-2 receptor a-chain blocker, an inhibitor of inosine monophosphate dehydrogenase, an inhibitor of dihydrofolic acid reductase, a corticosteroid or an immunosuppressive antimetabolite. The present invention allows conferring immunosuppressive resistance to T cells for immunotherapy by inactivating the target of the immunosuppressive agent in T cells. As non-limiting examples, targets for an immunosuppressive agent can be a receptor for an immunosuppressive agent such as: CD52, glucocorticoid receptor (GR), a FKBP family gene member and a cyclophilin family gene member.

[0269] In certain embodiments, editing of cells (such as by CRISPR/Cas), particularly cells intended for adoptive cell therapies, more particularly immunoresponsive cells such as T cells, may be performed to block an immune checkpoint, such as to knock-out or knockdown expression of an immune checkpoint protein or receptor in a cell. Immune checkpoints are inhibitory pathways that slow down or stop immune reactions and prevent excessive tissue damage from uncontrolled activity of immune cells. In certain embodiments, the immune checkpoint targeted is the programmed death- 1 (PD-1 or CD279) gene (PDCD1). In other embodiments, the immune checkpoint targeted is cytotoxic T-lymphocyte-associated antigen (CTLA-4). In additional embodiments, the immune checkpoint targeted is another member of the CD28 and CTLA4 Ig superfamily such as BTLA, LAG3, ICOS, PDL1 or KIR. In further additional embodiments, the immune checkpoint targeted is a member of the T FR superfamily such as CD40, OX40, CD 137, GITR, CD27 or TIM-3.

[0270] Additional immune checkpoints include Src homology 2 domain-containing protein tyrosine phosphatase 1 (SHP-1) (Watson HA, et al., SHP-1 : the next checkpoint target for cancer immunotherapy? Biochem Soc Trans. 2016 Apr 15;44(2):356-62). SHP-1 is a widely expressed inhibitory protein tyrosine phosphatase (PTP). In T-cells, it is a negative regulator of antigen-dependent activation and proliferation. It is a cytosolic protein, and therefore not amenable to antibody-mediated therapies, but its role in activation and proliferation makes it an attractive target for genetic manipulation in adoptive transfer strategies, such as chimeric antigen receptor (CAR) T cells. Immune checkpoints may also include T cell immunoreceptor with Ig and ITIM domains (TIGIT/Vstm3/WUCAM/VSIG9) and VISTA (Le Mercier I, et al., (2015) Beyond CTLA-4 and PD-1, the generation Z of negative checkpoint regulators. Front. Immunol. 6:418).

[0271] WO2014172606 relates to the use of MT1 and/or MT2 inhibitors to increase proliferation and/or activity of exhausted CD8+ T-cells and to decrease CD8+ T-cell exhaustion (e.g., decrease functionally exhausted or unresponsive CD8+ immune cells). In certain embodiments, metallothioneins are targeted by gene editing in adoptively transferred T cells.

[0272] In certain embodiments, targets of gene editing may be at least one targeted locus involved in the expression of an immune checkpoint protein. Such targets may include, but are not limited to CTLA4, PPP2CA, PPP2CB, PTPN6, PTPN22, PDCD1, ICOS (CD278),

PDL1, KIR, LAG3, HAVCR2, BTLA, CD 160, TIGIT, CD96, CRT AM, LAIR1, SIGLEC7,

SIGLEC9, CD244 (2B4), T FRSF10B, T FRSF10A, CASP8, CASP10, CASP3, CASP6,

CASP7, FADD, FAS, TGFBRII, TGFRBRI, SMAD2, SMAD3, SMAD4, SMADIO, SKI,

SKIL, TGIF1, IL10RA, IL10RB, HMOX2, IL6R, IL6ST, EIF2AK4, CSK, PAG1, SIT1,

FOXP3, PRDM1, BATF, VISTA, GUCY1A2, GUCY1A3, GUCY1B2, GUCY1B3, MT1,

MT2, CD40, OX40, CD 137, GITR, CD27, SHP-1, TIM-3, CEACAM-1, CEACAM-3, or

CEACAM-5. In preferred embodiments, the gene locus involved in the expression of PD-1 or CTLA-4 genes is targeted. In other preferred embodiments, combinations of genes are targeted, such as but not limited to PD-1 and TIGIT.

[0273] By means of an example and without limitation, WO2016196388 concerns an engineered T cell comprising (a) a genetically engineered antigen receptor that specifically binds to an antigen, which receptor may be a CAR; and (b) a disrupted gene encoding a PD- Ll, an agent for disruption of a gene encoding a PD- LI, and/or disruption of a gene encoding PD-Ll, wherein the disruption of the gene may be mediated by a gene editing nuclease, a zinc finger nuclease (ZFN), CRISPR/Cas9 and/or TALEN. WO2015142675 relates to immune effector cells comprising a CAR in combination with an agent (such as CRISPR, TALEN or ZFN) that increases the efficacy of the immune effector cells in the treatment of cancer, wherein the agent may inhibit an immune inhibitory molecule, such as PDl, PD-Ll, CTLA-4, TIM-3, LAG-3, VISTA, BTLA, TIGIT, LAIRl, CD 160, 2B4, TGFR beta, CEACAM-1, CEACAM-3, or CEACAM-5. Ren et al., (2017) Clin Cancer Res 23 (9) 2255-2266 performed lentiviral delivery of CAR and electro-transfer of Cas9 mRNA and gRNAs targeting endogenous TCR, β-2 microglobulin (B2M) and PDl simultaneously, to generate gene-disrupted allogeneic CAR T cells deficient of TCR, ULA class I molecule and PDl .

[0274] In certain embodiments, cells may be engineered to express a CAR, wherein expression and/or function of methylcytosine di oxygenase genes (TET1, TET2 and/or TET3) in the cells has been reduced or eliminated, such as by CRISPR, ZNF or TALEN (for example, as described in WO201704916).

[0275] In certain embodiments, editing of cells (such as by CRISPR/Cas), particularly cells intended for adoptive cell therapies, more particularly immunoresponsive cells such as

T cells, may be performed to knock-out or knock-down expression of an endogenous gene in a cell, said endogenous gene encoding an antigen targeted by an exogenous CAR or TCR, thereby reducing the likelihood of targeting of the engineered cells. In certain embodiments, the targeted antigen may be one or more antigen selected from the group consisting of CD38,

CD138, CS-1, CD33, CD26, CD30, CD53, CD92, CD100, CD148, CD150, CD200, CD261,

CD262, CD362, human telom erase reverse transcriptase (hTERT), survivin, mouse double minute 2 homolog (MDM2), cytochrome P450 1B1 (CYP1B), HER2/neu, Wilms' tumor gene 1 (WT1), livin, alphafetoprotein (AFP), carcinoembryonic antigen (CEA), mucin 16

(MUC16), MUC1, prostate-specific membrane antigen (PSMA), p53, cyclin (Dl), B cell maturation antigen (BCMA), transmembrane activator and CAML Interactor (TACI), and B- cell activating factor receptor (BAFF-R) (for example, as described in WO2016011210 and WO2017011804).

[0276] In certain embodiments, editing of cells (such as by CRISPR/Cas), particularly cells intended for adoptive cell therapies, more particularly immunoresponsive cells such as T cells, may be performed to knock-out or knock-down expression of one or more MHC constituent proteins, such as one or more HLA proteins and/or beta-2 microglobulin (B2M), in a cell, whereby rejection of non-autologous (e.g., allogeneic) cells by the recipient's immune system can be reduced or avoided. In preferred embodiments, one or more HLA class I proteins, such as HLA-A, B and/or C, and/or B2M may be knocked-out or knocked- down. Preferably, B2M may be knocked-out or knocked-down. By means of an example, Ren et al., (2017) Clin Cancer Res 23 (9) 2255-2266 performed lentiviral delivery of CAR and electro-transfer of Cas9 mRNA and gRNAs targeting endogenous TCR, β-2 microglobulin (B2M) and PDl simultaneously, to generate gene-disrupted allogeneic CAR T cells deficient of TCR, HLA class I molecule and PDl .

[0277] In other embodiments, at least two genes are edited. Pairs of genes may include, but are not limited to PDl and TCRa, PDl and TCRp, CTLA-4 and TCRa, CTLA-4 and TCRp, LAG3 and TCRa, LAG3 and TCRp, Tim3 and TCRa, Tim3 and TCRp, BTLA and TCRa, BTLA and TCRp, BY55 and TCRa, BY55 and TCRp, TIGIT and TCRa, TIGIT and TCRp, B7H5 and TCRa, B7H5 and TCRp, LAIR1 and TCRa, LAIR1 and TCRp, SIGLEC10 and TCRa, SIGLEC10 and TCRp, 2B4 and TCRa, 2B4 and TCRp, B2M and TCRa, B2M and TCRp.

[0278] In certain embodiments, a cell may be multiply edited (multiplex genome editing) as taught herein to (1) knock-out or knock-down expression of an endogenous TCR (for example, TRBCl, TRBC2 and/or TRAC), (2) knock-out or knock-down expression of an immune checkpoint protein or receptor (for example PDl, PD-L1 and/or CTLA4); and (3) knock-out or knock-down expression of one or more MHC constituent proteins (for example, HLA-A, B and/or C, and/or B2M, preferably B2M).

[0279] Whether prior to or after genetic modification of the T cells, the T cells can be activated and expanded generally using methods as described, for example, in U.S. Patents 6,352,694; 6,534,055; 6,905,680; 5,858,358; 6,887,466; 6,905,681; 7, 144,575; 7,232,566; 7, 175,843; 5,883,223; 6,905,874; 6,797,514; 6,867,041; and 7,572,631. T cells can be expanded in vitro or in vivo. [0280] Immune cells may be obtained using any method known in the art. In one embodiment, allogenic T cells may be obtained from healthy subjects. In one embodiment T cells that have infiltrated a tumor are isolated. T cells may be removed during surgery. T cells may be isolated after removal of tumor tissue by biopsy. T cells may be isolated by any means known in the art. In one embodiment, T cells are obtained by apheresis. In one embodiment, the method may comprise obtaining a bulk population of T cells from a tumor sample by any suitable method known in the art. For example, a bulk population of T cells can be obtained from a tumor sample by dissociating the tumor sample into a cell suspension from which specific cell populations can be selected. Suitable methods of obtaining a bulk population of T cells may include, but are not limited to, any one or more of mechanically dissociating (e.g., mincing) the tumor, enzymatically dissociating (e.g., digesting) the tumor, and aspiration (e.g., as with a needle).

[0281] The bulk population of T cells obtained from a tumor sample may comprise any suitable type of T cell. Preferably, the bulk population of T cells obtained from a tumor sample comprises tumor infiltrating lymphocytes (TILs).

[0282] The tumor sample may be obtained from any mammal. Unless stated otherwise, as used herein, the term "mammal" refers to any mammal including, but not limited to, mammals of the order Logomorpha, such as rabbits; the order Carnivora, including Felines (cats) and Canines (dogs); the order Artiodactyla, including Bovines (cows) and Swines (pigs); or of the order Perssodactyla, including Equines (horses). The mammals may be non- human primates, e.g., of the order Primates, Ceboids, or Simoids (monkeys) or of the order Anthropoids (humans and apes). In some embodiments, the mammal may be a mammal of the order Rodentia, such as mice and hamsters. Preferably, the mammal is a non-human primate or a human. An especially preferred mammal is the human.

[0283] T cells can be obtained from a number of sources, including peripheral blood mononuclear cells, bone marrow, lymph node tissue, spleen tissue, and tumors. In certain embodiments of the present invention, T cells can be obtained from a unit of blood collected from a subject using any number of techniques known to the skilled artisan, such as Ficoll separation. In one preferred embodiment, cells from the circulating blood of an individual are obtained by apheresis or leukapheresis. The apheresis product typically contains lymphocytes, including T cells, monocytes, granulocytes, B cells, other nucleated white blood cells, red blood cells, and platelets. In one embodiment, the cells collected by apheresis may be washed to remove the plasma fraction and to place the cells in an appropriate buffer or media for subsequent processing steps. In one embodiment of the invention, the cells are washed with phosphate buffered saline (PBS). In an alternative embodiment, the wash solution lacks calcium and may lack magnesium or may lack many if not all divalent cations. Initial activation steps in the absence of calcium lead to magnified activation. As those of ordinary skill in the art would readily appreciate a washing step may be accomplished by methods known to those in the art, such as by using a semi-automated "flow-through" centrifuge (for example, the Cobe 2991 cell processor) according to the manufacturer's instructions. After washing, the cells may be resuspended in a variety of biocompatible buffers, such as, for example, Ca-free, Mg-free PBS. Alternatively, the undesirable components of the apheresis sample may be removed and the cells directly resuspended in culture media.

[0284] In another embodiment, T cells are isolated from peripheral blood lymphocytes by lysing the red blood cells and depleting the monocytes, for example, by centrifugation through a PERCOLL™ gradient. A specific subpopulation of T cells, such as CD28+, CD4+,

CDC, CD45RA+, and CD45RO+ T cells, can be further isolated by positive or negative selection techniques. For example, in one preferred embodiment, T cells are isolated by incubation with anti-CD3/anti-CD28 (i.e., 3 28)-conjugated beads, such as DYNABEADS®

M-450 CD3/CD28 T, or XCYTE DYNABEADS™ for a time period sufficient for positive selection of the desired T cells. In one embodiment, the time period is about 30 minutes. In a further embodiment, the time period ranges from 30 minutes to 36 hours or longer and all integer values there between. In a further embodiment, the time period is at least 1, 2, 3, 4, 5, or 6 hours. In yet another preferred embodiment, the time period is 10 to 24 hours. In one preferred embodiment, the incubation time period is 24 hours. For isolation of T cells from patients with leukemia, use of longer incubation times, such as 24 hours, can increase cell yield. Longer incubation times may be used to isolate T cells in any situation where there are few T cells as compared to other cell types, such in isolating tumor infiltrating lymphocytes

(TIL) from tumor tissue or from immunocompromised individuals. Further, use of longer incubation times can increase the efficiency of capture of CD8+ T cells.

[0285] Enrichment of a T cell population by negative selection can be accomplished with a combination of antibodies directed to surface markers unique to the negatively selected cells. A preferred method is cell sorting and/or selection via negative magnetic immunoadherence or flow cytometry that uses a cocktail of monoclonal antibodies directed to cell surface markers present on the cells negatively selected. For example, to enrich for CD4+ cells by negative selection, a monoclonal antibody cocktail typically includes antibodies to CD14, CD20, CDl lb, CD16, HLA-DR, and CD8.

[0286] Further, monocyte populations (i.e., CD14+ cells) may be depleted from blood preparations by a variety of methodologies, including anti-CD 14 coated beads or columns, or utilization of the phagocytotic activity of these cells to facilitate removal. Accordingly, in one embodiment, the invention uses paramagnetic particles of a size sufficient to be engulfed by phagocytotic monocytes. In certain embodiments, the paramagnetic particles are commercially available beads, for example, those produced by Life Technologies under the trade name Dynabeads™. In one embodiment, other non-specific cells are removed by coating the paramagnetic particles with "irrelevant" proteins (e.g., serum proteins or antibodies). Irrelevant proteins and antibodies include those proteins and antibodies or fragments thereof that do not specifically target the T cells to be isolated. In certain embodiments, the irrelevant beads include beads coated with sheep anti-mouse antibodies, goat anti-mouse antibodies, and human serum albumin.

[0287] In brief, such depletion of monocytes is performed by preincubating T cells isolated from whole blood, apheresed peripheral blood, or tumors with one or more varieties of irrelevant or non-antibody coupled paramagnetic particles at any amount that allows for removal of monocytes (approximately a 20: 1 beadxell ratio) for about 30 minutes to 2 hours at 22 to 37 degrees C, followed by magnetic removal of cells which have attached to or engulfed the paramagnetic particles. Such separation can be performed using standard methods available in the art. For example, any magnetic separation methodology may be used including a variety of which are commercially available, (e.g., DYNAL® Magnetic

Particle Concentrator (DYNAL MPC®)). Assurance of requisite depletion can be monitored by a variety of methodologies known to those of ordinary skill in the art, including flow cytometric analysis of CD14 positive cells, before and after depletion.

[0288] For isolation of a desired population of cells by positive or negative selection, the concentration of cells and surface (e.g., particles such as beads) can be varied. In certain embodiments, it may be desirable to significantly decrease the volume in which beads and cells are mixed together (i.e., increase the concentration of cells), to ensure maximum contact of cells and beads. For example, in one embodiment, a concentration of 2 billion cells/ml is used. In one embodiment, a concentration of 1 billion cells/ml is used. In a further embodiment, greater than 100 million cells/ml is used. In a further embodiment, a concentration of cells of 10, 15, 20, 25, 30, 35, 40, 45, or 50 million cells/ml is used. In yet another embodiment, a concentration of cells from 75, 80, 85, 90, 95, or 100 million cells/ml is used. In further embodiments, concentrations of 125 or 150 million cells/ml can be used. Using high concentrations can result in increased cell yield, cell activation, and cell expansion. Further, use of high cell concentrations allows more efficient capture of cells that may weakly express target antigens of interest, such as CD28-negative T cells, or from samples where there are many tumor cells present (i.e., leukemic blood, tumor tissue, etc). Such populations of cells may have therapeutic value and would be desirable to obtain. For example, using high concentration of cells allows more efficient selection of CD8+ T cells that normally have weaker CD28 expression.

[0289] In a related embodiment, it may be desirable to use lower concentrations of cells. By significantly diluting the mixture of T cells and surface (e.g., particles such as beads), interactions between the particles and cells is minimized. This selects for cells that express high amounts of desired antigens to be bound to the particles. For example, CD4+ T cells express higher levels of CD28 and are more efficiently captured than CD8+ T cells in dilute concentrations. In one embodiment, the concentration of cells used is 5>< 10 ⁶ /ml. In other embodiments, the concentration used can be from about l x l0 ⁵ /ml to l x l0 ⁶ /ml, and any integer value in between.

[0290] T cells can also be frozen. Wishing not to be bound by theory, the freeze and subsequent thaw step provides a more uniform product by removing granulocytes and to some extent monocytes in the cell population. After a washing step to remove plasma and platelets, the cells may be suspended in a freezing solution. While many freezing solutions and parameters are known in the art and will be useful in this context, one method involves using PBS containing 20% DMSO and 8% human serum albumin, or other suitable cell freezing media, the cells then are frozen to -80° C at a rate of 1° per minute and stored in the vapor phase of a liquid nitrogen storage tank. Other methods of controlled freezing may be used as well as uncontrolled freezing immediately at -20° C. or in liquid nitrogen.

[0291] T cells for use in the present invention may also be antigen-specific T cells. For example, tumor-specific T cells can be used. In certain embodiments, antigen-specific T cells can be isolated from a patient of interest, such as a patient afflicted with a cancer or an infectious disease. In one embodiment, neoepitopes are determined for a subject and T cells specific to these antigens are isolated. Antigen-specific cells for use in expansion may also be generated in vitro using any number of methods known in the art, for example, as described in U.S. Patent Publication No. US 20040224402 entitled, Generation and Isolation of Antigen-Specific T Cells, or in U.S. Pat. Nos. 6,040, 177. Antigen-specific cells for use in the present invention may also be generated using any number of methods known in the art, for example, as described in Current Protocols in Immunology, or Current Protocols in Cell Biology, both published by John Wiley & Sons, Inc., Boston, Mass.

[0292] In a related embodiment, it may be desirable to sort or otherwise positively select

(e.g. via magnetic selection) the antigen specific cells prior to or following one or two rounds of expansion. Sorting or positively selecting antigen-specific cells can be carried out using peptide-MHC tetramers (Altman, et al., Science. 1996 Oct. 4; 274(5284):94-6). In another embodiment, the adaptable tetramer technology approach is used (Andersen et al., 2012 Nat

Protoc. 7:891-902). Tetramers are limited by the need to utilize predicted binding peptides based on prior hypotheses, and the restriction to specific HLAs. Peptide-MHC tetramers can be generated using techniques known in the art and can be made with any MHC molecule of interest and any antigen of interest as described herein. Specific epitopes to be used in this context can be identified using numerous assays known in the art. For example, the ability of a polypeptide to bind to MHC class I may be evaluated indirectly by monitoring the ability to promote incorporation of ¹²⁵ I labeled P2-microglobulin (β2πι) into MHC class I/p2m/peptide heterotrimeric complexes (see Parker et al., J. Immunol. 152: 163, 1994).

[0293] In one embodiment cells are directly labeled with an epitope-specific reagent for isolation by flow cytometry followed by characterization of phenotype and TCRs. In one embodiment, T cells are isolated by contacting with T cell specific antibodies. Sorting of antigen-specific T cells, or generally any cells of the present invention, can be carried out using any of a variety of commercially available cell sorters, including, but not limited to,

MoFlo sorter (DakoCytomation, Fort Collins, Colo.), FACSAria™, FACSArray™,

FACSVantage™, BD™ LSR II, and FACSCalibur™ (BD Biosciences, San Jose, Calif).

[0294] In a preferred embodiment, the method comprises selecting cells that also express

CD3. The method may comprise specifically selecting the cells in any suitable manner.

Preferably, the selecting is carried out using flow cytometry. The flow cytometry may be carried out using any suitable method known in the art. The flow cytometry may employ any suitable antibodies and stains. Preferably, the antibody is chosen such that it specifically recognizes and binds to the particular biomarker being selected. For example, the specific selection of CD3, CD8, TIM-3, LAG-3, 4-1BB, or PD-1 may be carried out using anti-CD3, anti-CD8, anti-TIM-3, anti-LAG-3, anti-4-lBB, or anti-PD-1 antibodies, respectively. The antibody or antibodies may be conjugated to a bead (e.g., a magnetic bead) or to a fluorochrome. Preferably, the flow cytometry is fluorescence-activated cell sorting (FACS). TCRs expressed on T cells can be selected based on reactivity to autologous tumors. Additionally, T cells that are reactive to tumors can be selected for based on markers using the methods described in patent publication Nos. WO2014133567 and WO2014133568, herein incorporated by reference in their entirety. Additionally, activated T cells can be selected for based on surface expression of CD 107a.

[0295] In one embodiment of the invention, the method further comprises expanding the numbers of T cells in the enriched cell population. Such methods are described in U.S. Patent No. 8,637,307 and is herein incorporated by reference in its entirety. The numbers of T cells may be increased at least about 3-fold (or 4-, 5-, 6-, 7-, 8-, or 9-fold), more preferably at least about 10-fold (or 20-, 30-, 40-, 50-, 60-, 70-, 80-, or 90-fold), more preferably at least about 100-fold, more preferably at least about 1,000 fold, or most preferably at least about 100,000- fold. The numbers of T cells may be expanded using any suitable method known in the art. Exemplary methods of expanding the numbers of cells are described in patent publication No. WO 2003057171, U.S. Patent No. 8,034,334, and U.S. Patent Application Publication No. 2012/0244133, each of which is incorporated herein by reference.

[0296] In one embodiment, ex vivo T cell expansion can be performed by isolation of T cells and subsequent stimulation or activation followed by further expansion. In one embodiment of the invention, the T cells may be stimulated or activated by a single agent. In another embodiment, T cells are stimulated or activated with two agents, one that induces a primary signal and a second that is a co-stimulatory signal. Ligands useful for stimulating a single signal or stimulating a primary signal and an accessory molecule that stimulates a second signal may be used in soluble form. Ligands may be attached to the surface of a cell, to an Engineered Multivalent Signaling Platform (EMSP), or immobilized on a surface. In a preferred embodiment both primary and secondary agents are co-immobilized on a surface, for example a bead or a cell. In one embodiment, the molecule providing the primary activation signal may be a CD3 ligand, and the co-stimulatory molecule may be a CD28 ligand or 4-1BB ligand.

[0297] In certain embodiments, T cells comprising a CAR or an exogenous TCR, may be manufactured as described in WO2015120096, by a method comprising: enriching a population of lymphocytes obtained from a donor subject; stimulating the population of lymphocytes with one or more T-cell stimulating agents to produce a population of activated

T cells, wherein the stimulation is performed in a closed system using serum-free culture medium; transducing the population of activated T cells with a viral vector comprising a nucleic acid molecule which encodes the CAR or TCR, using a single cycle transduction to produce a population of transduced T cells, wherein the transduction is performed in a closed system using serum-free culture medium; and expanding the population of transduced T cells for a predetermined time to produce a population of engineered T cells, wherein the expansion is performed in a closed system using serum-free culture medium. In certain embodiments, T cells comprising a CAR or an exogenous TCR, may be manufactured as described in WO2015120096, by a method comprising: obtaining a population of lymphocytes; stimulating the population of lymphocytes with one or more stimulating agents to produce a population of activated T cells, wherein the stimulation is performed in a closed system using serum-free culture medium; transducing the population of activated T cells with a viral vector comprising a nucleic acid molecule which encodes the CAR or TCR, using at least one cycle transduction to produce a population of transduced T cells, wherein the transduction is performed in a closed system using serum-free culture medium; and expanding the population of transduced T cells to produce a population of engineered T cells, wherein the expansion is performed in a closed system using serum-free culture medium. The predetermined time for expanding the population of transduced T cells may be 3 days. The time from enriching the population of lymphocytes to producing the engineered T cells may be 6 days. The closed system may be a closed bag system. Further provided is population of T cells comprising a CAR or an exogenous TCR obtainable or obtained by said method, and a pharmaceutical composition comprising such cells.

[0298] In certain embodiments, T cell maturation or differentiation in vitro may be delayed or inhibited by the method as described in WO2017070395, comprising contacting one or more T cells from a subject in need of a T cell therapy with an AKT inhibitor (such as, e.g., one or a combination of two or more AKT inhibitors disclosed in claim 8 of WO2017070395) and at least one of exogenous Interleukin-7 (IL-7) and exogenous Interleukin-15 (IL-15), wherein the resulting T cells exhibit delayed maturation or differentiation, and/or wherein the resulting T cells exhibit improved T cell function (such as, e.g., increased T cell proliferation; increased cytokine production; and/or increased cytolytic activity) relative to a T cell function of a T cell cultured in the absence of an AKT inhibitor.

[0299] In certain embodiments, a patient in need of a T cell therapy may be conditioned by a method as described in WO2016191756 comprising administering to the patient a dose of cyclophosphamide between 200 mg/m2/day and 2000 mg/m2/day and a dose of fludarabine between 20 mg/m2/day and 900 mg/m ² /day.

Diseases

[0300] It will be understood by the skilled person that treating as referred to herein encompasses enhancing treatment, or improving treatment efficacy. Treatment may include inhibition of tumor regression as well as inhibition of tumor growth, metastasis or tumor cell proliferation, or inhibition or reduction of otherwise deleterious effects associated with the tumor.

[0301] Efficaciousness of treatment is determined in association with any known method for diagnosing or treating the particular disease. The invention comprehends a treatment method comprising any one of the methods or uses herein discussed.

[0302] The phrase "therapeutically effective amount" as used herein refers to a sufficient amount of a drug, agent, or compound to provide a desired therapeutic effect.

[0303] As used herein "patient" refers to any human being receiving or who may receive medical treatment and is used interchangeably herein with the term "subject".

[0304] Therapy or treatment according to the invention may be performed alone or in conjunction with another therapy, and may be provided at home, the doctor's office, a clinic, a hospital's outpatient department, or a hospital. Treatment generally begins at a hospital so that the doctor can observe the therapy's effects closely and make any adjustments that are needed. The duration of the therapy depends on the age and condition of the patient, the stage of the cancer, and how the patient responds to the treatment.

[0305] The disclosure also provides methods for reducing resistance to immunotherapy and treating disease. Not being bound by a theory, cancer cells have many strategies of avoiding the immune system and by reducing the signature of the present invention cancer cells may be unmasked to the immune system. Not being bound by a theory, reducing a gene signature of the present invention may be used to treat a subject who has not been administered an immunotherapy, such that the subject's tumor becomes unmasked to their natural or unamplified immune system. In other embodiments, the cancer is resistant to therapies targeting the adaptive immune system (see e.g., Rooney et al., Molecular and genetic properties of tumors associated with local immune cytolytic activity, Cell. 2015 January 15; 160(1-2): 48-61). In one embodiment, modulation of one or more of the signature genes are used for reducing an immunotherapy resistant signature for the treatment of a subpopulation of tumor cells that are linked to resistance to targeted therapies and progressive tumor growth.

[0306] In general, the immune system is involved with controlling all cancers and the present application is applicable to treatment of all cancers. Not being bound by a theory, the signature of the present invention is applicable to all cancers and may be used for treatment, as well as for determining a prognosis and stratifying patients. The cancer may include, without limitation, liquid tumors such as leukemia (e.g., acute leukemia, acute lymphocytic leukemia, acute myelocytic leukemia, acute myeloblastic leukemia, acute promyelocytic leukemia, acute myelomonocytic leukemia, acute monocytic leukemia, acute erythroleukemia, chronic leukemia, chronic myelocytic leukemia, chronic lymphocytic leukemia), polycythemia vera, lymphoma (e.g., Hodgkin's disease, non-Hodgkin's disease),

Waldenstrom's macroglobulinemia, heavy chain disease, or multiple myeloma.

[0307] The cancer may include, without limitation, solid tumors such as sarcomas and carcinomas. Examples of solid tumors include, but are not limited to fibrosarcoma, myxosarcoma, liposarcoma, chondrosarcoma, osteogenic sarcoma, chordoma, angiosarcoma, endotheliosarcoma, lymphangiosarcoma, lymphangioendotheliosarcoma, synovioma, mesothelioma, Ewing's tumor, leiomyosarcoma, rhabdomyosarcoma, squamous cell carcinoma, basal cell carcinoma, adenocarcinoma, sweat gland carcinoma, sebaceous gland carcinoma, papillary carcinoma, papillary adenocarcinomas, cystadenocarcinoma, medullary carcinoma, epithelial carcinoma, bronchogenic carcinoma, hepatoma, colorectal cancer (e.g., colon cancer, rectal cancer), anal cancer, pancreatic cancer (e.g., pancreatic adenocarcinoma, islet cell carcinoma, neuroendocrine tumors), breast cancer (e.g., ductal carcinoma, lobular carcinoma, inflammatory breast cancer, clear cell carcinoma, mucinous carcinoma), ovarian carcinoma (e.g., ovarian epithelial carcinoma or surface epithelial-stromal tumour including serous tumour, endometrioid tumor and mucinous cystadenocarcinoma, sex-cord-stromal tumor), prostate cancer, liver and bile duct carcinoma (e.g., hepatocelluar carcinoma, cholangiocarcinoma, hemangioma), choriocarcinoma, seminoma, embryonal carcinoma, kidney cancer (e.g., renal cell carcinoma, clear cell carcinoma, Wilm's tumor, nephroblastoma), cervical cancer, uterine cancer (e.g., endometrial adenocarcinoma, uterine papillary serous carcinoma, uterine clear-cell carcinoma, uterine sarcomas and leiomyosarcomas, mixed mullerian tumors), testicular cancer, germ cell tumor, lung cancer

(e.g., lung adenocarcinoma, squamous cell carcinoma, large cell carcinoma, bronchioloalveolar carcinoma, non-small-cell carcinoma, small cell carcinoma, mesothelioma), bladder carcinoma, signet ring cell carcinoma, cancer of the head and neck (e.g., squamous cell carcinomas), esophageal carcinoma (e.g., esophageal adenocarcinoma), tumors of the brain (e.g., glioma, glioblastoma, medullablastoma, astrocytoma, medulloblastoma, craniopharyngioma, ependymoma, pinealoma, hemangioblastoma, acoustic neuroma, oligodenroglioma, schwannoma, meningioma), neuroblastoma, retinoblastoma, neuroendocrine tumor, melanoma, cancer of the stomach (e.g., stomach adenocarcinoma, gastrointestinal stromal tumor), or carcinoids. Lymphoproliferative disorders are also considered to be proliferative diseases.

Administrationit will be appreciated that administration of therapeutic entities in accordance with the invention will be administered with suitable carriers, excipients, and other agents that are incorporated into formulations to provide improved transfer, delivery, tolerance, and the like. A multitude of appropriate formulations can be found in the formulary known to all pharmaceutical chemists: Remington's Pharmaceutical Sciences (15th ed, Mack Publishing Company, Easton, PA (1975)), particularly Chapter 87 by Blaug, Seymour, therein. These formulations include, for example, powders, pastes, ointments, jellies, waxes, oils, lipids, lipid (cationic or anionic) containing vesicles (such as Lipofectin™), DNA conjugates, anhydrous absorption pastes, oil-in-water and water-in-oil emulsions, emulsions carbowax (polyethylene glycols of various molecular weights), semi-solid gels, and semi-solid mixtures containing carbowax. Any of the foregoing mixtures may be appropriate in treatments and therapies in accordance with the present invention, provided that the active ingredient in the formulation is not inactivated by the formulation and the formulation is physiologically compatible and tolerable with the route of administration. See also Baldrick P. "Pharmaceutical excipient development: the need for preclinical guidance." Regul. Toxicol Pharmacol. 32(2):210-8 (2000), Wang W. "Lyophilization and development of solid protein pharmaceuticals." Int. J. Pharm. 203(1-2): 1-60 (2000), Charman WN "Lipids, lipophilic drugs, and oral drug delivery- some emerging concepts." J Pharm Sci. 89(8):967-78 (2000), Powell et al. "Compendium of excipients for parenteral formulations" PDA J Pharm Sci Technol. 52:238-311 (1998) and the citations therein for additional information related to formulations, excipients and carriers well known to pharmaceutical chemists.

[0309] The medicaments of the invention are prepared in a manner known to those skilled in the art, for example, by means of conventional dissolving, lyophilizing, mixing, granulating or confectioning processes. Methods well known in the art for making formulations are found, for example, in Remington: The Science and Practice of Pharmacy, 20th ed., ed. A. R. Gennaro, 2000, Lippincott Williams & Wilkins, Philadelphia, and Encyclopedia of Pharmaceutical Technology, eds. J. Swarbrick and J. C. Boylan, 1988-1999, Marcel Dekker, New York.

[0310] Administration of medicaments of the invention may be by any suitable means that results in a compound concentration that is effective for treating or inhibiting (e.g., by delaying) the development of a disease. The compound is admixed with a suitable carrier substance, e.g., a pharmaceutically acceptable excipient that preserves the therapeutic properties of the compound with which it is administered. One exemplary pharmaceutically acceptable excipient is physiological saline. The suitable carrier substance is generally present in an amount of 1-95% by weight of the total weight of the medicament. The medicament may be provided in a dosage form that is suitable for administration. Thus, the medicament may be in form of, e.g., tablets, capsules, pills, powders, granulates, suspensions, emulsions, solutions, gels including hydrogels, pastes, ointments, creams, plasters, drenches, delivery devices, injectables, implants, sprays, or aerosols.

[0311] The agents disclosed herein (e.g., antibodies) may be used in a pharmaceutical composition when combined with a pharmaceutically acceptable carrier. Such compositions comprise a therapeutically-effective amount of the agent and a pharmaceutically acceptable carrier. Such a composition may also further comprise (in addition to an agent and a carrier) diluents, fillers, salts, buffers, stabilizers, solubilizers, and other materials well known in the art. Compositions comprising the agent can be administered in the form of salts provided the salts are pharmaceutically acceptable. Salts may be prepared using standard procedures known to those skilled in the art of synthetic organic chemistry.

[0312] The term "pharmaceutically acceptable salts" refers to salts prepared from pharmaceutically acceptable non-toxic bases or acids including inorganic or organic bases and inorganic or organic acids. Salts derived from inorganic bases include aluminum, ammonium, calcium, copper, ferric, ferrous, lithium, magnesium, manganic salts, manganous, potassium, sodium, zinc, and the like. Particularly preferred are the ammonium, calcium, magnesium, potassium, and sodium salts. Salts derived from pharmaceutically acceptable organic non-toxic bases include salts of primary, secondary, and tertiary amines, substituted amines including naturally occurring substituted amines, cyclic amines, and basic ion exchange resins, such as arginine, betaine, caffeine, choline, Ν,Ν'- dibenzylethylenediamine, diethylamine, 2-diethylaminoethanol, 2-dimethylaminoethanol, ethanolamine, ethylenediamine, N-ethyl-morpholine, N-ethylpiperidine, glucamine, glucosamine, histidine, hydrabamine, isopropylamine, lysine, methylglucamine, morpholine, piperazine, piperidine, polyamine resins, procaine, purines, theobromine, triethylamine, trimethylamine, tripropylamine, tromethamine, and the like. The term "pharmaceutically acceptable salt" further includes all acceptable salts such as acetate, lactobionate, benzenesulfonate, laurate, benzoate, malate, bicarbonate, maleate, bisulfate, mandelate, bitartrate, mesylate, borate, methylbromide, bromide, methylnitrate, calcium edetate, methyl sulfate, camsylate, mucate, carbonate, napsylate, chloride, nitrate, clavulanate, N- methylglucamine, citrate, ammonium salt, dihydrochloride, oleate, edetate, oxalate, edisylate, pamoate (embonate), estolate, palmitate, esylate, pantothenate, fumarate, phosphate/diphosphate, gluceptate, polygalacturonate, gluconate, salicylate, glutamate, stearate, glycollylarsanilate, sulfate, hexylresorcinate, subacetate, hydrabamine, succinate, hydrobromide, tannate, hydrochloride, tartrate, hydroxynaphthoate, teoclate, iodide, tosylate, isothionate, triethiodide, lactate, panoate, valerate, and the like which can be used as a dosage form for modifying the solubility or hydrolysis characteristics or can be used in sustained release or pro-drug formulations. It will be understood that, as used herein, references to specific agents (e.g., neuromedin U receptor agonists or antagonists), also include the pharmaceutically acceptable salts thereof.

[0313] Methods of administrating the pharmacological compositions, including agonists, antagonists, antibodies or fragments thereof, to an individual include, but are not limited to, intradermal, intrathecal, intramuscular, intraperitoneal, intravenous, subcutaneous, intranasal, epidural, by inhalation, and oral routes. The compositions can be administered by any convenient route, for example by infusion or bolus injection, by absorption through epithelial or mucocutaneous linings (for example, oral mucosa, rectal and intestinal mucosa, and the like), ocular, and the like and can be administered together with other biologically-active agents. Administration can be systemic or local. In addition, it may be advantageous to administer the composition into the central nervous system by any suitable route, including intraventricular and intrathecal injection. Pulmonary administration may also be employed by use of an inhaler or nebulizer, and formulation with an aerosolizing agent. It may also be desirable to administer the agent locally to the area in need of treatment; this may be achieved by, for example, and not by way of limitation, local infusion during surgery, topical application, by injection, by means of a catheter, by means of a suppository, or by means of an implant. [0314] Various delivery systems are known and can be used to administer the pharmacological compositions including, but not limited to, encapsulation in liposomes, microparticles, microcapsules; minicells; polymers; capsules; tablets; and the like. In one embodiment, the agent may be delivered in a vesicle, in particular a liposome. In a liposome, the agent is combined, in addition to other pharmaceutically acceptable carriers, with amphipathic agents such as lipids which exist in aggregated form as micelles, insoluble monolayers, liquid crystals, or lamellar layers in aqueous solution. Suitable lipids for liposomal formulation include, without limitation, monoglycerides, diglycerides, sulfatides, lysolecithin, phospholipids, saponin, bile acids, and the like. Preparation of such liposomal formulations is within the level of skill in the art, as disclosed, for example, in U.S. Pat. No. 4,837,028 and U.S. Pat. No. 4,737,323. In yet another embodiment, the pharmacological compositions can be delivered in a controlled release system including, but not limited to: a delivery pump (See, for example, Saudek, et al., New Engl. J. Med. 321 : 574 (1989) and a semi-permeable polymeric material (See, for example, Howard, et al., J. Neurosurg. 71 : 105 (1989)). Additionally, the controlled release system can be placed in proximity of the therapeutic target (e.g., a tumor), thus requiring only a fraction of the systemic dose. See, for example, Goodson, In: Medical Applications of Controlled Release, 1984. (CRC Press, Boca Raton, Fla.).

[0315] The amount of the agents which will be effective in the treatment of a particular disorder or condition will depend on the nature of the disorder or condition, and may be determined by standard clinical techniques by those of skill within the art. In addition, in vitro assays may optionally be employed to help identify optimal dosage ranges. The precise dose to be employed in the formulation will also depend on the route of administration, and the overall seriousness of the disease or disorder, and should be decided according to the judgment of the practitioner and each patient's circumstances. Ultimately, the attending physician will decide the amount of the agent with which to treat each individual patient. In certain embodiments, the attending physician will administer low doses of the agent and observe the patient's response. Larger doses of the agent may be administered until the optimal therapeutic effect is obtained for the patient, and at that point the dosage is not increased further. In general, the daily dose range of a drug lie within the range known in the art for a particular drug or biologic. Effective doses may be extrapolated from dose-response curves derived from in vitro or animal model test systems. Ultimately the attending physician will decide on the appropriate duration of therapy using compositions of the present invention. Dosage will also vary according to the age, weight and response of the individual patient.

[0316] Methods for administering antibodies for therapeutic use is well known to one skilled in the art. In certain embodiments, small particle aerosols of antibodies or fragments thereof may be administered (see e.g., Piazza et al., J. Infect. Dis., Vol. 166, pp. 1422-1424, 1992; and Brown, Aerosol Science and Technology, Vol. 24, pp. 45-56, 1996). In certain embodiments, antibodies are administered in metered-dose propellant driven aerosols. In certain embodiments, antibodies may be administered in liposomes, i.e., immunoliposomes (see, e.g., Maruyama et al., Biochim. Biophys. Acta, Vol. 1234, pp. 74-80, 1995). In certain embodiments, immunoconjugates, immunoliposomes or immunomicrospheres containing an agent of the present invention is administered by inhalation.

[0317] In certain embodiments, antibodies may be topically administered to mucosa, such as the oropharynx, nasal cavity, respiratory tract, gastrointestinal tract, eye such as the conjunctival mucosa, vagina, urogenital mucosa, or for dermal application. In certain embodiments, antibodies are administered to the nasal, bronchial or pulmonary mucosa. In order to obtain optimal delivery of the antibodies to the pulmonary cavity in particular, it may be advantageous to add a surfactant such as a phosphoglyceride, e.g. phosphatidylcholine, and/or a hydrophilic or hydrophobic complex of a positively or negatively charged excipient and a charged antibody of the opposite charge.

[0318] Other excipients suitable for pharmaceutical compositions intended for delivery of antibodies to the respiratory tract mucosa may be a) carbohydrates, e.g., monosaccharides such as fructose, galactose, glucose. D-mannose, sorbiose, and the like; disaccharides, such as lactose, trehalose, cellobiose, and the like; cyclodextrins, such as 2-hydroxypropyl-P- cyclodextrin; and polysaccharides, such as raffinose, maltodextrins, dextrans, and the like; b) amino acids, such as glycine, arginine, aspartic acid, glutamic acid, cysteine, lysine and the like; c) organic salts prepared from organic acids and bases, such as sodium citrate, sodium ascorbate, magnesium gluconate, sodium gluconate, tromethamine hydrochloride, and the like: d) peptides and proteins, such as aspartame, human serum albumin, gelatin, and the like; e) alditols, such mannitol, xylitol, and the like, and f) polycationic polymers, such as chitosan or a chitosan salt or derivative.

[0319] For dermal application, the antibodies of the present invention may suitably be formulated with one or more of the following excipients: solvents, buffering agents, preservatives, humectants, chelating agents, antioxidants, stabilizers, emulsifying agents, suspending agents, gel-forming agents, ointment bases, penetration enhancers, and skin protective agents.

[0320] Examples of solvents are e.g. water, alcohols, vegetable or marine oils (e.g. edible oils like almond oil, castor oil, cacao butter, coconut oil, corn oil, cottonseed oil, linseed oil, olive oil, palm oil, peanut oil, poppy seed oil, rapeseed oil, sesame oil, soybean oil, sunflower oil, and tea seed oil), mineral oils, fatty oils, liquid paraffin, polyethylene glycols, propylene glycols, glycerol, liquid polyalkylsiloxanes, and mixtures thereof.

[0321] Examples of buffering agents are e.g. citric acid, acetic acid, tartaric acid, lactic acid, hydrogenphosphoric acid, diethyl amine etc. Suitable examples of preservatives for use in compositions are parabenes, such as methyl, ethyl, propyl p-hydroxybenzoate, butylparaben, isobutylparaben, isopropylparaben, potassium sorbate, sorbic acid, benzoic acid, methyl benzoate, phenoxyethanol, bronopol, bronidox, MDM hydantoin, iodopropynyl butylcarbamate, EDTA, benzalconium chloride, and benzyl alcohol, or mixtures of preservatives.

[0322] Examples of humectants are glycerin, propylene glycol, sorbitol, lactic acid, urea, and mixtures thereof.

[0323] Examples of antioxidants are butylated hydroxy anisole (BHA), ascorbic acid and derivatives thereof, tocopherol and derivatives thereof, cysteine, and mixtures thereof.

[0324] Examples of emulsifying agents are naturally occurring gums, e.g. gum acacia or gum tragacanth; naturally occurring phosphatides, e.g. soybean lecithin, sorbitan monooleate derivatives: wool fats; wool alcohols; sorbitan esters; monoglycerides; fatty alcohols; fatty acid esters (e.g. triglycerides of fatty acids); and mixtures thereof.

[0325] Examples of suspending agents are e.g. celluloses and cellulose derivatives such as, e.g., carboxymethyl cellulose, hydroxyethylcellulose, hydroxypropylcellulose, hydroxypropylmethylcellulose, carraghenan, acacia gum, arabic gum, tragacanth, and mixtures thereof.

[0326] Examples of gel bases, viscosity -increasing agents or components which are able to take up exudate from a wound are: liquid paraffin, polyethylene, fatty oils, colloidal silica or aluminum, zinc soaps, glycerol, propylene glycol, tragacanth, carboxyvinyl polymers, magnesium-aluminum silicates, Carbopol®, hydrophilic polymers such as, e.g. starch or cellulose derivatives such as, e.g., carboxymethylcellulose, hydroxyethylcellulose and other cellulose derivatives, water-swellable hydrocolloids, carragenans, hyaluronates (e.g. hyaluronate gel optionally containing sodium chloride), and alginates including propylene glycol alginate.

[0327] Examples of ointment bases are e.g. beeswax, paraffin, cetanol, cetyl palmitate, vegetable oils, sorbitan esters of fatty acids (Span), polyethylene glycols, and condensation products between sorbitan esters of fatty acids and ethylene oxide, e.g. polyoxyethylene sorbitan monooleate (Tween).

[0328] Examples of hydrophobic or water-emulsifying ointment bases are paraffins, vegetable oils, animal fats, synthetic glycerides, waxes, lanolin, and liquid polyalkylsiloxanes. Examples of hydrophilic ointment bases are solid macrogols (polyethylene glycols). Other examples of ointment bases are triethanolamine soaps, sulphated fatty alcohol and polysorbates.

[0329] Examples of other excipients are polymers such as carmelose, sodium carmelose, hydroxypropylmethylcellulose, hydroxyethylcellulose, hydroxypropylcellulose, pectin, xanthan gum, locust bean gum, acacia gum, gelatin, carbomer, emulsifiers like vitamin E, glyceryl stearates, cetanyl glucoside, collagen, carrageenan, hyaluronates and alginates and chitosans.

[0330] The dose of antibody required in humans to be effective in the treatment of cancer differs with the type and severity of the cancer to be treated, the age and condition of the patient, etc. Typical doses of antibody to be administered are in the range of 1 μ§ to 1 g, preferably 1-1000 μg, more preferably 2-500, even more preferably 5-50, most preferably 10- 20 μg per unit dosage form. In certain embodiments, infusion of antibodies of the present invention may range from 10-500 mg/m ² .

[0331] There are a variety of techniques available for introducing nucleic acids into viable cells. The techniques vary depending upon whether the nucleic acid is transferred into cultured cells in vitro, or in vivo in the cells of the intended host. Techniques suitable for the transfer of nucleic acid into mammalian cells in vitro include the use of liposomes, electroporation, microinjection, cell fusion, DEAE-dextran, the calcium phosphate precipitation method, etc. The currently preferred in vivo gene transfer techniques include transduction with viral (typically lentivirus, adeno associated virus (AAV) and adenovirus) vectors.

[0332] In certain embodiments, an agent that reduces a gene signature as described herein is used to treat a subject in need thereof having a cancer. [0333] In one embodiment, the agent is a protein kinase C (PKC) activator. By "protein kinase C activator" is meant any compound that increases the catalytic activity of any protein kinase C (PKC) isoform (see, e.g., WO1998017299A1). The preferred catalytic activity that is enhanced is the kinase activity. Protein kinase C ("PKC") is a key enzyme in signal transduction involved in a variety of cellular functions, including cell growth, regulation of gene expression, and ion channel activity. The PKC family of isozymes includes at least 11 different protein kinases that can be divided into at least three subfamilies based on their homology and sensitivity to activators. Each isozyme includes a number of homologous ("conserved" or "C") domains interspersed with isozyme-unique ("variable" or "V") domains. Members of the "classical" or "cPKC" subfamily, α, βι, βΜ and yPKC, contain four homologous domains (CI , C2, C3 and C4) and require calcium, phosphatidylserine, and diacylglycerol or phorbol esters for activation. In members of the "novel" or "nPKC" subfamily, δ, ε, η and Θ PKC, a C2-like domain preceeds the CI domain. However, that C2 domain does not bind calcium and therefore the nPKC subfamily does not require calcium for activation. Finally, members of the "atypical" or "aPKC" subfamily, ζ and λ/iPKC, lack both the C2 and one-half of the CI homologous domains and are insensitive to diacylglycerol, phorbol esters and calcium. Studies on the subcellular distribution of PKC isozymes demonstrate that activation of PKC results in its redistribution in the cells (also termed trans location), such that activated PKC isozymes associate with the plasma membrane, cytoskeletal elements, nuclei, and other subcellular compartments (Saito, N. et al, Proc. Natl. Acad. Sci. USA 86:3409-3413 (1989); Papadopoulos, V. and Hall, P.F. J. Cell Biol. 108:553- 567 (1989); Mochly-Rosen, D., et al., Molec. Biol. Cell (formerly Cell Reg.) 1 :693-706, (1990)).

[0334] Mochly-Rosen, D., et al. discusses activation of PKC (Nat Rev Drug Discov.

2012 Dec; 11(12): 937-957). PKC isozymes are activated by a variety of hormones, such as adrenalin and angiotensin, by growth factors, including epidermal growth factor and insulin, and by neurotransmitters such as dopamine and endorphin; these stimulators, when bound to their respective receptors, activate members of the phospholipase C family, which generates diacylglycerol, a lipid-derived second messenger. The novel isozymes (PKC δ, ε, Θ and η) are activated by diacylglycerol alone, whereas the four conventional PKC isozymes (PKCa, βΐ, βΙΙ and γ) also require calcium for their activation. Cellular calcium levels are elevated along with diacylglycerol, because the latter is often co-produced with inositol trisphosphate (IP3), which triggers calcium release into the cytosol from internal stores. Activation of PKC can also occur in the absence of the above second messengers. High levels of cytosolic calcium can directly activate phospholipase C, thus leading to PKC activation in the absence of receptor activation. A number of post-translational modifications of PKC were also found to lead to activation of select PKC isozymes both in normal and disease states. These include activation by proteolysis between the regulatory and the catalytic domain that was noted to occur for PKC5, for example. Phosphorylation of a number of sites may be required for maturation of the newly synthesized enzyme, but also for activation of mature isozymes, e.g. H202-induced tyrosine phosphorylation of PKC5. Other modifications including oxidation, acetylation and nitration have also been found to activate PKC.

[0335] In one embodiment, the agent is an inhibitor of the FKB pathway. Inhibitors of the NFKB pathway have been described (see, e.g., Gilmore and Herscovitch, Inhibitors of F-kappaB signaling: 785 and counting. Oncogene (2006) 25, 6887-6899). These compounds include chemicals, metals, metabolites, synthetic compounds, antioxidants, peptides, small RNA/DNA, microbial and viral proteins, small molecules, and engineered dominant-negative or constitutively active polypeptides.

[0336] In one embodiment, the agent is an IGF1R inhibitor. IGF1R inhibitors are well known in the art (see, e.g., King et al., Can we unlock the potential of IGF-1R inhibition in cancer therapy? Cancer Treat Rev. 2014 Oct; 40(9): 1096-1105). IGF1R inhibitors may include, but are not limited to monoclonal anti-IGFIR antibodies, small molecule tyrosine kinase inhibitors (TKIs), and IGF ligand antibodies.

[0337] In one embodiment, the agent is Reserpine (methyl 18P-hydroxy-l 1, 17 a- dimethoxy-3p, 20a-yohimban-16P-carboxylate 3,4,5-trimethoxybenzoate) or derivative thereof. Reserpine is an alkaloid first isolated from Rauwolfia serpentina. Reserpine (also known by trade names Raudixin, Serpalan, Serpasil) is an indole alkaloid, antipsychotic, and antihypertensive drug that has been used for the control of high blood pressure and for the relief of psychotic symptoms, although because of the development of better drugs for these purposes and because of its numerous side-effects, it is rarely used today. The antihypertensive actions of reserpine are a result of its ability to deplete catecholamines

(among other monoamine neurotransmitters) from peripheral sympathetic nerve endings.

These substances are normally involved in controlling heart rate, force of cardiac contraction and peripheral vascular resistance. The daily dose of reserpine in antihypertensive treatment is as low as 0.1 to 0.25 mg. In certain embodiments, the dose is significantly higher for the treatment of cancer. A skilled practitioner would know to adjust the dose based on response to the drug. For example, reduction of an immunotherapy resistance signature or decrease in tumor size and/or proliferation. In certain embodiments, Reserpine is administered directly to a tumor. In certain embodiments, reserpine is administered over the course of a single day or week or month.

[0338] Typical of the known rauwolfia alkaloids are deserpidine, alperaxylon, reserpine, and rauwolfia serpentina. Oral dosage of the rauwolfia alkaloid should be carefully adjusted according to individual tolerance and response, using the lowest possible effective dosage. Typically, the amount of rauwolfia alkaloid administered daily is from about 0.001 to about 0.01 mg per kg of body weight.

[0339] In certain embodiments, the agent capable of modulating a signature as described herein is a cell cycle inhibitor (see e.g., Dickson and Schwartz, Development of cell-cycle inhibitors for cancer therapy, Curr Oncol. 2009 Mar; 16(2): 36-43). In one embodiment, the agent capable of modulating a signature as described herein is a CDK4/6 inhibitor, such as

LEE011, palbociclib (PD-0332991), and Abemaciclib (LY2835219) (see, e.g.,

US9259399B2; WO2016025650A1; US Patent Publication No. 20140031325; US Patent

Publication No. 20140080838; US Patent Publication No. 20130303543; US Patent

Publication No. 2007/0027147; US Patent Publication No. 2003/0229026; US Patent

Publication No 2004/0048915; US Patent Publication No. 2004/0006074; US Patent

Publication No. 2007/0179118; each of which is incorporated by reference herein in its entirety). Currently there are three CDK4/6 inhibitors that are either approved or in late-stage development: palbociclib (PD-0332991; Pfizer), ribociclib (LEE011; Novartis), and abemaciclib (LY2835219; Lilly) (see e.g., Hamilton and Infante, Targeting CDK4/6 in patients with cancer, Cancer Treatment Reviews, Volume 45, April 2016, Pages 129-138).

[0340] In certain embodiments, an agent that reduces an immunotherapy resistance signature is co-administered with an immunotherapy or is administered before or after administration of an immunotherapy. In certain embodiments, a subject in need thereof is treated with a phased combination therapy. The phased combination therapy may be a treatment regimen comprising checkpoint inhibition followed by a CDK4/6 inhibitor and checkpoint inhibitor combination. Checkpoint inhibitors may be administered every two weeks. The combination therapy may be administered when an immunotherapy resistance signature is detected. This may be after two weeks to six months after the initial checkpoint inhibition. The immunotherapy may be adoptive cell transfer therapy, as described herein or may be an inhibitor of any check point protein described herein. The checkpoint blockade therapy may comprise anti-TIM3, anti-CTLA4, anti-PD-Ll, anti-PDl, anti-TIGIT, anti- LAG3, or combinations thereof. Specific check point inhibitors include, but are not limited to anti-CTLA4 antibodies (e.g., Ipilimumab), anti-PD-1 antibodies (e.g., Nivolumab, Pembrolizumab), and anti-PD-Ll antibodies (e.g., Atezolizumab). Dosages for the immunotherapy and/or CDK4/6 inhibitors may be determined according to the standard of care for each therapy and may be incorporated into the standard of care (see, e.g., Rivalland et al., Standard of care in immunotherapy trials: Challenges and considerations, Hum Vaccin Immunother. 2017 Jul; 13(9): 2164-2178; and Pernas et al., CDK4/6 inhibition in breast cancer: current practice and future directions, Ther Adv Med Oncol. 2018). The standard of care is the current treatment that is accepted by medical experts as a proper treatment for a certain type of disease and that is widely used by healthcare professionals. Standard or care is also called best practice, standard medical care, and standard therapy.

[0341] In another aspect, provided is a pharmaceutical pack or kit, comprising one or more containers filled with one or more of the ingredients of the pharmaceutical compositions.

[0342] In another aspect, provided is a kit for detecting the gene signature as described herein.

[0343] With respect to general information on CRISPR-Cas Systems, components thereof, and delivery of such components, including methods, materials, delivery vehicles, vectors, particles, AAV, and making and using thereof, including as to amounts and formulations, all useful in the practice of the instant invention, reference is made to: US

Patents Nos. 8,999,641, 8,993,233, 8,945,839, 8,932,814, 8,906,616, 8,895,308, 8,889,418,

8,889,356, 8,871,445, 8,865,406, 8,795,965, 8,771,945 and 8,697,359; US Patent

Publications US 2014-0310830 (US APP. Ser. No. 14/105,031), US 2014-0287938 Al (U.S.

App. Ser. No. 14/213,991), US 2014-0273234 Al (U.S. App. Ser. No. 14/293,674), US2014-

0273232 Al (U.S. App. Ser. No. 14/290,575), US 2014-0273231 (U.S. App. Ser. No.

14/259,420), US 2014-0256046 Al (U.S. App. Ser. No. 14/226,274), US 2014-0248702 Al

(U.S. App. Ser. No. 14/258,458), US 2014-0242700 Al (U.S. App. Ser. No. 14/222,930), US

2014-0242699 Al (U.S. App. Ser. No. 14/183,512), US 2014-0242664 Al (U.S. App. Ser.

No. 14/104,990), US 2014-0234972 Al (U.S. App. Ser. No. 14/183,471), US 2014-0227787

Al (U.S. App. Ser. No. 14/256,912), US 2014-0189896 Al (U.S. App. Ser. No. 14/105,035),

US 2014-0186958 (U.S. App. Ser. No. 14/105,017), US 2014-0186919 Al (U.S. App. Ser.

No. 14/104,977), US 2014-0186843 Al (U.S. App. Ser. No. 14/104,900), US 2014-0179770 Al (U.S. App. Ser. No. 14/104,837) and US 2014-0179006 Al (U.S. App. Ser. No.

14/183,486), US 2014-0170753 (US App Ser No 14/183,429); European Patents EP 2 784

162 Bl and EP 2 771 468 Bl; European Patent Applications EP 2 771 468 (EP13818570.7),

EP 2 764 103 (EP13824232.6), and EP 2 784 162 (EP 14170383.5); and PCT Patent

Publications PCT Patent Publications WO 2014/093661 (PCT/US2013/074743), WO

2014/093694 (PCT/US2013/074790), WO 2014/093595 (PCT/US2013/074611), WO

2014/093718 (PCT/US2013/074825), WO 2014/093709 (PCT/US2013/074812), WO

2014/093622 (PCT/US2013/074667), WO 2014/093635 (PCT/US2013/074691), WO

2014/093655 (PCT/US2013/074736), WO 2014/093712 (PCT/US2013/074819),

WO2014/093701 (PCT/US2013/074800), WO2014/018423 (PCT/US2013/051418), WO

2014/204723 (PCT/US2014/041790), WO 2014/204724 (PCT/US2014/041800), WO

2014/204725 (PCT/US2014/041803), WO 2014/204726 (PCT/US2014/041804), WO

2014/204727 (PCT/US2014/041806), WO 2014/204728 (PCT/US2014/041808), WO

2014/204729 (PCT/US2014/041809). Reference is also made to US provisional patent applications 61/758,468; 61/802, 174; 61/806,375; 61/814,263; 61/819,803 and 61/828, 130, filed on January 30, 2013; March 15, 2013; March 28, 2013; April 20, 2013; May 6, 2013 and May 28, 2013 respectively. Reference is also made to US provisional patent application

61/836, 123, filed on June 17, 2013. Reference is additionally made to US provisional patent applications 61/835,931, 61/835,936, 61/836, 127, 61/836, 101, 61/836,080 and 61/835,973, each filed June 17, 2013. Further reference is made to US provisional patent applications

61/862,468 and 61/862,355 filed on August 5, 2013; 61/871,301 filed on August 28, 2013;

61/960,777 filed on September 25, 2013 and 61/961,980 filed on October 28, 2013.

Reference is yet further made to: PCT Patent applications Nos: PCT/US2014/041803,

PCT/US2014/041800, PCT/US2014/041809, PCT/US2014/041804 and

PCT/US2014/041806, each filed June 10, 2014 6/10/14; PCT/US2014/041808 filed June 11,

2014; and PCT/US2014/62558 filed October 28, 2014, and US Provisional Patent

Applications Serial Nos. : 61/915, 150, 61/915,301, 61/915,267 and 61/915,260, each filed

December 12, 2013; 61/757,972 and 61/768,959, filed on January 29, 2013 and February 25,

2013; 61/835,936, 61/836, 127, 61/836, 101, 61/836,080, 61/835,973, and 61/835,931, filed

June 17, 2013; 62/010,888 and 62/010,879, both filed June 11, 2014; 62/010,329 and

62/010,441, each filed June 10, 2014; 61/939,228 and 61/939,242, each filed February 12,

2014; 61/980,012, filed April 15,2014; 62/038,358, filed August 17, 2014; 62/054,490,

62/055,484, 62/055,460 and 62/055,487, each filed September 25, 2014; and 62/069,243, filed October 27, 2014. Reference is also made to US provisional patent applications Nos. 62/055,484, 62/055,460, and 62/055,487, filed September 25, 2014; US provisional patent application 61/980,012, filed April 15, 2014; and US provisional patent application 61/939,242 filed February 12, 2014. Reference is made to PCT application designating, inter alia, the United States, application No. PCT/US14/41806, filed June 10, 2014. Reference is made to US provisional patent application 61/930,214 filed on January 22, 2014. Reference is made to US provisional patent applications 61/915,251; 61/915,260 and 61/915,267, each filed on December 12, 2013. Reference is made to US provisional patent application USSN 61/980,012 filed April 15, 2014. Reference is made to PCT application designating, inter alia, the United States, application No. PCT/US 14/41806, filed June 10, 2014. Reference is made to US provisional patent application 61/930,214 filed on January 22, 2014. Reference is made to US provisional patent applications 61/915,251; 61/915,260 and 61/915,267, each filed on December 12, 2013.

[0344] Mention is also made of US application 62/091,455, filed, 12-Dec-14, PROTECTED GUIDE RNAS (PGRNAS); US application 62/096,708, 24-Dec-14, PROTECTED GUIDE RNAS (PGRNAS); US application 62/091,462, 12-Dec-14, DEAD GUIDES FOR CRISPR TRANSCRIPTION FACTORS; US application 62/096,324, 23-Dec- 14, DEAD GUIDES FOR CRISPR TRANSCRIPTION FACTORS; US application 62/091,456, 12-Dec-14, ESCORTED AND FUNCTIONALIZED GUIDES FOR CRISPR- CAS SYSTEMS; US application 62/091,461, 12-Dec-14, DELIVERY, USE AND THERAPEUTIC APPLICATIONS OF THE CRISPR-CAS SYSTEMS AND COMPOSITIONS FOR GENOME EDITING AS TO HEMATOPOETIC STEM CELLS

(HSCs); US application 62/094,903, 19-Dec-14, UNBIASED IDENTIFICATION OF DOUBLE-STRAND BREAKS AND GENOMIC REARRANGEMENT BY GENOME- WISE INSERT CAPTURE SEQUENCING; US application 62/096,761, 24-Dec-14, ENGINEERING OF SYSTEMS, METHODS AND OPTIMIZED ENZYME AND GUIDE SCAFFOLDS FOR SEQUENCE MANIPULATION; US application 62/098,059, 30-Dec-14, RNA-TARGETING SYSTEM; US application 62/096,656, 24-Dec-14, CRISPR HAVING OR ASSOCIATED WITH DESTABILIZATION DOMAINS; US application 62/096,697, 24-Dec-14, CRISPR HAVING OR ASSOCIATED WITH AAV; US application 62/098, 158, 30-Dec-14, ENGINEERED CRISPR COMPLEX INSERTIONAL TARGETING SYSTEMS; US application 62/151,052, 22-Apr-15, CELLULAR TARGETING FOR

EXTRACELLULAR EXOSOMAL REPORTING; US application 62/054,490, 24-Sep-14, DELIVERY, USE AND THERAPEUTIC APPLICATIONS OF THE CRISPR-CAS SYSTEMS AND COMPOSITIONS FOR TARGETING DISORDERS AND DISEASES USING PARTICLE DELIVERY COMPONENTS; US application 62/055,484, 25-Sep-14, SYSTEMS, METHODS AND COMPOSITIONS FOR SEQUENCE MANIPULATION WITH OPTIMIZED FUNCTIONAL CRISPR-CAS SYSTEMS; US application 62/087,537, 4-Dec-14, SYSTEMS, METHODS AND COMPOSITIONS FOR SEQUENCE MANIPULATION WITH OPTIMIZED FUNCTIONAL CRISPR-CAS SYSTEMS; US application 62/054,651, 24-Sep-14, DELIVERY, USE AND THERAPEUTIC APPLICATIONS OF THE CRISPR-CAS SYSTEMS AND COMPOSITIONS FOR MODELING COMPETITION OF MULTIPLE CANCER MUTATIONS IN VIVO; US application 62/067,886, 23-Oct-14, DELIVERY, USE AND THERAPEUTIC APPLICATIONS OF THE CRISPR-CAS SYSTEMS AND COMPOSITIONS FOR MODELING COMPETITION OF MULTIPLE CANCER MUTATIONS IN VIVO; US application 62/054,675, 24-Sep-14, DELIVERY, USE AND THERAPEUTIC APPLICATIONS OF THE CRISPR-CAS SYSTEMS AND COMPOSITIONS IN NEURONAL CELLS/TISSUES; US application 62/054,528, 24-Sep-14, DELIVERY, USE AND THERAPEUTIC APPLICATIONS OF THE CRISPR-CAS SYSTEMS AND COMPOSITIONS IN IMMUNE DISEASES OR DISORDERS; US application 62/055,454, 25-Sep-14, DELIVERY, USE AND THERAPEUTIC APPLICATIONS OF THE CRISPR- CAS SYSTEMS AND COMPOSITIONS FOR TARGETING DISORDERS AND DISEASES USING CELL PENETRATION PEPTIDES (CPP); US application 62/055,460, 25-Sep-14, MULTIFUNCTIONAL-CRISPR COMPLEXES AND/OR OPTIMIZED ENZYME LINKED FUNCTIONAL-CRISPR COMPLEXES; US application 62/087,475, 4- Dec-14, FUNCTIONAL SCREENING WITH OPTIMIZED FUNCTIONAL CRISPR-CAS SYSTEMS; US application 62/055,487, 25-Sep-14, FUNCTIONAL SCREENING WITH OPTIMIZED FUNCTIONAL CRISPR-CAS SYSTEMS; US application 62/087,546, 4-Dec- 14, MULTIFUNCTIONAL CRISPR COMPLEXES AND/OR OPTIMIZED ENZYME LINKED FUNCTIONAL-CRISPR COMPLEXES; and US application 62/098,285, 30-Dec- 14, CRISPR MEDIATED IN VIVO MODELING AND GENETIC SCREENING OF TUMOR GROWTH AND METASTASIS.

[0345] Each of these patents, patent publications, and applications, and all documents cited therein or during their prosecution ("appln cited documents") and all documents cited or referenced in the appln cited documents, together with any instructions, descriptions, product specifications, and product sheets for any products mentioned therein or in any document therein and incorporated by reference herein, are hereby incorporated herein by reference, and may be employed in the practice of the invention. All documents (e.g., these patents, patent publications and applications and the appln cited documents) are incorporated herein by reference to the same extent as if each individual document was specifically and individually indicated to be incorporated by reference.

[0346] Also with respect to general information on CRISPR-Cas Systems, mention is made of the following (also hereby incorporated herein by reference):

Multiplex genome engineering using CRISPR/Cas systems. Cong, L., Ran, F.A., Cox, D., Lin, S., Barretto, R., Habib, N., Hsu, P.D., Wu, X., Jiang, W., Marraffini, L.A., & Zhang, F. Science Feb 15;339(6121):819-23 (2013);

> RNA-guided editing of bacterial genomes using CRISPR-Cas systems. Jiang W., Bikard D., Cox D., Zhang F, Marraffini LA. Nat Biotechnol Mar;31(3):233-9 (2013);

One-Step Generation of Mice Carrying Mutations in Multiple Genes by CRISPR/Cas-Mediated Genome Engineering. Wang H., Yang H., Shivalila CS., Dawlaty MM., Cheng AW., Zhang F., Jaenisch R. Cell May 9; 153(4):910-8 (2013);

Optical control of mammalian endogenous transcription and epigenetic states. Konermann S, Brigham MD, Trevino AE, Hsu PD, Heidenreich M, Cong L, Piatt RJ, Scott DA, Church GM, Zhang F. Nature. Aug 22;500(7463):472-6. doi: 10.1038/Naturel2466. Epub 2013 Aug 23 (2013);

> Double Nicking by RNA-Guided CRISPR Cas9 for Enhanced Genome Editing Specificity. Ran, FA., Hsu, PD., Lin, CY., Gootenberg, JS., Konermann, S., Trevino, AE., Scott, DA., Inoue, A., Matoba, S., Zhang, Y., & Zhang, F. Cell Aug 28. pii: S0092-8674(13)01015-5 (2013-A);

> DNA targeting specificity of RNA-guided Cas9 nucleases. Hsu, P., Scott, D., Weinstein, J., Ran, FA., Konermann, S., Agarwala, V., Li, Y., Fine, E., Wu, X., Shalem, O., Cradick, TJ., Marraffini, LA., Bao, G., & Zhang, F. Nat Biotechnol doi: 10.1038/nbt.2647 (2013);

Genome engineering using the CRISPR-Cas9 system. Ran, FA., Hsu, PD., Wright, J., Agarwala, V., Scott, DA., Zhang, F. Nature Protocols Nov;8(l 1):2281- 308 (2013-B); Genome-Scale CRISPR-Cas9 Knockout Screening in Human Cells. Shalem, O., Sanjana, E., Hartenian, E., Shi, X., Scott, DA., Mikkelson, T., Heckl, D., Ebert, BL., Root, DE., Doench, JG, Zhang, F. Science Dec 12. (2013). [Epub ahead of print];

Crystal structure of cas9 in complex with guide RNA and target DNA. Nishimasu, H., Ran, FA., Hsu, PD., Konermann, S., Shehata, SI, Dohmae, N., Ishitani, R., Zhang, F., Nureki, O. Cell Feb 27, 156(5):935-49 (2014);

Genome-wide binding of the CRISPR endonuclease Cas9 in mammalian cells. Wu X., Scott DA., Kriz AJ., Chiu AC, Hsu PD., Dadon DB., Cheng AW., Trevino AE., Konermann S., Chen S., Jaenisch R., Zhang F., Sharp PA. Nat Biotechnol. Apr 20. doi: 10.1038/nbt.2889 (2014);

CRISPR-Cas9 Knockin Mice for Genome Editing and Cancer Modeling. Piatt RJ, Chen S, Zhou Y, Yim MJ, Swiech L, Kempton HR, Dahlman JE, Parnas O, Eisenhaure TM, Jovanovic M, Graham DB, Jhunjhunwala S, Heidenreich M, Xavier RJ, Langer R, Anderson DG, Hacohen N, Regev A, Feng G, Sharp PA, Zhang F. Cell 159(2): 440-455 DOI: 10.1016/j .cell.2014.09.014(2014);

Development and Applications of CRISPR-Cas9 for Genome Engineering, Hsu PD, Lander ES, Zhang F., Cell. Jun 5; 157(6): 1262-78 (2014).

Genetic screens in human cells using the CRISPR/Cas9 system, Wang T, Wei JJ, Sabatini DM, Lander ES., Science. January 3; 343(6166): 80-84. doi: 10.1126/science.1246981 (2014);

Rational design of highly active sgRNAs for CRISPR-Cas9-mediated gene inactivation, Doench JG, Hartenian E, Graham DB, Tothova Z, Hegde M, Smith I, Sullender M, Ebert BL, Xavier RJ, Root DE., (published online 3 September 2014) Nat Biotechnol. Dec;32(12): 1262-7 (2014);

In vivo interrogation of gene function in the mammalian brain using CRISPR- Cas9, Swiech L, Heidenreich M, Banerjee A, Habib N, Li Y, Trombetta J, Sur M, Zhang F., (published online 19 October 2014) Nat Biotechnol. Jan;33(l): 102-6 (2015);

Genome-scale transcriptional activation by an engineered CRISPR-Cas9 complex, Konermann S, Brigham MD, Trevino AE, Joung J, Abudayyeh OO, Barcena C, Hsu PD, Habib N, Gootenberg JS, Nishimasu H, Nureki O, Zhang F., Nature. Jan 29;517(7536):583-8 (2015). A split-Cas9 architecture for inducible genome editing and transcription modulation, Zetsche B, Volz SE, Zhang F., (published online 02 February 2015) Nat Biotechnol. Feb;33(2): 139-42 (2015);

Genome-wide CRISPR Screen in a Mouse Model of Tumor Growth and Metastasis, Chen S, Sanjana NE, Zheng K, Shalem O, Lee K, Shi X, Scott DA, Song J, Pan JQ, Weissleder R, Lee H, Zhang F, Sharp PA. Cell 160, 1246-1260, March 12, 2015 (multiplex screen in mouse), and

> In vivo genome editing using Staphylococcus aureus Cas9, Ran FA, Cong L, Yan WX, Scott DA, Gootenberg JS, Kriz AJ, Zetsche B, Shalem O, Wu X, Makarova KS, Koonin EV, Sharp PA, Zhang F., (published online 01 April 2015), Nature. Apr 9;520(7546): 186-91 (2015).

Shalem et al., "High-throughput functional genomics using CRISPR-Cas9," Nature Reviews Genetics 16, 299-311 (May 2015).

Xu et al., "Sequence determinants of improved CRISPR sgRNA design," Genome Research 25, 1147-1157 (August 2015).

Parnas et al., "A Genome-wide CRISPR Screen in Primary Immune Cells to Dissect Regulatory Networks," Cell 162, 675-686 (July 30, 2015).

Ramanan et al., CRISPR/Cas9 cleavage of viral DNA efficiently suppresses hepatitis B virus," Scientific Reports 5: 10833. doi: 10.1038/srepl0833 (June 2, 2015)

> Nishimasu et al., Crystal Structure of Staphylococcus aureus Cas9," Cell 162, 1113-1126 (Aug. 27, 2015)

> BCL11A enhancer dissection by Cas9-mediated in situ saturating mutagenesis, Canver et al., Nature 527(7577): 192-7 (Nov. 12, 2015) doi: 10.1038/naturel5521. Epub 2015 Sep 16.

Cpfl Is a Single RNA-Guided Endonuclease of a Class 2 CRISPR-Cas System, Zetsche et al., Cell 163, 759-71 (Sep 25, 2015).

Discovery and Functional Characterization of Diverse Class 2 CRISPR-Cas Systems, Shmakov et al., Molecular Cell, 60(3), 385-397 doi: 10.1016/j .molcel.2015.10.008 Epub October 22, 2015.

Rationally engineered Cas9 nucleases with improved specificity, Slaymaker et al., Science 2016 Jan 1 351(6268): 84-88 doi: 10.1126/science.aad5227. Epub 2015 Dec 1. Gao et al, "Engineered Cpf 1 Enzymes with Altered PAM Specificities," bioRxiv 091611; doi: http://dx.doi.org/10.1101/091611 (Dec. 4, 2016).

each of which is incorporated herein by reference, may be considered in the practice of the instant invention, and discussed briefly below:

Cong et al. engineered type II CRISPR-Cas systems for use in eukaryotic cells based on both Streptococcus thermophilus Cas9 and also Streptococcus pyogenes Cas9 and demonstrated that Cas9 nucleases can be directed by short RNAs to induce precise cleavage of DNA in human and mouse cells. Their study further showed that Cas9 as converted into a nicking enzyme can be used to facilitate homology-directed repair in eukaryotic cells with minimal mutagenic activity. Additionally, their study demonstrated that multiple guide sequences can be encoded into a single CRISPR array to enable simultaneous editing of several at endogenous genomic loci sites within the mammalian genome, demonstrating easy programmability and wide applicability of the RNA-guided nuclease technology. This ability to use RNA to program sequence specific DNA cleavage in cells defined a new class of genome engineering tools. These studies further showed that other CRISPR loci are likely to be transplantable into mammalian cells and can also mediate mammalian genome cleavage. Importantly, it can be envisaged that several aspects of the CRISPR-Cas system can be further improved to increase its efficiency and versatility.

Jiang et al. used the clustered, regularly interspaced, short palindromic repeats

(CRISPR)-associated Cas9 endonuclease complexed with dual-RNAs to introduce precise mutations in the genomes of Streptococcus pneumoniae and Escherichia coli. The approach relied on dual -RNA: Cas9-directed cleavage at the targeted genomic site to kill unmutated cells and circumvents the need for selectable markers or counter-selection systems. The study reported reprogramming dual-

RNA:Cas9 specificity by changing the sequence of short CRISPR RNA (crRNA) to make single- and multinucleotide changes carried on editing templates. The study showed that simultaneous use of two crRNAs enabled multiplex mutagenesis. Furthermore, when the approach was used in combination with recombineering, in S. pneumoniae, nearly 100% of cells that were recovered using the described approach contained the desired mutation, and in E. coli, 65% that were recovered contained the mutation. Wang et al. (2013) used the CRISPR/Cas system for the one-step generation of mice carrying mutations in multiple genes which were traditionally generated in multiple steps by sequential recombination in embryonic stem cells and/or time- consuming intercrossing of mice with a single mutation. The CRISPR/Cas system will greatly accelerate the in vivo study of functionally redundant genes and of epistatic gene interactions.

Konermann et al. (2013) addressed the need in the art for versatile and robust technologies that enable optical and chemical modulation of DNA-binding domains based CRISPR Cas9 enzyme and also Transcriptional Activator Like Effectors

Ran et al. (2013 -A) described an approach that combined a Cas9 nickase mutant with paired guide RNAs to introduce targeted double-strand breaks. This addresses the issue of the Cas9 nuclease from the microbial CRISPR-Cas system being targeted to specific genomic loci by a guide sequence, which can tolerate certain mismatches to the DNA target and thereby promote undesired off-target mutagenesis. Because individual nicks in the genome are repaired with high fidelity, simultaneous nicking via appropriately offset guide RNAs is required for double-stranded breaks and extends the number of specifically recognized bases for target cleavage. The authors demonstrated that using paired nicking can reduce off-target activity by 50- to 1,500-fold in cell lines and to facilitate gene knockout in mouse zygotes without sacrificing on-target cleavage efficiency. This versatile strategy enables a wide variety of genome editing applications that require high specificity.

Hsu et al. (2013) characterized SpCas9 targeting specificity in human cells to inform the selection of target sites and avoid off-target effects. The study evaluated >700 guide RNA variants and SpCas9-induced indel mutation levels at

>100 predicted genomic off-target loci in 293T and 293FT cells. The authors that

SpCas9 tolerates mismatches between guide RNA and target DNA at different positions in a sequence-dependent manner, sensitive to the number, position and distribution of mismatches. The authors further showed that SpCas9-mediated cleavage is unaffected by DNA methylation and that the dosage of SpCas9 and sgRNA can be titrated to minimize off-target modification. Additionally, to facilitate mammalian genome engineering applications, the authors reported providing a web-based software tool to guide the selection and validation of target sequences as well as off-target analyses.

Ran et al. (2013-B) described a set of tools for Cas9-mediated genome editing via non-homologous end joining ( HEJ) or homology-directed repair (HDR) in mammalian cells, as well as generation of modified cell lines for downstream functional studies. To minimize off-target cleavage, the authors further described a double-nicking strategy using the Cas9 nickase mutant with paired guide RNAs. The protocol provided by the authors experimentally derived guidelines for the selection of target sites, evaluation of cleavage efficiency and analysis of off- target activity. The studies showed that beginning with target design, gene modifications can be achieved within as little as 1-2 weeks, and modified clonal cell lines can be derived within 2-3 weeks.

Shalem et al. described a new way to interrogate gene function on a genome-wide scale. Their studies showed that delivery of a genome-scale CRISPR-Cas9 knockout (GeCKO) library targeted 18,080 genes with 64,751 unique guide sequences enabled both negative and positive selection screening in human cells. First, the authors showed use of the GeCKO library to identify genes essential for cell viability in cancer and pluripotent stem cells. Next, in a melanoma model, the authors screened for genes whose loss is involved in resistance to vemurafenib, a therapeutic that inhibits mutant protein kinase BRAF. Their studies showed that the highest-ranking candidates included previously validated genes NF1 and MED12 as well as novel hits NF2, CUL3, TADA2B, and TADAl . The authors observed a high level of consistency between independent guide RNAs targeting the same gene and a high rate of hit confirmation, and thus demonstrated the promise of genome-scale screening with Cas9.

Nishimasu et al. reported the crystal structure of Streptococcus pyogenes Cas9 in complex with sgRNA and its target DNA at 2.5 A° resolution. The structure revealed a bilobed architecture composed of target recognition and nuclease lobes, accommodating the sgRNA:DNA heteroduplex in a positively charged groove at their interface. Whereas the recognition lobe is essential for binding sgRNA and

DNA, the nuclease lobe contains the HNH and RuvC nuclease domains, which are properly positioned for cleavage of the complementary and non-complementary strands of the target DNA, respectively. The nuclease lobe also contains a carboxyl-terminal domain responsible for the interaction with the protospacer adjacent motif (PAM). This high-resolution structure and accompanying functional analyses have revealed the molecular mechanism of RNA-guided DNA targeting by Cas9, thus paving the way for the rational design of new, versatile genome-editing technologies.

Wu et al. mapped genome-wide binding sites of a catalytically inactive Cas9 (dCas9) from Streptococcus pyogenes loaded with single guide RNAs (sgRNAs) in mouse embryonic stem cells (mESCs). The authors showed that each of the four sgRNAs tested targets dCas9 to between tens and thousands of genomic sites, frequently characterized by a 5-nucleotide seed region in the sgRNA and an NGG protospacer adjacent motif (PAM). Chromatin inaccessibility decreases dCas9 binding to other sites with matching seed sequences; thus 70% of off-target sites are associated with genes. The authors showed that targeted sequencing of 295 dCas9 binding sites in mESCs transfected with catalytically active Cas9 identified only one site mutated above background levels. The authors proposed a two-state model for Cas9 binding and cleavage, in which a seed match triggers binding but extensive pairing with target DNA is required for cleavage.

Piatt et al. established a Cre-dependent Cas9 knockin mouse. The authors demonstrated in vivo as well as ex vivo genome editing using adeno-associated virus (AAV)-, lentivirus-, or particle-mediated delivery of guide RNA in neurons, immune cells, and endothelial cells.

Hsu et al. (2014) is a review article that discusses generally CRISPR-Cas9 history from yogurt to genome editing, including genetic screening of cells.

Wang et al. (2014) relates to a pooled, loss-of-function genetic screening approach suitable for both positive and negative selection that uses a genome- scale lentiviral single guide RNA (sgRNA) library.

Doench et al. created a pool of sgRNAs, tiling across all possible target sites of a panel of six endogenous mouse and three endogenous human genes and quantitatively assessed their ability to produce null alleles of their target gene by antibody staining and flow cytometry. The authors showed that optimization of the PAM improved activity and also provided an on-line tool for designing sgRNAs. Swiech et al. demonstrate that AAV-mediated SpCas9 genome editing can enable reverse genetic studies of gene function in the brain.

> Konermann et al. (2015) discusses the ability to attach multiple effector domains, e.g., transcriptional activator, functional and epigenomic regulators at appropriate positions on the guide such as stem or tetraloop with and without linkers.

Zetsche et al. demonstrates that the Cas9 enzyme can be split into two and hence the assembly of Cas9 for activation can be controlled.

> Chen et al. relates to multiplex screening by demonstrating that a genome-wide in vivo CRISPR-Cas9 screen in mice reveals genes regulating lung metastasis.

Ran et al. (2015) relates to SaCas9 and its ability to edit genomes and demonstrates that one cannot extrapolate from biochemical assays.

Shalem et al. (2015) described ways in which catalytically inactive Cas9 (dCas9) fusions are used to synthetically repress (CRISPRi) or activate (CRISPRa) expression, showing, advances using Cas9 for genome-scale screens, including arrayed and pooled screens, knockout approaches that inactivate genomic loci and strategies that modulate transcriptional activity.

Xu et al. (2015) assessed the DNA sequence features that contribute to single guide RNA (sgRNA) efficiency in CRISPR-based screens. The authors explored efficiency of CRISPR/Cas9 knockout and nucleotide preference at the cleavage site. The authors also found that the sequence preference for CRISPRi/a is substantially different from that for CRISPR/Cas9 knockout.

Parnas et al. (2015) introduced genome-wide pooled CRISPR-Cas9 libraries into dendritic cells (DCs) to identify genes that control the induction of tumor necrosis factor (Tnf) by bacterial lipopolysaccharide (LPS). Known regulators of Tlr4 signaling and previously unknown candidates were identified and classified into three functional modules with distinct effects on the canonical responses to LPS. Ramanan et al (2015) demonstrated cleavage of viral episomal DNA (cccDNA) in infected cells. The HBV genome exists in the nuclei of infected hepatocytes as a 3.2kb double-stranded episomal DNA species called covalently closed circular DNA (cccDNA), which is a key component in the HBV life cycle whose replication is not inhibited by current therapies. The authors showed that sgRNAs specifically targeting highly conserved regions of HBV robustly suppresses viral replication and depleted cccDNA. > Nishimasu et al. (2015) reported the crystal structures of SaCas9 in complex with a single guide RNA (sgRNA) and its double-stranded DNA targets, containing the 5'-TTGAAT-3' PAM and the 5'-TTGGGT-3' PAM. A structural comparison of SaCas9 with SpCas9 highlighted both structural conservation and divergence, explaining their distinct PAM specificities and orthologous sgRNA recognition. Canver et al. (2015) demonstrated a CRISPR-Cas9-based functional investigation of non-coding genomic elements. The authors developed pooled CRISPR-Cas9 guide RNA libraries to perform in situ saturating mutagenesis of the human and mouse BCL11 A enhancers which revealed critical features of the enhancers.

Zetsche et al. (2015) reported characterization of Cpfl, a class 2 CRISPR nuclease from Francisella novicida U112 having features distinct from Cas9. Cpfl is a single RNA-guided endonuclease lacking tracrRNA, utilizes a T-rich protospacer- adjacent motif, and cleaves DNA via a staggered DNA double-stranded break. Shmakov et al. (2015) reported three distinct Class 2 CRISPR-Cas systems. Two system CRISPR enzymes (C2cl and C2c3) contain RuvC-like endonuclease domains distantly related to Cpfl. Unlike Cpfl, C2cl depends on both crRNA and tracrRNA for DNA cleavage. The third enzyme (C2c2) contains two predicted HEPN RNase domains and is tracrRNA independent.

Slaymaker et al (2016) reported the use of structure-guided protein engineering to improve the specificity of Streptococcus pyogenes Cas9 (SpCas9). The authors developed "enhanced specificity" SpCas9 (eSpCas9) variants which maintained robust on-target cleavage with reduced off-target effects.

[0347] Also, "Dimeric CRISPR RNA-guided Fokl nucleases for highly specific genome editing", Shengdar Q. Tsai, Nicolas Wyvekens, Cyd Khayter, Jennifer A. Foden, Vishal Thapar, Deepak Reyon, Mathew J. Goodwin, Martin J. Aryee, J. Keith Joung Nature Biotechnology 32(6): 569-77 (2014), relates to dimeric RNA-guided Fokl Nucleases that recognize extended sequences and can edit endogenous genes with high efficiencies in human cells.

[0348] The methods and tools provided herein are may be designed for use with or

Casl3, a type II nuclease that does not make use of tracrRNA. Orthologs of Casl3 have been identified in different bacterial species as described herein. Further type II nucleases with similar properties can be identified using methods described in the art (Shmakov et al. 2015,

60:385-397; Abudayeh et al. 2016, Science, 5;353(6299)). In particular embodiments, such methods for identifying novel CRISPR effector proteins may comprise the steps of selecting sequences from the database encoding a seed which identifies the presence of a CRISPR Cas locus, identifying loci located within 10 kb of the seed comprising Open Reading Frames (ORFs) in the selected sequences, selecting therefrom loci comprising ORFs of which only a single ORF encodes a novel CRISPR effector having greater than 700 amino acids and no more than 90% homology to a known CRISPR effector. In particular embodiments, the seed is a protein that is common to the CRISPR-Cas system, such as Casl . In further embodiments, the CRISPR array is used as a seed to identify new effector proteins.

[0349] One type of programmable DNA-binding domain is provided by artificial zinc- finger (ZF) technology, which involves arrays of ZF modules to target new DNA-binding sites in the genome. Each finger module in a ZF array targets three DNA bases. A customized array of individual zinc finger domains is assembled into a ZF protein (ZFP).

[0350] ZFPs can comprise a functional domain. The first synthetic zinc finger nucleases (ZFNs) were developed by fusing a ZF protein to the catalytic domain of the Type IIS restriction enzyme Fokl. (Kim, Y. G. et al., 1994, Chimeric restriction endonuclease, Proc. Natl. Acad. Sci. U.S.A. 91, 883-887; Kim, Y. G. et al., 1996, Hybrid restriction enzymes: zinc finger fusions to Fok I cleavage domain. Proc. Natl. Acad. Sci. U.S.A. 93, 1156-1160). Increased cleavage specificity can be attained with decreased off target activity by use of paired ZFN heterodimers, each targeting different nucleotide sequences separated by a short spacer. (Doyon, Y. et al., 2011, Enhancing zinc-finger-nuclease activity with improved obligate heterodimeric architectures. Nat. Methods 8, 74-79). ZFPs can also be designed as transcription activators and repressors and have been used to target many genes in a wide variety of organisms.

[0351] In advantageous embodiments of the invention, the methods provided herein use isolated, non-naturally occurring, recombinant or engineered DNA binding proteins that comprise TALE monomers or TALE monomers or half monomers as a part of their organizational structure that enable the targeting of nucleic acid sequences with improved efficiency and expanded specificity.

[0352] Naturally occurring TALEs or "wild type TALEs" are nucleic acid binding proteins secreted by numerous species of proteobacteria. TALE polypeptides contain a nucleic acid binding domain composed of tandem repeats of highly conserved monomer polypeptides that are predominantly 33, 34 or 35 amino acids in length and that differ from each other mainly in amino acid positions 12 and 13. In advantageous embodiments the nucleic acid is DNA. As used herein, the term "polypeptide monomers", "TALE monomers" or "monomers" will be used to refer to the highly conserved repetitive polypeptide sequences within the TALE nucleic acid binding domain and the term "repeat variable di-residues" or "RVD" will be used to refer to the highly variable amino acids at positions 12 and 13 of the polypeptide monomers. As provided throughout the disclosure, the amino acid residues of the RVD are depicted using the IUPAC single letter code for amino acids. A general representation of a TALE monomer which is comprised within the DNA binding domain is Xl-l l-(X12X13)-X14-33 or 34 or 35, where the subscript indicates the amino acid position and X represents any amino acid. X12X13 indicate the RVDs. In some polypeptide monomers, the variable amino acid at position 13 is missing or absent and in such monomers, the RVD consists of a single amino acid. In such cases the RVD may be alternatively represented as X*, where X represents X12 and (*) indicates that X13 is absent. The DNA binding domain comprises several repeats of TALE monomers and this may be represented as (Xl-l l-(X12X13)-X14-33 or 34 or 35)z, where in an advantageous embodiment, z is at least 5 to 40. In a further advantageous embodiment, z is at least 10 to 26.

[0353] The TALE monomers have a nucleotide binding affinity that is determined by the identity of the amino acids in its RVD. For example, polypeptide monomers with an RVD of NI preferentially bind to adenine (A), monomers with an RVD of NG preferentially bind to thymine (T), monomers with an RVD of HD preferentially bind to cytosine (C) and monomers with an RVD of NN preferentially bind to both adenine (A) and guanine (G). In yet another embodiment of the invention, monomers with an RVD of IG preferentially bind to T. Thus, the number and order of the polypeptide monomer repeats in the nucleic acid binding domain of a TALE determines its nucleic acid target specificity. In still further embodiments of the invention, monomers with an RVD of NS recognize all four base pairs and may bind to A, T, G or C. The structure and function of TALEs is further described in, for example, Moscou et al., Science 326: 1501 (2009); Boch et al., Science 326: 1509-1512 (2009); and Zhang et al., Nature Biotechnology 29: 149-153 (2011), each of which is incorporated by reference in its entirety.

[0354] The polypeptides used in methods of the invention are isolated, non-naturally occurring, recombinant or engineered nucleic acid-binding proteins that have nucleic acid or DNA binding regions containing polypeptide monomer repeats that are designed to target specific nucleic acid sequences. [0355] As described herein, polypeptide monomers having an RVD of HN or NH preferentially bind to guanine and thereby allow the generation of TALE polypeptides with high binding specificity for guanine containing target nucleic acid sequences. In a preferred embodiment of the invention, polypeptide monomers having RVDs RN, NN, NK, SN, NH, KN, HN, NQ, HH, RG, KH, RH and SS preferentially bind to guanine. In a much more advantageous embodiment of the invention, polypeptide monomers having RVDs RN, NK, NQ, HH, KH, RH, SS and SN preferentially bind to guanine and thereby allow the generation of TALE polypeptides with high binding specificity for guanine containing target nucleic acid sequences. In an even more advantageous embodiment of the invention, polypeptide monomers having RVDs HH, KH, NH, NK, NQ, RH, RN and SS preferentially bind to guanine and thereby allow the generation of TALE polypeptides with high binding specificity for guanine containing target nucleic acid sequences. In a further advantageous embodiment, the RVDs that have high binding specificity for guanine are RN, NH RH and KH. Furthermore, polypeptide monomers having an RVD of NV preferentially bind to adenine and guanine. In more preferred embodiments of the invention, monomers having RVDs of H*, HA, KA, N*, NA, NC, NS, RA, and S* bind to adenine, guanine, cytosine and thymine with comparable affinity.

[0356] The predetermined N-terminal to C-terminal order of the one or more polypeptide monomers of the nucleic acid or DNA binding domain determines the corresponding predetermined target nucleic acid sequence to which the polypeptides of the invention will bind. As used herein the monomers and at least one or more half monomers are "specifically ordered to target" the genomic locus or gene of interest. In plant genomes, the natural TALE- binding sites always begin with a thymine (T), which may be specified by a cryptic signal within the non-repetitive N-terminus of the TALE polypeptide; in some cases, this region may be referred to as repeat 0. In animal genomes, TALE binding sites do not necessarily have to begin with a thymine (T) and polypeptides of the invention may target DNA sequences that begin with T, A, G or C. The tandem repeat of TALE monomers always ends with a half-length repeat or a stretch of sequence that may share identity with only the first 20 amino acids of a repetitive full length TALE monomer and this half repeat may be referred to as a half-monomer. Therefore, it follows that the length of the nucleic acid or DNA being targeted is equal to the number of full monomers plus two.

[0357] As described in Zhang et al., Nature Biotechnology 29: 149-153 (2011), TALE polypeptide binding efficiency may be increased by including amino acid sequences from the "capping regions" that are directly N-terminal or C-terminal of the DNA binding region of naturally occurring TALEs into the engineered TALEs at positions N-terminal or C-terminal of the engineered TALE DNA binding region. Thus, in certain embodiments, the TALE polypeptides described herein further comprise an N-terminal capping region and/or a C- terminal capping region.

[0358] As used herein the predetermined "N-terminus" to "C terminus" orientation of the N-terminal capping region, the DNA binding domain comprising the repeat TALE monomers and the C-terminal capping region provide structural basis for the organization of different domains in the d-TALEs or polypeptides of the invention.

[0359] The entire N-terminal and/or C-terminal capping regions are not necessary to enhance the binding activity of the DNA binding region. Therefore, in certain embodiments, fragments of the N-terminal and/or C-terminal capping regions are included in the TALE polypeptides described herein.

[0360] In certain embodiments, the TALE polypeptides described herein contain a N- terminal capping region fragment that included at least 10, 20, 30, 40, 50, 54, 60, 70, 80, 87,

90, 94, 100, 102, 110, 117, 120, 130, 140, 147, 150, 160, 170, 180, 190, 200, 210, 220, 230,

240, 250, 260 or 270 amino acids of an N-terminal capping region. In certain embodiments, the N-terminal capping region fragment amino acids are of the C-terminus (the DNA-binding region proximal end) of an N-terminal capping region. As described in Zhang et al., Nature

Biotechnology 29: 149-153 (2011), N-terminal capping region fragments that include the C- terminal 240 amino acids enhance binding activity equal to the full length capping region, while fragments that include the C-terminal 147 amino acids retain greater than 80% of the efficacy of the full length capping region, and fragments that include the C-terminal 117 amino acids retain greater than 50% of the activity of the full-length capping region.

[0361] In some embodiments, the TALE polypeptides described herein contain a C- terminal capping region fragment that included at least 6, 10, 20, 30, 37, 40, 50, 60, 68, 70,

80, 90, 100, 110, 120, 127, 130, 140, 150, 155, 160, 170, 180 amino acids of a C-terminal capping region. In certain embodiments, the C-terminal capping region fragment amino acids are of the N-terminus (the DNA-binding region proximal end) of a C-terminal capping region. As described in Zhang et al., Nature Biotechnology 29: 149-153 (2011), C-terminal capping region fragments that include the C-terminal 68 amino acids enhance binding activity equal to the full length capping region, while fragments that include the C-terminal

20 amino acids retain greater than 50% of the efficacy of the full length capping region. [0362] In certain embodiments, the capping regions of the TALE polypeptides described herein do not need to have identical sequences to the capping region sequences provided herein. Thus, in some embodiments, the capping region of the TALE polypeptides described herein have sequences that are at least 50%, 60%, 70%, 80%, 85%, 90%, 91%, 92%, 93%, 94%), 95%), 96%), 97%), 98%> or 99% identical or share identity to the capping region amino acid sequences provided herein. Sequence identity is related to sequence homology. Homology comparisons may be conducted by eye, or more usually, with the aid of readily available sequence comparison programs. These commercially available computer programs may calculate percent (%) homology between two or more sequences and may also calculate the sequence identity shared by two or more amino acid or nucleic acid sequences. In some preferred embodiments, the capping region of the TALE polypeptides described herein have sequences that are at least 95% identical or share identity to the capping region amino acid sequences provided herein.

[0363] Sequence homologies may be generated by any of a number of computer programs known in the art, which include but are not limited to BLAST or FASTA. Suitable computer program for carrying out alignments like the GCG Wisconsin Bestfit package may also be used. Once the software has produced an optimal alignment, it is possible to calculate %> homology, preferably %> sequence identity. The software typically does this as part of the sequence comparison and generates a numerical result.

[0364] In advantageous embodiments described herein, the TALE polypeptides of the invention include a nucleic acid binding domain linked to the one or more effector domains. The terms "effector domain" or "regulatory and functional domain" refer to a polypeptide sequence that has an activity other than binding to the nucleic acid sequence recognized by the nucleic acid binding domain. By combining a nucleic acid binding domain with one or more effector domains, the polypeptides of the invention may be used to target the one or more functions or activities mediated by the effector domain to a particular target DNA sequence to which the nucleic acid binding domain specifically binds.

[0365] In some embodiments of the TALE polypeptides described herein, the activity mediated by the effector domain is a biological activity. For example, in some embodiments the effector domain is a transcriptional inhibitor (i.e., a repressor domain), such as an mSin interaction domain (SID). SID4X domain or a Kriippel-associated box (KRAB) or fragments of the KRAB domain. In some embodiments, the effector domain is an enhancer of transcription (i.e. an activation domain), such as the VP 16, VP64 or p65 activation domain. In some embodiments, the nucleic acid binding is linked, for example, with an effector domain that includes but is not limited to a transposase, integrase, recombinase, resolvase, invertase, protease, DNA methyltransferase, DNA demethylase, histone acetylase, histone deacetylase, nuclease, transcriptional repressor, transcriptional activator, transcription factor recruiting, protein nuclear-localization signal or cellular uptake signal.

[0366] In some embodiments, the effector domain is a protein domain which exhibits activities which include but are not limited to transposase activity, integrase activity, recombinase activity, resolvase activity, invertase activity, protease activity, DNA methyltransferase activity, DNA demethylase activity, histone acetylase activity, histone deacetylase activity, nuclease activity, nuclear-localization signaling activity, transcriptional repressor activity, transcriptional activator activity, transcription factor recruiting activity, or cellular uptake signaling activity. Other preferred embodiments of the invention may include any combination the activities described herein.

[0367] In certain embodiments, the invention involves targeted nucleic acid profiling (e.g., sequencing, quantitative reverse transcription polymerase chain reaction, and the like) (see e.g., Geiss GK, et al., Direct multiplexed measurement of gene expression with color- coded probe pairs. Nat Biotechnol. 2008 Mar;26(3):317-25). In certain embodiments, a target nucleic acid molecule (e.g., RNA molecule), may be sequenced by any method known in the art, for example, methods of high-throughput sequencing, also known as next generation sequencing or deep sequencing. A nucleic acid target molecule labeled with a barcode (for example, an origin-specific barcode) can be sequenced with the barcode to produce a single read and/or contig containing the sequence, or portions thereof, of both the target molecule and the barcode. Exemplary next generation sequencing technologies include, for example, Illumina sequencing, Ion Torrent sequencing, 454 sequencing, SOLiD sequencing, and nanopore sequencing amongst others. Methods for constructing sequencing libraries are known in the art (see, e.g., Head et al., Library construction for next-generation sequencing: Overviews and challenges. Biotechniques. 2014; 56(2): 61-77).

[0368] In certain embodiments, the invention involves plate based single cell RNA sequencing (see, e.g., Picelli, S. et al., 2014, "Full-length RNA-seq from single cells using Smart-seq2" Nature protocols 9, 171-181, doi: 10.1038/nprot.2014.006).

[0369] In certain embodiments, the invention involves high-throughput single-cell RNA- seq and/or targeted nucleic acid profiling where the RNAs from different cells are tagged individually, allowing a single library to be created while retaining the cell identity of each read. In this regard reference is made to Macosko et al., 2015, "Highly Parallel Genome-wide Expression Profiling of Individual Cells Using Nanoliter Droplets" Cell 161, 1202-1214; International patent application number PCT/US2015/049178, published as WO2016/040476 on March 17, 2016; Klein et al., 2015, "Droplet Barcoding for Single-Cell Transcriptomics Applied to Embryonic Stem Cells" Cell 161, 1187-1201; International patent application number PCT/US2016/027734, published as WO2016168584A1 on October 20, 2016; Zheng, et al., 2016, "Haplotyping germline and cancer genomes with high-throughput linked-read sequencing" Nature Biotechnology 34, 303-311; Zheng, et al., 2017, "Massively parallel digital transcriptional profiling of single cells" Nat. Commun. 8, 14049 doi: 10.1038/ncommsl4049; International patent publication number WO 2014210353 A2; Zilionis, et al., 2017, "Single-cell barcoding and sequencing using droplet microfluidics" Nat Protoc. Jan; 12(l):44-73; Cao et al., 2017, "Comprehensive single cell transcriptional profiling of a multicellular organism by combinatorial indexing" bioRxiv preprint first posted online Feb. 2, 2017, doi: dx.doi. org/10.1101/104844; Rosenberg et al., 2017, "Scaling single cell transcriptomics through split pool barcoding" bioRxiv preprint first posted online Feb. 2, 2017, doi: dx.doi. org/10.1101/105163; Vitak, et al., "Sequencing thousands of single-cell genomes with combinatorial indexing" Nature Methods, 14(3):302-308, 2017; Cao, et al., Comprehensive single-cell transcriptional profiling of a multicellular organism. Science, 357(6352):661-667, 2017; and Gierahn et al., "Seq-Well: portable, low-cost RNA sequencing of single cells at high throughput" Nature Methods 14, 395-398 (2017), all the contents and disclosure of each of which are herein incorporated by reference in their entirety.

[0370] In certain embodiments, the invention involves single nucleus RNA sequencing

(sn-RNA-seq). In this regard reference is made to Swiech et al., 2014, "In vivo interrogation of gene function in the mammalian brain using CRISPR-Cas9" Nature Biotechnology Vol.

33, pp. 102-106; Habib et al., 2016, "Div-Seq: Single-nucleus RNA-Seq reveals dynamics of rare adult newborn neurons" Science, Vol. 353, Issue 6302, pp. 925-928; and Habib et al.,

2017, "Massively parallel single-nucleus RNA-seq with DroNc-seq" Nat Methods. 2017

Oct; 14(10):955-958, which are herein incorporated by reference in their entirety.

[0371] In certain embodiments, the immunotherapy resistance signature comprises EGR1 and/or MAZ. In other embodiments, EGR1 and/or MAZ are targeted for therapeutic intervention. In one embodiment, EGR1 and/or MAZ are targeted to reduce a resistance signature. EGR1 and MAZ are zinc finger transcription factors (TF). EGR1 is down regulated in malignant cells of the post-treatment tumors, and MAZ (Myc-associated *zinc* finger protein) is up-regulated. These TFs may be connected to the decrease in metallothioneins post-treatment and availability to metal ions. Applicants saw an enrichment in EGRl targets in the genes which are down-regulated post-treatment. Applicants also saw an overlap with a signature identified in synovial sarcoma. In synovial sarcoma EGRl is repressed. Mutations in the BAF complex are strongly associated with the response to immunotherapy/resistance to T-cells, and is related to the present invention.

[0372] In certain embodiments, the gene signatures described herein are screened by perturbation of target genes within said signatures. In certain embodiments, perturbation of any signature gene or gene described herein may reduce or induce the immunotherapy resistance signature. In preferred embodiments, the perturbed genes include MAZ, FKBIZ, MYC, ANXA1, SOX4, MT2A, PTP4A3, CD59, DLL3, SERPINE2, SERPINF1, PERP, EGRl, SERPINA3, IFNGR2, B2M, and PDL1. In certain embodiments, after perturbation, gene expression may be evaluated to determine whether the gene signature is reduced.

[0373] Methods and tools for genome-scale screening of perturbations in single cells using CRISPR-Cas9 have been described, herein referred to as perturb-seq (see e.g., Dixit et al., "Perturb-Seq: Dissecting Molecular Circuits with Scalable Single-Cell RNA Profiling of Pooled Genetic Screens" 2016, Cell 167, 1853-1866; Adamson et al., "A Multiplexed Single-Cell CRISPR Screening Platform Enables Systematic Dissection of the Unfolded Protein Response" 2016, Cell 167, 1867-1882; and International publication serial number WO/2017/075294). The present invention is compatible with perturb-seq, such that signature genes may be perturbed and the perturbation may be identified and assigned to the proteomic and gene expression readouts of single cells. In certain embodiments, signature genes may be perturbed in single cells and gene expression analyzed. Not being bound by a theory, networks of genes that are disrupted due to perturbation of a signature gene may be determined. Understanding the network of genes effected by a perturbation may allow for a gene to be linked to a specific pathway that may be targeted to modulate the signature and treat a cancer. Thus, in certain embodiments, perturb-seq is used to discover novel drug targets to allow treatment of specific cancer patients having the gene signature of the present invention.

[0374] The perturbation methods and tools allow reconstructing of a cellular network or circuit. In one embodiment, the method comprises (1) introducing single-order or combinatorial perturbations to a population of cells, (2) measuring genomic, genetic, proteomic, epigenetic and/or phenotypic differences in single cells and (3) assigning a perturbation(s) to the single cells. Not being bound by a theory, a perturbation may be linked to a phenotypic change, preferably changes in gene or protein expression. In preferred embodiments, measured differences that are relevant to the perturbations are determined by applying a model accounting for co-variates to the measured differences. The model may include the capture rate of measured signals, whether the perturbation actually perturbed the cell (phenotypic impact), the presence of subpopulations of either different cells or cell states, and/or analysis of matched cells without any perturbation. In certain embodiments, the measuring of phenotypic differences and assigning a perturbation to a single cell is determined by performing single cell RNA sequencing (RNA-seq). In preferred embodiments, the single cell RNA-seq is performed by any method as described herein (e.g.,

Drop-seq, InDrop, 10X genomics). In certain embodiments, unique barcodes are used to perform Perturb-seq. In certain embodiments, a guide RNA is detected by RNA-seq using a transcript expressed from a vector encoding the guide RNA. The transcript may include a unique barcode specific to the guide RNA. Not being bound by a theory, a guide RNA and guide RNA barcode is expressed from the same vector and the barcode may be detected by

RNA-seq. Not being bound by a theory, detection of a guide RNA barcode is more reliable than detecting a guide RNA sequence, reduces the chance of false guide RNA assignment and reduces the sequencing cost associated with executing these screens. Thus, a perturbation may be assigned to a single cell by detection of a guide RNA barcode in the cell. In certain embodiments, a cell barcode is added to the RNA in single cells, such that the RNA may be assigned to a single cell. Generating cell barcodes is described herein for single cell sequencing methods. In certain embodiments, a Unique Molecular Identifier (UMI) is added to each individual transcript and protein capture oligonucleotide. Not being bound by a theory, the UMI allows for determining the capture rate of measured signals, or preferably the binding events or the number of transcripts captured. Not being bound by a theory, the data is more significant if the signal observed is derived from more than one protein binding event or transcript. In preferred embodiments, Perturb-seq is performed using a guide RNA barcode expressed as a polyadenylated transcript, a cell barcode, and a UMI.

[0375] Perturb-seq combines emerging technologies in the field of genome engineering, single-cell analysis and immunology, in particular the CRISPR-Cas9 system and droplet single-cell sequencing analysis. In certain embodiments, a CRISPR system is used to create an INDEL at a target gene. In other embodiments, epigenetic screening is performed by applying CRISPRa/i/x technology (see, e.g., Konermann et al. "Genome-scale transcriptional activation by an engineered CRISPR-Cas9 complex" Nature. 2014 Dec 10. doi: 10.1038/naturel4136; Qi, L. S., et al. (2013). "Repurposing CRISPR as an RNA-guided platform for sequence-specific control of gene expression". Cell. 152 (5): 1173-83; Gilbert, L. A., et al., (2013). "CRISPR-mediated modular RNA-guided regulation of transcription in eukaryotes". Cell. 154 (2): 442-51; omor et al., 2016, Programmable editing of a target base in genomic DNA without double-stranded DNA cleavage, Nature 533, 420-424; Nishida et al., 2016, Targeted nucleotide editing using hybrid prokaryotic and vertebrate adaptive immune systems, Science 353(6305); Yang et al., 2016, Engineering and optimising deaminase fusions for genome editing, Nat Commun. 7: 13330; Hess et al ., 2016, Directed evolution using dCas9 argeted somatic hypermutation in mammalian cells, Nature Methods 13, 1036-1042; and Ma et al., 2016, Targeted AID-mediated mutagenesis (TAM) enables efficient genomic diversification in mammalian ceils, Nature Methods 13, 1029-1035). Numerous genetic variants associated with disease phenotypes are found to be in non-coding region of the genome, and frequently coincide with transcription factor (TF) binding sites and non-coding RNA genes. Not being bound by a theory, CRISPRa/i/x approaches may be used to achieve a more thorough and precise understanding of the implication of epigenetic regulation. In one embodiment, a CRISPR system may be used to activate gene transcription. A nuclease-dead RNA-guided DNA binding domain, dCas9, tethered to transcriptional repressor domains that promote epigenetic silencing (e.g., KRAB) may be used for "CRISPRi" that represses transcription. To use dCas9 as an activator (CRISPRa), a guide RNA is engineered to carry RNA binding motifs (e.g., MS2) that recruit effector domains fused to RNA-motif binding proteins, increasing transcription. A key dendritic cell molecule, p65, may be used as a signal amplifier, but is not required.

[0376] In certain embodiments, other CRISPR-based perturbations are readily compatible with Perturb-seq, including alternative editors such as CRISPR/Cpfl . In certain embodiments, Perturb-seq uses Cpfl as the CRISPR enzyme for introducing perturbations. Not being bound by a theory, Cpfl does not require Tracr RNA and is a smaller enzyme, thus allowing higher combinatorial perturbations to be tested.

[0377] The cell(s) may comprise a cell in a model non-human organism, a model non- human mammal that expresses a Cas protein, a mouse that expresses a Cas protein, a mouse that expresses Cpfl, a cell in vivo or a cell ex vivo or a cell in vitro (see e.g., WO

2014/093622 (PCT/US 13/074667); US Patent Publication Nos. 20120017290 and 20110265198 assigned to Sangamo Biosciences, Inc.; US Patent Publication No. 20130236946 assigned to Cellectis; Piatt et al., "CRISPR-Cas9 Knockin Mice for Genome Editing and Cancer Modeling" Cell (2014), 159(2): 440-455; "Oncogenic models based on delivery and use of the CRISPR-Cas systems, vectors and compositions" WO2014204723A1 "Delivery and use of the CRISPR-Cas systems, vectors and compositions for hepatic targeting and therapy" WO2014204726A1; "Delivery, use and therapeutic applications of the CRISPR-Cas systems and compositions for modeling mutations in leukocytes" WO2016049251; and Chen et al., "Genome-wide CRISPR Screen in a Mouse Model of Tumor Growth and Metastasis" 2015, Cell 160, 1246-1260). The cell(s) may also comprise a human cell. Mouse cell lines may include, but are not limited to neuro-2a cells and EL4 cell lines (ATCC TIB-39). Primary mouse T cells may be isolated from C57/BL6 mice. Primary mouse T cells may be isolated from Cas9-expressing mice.

[0378] In one embodiment, CRISPR/Cas9 may be used to perturb protein-coding genes or non-protein-coding DNA. CRISPR/Cas9 may be used to knockout protein-coding genes by frameshifts, point mutations, inserts, or deletions. An extensive toolbox may be used for efficient and specific CRISPR/Cas9 mediated knockout as described herein, including a double-nicking CRISPR to efficiently modify both alleles of a target gene or multiple target loci and a smaller Cas9 protein for delivery on smaller vectors (Ran, F.A., et al., In vivo genome editing using Staphylococcus aureus Cas9. Nature. 520, 186-191 (2015)). A genome-wide sgRNA mouse library (-10 sgRNAs/gene) may also be used in a mouse that expresses a Cas9 protein (see, e.g., WO2014204727A1).

[0379] In one embodiment, perturbation is by deletion of regulatory elements. Non- coding elements may be targeted by using pairs of guide RNAs to delete regions of a defined size, and by tiling deletions covering sets of regions in pools.

[0380] In one embodiment, perturbation of genes is by RNAi. The RNAi may be shRNA's targeting genes. The shRNA's may be delivered by any methods known in the art. In one embodiment, the shRNA's may be delivered by a viral vector. The viral vector may be a lentivirus, adenovirus, or adeno associated virus (AAV).

[0381] A CRISPR system may be delivered to primary mouse T-cells. Over 80% transduction efficiency may be achieved with Lenti-CRISPR constructs in CD4 and CD8 T- cells. Despite success with lentiviral delivery, recent work by Hendel et al, (Nature

Biotechnology 33, 985-989 (2015) doi: 10.1038/nbt.3290) showed the efficiency of editing human T-cells with chemically modified RNA, and direct RNA delivery to T-cells via electroporation. In certain embodiments, perturbation in mouse primary T-cells may use these methods.

[0382] In certain embodiments, whole genome screens can be used for understanding the phenotypic readout of perturbing potential target genes. In preferred embodiments, perturbations target expressed genes as defined by a gene signature using a focused sgRNA library. Libraries may be focused on expressed genes in specific networks or pathways. In other preferred embodiments, regulatory drivers are perturbed. In certain embodiments, Applicants perform systematic perturbation of key genes that regulate T-cell function in a high-throughput fashion. In certain embodiments, Applicants perform systematic perturbation of key genes that regulate cancer cell function in a high-throughput fashion (e.g., immune resistance or immunotherapy resistance). Applicants can use gene expression profiling data to define the target of interest and perform follow-up single-cell and population RNA-seq analysis. Not being bound by a theory, this approach will accelerate the development of therapeutics for human disorders, in particular cancer. Not being bound by a theory, this approach will enhance the understanding of the biology of T-cells and tumor immunity, and accelerate the development of therapeutics for human disorders, in particular cancer, as described herein.

[0383] Not being bound by a theory, perturbation studies targeting the genes and gene signatures described herein could (1) generate new insights regarding regulation and interaction of molecules within the system that contribute to suppression of an immune response, such as in the case within the tumor microenvironment, and (2) establish potential therapeutic targets or pathways that could be translated into clinical application.

[0384] In certain embodiments, after determining Perturb-seq effects in cancer cells and/or primary T-cells, the cells are infused back to the tumor xenograft models (melanoma, such as B16F10 and colon cancer, such as CT26) to observe the phenotypic effects of genome editing. Not being bound by a theory, detailed characterization can be performed based on (1) the phenotypes related to tumor progression, tumor growth, immune response, etc. (2) the TILs that have been genetically perturbed by CRISPR-Cas9 can be isolated from tumor samples, subject to cytokine profiling, qPCR/RNA-seq, and single-cell analysis to understand the biological effects of perturbing the key driver genes within the tumor-immune cell contexts. Not being bound by a theory, this will lead to validation of TILs biology as well as lead to therapeutic targets. [0385] The invention is further described in the following examples, which do not limit the scope of the invention described in the claims.

EXAMPLES

Example 1 - Identifying Signatures of Resistance

[0386] Applicants leveraged single-cell RNA-sequencing (scRNA-Seq) of thousands of cells from melanoma tumors and a novel data-driven method to systematically map cancer programs that promote ICR and T cell exclusion. Applicants collected 10, 123 scRNA-seq profiles from the tumors of 31 patients, consisting of 15 treatment naive (TN) patients, and 16 post-ICI tumors. Of these 16 post-ICI specimens, 15 had clinical resistance and were therefore termed ICI-resistant (ICR), and one had a partial response (PR) according to the RECIST criteria (Eisenhauer et al., 2009) (Fig. 1A, table 1), and was termed as having clinical benefit (CB). Applicants filtered lower-quality cells to retain 7, 186 high-quality transcriptomes, including 4, 199 cells from 16 patients that Applicants previously reported (Tirosh et al., 2016a), and 2,987 cells from 16 newly collected patient tumors (table 1).

[0387] Applicants first aimed to determine the effects ICI has on different cell types in the tumor at the time of post-ICI progression, by comparing between the ICR and TN tumors. Although the specimens in the different treatment groups were not from the same patients, Applicants reasoned that the high resolution and large number of cells profiled will provide sufficient power to detect some of these effects.

[0388] It revealed that, despite the lack of clinical response, CD8 T-cells in the ICR tumors manifested heterogeneous phenotypes of T-cell activation. Conversely, the malignant cells of ICR tumors had a distinct transcriptional state that was substantially less frequent in the TN tumors.

[0389] Next, for any such transcriptional program that may reflect ICI effects, Applicants examined its potential causal connection to immune evasion or resistance. Applicants acknowledged the possibility that malignant cells derived from TN tumors could contain both treatment-sensitive and intrinsically resistant cells. Thus, Applicants tested the malignant signatures in two independent validation cohorts (Fig. 1A), where pre-ICI patient biopsies were profiled with bulk RNA-Seq, and the response to ICI therapy was monitored. Applicants demonstrated that this oncogenic state is tightly linked to immune evasion and exclusion, and that it can be used to predict ICR based on the bulk RNA-seq of the pre-ICI biopsy. [0390] Applicants collected scRNA-Seq of dissociated individual cells from fresh tumor resections, sorted into immune and non-immune cells based on the CD45 expression, and profiled them with a modified full-length SMART-Seq2 protocol (materials and methods, table 2). Applicants distinguished different cell subsets and clones both by their expression profiles and by their inferred genetic features. In the non-immune compartment (Fig. IB), Applicants distinguished malignant from non-malignant cells (materials and methods) according to (1) their inferred CNV profiles (Tirosh et al., 2016a) (fig. 5); (2) under- expression of different non-malignant cell-type signatures (fig. 5B); and (3) high similarity to bulk RNA-Seq profiles of melanoma tumors compared to adjacent normal tissue. The cell assignments by the different criteria were highly consistent (hypergeometric p-value < 10 ^"17 , fig. 5, materials and methods). Within non-malignant cells, Applicants used unsupervised clustering to identify (materials and methods) CD8 and CD4 T cells, B cells, NK cells, macrophages, Cancer Associated Fibroblasts (CAFs) and endothelial cells (Fig. 1C, fig. 6, table 3). Overall, malignant cells clustered first by their tumor of origin (Fig. IB), while the non-malignant cells clustered primarily by their cell type, and only then by their tumor of origin (Fig. 1C).

[0391] Applicants identified transcriptional features that distinguish between the cells of TN and ICR tumors, analyzing separately each cell type with a sufficient number (>100) of cells: malignant cells, macrophages, B cells, CD8 T cells, and CD4 T cells. Applicants applied a subsampling procedure to prevent tumors with a particularly large number of cells of a given type from dominating the results and to mitigate the effects of outliers. For each cell type Applicants defined an ICR-up and ICR-down signature, consisting of genes that were significantly up or down regulated in the cells from the ICR tumors, respectively (Kharchenko, et al., 2014). Applicants used a mixed-effect model to test the ability of a given gene signature to distinguish between cells from ICR and TN tumors, while accounting for potential confounders, including other clinical characteristics and cell quality (materials and methods).

[0392] The CD8 T cells and malignant cells subset derived from ICR patients were markedly different from their TN counterparts (fig. 7, tables 4 and 5), and are the focus of this analysis. Macrophages also showed ICR associated expression programs (table 4), but due to their relatively small number in the dataset, Applicants did not pursue them further. Conversely, very few genes where differentially expressed between the ICR vs. TN groups when analyzing B cells or CD4 T cells (table 4). Deeper sampling of these and other cell types might identify significant distinctions.

[0393] The CD8 T-cell-ICR signatures (Fig. ID) revealed the induction of cytotoxicity genes and the repression of some exhaustion features. Compared to TN CD8 T cells, ICR CD 8 T cells up regulated the T cell activation markers STAT1, GBP2, GBP 5 and IRF1, and down regulated W K1. Inhibition of W K1 has been shown to increase T cell infiltration and accumulation in tumors in an in vivo shRNA screen (Zhou et al., 2014). Lactate dehydrogenase A (LDHA) was also up regulated in the ICR CD8 T cells, suggesting that the cells may have infiltrated the hypoxic tumor microenvironment. Among the immune checkpoints, HAVCR2 (TIM3) and CD27 are significantly, though modestly, down- regulated. Although the inhibitory checkpoints CTLA-4, TIGIT, LAG-3, PD-1, and TIM3 co- vary across cells (along with the transcription factor PRDMl), as Applicants previously reported (Tirosh et al., 2016a; and Singer et al., 2016), Applicants did not detect a significant difference in their expression between TN and ICR cells (fig. 8A). Rather, CD8 T cells from both TN and ICR tumor specimens spanned a spectrum of states in the exhaustion- cytotoxicity space, even within the CD8 T cells of the same tumor (Tirosh et al., 2016a), with a strong association between dysfunction ("exhaustion") and cytotoxicity scores at the single cell level (Fig. IE, fig. 8B), as Applicants previously reported (Tirosh et al., 2016a). Notably, the CD8 T cells of the one ICI responder patient are both highly cytotoxic and significantly less dysfunctional than cells of other patients (Fig. IE, P = 1.31 * 10 ^"6 , hypergeometric test). However, since a similar trend was observed in one of the ICR patients (Mel 126, P = 4.08* 10 ^"13 , hypergeometric test), such an enhanced cytotoxic state may not necessarily mark clinical response. These findings were robust when using different T cell dysfunction signatures (materials and methods), including single-cell signatures that were recently identified in T cells from hepatocellular carcinoma tumors (Zheng et al., 2017) (fig. 8B, P < 2.46* 10 ^"4 , hypergeometric test). A list of differentially expressed genes obtained when comparing the CD8 T cells of the CB patients to those from the ICR patients is provided in table 6.

[0394] To examine the association between CD8 T cell profiles and clonal expansion

Applicants reconstructed full-length T cell receptors (TCR) and identified 137 CD8 T cell clones of varying sizes (Stubbington et al., 2016) (Fig. IF, fig. 9). Three patients, all of them

ICR, had exceptionally large clonal expansions, with 39-51% of the CD8 T cells in these tumors as members of large (>20 cells) clonotypes (Fig. IF). These three ICR patients had extremely expanded CD8 T cells, even after controlling for the number of CD8 T cells profiled and the success rate of TCR reconstruction (materials and methods, P = 4.54* 10 ^"3 , one-sided Wilcoxon ranksum, fig. 9B). For one ICR patient with extreme clonal expansions, Applicants obtained two lesions a year apart: 15 of the 28 clones identified in these specimens included cells from both lesions, such that 71% and 52% of the CD8 T cells in the early and late samples, respectively, were in the shared clones, demonstrating their stability and persistence (fig. 9C,D). T cell clonality pre-treatment has previously been identified as a potential predictive marker of response to anti-PD-1 therapy (6); the results herein suggest that the extent of clonal expansion post ICI may not be coupled to clinical response.

[0395] The expression of the ICR signature is higher in expanded CD8 T cells within each subset of patients, with the clonally expanded ICR CD8 T cells scoring highest (Fig. 1D,G, left, P = 3.23* 10 ^"5 , mixed-effects test). Nonetheless, even when completely removing the T cells of the three ICR patients with the large T cell clonal expansion, the T-cell-ICR signature still significantly distinguished between the TN and ICR CD8 T cells (Fig. 1G, right, P = 5.56* 10 ^"53 and 7.41 * 10 ^"3 , t-test and mixed effects test, respectively). The expanded T cells had a gene signature that included significant down-regulation of KLRG1 (table 10).

[0396] According to the expression of cell cycle signatures in each cell (materials and methods), five patients had a significantly larger fraction of cycling CD8 T cells (hypergeometric p-value <0.01), four of them were ICR patients. Proliferating CD8 T cells expressed some unique genes compared to proliferating malignant cells (Fig. 1H, table 7), including induction of oxidative phosphorylation (P = 7.89* 10 ^"6 , hypergeometric test) and repression of the hematopoietic lineage genes CD37, IL11RA, and IL7R (P = 1.28* 10 ^"4 , hypergeometric test). Thus, it may be possible to perturb T cell proliferation specifically, without affecting tumor cells (i.e. tumor growth).

[0397] Taken together, these findings demonstrate that even in ICR patients CD8 T cells following ICI can show some indicators of enhanced functionality, such as expansion and transcriptional changes. In other words, these findings demonstrate that ICI can promote the expansion and functionality of the CD8 T cells without leading to a clinical response. Additional data from ICI responders is needed to examine if insufficient T cell functionality nonetheless limited the clinical response in such ICR patients. Nevertheless, Applicants hypothesized that the malignant cell compartment may contribute to ICR in these patients, at least in part. [0398] Applicants thus turned to examine the effect of ICI on the malignant cell profiles, and identified signatures that distinguish malignant cells from ICR vs. TN tumors: oncogenic-ICR-up and oncogenic-ICR-down (Fig. 2A,B _? table 5). The signatures were robust and generalizable in cross-validation (withholding data from each patient in turn and classifying the withheld test set; materials and methods, Fig. 2A, AUC=0.86). The variation in the expression of the oncogenic-ICR signatures in either this data or across TCGA melanoma bulk tumors was not significantly associated with potential confounders (materials and methods, mixed-effect model and ANOVA, respectively). Finally, a proportion of malignant cells in TN tumors manifested the oncogenic-ICR state (Fig. 2B, right), suggesting that it may precede ICI at least in some patients. This is discussed further below.

[0399] The oncogenic-ICR-down signature genes were enriched both in pathways that reflect established mechanisms of resistance, including downregulation of IFN- signaling and MHC class I presentation (Zaretsky et al., 2016), and in additional processes, not previously implicated in ICR (Fig. 2B, tables 5 and 8, materials and methods). These include suppression of other innate immune responses, such as TNF-amediated NF B signaling, apoptosis, response to the complement system, IL2/STAT5 signaling, and the reduced expression of metallothioneins. NFKB pathway activation can induce expression of cytokines with either negative or positive immune-modulatory effects (Muthuswamy et al., 2012; and Pikarsky et al., 2004). The results suggest that under-expression of TNF-amediated NFKB signaling genes may be detrimental for response. The oncogenic-ICR-up genes include several transcriptional and chromatin regulators (e.g., SNAI2, HMGA1), and are enriched for Myc and CDK7/8 targets (P<10 ^"u , hypergeometric p-value). Myc-activation has been previously linked to increased expression of immunosuppressive signals, including the upregulation of PD-Ll and β-catenin, which in turn inhibits dendritic cell recruitment to the tumor microenvironment via CCL4 (11). Similar results were obtained when comparing predefined gene modules directly between malignant cells of ICR and TN patients (Fig. 2C, materials and methods), including repression of the IL6/JAK/STAT3 pathway; mutations in this pathway were recently reported as an escape mechanism to anti-PD-1 therapy (Zaretsky et al., 2016).

[0400] Gene modules are more robust to noise and provide more coherent signals than the expression of single genes. Applicants thus applied the mixed-effect models to test which biological pathways are differentially expressed between the two groups. The analysis revealed similar pathways to those outlined above, as well as the repression of the JAK/STAT pathway. Mutations in this pathway were previously reported as an escape mechanism to anti-PD-1 therapy.

[0401] Several lines of evidence suggest that the oncogenic-ICR-up and oncogenic-ICR- down signatures are under shared control by one or few master regulators with opposing effects on these two programs. First, the expression of the oncogenic-ICR-up and oncogenic- ICR-down signatures is anti -correlated within the malignant cells of the same tumor and across hundreds of (TCGA) melanoma tumors (Fig. 2D,E). Second, in the Connectivity Map (Lamb et al., 2006), there is a significant overlap between the genetic perturbations that induce the oncogenic-ICR-down signature and those that repress the oncogenic-ICR-up signature (hypergeometric p-value = 1.9* 10 ^"6 ), including overexpression of IFN-γ and IFN-β and the knockdown of MYC. Indeed, MYC knockdown is the top perturbation to repress oncogenic-ICR-up, which is enriched for Myc targets. Moreover, there are 1,583 protein- protein interactions within and between the genes in the two oncogenic-ICR signatures (P <10 ^"3 , empirical test), consistent with participation in convergent biological processes. Applicants therefore defined the oncogenic-ICR state as a concurrent induction of the oncogenic-ICR-up signature and repression of the oncogenic-ICR-down signature, which Applicants quantify by the overall expression (materials and methods) of the oncogenic- ICR-up signature minus the overall expression of the oncogenic-ICR-down signature.

[0402] Next, Applicants hypothesized that the oncogenic-ICR signatures reflect an active resistance program, rather than only a post-ICI malignant cell state. This would be consistent with the presence of cells expressing the program in TN patients. In particular, to resist ICI, malignant cells may not only evade the immune cells (e.g., through the repression of MHC I and IFN-γ in oncogenic- ICR-down) but may also actively exclude the immune cells. The latter will impact the extent of CD8 T cell infiltration, which is a known pre-treatment predictor of ICI response (Tumeh et al., 2014; and Taube et al., 2012). To explore this possibility, Applicants developed a data-driven approach that characterizes malignant cells in non-infiltrated niches or tumors (Fig. 2F). In this approach, Applicants combined single cell profiles (irrespective of treatment status) with 473 melanoma bulk expression profiles from TCGA. First, Applicants used the single-cell profiles to define a T cell specific signature of 143 genes, and a signature of 332 genes that were primarily expressed by malignant cells (table 3). Then Applicants estimated the T cell infiltration level of the TCGA tumors based on their expression of the T cell signature (materials and methods), and identified malignant genes whose expression was correlated to the estimated T cell infiltration levels. Six and 20 of the 332 malignant cell genes were significantly correlated or anti -correlated to the T cell infiltration level, respectively, which Applicants termed the seed T cell exclusion (Exclusion)-down and -up modules, respectively. However, the seed modules would neglect genes that are expressed also by other, non-malignant cells in the tumor (as MHC I, IFN-γ). To recover these, Applicants correlated the expression of each gene to the expression of the seed Exclusion modules across the entire malignant single-cell profiles. This yielded the final Exclusion -up and down modules, with 101 and 134 genes, respectively (table 5).

[0403] The Exclusion-down module was enriched for antigen processing and presentation genes (B2M, CTSB, CTSL1, HLA-B/C/F, HSPA1A, HSPA1B, P = 4.19* 10 ^"7 , hypergeometric test), immune modulation genes (P = 3.84* 10 ^"9 , as CD58 and the FKB inhibitor, FKBIA), and genes involved in the response to the Complement system (P = 2.26* 10 ^"7 , e.g., CD59 and C4A). CD58 KO in malignant cells was recently shown to enhance the survival of melanoma cells in a genome-scale CRISPR screen of melanoma/T cell co- cultures (28), and its genetic loss or epigenetic inactivation are frequent immune evasion drivers in diffuse large B cell lymphoma (Challa-Malladi et al., 2011). The Exclusion-up module included MYC itself and Myc targets (P = 6.8* 10 ^"12 ), as well as the transcription factors SNAI2 and SOX4.

[0404] Even though the Exclusion modules were identified without considering the treatment status of the tumors (TN or ICR), they significantly overlapped the corresponding oncogenic-ICR signatures (64 and 52 overlapping genes in oncogenic-ICR-up and -down, respectively, P <10 ^"16 , hypergeometric test, Fig. 2G,H). Both oncogenic-ICR (AUC = 0.83, in cross-validation) and the Exclusion signatures (AUC = 0.86) robustly classified individual cells as TN or ICR (Fig. 2A,G). In light of this congruence, Applicants defined a unified resistance program (uICR-up and uICRdown) as the union of the corresponding oncogenic- ICR and Exclusion signatures.

[0405] Importantly, there was no significant difference between the fraction of cycling cells in ICR vs. TN tumors (P = 0.696, t-test), and the oncogenic-ICR signatures were identical when identified only based on non-cycling cells. Interestingly however, the oncogenic-ICR state was more pronounced in cycling cells, both within the same patient group and among cells of the same tumor (Fig. 2B,H _? fig- 10A,B _? P < 10 ^"16 , mixed effects model). Thus, cycling malignant cells may have induced stronger immune evasion capacities compared to their non-cycling counterparts. Moreover, CDK4 was a member of the of the induced resistance program (uICRup). Applicants thus hypothesized that its targeted inhibition could shift the malignant cells to a less resistant state.

[0406] Unlike other biomarkers, such as PDL1 expression, mutational load, or T cell infiltration levels, the immune resistance signature could potentially provide a basis to develop novel treatment strategies. Next, Applicants explored therapeutic strategies to overcome resistance by reversing the uICR cell state in cancer cells. As CDK4 and multiple CDK target were members of the of the induced resistance program (uICR-up) and as the ICR state was more pronounced in cycling cells, Applicants hypothesized that cell cycle arrest through CDK4/6 inhibition could shift the malignant cells to a less resistant state. Additionally, CDK4/6 inhibitors could potentially increase tumor cell immunogenicity by inducing SASP, which was significantly repressed in the cancer cells from the ICR tumors compared to those from the untreated ones.

[0407] To test this assumption, Applicants first analyzed a recently published data set (Goel et al., 2017) in breast cancer cell lines and in vivo models and showed that CDK4/6 inhibition through abemaciclib treatment represses the ICR state defined by our signatures (Fig. 3A-B, fig. IOC). Applicants found that the CDK4/6 inhibitor abemaciclib strongly repressed uICR-up (which includes CDK4) and induced uICR-down (which includes the D- cyclin, CCND3). Indeed, abemaciclib, approved for the treatment of i?RC4-mutated breast cancer, was recently shown to trigger anti-tumor activity by inducing type III interferon production and suppressing T regulatory cells (Goel et al., 2017). Furthermore it was shown to sensitize solid tumors to anti-PDLl in mouse models (Goel et al., 2017) in an RB- dependent manner.

[0408] To determine this effect in melanoma, Applicants identified melanoma cell lines in the Cancer Cell Line Encyclopedia (CCLE) with the strongest expression of the uICR signature, including IGR37, UACC257 (both RB- sufficient) and A2058 (RB -deficient). Applicants performed scRNA-seq on these cell lines before and after treatment with abemaciclib for 1 week (Fig. 41). In both IGR37 and UACC257, Applicants saw a decrease in the expression of the uICR state (P < 3.59* 10 ^"34 , one-sided t-test). The single-cell resolution of the data revealed that in IGR37 there was a subpopulation of cells with an exceptionally strong expression of the uICR signature prior to the treatment with abemaciclib (Fig. 43). This population decreased from 10% before treatment (2,454 cells) to 2% in the post-treatment condition (1,570 cells). In contrast, the RB-deficient cell line A2058 did not show changes in the uICR expression, consistent with the hypothesis that this effect depends on RB-sufficiency.

[0409] Interestingly, Applicants found that DNMTl is repressed while ERV-3 is induced in IGR37 and UACC257 cells post-treatment. These findings support previous observations that CDK4/6 inhibition leads to DNMTl repression, allowing the methylation of endogenous retroviral genes (ERVs). The induction of ERVs triggers 'viral mimicry' and a double- stranded RNA (dsRNA) response, which stimulates type III IFN production to activate IFN- stimulated genes. Interestingly, Applicants also find that abemaciclib induces the expression of an MITF signature (Tirosh I, et al., Science. 2016 Apr 8;352(6282): 189-96) and of the SASP module (Fig. 42). The resistant cells, which are eradicated or altered by abemaciclib, had the lowest expression of the MITF and SASP signatures. While this pattern is decoupled from the expression of the MITF gene itself, it nonetheless indicates that, unlike the mechanism described in breast cancer cells (Goel et al., 2017), abemaciclib might trigger SASP and cell differentiation in melanoma cells.

[0410] To explore the potential of abemaciclib to induce T cell mediated toxicity to tumor cells, Applicants leveraged a patient-derived co-culture model of melanoma cells and ex-vivo expanded tumor infiltrating lymphocytes (TILs) from a metastatic melanoma lesion. Following one week of treatment of tumor cells with abemaciclib, cells were treated with their autologous TILs vs. control, and surviving tumor cells were submitted to scRNA-seq. The exposure to TILs reduced the expression of the uICR signature, both in the control and abemaciclib-treated cells (P < 4.91 * 10 ^"13 ). The treatment with abemaciclib further intensifies these effects, such that in the abemaciclib-treated cells there was an increase in a sensitive (ICR-low) subpopulation of cells post-TILs (Fig. 42). These sensitive cells are also characterized by a low expression of DNMTl, overexpression of ERV-3, and higher expression of the MITF and SASP modules. Furthermore, Applicants measured 40 human cytokines/chemokines in the conditioned media of abemaciclib treated cancer cells (before co-culture) and found the induction of several secreted factors (Fig. 42): macrophage inhibition factor (MIF), CX3CL1 a chemokine that induces migration and adhesion of T and NK cells and is linked to clinical outcomes in immunotherapy treatment (Akbani, et al., 2015; and Ayers, et al., 2017), and CCL20, an important factor for T cell differentiation that may enhance immunity in melanoma (Barretina, et al., 2012).

[0411] The relevance of the uICR as a resistance program is further supported by several lines of evidence. First, the induced uICR is overexpressed in uveal melanoma, which resides in an immune-privileged environment and has very low response rates to immunotherapy

(Zimmer et al., 2015; and Algazi et al., 2016), compared to cutaneous melanoma (Fig. 3D).

Second, perturbations of genes from the repressed resistance program (uICR-down) in malignant melanoma cells conferred resistance to cytotoxic CD8 T cells in a genome-wide

CRISPR KO screen (P = 6.37* 10 ^"3 , hypergeometric test). Third, malignant cells in the resistant state substantially repress interaction routes with other cell types in the tumor (Fig.

3E), as defined by cognate pairs of interacting surface molecules (materials and methods), including MHC LTCR (T cells), CD58:CD2 (T cells), and ILIRAPTLIB (macrophages).

[0412] These results support a model, in which malignant cells from ICR tumors either had active resistance programs prior to treatment or induced the resistance program upon ICI exposure. Because some of the malignant cells from the TN patients expressed the resistance programs (Fig. 2B,H) Applicants next tested their prognostic value in independent datasets and cohorts. To this end, Applicants used both the full uICR and further filtered/refined uICR signatures. The refined signatures include only uICR genes that were also co-regulated with genes whose inhibition enhanced melanoma cell resistance to T cell mediated killing in functional screens (Patel et al., 2017) (table5, materials and methods); the oncogenic-ICR and Exclusion signatures show the same behavior (Fig 4E-H, figs. 11-13).

[0413] The uICR programs are prognostic and predictive for response in external data sets. First, the signatures strongly associated with survival in 431 TCGA melanoma patients

(who did not receive ICI, Fig. 4A, fig. 11), even after controlling for tumor purity and T cell infiltration, a known prognostic marker in melanoma (Azimi et al., 2012; and Bogunovic et al., 2009). Furthermore, combining resistance signatures and T cell infiltration levels yielded a significantly stronger association of patient survival than either alone (COX p-value =

1.4* 10 ^"8 , Fig. 4A, right). Other proposed mechanisms, such as dedifferentiation of melanoma cells (Landsberg et al., 2012), as reflected by an MITF-low signature, and other malignant signatures from the single cell profiles (e.g., cell cycle and the AXL program) (Tirosh et al.,

2016a), did not show an association to patient survival, indicating that mere variation across malignant cells is insufficient as a prognostic signature. Second, the signatures were associated with benefit of ICI in published pre-treatment and early on-treatment bulk expression profiles. In a lung cancer mouse model, which was mostly free of confounding genetic variability, the uICR clearly separated anti-CTLA-4 responders from non-responders based on early on-treatment profiles (P = 3.6* 10 ^"7 , one-sided t-test, Fig. 4B) (Lesterhuis et al., 2015). In bulk pre-treatment RNA-Seq data from 27 melanoma patients that were subsequently treated with Pembrolizumab (Hugo et al., 2016), the uICR program was lower in the five complete responders, though just above statistical significance (P=6.3* 10 ^"2 , Fig. 4C). In bulk pre-treatment RNA-Seq data from 42 melanoma patients that were subsequently treated with the CTLA-4 inhibitor ipilimumab (Van Allen et al., 2015), the uICR program was significantly lower in the two complete responders (P = 5.2* 10 ^"3 ).

[0414] To test the predictive value of the resistance program in a larger independent setting, Applicants assembled a validation cohort of 112 patients with metastatic melanoma who underwent pretreatment biopsy and bulk RNA-Seq followed by Pembrolizumab (anti- PD-1) therapy (Fig. 1A, table 1). The cohort was collected in a different hospital and country (Germany), and samples were processed and sequenced on the same platform at the Broad Institute (materials and methods). Applicants evaluated the performances of the malignant resistance modules in predicting anti-PD-1 responses, with respect to three parameters (materials and methods): (1) progression-free survival (PFS, recorded for 104 of the 112 patients), (2) clinical benefit (CB, defined as either partial or complete response by RECIST criteria), and (3) complete response (CR). To compare the performance of the predictors to prior knowledge and clinically used markers, Applicants assembled a set of 32 other transcriptional signatures, including the top hits of two ICR functional CRISPR screens (Patel et al., 2017; and Manguso et al., 2017) (table 9).

[0415] Our malignant cell resistance signatures were predictive of PFS in the validation cohort (Fig. 4D,E, figs. 12 and 13). Their predictive value was significant even when accounting for other known predictors of ICI response, including inferred T cell infiltration levels and PD-L1 expression (figs. 12E and 13E). Although cell cycle alone is not associated with CB (COX P > 0.25), filtering the cell-cycle component from the uICR overexpression score (materials and methods) further improved the PFS predictions (Fig. 4D, right), suggesting that a tumor ICR level should be evaluated conditioning on its proliferation level. The additional predictive value of the malignant resistance signatures beyond T cell infiltration was significantly higher than that of other signatures (P = 3.37* 10 ^"6 , Wilcoxon- ranksum test), and they were the only ones negatively associated with PFS. Other alternative predictors were either not predictive or highly associated with T cell infiltration levels, such that they did not provide an additive predictive value once accounting for T cell infiltration levels (Fig. 4E).

[0416] The uICR state was overexpressed in patients with CB vs. no-CB (Fig. 4F).

Applicants noted however that some CB patients had high pre-treatment uICR expression and hypothesized that these patients, while experiencing an initial CB, might cease to respond quickly. Indeed, when stratifying patients with CB based on the duration of their response (>12 months, <12 months but >6 months, and <6 months), Applicants found that patients with an initial CB but high uICR score pretreatment were significantly more likely to experience subsequent progressive disease (Fig. 4F). Indeed, patients with rapid progression, that is CB<6 months had the highest uICR score, even compared to those with no-CB. Consistently, the resistance signatures were most accurate in predicting patients with complete responses (P < 6.31 * 10 ^"3 , one-sided t-test, Fig. 4G, fig. 14). In this task, they were superior to all the other alternative predictors (P = 1.64* 10 ^"8 , Wilcoxon ranksum test), all of which, including the clinically used markers, failed to predict complete response (Fig. 4H).

[0417] Finally, Applicants explored intrinsic vs. acquired uICR programs in an additional independent cohort, collected in yet another hospital (materials and methods), consisting of 90 samples from 26 patients with metastatic melanoma who underwent both pre-treatment and post-progression biopsies with bulk RNA-Seq, including 17 patients with on-treatment biopsy (Fig. 1A). The ICR state was induced following ICI compared to pre-ICI lesions from the same patient (P = 1.26* 10 ^"4 and 0.01, for the refined uICR and uICR-up, respectively; mixed-effect test, materials and methods). However, inter-patient variation in uICR expression was significantly higher than intra-patient changes (P < 10 ^"8 , ANOVA). This suggests that one pre-treatment sample per patient may suffice to evaluate ICR for many patients, and that intrinsic resistance may be more prevalent than acquired resistance, consistent with clinical observations (Sharma, et al., 2017). Notably, Applicants did not observe an induction in uICR expression following RAF/MEK-inhibition (materials and methods), indicating that the ICR state is specific to ICI therapy and not merely a marker of a generally drug resistant tumor ecosystem.

Discussion

[0418] Applicants discovered new features linked to response and resistance to immunotherapy in metastatic melanoma with a strong prognostic and predictive value in independent patient cohorts. T cell profiles from ICR patients reflect variability in T cell responses, which are often decoupled from the clinical response. In some ICR patients, T cells manifest substantial clonal expansions, in others higher frequency of T cell proliferation, or a shift in the cytotoxicity/exhaustion balance. While more data is needed to distinguish between proper and insufficient T cell response to ICI, the results suggest that malignant cell-autonomous programs may be another key contributor to ICR, even in the presence of properly activated T cells (Fig. 41).

[0419] Malignant cell programs that suppress interactions with the tumor microenvironment, modulate key inflammatory pathways and activate mechanisms of T cell exclusion were distinguishing features of ICR tumors. These may be jointly controlled as a single coherent resistance program to confer ICR, through master regulators like Myc and CDK4/6. While these programs were initially identified in post-progression samples using scRNA-Seq, Applicants validated their predictive value in a pre-ICI cohort and explored their expression in matched pre/post specimens of ICI-treated patients. The ICR signatures Applicants identified were superior to a comprehensive and diverse set of alternative predictors in several ways, especially in predicting complete responders and patients that responded for more than 6 months. Unlike other predictors, the ICR signatures have a significant additional predictive value beyond pre-treatment T cell infiltration levels, indicating that they highlight new and yet unappreciated aspects of ICR. In light of these results, the signatures may help stratify patients for ICI beyond currently used biomarkers.

[0420] The pathways represented in the resistance program also highlight potential mechanistic causes of ICR that could be reversed by combining ICI with other drugs. Combination of ICI with CDK4/6 inhibitors (such as abemaciclib) may be particularly attractive in light of the findings that abemaciclib reverses the resistant oncogenic state and that there are distinctions between the cell cycle programs of malignant cells and T cells.

[0421] The malignant resistance programs may be relevant in other subtypes of melanoma and even in other lineage-independent cancer types. Among different types of melanoma, uveal melanoma has more active resistance programs compared to cutaneous melanoma (Fig. 3D); across cancers, the resistance program is higher in some cancer types that are less responsive to immunotherapy and/or arise from immune-privileged tissues (eye, testis) and lower in some of the more responsive tissues (head and neck, kidney, skin, lung) (fig. 15). This distinction, however, is imperfect, and additional, tumor-specific resistance programs may be discovered by similar strategies. Our study uncovers an improved, potentially clinically applicable biomarker for patient selection, provides a rationale to examine novel mechanisms of ICR, and reveals guiding principles to further dissect and repress mechanistic underpinnings that mediate ICI resistance.

[0422] Applicants demonstrated that cancer cell-autonomous ICR programs identified by scRNA-Seq predict clinical response (per RECIST criteria) and progression-free survival in two independent cohorts: one of patients who underwent RNA-seq of matched pre-treatment and progression (ICR) specimens; and another of 112 melanoma patients with pre-treatment RNA-seq who receive anti-PD-1 monotherapy. Applicants also validated the prognostic value of these cell programs in TCGA. Lastly, Applicants demonstrated that pharmacological reversal of these oncogenic cell states can be achieved by CDK4/6-inhibition, and explored the impact of this treatment in melanoma at the single cell level. To determine the role of T cell exclusion from the TME as a potential mechanism of ICR, Applicants performed spatially resolved 30-plex single-cell protein analysis of matching FFPE specimens from 16 of the patients who also underwent scRNA-seq. Thus, the presented analytical platforms provide a promising approach to understanding drug resistance within preserved tumor ecosystems.

[0423] In conclusion, this study provides a high-resolution landscape of oncogenic ICR states, identifies clinically predictive signatures, and forms a basis to develop novel therapeutic strategies that could overcome immunotherapy resistance in melanoma.

Table 1. Clinical characteristics of the patients and samples in the scRNA-Seq cohort, and in the two validation cohorts.

scRNA-Seq cohort

Table 2

Table 3 l ablc ⁽ .oil Ivpi' si.nn.i lures i hn l were derived I roin Hie .in.dvsis ol I he scKNA-seq d.il.i ( see secl ion Π,ιΙ.ι- u riven ; ires «1 sp ci lie :eii-types

Endoth CD4

elial Macro Malign NK T CD8 T Lymph Stroma

B cell CAF cell phage ant cell cell T cell cell cell Immune cell ocyte cell

COLl KLR PAS ARHGA ARHGE

CD22 4A1 CDH5 AQP9 APOD Fl CD2 K CD8A AKNA IFNGR1 P15 F15

COLl KLR PBX AKR1 ARHGA

CD24 Al CFI ATF5 APOE Kl CD247 IP1 CD8B Al IFNGR2 P9 ASPN

COLl NCA SLA ALDH ARHGE

CD37 A2 CLDN5 ATG3 ATP1A1 Ml CD27 MF1 CD96 2 IGFLR1 Fl BGN

COL3 CLEC14 NK SPO ALDH

CD52 Al A ATG7 ATP1B1 G7 CD28 CK2 CLEC2D 3B1 IGLL1 ASB2 C1R

CD79 COL5 COL15A ATP6V PRF TCF ALOX

A Al 1 OB ATP5C1 1 CD3D 7 CRTAM 5 IGLL3P ATHL1 CIS

CD79 COL5 ATP6V PTG TNF ALOX

B A2 COL4A1 0D1 ATP5G1 DR CD3E SF8 CST7 5AP IGLL5 ATP2A3 CALCRL

COL6 ATP6V SH2 AMIC

CD82 Al COL4A2 1B2 ATP5G2 DIB CD3G CTSW Al IGSF6 ATP8A1 CALD1

CHMP COL6 BCL2A ATP6V0 XCL ANKR

7 A2 CRIP2 1 E2 1 CD5 CXCL13 D22 IKZF1 BANK1 CCDC80

COL6 ATP6V1 ANKR

CIITA A3 CXorf36 BID CI CD6 CXCR6 D44 IKZF3 BCL11A CCL14

CLEC COL8 ATP6V1

17A Al CYYR1 BLVRA El CD7 DTHD1 AOAH ILIORA BCL11B CD200

CREB ATP6V1 AP1B IL12RB

CNR2 3L1 DARC BLVRB Gl CD8A DUSP2 1 1 BIRC3 CD248

COLl CXCL Cllorf APOB

9A1 14 DCHS1 75 AZGP1 CD8B EOMES EC3C IL16 BLK CD34

COL4 CYBR C15orf APOB

A3 Dl DOCK6 48 BAIAP2 CD96 FASLG EC3D IL18 BLNK CD93

C19orf CDC42S APOB

CR2 DCN DOCK9 38 BANCR E2 FYN EC3G IL1B BTLA CDH11

CXCR Clorfl BTN3A

5 DPT DYSF 62 BCAN CELF2 GPR171 AQP3 IL1RN 1 CDH5

ELK2 EFEM BTN3A CERCA AP P2 ECE1 C1QA BCAS3 CLEC2D GZMA AQP9 IL2RB 2 M

FAIM FBLN ARAP C16orf5 3 1 ECSCR C1QB BCHE CNOT6L GZMB 2 IL2RG 4 CFI

FAM1 FBLN ARHG

29C 5 EGFL7 C1QC BIRC7 CST7 GZMH AP15 IL32 CBLB CLDN5

FCER ARHG CLEC14 2 FGF7 ELK3 C2 BZW2 CTLA4 GZMK AP30 IL4I1 CCL4 A

FCRL GPR1 C10orf9 ARHG COL12A 1 76 ELTD1 C3AR1 0 CTSW ID2 AP4 IL6R CCL4L1 1

FCRL HSPB Cllorf3 ARHG COL14A 2 6 EMCN C5AR1 1 CXCL13 IFNG AP9 IL7R CCL4L2 1

FCRL INHB C9orf7 C12orf7 ARHG COL15A 5 A ENG 2 6 CXCR3 IKZF3 DIB IL8 CCL5 1

FCRL C17orf8 ARHG

A ISLR EPAS1 CAPG 9 CXCR6 IL2RB EF1 INPP4B CCR4 COL1A1

HLA- ITGA ARPC

DOB 11 EPHB4 CARD9 Clorf43 DEF6 ITGA4 3 INPP5D CCR6 COL1A2

HLA- DENND ARRB

DQA2 LOX ERG CASP1 Clorf85 2D ITGB7 2 IPCEF1 CCR7 COL3A1

HVCN LPAR JAKMIP

1 1 ESAM CCR1 C4orf48 DGKA 1 ASB2 IRF5 CD19 COL4A1

LTBP KIR2DL

IGLL1 2 FGD5 CCR2 CA14 DTHD1 4 ATF5 IRF8 CD1C COL4A2

IGLL3

P LUM FKBP1A CD14 CA8 DUSP2 KLRC1 ATG3 ISG20 CD2 COL5A1

MAP

IGLL5 1A FLT4 CD163 CACYBP EMB KLRC2 ATG7 ITGA4 CD22 COL5A2

MEG GALNT1 ATHL

IRF8 3 8 CD274 CAPN3 EVL KLRC3 1 ITGAL CD24 COL6A1

KBTB MIR1 CD300 ATP2

D8 00HG GPR116 C CBX3 FASLG KLRC4 A3 ITGAM CD244 COL6A2

KIAAO MRC HERC2P CD300 KLRC4- ATP6

125 2 2 E CCDC47 FYN KLRK1 VOB ITGAX CD247 COL6A3 l ablc ⁽ .oil Ivpi' si.nn.i lures i hn l were derived I roin Hie .in.dvsis ol I he scKNA-seq d.il.i ( see secl ion Π,ιΙ.ι- u riven ; ires «1 sp ci lie :eii-types

Endoth CD4

elial Macro Malign NK T CD8 T Lymph Stroma

B cell CAF cell phage ant cell cell T cell cell cell Immune cell ocyte cell

KIAAO MXR CD300 ATP6

226L A8 HSPG2 LB CCND1 GATA3 KLRD1 V0D1 ITGB2 CD27 COL8A1

LOC2 CD300 ATP6 CREB3L 83663 MYL9 HYAL2 LF CCT2 GPR171 KLRK1 V1B2 ITGB7 CD28 1

ATP8

LRMP NID2 ICA1 CD302 CCT3 GPR174 LAG3 Al ITK CD37 CRIP2

OLF LOCIOO BANK

LTB ML3 ID1 CD33 CCT6A GPRIN3 506776 1 JAK3 CD3D CXCL14

MS4A PALL BCL1 JAKMIP

1 D IL3RA CD4 CCT8 GRAP2 LYST 1A 1 CD3E CXorf36

NAPS PCDH MIR155 BCL1 KBTBD

B 18 ITGB4 CD68 CDH19 GZMA HG IB 8 CD3G CYBRD1

NCOA PCOL BCL2 KCNMA

3 CE KDR CD80 CDH3 GZMB NELL2 Al 1 CD4 CYYR1

P2RX PDGF KIAAO 1

5 RA LAMA5 CD86 CDK2 GZMH NKG7 BID 25 CD40LG DARC

PDGF CHCHD KIAA02

PAX5 RB LDB2 CECR1 6 GZMK OASL BIN2 26L CD5 DCHS1

PLEK PDGF LOCIOO KIR2DL

HF2 RL 505495 CFP CITEDl GZMM PARP8 BIRC3 4 CD52 DCN

PLAC CLEC1 HNRNP

PNOC 9 MALL OA CLCN7 A1P10 PDCD1 BLK KLRB1 CD6 DOCK6

POLD POD CLEC1 PIP4K2

4 N MMRN1 2A CLNS1A ICOS A BLNK KLRC1 CD69 DOCK9

POU2 PRRX CLEC4 BLVR

AF1 1 MMRN2 A CMC2 IFNG PRF1 A KLRC2 CD7 DPT

POU2 RARR CLEC4 BLVR

F2 ES2 MYCT1 E COA6 IKZF1 PRKCH B KLRC3 CD79A DYSF

QRSL CLEC5 PSTPIP

1 RCN3 NOS3 A COX5B IKZF3 1 BTK KLRC4 CD79B ECE1

RALG NOTCH CLEC7 IL12RB KLRC4- PS2 SDC2 4 A COX7A2 1 PTPN22 BTLA KLRK1 CD82 ECSCR

RPL1 SFRP CMKL BTN3 EFEMP 3 2 NPDC1 Rl COX7C IL2RB PVRIG Al KLRD1 CD8A 2

RPS2 BTN3

0 SLIT3 PALMD CNPY3 CRYL1 IL2RG PYHIN1 A2 KLRF1 CD8B EGFL7

RPS2 SMOC Cllor

3 2 PCDH17 COTL1 CSAG1 IL32 RAB27A f75 KLRK1 CD96 EHD2

SEL1L SPOC RARRES C15or CDC42S 3 Kl PDE2A CPVL CSAG2 IL7R 3 f48 KYNU E2 ELK3

SULF C16or

SELL 1 PDLIM1 CREG1 CSAG3 INPP4B RUNX3 f54 LAG3 CELF2 ELTD1

SMIM SVEP PECAM C19or

14 1 1 CSF1R CSPG4 IPCEF1 SAMD3 f38 LAIR1 CHMP7 EMCN

SNX2 TAGL CSF2R CTNNB Clorf LAPTM

9 N PLVAP A 1 ITGAL SH2D1A 162 5 CIITA ENG

SNX2 THBS CLEC17 9P1 2 PLXND1 CSF3R CYC1 ITK SLA2 C1QA LAT A EPAS1

CYP27A

SPIB THY1 PODXL CSTA 1 JAK3 SLAMF6 C1QB LAT2 CLEC2D EPHB4

ST6G TME JAKMIP

AL1 M119 PRCP CTSB DAAM2 1 SYTL3 C1QC LBH CNOT6L ERG

STAG

3 TPM1 PREX2 CTSC DANCR KLRC4 TARP C2 LCK CNR2 ESAM

STAP C3AR COL19A 1 TPM2 PTPRB CTSD DAP3 KLRD1 THEMIS 1 LCP1 1 FBLN1

TCL1 C5AR

A PVRL2 CTSH DCT KLRK1 TIGIT 1 LCP2 COL4A3 FBLN5

TLR1 TNFRSF C9orf LEPROT COROl

0 RAMP2 CTSS DCXR LAG3 9 72 LI A FBN1

TME CXCL1

M154 RAMP3 0 DDIT3 LAT TNIP3 CAPG LGALS2 CR2 FGD5

TNFR CXCL1 CARD

SF13B RHOJ 6 DDT LCK TOX 9 LGMN CRTAM FGF7 l ablc ⁽ .oil Ivpi' si.nn.i lures i hn l were derived I roin Hie .in.dvsis ol I he scKNA-seq d.il.i ( see secl ion Π,ιΙ.ι- u riven ; ires «1 sp ci lie :eii-types

Endoth CD4

elial Macro Malign NK T CD8 T Lymph Stroma

B cell CAF cell phage ant cell cell T cell cell cell Immune cell ocyte cell

VPRE LEPROT CASP

B3 ROB04 CXCL9 DFNB31 LI TTC24 1 LILRAl CST7 FKBP1A

WD FY CXCR2

4 S1PR1 PI DLL3 LIME1 WIPF1 CBLB LILRA2 CTLA4 FLT4

ZCCH DNAH1 LOCIOO

C7 SDPR CYBB 4 130231 XCL1 CCL3 LILRA3 CTSW FSTL1

CYP2S MAP4K GALNT1

SELP 1 DNAJA4 1 XCL2 CCL4 LILRA5 CXCL13 8

SHROO DAPK CCL4

M4 1 DSCR8 MI AT LI LILRA6 CXCR3 GNG11

SLC02A CCL4

1 DHRS9 DUSP4 NELL2 L2 LILRB1 CXCR4 GPR116

DMXL

SMAD1 2 EDNRB NKG7 CCL5 LILRB2 CXCR5 GPR176

DNAJC HERC2P

STOM 5B EIF3C NLRC3 CCR1 LILRB3 CXCR6 2

SYNPO EBI3 EIF3D NLRC5 CCR2 LILRB4 CYFIP2 HSPB6

OXNAD

TAOK2 EMR2 EIF3E 1 CCR4 LILRB5 CYTIP HSPG2

EPSTI

TEK 1 EIF3H PAG1 CCR6 LIMD2 DEF6 HYAL2

DENND

TENC1 F13A1 EIF3L PARP8 CCR7 LIME1 2D ICA1

FAM1

TGFBR2 57B ENOl PCED1B CD14 LIPA DGKA ID1

FAM2 PCED1B CD16

TGM2 6F EN02 -AS1 3 LITAF DTHD1 ID3

ENTHD LOCIOO

THBD FBP1 1 PDCD1 CD19 130231 DUSP2 IFITM3

FCER1 ENTPD LOCIOO

TIE1 G 6 PIK3IP1 CD1C 506776 ELK2AP IGFBP4

FCGR1 LOC283

TM4SF1 A ERBB3 PIM2 CD2 663 EMB IGFBP7

TM4SF1 FCGR1 PIP4K2 LOC729

8 B ESRP1 A CD22 737 EOMES IL3RA

TMEM2 FCGR1 PPP2R5

55B C ETV4 C CD24 LPXN EVL INHBA

TSPAN1 FCGR2 CD24

8 A ETV5 PRDM1 4 LRMP EZR ISLR

FCGR2 CD24

TSPAN7 C EXOSC4 PRF1 7 LRRC25 F5 ITGA11

VWF FCN1 EXTL1 PRKCQ CD27 LSP1 FAAH2 ITGA5

ZNF385 FAHD2 PSTPIP CD27

D FGL2 B 1 4 LST1 FAIM3 ITGB4

FAM10 FAM12

FOLR2 3A1 PTPN22 CD28 LTA4H 9C KDR

FAM17 CD30 FAM65

FPR1 8B PTPN7 OA LTB B LAMA5

CD30

FPR2 FANCL PVRIG OC LY86 FASLG LAMB1

CD30

FPR3 FARP2 PYHIN1 0E LY9 FCER2 LDB2

CD30 LOCIOO

FTH1 FASN RAB27A OLB LYN FCRL1 505495

RAPGEF CD30

FTL FBX032 6 OLF LYST FCRL2 LOX

RARRES CD30

FUCA1 FBX07 3 2 LYZ FCRL3 LPAR1

FUOM FDFT1 RASAL3 CD33 M6PR FCRL5 LTBP2

GABA RASGRP RAP FKBP4 1 CD37 MAFB FCRLA LUM l ablc ⁽ .oil Ivpi' si.nn.i lures i hn l were derived I roin Hie .in.dvsis ol I he scKNA-seq d.il.i ( see secl ion Π,ιΙ.ι- u riven ; ires «1 sp ci lie :eii-types 1-

Endoth CD4

elial Macro Malign NK T CD8 T Lymph Stroma

B cell CAF cell phage ant cell cell T cell cell cell Immune cell ocyte cell

MAN2B

GATM FMN1 RGS1 CD38 1 FOXP3 MALL

MAP4K

GBP1 FXYD3 RHOF CD3D 1 FYB MAP1A

GCA GALE RNF213 CD3E 1-Mar FYN MEG3

MIR100

GK GAPDH RUNX3 CD3G MARCO GATA3 HG

GAPDH

GLA S SCML4 CD4 MFSD1 GNLY MMP2

SEMA4 CD40

GLRX GAS2L3 D LG MI AT GPR171 MMRN1

GLUL GAS5 1-Sep CD48 MILR1 GPR174 MMRN2

MIR155

GM2A GAS7 SH2D1A CD5 HG GPRIN3 MRC2

GNA15 GDF15 SH2D2A CD52 MNDA GRAP2 MXRA8

GPBA

Rl GJB1 SIRPG CD53 MOB1A GZMA MYCT1

GPATC

GPR34 H4 SIT1 CD6 MPEG1 GZMB MYL9

GPR84 GPM6B SKAP1 CD68 MPP1 GZMH NFIB

GPX1 GPNMB SLA2 CD69 MS4A1 GZMK NID2

GPR137 SPATA1 MS4A4

CRN B 3 CD7 A GZMM NNMT

HCAR MS4A6 HLA- 2 GPR143 SPN CD72 A DOB NOS3

HCAR HLA- NOTCH 3 GPS1 SPOCK2 CD74 MS4A7 DQA2 4

CD79

HCK GSTP1 STAT4 A MSR1 HMHA1 NPDC1

CD79 MTMR1 HNRNP OLFML

HK2 GYG2 SYTL3 B 4 A1P10 3

HK3 H2AFZ TARP CD80 MYD88 HOPX PALLD

HLA- TBC1D1

DMA HAX1 OC CD82 MYOIF HSH2D PALMD

HLA- HIST1H

DMB 2BD TC2N CD83 NAAA HVCN1 PCDH17

HLA- HIST3H

DPA1 2A TESPA1 CD84 NADK ICOS PCDH18

HLA- HMG20

DPB1 B THEMIS CD86 NAGA ID2 PCOLCE

HLA- DPB2 HMGA1 TIGIT CD8A NAGK IFNG PDE2A

HLA- TNFAIP PDGFR DRA HPGD 3 CD8B NAIP IGLL1 A

HLA- TNFRSF PDGFR DRB1 HPS4 9 CD96 NAPSB IGLL3P B

HLA- DRB5 HPS5 TOX CD97 NCAM1 IGLL5 PDGFRL

HLA- HSP90A CDC4

DRB6 Al TRAFl 2SE2 NCF1 IKZF1 PDLIM1

HMOX HSP90A CECR PECAM 1 Bl TRATl 1 NCF1B IKZF3 1

CELF IL12RB

HSPA6 HSPA9 TTC39C 2 NCF1C 1 PLAC9

UBASH

HSPA7 HSPD1 3A CFP NCF2 IL16 PLVAP

CHMP

IFI30 HSPE1 WIPF1 7 NCF4 IL2RB PLXND1

IFNGR IGSF11 ZAP70 CIITA NCKAP IL2RG PODN l ablc ⁽ .oil Ivpi' si.nn.i lures i hn l were derived I roin Hie .in.dvsis ol I he scKNA-seq d.il.i ( see secl ion Π,ιΙ.ι- u riven ; ires «1 sp ci lie :eii-types 1-

Endoth CD4

elial Macro Malign NK T CD8 T Lymph Stroma

B cell CAF cell phage ant cell cell T cell cell cell Immune cell ocyte cell

MAN2 MAGEC PCED1B

Bl 1 CTSW -AS1 LIMD2 SYNPO

MARC CXCL

0 MDH1 10 PCK2 LIME1 TAGLN

MFSD CXCL LOCIOO

1 MDH2 13 PDCD1 130231 TAOK2

CXCL PIK3AP LOCIOO

MILR1 MFI2 16 1 506776 TEK

MFSD1 CXCL LOC283

MNDA 2 9 PIK3IP1 663 TENC1

MOB1 CXCR

A MIA 2P1 PIK3R5 LRMP TGFBR2

MPEG CXCR

1 MIF 3 PILRA LTB TGM2

CXCR

MPP1 MITF 4 PIM2 LY9 THBD

MS4A CXCR

4A MLANA 5 PION LYST THBS2

MS4A CXCR PIP4K2 MAP4K

6A MLPH 6 A 1 THY1

MS4A

7 MOK CYBA PLA2G7 MI AT TIE1

MRPS2 MIR155

MSR1 1 CYBB PLAC8 HG TM4SF1

MTMR MRPS2 CYFIP TM4SF1 14 5 2 PLAUR MS4A1 8

MYD8 MRPS2 CYP2 TMEM1 8 6 SI PLBD1 NAPSB 19

CYTH TMEM2

NAAA MRPS6 4 PLCB2 NCAM1 55B

NADK MSI2 CYTIP PLEK NCOA3 TPM1

DAPK PLEKH

NAGA MXI1 1 A2 NELL2 TPM2

DAPP PLEKHF TSPAN1

NAGK MYO10 1 2 NKG7 8

PLEKH

NAIP NAV2 DEF6 01 NLRC3 TSPAN7

NDUFA DENN

NCF2 4 D2D PLIN2 NLRC5 VWF

NDUFB ZNF385

NCF4 9 DGKA PNOC OASL D

NCOA DHRS OXNAD

4 NDUFS2 9 POLD4 1

NFAM NEDD4 DMXL POU2AF

1 L 2 1 P2RX5

DNAJ

NINJ1 NELFCD C5B POU2F2 PAG1

DOCK

NLRC4 NHP2 2 PPM1K PARP15

DOCK PPP2R5

NLRP3 NME1 8 C PARP8

NMI NOP58 DOK2 PPT1 PASK

NPC2 NPM1 DOK3 PRAMl PAX5

DTHD

NPL NSG1 1 PRDM1 PBXIP1

DUSP

OAS1 NT5C3 2 PRF1 PCED1B

PCED1B

OAZ1 NT5DC3 EBI3 PRKCB -AS1

ELK2

OLR1 OSTM1 AP PRKCD PDCD1 l ablc ⁽ .oil Ivpi' si.nn.i lures l lin l were derived I roin Hie .in.dvsis ol I he scKNA-seq d.il.i ( see sccl ion D.il.i- u riven ; ires «1 sp ci lie :eii-types

Endoth CD4

elial Macro Malign NK T CD8 T Lymph Stroma

B cell CAF cell phage ant cell cell T cell cell cell Immune cell ocyte cell

UBASH

TC2N 3A

TCF7 UBE2D1

TCL1

A UCP2

TESP

Al VAMP8

TGFBI VAV1

THEM IS VMOl

THEM IS2 VPREB3

TIFAB VSIG4

TIGIT WDFY4

TLR1 WIPF1

TLR1

0 XCL1

TLR2 XCL2

TLR5 ZAP70

ZC3HAV

TLR8 1

TMC8 ZCCHC7

TME

M106 ZNF385

A A

TME

M154

Table 4

STATl KLF12 CRTAP

STOM MIR155HG CYFIP1

UBE2Q2P3 MTA2 DDOST

MTRNR2L1 DHRS3

MTRNR2L3 EGFL7

PIK3IP1 EIF1AY

RPL26 ETS2

RPL27 FCGR2A

RPL27A FOLR2

RPL35A GATM

RPS11 GBP3

RPS16 GNG2

RPS20 GSTT1

RPS26 GYPC

SPOCK2 HIST1H1E

SYTL3 HPGDS

TOB1 IFI44L

TPT1 IGFBP4

TTN ITGA4

TXNIP KCTD12

WNK1 LGMN

ZFP36L2 LOC441081

LTC4S

LYVE1

MERTK

METTL7B

MS4A4A

MS4A7

MTSS1

NLRP3

OLFML3

PLA2G15

PLXDC2

PMP22

POR

PRDX2

PTGS1

RNASE1

ROCK1

RPS4Y1

S100A9

SCAMP2

SEPP1

SESN1

SLC18B1

SLC39A1

SLC40A1

SLC7A8

SORL1

SPP1

STAB1

TMEM106C

TMEM86A

TMEM9

TNFRSF1B

TNFRSF21

TPD52L2

ULK3

ZFP36L2

Table 5 Table 6. Genes differentially expressed in CD8 T cells of the CB patient compared to those of the ICR patients.

Up-regulated in CB vs. ICR Down-regulated in CB vs. ICR

ALOX5AP AKIRIN2

C1D APIP

C3orfl4 ARL5A

CCL5 ASF1B

CCR2 ATP6V0C

CD52 ATP9B

CDC26 BRAT1

CIDECP BRD7

CISH C17orf89

COX5B C1GALT1C1

CRIPl C4orf48

CTSW CALR

CXCR6 CCDC137

DDX3Y CDC73

EDF1 CDCA7

EIF1AY CDK1

FAM127B CENPM

FASLG CEP78

FAU CHMP6

FCGR3A CITED2

FTL CUNT1

GZMA CMTM7

GZMB COTL1

GZMH CRIPT

HCG26 CSNK1G3

HCST CYB5R4

HLA-A DCPS

HLA-C DNAJB14

HLA-DQA2 DND1

HLA-H DPH3

HSPA1B EFR3A

ID2 EMC2

KDM5D EML3

LAIR2 FAM160B1

MIR4461 FAM168B

MTRNR2L1 FAM46C

MTRNR2L10 FAM53C

MTRNR2L6 FAM69A

NACA FARSB

NCF4 FBX022

NDUFA13 FEM1A

NDUFS5 FTSJD1

NDUFV2 GATAD2A

RBPJ GET4

RNASEK GGA3

RPL10 GLTSCR2

RPL11 GNL3

RPL12 GOLT1B

RPL13 GPR137B

RPL13AP5 GTDC1

RPL15 HIST1H1E

RPL17 HMGA1

RPL18 HMHA1 Up-regulated in CB vs. ICR Down-regulated in CB vs. ICR

RPL18A HSF1

RPL19 IARS2

RPL21 IL6ST

RPL23 JUNB

RPL23A KATNA1

RPL24 KIAA1429

RPL26 LATS1

RPL29 LOC100294145

RPL30 LRIG2

RPL32 MAN2A1

RPL35 MAP3K2

RPL35A MB21D1

RPL36 MCM2

RPL36AL MCM4

RPL37A MED23

RPL4 MGEA5

RPL41 MPLKIP

RPL6 MRPS33

RPL7 MZT1

RPL7A NAGK

RPL9 NEK1

RPLP1 NOA1

RPLP2 NPC2

RPS10 NUDT1

RPS11 NUP107

RPS12 OSGEP

RPS13 PARP10

RPS14 PEU1

RPS15 PGS1

RPS15A PITHD1

RPS16 PLEKHF2

RPS18 POLR3E

RPS19 PPIF

RPS20 PPP1R21

RPS24 PRKAB1

RPS25 PSMD2

RPS27 PTGDR

RPS27A PYG02

RPS3 RAB11B

RPS3A RABEP1

RPS4X RALB

RPS4Y1 REC8

RPS5 REEP4

RPS6 RNF216P1

RPS8 RNF219

SAMD3 RPIA

SELM RPS6KA5

SH3BGRL3 RPSAP58

SYMPK SFSWAP

TMSB10 SGSM2

TMSB4X SLC1A5

TNFSF4 SLC25A26

TPT1 SLC33A1

TXLNG2P SLC39A3

SLC7A5

SMC1A

SMC4 Up-regulated in CB vs. ICR Down-regulated in CB vs. ICR

SNX4

SPPL2A

STAT1

STX17

SYPL1

TAF1B

TAF6

TCERG1

TCF7

TEKT4P2

TERF2IP

TIMM44

TMEM161B

TMEM170A

TMEM189

TMEM69

TMX4

TNIP1

TNPOl

TOP2A

TPX2

TRIES2

TSC22D1

TUBGCP3

TYMS

UBA5

UBE2J1

UBE2Q2

UBE2T

USP38

UVRAG

WDR18

ZBED6

ZBTB20

ZFYVE28

ZNF259

ZNF511

Table 7

Table 7. 'll-cvrlc sic;n.i tinvs spccilic to ' c ells.

Up-regulated in cycling CD8 T cells Down-regulated in cycling CD8 T cells

ACTG1 AOAH

ANXA5 ATHL1

ARHGDIB Cllorf21

ARL6IP1 CCL3L1

ARPC2 CD37

ATP5L CISH

CD74 CX3CR1

CNTRL DENND2D

COROIA GNPDA1

COTL1 GZMM

COX6A1 IL11RA

COX6C IL7R

COX8A KLRB1

DDOST LDLRAP1 GALM LINC00612

GMFG LY9

GNG5 NR4A3

HLA-DRA PDGFD

HP1BP3 PLCB2

LCP1 PTGDR

LRRFIP1 RAB37

MPC2 RPS27

MT2A S0RL1

NDUFA4 TRIM22

NDUFC2 TRMU

NUP50 TTN

PCBP1 UPRT

PKM ZNF121

P0LR2A

PSMB2

SNX1

SRRM1

TMA7

VIM

YWHAE

YWHAQ

Table 8. The topmost differentially expressed gene sets in the malignant cells from ICR vs. TN tumors

Table 9. Signatures that were used as alternative ICR predictors.

Description

Signature name Reference

AXL (Tirosh) Tirosh et al Science 2016 Melanoma cell cycle (Tirosh) Tirosh et al Science 2016

Gl S (Tirosh) Tirosh et al Science 2016

G2 M (Tirosh) Tirosh et al Science 2016

Melanoma cells (Tirosh) Tirosh et al Science 2016

MITF (Tirosh) Tirosh et al Science 2016

TME B cell Tumor microenvironment (TME): Current study

TME CAF TME: Current study

TME Endo TME: Current study

TME Mai TME: Current study

TME NK TME: Current study

TME Neutrophil TME: Current study

TME T cells TME: Current study

TME T CD4 TME: Current study

TME T CD8 TME: Current study

TME Macrophage TME: Current study

TME immune cells TME: Current study

TME lymphocytes TME: Current study

TME meyloid TME: Current study

TME stroma TME: Current study

www.fluidigm.com/applications/advanta-immuno-oncology-gene-

Fluidgm Panel A

expression-assay

www.fluidigm.com/applications/advanta-immuno-oncology-gene-

Fluidgm Panel B

expression-assay

in-vivo screen GVAXPDl vs TCRaKO depleted Manguso et al. Cell 2017

in-vivo screen GVAX vs TCRaKO depleted Manguso et al. Cell 2017

in-vivo screen TCRaKO vs in-vitro depleted Manguso et al. Cell 2017

in-vivo screen GVAXPDl vs TCRaKO enriched Manguso et al. Cell 2017

in-vivo screen GVAX vs TCRaKO enriched Manguso et al. Cell 2017

in-vivo screen TCRaKO vs in-vitro enriched Manguso et al. Cell 2017

co-culture screen top 10 hits Patel et al. Nature 2017

co-culture screen top 50 hits Patel et al. Nature 2017

Ayers IFNg sig Ayers et al. JCI 2017

Ayers immune sig Ayers et al. JCI 2017

DPB2

PLXND HLA- FAM11

TCL1A MEG3 CSAG3 SIT1 CD48 IRF8 IRF5

1 DRB1 4A1

HLA-

TLR10 MFAP4 PODXL CSAG4 DEF6 CD5 ITK KYNU FAP

DRB5

VPREB HLA-

MFAP5 PRCP CSPG4 GZMH CD52 JAK3 LAIR1 FBLN1

3 DRB6

WD FY MIR100

PTPRB CYC1 LIME1 HMOX1 CD53 KLRB1 LILRA1 FBLN2 4 HG

MMP2 PVRL2 CYP27A1 GZMA IFI30 CD6 KLRC4 LILRA2 FBLN5

MRC2 RAMP2 DAAM2 JAK3 IL4I1 CD68 KLRD1 LILRA3 FBN1

DENND

MXRA5 RAMP3 DANCR IRF5 CD69 KLRK1 LILRA6 FGF7

2D

SEMA4

MXRA8 RHOJ DAP3 KCNMA1 CD7 LAG 3 LILRB1 FHL1

D

MYL9 R0B04 DCT SIRPG KYNU CD72 LAT LILRB2 FN1

CLEC2

NID2 S1PR1 DCXR LAIR1 CD74 LCK LILRB3 FSTL1

D

LOC283

NUPR1 SDPR DDT CD8B LGALS2 CD79A LILRB4 GNG11

663

0LFML2 THEMI

SELP DLGAP1 LILRB1 CD79B LTB LRRC25 GPR116 B S

SHROO

0LFML3 DLL3 NLRC3 LILRB4 CD83 LY9 LST1 HSPG2 M4

SLC02A MAP4K

PALLD DNAH14 ZAP70 LILRB5 CD86 LYZ HTRA1 1 1

IL12RB

PCDH18 SMAD1 DNAJA4 LIPA CD8A MS4A1 MAFB HYAL2

1

MAN2B

PCOLCE STOM DSCR8 CTSW MAFB CD8B NAPSB ID1

1

MAP4K

PDGFRA TEK DUSP4 MAN2B1 CD96 NKG7 MFSD1 ID3

1

PDGFRB TGM2 EDNRB IFNG MARCO CDC42SE2 PARP15 MNDA IFITM3

SPOCK

PDGFRL THBD EIF3C MFSD1 CECR1 PAX5 MPEG1 IGFBP4

2

PCED1B

PLAC9 TIE1 EIF3D DTHD1 MPEG1 CELF2 MPP1 IGFBP7

-AS1

TM4SF APOBE

PODN EIF3E MS4A4A CIITA PDCD1 MS4A4A IL33 1 C3G

TM4SF PSTPIP

PRRX1 EIF3H MS4A6A CLEC2D PLAC8 MS4A6A ISLR 18 1

RARRES TMEM2 POU2AF

EIF3L CD2 MS4A7 CLEC4A MS4A7 KDR 2 55B 1

TSPAN1

RCN3 ENOl PRF1 MSR1 CLEC7A POU2F2 MSR1 LAMA5 8

BCL11 MTMR1

SDC1 TSPAN7 EN02 COR01A PRDM1 MXD1 LAMB1

B 4

SDC2 VWF ENTHD1 PARP8 NAGA CPVL PRF1 NAIP LAMC1

ZNF385

SEC24D ENTPD6 CXCR3 NPC2 CSF1R PTPN7 NCF2 LDB2

D

SERPINF PTPRCA

ERBB3 CELF2 OAS1 CSF2RA NINJ1 LHFP 1 P

SFRP2 ESRP1 CCL5 OLR1 CSF3R PYHIN1 NPC2 LIMA1

SFRP4 ETV4 IL32 PLA2G7 CST7 RHOH NPL LIMS2

SLIT3 ETV5 PRKCQ PPT1 CSTA RNF213 PILRA LOX

SM0C2 EX0SC4 WIPF1 PTPRO CTSB RPL13 PPT1 LOXL2

SPARC EXTL1 GZMK RASSF4 CTSC RPS27 PSAP LPAR1

SP0CK1 FAHD2B ATHL1 RGS10 CTSD RPS3A PTAFR LTBP2

FAM103 ZC3HA

SPON1 RHBDF2 CTSS RPS6 PYCARD LUM

Al VI

SULF1 FAM178B CD7 RNASE6 CTSW RUNX3 RAB20 MAP1B

RNASET

SVEP1 FANCL CD3D CXCL16 1-Sep RASSF4 MEG3

2

RASGR

TAGLN FARP2 RTN1 CXCR4 SH2D1A RBM47 MFAP4

PI

TBC1D

THBS2 FASN SDS CXCR5 SH2D2A RGS2 MGP

IOC

THY1 FBX032 TRAF1 SIGLECl CYBA SIRPG RNASE6 MMP2

TMEM1 ARHGE

FBX07 SLAMF8 CYBB SIT1 RNF130 MXRA8 19 Fl

SLC15A RNF144

TPM1 FDFT1 TARP CYFIP2 SKAP1 MYCT1

3 B

SPATA SLC6A1

TPM2 FKBP4 CYTH4 SP140 S100A8 MYL9

13 2

PCEDl

VCAN FMN1 SLC7A7 CYTIP SPOCK2 S100A9 NFIB

B-ASl

SLC02B

FOXD3 RUNX3 DENND2D STAP1 SAT1 NID2

1

SERPIN

FXYD3 CD6 SPINT2 DGKA STAT4 NNMT

Al

GAPDH CD8A TFEC DOCK2 TARP SIGLECl NPDC1

GAPDHS NELL2 TIFAB D0CK8 TIGIT SIGLEC9 OLFML

Table 10. Signatures of Expanded T cells

Up/down regulated iti expanded T tells compared ti> ti on -exp nded T tells.

u (expanded) down (expanded) up ) all) dowr • fall)

ABCD2 ALOX5AP ABCD2 NAB1 AAK1 MCM5

ADAM28 ANXA1 ADAM28 NCALD AHNAK MRPS24

AIM2 ARL4C AIM2 NEK7 ALOX5AP MRPS34

AKAP5 C12orf75 AKAP5 NFAT5 ANAPC15 MUTYH

AP1AR CAMK4 AKAP8L NMB ANXA1 MXD4

ARID5A CD200R1 ANAPC4 NOD2 AP5S1 MYH9

ARNT CD44 AP1AR NOTCH1 APOBEC3G NDUFB9

ATHL1 CD5 AQR NSUN2 ARL4C NEDD8

ATP2C1 COX7A2 ARID5A OPA1 ASF1B NFKBIZ

BCOR DBF4 ARNT ORMDL3 ATG16L2 NR4A3

CADM1 EMP3 ATHL1 OSBPL3 AURKA NUP37

CCL3L3 FAM46C ATM PAPOLA BOLA3 PCK2

DGKD FOSB ATP2C1 PARP11 BUB1 PCNA

DTHD1 GZMH ATXN7L1 PCED1B C12orf75 PDCD5

ETV1 HMGA1 BCOR PCM1 C3orf38 PDE4B

G3BP1 KIAA0101 C17orf59 PDE7B CAMK4 PFDN2

HSPA1B KLRG1 C18orf25 PDGFD CARD16 PHLDA1

ID3 LIME1 CADM1 PDXDC2P CCR5 POLR2K

ITM2A LMNB1 CAV1 PIK3AP1 CCR7 PRDX3

KCNK5 MAB21L3 CCL3L3 PIKFYVE CD200R1 PRPF4

KLRC2 NR4A3 CD200 PJA2 CD44 PRR5L

KLRC3 PCK2 CDC73 PRKCH CD5 PXN

KLRC4 PCNA CEP85L PROSER1 CD97 RDH11

KLRK1 PDCD5 DDX3Y PSTPIP1 CKS1B REX02

LOC220729 PDE4B DDX6 PTPN6 COX7A2 RNASEH2C

LONP2 PFDN2 DGKD PYHIN1 DBF4 RNASEK

LRBA RDH11 DGKH RALGDS DNAJC9 RPUSD3

LYST S100A10 DNAJA2 RCBTB2 DTYMK RTCA

NAB1 S100A4 DTHD1 RGS2 ECE1 S100A10

NMB SAMD3 ELF1 RGS4 ECHS1 S100A4

PAPOLA SPOCK2 ELMOl RHOB ELL S100A6

PDE7B TKT ETNK1 RIN3 EMP3 S1PR1

PIK3AP1 TNF ETV1 RNF19A F2R SAMD3

PRKCH TOB1 FAIM3 RWDD2B FAM46C SELL

PROSER1 TOMM7 FBXW11 S100PBP FAM50B SLIRP

PTPN6 TUBA1C FCRL3 SATB1 FOSB SPOCK2

PYHIN1 UGDH-AS1 FOXN2 SDAD1 FOXP1 STX16

RGS2 G3BP1 SEC24C GMCL1 TANK

RGS4 GALT SERINC3 GNPTAB TKT

S100PBP GFOD1 SFI1 GPR183 TMEM173

SH2D1B GNG4 SH2D1B GTF3C6 TNF

SNAP47 HIF1A SKIV2L GYPC TNFAIP3

SPDYE8P HIST1H2BG SLC30A7 GZMA TNFSF4

SPRY2 HIST2H2BE SLC7A5P1 GZMH TOB1

SYVN1 HSPA1B SLFN11 HAUS4 TOMM5

TACOl HSPB1 SNAP47 HMGA1 TOMM7

THADA ID3 SOD1 HMOX2 TPT1

TP53INP1 IL6ST SPATA13 INSIG1 TUBA1B

TSC22D1 INPP5B SPDYE8P ITM2C TUBA1C

UBA7 INPP5F SPRY2 KIAA0101 TUBB4B

ZMYM2 IRF8 STT3B KLF6 TXN lip/down regulated in expanded T cells compared to turn -expanded T cells. u (expanded) down (expanded) up ) all) dowr • fall)

ITM2A SYVN1 KLRB1 UBE2Q2P3

KCNK5 TACOl KLRG1 UCHL3

KDM4C TBC1D23 LEF1 UGDH-AS1

KLRC2 TBC1D4 LIME1 UQCRB

KLRC3 THADA LMNB1 VIM

KLRC4 TNFRSF9 LTB WBP11

KLRD1 TNIP1 LY6E ZNF683

KLRK1 TP53INP1 MAB21L3

LOC100190986 TRAF5

LOC220729 TSC22D1

LOC374443 TTI2

LONP2 TTTY15

LRBA TXNDC11

LRRC8D UBA7

LSM14A VMA21

LY9 VPRBP

LYST WWC3

MBP ZBED5

MED13 ZMYM2

MGA ZMYM5

MGEA5 ZNF384

MS4A1 ZNF468

MST4 ZNF83

NAA16

Example 2 - Immunotherapy Resistance Signature from 26 Melanoma Tumors

[0424] Applicants performed single-cell RNA-seq on 26 melanoma tumors (12 treatment naive, 14 post immunotherapy) (Figure 17). Applicants discovered that immunotherapy leads to profound transcriptional alterations in both the malignant and immune cells. Applicants also discovered that these transcriptional programs are associated the response to immunotherapy by analyzing prior data sets (Hugo et al. Cell. 2016 Mar 24; 165(l):35-44. doi: 10.1016/j.cell.2016.02.065; and Riaz et al. Nature Genetics 48, 1327-1329 (2016) doi: 10.1038/ng.3677). Applicants also discovered that these transcriptional programs are associated Intra-tumor: heterogeneity, location, and antigen presentation. Applicants explored and characterized the effect immunotherapies have on different cell types within the tumor (i.e., Malignant cells, CD8/CD4 T-cells, B cells and Macrophages). The data includes twenty six samples (14 post immunotherapy, 8 anti-CTLA4 & anti-PD-1, 2 anti-PDl(Nivolumab), 4 anti-CTLA4 (Ipilimumab), and 12 treatment naive (Figure 17).

[0425] Applicants performed principal component analysis on the expression data. The second Principle Component (PC) separates between immunotherapy resistant and untreated tumors (Figure 18). Applicants discovered that treatment is the main source of variation in malignant cells between tumors, reflected by the difference in the score of malignant cells from treatment naive and resistant tumors on the second principle component. [0426] Applicants analyzed the transcriptome of the malignant cells to identify cell states that are associated with immunotherapy. To this end, Applicants identified differentially expressed genes and derived two post-immunotherapy (PIT) modules, consisting of genes that are up (PIT-up) or down (PIT-down) regulated in PIT malignant cells compared to the untreated ones. In comparison to the treatment naive tumors, all the PIT tumors overexpress the PIT-up module and underexpress the PIT-down module, such that there is a spectrum of expression levels also within each patient group and within the malignant cell population of a single tumor (Figure 19). The genes within each module are co-expressed, while the two modules are anti -correlated with each other, not only across tumors but also within the malignant cell population of a single tumor. Additionally, the two modules have heavy and opposite weights in the first principle components of the malignant single-cell expression profiles, indicating that immunotherapy is one of the main sources of inter-tumor heterogeneity in the data.

[0427] Applicants applied down sampling and cross-validation to confirm that the PIT modules are robust and generalizable (Figure 20). More specifically, Applicants repeatedly identified the signatures without accounting for the data of one of the tumors, and showed that the modules were similar to those derived with the full dataset. Furthermore, the modules that were derived based on a training data could still correctly classify the test tumor as either

PIT or treatment naive. The signature is very robust. If Applicants leave out all the malignant cells from a given tumor, recalculate it and then assign the cells, Applicants make only one

"error" when guessing if the tumor is treatment naive or ITR. This one tumor has a particularly high T cell infiltration. These results testify that, while more data and samples will enable us to refine these modules, the resulting modules are not likely to change substantially. The signature is also supported by the mutual exclusive expression of the up and down genes across malignant cells, and their anti -correlation in TCGA (Figure 21).

[0428] Gene set enrichment analysis of the PIT programs highlights well-established immune-evasion mechanisms as the down-regulation of MHC class I antigen presentation machinery and interferon gamma signaling in PIT cells (Table 11). Cells with less MHC -I expression are more resistant to immunotherapy (Figure 22). Additionally, it has been recently shown that melanoma tumors that are resistant to ipilimumab therapy contain genomic defects in IFN-gamma pathway genes, and that the knockdown of IFNGR1 promotes tumor growth and reduces mouse survival in response to anti-CTLA-4 therapy. The

PIT-down program is also enriched with genes involved in coagulation, IL2-STAT5 signaling, TNFa signaling via NFkB, hypoxia, and apoptosis. The PIT-up program is tightly linked to MYC. It is enriched with MYC targets and according to the connectivity map data (c-map) - MYC knockout alone is able to repress the expression of the entire PIT-up signature. Supporting these findings, it has been shown that MYC modulates immune regulatory molecules, such that its inactivation in mouse tumors enhances the antitumor immune response. Interestingly, Applicants find that metalothionines (MTs) are overrepresented in the PIT-down program, and show that their expression alone separates between the PIT and untreated samples (Figure 23). MTs are a family of metal-binding proteins that function as immune modulators and zinc regulators. The secretion of MTs to the extracellular matrix can suppress T-cells and promote T-cell chemotaxis. Interestingly, it has been recently shown that MT2A is a key regulator of CD8 T-cells, such that its inhibition promotes T-cell functionality in the immunosuppressive tumor microenvironment (Singer et al. Cell. 2016 Sep 8; 166(6): 1500-1511). The underexpression of MTs in the malignant cells of post-immunotherapy tumors could potentially be linked to the role of MT2A in T-cells and to the abundance of zinc in the tumor microenvironment.

Table 11. Functional classification of PIT module genes.

Pathway Genes

CTSB, HLA-A, HLA- HLA-E, HLA-F, PSME1, TAP1,

M HC class I antigen presentation machinery

TAPBP

ANXA1, CD9, CFB, CTSB, FN1, ITGB3, LAMP2,

Coagulation PROS1, PRSS23, SERPINE1, SPARC, TF

ATF3, BCL6, BIRC3, CD44, EGR1, GADD45B, GEM,

TNFa signaling via NFkB JUNB, KLF4, KLF6, NR4A1, PDE4B, SERPINE1, TAP1,

TNC

AHNAK, AHR, CCND3, CD44, EMP1, GADD45B,

I L2/STAT5 signaling

IFITM3, IGF1R, ITGA6, KLF6, NFKBIZ, PRNP, RNH1 Metallothioneins MT1E, MT1F, MT1G, MT1M, MUX, MT2A

MYC targets EIF4A1, FBI, HDAC2, ILF2, NCBP1, NOLC1, PABPC1,

PRDX3, RPS3, RUVBL2, SRSF7

[0429] Applicants identified an immunotherapy resistance signature by identifying genes that were up and down regulated in immunotherapy treated subjects as compared to untreated subjects (Table 12, 13). The signature was compared to clinical data of subjects that were complete responders to immunotherapy, partial responders and non-responders. The data was also compared to subjects with high survival and low survival.

Table 12. Analysis of all gene expression data and clinical data

cl i nic. in cl i iiir sc.Hiil <H,i.l iicn -<l. l<'!><i.l ii <-.is<-<l.i'Mi tin- less sc sc. Old scAcw U risk .cells

8.19E-

ANXAl 7.58E-02 01 202.40 -2.44 -200.00 -3.02 FALSE -2.64 -1.37

8.96E-

EMP1 4.92E-01 02 189.84 -20.93 -75.82 -2.58 FALSE 0.69 0.60

4.63E-

TSC22D3 4.26E-01 01 175.14 -13.19 -82.60 -2.43 FALSE -1.52 -0.32

7.81E-

MT2A 4.06E-02 01 174.76 -18.16 -67.52 -4.41 FALSE -2.83 -1.80

5.87E-

CTSB 4.03E-01 01 165.96 -25.70 -112.90 -2.50 FALSE -0.44 0.56

7.74E- 5.621836 165.507

TM4SF1 1.76E-01 01 164.10 397 1875 -1.14 FALSE 0.45 0.32

4.15E-

CDH19 4.35E-02 01 155.59 -3.79 -42.42 -1.53 FALSE -2.24 -1.86

4.96E-

MIA 3.62E-01 01 152.98 -4.22 -60.91 -1.53 FALSE -1.60 -0.91

1.70E-

SERPINE2 2.27E-02 01 151.17 -31.78 -46.03 -1.68 FALSE -3.66 -3.12

4.64E-

SERPINA3 1.43E-01 01 148.25 13.63 -229.59 -1.37 FALSE -2.64 -2.04

2.01E-

S100A6 2.91E-01 01 128.57 -12.30 -49.34 -2.42 FALSE -0.40 -0.47

9.20E- 1.882158 83.8067

ITGA3 3.35E-02 01 123.57 19 0184 -0.97 FALSE -0.51 -0.49

4.71E-

SLC5A3 4.64E-01 01 119.83 1.06 -96.80 -1.71 FALSE -6.19 -4.10

4.38E- 15.73720 30.2916

A2M 3.01E-02 01 118.06 409 1959 -1.07 FALSE -2.81 -1.47

4.22E-

MFI2 3.67E-01 01 117.29 -3.06 -44.01 -1.41 FALSE 0.46 0.38

2.24E-

CSPG4 7.50E-01 01 112.90 -5.56 -30.13 -1.87 FALSE -1.60 -1.41

7.09E-

AHNAK 5.70E-02 01 112.83 -12.69 -13.16 -2.03 FALSE -0.45 -0.38

1.57E- 4.108007 92.3401

APOC2 6.76E-01 01 111.01 818 2794 -0.52 FALSE -0.55 0.51

3.79E-

ITGB3 1.66E-01 01 110.25 0.79 -109.99 -1.75 FALSE -2.25 -1.42

6.63E-

NNMT 4.47E-01 01 110.12 -1.62 -122.65 -2.51 FALSE -2.28 -0.87

4.92E-

ATP1A1 2.34E-01 01 107.58 -19.25 -26.63 -1.40 FALSE 0.52 0.30

9.69E- 2.022007 74.1899

SEMA3B 8.03E-02 01 106.75 432 8319 -1.06 FALSE -1.65 -1.08

7.57E-

CD59 3.34E-02 01 101.92 -16.59 -40.13 -1.86 FALSE -1.71 -0.90

9.58E- 2.618926 123.085

PERP 1.03E-01 01 -99.65 27 1115 -1.13 FALSE 0.78 -0.77

8.54E-

EGR1 1.98E-01 01 -96.70 -1.43 -25.74 -1.30 FALSE -0.80 0.30

6.41E- 57.79606 1.17499

LGALS3 2.66E-01 01 -96.06 403 1366 -1.19 FALSE -0.42 -0.50

2.65E- 0.615403 34.7461

SLC26A2 1.86E-01 01 -95.69 346 3485 -0.92 FALSE -3.62 -2.73

5.72E-

CRYAB 2.26E-02 01 -94.74 0.85 -139.66 -1.89 FALSE -0.84 -0.63

9.62E-

HLA-F 4.70E-02 01 -94.42 -12.84 -23.07 -1.82 FALSE -4.49 -1.03 clinic. U. m . . sc. Bill Irj-a. lucre,! scil. Uj>a. Increased. risk ore less si-.All -.Okl st.Now k '.IJ.Kl risk .beyond.T.cells

02 465 3996

2.26E- 9.995109 0.58923

AIMP2 1.98E-01 01 14.54 565 4557 0.68 FALSE 3.46 1.01

1.21E- 0.524094 17.2621

SUPT5H 7.15E-01 01 14.56 651 3471 0.54 FALSE 2.66 1.82

9.71E- 25.61569 8.58471

POSTN 2.42E-01 02 14.57 592 8074 0.72 FALSE 0.46 0.73

1.69E- 0.403995 5.92699

GTF2H2C 6.04E-01 01 14.58 243 8115 2.48 FALSE -1.77 -1.09

4.02E- 3.602849 4.80721

GNL3 3.37E-01 01 14.61 144 8992 0.66 FALSE -1.34 -1.91

2.58E- 3.050038 8.16550

GBAS 2.19E-01 01 14.62 089 5882 1.17 FALSE -1.66 -2.61

1.23E- 26.73500 1.52135

MEST 4.42E-01 01 14.64 059 4639 0.45 FALSE 0.43 0.43

4.14E- 4.060021 27.3758

CDH3 6.93E-02 02 14.67 324 8719 0.38 FALSE 3.88 3.59

1.16E- 3.793428 7.78082

PLEKH|1 5.88E-01 01 14.68 817 4818 0.33 FALSE 0.67 0.70

2.20E- 1.041998 13.0804

ECHS1 1.07E-01 01 14.72 674 2231 1.96 FALSE 2.27 1.81

3.24E- 11.23157 20.3450

SLC45A2 4.80E-01 02 14.73 773 5987 1.51 FALSE 2.62 2.58

1.52E- 11.86664 10.8669

NEUROD1 5.30E-01 01 14.75 298 9078 0.69 FALSE -0.77 -1.69

2.17E- 0.616928 16.2420

ACTR1A 2.03E-01 02 14.76 184 2821 0.49 FALSE 3.57 3.89

2.06E- 1.079125 1.07939

CD24 2.14E-01 01 14.78 614 1239 0.79 FALSE 0.64 1.79

LOC38879 0.443428 8.56270

6 Inf Inf 14.79 997 6973 -0.46 FALSE 1.60 0.61

4.34E- 4.913073 0.75366

CDC20 5.51E-01 02 14.80 148 6063 0.63 FALSE 2.89 2.24

1.30E- 5.327916 0.74437

TPI1 4.34E-01 01 14.82 572 8475 0.77 TRUE 3.41 1.46

2.28E- 16.26533 1.95820

NOC2L 6.32E-01 01 14.83 11 0998 1.14 TRUE 1.46 0.80

5.42E- 2.622835 9.47306

CHCHD1 1.48E-01 03 14.88 248 062 0.94 FALSE 0.45 0.40

3.31E- 0.922296 19.4401

ALDH1B1 6.57E-01 01 14.98 057 6174 2.22 FALSE 0.94 0.33

1.32E- 10.15717 2.44653

NTHL1 3.95E-01 01 15.01 558 6902 1.34 FALSE 1.35 0.87

5.11E- 4.873224 0.30197

RARRES2 2.25E-01 01 15.05 671 6127 0.91 FALSE -1.43 -0.37

1.85E- 1.806177 12.4270

SLC25A44 2.69E-01 01 15.12 902 7653 0.82 FALSE 2.81 2.10

3.29E- 0.508216 14.9260

ECD 3.16E-02 01 15.16 518 2402 1.10 FALSE -0.56 -0.81

9.99E- 4.540031 6.49273

ACBD6 4.72E-01 02 15.18 42 1101 0.49 FALSE 1.54 -0.33

5.48E- 4.926437 1.29370

AURKA 4.90E-01 03 15.18 071 898 1.38 FALSE 1.99 1.32

3.22E- 7.873906 2.41451

PRMT1 5.78E-01 01 15.18 75 4677 0.56 FALSE 1.52 0.88

4.07E- 0.754171 3.35276

GNB2L1 3.13E-02 01 15.22 752 588 0.35 TRUE 0.40 -0.33

5.50E- 16.83196 1.22189

TOMM5 2.75E-01 02 15.24 592 3499 1.00 FALSE 1.00 -0.31

1.95E- 15.00145 3.09428

SNRPF 2.17E-01 01 15.27 479 1947 0.67 FALSE 1.20 0.60

7.18E- 24.8128

KLHL9 1.47E-01 01 15.27 0.397375 9951 0.85 FALSE -1.85 -1.54 R. in clink .R. tcga.Incrcascd.ri.sk

.All .Olil sc.Ncw k risk .bcyond.T.cclls

031

4.75E- 2.320398 3.78227

RNPSl 1.42E-01 01 15.29 903 1567 1.76 FALSE 1.11 0.72

3.71E- 2.178512 26.4170

RPL36 5.72E-02 01 15.33 724 9158 -0.33 FALSE 0.50 0.33

2.68E- 12.13755 0.76179

SLC25A11 6.01E-01 01 15.38 268 644 0.69 FALSE 1.65 1.15

1.03E- 3.097761 7.76264

FDPS 3.64E-01 01 15.41 019 8036 0.62 FALSE 4.01 2.54

1.22E- 9.218191 2.29874

PRPSAP2 4.16E-01 01 15.41 038 1055 1.45 FALSE -0.83 -1.15

3.37E- 5.352399 1.24736

HAUS1 2.26E-01 01 15.43 583 9224 0.96 FALSE -1.42 -1.32

8.81E- 13.15051 22.8032

P0LR2A 2.03E-01 01 15.51 816 9056 2.32 FALSE 4.89 3.89

3.25E- 6.013013 1.03069

TDG 9.85E-01 02 15.51 072 4741 1.73 FALSE -0.62 -0.69

2.30E- 4.254455 6.34470

EGLN2 1.62E-01 01 15.51 956 7044 1.09 FALSE 1.99 2.30

1.06E- 5.285026 0.30704

CDCA5 5.88E-01 01 15.53 282 5502 0.82 FALSE 1.49 1.03

1.23E- 8.293233 0.58456

EIF2S2 6.74E-01 02 15.55 204 1792 0.79 FALSE -1.33 -2.61

5.28E- 2.448860 6.78446

CACYBP 5.67E-01 02 15.56 208 5091 1.43 FALSE -0.90 -1.21

3.03E- 11.70143 1.10512

TOMM22 5.29E-01 03 15.57 787 845 1.41 FALSE 1.63 0.57

1.68E- 0.524584 13.6220

GLUL 4.19E-01 01 15.60 718 7707 0.68 FALSE -1.32 0.33

5.18E- 4.991817 6.63982

KPNA2 2.93E-01 03 15.60 798 0973 0.58 FALSE 3.86 3.97

5.56E- 0.783473 2.04871

GTF2E1 2.03E-01 01 15.64 28 9802 1.04 FALSE -1.63 -1.64

8.43E- 1.516171 5.78048

LINC00665 1.28E-01 01 15.74 688 6589 1.43 FALSE NA NA

1.64E- 3.244718 7.16795

TARS2 4.95E-01 01 15.74 053 3196 1.02 FALSE 2.01 1.13

4.57E- 5.395171 2.00074

ZSWIM7 4.97E-01 01 15.77 027 9052 0.66 FALSE -0.62 -1.46

4.71E- 0.748477 8.22009

SPDYE5 2.06E-01 01 15.80 234 067 1.06 FALSE -0.85 -0.64

1.59E- 4.470623 2.25169

LSM4 6.34E-01 01 15.82 28 3195 0.39 FALSE 3.16 1.48

5.72E- 0.696709 7.75093

MYL9 4.21E-01 02 15.88 556 8059 0.63 FALSE 0.83 0.90

7.46E- 2.737412 3.55705

ATP5B 4.63E-01 02 15.89 219 0178 1.66 FALSE 3.60 1.19

4.95E- 6.172391 3.48462

RGS3 2.55E-01 01 15.91 972 9082 -0.38 FALSE -0.57 0.57

8.77E- 10.10615 5.69056

CHTOP 6.15E-01 02 15.91 811 281 0.97 FALSE NA NA

6.60E- 5.209483 11.9910

SMG7 5.02E-01 03 15.93 431 1659 2.02 FALSE 1.66 1.06

1.88E- 14.28593 0.67422

EIF3J 2.68E-01 01 16.00 134 3072 0.92 FALSE -2.31 -3.82

2.904335 2.48840

MGC2752 Inf Inf 16.00 761 784 0.80 FALSE 1.05 0.69

5.38E- 0.837075 10.5175

PAM 3.98E-01 03 16.04 37 5539 0.48 FALSE -0.65 -0.55

5.15E- 1.337030 62.1927

GSTOl 6.07E-02 01 16.05 558 9211 0.95 FALSE 1.72 0.92

1.42E- 21.29284 4.65628

RABEP1 8.74E-01 01 16.06 48 2388 0.49 FALSE -0.59 -0.83

4.29E- 6.859855 1.85427

K1F2C 7.82E-01 02 16.11 363 0407 0.97 FALSE 2.25 1.77

2.26E- 3.919230 0.97304

CCNB2 2.81E-01 01 16.12 216 1322 0.76 FALSE 1.37 0.69 rliiii .ll.in iiiicll. sr.Riil li na.lncr<'.is<'<l. tcga.Iiicreu.sctl. risk ore less « ^■ .ΛΙΙ sc-.OUl sc.Now k '.lJ.Ul risk .beyoml.T.cells

01 01 1044

2.28E- 5.585866 14.8464

SLC19A1 5.55E-01 01 17.15 639 6384 0.81 FALSE 2.13 2.18

2.36E- 17.96014 14.6809

GAGE12J 1.82E-01 01 17.16 408 6465 0.33 FALSE -1.39 -2.77

2.52E- 5.354814 28.5171

OCA2 1.40E-01 02 17.16 935 977 1.11 FALSE 5.56 3.33

1.59E- 7.902170 3.95826

BBP4 8.19E-01 01 17.17 54 2309 1.72 FALSE -0.54 0.47

4.29E- 7.740805 3.79024

NIP7 1.48E-01 01 17.34 625 9229 0.73 FALSE 0.63 -0.54

4.74E- 3.746194 5.15393

PRPF31 6.36E-01 01 17.37 298 4765 0.79 FALSE 1.42 0.91

4.41E- 5.342737 3.95036

MKI67IP 4.95E-01 01 17.46 904 9618 0.74 FALSE -0.37 -1.42

7.54E- 4.615751 4.89377

TRUB2 7.07E-01 02 17.48 42 5965 2.04 FALSE 2.77 1.68

4.85E- 3.105289 5.77183

METTL13 3.47E-01 02 17.49 5 743 0.61 FALSE 2.17 1.65

2.08E- 6.146315 2.06010

HMGB1 3.33E-01 01 17.50 189 4614 0.82 FALSE -1.52 -1.07

2.04E- 6.917331 3.98125

RCC1 6.07E-01 01 17.52 724 4561 0.87 FALSE 3.62 1.69

4.21E- 5.961074 5.61797

RPA1 3.28E-01 01 17.53 344 7147 1.25 FALSE 1.36 1.23

2.70E- 0.680339 16.4264

HNRNPUL1 1.01E-01 01 17.55 536 6971 0.56 FALSE 3.18 3.24

2.61E- 2.992981 18.7577

NDUFV3 4.85E-01 01 17.56 728 1812 1.14 FALSE 2.18 2.14

1.40E- 2.435033 2.12079

RQCD1 7.06E-01 01 17.57 782 1626 -0.41 FALSE 1.93 1.80

1.16E- 9.236103 2.67978

TCF4 3.80E-01 01 17.62 162 4236 0.53 FALSE -1.45 -0.68

4.60E- 7.631118 10.6194

C20orf27 4.98E-01 01 17.62 695 9581 0.86 FALSE 3.11 2.07

9.10E- 2.170402 6.39931

CCT4 3.45E-01 02 17.65 339 7541 2.01 FALSE 0.42 -0.48

3.30E- 0.335449 37.0197

VPS53 1.15E-01 01 17.69 031 0924 1.02 FALSE 5.99 4.71

4.31E- 8.702406 1.72587

WDR46 2.26E-01 01 17.76 207 4114 1.39 FALSE 1.37 0.53

2.22E- 11.97364 5.92116

NEFL 7.01E-01 02 17.76 126 5572 0.60 FALSE 1.26 0.51

7.29E- 0.459042 4.03801

TCEA3 8.40E-01 02 17.83 162 4366 1.40 FALSE 0.52 -0.40 l.OOE+0 16.08931 14.7586

GAGE6 1.00E+00 0 17.86 781 0399 0.66 FALSE NA NA

6.34E- 1.976498 20.9818

GALT 1.33E-01 01 17.87 Oil 5221 2.04 FALSE -0.54 0.38

5.60E- 8.554249 4.94873

SNRNP40 8.89E-01 02 17.90 159 4856 0.85 FALSE 0.87 1.24

1.99E- 3.670575 7.55391

CRK 8.58E-01 01 17.94 611 113 0.91 FALSE 0.87 0.76

2.97E- 4.387265 23.9081

GNL3L 5.40E-01 01 17.96 453 4734 1.25 FALSE 2.02 2.37

7.74E- 4.131933 3.64760

NUF2 7.59E-01 02 17.97 124 7035 1.05 FALSE -0.49 -0.70

9.95E- 2.380561 2.91478

SERPINB9 2.32E-01 02 17.99 98 6989 1.08 FALSE -1.77 -0.41

4.84E- 5.938605 19.4299

ZFP36L1 1.21E-01 01 18.01 734 0388 1.51 FALSE -0.55 0.31

1.72E- 4.542140 7.77927

MRPS2 3.15E-02 01 18.02 417 5401 2.47 FALSE 6.06 4.32

2.86E- 6.800958 30.6559

NENF 7.99E-01 01 18.04 187 8274 1.02 FALSE 1.98 0.56 R. in cl ink .R. (CKii tcga.Incrcascd.ri.sk Irss .All .Olil sc.Ncw k risk .bcyond.T.cclls

2.93E- 3.468611 6.13291

DUSP12 8.17E-01 01 18.14 254 7887 1.25 FALSE -0.48 -1.03

8.71E- 0.598011 3.40798

FL[30403 7.61E-02 01 18.15 003 8308 1.44 FALSE NA NA

1.70E- 5.445008 9.91907

APEX1 7.41E-02 01 18.19 003 6697 0.96 FALSE -0.31 -0.60

4.64E- 2.387450 4.82254

NUP62 5.48E-01 01 18.22 184 016 1.22 FALSE 1.90 3.41

4.36E- 13.82195 2.61593

LYPLA2 4.25E-01 01 18.23 911 9526 1.18 FALSE 1.38 0.79

6.12E- 0.985759 7.45131

EEF1D 3.44E-01 01 18.28 893 1433 1.02 FALSE -0.45 1.00

1.35E- 7.435248 0.35607

ABCF1 4.22E-01 01 18.31 233 0614 1.34 FALSE 3.23 2.37

3.45E- 0.456404 23.7208

S AP2 2.81E-01 01 18.37 247 6612 0.76 TRUE -5.45 -3.16

3.04E- 4.308701 7.88118

GPS2 6.67E-01 01 18.40 037 5647 0.55 FALSE 0.87 -0.37

1.16E- 3.411530 7.83545

SNRPA 2.81E-01 01 18.50 561 4232 1.66 FALSE 1.41 1.64

2.38E- 21.15658 0.55411

SNRPD1 5.32E-01 02 18.60 975 3785 0.82 TRUE 0.74 -0.30

3.63E- 8.495360 6.72771

NR2F6 5.66E-01 01 18.64 144 0363 1.64 FALSE 3.63 2.14

4.30E- 0.535373 30.6857

IMPDH2 7.55E-02 01 18.71 592 4445 1.02 FALSE 1.81 1.03

1.04E- 8.390998 3.11400

PSMC4 9.11E-01 01 18.73 517 1291 0.46 FALSE 1.33 0.75

7.52E- 4.862310 33.4728

GPM6B 3.21E-01 01 18.77 428 9854 0.32 FALSE -0.57 -1.24

3.43E- 16.92686 0.33193

SNRPE 7.55E-01 02 18.80 645 7635 0.74 TRUE 1.03 -0.49

1.92E- 14.90230 0.46335

ASS1 4.62E-01 01 18.80 724 7928 0.85 FALSE 0.92 1.15

6.96E- 10.70469 15.0156

SF3B2 2.20E-01 01 18.81 624 9271 0.94 FALSE -0.31 -0.94

6.10E- 7.522230 12.7278

NDST1 3.03E-01 02 18.82 908 3941 0.34 FALSE 2.20 2.95

4.82E- 12.59107 10.0007

RBM4 5.21E-01 01 18.84 638 1396 1.52 FALSE 0.55 0.52

8.95E- 37.92813 8.20048

SERPINH1 9.28E-01 03 18.85 3 5704 0.49 FALSE 0.99 0.91

2.16E- 12.31936 4.52201

RBP1 8.03E-01 01 18.86 246 5287 -0.31 FALSE 0.36 -0.37

2.85E- 12.77799 2.97447

SCOl 8.30E-01 01 18.86 115 8737 0.72 FALSE 0.54 -0.48

1.55E- 0.538124 16.5852

RAB20 7.25E-01 01 18.87 767 5585 1.08 FALSE -0.59 1.11

4.25E- 5.991748 0.81829

CRABP2 4.46E-01 02 18.88 766 6256 0.73 FALSE 2.76 1.86

1.81E- 9.869762 0.85916

AURKB 5.17E-01 02 18.88 355 5871 0.75 FALSE 2.28 1.41

3.03E- 3.150239 6.14026

DCTN5 1.03E-01 01 18.90 057 7676 1.32 FALSE 1.98 1.58

2.17E- 2.322155 4.86595

POLD1 4.07E-01 01 18.90 697 6872 0.55 FALSE 1.04 1.35

3.68E- 24.95069 0.41050

ENY2 6.49E-01 01 18.91 297 8403 1.77 FALSE -1.25 -1.00

3.13E- 3.706877 9.48829

QARS 4.42E-02 01 18.96 301 2408 2.20 FALSE 2.33 1.73

1.59E- 2.138074 7.06162

TOP1MT 7.94E-01 01 19.00 483 2399 1.01 FALSE 0.46 -0.34

1.02E- 12.07276 5.75865

MPDU1 2.78E-01 01 19.02 379 2693 1.46 FALSE 2.19 2.00

2.89E- 2.200475 26.6551

SMC3 1.43E-01 01 19.04 748 6067 1.37 FALSE -1.26 -1.19 dink. R. in clinic. K. si [Iiil n .liicic.isi'd. ttga.Incroascd.ri.sk Irs.s sc.All sc.Olil k risk Jjcyond.T.cell

7.38E- 0.454680 11.4742

DTD2 7.61E-02 01 19.06 038 5732 1.86 FALSE NA NA

6.67E- 6.785825 2.25200

TATDN1 1.17E-01 01 19.10 964 4297 1.28 FALSE -2.97 -3.70

3.72E- 7.938348 5.09044

UQCRC2 2.53E-02 01 19.12 231 0135 0.94 FALSE 0.45 -0.44

2.11E- 0.301420 11.7773

RPP30 1.91E-01 01 19.13 634 3863 1.87 FALSE -0.60 -1.17

2.97E- 15.77144 13.4473

ATXN10 6.94E-01 01 19.14 524 554 2.30 FALSE 0.57 -0.50

8.16E- 1.702392 25.9390

WDR81 9.64E-02 01 19.17 177 4876 1.27 FALSE 2.80 2.13

2.73E- 4.936443 11.4957

PEPD 5.58E-01 01 19.18 511 8245 1.14 FALSE 2.63 1.77

4.80E- 17.70105 15.3573

GAGE2B 2.57E-01 01 19.18 474 6178 0.61 FALSE -0.98 -2.19

2.62E- 8.650445 5.65384

FEN1 1.07E-01 01 19.24 933 7713 0.63 FALSE 1.14 0.66

1.66E- 5.930175 5.31161

MRPS12 5.69E-01 01 19.31 903 9169 1.32 FALSE 2.84 1.58

5.52E- 10.29840 1.10843

FKBP4 6.18E-01 02 19.36 259 4516 1.06 FALSE 3.95 2.47

3.19E- 5.938125 9.87863

ALAS1 5.54E-01 02 19.38 987 5076 1.06 FALSE 1.02 1.71

1.89E- 0.678639 18.4124

DPP9 1.83E-01 01 19.42 926 4692 0.58 FALSE 2.05 1.88

2.82E- 12.02634 3.28783

ELAC2 5.97E-01 01 19.45 776 9364 0.85 FALSE 3.04 1.34

5.10E- 15.48074 4.43365

RPS21 3.21E-01 02 19.59 181 2949 0.81 FALSE -0.61 -0.82

8.26E- 15.88253 0.54156

HYPK 9.14E-02 02 19.62 495 1047 0.94 TRUE NA NA

4.66E- 2.641838 14.1049

THEM4 3.55E-01 01 19.63 036 993 1.04 FALSE 0.60 -0.35

1.25E- 0.570380 4.96539

NXN 9.91E-01 02 19.72 212 098 0.91 FALSE 0.84 1.70

6.70E- 1.706300 19.3613

ABR 3.48E-01 01 19.73 196 9174 0.77 FALSE 2.16 1.33

2.45E- 5.495581 7.54473

DARS 3.52E-01 01 19.76 21 926 1.48 FALSE -1.49 -3.22

6.76E- 3.601301 82.1749

KCNAB2 6.30E-02 01 19.79 043 82 1.14 FALSE 1.31 1.95

1.92E- 4.885093 2.57669

NUSAP1 1.31E-01 01 19.90 685 1979 0.97 FALSE 0.59 0.37

6.99E- 8.770091 2.09821

ST0ML2 3.74E-01 02 20.04 625 2208 1.02 FALSE 0.98 0.41

4.05E- 4.271010 1.77593

T0P2A 7.94E-01 02 20.04 52 0792 1.05 FALSE 0.51 0.43

4.00E- 6.644441 3.72007

INTS7 8.16E-01 02 20.23 6 6088 0.79 FALSE 0.71 0.87

1.24E- 17.64876 2.07063

MFAP4 2.69E-01 01 20.27 071 2726 1.07 FALSE 0.53 2.01

6.15E- 10.61246 11.6747

MYADM 1.93E-01 01 20.29 616 5742 1.39 FALSE 0.56 0.81

1.79E- 1.698797 13.4863

P0LR3C 8.17E-01 01 20.29 211 1224 1.26 FALSE 2.24 0.39

3.08E- 0.321055 42.3874

0XA1L 1.12E-02 01 20.35 708 6933 2.14 FALSE 1.48 0.84

1.43E- 4.607755 2.11199

RRP15 6.36E-01 01 20.36 076 0874 0.77 FALSE -0.71 -2.44

5.14E- 0.472735 48.1546

GAS5 1.29E-01 01 20.37 128 2574 0.76 FALSE 0.36 -0.61

1.36E- 6.749846 4.09002

HMGN1 6.43E-01 01 20.39 284 5383 2.61 FALSE -1.19 -0.56 clinic. U. . . sc. Bill Irj-a. lucre,! scil. Uj>a. Increased. risk ore less -.Λ1Ι -.Okl st.Now k '.IJ.Kl risk .beyond.T.cells

2.77E- 3.988960 2.58911

BIRC5 4.62E-01 01 20.53 147 6396 0.84 FALSE 2.08 1.65

3.28E- 5.416078 2.17649

NEK2 8.14E-01 02 20.55 429 1052 1.71 FALSE 1.32 0.82

1.39E- 10.21643 1.58067

RRS1 8.28E-01 01 20.58 123 3648 0.47 FALSE 0.67 0.47

2.16E- 1.771526 8.36898

PPP5C 4.71E-01 01 20.62 742 8743 0.76 FALSE 1.43 0.61

8.71E- 1.972299 13.3833

ARPC5 1.89E-01 02 20.70 705 9241 1.47 FALSE -3.00 -2.34

7.69E- 8.747393 9.67767

TMEM206 3.87E-01 02 20.75 842 2637 2.21 FALSE 0.45 -0.31

9.02E- 20.72965 14.0070

GAGE4 9.87E-02 01 20.76 183 9129 0.42 FALSE -1.23 -2.28

8.77E- 12.05217 6.93482

EML4 9.25E-01 02 20.79 543 5832 1.60 FALSE -0.36 0.76

3.47E- 8.113534 5.66234

NT5DC2 1.03E-01 02 20.89 256 2879 0.87 FALSE 4.32 1.93

2.28E- 18.51606 13.9733

GAGE12H 6.82E-01 01 20.99 224 8677 0.70 FALSE NA NA

1.03E- 5.497595 1.67997

PA2G4 1.68E-01 01 21.05 07 1385 1.66 FALSE 3.15 1.29

LOC10013 3.78E- 3.452678 36.5509

3445 5.36E-01 01 21.09 468 2064 0.98 FALSE NA NA

5.40E- 3.042468 2.54502

RRM2 4.18E-01 02 21.19 097 9055 0.55 FALSE 0.92 0.82

3.59E- 20.08829 14.2805

GAGE2D 8.73E-03 01 21.20 393 9448 0.62 FALSE -1.16 -2.67

4.07E- 5.975779 6.14648

MRPL9 8.73E-01 03 21.35 42 4827 1.12 FALSE 2.40 1.13

1.35E- 20.12015 1.01846

TMEM11 4.08E-01 01 21.40 326 9789 0.89 FALSE 2.30 0.92

6.94E- 8.611761 10.1410

TPM4 2.84E-01 02 21.55 357 9291 -0.31 FALSE -0.32 -0.56

7.18E- 0.451092 19.1285

ESRG 1.86E-01 01 21.56 433 2841 1.43 FALSE NA NA

6.97E- 2.102500 13.0975

SLC25A5 1.55E-01 02 21.57 624 1618 0.79 FALSE 1.48 1.20

6.21E- 1.084958 22.7515

CYP51A1 2.25E-01 01 21.57 837 9578 0.35 FALSE 0.48 -0.53

7.92E- 1.441369 22.2980

TBXA2R 7.68E-01 02 21.58 813 5571 1.63 FALSE -0.58 -0.43

LOC10012 25.17189 14.0963

8252 Inf Inf 21.59 358 2693 0.36 FALSE NA NA

9.62E- 5.316547 9.93793

SKA2 8.87E-01 02 21.67 277 0469 1.05 FALSE -0.60 0.37

3.03E- 1.660172 20.8932

RUSC1 4.21E-02 01 21.75 441 2619 0.95 FALSE 2.59 1.08

3.55E- 1.750472 11.7213

PSTPIP2 5.69E-01 01 21.76 311 1361 1.49 FALSE -2.63 0.44

9.29E- 6.221082 20.6117

LMCD1 1.57E-01 01 21.91 642 2886 2.05 FALSE -0.68 -0.33

8.93E- 5.327664 21.5501

TIMM23 6.53E-03 02 21.92 989 0632 2.07 FALSE NA NA

9.12E- 7.661886 16.6734

NARS2 5.28E-01 02 21.93 481 0475 1.86 FALSE 2.52 0.96

3.63E- 4.999612 3.18913

STRAP 6.79E-01 01 21.97 565 343 1.85 FALSE 2.08 0.65

2.58E- 10.20245 3.78386

XRCC5 7.17E-01 01 22.00 23 2242 2.03 FALSE 0.45 -0.49

6.07E- 3.623195 11.3778

EEF1G 4.35E-03 01 22.24 074 5233 0.69 FALSE 0.57 0.44

FLAD1 2.73E-01 9.01E- 22.24 9.115959 4.88990 1.14 FALSE 5.30 3.34 clink . R. in ilinii.R. sc.Iiiil lcj-.i.lncrciscil. tcga.Incroiiscd.ri.sk ore l ss st-.All -.Okl sc.Now k risk .bcyond.T.cclls

02 046 0661

7.54E- 1.506889 32.2419

PRDX3 1.28E-01 01 22.26 444 1804 1.77 FALSE -2.28 -1.43

2.55E- 20.18764 14.8056

GAGE2E 1.19E-01 01 22.36 216 0626 0.69 FALSE -1.21 -2.41

5.85E- 0.633889 43.1529

TUBGCP2 1.31E-01 02 22.66 067 1198 0.99 FALSE 0.85 1.13

1.58E- 0.700919 7.21907

ORC6 7.21E-01 01 22.71 811 4042 1.94 FALSE NA NA

1.69E- 21.55374 14.0475

GAGE12G 4.76E-01 01 22.73 302 5971 0.65 FALSE NA NA

9.76E- 4.022382 28.1798

TSTD1 3.33E-02 01 22.77 197 6342 0.77 FALSE -1.68 -0.68

6.52E- 22.08978 14.2987

GAGE12E 8.00E-01 01 22.80 66 637 0.63 FALSE NA NA

4.14E- 22.08782 14.3028

GAGE12C 6.13E-01 01 22.81 445 4956 0.63 FALSE NA NA

1.32E- 5.832178 12.6509

NOP56 2.92E-01 01 22.85 979 4704 0.93 FALSE 1.58 0.68

HNRNPA1P 2.94E- 10.61174 6.92785

10 4.99E-01 01 22.87 151 4056 1.18 FALSE NA NA

6.95E- 11.05089 0.79095

H3F3AP4 3.96E-01 01 22.91 081 3059 1.18 FALSE NA NA

2.20E- 15.61796 10.1284

ALDH18A1 3.46E-01 02 22.94 755 6167 0.91 FALSE 1.76 1.87

5.05E- 12.03860 3.77552

HN1 1.94E-01 02 23.04 552 5297 0.96 FALSE 1.78 1.68

3.38E- 34.54741 19.2357

CPXM1 5.09E-01 02 23.05 553 018 0.59 FALSE 2.24 1.64

2.53E- 2.112698 36.8658

SEMA6A 2.72E-01 01 23.06 771 6147 0.89 FALSE 5.02 3.59

1.21E- 0.705496 32.7770

PLTP 1.26E-01 01 23.23 057 504 -0.35 FALSE 0.93 1.16

7.78E- 2.243806 26.6341

NAPRT1 1.05E-01 01 23.49 067 8143 1.37 TRUE 0.57 0.58

5.25E- 4.938813 18.9944

CPSF1 4.77E-01 01 23.53 475 5597 2.32 FALSE 0.49 1.64

2.03E- 3.787914 14.6604

BUB3 5.98E-03 01 23.57 349 4954 0.94 FALSE -0.59 -0.47

1.09E- 24.77150 1.06162

RGS16 7.20E-01 01 23.66 312 3763 0.59 FALSE -1.88 -0.96

6.89E- 3.422504 5.08900

AFMID 4.63E-01 01 23.73 125 0714 1.48 FALSE 0.59 -0.43

3.81E- 3.232954 13.3560

SSR2 8.95E-01 02 23.74 04 7135 0.81 FALSE 1.29 0.98

3.96E- 10.75636 2.52781

NDUFAF6 1.88E-01 01 23.75 07 3066 1.97 FALSE NA NA

1.51E- 0.434598 25.1751

HSD17B14 6.74E-01 01 23.76 607 0233 1.72 FALSE 1.16 1.55

1.16E- 28.39313 5.63330

GPC3 5.12E-01 02 23.81 231 805 1.17 TRUE 1.77 1.50

1.70E- 1.192883 16.0990

PGAM1 1.41E-01 01 23.81 052 166 0.93 FALSE 2.85 2.14

7.76E- 16.56262 4.40464

C16orf88 7.89E-01 02 23.89 336 8103 2.01 FALSE 2.80 0.95

1.41E- 4.649573 15.3472

MSTOl 6.69E-01 01 23.89 196 1826 2.10 FALSE 2.66 2.24

3.22E- 3.151005 16.3785

TSTA3 3.55E-01 01 23.94 81 3925 2.68 FALSE 1.80 2.04

5.08E- 1.815656 18.6483

UBAP2L 1.55E-01 01 23.97 305 2265 1.97 FALSE 5.67 2.94

5.96E- 3.577483 22.4333

Clorfl98 9.00E-01 04 24.06 523 289 0.58 FALSE 0.91 0.42 rliiii .ll.in iiiicll. sr.Riil li na.lncr<'.is<'<l. tcga.Iiicreu.sctl. risk

S ore less « ^■ .ΛΙΙ sc-.OUl sc.Now k '.lJ.Ul risk .beyoml.T.cells

02 625 6832

7.35E- 4.191072 36.2446

PPAl 1.68E-02 01 34.57 237 0964 1.33 FALSE -3.57 -1.51

3.11E- 23.72211 8.65559

THOC5 4.22E-01 01 34.76 148 4417 1.61 FALSE 0.56 -0.39

4.46E- 5.935951 29.6830

NF2 2.21E-01 01 35.44 855 3947 1.87 FALSE 3.24 2.59

3.36E- 10.57117 7.55438

SMS 3.48E-01 01 35.45 775 5933 3.53 FALSE 0.82 0.45

8.98E- 1.393466 26.7190

MA CKS 2.18E-01 01 35.55 011 5725 0.42 TRUE -0.60 -0.35

4.37E- 18.29374 70.9018

TRPM1 2.73E-02 01 35.72 495 7013 0.92 TRUE 3.10 2.37

3.71E- 6.395271 19.8959

RPL10A 4.87E-02 01 35.75 832 5719 1.43 FALSE 0.56 0.44

5.06E- 10.23638 8.32018

LYPLA1 3.39E-01 01 36.15 354 4641 1.87 FALSE -2.44 -1.87

3.43E- 4.637441 24.8528

FBL 5.03E-01 01 36.53 097 6255 1.35 FALSE 2.64 1.65

4.19E- 14.14241 2.76828

ZNF286A 9.41E-01 02 36.53 98 4631 1.36 FALSE -0.47 -0.77

1.46E- 2.122873 9.29510

LIMD2 5.49E-01 01 36.60 767 2203 1.17 FALSE -0.75 2.94

8.43E- 3.566475 21.1174

TULP4 2.15E-01 02 36.72 392 1429 1.35 FALSE 0.87 1.16

2.65E- 13.78610 7.02180

TIMM13 5.36E-01 01 37.26 742 3959 0.77 FALSE 2.20 1.24

1.47E- 20.39074 4.48494

RPAIN 5.60E-01 01 37.35 062 7614 1.21 FALSE -0.81 -1.76

2.16E- 2.249744 18.8675

RBM34 3.24E-01 01 37.89 298 2144 2.58 FALSE -1.41 -2.72

5.00E- 10.57704 15.4687

AHCY 3.78E-01 02 38.02 66 9045 2.09 FALSE 2.49 1.19

1.52E- 44.02874 1.88444

MLLT11 9.77E-01 02 38.08 412 4301 0.56 TRUE 0.76 0.55

2.83E- 29.53471 4.32435

MYBBP1A 6.00E-01 01 38.23 619 2219 1.57 FALSE 2.43 1.71

2.42E- 14.49457 12.6910

AEN 5.21E-02 01 38.35 588 7053 2.30 FALSE 3.38 2.32

3.31E- 14.93519 7.65022

TRIM28 3.81E-01 01 38.48 938 211 1.28 FALSE 2.93 2.05

2.92E- 8.507240 23.2024

N0LC1 2.47E-02 01 38.64 496 8731 1.84 FALSE 3.61 2.77

1.72E- 7.774111 5.09944

SHMT2 2.12E-01 01 38.82 14 1692 0.97 FALSE 2.62 1.34

1.60E- 5.796612 6.72125

TYMS 4.65E-01 01 38.85 685 9278 1.64 FALSE 2.02 1.91

4.01E- 6.384081 4.08278

RPS12 3.71E-02 01 38.95 023 2447 1.08 FALSE 0.45 0.39

3.55E- 9.939454 11.4966

SORD 2.73E-02 01 38.98 508 5193 2.10 FALSE 3.16 1.05

3.36E- 11.15340 3.78274

RPL7 4.01E-01 01 39.04 377 3401 1.06 FALSE -0.38 0.30

4.5SE- 10.06244 25.1069

ESRP1 4.44E-01 02 39.09 484 7937 1.20 FALSE 2.42 1.76

1.05E- 21.62172 26.9244

BZW2 6.62E-01 01 39.22 441 2566 0.92 FALSE 1.37 0.90

3.34E- 2.878936 36.6984

RPL18A 8.24E-02 01 39.43 474 4039 0.51 TRUE 1.13 1.24

1.81E- 3.998230 67.4306

CA14 3.81E-02 01 39.82 163 5241 0.77 FALSE 2.21 1.79

1.14E- 21.51868 1.28341

SKP2 9.82E-01 02 39.93 872 7716 1.83 FALSE 1.68 1.42

2.72E- 24.87612 1.56429

DCAF13 4.60E-01 01 40.41 305 7695 2.88 TRUE -1.21 -1.72

6.40E- 19.74301 5.93647

HMGA1 6.81E-02 01 40.42 642 9134 0.83 FALSE 0.84 0.52

KIAA0101 4.38E-01 5.20E- 41.14 5.177374 9.34349 1.31 FALSE -0.55 -0.59 rliiii .ll.in iiiicll. sr.Riil li na.lncr<'.is<'<l. tcga.Iiicreu.sctl. risk

¾ ore less « ^■ .ΛΙΙ sc-.OUl sc.Ncw k .Ul risk .beyoml.T.cells

02 736 1776

8.35E- 24.76379 7.76565

CTPSl 8.43E-01 02 41.34 084 0207 1.78 FALSE NA NA

5.52E- 5.321317 16.8131

PPP2R1A 3.35E-01 01 42.96 629 3352 1.23 FALSE 5.38 2.24

4.76E- 7.246750 20.2794

FBLN1 5.09E-01 03 43.12 299 9953 1.92 FALSE 1.65 2.28

2.83E- 8.672094 7.73690

RNF2 8.06E-01 02 43.71 386 4785 2.07 FALSE -0.38 -0.97

3.99E- 5.924051 11.4716

CDCA7 6.15E-01 02 43.91 047 3669 1.55 FALSE 0.55 0.97

5.20E- 1.692897 54.0756

RPS6 8.53E-02 01 43.91 361 381 0.83 TRUE -1.35 -1.38

1.77E- 6.943339 14.8497

ILF2 8.63E-01 03 45.26 213 2817 1.39 FALSE 1.31 0.79

2.25E- 3.114484 48.2506

RPL18 9.66E-02 01 45.37 434 6529 0.95 FALSE 1.39 1.27

1.04E- 2.404437 31.0840

UQCRFS1 4.79E-01 01 45.94 46 894 0.72 FALSE 3.57 1.57

3.34E- 9.456736 13.3900

RUVBL2 7.03E-01 01 46.06 484 2528 1.57 FALSE 2.93 1.38

1.65E- 16.99198 14.0939

RPL26 1.01E-01 01 46.82 955 6856 0.84 FALSE -2.08 -2.60

3.83E- 6.873462 48.3169

RPS27 1.47E-02 01 47.85 208 4024 0.66 FALSE -0.90 0.30

6.49E- 1.937507 16.9016

CD N2A 5.27E-01 01 48.20 613 692 0.77 TRUE -0.46 -0.33

1.12E- 5.488218 21.5615

MIR4461 9.23E-01 02 48.20 285 8776 1.49 FALSE NA NA

2.36E- 47.15134 0.45206

TPM2 5.40E-01 02 48.33 153 8271 0.90 TRUE -0.30 0.49

5.26E- 10.22154 16.2593

CNRIP1 4.03E-01 01 48.87 305 5254 1.06 FALSE -0.36 -0.36

4.49E- 9.159237 28.8635

PAFAH1B3 3.38E-01 01 49.53 785 675 1.14 FALSE 1.48 0.86

2.83E- 15.22332 36.2291

FAM174B 6.29E-01 01 50.07 615 0751 1.63 FALSE 3.44 1.88

4.65E- 32.02385 8.72117

USP22 4.57E-01 01 51.05 954 1083 1.03 FALSE 2.18 1.05

2.11E- 89.51451 29.3956

GTSF1 8.47E-01 01 51.20 745 8184 1.35 TRUE -3.43 -1.39

3.37E- 8.162255 38.3377

ISYNA1 5.19E-01 01 51.20 211 3761 3.05 FALSE 1.99 1.79

6.01E- 14.88708 20.3077

DLL3 8.77E-01 02 51.70 119 5936 3.27 FALSE 3.09 2.42

5.51E- 5.290669 67.7112

TMC6 3.36E-01 02 52.13 679 702 2.25 FALSE 2.61 3.47

7.13E- 27.56806 18.6352

RPS18 7.25E-02 01 52.28 633 6549 0.69 FALSE 0.61 0.32

6.71E- 66.79439 16.6762

NREP 6.54E-01 03 52.32 813 9308 0.68 TRUE NA NA

2.13E- 3.737360 14.0661

RPL21 3.07E-01 01 52.38 847 9494 2.11 TRUE -1.10 -1.33

3.60E- 10.48799 69.4537

RPS3 5.62E-02 01 52.44 182 1116 1.37 FALSE 0.97 0.76

3.71E- 4.847150 32.7126

RPS5 2.04E-02 01 56.38 55 0656 0.81 TRUE 1.33 0.83

1.85E- 12.44176 23.7977

EIF4A1 7.28E-01 01 56.54 552 7896 1.45 FALSE 1.80 0.60

3.72E- 1.130371 45.7648

GPI 1.17E-01 01 57.12 128 0744 1.30 TRUE 4.46 2.91

2.02E- 2.308514 72.9791

BCAN 7.45E-01 01 57.20 409 1384 0.48 FALSE 3.07 3.42

3.99E- 1.205064 75.2369

FTL 2.64E-01 01 57.23 194 9673 1.17 FALSE 0.51 2.31

4.11E- 1.023830 123.936

DCT 3.01E-01 01 58.58 081 0976 0.58 TRUE 1.78 2.06

RPS16 2.08E-01 4.47E- 58.91 5.580237 61.9000 1.24 FALSE 0.90 0.61

Table 13. Down-regulated and Up-regulated genes post-immunotherapy treatment in malignant cells

[0430] The signature was down-regulated in resistant tumors for genes associated with coagulation, apoptosis, T F-alpha signaling via NFKB ( FKBIZ), Antigen processing and presentation (e.g., MHC-I, HSPA1A), metallothioneins (e.g., MT2A, MT1E) involved in metal storage, transport, and detoxification, and IFNGR2 (Gao et al. Cell 2016).

[0431] The signature was up-regulated in resistant tumors for genes associated with negative regulation of angiogenesis and MYC targets.

[0432] Serine protease inhibitors (SERPINs), which are involved in protease inhibition and control of coagulation and inflammation were differentially expressed in the signature. Prior studies relate to recurrent SERPINB3 and SERPINB4 mutations in patients who respond to anti-CTLA4 immunotherapy (Riaz et al. NG 2016). SERPINA3, SERPINAl, SERPINE2 were down-regulated in resistant tumors. SERPINFl, SERPINB9 were up-regulated in resistant tumors.

[0433] The resistance signature also strongly correlated with MHC-I expression (Figure 22). One of the tumors in the cohort has a wide range of MHC-I expression in the malignant cells. Applicants filtered HLA genes from the resistance signature, and scored the malignant cells. The malignant cells with the highest resistance scores in this tumor under express MHC-I.

[0434] There are 13 different metallothioneins and 6 of them are moderately/highly expressed in the melanoma malignant cells. When Applicants scored the cells according to this mini-signature separation between the treated and untreated samples was observed (Figure 23). Therefore, a signature only including metallothioneins may be used in the methods of the present invention.

The prognostic value of the post-immunotherapy modules

[0435] Applicants discovered that the immunotherapy resistance signature was also predictive of survival rates in tumors. The prognostic value of the signature is significant (P = 1.6e-05), even when accounting for T-cell infiltration scores as shown by analyzing samples in the cancer genome atlas (TCGA) (Figure 24). The resistance signature performs better than other single-cell based signatures in predicting high and low survival rates (Figure 25).

[0436] To further examine the generalizability of the PIT modules Applicants analyzed the bulk gene expression data of melanoma tumors from The Cancer Genome Atlas (TCGA). As Applicants saw at the single-cell level, Applicants find that the genes within each module are co-expressed across tumors, while the two modules are negatively correlated. Applicants postulated that higher expression of the PIT -up program and a lower expression of the PIT- down program might indicate that the tumor is more resilient against immune-mediated clearing, resulting in a more aggressive disease. To test this hypothesis, Applicants scored each tumor according to the immunotherapy modules and examined the prognostic value of these scores. Indeed, the immunotherapy scores are significantly associated with patient survival, such that the expression of the PIT-up (down) signature is associated with lower (higher) survival rates (Figure 24, 25).

[0437] To examine the significance of this finding Applicants performed the same analysis with signatures that were previously identified based on the analysis of the single cell melanoma data (Tirosh et al, Dissecting the multicellular ecosystem of metastatic melanoma by single-cell RNA-seq. Science. 2016 Apr 8;352(6282): 189-96). Applicants divided these signatures into two groups: (1) malignant signatures - signatures that describe the state of the malignant cells, as cell cycle, and the AXL and MITF signatures, which were previously shown to be associated with the response to targeted therapy; (2) tumor composition signatures that describe a specific cell type or the state of a non-malignant cell type within the tumor microenvironment. None of the malignant signatures is significantly associated with patient survival, indicating that mere variation across malignant cells is not sufficient to yield such results. The cell-type signatures are associated with patient survival, especially those that related to T-cell infiltration, though their prognostic signal is redundant when accounting for tumor purity. The latter is estimated based on CNVs. [0438] Importantly, the prognostic value of the PIT scores is significant even when accounting for the tumor purity and T-cell infiltration scores. Interestingly, the PIT -up (down) scores are negatively (positively) correlated to the T-cell scores, as Applicants further describe herein. Nonetheless, the combination of the PIT and T-cell scores yields significantly more accurate predictions of patient survival compared to those obtained when using each score separately, indicating that the PIT modules capture tumor properties that cannot be explained just by T-cell infiltration levels.

The post-immunotherapy modules are associated with response to anti-PDl and anti- CTLA4 in the clinic and in mouse models

[0439] Immunotherapy introduces selective pressures that, in case of an unsuccessful treatment, are likely to increase the abundance of immunotherapy -resistant cells. The post- immunotherapy signatures Applicants derived might capture these resistant cell states, and, as such, may help to detect innate resistance to anti-PD-1 or anti-CTLA4 therapy - pretreatment. To examine this concept Applicants analyzed the gene expression profiles of responding (n = 15) and non-responding (n = 13) tumors sampled prior to anti-PD-1 therapy. Indeed, the tumors of responders overexpressed the PIT-down signature and underexpressed the PIT -up signature, resulting in accurate predictors of response to anti-PD-1 (P = 3.38e-02 and 5.5e-04, Area Under the Receiver Operating Characteristic Curve (ROC-AUC) = 0.91 and 0.77. In another gene expression cohort of pre-anti-CTLA-4 melanoma tumors the signatures did not yield a significant separation between the responders and non-responders. Therefore, Applicants set out to test the signatures in a more controlled setting of a murine model, in which genetically identical mice that experienced the same environment and treatment display a dichotomous response to anti-CTLA4. Indeed, responders scored higher for the PIT-down signature and lower for the PIT -up signature, resulting in accurate predictors of response to anti-CTLA4 in this model (P = 1.2e-05, ROC-AUC = 0.99). The ITR signature was predictive of eventual outcome in both mouse and human data. First, in a bulk RNA-Seq study of anti-CTLA4 therapy in mouse, the malignant ITR score predicted well non-responders compared to responders. Applicants analyzed 27 patients associated with anti-PDl response (Hugo et al., 2016). The malignant ITR was significantly lower in pre-treatment samples from patients with complete response compared to those with partial or no response (Figure 26). The (5) complete-responders in the data of Hugo et al. scored lower for the sc-resistance signature compared to the other 22 patients (P = 9.37e-04). These results indicate that the signatures identified capture cell states that are linked to anti-PDl and anti-CTLA4 resistance.

[0440] Genes that were up-regulated in the resistant tumors (single cell) were down- regulated in CR vs. others (P = 9.6e-14) and C/PR vs. R (NS) (Figure 27). Genes that were down-regulated in the resistant tumors (single cell) were up-regulated in CR vs. others (P = 2.8e-l 1) and C/PR vs. NR (P = 2.8e-03) (Figure 28).

Associating melanoma-cell-intrinsic states with T-cell infiltration and exclusion.

[0441] Tumor infiltration with T cells is one of the strongest predictors of patient response to immune checkpoint inhibitors in various cancer types. Understanding the molecular mechanisms that underlie spontaneous T-cell infiltration could aid the development of therapeutic solutions for patients with non-inflamed tumors. Applicants leveraged the single-cell data and bulk gene expression cohorts of melanoma tumors to map malignant transcriptional states that are associated with T-cell infiltration or exclusion.

[0442] First, Applicants analyzed the single-cell data to derive a CD8 T-cell signature, consisting of genes that are primarily expressed by CD8 T-cells (Methods). Applicants used this signature to estimate the T-cell infiltration level of melanoma tumors based on their bulk gene expression profiles. Applicants show that patients with more T-cell infiltration, according to this measure, are more likely to respond to anti-CTLA4 and to MAGE-A3 antigen-specific immunotherapy, and have better overall survival. Next, Applicants identified based on the single-cell data genes that are expressed primarily by malignant melanoma cells. Applicants then searched for genes that are correlated with T cell abundance in the bulk TCGA gene expression cohort, while restricting the search only to the malignant-specific genes to derive an initial T-cell-infiltration signature (T cell exclusion signature (T-ex).

[0443] While the initial signature is informative, it is limited for two main reasons. First, there are only 384 genes that could be confidently defined as exclusively expressed by the malignant melanoma cells. Second, it cannot confidently identify genes whose expression in the malignant cells will exclude T-cells. To overcome these limitations, Applicants used the initial T-cell infiltration signature only as an anchor, and searched for genes whose expression level in the individual malignant cells is positively or negatively correlated to the overall expression of this initial signature. Applicants defined genes that are strongly positively (negatively) correlated to the initial signature as the infiltrated (non-infiltrated) module. Of note, non-malignant cells express most of the genes in these modules, and hence it would have been difficult to associate them with T-cell infiltration without leveraging the single-cell data. [0444] The genes in the infiltrated module (exclusion-down) play a major role in antigen processing and presentation (HLA-A/B/C, B2M, TAPBP) and interferon gamma response (e.g., IFI27, IFI35, IRF4, IRF9, STAT2). In certain embodiments, the infiltrated module includes the following genes: A2M, AEBP1, AHNAK, ANXA1, APOC2, APOD, APOE, ATP1A1, ATP1B1, C4A, CAPN3, CAV1, CD151, CD59, CD63, CDH19, CRYAB, CSPG4, CSRP1, CST3, CTSB, CTSD, DAG1, DDR1, DUSP6, ETV5, EVA1A, FBX032, FCGR2A, FGFR1, GAA, GATSL3, GJB1, GRN, GSN, HLA-B, HLA-C, HLA-F, HLA-H, IFI35, IGFBP7, IGSF8, ITGA3, ITGA7, ITGB3, LAMP2, LGALS3, LOXL4, LRPAPl, LY6E, LYRM9, MATN2, MFGE8, MIA, MPZ, MT2A, MTR R2L3, MTR R2L6, PC1, PC2, NSGl, PERP, PKM, PLEKHBl, PROSl, PRSS23, PYGB, RDH5, ROPNl, SlOOAl, S100A13, S100A6, S100B, SCARB2, SCCPDH, SDC3, SEMA3B, SERPINA1, SERPINA3, SERPINE2, SGCE, SGK1, SLC26A2, SLC5A3, SPON2, SPP1, TIMP1, TIMP2, TIMP3, TM4SF1, TMEM255A, TMX4, TNFSF4, TPP1, TRIML2, TSC22D3, TXNIP, TYR, UBC and WBP2.

[0445] The non-infiltrated module (exclusion-up) is mainly enriched with MYC targets and MYC itself. It also includes STRAP, which is an inhibitor of TGF-beta signaling, and SMARCA4 (or BRG1) - a subunit of the BAF complex that has a key role in mediating beta- catenin signaling. The latter has been shown to promote T-cell exclusion in mice. In certain embodiments, the non-infiltrated module includes the following genes: AHCY, BZW2, CCNBIIPI, CCT6A, EEF2, EIF3B, GGCT, ILF3, IMPDH2, MDH2, MYBBPIA, NT5DC2, PAICS, PFKM, POLD2, PTK7, SLC19A1, SMARCA4, STRAP, TIMM13, TOP1MT, TRAPl and USP22.

[0446] Interestingly, these results mirror and overlap the PIT signatures. When scoring the malignant cells according to these infiltration signatures Applicants find that the treatment naive malignant cells score significantly higher for infiltration compared to the post-treatment malignant cells. In other words, malignant cells having the ITR signature have higher exclusion signatures and treatment naive malignant cells have higher infiltration signatures (Figure 29). These results indicate that cells which survive post-immunotherapy either reside in less infiltrated niches within the tumor or have increased capacity to exclude T-cells from their immediate microenvironment. Not being bound by a theory, malignant cells that survive immunotherapy are either to begin with are in a T cell excluded TME or became T cell excluding.

Immunotherapy triggers significant transcriptional changes in CD8 T-cells [0447] Next Applicants set out to map the transcriptional landscape of the immune cells and examine the association of these states with immunotherapy. Applicants performed the analysis separately for each cell type (CD8 T-cells, CD4 T-cells, B-cells, and macrophages). First, Applicants performed an unbiased analysis to explore the main sources of heterogeneity in melanoma CD8 T-cells. To this end, Applicants applied Principle Component Analysis (PCA) followed by nonlinear dimensionality reduction (t-distributed stochastic neighbor embedding (t-SNE)). Interestingly, in the first PCs and the t-SNE dimensions, the CD8 T-cells are segregated according to their treatment history, such that post-treatment cells cluster together and apart from the treatment naive cells. These findings demonstrate that immunotherapy triggers significant transcriptional changes in CD8 T-cells, and highlight two additional and orthogonal sources of heterogeneity: one that is attributed to cell cycle, and another that is attributed to the expression of inhibitory checkpoints (Figure 30, 31)

[0448] Applicants performed supervised analyses to identify the genes and pathways that are differentially expressed in the post-immunotherapy CD8 T-cells compared to the treatment naive cells. The resulting signatures indicate that the post-treatment CD8 T-cells are more cytotoxic and exhausted, such that naive T-cell markers are downregulated, while IL-2 signaling, T-cell exhaustion and activation-dysfunction pathways are up regulated. Applicants then scored the CD8 T-cells according to these two signatures, revealing a spectrum of phenotypes also within the PIT and treatment naive populations, and within the CD8 T-cell population of the same tumor.

[0449] Applicants speculated that this spectrum might be related to clonal expansion.

Clonal expansion occurs when T cells that recognize a specific (tumor) antigen proliferate to generate discernible clonal subpopulations defined by an identical T cell receptor (TCR) sequence. Applicants applied TraCeR to reconstruct the TCR chains of the T-cells and identify cells that are likely to be a part of the same clone (Stubbington et al., Nature

Methods 13, 329-332 (2016)). Overall, Applicants identified 113 clones of varying sizes, three of which consist of more than 20 cells (Figure 32). Specifically, Applicants used the

TcR sequence to determine the clone of each T cell, and distinguished four categories: treatment naive or ITR, and expanded or not. Applicants analyzed their gene expression and saw that cells vary in two ways. First CD8 T cells from ITR patients have distinct expression, and this is especially pronounced in expanded cells. All the major expanded clones were in

ITR samples, and only very few cells were expanded in treatment naive patients. These few expanded cells look more like cells from the treated patients. Similar to results reported in mice there is an expanded population of Bcl6+Tcf7+ cells in the ITR samples, some also CXCR5+. When Applicants turn to their functional state, Applicants observed that across all patients, regardless of treatment, some cells are more exhausted and others more naive.

[0450] These large clones are from post-treatment patients, indicating that immunotherapy is triggering T-cell activation and proliferation even when no objective clinical response is observed. Moreover, Applicants find that clonal expansion is strongly associated with the PIT scores, not only across all patients, but also when considering only the post-immunotherapy or treatment naive cells. Next Applicants compared clonally expanded T-cells to the other T-cells within the same tumor to derive signatures of clonal expansion. By leveraging intra-tumor T-cell heterogeneity in this manner Applicants were able to mitigate the problem of batch effects. In concordance with the previous results Applicants find that genes, which are over (under) expressed post-immunotherapy, are overrepresented in the up (down) regulated clonal -expansion module (Figure 33).

[0451] Not being bound by a theory, inhibition of genes, which are under expressed in the T-cells post immunotherapy, could potentially promote T-cell survival and expansion in the tumor microenvironment. Indeed, these genes are ranked significantly high in the results of an in-vivo shRNA screen that identified negative regulators of T-cell proliferation and survival in mice tumors (P = 4.98e-03). All in all, these results suggest that post- immunotherapy T-cells are more activated, even in this cohort of non-responders.

Table 14

Post-immunotherapy state in

Pathway Genes

CD8 T-cells

ZBTB24, ZNF526, ZNF528, ZNF543,

Zinc TFs ZNF620, ZNF652, ZSCAN2,

Up-regulated ZSCAN22

I FN gamma signaling GBP2, GBP5, IRF1, PTPN2, STAT1

CD3D, CD3E, CD3G, HLA-DQA1,

PD1 signaling

HLA-DQA2, HLA-DRB5, PDCD1

Down-regulated BIRC5, BUB1, GMNN, MAD2L1,

Cell cycle

NDC80, UN, UBE2C, ZWINT

Negative regulators of T-cell CBLB, WNK1, PDCD1

survival/proliferation in the TM E (Zhou et al. 2014)

[0452] Not being bound by a theory, immunotherapy is triggering transcriptional changes both in the malignant cells and in the CD8 T-cells. The results suggest that the T-cells become more effective, while the malignant cells become more "immune-edited" (e.g., evasion (MHC-1) vs. T-cell exclusion).

Example 3 - C-map analysis

[0453] Drugs that could reduce the resistance signature were analyzed by c-map analysis. The analysis showed that the following drugs could reduce the immunotherapy resistance signature:

• PKC activators;

• NFKB pathway inhibitors;

• IGF 1R inhibitors; and

• Reserpine (Used to control high blood pressure & psychotic symptoms and blocks the vesicular monoamine transporter (VMAT)).

[0454] The signature is associated with drug response/effects. There was an association between the toxicity of different drugs and their resistance scores (according to the resistance signatures). C-map results indicated drugs that can sensitize/de-sensitize the cells to immunotherapy. The results of this analysis are summarized in Table 15-17.

Table 15. Drugs that modulate Gene Signature

The correlation between the resistance scores of the cell lines and their sensitivity (IC50) to the pertaining drug (based on the CCLE gene expression and the Garnett et al. Nature 2012)

Negative R -> more toxic/selective to the immuno-resistant cells.

Positive R -> less toxic/selective to the imn nuno-resista nt cells.

Driis; All.li A11.I-* im-lii iimiiii.K im-lii iimiiii.l'

Pazopanib -0.01 8.62E-01 -0.48 3.27E-02

Shikonin -0.05 4.55E-01 -0.48 3.97E-02

Etoposide -0.16 2.02E-02 -0.48 4.05E-02

JNK.9L -0.13 4.97E-02 -0.39 l.OOE-01

GSK.650394 -0.17 1.02E-02 -0.37 1.05E-01

X681640 -0.08 1.56E-01 -0.37 1.55E-01

Vinorelbine -0.14 3.68E-02 -0.34 1.54E-01

AZD6482 0.16 1.46E-02 -0.34 1.56E-01

BIRB.0796 -0.11 6.17E-02 -0.33 2.13E-01

NVP.BEZ235 0.00 9.79E-01 -0.30 1.59E-01

Roscovitine 0.03 6.90E-01 -0.30 4.37E-01

Sunitinib -0.04 6.12E-01 -0.30 4.37E-01

Gemcitabine -0.05 4.18E-01 -0.29 2.19E-01

Epothilone.B -0.05 4.40E-01 -0.29 2.21E-01

ATRA -0.20 6.16E-04 -0.28 3.14E-01

VX.702 -0.16 6.16E-03 -0.27 2.62E-01

QS11 -0.17 7.40E-03 -0.27 2.50E-01

Lapatinib 0.29 4.69E-04 -0.27 4.93E-01

BMS.536924 0.32 7.64E-05 -0.25 5.21E-01

Vorinostat -0.37 2.73E- 11 -0.25 3.02E-01 PD.0332991 -0.06 2.82E-01 -0.22 3.75E-01

Parthenolide 0.08 3.55E-01 -0.22 5.81E-01

AZD.2281 -0.18 1.72E-03 -0.21 3.71E-01

FTI.277 0.18 6.29E-03 -0.21 3.85E-01

IPA.3 -0.08 2.14E-01 -0.21 3.75E-01

PF.562271 0.05 4.31E-01 -0.20 4.10E-01

PD.173074 -0.18 1.89E-03 -0.19 3.74E-01

Tipifarnib -0.09 1.93E-01 -0.18 4.33E-01

A.770041 0.24 4.60E-03 -0.18 6.44E-01

Z.LLNle.CHO 0.23 5.71E-03 -0.18 6.44E-01

CEP.701 -0.10 9.73E-02 -0.17 4.75E-01

PAC.l -0.09 1.52E-01 -0.17 4.76E-01

BI.2536 0.14 9.25E-02 -0.17 6.78E-01

GW843682X 0.05 5.52E-01 -0.17 6.78E-01

Midostaurin 0.06 3.70E-01 -0.16 5.03E-01

Metformin -0.21 9.02E-05 -0.16 4.24E-01

ZM.447439 -0.09 1.27E-01 -0.14 5.21E-01

Elesclomol 0.07 2.48E-01 -0.14 6.21E-01

AZD7762 -0.08 1.48E-01 -0.14 5.68E-01

Sorafenib -0.03 7.33E-01 -0.13 7.44E-01

XMD8.85 0.00 9.81E-01 -0.13 7.44E-01

BAY.61.3606 -0.05 4.84E-01 -0.13 5.81E-01

BI.D1870 -0.02 7.72E-01 -0.13 6.41E-01

Doxorubicin -0.03 6.08E-01 -0.11 6.44E-01

DMOG 0.17 1.05E-02 -0.10 6.78E-01

BMS.509744 0.08 3.30E-01 -0.10 8.10E-01

Bosutinib -0.05 3.91E-01 -0.09 7.05E-01

CMK 0.17 3.68E-02 -0.08 8.43E-01

KIN001.135 0.19 2.39E-02 -0.08 8.43E-01

WZ.1.84 0.21 1.47E-02 -0.08 8.43E-01

AZD8055 -0.11 5.79E-02 -0.08 7.33E-01

Paclitaxel 0.18 3.31E-02 -0.07 8.80E-01

VX.680 -0.01 9.30E-01 -0.07 8.80E-01

LFM.A13 0.12 5.87E-02 -0.06 8.11E-01

Methotrexate -0.35 1.27E-09 -0.06 8.42E-01

NU.7441 0.10 1.02E-01 -0.06 8.39E-01

KU.55933 0.07 2.68E-01 -0.05 8.48E-01

JW.7.52.1 0.11 1.80E-01 -0.05 9.12E-01

OSI.906 0.06 3.67E-01 -0.05 8.36E-01

PD.0325901 0.23 4.75E-05 -0.04 8.51E-01

JNK.Inhibitor.VIII 0.03 6.13E-01 -0.04 9.00E-01

Gefitinib -0.02 6.99E-01 -0.03 9.23E-01

BMS.754807 0.01 8.32E-01 -0.02 9.32E-01

BIBW2992 0.04 5.07E-01 -0.02 9.43E-01

Salubrinal -0.11 1.93E-01 -0.02 9.82E-01

Camptothecin.3 0.03 6.44E-01 -0.01 9.57E-01

Camptothecin.5 0.03 6.44E-01 -0.01 9.57E-01

A.443654 0.14 9.40E-02 0.00 l.OOE+00

Thapsigargin -0.02 7.97E-01 0.00 9.92E-01

NSC.87877 -0.17 1.36E-02 0.01 9.86E-01

BX.795 0.03 6.53E-01 0.01 9.73E-01

X17.AAG 0.22 2.11E-04 0.03 9.26E-01

Mitomycin.C -0.12 7.40E-02 0.03 9.11E-01

Temsirolimus -0.12 4.14E-02 0.03 9.13E-01

Docetaxel 0.13 2.39E-02 0.03 8.84E-01

Cyclopamine 0.01 8.84E-01 0.03 9.48E-01

Camptothecin -0.12 3.84E-02 0.04 8.74E-01

Camptothecin.4 -0.12 3.84E-02 0.04 8.74E-01

GDC0941 0.02 7.65E-01 0.04 8.41E-01

Obatoclax.Mesylate -0.05 4.59E-01 0.05 8.41E-01

CGP.082996 -0.01 9.29E-01 0.07 8.80E-01

Bleomycin -0.09 1.92E-01 0.08 7.53E-01

AS601245 -0.03 6.96E-01 0.08 7.29E-01

Bryostatin.l -0.01 8.31E-01 0.08 7.29E-01

Embelin -0.01 9.13E-01 0.09 7.05E-01

AKT.inhibitor.VIII -0.10 1.35E-01 0.09 7.05E-01

AP.24534 0.13 6.29E-02 0.09 7.05E-01

RDEA119 0.27 1.44E-06 0.12 5.98E-01 Nilotinib -0.09 1.34E-01 0.13 6.00E-01

CGP.60474 0.26 1.85E-03 0.13 7.44E-01

S.Trityl.L.cysteine 0.00 9.82E-01 0.13 7.44E-01

Erlotinib 0.18 4.08E-02 0.15 7.08E-01

ABT.888 -0.11 6.48E-02 0.15 5.17E-01

MK.2206 -0.09 1.47E-01 0.16 5.14E-01

Dasatinib 0.38 4.98E-06 0.17 6.78E-01

MG.132 0.25 2.24E-03 0.17 6.78E-01

PF.02341066 0.14 7.89E-02 0.17 6.78E-01

Cisplatin -0.01 8.94E-01 0.18 5.12E-01

WH.4.023 0.23 5.25E-03 0.18 6.44E-01

CI.1040 0.09 1.24E-01 0.20 4.74E-01

SL.0101.1 -0.06 2.74E-01 0.20 4.56E-01

SB590885 -0.11 5.08E-02 0.21 3.61E-01

A.769662 0.06 3.85E-01 0.21 3.85E-01

AZ628 0.17 4.24E-02 0.22 5.81E-01

GSK269962A 0.21 1.14E-02 0.22 5.81E-01

MS.275 0.00 9.71E-01 0.22 5.81E-01

Cytarabine -0.02 7.54E-01 0.22 4.10E-01

Axitinib -0.19 1.11E-03 0.22 3.54E-01

Vinblastine -0.07 2.38E-01 0.23 3.91E-01

Bicalutamide 0.02 7.59E-01 0.24 2.99E-01

PLX4720 0.07 2.41E-01 0.25 3.43E-01

RO.3306 0.11 6.07E-02 0.25 2.41E-01

AUY922 0.01 9.32E-01 0.26 2.75E-01

GNF.2 0.27 1.27E-03 0.27 4.93E-01

Lenalidomide -0.11 5.30E-02 0.27 2.69E-01

GDC.0449 -0.12 3.17E-02 0.29 2.20E-01

AICAR -0.16 3.97E-03 0.30 1.33E-01

AZD6244 0.17 4.19E-03 0.32 1.97E-01

Nutlin.3a -0.09 1.18E-01 0.32 1.36E-01

Bexarotene -0.01 9.08E-01 0.34 1.41E-01

Imatinib 0.15 6.78E-02 0.35 3.59E-01

Rapamycin 0.09 2.59E-01 0.35 3.59E-01

GW.441756 -0.09 1.17E-01 0.35 1.41E-01

ABT.263 -0.12 3.89E-02 0.37 8.43E-02

CHIR.99021 0.19 3.91E-03 0.38 l.lOE-01

Bortezomib 0.36 6.13E-06 0.38 3.13E-01

Pyrimethamine 0.09 2.84E-01 0.38 3.13E-01

FH535 -0.24 1.51E-04 0.40 8.41E-02

AMG.706 -0.04 4.43E-01 0.45 3.14E-02

SB.216763 0.02 7.29E-01 0.46 4.84E-02

AZD.0530 0.31 1.05E-04 0.53 1.48E-01

PHA.665752 0.18 2.41E-02 0.68 5.03E-02

NVP.TAE684 0.21 8.27E-03 0.72 3.69E-02

Table 16. Top 200 drugs that induce downregulated genes in the signature

Table 17. Top 200 drugs that repress upregulated genes in the signature

[0455] Applicants can also identify novel immunotherapy targets by looking for genes which are co-regulated with the immune-checkpoints (PDCDl, TIGIT, HAVCR2, LAG3, CTLA4) in CD4 and CD8 T-cells. For example, Applicants found CD27, an immune checkpoint and the target of an experimental cancer treatment (Varlilumab). The results of this analysis are for the top 200 genes summarized in Table 18.

Table 18. Top 200 genes that are co-regulated with immune-checkpoints

FAM3C 0.34 1.47E-48

CXCL13 0.34 1.47E-47 0.27 2.41E-21

SP47 0.33 1.43E-46 0.11 0.000202982

CBLB 0.33 7.16E-46 0.20 1.64E-12

SNX9 0.33 1.35E-45 0.11 6.89E-05

SIRPG 0.33 5.21E-45 0.33 2.62E-31

TNFRSF1B 0.33 1.09E-44 0.22 3.31E-15

FCRL3 0.32 1.36E-41 0.26 9.32E-20

VCAM1 0.31 3.44E-41

DGKH 0.31 1.67E-39

PRDM1 0.30 3.07E-38 0.20 2.24E-12

IGFLR1 0.30 6.12E-38 0.21 7.66E-14

ETV1 0.30 1.03E-37

RGS1 0.30 4.15E-37 0.30 3.35E-27

WARS 0.30 1.32E-36 0.14 4.98E-07

MY07A 0.30 3.10E-36

ITM2A 0.29 2.65E-35 0.31 1.30E-27

GBP2 0.29 1.24E-34 0.21 3.93E-13

ENTPD1 0.28 1.21E-33 0.12 4.17E-05

TOX 0.28 2.39E-32 0.44 2.27E-58

DUSP4 0.28 2.48E-32 0.36 1.94E-38

TP53INP1 0.28 7.24E-32 0.23 2.04E-16

GAPDH 0.28 1.57E-31 0.36 1.21E-37

DFNB31 0.27 6.10E-31

ATHL1 0.27 1.19E-30 0.01 0.71761873

TRAF5 0.27 2.83E-30 0.10 0.000897484

CLEC2D 0.27 5.88E-30 -0.02 0.535704689

SLA 0.26 6.03E-29 0.20 1.37E-12

CCL3 0.26 1.26E-28 0.04 0.161249379

IL6ST 0.26 2.25E-28 0.02 0.440674275

PCED1B 0.26 3.01E-28 0.21 3.65E-13

RAB27A 0.26 3.09E-28 0.13 6.49E-06

CD7 0.26 3.23E-28 0.06 0.049851187

ICOS 0.25 3.99E-27 0.31 2.87E-28

FUT8 0.25 1.41E-26 0.10 0.000314275

RNF19A 0.25 4.44E-26 0.29 1.51E-24

TBC1D4 0.25 1.16E-25 0.31 6.28E-29

FABP5 0.25 1.63E-25 0.18 2.19E-10

Bl 0.24 3.89E-24 0.24 9.16E-18

TTN 0.24 6.97E-24

SRGN 0.24 9.35E-24 0.36 1.61E-37

SARDH 0.24 2.50E-23 0.19 3.48E-11

IFNG 0.24 3.00E-23 0.14 4.84E-07

INPP5F 0.23 3.38E-23 0.14 4.75E-07

RGS2 0.23 4.50E-23 0.18 7.21E-10

CD38 0.23 5.61E-23 0.15 1.54E-07

ID3 0.23 1.34E-22 0.05 0.066457964

PHLDA1 0.23 1.35E-22 0.11 0.000184209

TIMD4 0.23 3.53E-22

PAM 0.23 3.69E-22 0.28 2.82E-23

PTMS 0.23 1.99E-21

CXCR6 0.22 6.84E-21 0.26 6.42E-20

LBH 0.22 1.48E-20 0.18 3.85E-10

PRF1 0.22 1.90E-20 0.09 0.001065922

ASB2 0.22 1.90E-20 0.29 8.22E-25

KIR2DL4 0.22 2.29E-20

STAT3 0.22 4.75E-20 0.05 0.063080818

GLDC 0.22 5.92E-20

MIR155HG 0.22 8.11E-20 0.15 9.54E-08

CD8B 0.22 1.10E-19 -0.14 2.30E-06

CD200 0.22 1.25E-19 0.25 1.49E-18

CD2BP2 0.21 1.79E-19 0.17 5.47E-09

CD84 0.21 2.59E-19 0.11 0.000105368

CD2 0.21 3.46E-19 0.32 5.24E-31

UBE2F 0.21 3.72E-19 0.06 0.035820564

TNS3 0.21 6.38E-19

ATXN1 0.21 1.35E-18

HNRPLL 0.21 1.51E-18 0.26 1.96E-20 FKBP1A 0.21 2.34E-18 0.19 2.16E-11

GALM 0.21 2.95E-18 0.19 3.98E-11

TOX2 0.20 6.98E-18 0.35 2.14E-35

AFAP1L2 0.20 1.90E-17

GEM 0.20 2.64E-17 0.16 5.19E-08

HSPB1 0.20 2.75E-17 0.09 0.002636939

CCL3L3 0.20 3.71E-17

CADM1 0.20 3.76E-17

GF0D1 0.20 3.88E-17

SH2D2A 0.20 3.90E-17 0.13 6.62E-06

PKM 0.20 4.16E-17 0.26 1.71E-19

HAPLN3 0.20 9.31E-17 -0.02 0.483961847

MTSS1 0.20 1.03E-16

ZNF79 0.20 1.79E-16 0.03 0.275651913

EID1 0.19 2.53E-16 0.09 0.003034835

ZBED2 0.19 2.96E-16 0.14 1.69E-06

PTPN6 0.19 1.31E-15 0.04 0.210702886

HMOX1 0.19 1.51E-15

SAMSN1 0.19 1.97E-15 0.10 0.00025252

SIT1 0.19 2.34E-15 0.08 0.007781849

CCDC64 0.19 2.65E-15 0.09 0.000993524

PTPN7 0.19 4.49E-15 0.25 3.66E-18

NDFIP2 0.19 6.66E-15 0.17 6.39E-09

CD74 0.19 7.63E-15 0.28 1.23E-22

CREM 0.18 1.94E-14 0.05 0.106041668

IRF4 0.18 1.98E-14 0.16 4.09E-08

ARNT 0.18 2.23E-14 0.10 0.000571869

TRPS1 0.18 2.93E-14

ZC3H7A 0.18 3.28E-14 0.14 1.33E-06

RHOB 0.18 3.58E-14

ASXL2 0.18 3.99E-14

ITGA4 0.18 4.04E-14 0.08 0.008613713

CCL4L2 0.18 5.53E-14 0.11 0.000238679

CCL4L1 0.18 5.69E-14 0.11 0.000238679

IGF2R 0.18 1.06E-13

SOD1 0.18 1.26E-13 0.18 4.99E-10

SYNGR2 0.18 1.31E-13 0.11 0.00010303

PDE3B 0.18 1.38E-13 -0.11 0.000178183

IFI16 0.18 1.43E-13 0.20 5.81E-12

PDE7B 0.18 1.46E-13

SLC2A8 0.18 1.59E-13

FYN 0.17 2.58E-13 0.23 2.55E-16

ARID5B 0.17 4.06E-13 0.22 2.72E-15

NFATC1 0.17 4.72E-13 0.10 0.000521207

TPI1 0.17 4.96E-13 0.17 2.07E-09

DTHD1 0.17 6.29E-13

CD3E 0.17 7.13E-13 0.03 0.271016862

CRIM1 0.17 7.24E-13

TMEM155 0.17 1.02E-12

INPP4B 0.17 1.66E-12 -0.06 0.035577188

OSBPL3 0.17 1.74E-12 0.16 4.35E-08

LIMS1 0.17 1.76E-12 0.17 1.29E-09

KCNK5 0.17 1.76E-12

KLRC2 0.17 2.17E-12

RGS4 0.17 3.04E-12

ACP5 0.17 3.13E-12 0.19 5.03E-11

DENND2D 0.17 3.30E-12 0.01 0.631199717

FAIM3 0.17 3.53E-12 0.04 0.189542882

DDX3Y 0.17 4.25E-12 0.00 0.907797482

HLA-H 0.16 4.66E-12 0.21 1.54E-13

GPR56 0.16 5.64E-12 0.11 6.30E-05

MAF 0.16 5.82E-12 0.36 2.14E-38

TRIM69 0.16 7.34E-12

SEMA4A 0.16 9.52E-12

IL2RG 0.16 1.04E-11 0.18 6.51E-10

TMEM140 0.16 l.llE-11 0.09 0.00163736

GMDS 0.16 1.18E-11 0.08 0.008326449

LITAF 0.16 1.19E-11 -0.05 0.063294972 HSPA1A 0.16 1.56E-11 0.11 0.000172577

PAPOLA 0.16 1.56E-11 -0.01 0.70579933

AHI1 0.16 2.36E-11 0.16 9.85E-09

EZR 0.16 2.40E-11 0.14 1.92E-06

MIS18BP1 0.16 2.58E-11 0.17 6.15E-09

HLA-A 0.16 2.74E-11 0.32 9.78E-31

PSTPIP1 0.16 3.27E-11 0.11 9.40E-05

GBP5 0.16 3.71E-11 0.13 5.66E-06

RIN3 0.16 3.77E-11

HIF1A 0.16 3.97E-11 0.06 0.048813828

HLA-DRB6 0.16 4.67E-11

PAGl 0.16 5.87E-11 -0.08 0.003384546

AKAP5 0.16 6.76E-11

KLRC3 0.16 6.90E-11

RFX5 0.16 8.25E-11 0.07 0.014179979

UBB 0.15 8.74E-11 0.13 5.13E-06

TXNDC11 0.15 9.85E-11 0.14 1.74E-06

FOXN2 0.15 l.OOE-10 0.05 0.082411107

DUSP16 0.15 1.15E-10 0.13 1.07E-05

CD82 0.15 1.38E-10 0.18 1.30E-10

PELI1 0.15 1.40E-10 0.20 6.92E-13

AMIG02 0.15 2.03E-10

CCDC141 0.15 2.42E-10 0.06 0.036155173

TNIP3 0.15 2.63E-10 0.10 0.000563452

SATl 0.15 2.71E-10 0.26 2.07E-20

LRBA 0.15 3.00E-10 0.12 2.66E-05

HLA-DMA 0.15 3.36E-10 0.20 2.02E-12

MAPRE2 0.15 3.48E-10 0.10 0.000867905

BIRC3 0.15 3.71E-10 -0.01 0.720398325

EPSTI1 0.15 4.13E-10 0.18 5.86E-10

NCALD 0.15 4.21E-10 0.22 5.12E-15

ID2 0.15 4.32E-10 -0.04 0.201480439

NFAT5 0.15 4.95E-10 0.14 5.55E-07

GOLIM4 0.15 6.33E-10

ZBTB32 0.15 6.70E-10

NDUFB3 0.15 6.70E-10 0.13 3.74E-06

CALM3 0.15 7.24E-10 0.22 2.32E-14

SHFM1 0.15 8.32E-10 0.09 0.000949937

HLA-DRB5 0.15 9.22E-10 0.17 1.46E-09

C21orf91 0.15 9.87E-10 0.07 0.011223721

CCND2 0.15 1.09E-09 0.02 0.530718461

BTLA 0.14 1.29E-09 0.16 1.30E-08

PRKCH 0.14 1.31E-09 0.12 3.11E-05

GALNT2 0.14 1.53E-09

IKZF3 0.14 1.77E-09 0.12 3.13E-05

AMICA1 0.14 2.14E-09 -0.06 0.026070815

STAT1 0.14 2.64E-09 0.05 0.064028082

IRF8 0.14 2.81E-09

ELFl 0.14 2.91E-09 0.02 0.548742854

CD3D 0.14 2.93E-09 0.16 5.77E-08

RBPJ 0.14 3.26E-09 0.12 2.32E-05

BATF 0.14 3.46E-09 0.34 3.15E-33

LRRC8D 0.14 3.57E-09 0.07 0.014705554

PMFl 0.14 3.60E-09 0.10 0.000379898

TNFSF4 0.14 4.01E-09

Example 4 - Tumor microenvironment analysis in melanoma tumors

[0456] T cells were also analyzed and the T cells contributed to the predicative value of the signature of the present invention (Figure 30).

[0457] The novel microenvironment cell-type signatures were very much associated with survival in both immunotherapy treated patients, and in general. The genes which are up/down regulated in the immune cells after immunotherapy (CD4 T-cells, CD8 T-cells, cells, and macrophages) are shown in Table 19.

Table 19. All Cell Type Signatures

iiiiiii^^ iiiiiiiiiiiiiiiiii T«.N* «IH

1 ZN F462

Table 20. Down-regulated and Up-regulated genes post-immunotherapy treatment in microenvironment

iiiiiiiie eiiiiiiiii iiiiiie §ili$llillll§ Macro.duw.,

Table 21. Top Genes from Table 20

Example 5

Protein-Protein interactions between genes in the resistance signatures

[0458] In line with the co/anti-regulatory patterns of the PIT-Up (ICR-Up, post- treatment-up) and PIT-Down (ICR-down, post-treatment-down) modules, a significantly large number of protein-protein interactions occur within and between the two modules (253 interactions, P = <le-3,) (Table 22). The number of interactions is ~7 times more than expected (empirical p-value)

Table 22.

GeneA GeneB GeneA GeneB

ACAA2 PFN1 FOXRED2 OS9

ACAA2 ATP1B3 FXYD3 NR4A1

ACAA2 ISYNA1 G6PD GBP2

ACSL4 PTPMT1 G6PD TSTA3

ACSL4 HTATIP2 G6PD IDH2

ADSL UBC GEM LZTS2

ADSL XPNPEP1 GLOD4 NR4A1

ADSL PAICS GLOD4 NNMT

AEN LZTS2 GLOD4 PAICS

AHNAK FN1 HDAC2 SMC3

AHNAK S100A10 HDAC2 KLF4

ALDH1B1 UBC HDAC2 RUVBL2

ALDH1B1 FN1 HDAC2 SNAI2

ALDH1B1 XPNPEP1 HDAC2 TSC22D3

ANXA1 UCHL5 HLA-A TAPBP

ANXA1 FN1 HLA-A TAP1

ANXA2 CTSB HLA-A UBC

ANXA2 S100A10 HLA-A ITM2B

ANXA2 MIDI HLA-A HLA-C

ANXA2 FN1 HLA-A HLA-E

ANXA2 LGALS1 HLA-C UBC

ARHGEF1 CD44 HLA-C HLA-F

ARHGEF1 FN1 HLA-C HLA-E

ATF3 STAT1 HLA-C ITGA6

ATF3 JUNB HLA-E HLA-F

ATP1A1 UBC HLA-E ITGA6

ATP1A1 ATP1B3 HSP90B1 OS9

ATP1B3 PTP4A3 HSP90B1 TPM1

ATP1B3 HLA-C HSP90B1 RPN2

ATP1B3 RPL17 HSP90B1 TSR1

ATXN10 BSG HSP90B1 STAT1

ATXN10 FN1 IDH2 UBC

ATXN10 MRPS16 IGF1R IGFBP3

ATXN2L GALNS IGFBP3 TF

ATXN2L PABPC1 ILF2 XRCC5

BCCIP EIF6 ILF2 RPL17

BCCIP FAM46A ILF2 RPL10A

BCCIP SORD ILF2 RPS3

BCCIP SMS ILF2 SRSF7

BCL6 JUNB ILF2 PRKCDBP GeneA GeneB GeneA GeneB

BCL6 HDAC2 ILF2 TOMM22 BCL6 PELIl ILF2 PTRF

BIRC3 UBC ILF2 RUVBL2

BSG 0S9 ILF2 MYBBP1A

BSG MYBBP1A ILF2 KIAA0020

BSG XP07 ITGA6 LGALS3BP

BSG METAP2 KLF4 KLF6

BSG PTPMT1 LAMB1 UBC

CALU GAA LGALS1 LGALS3BP

CALU PRKCDBP LZTS2 TSNAX

CALU CTNNAL1 LZTS2 SMIM3

CALU HSP90B1 MIDI RPS3

CAV1 CD44 MIDI UBC

CAV1 PTRF MTG1 PRNP

CD151 CD46 MYBBP1A NR4A1

CD44 IGFBP3 MYBBP1A RPS3

CD44 FN1 MYBBP1A PTRF

CD44 NF2 NCBP1 THOC5

CD46 CD9 NCBP1 SERPINE2

CD9 LGALS3BP NF2 XRCC5

CFB FN1 NF2 RPS3

CPSF1 P0LR2A NF2 RPS7

CRELD1 EIF6 NF2 SMC3

CRYAB CS NOLC1 PTRF

CRYAB SORD OXA1L PTPMT1

CS CTPS1 PABPC1 RPSA

CST3 CTSB PABPC1 RBM4

CTSA CTSD PABPC1 RPL10A

CTSB S100A10 PABPC1 RPL17

CTSB SPRY2 PELIl UBC

CTSD UCHL5 PFN1 UCHL5

CTSD HSP90B1 POLR2A XRCC5

DCBLD2 ITM2B POLR2A SMC3

DCTN6 RPSA POLR2A PSMB9

ECHS1 UCHL5 POLR2A RUVBL2

ECHS1 ISYNA1 PRAME UBC

EGR1 JUNB PRDX3 UCHL5

EIF4A1 PABPC1 PRDX3 PSME1

EIF4A1 UCHL5 PROS1 RPSA

EIF4A1 RPSA PSMB9 PSME1

EIF4A1 TMEM43 PSMB9 UCHL5

EIF4A1 ILF2 PTP4A3 XP07

EIF4A1 FN1 RND3 SKP2

EIF6 PAICS RPL10A RPS3

EIF6 PSME1 RPL10A RPL17

EIF6 FBL RPL10A RPSA

EIF6 RPL17 RPL10A S100A10

EIF6 RUVBL2 RPL10A RPS7

EIF6 TSNAX RPL17 RPS3

EIF6 KIAA0020 RPL17 RPSA

EMP1 SMIM3 RPN2 UBC

EPDR1 NF2 RPS3 RPS7

FAM213A HLA-C RPS3 RPSA

FAM46A PRSS23 RPS3 TPM1

FAM46A SQRDL RPS3 TSR1

FAM46A FNDC3B RPS3 UBC

FBL RUVBL2 RPS3 TSNAX GeneA GeneB GeneA GeneB

FBL KLF6 RPS7 RPSA

FBL UBC RPS7 TSR1

FBL N0LC1 RPSA TSR1

FBL RPL17 RUVBL2 SRCAP

FBL RPS7 RUVBL2 UCHL5

FBL RPS3 RUVBL2 UBC

FBL FN1 RUVBL2 VPS72

FBL GPATCH4 SAM M 50 TOMM22

FBL KIAA0020 SAM M 50 SQRDL

FBLN1 FN1 SAM M 50 SERINCl

FN1 IGFBP3 SMG7 TSNAX

FN1 MIA SMS SORD

FN1 TNC SORD TPM1

FN1 LGALS1 SRCAP VPS72

FN1 LYPLA1 STAT1 TSNAX

FN1 RPL17 TAP1 TAPBP

FN1 RNH1 TPM1 UBC

FN1 G6PD TSC22D3 UBC

FN1 PAICS TSTA3 UBC

FN1 SLC5A3 UBA7 UBE2L6

FN1 NCBP1 UBC UCHL5

FN1 PPA1 UBC XPNPEP1

FN1 XRCC5 UCHL5 XPNPEP1

FN1 RPSA

FN1 RUVBL2

FN1 PRDX3

FN1 RPL10A

FN1 RPS7

FN1 ILF2

FN1 PFN1

FN1 UBAP2L

FN1 PABPC1

FN1 RPS3

FN1 UBC

FN1 RBM4

FN1 TF

Example 6 - Tumor microenvironment interaction analysis

[0459] The ITR-down genes and ITR-up genes interact with stromal and immune genes. The ITR-down genes interact with more genes (Figure 34, 35). Figure 33 shows that genes that are down in malignant cells in immunotherapy resistant samples are rich in interactors of immune and stromal cells. Conversely, few such interaction genes are induced in malignant cells in immunotherapy resistant samples.

Example 7 -ITR signature scores from melanoma tumors in different cancers

[0460] The ITR scores are different in different cancers (Figure 36, 37). Bladder cancer has the highest. Thymoma has the lowest. Uveal melanoma has the fourth highest. Applicants observed a difference in score between two melanomas (uveal and skin cutaneous). Not being bound by a theory, cancers with the highest ITR scores are more resistant to immunotherapy than cancers with a lower score. Not being bound by a theory, cancers with the highest ITR scores have a worse prognosis. The cancers on the right are more sensitive to immunotherapy (Figure 36). Furthermore, they have less of an anti -correlation between ITR and T cell infiltration.

Example 8 -Analysis of Single Cells from ER+ Metastatic Breast Cancer and Colon Cancer

[0461] Applicants also analyzed single cells in other cancers having an ICR signature, (see, e.g., Figure 15A, B). Applicants further extended the melanoma ecosystem studies to study response to immunotherapy, using massively parallel droplet scRNA-Seq to analyze cells from colon tumors, using snRNA-Seq methods to profile metastatic breast cancer samples and profiling pancreatic tumors. Cancer cells may be more or less resistant to immunotherapy based on uICR scores. Single cells in other cancers may be shifted to an immunotherapy sensitive signature by treating with CDK4/6 inhibitors. Analysis of this signature and measuring shifts in the signature after CDK4/6 inhibition can allow the proper administration of an immunotherapy in a combination treatment.

[0462] Applicants analyzed ER+ metastatic breast cancer using single nuclei RNA-seq (snRNA-seq) on fresh and frozen tissue samples (Figure 38). snRNA-seq as described herein is compatible with frozen tissue samples. Non-malignant cells clustered by cell type in both frozen and fresh tissue samples. Malignant cells clustered by patient.

[0463] Applicants analyzed 22 colon cancer samples using scRNA-seq (Figure 39). With strict quality control (QC) on the 22 samples analyzed Applicants obtained 12,215 epithelial cells and 17, 143 non-epithelial cells.

Example 9 - Immunotherapy Resistance Signature

[0464] Immunotherapies have transformed the therapeutic landscape of several cancer types (Sharma and Allison, 2015). However, despite the durable responses in some patients, most patients' tumors manifest unpredictable resistance to immunotherapies (Gibney et al., 2016; Sharma et al., 2017). This hampers appropriate selection of patients for therapies, rational enrollment to clinical trials and the development of new therapeutic strategies that could overcome resistance (Sharma and Allison, 2015). Most non-responding patients manifest intrinsic resistance, reflected as continued tumor growth or occurrence of new metastatic lesions despite therapy, whereas some patients develop acquired resistance following an initial clinical disease regression. It is unknown whether these clinically discrete manifestations are associated with shared or distinct molecular mechanisms of resistance (Sharma et al., 2017).

[0465] Recent studies characterized resistance to immune checkpoint inhibitors (ICI) by analyzing Whole Exome Sequencing (WES) and transcriptional profiles of bulk tumors (Hugo et al., 2016; Mariathasan et al., 2018; Van Allen et al., 2015). These studies demonstrated that tumors with a high mutational load (Van Allen et al., 2015) and a high level of immune cell infiltration (Riaz et al., 2017; Tumeh et al., 2014) are more likely to respond, and linked ICI resistance in patients to functional immune evasion phenotypes, including defects in the JAK/STAT pathway (Zaretsky et al., 2016) and interferon gamma (IFN-γ) response (Gao et al., 2016; Zaretsky et al., 2016), impaired antigen presentation (Hugo et al., 2016; Zaretsky et al., 2016), and PTEN loss (Peng et al., 2016). While these studies significantly contributed to the understanding of the cancer-immune interplay, the resulting biomarkers where only partially predictive (Sharma et al., 2017). This may be due to the fact that they only reflect some facets of the causes of resistance (WES) or combine signals from malignant and non-malignant (immune and stroma) cells (RNA and copy- number variations).

[0466] Because immune checkpoint inhibitors target the interactions between different cells in the tumor, their impact depends on multicellular circuits between malignant and non- malignant cells (Tirosh et al., 2016a). In principle, resistance can stem from different compartment of the tumor' s ecosystem, for example, the proportion of different cell types (e.g., T cells, macrophages, fibroblasts), the intrinsic state of each cell (e.g., memory or dysfunctional T cell), and the impact of one cell on the proportions and states of other cells in the tumor (e.g., malignant cells inducing T cell dysfunction by expressing PD-L1 or promoting T cell memory formation by presenting neoantigens). These different facets are inter-connected through the cellular ecosystem: intrinsic cellular states control the expression of secreted factors and cell surface receptors that in turn affect the presence and state of other cells, and vice versa. In particular, brisk tumor infiltration with T cell has been associated with patient survival and improved immunotherapy responses (Fridman et al., 2012), but the determinants that dictate if a tumor will have high ("hot") or low ("cold") levels of T cell infiltration are only partially understood. Among multiple factors, malignant cells may play an important role in determining this phenotype (Spranger et al., 2015). Resolving this relationship with bulk genomics approaches has been challenging; single-cell RNA-seq (scRNA-seq) of tumors (Li et al., 2017; Patel et al., 2014; Tirosh et al., 2016a, 2016b; Venteicher et al., 2017) has the potential to shed light on a wide range of immune evasion mechanisms and immune suppression programs.

[0467] Here, Applicants used scRNA-seq and a new computational approach to identify immune evasion or suppression mechanisms in the melanoma ecosystem (Figure 44A,B) Applicants developed a data-driven approach that integrates scRNA-seq with other data sources to characterize malignant cell states that drive immune resistance in melanoma (Figure 44B). Applicants identified a program in malignant cells that is associated with T cell exclusion prior to immunotherapy, and with the melanoma cell states in patients who were resistant to immunotherapies. Applicants confirmed its presence in situ in tumors with multiplex protein imaging. This program predominantly reflects intrinsic resistance to immune checkpoint inhibitors (but not to RAF/MEK-targeted therapy) and its expression predicts responses to ICI and clinical outcomes in independent patient cohorts. Applicants further associated the CDK4/6 pathway with control of this program and showed that treatment with CDK4/6 inhibitors reverses it and promotes a senescent-like state and when combined with immunotherapies, may even overcome resistance in vivo.. This work provides a new predictive biomarker for ICI response, suggests a new therapeutic modality that may re-sensitize malignant melanoma cells to ICI, and provides a general framework to study the effect of immunotherapies and other drugs on complex tumor ecosystems.

RESULTS

Systematic approach to discover malignant cell programs associated with immune cell infiltration or exclusion

[0468] To identify malignant cell programs that characterize "cold" melanoma tumors, Applicants devised a new strategy that combines scRNA-seq and bulk RNA-Seq data to relate the cellular state of one cell type {e.g., malignant cell states) to the cellular composition of the tumors {e.g., T cell infiltration vs. exclusion) (Figure 44B). For clarity, Applicants describe the strategy in this specific context, though it can be applied to any two cell-types of interest. Applicants first use scRNA-seq profiles to define cell type specific signatures of T cells and of malignant cells in melanoma tumors. Next, Applicants use the T cell signature to estimate T cell infiltration levels in each of hundreds of tumors, based on their bulk RNA-Seq profile. For the analysis outlined here, Applicants focused on CD8+ T cells, but Applicants have inferred the relationship between cancer cells and other T cell populations, including pan-T cells (CD3 ⁺ ), CD8 ⁺ T cells, and CD4 ⁺ T cells; naive, cytotoxic, and exhausted CD8 ⁺ T cell; and naive, exhausted, and regulatory CD4 ⁺ T cells (Methods).

[0469] Applicants then define a "seed exclusion program" by identifying genes from the malignant cell signature whose expression is strongly correlated (positively or negatively) with the T cell infiltration level across those bulk tumors. Because the seed program is identified only among a few hundred genes that are exclusively expressed by scRNA-Seq in malignant cells, it avoids contamination from the tumor microenvironment; however, important genes that promote exclusion or infiltration may also be expressed by non- malignant cells {e.g., MHC class I molecules). To recover these genes, Applicants finally return to the scRNA-seq data of the malignant cells and expand the seed program by searching for genes that are correlated with it across the single malignant cells, irrespective of their expression in other cell types. In this way, Applicants derive a genome-scale, malignant-cell exclusion program, consisting of genes induced ("up") or repressed ("down") by malignant cells in "cold" vs. "hot" tumors. Applicants can then score each cell or tumor for expression of the program, such that overexpression of the program is defined as the overexpression of its induced part and underexpression of its repressed part, and vice versa (Methods)

Analysis of clinical scRNA-seq identifies a malignant cell program associated with T cell exclusion from melanoma tumors

[0470] Applicants applied the approach to 7, 186 high-quality scRNA-seq profiles from the tumors of 31 melanoma patients, comprised of 2,987 cells from 16 newly collected patient tumors (Figure 44A, Table 1), and 4, 199 cells from 16 patients that Applicants previously reported (Tirosh et al., 2016a), along with 473 bulk RNA-seq melanoma profiles from The Cancer Genome Atlas (TCGA) (Akbani et al., 2015). Applicants dissociated individual cells from fresh tumor resections, isolated immune and non-immune cells by FACS based on CD45 staining, and profiled them with a modified full-length SMART-Seq2 protocol (Methods, Table 2). Applicants distinguished different cell subsets and genetic clones both by their expression profiles and by their inferred CNV profiles (Tirosh et al., 2016a) (Methods), identifying: malignant cells, CD 8 and CD4 T cells, B cells, K cells, macrophages, Cancer Associated Fibroblasts (CAFs) and endothelial cells (Figures 44C,D and 51, Tables 26C and 3). Overall, malignant cells primarily grouped by their tumor of origin (Figure 44C), while the non-malignant cells grouped primarily by their cell type, and only then by their tumor of origin (Figure 44D), as Applicants have previously reported for melanoma and other tumor types (Puram et al., 2017; Tirosh et al., 2016a; Venteicher et al., 2017).

[0471] The resulting exclusion program (Figure 44E, Table 5) highlights the repression of diverse immune response pathways and the induction of a co-regulated gene module of Myc and CDK targets. The repressed genes were enriched for antigen processing and presentation genes (B2M, CTSB, CTSL1, HLA-B/C/F, HSPA1A, HSPA1B, P = 4.19* 10 ^"7 , hypergeometric test), immune modulation genes (P = 3.84* 10 ^"9 , e.g., CD58 and the NFKB inhibitor, NFKBIA), and genes involved in the response to the complement system (P = 2.26* 10 ^"7 , e.g., CD59 and C4A). CD58 KO in malignant cells was recently shown to enhance the survival of melanoma cells in a genome-scale CRISPR screen of melanoma/T cell co- cultures (Patel et al., 2017), and its genetic loss or epigenetic inactivation are frequent immune evasion drivers in diffuse large B cell lymphoma (Challa-Malladi et al., 2011). The induced genes included MYC and Myc targets (P = 2.8* 10 ^"14 ), many CDK7/8 targets (P < 3* 10 ^"9 ) (Oki et al., 2018), and transcription factors, such as SNAI2 and SOX4. Myc-activation has been previously linked to increased expression of immunosuppressive signals, including the upregulation of PD-Ll and β-catenin, which in turn inhibits dendritic cell recruitment to the tumor microenvironment via CCL4 (Spranger et al., 2015).

[0472] Applicants tested whether other cell populations with sufficient scRNA-seq profiles, including macrophages and B cells, contributed to T cell exclusion/infiltration, but did not find significant impact on regulating T cell abundance.

The exclusion program characterizes individual malignant cells from patients who developed progressive disease on immunotherapy

[0473] To determine whether the malignant T cell exclusion program manifests in the context of immune checkpoint inhibitor therapy, Applicants leveraged the fact that the scRNA-seq cohort included both untreated patients and post-ICI patients who manifested intrinsic resistance. As clinical response rates to ICI vary, with up to 61% responders with combination therapies (Hodi et al., 2010; Larkin et al., 2015; Postow et al., 2015; Ribas et al., 2015), the untreated tumors Applicants profiled likely include both ICI sensitive and ICI resistant tumors, whereas the tumors from ICI resistant patients are expected to include primarily resistant malignant cells. Applicants thus turned to examine if the exclusion program is more pronounced in the malignant cells from ICI resistant vs. untreated patients. ScRNA-seq data provide particular power for such inter-patient comparisons, even when considering only a small number of tumors, because of the larger number of cells per tumor and because non-malignant cells in the tumor microenvironment do not confound the analyses.

[0474] Applicants thus independently identified a post-treatment transcriptional program, consisting of features that distinguish individual malignant cells from post-ICI resistant tumors compared to malignant cells from untreated tumors (Table 5). Applicants found a robust post-treatment program, consisting of genes induced (up) and repressed (down) by malignant cells from the post-treatment resistant vs. untreated patients, which is stable and generalizable in cross-validation (Methods, Figure 45A, AUC=0.83). In principle, the program might reflect both the overall impact of ICI therapy and intrinsic ICI resistance per se, but those cannot be directly distinguished based on the single-cell cohort, where Applicants did not have matched samples from the same patient or pre-treatment tumors from responders and non-responders. Applicants address this below by analyzing two independent validation cohorts.

[0475] The post-treatment program substantially overlapped the exclusion program (Figures 44E and 45B,C, Table 5; P <10 ^"16 , hypergeometric test, Jaccard index = 0.27 and 0.23, for induced and repressed genes, respectively) and highlighted similar modules and pathways (Figure 45D), even though the exclusion program was identified without considering the treatment status of the tumors in the scRNA-seq data and with bulk RNA-Seq data of untreated patients. Both programs robustly classified individual cells as untreated or post-treatment (AUC = 0.83 and 0.86 for cross-validation post-treatment and exclusion, respectively, Figure 45A,E). Notably, a number of overlapping genes encode for ribosomal proteins (including 46 genes in the upregulated components of both signatures). This is consistent with the observation of Myc upregulation in both signatures, which is a major regulator of ribosome biogenesis (Kress et al., 2015), and whose knockdown is among the top perturbations predicted to repress the program according to the Connectivity map (Subramanian et al.). To exclude the possibility that the overlap was dominated only by this signal, Applicants removed the ribosomal genes from the signatures altogether, but observed a preserved significant overlap (P < 10 ^"17 ) between both signatures with 41 and 77 overlapping genes out of a total of 197 and 244 induced or repressed compartments, respectively. Overall, in light of the congruence of the signatures, Applicants defined a unified immune resistance program as the union of the corresponding post-treatment and exclusion programs, and used it in all subsequent analyses, unless indicated otherwise.

The immune resistance program reflects a coherent multifaceted state of immune evasion

[0476] The program is consistent with several hallmarks of active immune evasion, suppression and exclusion. First, even though the program was derived in cutaneous melanoma, it is more pronounced in uveal melanoma, which resides in an immune-privileged environment and has very low response rates to immunotherapy, compared to cutaneous melanoma (Figure 46A) (Algazi et al., 2016; Zimmer et al., 2015). Second, the inhibition of genes from the repressed component of the program in malignant melanoma cells conferred resistance to CD8 T cells in a genome-wide CRISPR KO screen (P = 6.37* 10 ^"3 , hypergeometric test) (Patel et al., 2017). Third, malignant cells which express the program substantially repress a significant number of interaction routes with other cell types in the tumor microenvironment, including MHC LTCR (T cells), CD58.CD2 (T cells), and ILIRAP JLIB (macrophages) (Figure 46B, Methods), as well as the overall Senescence Associated Secretory Phenotype (SASP) (P = 4.3* 10 ^"166 and 3.6* 10 ^"3 , one-sided t-test and mixed effects, respectively, Figure 45D, right).

[0477] The program genes appear to be under shared control by one or a few master regulators, with opposing effects on the repressed and induced components of the program. There was a strong positive correlation within the induced or repressed genes, and a strong anti -correlation between the induced and repressed genes, both across single cells in the same tumor and across TCGA tumors (Figures 46C,D). The co-variation patterns were remarkably reproducible within each one of the tumors in the cohort (Figure 52), such that any given aspect of the program {e.g., under-expression of MHC-1 genes in a cell) is coupled to the state of the entire program. Moreover, there is a significant overlap between the perturbations that reverse the expression of the program's repressed and induced components (p- value=2.33* 10 ^"14 , hypergeometric test), including the overexpression of IFN-γ and IFN-β and the knockdown of MYC (Subramanian et al., 2017). Indeed, MYC knockdown is among the top perturbation to repress the program, which is enriched for Myc targets.

Expression of resistance program features in malignant cells in T cell-depleted niches in situ [0478] If the immune resistance program in malignant cells is associated with T cell exclusion, malignant and T cells should vary in their relative spatial distribution in tumors depending on the activity of the program. To explore this, Applicants used multiplexed immunofluorescence (t-CyCIF) (Lin et al., 2017) to stain histological sections of 19 tumors from the single-cell cohort for 14 proteins: six cell type markers (CD3, CD8, MHC-II, FOXP3, S100, and MITF) and eight members of the immune resistance program (induced: p53, CEP170, Myc, DLL3; repressed: HLA-A, c-Jun, SQSTM1, LAMP2). Following cell segmentation and estimation of antibody staining intensities (Methods), Applicants assigned cells (424,000 cells/image on average) into malignant cells (S100 ⁺ , MITF ⁺ ), T cells (CD3 ⁺ ) and cytotoxic T cells (CD8 ⁺ ); the rest were defined as uncharacterized.

[0479] To explore the association between the program markers and the "cold" phenotype, Applicants first generated a Delaunay neighborhood graph for each image (linking cells that are immediate neighbors) and computed the observed frequency of cell-to- cell interaction compared to that expected by chance, as recently described (Goltsev et al., 2017). Malignant cells were significantly more likely to reside next to other malignant cells, and significantly less likely to reside next to T cells (P < 1 * 10 ^"16 , binomial test, Methods). Next, for each frame in the imaged section (1,377 cells/frame on average; Methods), Applicants computed the fraction of T cells and the average expression of the different markers in the malignant cells. Applicants then quantified the association between expression of the immune resistance program markers and T cell infiltration levels across frames from the different images (Methods). Confirming this analysis approach, malignant cells in highly infiltrated niches had significantly higher levels of HLA-A (Figure 47A, P = 2.61 * 10 ^"46 , mixed-effects). Moreover, in line with the predictions, malignant cells in cold/hot niches had significantly lower/higher levels of c-Jun (repressed in the resistance program), respectively (Figure 47B, P = 2.85* 10 ^"12 , mixed-effects), whereas p53, induced in the resistance program) characterized cold niches (P = 6.16* 10 ^"7 , mixed-effects). Applicants do note, however, that LAMP2 expression (repressed in the resistance program) was also associated with cold niches, potentially due to its post-transcriptional regulation (Feng et al., 2015).

[0480] Finally, since only a few markers were analyzed in situ, Applicants tested whether scRNA-seq and multiplex in situ protein profiles can be combined to jointly learn cell states, using a variant of canonical correlation analysis (CCA) (Butler and Satija, 2017) (Methods). The cells were primarily embedded and clustered based on their cell types, and not according to source, confirming the congruence of the two datasets, and that the markers tested can link global transcriptional cell states to spatial organization in tissue (Figures 47C,D and 53). Taken together, these results support the association between the expression of the immune resistance program and the cold phenotype.

The immune resistance program is intrinsic in melanoma cells prior to treatment and is enhanced specifically post-immunotherapy

[0481] Applicants hypothesized that the immune resistance program, while more pronounced in the malignant cell of patients after ICI, in fact reflects an intrinsic resistance mechanism, present even before immunotherapy. First, the program is detected in TCGA tumors, which were all untreated. Second, while the program is more predominant in the malignant cells of the post-treatment resistant patients, it is also overexpressed in a subset of the malignant cells from untreated patients (Figure 44E and 45C, right plots). This is aligned with clinical observations that intrinsic ICI resistance is more prevalent than acquired ICI resistance (Sharma et al., 2017). However, because the scRNA-seq cohort did not include matched samples from the same patient or pre-treatment tumors from subsequent responders vs. non-responders, Applicants could not directly distinguish intrinsic resistance from post- treatment effects.

[0482] To test this hypothesis, Applicants therefore analyzed an independent cohort of 90 specimens collected from 26 patients with metastatic melanoma who underwent ICI therapy, with bulk RNA-Seq from biopsies collected pre-treatment (n = 29), on-treatment (n = 35), and at the time of progression (n = 26) (Figure 44A, validation cohort 1). Applicants tested for changes in the program score during the course of treatment, while accounting for tumor composition (Methods). The program was induced in on- and post-treatment samples compared to pre-treatment samples from the same patient (P = 1.36* 10 ^"4 and 4.98* 10 ^"2 , immune resistance program, refined and non-refined, respectively, mixed-effect test,

Methods), consistent with its overexpression in individual post-ICI malignant cells in the unmatched single-cell cohort (Figures 44E and 45C). However, inter-patient variation in the program's expression was significantly higher than these intra-patient changes (P < 10 ^"8 ,

ANOVA). This suggested that the major differences between the post-treatment and untreated tumors in the single-cell cohort reflect, at least in part, intrinsic differences between the two groups, which preceded the treatment, which Applicants turned to assess in a second validation cohort (below). Notably, Applicants did not observe an induction in the program following RAF/MEK-inhibition, indicating that the immune resistance state it defines is specific to ICI therapy and not merely a generic marker of any drug resistant tumor. The immune resistance program predicts patient survival and clinical responses to ICI

[0483] The association of the program with T cell infiltration, its functional enrichment with immune evasion and exclusion mechanisms, its intrinsic expression in some malignant cells prior to treatment, and its further induction in post-ICI resistant lesions could make it a compelling biomarker for response to immunotherapy. To test this hypothesis, Applicants examined the program in multiple independent cohorts. Applicants used both the full program and one refined to the subset of genes that are co-regulated (positively) or anti- regulated (negatively) with genes whose inhibition desensitized melanoma cells to T cell mediated killing in functional screens (Patel et al., 2017) (Table 5, Methods) (The exclusion and post-treatment programs show similar signals and trends; Figures 48E-H and 54-55).

[0484] The underexpression of the program was strongly associated with improved survival in 473 TCGA melanoma patients (who did not receive ICI immunotherapy, Figures 48A and 54), even after controlling for tumor purity and inferred T cell infiltration (Azimi et al., 2012; Bogunovic et al., 2009). Furthermore, combining the program with inferred T cell infiltration levels yielded significantly more accurate predictions of patient survival than either alone (COX p-value = 1.4* 10 ^"8 , Figure 48A, right). Other proposed mechanisms, such as de-differentiation of melanoma cells (Landsberg et al., 2012), as reflected by an MITF-low signature, and other malignant cell signatures (e.g., cell cycle or the AXL program) (Tirosh et al., 2016a), did not show an association with patient survival, indicating that mere biological variation across malignant cells is insufficient as a prognostic signature.

[0485] The program expression in published pre-treatment and early on-treatment bulk expression profiles also distinguished eventual ICI responders from non-responders in those studies (Figures 48B,C). In a lung cancer mouse model, the program expression in early on- treatment profiles clearly separated anti-CTLA-4 responders from non-responders (P = 3.6* 10 ^"7 , one-sided t-test, Figure 48B) (Lesterhuis et al., 2015). In bulk pre-treatment RNA- Seq data from 27 melanoma patients that were subsequently treated with Pembrolizumab (anti-PD-1) (Hugo et al., 2016), the program was underexpressed in the five complete responders, though just above statistical significance (P = 6.3* 10 ^"2 , one-sided t-test, Figure 48C). In bulk pre-treatment RNA-Seq data from 42 melanoma patients that were subsequently treated with the CTLA-4 inhibitor ipilimumab (Van Allen et al., 2015), the program was significantly lower in the two complete responders (P = 5.2* 10 ^"3 , one-sided t- test). [0486] To test the predictive value of the program in a larger independent setting, Applicants assembled a validation cohort of 112 patients with metastatic melanoma who underwent a pre-treatment biopsy and bulk RNA-Seq followed by Pembrolizumab (anti-PD- 1) therapy (Figure 44A, validation cohort 2, Table 1). The cohort was collected in a different hospital and country (Germany; Methods), and samples were processed and sequenced on the same platform (Methods). Applicants evaluated the program's performance in predicting anti-PD-1 responses as reflected by: (1) progression-free survival (PFS, recorded for 104 of the 112 patients), (2) clinical benefit (CB, defined as either partial or complete response by RECIST criteria), and (3) complete response (CR) (Methods). Applicants also compared the performance of the predictors to those of 32 other signatures, including the top hits of two functional CRISPR screens of resistance to T cells and ICI (Manguso et al., 2017; Patel et al., 2017) (Table 9, Methods).

[0487] The programs were predictive of PFS in the validation cohort (Figures 48D and

55A-E), even when accounting for other known predictors of ICI response, including inferred

T cell infiltration levels and PD-L1 expression (Figure 55E). Although cell cycle alone is not associated with PFS (COX P > 0.25), filtering the cell-cycle component from the program score (Methods, and below) further improved PFS predictions (Figure 48D, right), suggesting that a tumor's immune resistance should be evaluated conditioning on its proliferation level. The program had a strong predictive value beyond T cell infiltration (P =

3.37* 10 ^"6 , Wilcoxon-ranksum test), and was the only one negatively associated with PFS.

Other alternative signatures were either not predictive or did not provide any additive predictive value once accounting for T cell infiltration levels (Figure 48E).

[0488] The program was underexpressed in patients with clinical benefit (CB) compared to those without benefit (no-CB) (Figure 48F). Nevertheless, some patients with clinical benefit had high pre-treatment expression of the program. Applicants hypothesized that these patients might cease to respond quickly, due to pre-existing intrinsically resistant cells, like those Applicants observed in the single-cell cohort and in validation cohort 1. Indeed, among patients with clinical benefit, those with high expression of the program pre-treatment were significantly more likely to experience subsequent progressive disease (Figure 48F), and those with rapid progression (CB<6 months) had the highest scores of the program, even compared to those with no clinical benefit. Consistently, the program was most accurate in predicting patients with complete responses (P < 6.31 * 10 ^"3 , one-sided t-test, Figures 48G and 55F), outperforming all the other predictors (P = 1.64* 10 ^"8 , Wilcoxon ranksum test), all of which, including clinically-used markers and inferred T cell infiltration levels, failed to predict complete response (Figure 48H).

The immune resistance program is coherently controlled by CDK4/6

[0489] Applicants reasoned that the program could be a compelling drug target: it was identified by its association with a critical process - T cell exclusion - that affects resistance to immunotherapy; it is a significantly predictive biomarker of ICI resistance; and it appears to be coherently regulated, such that a shared control mechanism could be targeted to reverse it.

[0490] To this end, Applicants identified drugs that were significantly more toxic to cell lines overexpressing the immune resistance program (controlling for cancer types, Methods), according to the efficacy measures of 131 drugs across 639 human cancer cell lines (Garnett et al., 2012). The top scoring drug was a CDK4/6-inhibitor (palbociclib) (P = 6.28* 10 ^"6 , mixed-effects). Furthermore, the efficacy of CDK4/6 inhibition and the expression of the resistance program were also correlated in a study where the efficacies of CDK4/6 inhibitors palbociclib and abemaciclib were measured across a collection of cancer cell lines (P = 7.15* 10- ⁶ , mixed-effects) (Gong et al., 2017).

[0491] Applicants further hypothesized that CDK4 and 6 may act as the master regulators of the immune resistance program. First, both CDK4 itself and multiple CDK target genes, are members of the of the induced program (Figure 45C, Table 5). Second, the program is more pronounced in cycling cells (where CDK4/6 are active), both within the same patient group and among cells of the same tumor (Figures 44E, 45C, and 56A,B, P < 10 ^"16 , mixed effects model). Importantly, the program is not merely a proxy of the cell's proliferation state: there was no significant difference between the fraction of cycling cells in untreated vs. post-treatment tumors (P = 0.696, t-test), the program was nearly identical when identified only based on non-cycling cells, and - unlike the expression of the resistance program - the expression of cell cycle signatures was not associated with the efficacy of CDK4/6 inhibitors across the cell lines. Finally, Applicants analyzed recently published expression profiles (Goel et al., 2017) of breast cancer cell lines and in vivo mouse models and found that CDK4/6 inhibition by abemaciclib represses the program (Figures 49A-C and 56C). Thus, multiple lines of evidence suggest that CDK4/6 inhibition could repress the expression of the immune resistance program and shift the cancer cell population to a less immune resistant state. The immune resistance program can be intrinsically expressed and repressed by CDK4/6 inhibitors in melanoma cells

[0492] To test this hypothesis, Applicants studied the effect of abemaciclib on the immune resistance program in melanoma cell lines. Applicants selected three melanoma cell lines from the Cancer Cell Line Encyclopedia (Barretina et al., 2012) that exhibited strong expression of the resistance program (Table 23), two of which are RBI -sufficient (IGR37, UACC257) and one is RBl-deficient (A2058). Notably, these cells expressed the resistance program in the absence of microenvironmental cues, indicating the importance of intrinsic expression of this program in cancer cells. Applicants profiled each cell line with scRNA-seq before and after treatment with abemaciclib for 1 week (Figures 49D-E), analyzing over 23,000 cells in these and follow-up conditions (below).

[0493] Table 23. The overall expression (OE) of the immune resistance signature across the CCLE melanoma cell lines.

Melanoma cell Immune

line resistance OE

HMCB 0.818

LOXI MVI 0.72

UACC257 0.706

CHL1 0.698

IGR37 0.57

M ELHO 0.522

COL0741 0.5

G361 0.476

COL0679 0.468

A2058 0.465

SKM EL3 0.443

G RM 0.431

SKM EL30 0.405

M EWO 0.371

A375 0.368

HS936T 0.339

K029AX 0.308

I PC298 0.261

IGRl 0.243

SKM EL1 0.238

SKM EL5 0.182

COL0783 0.174

COL0849 0.082

CJM 0.06

M EUUSO 0.049

COL0792 0.041

UACC62 0.015

M DAM B435S 0.005

IGR39 0

WM2664 -0.015 WM88 -0.045

HS944T -0.053

RPMI7951 -0.067

WM983B -0.09

WM 1799 -0.091

A101D -0.097

HS895T -0.126

SKM EL28 -0.152

SH4 -0.226

RVH421 -0.227

HT144 -0.23

SKM EL2 -0.242

COLO800 -0.251

HS294T -0.264

WM793 -0.265

HS852T -0.341

HS934T -0.368

COL0829 -0.377

HS839T -0.386

C32 -0.427

HS940T -0.434

HS688AT -0.435

HS939T -0.464

HS600T -0.464

COL0818 -0.466

HS695T -0.5

WM 115 -0.513

MALME3M -0.607

SKM EL31 -0.759

SKM EL24 -0.975

[0494] Consistent with the hypothesis, only in the RB-sufficient cell lines, abemaciclib dramatically decreased the proportion of cells overexpressing the immune resistance program and induced an immune response in the surviving cells. In the RBI -sufficient lines, IGR37 and UACC257, 10% of the cells had exceptionally strong expression of the immune resistance program ("immune resistant" cells) prior to treatment, decreasing to 2% and 1% of cells post-treatment, respectively (P < 1 * 10 ^"30 , hypergeometric test) (Figures 49D,E). In contrast, in the RBI-deficient line A2058 the treatment did not repress the immune resistant state (P > 0.5, one-sided t-test), consistent with the hypothesis that the effects of CDK4/6 inhibitors are RB-dependent.

[0495] Moreover, in the two RB-sufficient lines, the remaining cells that underexpressed the immune resistance program, underwent substantial transcriptional changes, including the induction of key repressed component of the immune resistance program, such as the senescence-associated secretory phenotype (SASP). In particular, abemaciclib repressed the expression of D MT1 (P < 2.23 * 10 ^"106 , likelihood-ratio test), consistent with previous observations (Goel et al., 2017) that CDK4/6 inhibition leads to D MT1 repression, allowing the methylation of endogenous retroviral genes (ERVs), which in turn triggers a double- stranded RNA (dsRNA) response and stimulates type III IFN production (Goel et al., 2017). Following abemaciclib treatment there was also a higher portion of cells with induction of a MITF program (Tirosh et al., 2016a), which is repressed in "immune resistant" cells (P < 3.33* 10 ^"15 , hypergeometric test, Figure 49D,E).

[0496] In particular, abemaciclib induced SASP, which is a major repressed component in the resistance program. First, the SASP module was significantly induced at the transcriptional level (P < 3.91 * 10 ^"12 , hypergeometric test, Figures 49D,E). Moreover, when Applicants measured 40 human cytokines and chemokines in the conditioned media of abemaciclib treated cancer cells, Applicants found it induced several secreted factors (Figure 49F), including macrophage inhibition factor (MIF), CX3CL1 (which induces migration and adhesion of T and NK cells and is linked to clinical outcomes in immunotherapy treatment (Herbst et al., 2014; Nelson and Muenchmeier, 2013)), and CCL20 (an important factor for T cell differentiation, which may enhance immunity in melanoma (Gordy et al., 2016)). Consistently, abemaciclib also induced alpha-galactosidase activity and morphological alterations that reflect cellular senescence (Figure 49G). Thus, unlike the mechanism described in breast cancer cells (Goel et al., 2017), abemaciclib might trigger SASP and cell differentiation in malignant melanoma cells. In line with this hypothesis, Applicants do not find significant cytotoxic effects of abemaciclib, but only a reduced rate of proliferation compared to DMSO (0.3 doublings/24 hrs vs. 0.64 doublings/24 hrs, P <0.0001, two-tailed t test).

[0497] Finally, Applicants tested if the effect of abemaciclib treatment on malignant cells is impacted by the presence of tumor infiltrating lymphocytes (TILs) in a patient-derived co- culture model of melanoma cells and ex vivo expanded TILs from the same metastatic melanoma lesion. After treating the malignant cells with abemaciclib for one week, Applicants added autologous TILs to the cultures. Applicants compared scRNA-seq profiles between these melanoma cells to co-cultured cells without prior abemaciclib treatment cells with neither abemaciclib treatment nor co-culture with TILs. Exposure to TILs reduced the expression of the immune resistance program, both in the control and in the abemaciclib- treated cells (P < 9.85* 10 ^"14 , one-sided t-test). Abemaciclib further intensified these effects, as it further repressed the immune resistance program in both conditions (with and without the exposure to TILs, P < 3.60* 10 ^"7 , one-sided t-test). Together with observations above, these results indicate that the resistance program can be intrinsically expressed and modulated by CDK4/6 inhibition and tumor-immune interactions.

[0498] Phased combination with CDK4/6 inhibitor enhances immune checkpoint blockade in vivo.

[0499] Applicants next sought to determine the efficacy of abemaciclib in promoting anti-tumor activity in a syngeneic mouse model. To determine the expression of the resistance signature identified in humans in commonly used immunocompetent mouse models of solid tumors, Applicants performed scRNA-seq on B16 (melanoma, relatively resistant to immune checkpoint inhibition), MC38 and CT26 cells (both colorectal cancer, partially sensitive to anti-PDl and anti-CTLA-4 therapy, respectively). Applicants found strong expression of the resistance signature in B16 cells, while CT26 and MC38 had a mixture of high and low expressing cells, recapitulating their partial sensitivity to checkpoint inhibition. In line with results above, this analysis indicated that the resistance signature was strongly expressed in the absence of any microenvironmental cues. Next, Applicants tested whether addition of CDK4/6 inhibition could overcome resistance to immune checkpoint blockade in vivo. Applicants implanted B16 tumors in C57BL/6 mice and treated with either vehicle control, combination immune checkpoint blockade, abemaciclib monotherapy, or a combination of immune checkpoint blockade and abemaciclib with different dosing schedules (Figure 58). Compared to vehicle, abemaciclib monotherapy had no impact on the rate of tumor outgrowth, but when used in a phased combination (that is ICB followed by ICB plus abemaciclib), there was a strong reduction in the rate of developing tumors compared to all other groups, including ICB alone (Figure 59). Compared to vehicle, abemaciclib monotherapy had no impact on survival, but when used in a phased combination (that is ICB followed by ICB plus abemaciclib), there was a strong survival compared to all other groups, including ICB alone (Figure 60). Together, these results indicate that addition of abemaciclib may improve the sensitivity to immune checkpoint inhibitors, even in otherwise highly resistant models of immunotherapy. Future studies can pursue both the underlying mechanisms by which CDK4/6 inhibition is repressing the resistance program and sensitizing the tumor to immunotherapy, and could apply high throughput genetic screening methods to identify other regulators that repress the program.

Discussion [0500] Most melanoma patients have either intrinsic or acquired resistance to ICI, yet the systematic characterization of molecular resistance mechanisms has been limited. Here, Applicants leverage clinical scRNA-seq data and multiple cohorts to map malignant cell states associated with resistance to ICI, revealing a coherently co-regulated program that may be therapeutically targeted to overcome immune evasion and suppression.

[0501] The malignant cell resistance program showed prognostic and predictive power in several independent ICI cohorts, including a large new clinically annotated cohort of patients with pre-treatment (anti-PD-1) biopsies profiled by RNA-seq. The program outperformed other published biomarkers in the space, and may help to prospectively stratify patients to clinical trials and therapies. Even though the program was initially derived, in part, based on associations with inferred T cell infiltration levels, unlike many other biomarkers, it has a significant predictive value beyond T cell infiltration.

[0502] The program Applicants uncovered is primarily associated with intrinsic ICI resistance. It is manifested also in malignant cells of untreated patients in the single-cell cohort, and in bulk RNA-seq data from three independent cohorts of untreated patients:

TCGA, a longitudinal cohort of ICI-treated patients (validation cohort 1), and a cohort of 112 pre-ICI patients (validation cohort 2). Among single cells of pre-treated patients, a subset

(20.9% cells from 10 different patients) already overexpresses the program. In bulk samples collected before and after ICI, inter-patient variation exceeded intra-patient variation, further supporting an intrinsic role. In 112 melanoma patients, this pre-ICI inter-patient variation is tightly associated with ICI responses. Notably, while the resistance signature was derived from scRNA-seq data in patients with prior treatment with either monotherapy (anti-CTLA-4 or anti-PDl) or a combination, it validated in previously published and newly added data sets of patients who were treated with any immune checkpoint inhibitor. Finally, the program is more pronounced after ICI failure, but not post targeted therapy as Applicants show in previously published data sets (Hugo et al.) and validation cohort 1 in this study., and thus it is unlikely to merely reflect the impact of any therapeutic intervention. However, whether the

ICR signature may be more pronounced in RAF/MEK-resistant melanoma cannot be conclusively determined from these, and should be addressed in future work. This may be of particular clinical interest for patients with RAF/MEK-resistant melanoma, who appear to be less likely to respond to subsequent therapy with ICI (Ackerman et al., 2014).

[0503] Some of the concepts established for drug resistance to targeted cancer therapies with RAF/MEK-inhibitors in melanoma may also be applicable to immunotherapies. Similar to the presence of a small sub-population of cells expressing a MITF-low program, which confers resistance to RAF/MEK-inhibitors, and rises in frequency under the pressure of a drug (Shaffer et al., 2017; Tirosh et al., 2016a, Hangauer et al., 2017; Viswanathan et al., 2017), patient tumors who have not been treated with ICI contain some cells expressing the immune resistance program. It is plausible that these cells are responsible for either intrinsic resistance to ICI or lie in protected niches, and thus emerge in the context of ICI resistance. Selective targeting of these cells in combination with ICI may delay or prevent ICI resistance.

[0504] Applicants have focused on malignant cells, but T cell states or clones, beyond their extent of infiltration, might also predict the success of ICI. Within the limitation of the unmatched single-cell cohort, comparing the individual T cells of untreated vs. post-treatment (resistant) patients, suggested that treatment has activated the T cells and caused their expansion (data not shown). While Applicants cannot rule out the presence of other intrinsic T cell dysfunction mechanisms, this is consistent with a model where, at least partly, malignant cells cause ICI resistance despite at least some T cell functionality.

[0505] Because of the potential functional role of the program and its coherent underlying regulation, compounds that repress it may sensitize malignant cells to immunotherapy and/or T-cell mediated killing (Figure 50), especially in patients with a high intrinsic (pre-ICI) expression of the immune resistance program. Based on a systematic analysis of drug efficacies and the program features Applicants hypothesized that CDK4/6 inhibition could have such a sensitizing effect, and tested this in malignant melanoma cell lines and in co-cultures of patient cells with autologous TILs. CDK4/6 inhibition reversed the resistant transcriptional state: subpopulations of highly immune resistant cancer cells were dramatically reduced, either because the drug selectively eradicated them or because it triggered them to adopt a less immune resistant state. In parallel, CDK4/6 inhibition triggered the melanoma cells to adopt a senescent-like phenotype accompanied by secretion of key chemokines, which have been previously shown to enhance T cell responses (Gordy et al., 2016; Herbst et al., 2014; Nelson and Muenchmeier, 2013). Phased combination of ICB with abemaciclib reduced the rate of tumor outgrowth in an otherwise ICB-resistant syngeneic mouse model (B16), which exhibits strong intrinsic expression of the resistance program, indicating that this may be a potential therapeutic avenue for patients with intrinsic or acquired resistance to immune checkpoint inhibition. [0506] The malignant resistance programs may be relevant in other subtypes of melanoma as well as in other tumor types. Among different types of melanoma, uveal melanoma has more active resistance programs compared to cutaneous melanoma (Figure 46A); across cancers, the immune resistance program is lower in some of the more responsive tumors (head and neck, kidney, skin, lung) and higher in tumor types that are less responsive to immunotherapy and/or arise from immune-privileged tissues (eye, testis) (Figure 57). Interestingly, synovial sarcoma, which is driven by a single genomic aberration in the BAF complex, has the highest resistance scores. The BAF complex has been recently shown to play a key role in resistance to ICI immunotherapy (Miao et al., 2018; Pan et al., 2018). While this pan-cancer analysis is intriguing, it may still be impacted by the composition of the tumor microenvironment, which is challenging to control without single- cell data.

[0507] Future similar studies of other tumors could apply the approach to identify other tumor-specific resistance programs. For example, Applicants performed such analysis with the recent head and neck cancer single cell cohort (Puram et al., 2017) and found that CAFs in cold tumors overexpressed genes up-regulated by TGFB1 (P = 1.70* 10 ^"7 , hypergeometric test). Indeed, TGFB1 and TGFB signaling has been recently shown to be highly associated with lack of response to anti-PD-Ll treatment in urothelial cancer patients (Mariathasan et al., 2018). In line with the findings, co-administration of TGFP-blocking and anti-PD-Ll has been shown to modulated the tumor CAFs, which in turn facilitated T cell infiltration and tumor regression in mouse models (Mariathasan et al., 2018).

[0508] Overall, the analysis sheds light on the way cells shape and are being shaped by their microenvironment in tumors, and the approaches can be applied in other tumors to systematically map immune resistant malignant cell states, uncover improved biomarkers for patient selection, and reveal principles for the development of new therapeutics.

Example 10 - Mechanisms of Immune Resistance and Immunotherapy Resistance

Signature

[0509] Immune checkpoint inhibitors (ICI) have transformed the therapeutic landscape of several cancer types (Sharma and Allison, 2015), especially in melanoma. Nonetheless, many patients manifest resistance, which is often intrinsic (Sharma et al., 2017). Because ICI targets cell-cell interactions, resistance can stem from different cells and their interactions in the tumor ecosystem. Recent studies illuminated ICI resistance with Whole Exome

Sequencing (WES) and transcriptional profiles of bulk tumors (Hugo et al., 2016; Riaz et al., 2017; Van Allen et al., 2015), but had limited ability to dissect the cancer-immune interplay and generate reliable response biomarkers. Single-cell RNA-seq (scRNA-seq) of patient tumors (Tirosh et al., 2016) can alleviate this limitation.

[0510] Infiltration of the tumor with T cells has been associated with patient survival and improved immunotherapy responses (Fridman et al., 2012), but the determinants that dictate if a tumor will have high ("hot") or low ("cold") levels of T cell infiltration are only partially understood. Among multiple factors, malignant cells may play an important role in determining this phenotype. However, while current methods use bulk genomics to deconvolve the tumor' s composition (Newman et al., 2015), they cannot recover the salient intracellular programs of malignant cells. Hence linking malignant cell states to T cell infiltration levels has been challenging.

[0511] Here, using an integrative data-driven approach (Figure 62A,B), Applicants identified a malignant cell program that is associated with T cell exclusion and is predictive of ICI resistance. Applicants demonstrated that CDK4/6 inhibitors repress this program and sensitize melanoma tumors to ICI in mouse models. This work provides a predictive biomarker for ICI response, suggests a new therapeutic modality that may sensitize melanoma tumors to ICI, and provides a framework to study cell-cell interactions and drug effects in other tumor ecosystems.

RESULTS

Systematic approach to discover cancer cell-autonomous programs associated with T cell exclusion

[0512] To identify malignant cell programs that characterize "cold" tumors, Applicants combined scRNA-seq and bulk RNA-Seq data to relate the state of one cell type to the tumor composition (Figure 62B, Methods). Applicants describe the strategy in a specific context, but it can be applied to other pairs of cell types. First, Applicants use scRNA-seq profiles to define cell type specific signatures of T cells and malignant cells in melanoma. Using the T cell signature and bulk RNA-Seq profiles, Applicants infer T cell infiltration levels in hundreds of tumors. Applicants then define a "seed exclusion program": genes from the malignant cell signature whose expression is strongly correlated (positively or negatively) with T cell abundance across those bulk tumors. To avoid mRNA contamination by the tumor microenvironment Applicants restrict the seed program only to a few hundred genes that are exclusively expressed by malignant cells. To recover potentially important genes which are also expressed by non-malignant cells (e.g., MHC class I), Applicants search for genes that are correlated with the seed program across the malignant cells in the scRNA-seq data, irrespective of their expression in other cell types. Finally, Applicants define a genome- scale, malignant-cell exclusion program, consisting of genes induced or repressed by malignant cells in "cold" vs. "hot" tumors. Applicants then score each cell or tumor based on its Overall Expression (OE) of the program, defined as the overexpression of its induced part and underexpression of its repressed part (Methods).

Analysis of clinical scRNA-seq identifies a malignant cell program associated with T cell exclusion

[0513] Applicants applied the approach to 7, 186 high-quality scRNA-seq profiles from 33 human melanoma tumors (from 31 patients), comprised of 2,987 cells from 17 newly collected patient tumors, and 4, 199 cells from 16 patient tumors that Applicants previously reported (Tirosh et al., 2016) (Figure 62A, Tables 24A and 25, Methods; one patient overlaps), along with 473 bulk RNA-seq melanoma profiles from The Cancer Genome Atlas (TCGA) (Akbani et al., 2015). Fifteen of the tumors in the single-cell cohort are post-ICI resistant tumors (Table 24A).

[0514] Applicants distinguished different cell subsets based on their expression profiles and inferred Copy Number Variation (CNV) profiles (Methods), identifying: malignant cells, CD8 ⁺ and CD4 ⁺ T cells, B cells, NK cells, macrophages, Cancer Associated Fibroblasts (CAFs) and endothelial cells (Figures 62C,D and 69, Table 26). Malignant cells primarily grouped by their tumor of origin (Figure 62C), and non-malignant cells by their cell type (Figure 62D), as Applicants previously observed (Tirosh et al., 2016).

[0515] Applicants applied the approach to delineate the relationship between malignant cell states and CD8 ⁺ T cell infiltration, identifying a T cell exclusion program (Figure 62E, Table 27A). The repressed part of the program was enriched for genes involved in antigen processing and presentation (e.g., B2M, CTSB, HLA-A/B/C, TAPBP, P = 3.26* 10 ^"10 , hypergeometric test), IFN-γ signaling pathways (P = 2.94* 10 ^"9 ), response to the complement system (P = 1.13* 10 ^"8 , e.g., CD59 and C4A), and immune modulation (P = 2.10* 10 ^"7 , e.g., CD47 and CD 58). The induced part included CDK4 and its downstream E2F targets (P = 3.97* 10 ^"5 ), transcriptional regulators {e.g., SOX4, SMARCA4), and numerous CDK7 and Myc targets (P < 1 * 10 ^"17 ; Table 27A). Notably, the malignant cell programs associated with exclusion of different T cell subsets were highly overlapping (Figures 70A-C, Tables 26B and 27B, Methods) The exclusion program characterizes malignant cells from patients who progressed on immunotherapy

[0516] To determine whether the exclusion program is associated with ICI resistance, Applicants tested if it is more pronounced in malignant cells from ICI resistant vs. untreated patients in the scRNA-seq cohort. As clinical response rates to ICI vary, with up to -57% responders to ICI combinations (Larkin et al., 2015), the untreated tumors Applicants profiled likely include both ICI sensitive and ICI resistant ones, whereas the ICI resistant tumors likely include mostly resistant malignant cells. Comparing malignant cells from post- ICI resistant tumors to malignant cells from untreated tumors, Applicants found a robust and generalizable post-treatment transcriptional program (cross-validation AUC=0.83; Figure 63A, Table 27A, Methods). This program might reflect both the overall impact of ICI therapy and intrinsic ICI resistance per se, but those cannot be distinguished based on the single-cell cohort, which neither includes matched samples from the same patient nor pre- treatment tumors from responders and non-responders. Applicants address this later in two validation cohorts (Tables 24B-C).

[0517] The post-treatment and exclusion programs substantially overlapped (Figures 62E and 63B,C, Table 27A; P <10 ^"16 , hypergeometric test) and highlighted similar modules and pathways (Figure 63D, Table 28). Both programs were more pronounced in the post- treatment malignant cells, and robustly classified malignant cells as untreated or post- treatment (AUC = 0.83 and 0.81 for cross- validation post-treatment and exclusion, respectively, Figure 63A,E). The upregulated components of both programs include 46 ribosomal protein (RPs) genes, but their overlap remains significant even after removing RPs (P <10 ^"16 , hypergeometric test, Figure 63B). As Myc is a master regulator of ribosome biogenesis (Kress et al., 2015), the induced RP genes might reflect Myc activation. Indeed, the programs are enriched for Myc targets, even after removing RP genes (P < 7.18* 10 ^"10 ), and are predicted to be repressed by MYC knockdown according to the Connectivity map (Subramanian et al., 2017).

[0518] In light of the congruence of the programs, Applicants defined a unified immune resistance program as the union of the post-treatment and exclusion programs (Table 27A), and used it in all subsequent analyses, unless indicated otherwise (Methods).

The immune resistance program reflects a coherent state of immune evasion

[0519] The immune resistance program manifests hallmarks of immune evasion, suppression and exclusion. First, compared to cutaneous melanoma (where Applicants initially identified it), the program is more pronounced in uveal melanoma (Figure 64A), which resides in an immune-privileged environment and has very low response rates to immunotherapy (Algazi et al., 2016). Second, inhibition of genes from the repressed component of the program in malignant melanoma cells conferred resistance to CD8 ⁺ T cells in a genome-wide CRISPR screen (P = 1.67* 10 ^"3 , hypergeometric test) (Patel et al., 2017). Third, the program marks the suppression of physical interactions between resistant malignant cells and other cell types in the tumor microenvironment, including MHC LTCR (T cells), CD58-.CD2 (T cells), and IL1RAP:IL1B (macrophages) (Figure 64B, Methods), and of the Senescence Associated Secretory Phenotype (SASP) (P = 4.3* 10 ^{" 166} and 3.6* 10 ^"3 , one-sided t-test and mixed-effects, respectively, Figure 63D), which has been shown to enhance T cell responses (Gordy et al., 2016).

[0520] The program's genes appear to be under shared control by a few master regulators. The expression of genes within each components (induced or repressed) is positively correlated, while the induced genes are anti -correlated with the repressed genes, both across single cells in one tumor and across TCGA tumors (Figures 64C,D and 71). Thus, any given aspect of the program {e.g., under-expression of antigen presentation) is coupled to the state of the entire program. Moreover, there is a significant overlap between the perturbations that reverse the expression of the program's repressed and induced components (P = 4.35* 10 ^"6 , hypergeometric test), including the overexpression of IFN-γ and IFN- β and the knockdown of MFC and CDK7 (Subramanian et al., 2017). The latter mirrors the significantly large number of Myc and CDK7 (direct) targets (Oki et al., 2018; Subramanian et al., 2005) in the program (P < 1 * 10 ^"17 , hypergeometric test). Further supporting the role of CDKs as regulators, the program is more pronounced in cycling cells, albeit present and detectable in non-cycling cells (Figures 62E, P < 8.42* 10 ^"27 , mixed- effects). Notably, the association between cellular proliferation and the resistant program is only partial, and the two cell states can be decoupled (Methods, Table 27B, Figures 70D- H)

[0521] Applicants compared the immune resistance program to 12 signatures (Table 29) previously associated with the response to immunotherapy (Ayers et al., 2017; Hugo et al., 2016; Riaz et al., 2017) or targeted therapy (RAF and MEK inhibitors) (Hugo et al., 2015; Tirosh et al., 2016) in melanoma patients. Four of the six signatures that characterize immunotherapy sensitive melanoma were enriched with one or more of the T cell signatures (P < 1 * 10 ^"3 , hypergeometric test), suggesting that they capture tumor composition and not malignant cell states. The induced component of the resistance program was not enriched in any of the previous 12 signatures. The repressed component was enriched in two signatures of immunotherapy sensitivity (P < 2.65* 10 ^"3 , hypergeometric test), and with signatures associated with sensitivity and resistance to targeted therapy (P < 1.48* 10 ^"4 ) (Tirosh et al., 2016).

Malignant cells in T cell-depleted niches express features of the resistance program in situ

[0522] To test if the resistance program in malignant cells is associated with T cell exclusion in situ, Applicants used multiplexed immunofluorescence (t-CyCIF) (Lin et al., 2018). Applicants stained histological sections of 19 tumors (472,771 cells/image on average) from the single-cell cohort for 14 proteins: six cell type markers (CD3, CD8, MHC- II, FOXP3, S100, and MITF) and seven resistance program members (induced: p53, Myc, DLL3; repressed: HLA-A, c-Jun, SQSTM1, LAMP2). Following cell segmentation and intensity quantification (Methods), Applicants assigned malignant cells (S100 ⁺ , MITF ⁺ ), T cells (CD3 ⁺ ) and cytotoxic T cells (CD8 ⁺ ); the rest were defined as uncharacterized.

[0523] The scRNA-seq and multiplex in situ protein profiles were congruent by cell type assignment and by resistance program assessment. First, combining the two data sets using a variant of canonical correlation analysis (CCA) (Butler and Satija, 2017) (Methods) successfully embedded and clustered cells primarily by type and not by method (Figures 65A,B and 72). Second, the average immune resistance scores of the different tumors according to their in situ images were correlated with their scores according to scRNA-seq (R = 0.57, P = 0.041) (Methods), even though the scRNA-seq and the in situ image of each tumor were obtained from separated specimens, measuring RNA vs. protein, respectively. Additionally, in both cases, the inter-tumor variation of the program was significantly greater than its intra-tumor variation (P < 1 * 10 ^"30 , ANOVA).

[0524] As predicted, the resistance score Applicants computed from all seven program markers (Methods) was significantly higher in malignant cells that reside in cold niches (P = 1.18* 10 ^"6 , mixed-effects). Aside from LAMP2, individual markers also showed the predicted trend: Malignant cells in cold niches had significantly lower levels of markers repressed in the resistance program (Figures 65C-D, P = 1.41* 10 ^"13 and 8.35* 10 ^"18 , mixed-effects, for c- Jun and ULA-A, respectively), whereas p53 (induced in the resistance program) characterized cold niches (P = 5.25* 10 ^"3 , mixed-effects). Thus, this analysis validates the signature and its association with cold niches at the protein level in situ.

The resistance program is expressed prior to treatment and is enhanced following immunotherapy in resistant lesions

[0525] Applicants hypothesized that the immune resistance program, while more pronounced in the malignant cells of resistant patients after ICI, in fact reflects intrinsic resistance. Supporting this, the program is detected in untreated TCGA melanoma tumors and in a subset of malignant cells from untreated patients (Figures 62E and 63C, right plots).

[0526] To test this hypothesis, Applicants analyzed an independent RNA-Seq cohort of 90 specimens collected from 26 metastatic melanoma patients throughout the course of treatment. Fourteen patients received ICI therapy (anti-PDl or anti-CTLA4) without prior targeted therapy, and 12 patients first received targeted therapy (BRAF/MEK inhibitors) followed by ICI after tumor progression (Figure 62A, Table 24B, validation cohort 1). The cohort has several partially overlapping sets (Table 24B): treatment naive (n = 18), on targeted therapy (n = 17), post targeted therapy (n = 25), on ICI (n = 35), and post-ICI (n = 50). Given this composition, Applicants used a mixed-effects model to determine the effects of the different treatments. As expected, Applicants found a significant induction in the (inferred) T cell fraction of tumors on ICI treatment (P = 1.85* 10 ^"3 , mixed-effects test), but not on targeted therapy.

[0527] The program was induced in on- and post-ICI samples compared to pre-ICI samples from the same patient (P = 7.41 * 10 ^"3 , mixed-effect test, controlling for tumor composition; Methods). However, inter-patient variation in the program's expression was significantly higher than these intra-patient changes (P < 4.98* 10 ^"14 , ANOVA). This suggested that the major differences between the post-ICI and untreated tumors in the single- cell cohort reflect, at least in part, intrinsic differences between the two groups, which preceded the treatment.

[0528] Applicants did not observe an induction of the program following RAF/MEK- inhibition. Applicants confirmed this in another cohort of patient-matched melanoma tumors biopsied before MAPK-inhibition and during disease progression (Hugo et al., 2015) (P > 0.1, mixed-effects).

The resistance program predicts ICI responses in melanoma patients

[0529] Next, Applicants used the Overall Expression (OE) of the program (with and without an additional refinement, Table 27A, Methods) to estimate the immune resistance level of a given tumor, and tested its ability to predict clinical outcomes (Figures 66, 73 and 74).

[0530] The program's expression was associated with poor survival in 473 TCGA melanoma patients (Figures 66A and 73), also when controlling for tumor purity and inferred T cell infiltration. Combining the program with inferred T cell infiltration levels yielded significantly more accurate predictions than either alone (P = 9.1 * 10 ^"8 , COX regression, Figure 66A, right). Other proposed mechanisms, such as de-differentiation of melanoma cells reflected by an MITF-low state, and other malignant cell signatures (Tirosh et al., 2016), were not associated with survival, indicating that mere biological variation across malignant cells is insufficient for prognosis.

[0531] To test if the program can predict clinical responses to ICI, Applicants analyzed five RNA-Seq cohorts collected from melanoma patients prior to ICI treatment: Validation cohort 2 collected by us across 112 patients (validation cohort 2; Figure 62A), Validation Cohort 1 (pre-ICI samples; Figure 62A), and three published cohorts of less than 50 patients each (Hugo et al., 2015; Riaz et al., 2017; Van Allen et al., 2015). Applicants compared the predictors to 47 other gene signatures (Table 29, Methods), which Applicants tested as alternative predictors, including: commercial immune panels, the top hits of two CRISPR screens of resistance to T cells and anti-PD-1 (Manguso et al., 2017; Patel et al., 2017), and signatures generated by analyzing previous melanoma ICI cohorts (Hugo et al., 2016; Riaz et al., 2017).

[0532] The program's expression distinguished ICI responders from non-responders (Figures 66B,C). In a lung cancer mouse model, its expression early on-treatment separated anti-CTLA-4 non-responders from responders (P = 4.89* 10 ^"7 , one-sided t-test, Figure 66B) (Lesterhuis et al., 2015). In 27 melanoma patients treated with Pembrolizumab (anti-PD-1) (Hugo et al., 2016), underexpression of the program pre-treatment distinguished the five complete responders (P = 5.80* 10 ^"3 and 1.89* 10 ^"2 , one-sided t-test, refined and non-refined version, respectively, Figure 66C). In 42 melanoma patients treated with CTLA-4 blockade using Ipilimumab (Van Allen et al., 2015), it was lower in the two complete responders pre- treatment. In 43 melanoma patients profiled before and early on treatment with Nivolumab (anti-PD-1) (Riaz et al., 2017), it was down- regulated early on-treatment specifically in responders (P < 9.60* 10 ^"6 , hypergeometric test). However, in this specific cohort, the pre- treatment expression of the program (and of all other alternative predictors) was not associated with response, possibly due to the small number (3) of complete responders. In validation cohort 1, the program was under-expressed in the 7 pre-ICI samples from patients with an objective response (OR, including partial or complete response; in some examples OR is also referred to as CB, clinical benefit) compared to 12 pre-ICI samples from non- responders (progressive disease; P = 7.88* 10 ^"3 , one-sided t-test).

[0533] Finally, Applicants tested the predictive value of the program in 112 patients with metastatic melanoma who underwent a pre-treatment biopsy and RNA-Seq followed by anti- PD-1 therapy (Figure 62A, validation cohort 2, Tables 24C). Applicants evaluated the program's performance in predicting (1) progression-free survival (PFS, available for 104 patients; Figure 66D), (2) objective response (OR, including partial or complete response; Figure 66E), and (3) complete response (Figure 66F; Methods).

[0534] The program was predictive of PFS (Figures 66D and 74), including when accounting for other potential biomarkers (T cell infiltration levels and PD-L1 expression) (Figure 74E). It outperformed all the alternative predictors Applicants tested (Table 29, P = 1.75* 10 ^"8 , Wilcoxon-ranksum test), which were either not predictive or did not provide additional predictive value once accounting for T cell infiltration levels of the tested tumors (Figure 66G). Although the program was more pronounced in cycling cells, cell cycle alone was not associated with PFS (P > 0.25, COX regression), nor was a signature of malignant- specific genes that characterizes cycling malignant cells (P > 0.05, COX regression). Filtering the cell-cycle component from the resistance program score (Methods) further improved PFS predictions (Figure 66D), suggesting that a tumor's immune resistance profile should be evaluated conditioning on its proliferation level.

[0535] The program was strongly underexpressed in patients with OR compared to those without response (PD, progressive disease) (Figure 66E). Moreover, patients with OR that nonetheless had high pre-treatment expression of the program were significantly more likely to rapidly (<6 months) develop progressive disease (Figure 66E). Consistently, the program was most accurate in predicting complete responses (P = 1.34* 10 ^"4 , one-sided t-test, Figure 66F), outperforming all other tested predictors (P = 1.24* 10 ^"7 , Wilcoxon ranksum test) (Figure 66H)

The resistance program is coherently controlled by CDK4/6

[0536] Next, Applicants sought to pharmacologically target the program. Applicants first identified drugs that were significantly more toxic to cell lines intrinsically overexpressing the program in a screen of 131 drugs across 639 human cell lines (Methods) (Garnett et al.,

2012). The 3 ^rd highest scoring drug was the CDK4/6 inhibitor (CDK4/6i) palbociclib (P = 1.01 * 10 ^"4 , mixed-effects). Applicants confirmed this in another screen of two CDK4/6i (palbociclib and abemaciclib) across hundreds of cell lines (Gong et al., 2017) (P = 3.96* 10 ^"5 , mixed-effects, Figure 67A).

[0537] Applicants hypothesized that CDK4/6 may act as master regulators of the program. Multiple CDK target genes are members of the induced program (Table 27A), and CDK4 is a member of the induced component of both the exclusion and the post-treatment programs (Figures 62E, 63C). Three genes (CDKN2C/p\&, CDKNIBIpll, CDKNIAIpll) that inhibit CDK4 represses the program when overexpressed (Subramanian et al., 2017) (Methods), and the program is more pronounced in cycling cells (Figures 62E, 63C, and 70E), where CDK4/6 are active. Finally, analysis of published gene expression profiles of breast cancer cell lines and mouse models (Goel et al., 2017) showed that CDK4/6i represses the resistance program (Figures 67B-D).

CDK4/6 inhibitors repress the resistance program in melanoma cells

[0538] Applicants therefore tested if CDK4/6i could shift the malignant cell population to a less immune resistant state. Applicants selected three melanoma cell lines that strongly expressed the program (Table 30A), two of which are RBI -sufficient (IGR37, UACC257) and one is RBI-deficient (A2058). Applicants profiled each cell line with scRNA-seq before and after treatment with abemaciclib, analyzing >23,000 cells (Figures 67E,F, Table 25). The program's expression varied between cells within each line, despite the absence of non- malignant cells, suggesting cell intrinsic regulation (Figures 67E,F panel 4). In the RB- sufficient cell lines, IGR37 and UACC257, 10% of cells had exceptionally strong expression of the program ("immune resistant" cells) prior to treatment. Post-treatment the relative abundance of these cells decreased to 2% and 0.6% of the total population, respectively (Figures 67E,F panel 4). In the RBI-deficient cell line A2058 the treatment did not repress the resistant state, consistent with the fact that the impact of CDK4/6i is RBI -dependent (Goel et al., 2017) (Figure 75A). In the two RB-sufficient cell lines, post-treatment cells showed substantial transcriptional changes linked to the resistance program. Abemaciclib induced the MITF program (Tirosh et al., 2016) (P < 1 * 10 ^"17 , hypergeometric test, Figures 67E,F, panel 5), which is repressed in "immune resistant" cells and is associated with melanocytic differentiation. Abemaciclib also repressed the expression of D MT1 (P < 2.23 * 10 ^"106 , likelihood-ratio test, Figures 67E,F, panel 7), which has been shown to confer an immunogenic phenotype (Goel et al., 2017). [0539] Expression of the SASP - a repressed component in the resistance program - was induced in abemaciclib-treated cells (P < 3.33* 10 ^"16 , hypergeometric test, Figures 67E,F, panel 6). Abemaciclib also increased cytokine secretion (Figure 67G, Table 30B), β - galactosidase activity, and morphological alterations that reflect cellular senescence (Figure 67H). It reduced proliferation rates compared to DMSO (0.3 vs. 0.64 doublings/24 hours, P <1 * 10 ^"4 , t-test; Figures 67E,F, panel 3), but was not cytotoxic.

[0540] Next, Applicants tested abemaciclib effects on malignant cells in the presence of tumor infiltrating T lymphocytes (TILs) in a patient-derived co-culture of melanoma cells and autologous ex vivo expanded TILs. While TIL exposure alone represses the immune resistance program in both conditions (P < 7.94* 10 ^"7 , one-sided t-test), this effect was smaller compared to the intrinsic variation between cells of the same cell line (IGR37, Figure 67E, panel 4, P < 8.17* 10 ^"12 , F-test). Treatment with abemaciclib alone or with additional TIL exposure significantly repressed the resistance program (P < 7.72* 10 ^"3 , one-sided t-test, Figure 75B). Overall, these results indicate that the resistance program is mostly intrinsically regulated, and can be repressed by CDK4/6L

CDK4/6 inhibition enhances ICI efficacy in vivo

[0541] To determine abemaciclib' s efficacy in promoting anti-tumor activity in vivo, Applicants tested its effect in the context of ICI therapy in the B 16 melanoma model, which is relatively resistant to immune checkpoint inhibitors (Curran et al., 2010). scRNA-seq of B16, MC38 and CT26 cell lines in vitro showed that the resistance program is intrinsically expressed in most B16 cells, but only in a portion of CT26 and MC38 cells (Figures 75C,D), corresponding to the responses of these models to ICI in vivo. Applicants implanted B16 tumors in C57BL/6 mice and treated with different therapy arms (Figure 68A). Compared to vehicle, abemaciclib monotherapy had no impact on the rate of tumor outgrowth, but when used in a phased combination (ICI followed by ICI plus abemaciclib), there was a significant reduction in the rate of tumor outgrowth and improved survival (Figures 68B,C). Depletion of CD8 ⁺ T cells resulted in loss of the beneficial effect of phased combination therapy (Figures 75E,F) and the effect was at least in part RB-dependent in the malignant cells (data not shown). Thus, abemaciclib may sensitize melanoma tumors to immunotherapies, even in the case of intrinsic resistance.

DISCUSSION [0542] By leveraging clinical scRNA-seq data and multiple patient cohorts, Applicants mapped malignant cell states associated with ICI resistance, revealing a coherent program that has a prognostic and predictive value and may be therapeutically targeted.

[0543] The program predicted ICI responses in several independent cohorts, outperforming other published signature-based biomarkers. Unlike the program described herein, many of the existing biomarkers capture the tumor composition, and do not have an additive predictive value once accounting for the inferred T cell levels. The program described herein predicts responses to anti-PD-1, and to some extent also to anti-CTLA-4 therapy, yet additional studies are required to dissect treatment-specific effects and predict ICI in all patients/cohorts.

[0544] The program is primarily associated with intrinsic ICI resistance. It is observed in bulk RNA-Seq of untreated tumors, and in a subset of -24% of malignant cells of -80% of untreated tumors. Applicants predict that these malignant cells will have a selective advantage during ICI treatment. Indeed, the program is more pronounced after ICI failure, but not post targeted therapy, indicating that it does not merely reflect the impact of any therapeutic intervention.

[0545] By integrating scRNA-seq and in situ images of matched tissue slides Applicants showed that the program is robustly detected and consistent across data modalities and patient samples, and is associated with cold niches within tumors. A key question is whether the program merely captures the response of malignant cells to immune infiltrates, or marks an intrinsic mechanism that allows malignant cells to escape immunity and shape their microenvironment. As Applicants show, the program expression varies across malignant human cell lines, which are not exposed to cues from non-malignant cells. Such intrinsic expression in vitro across mouse cell lines is aligned with their in vivo response to ICI.

[0546] Compounds that repress the program may sensitize malignant cells to immunotherapy and T-cell mediated killing (Figure 68D). Applicants demonstrated that a CDK4/6i reverses the resistant cell state, induces SASP, and improves responses to ICI in vivo. These mechanisms are distinct from previously described immune enhancing mechanisms of CDK4/6i (Deng et al., 2018; Goel et al., 2017), and indicate a potential role of CDK4/6, and specifically CDK4, as one of the master regulators of the program. Thus, CDK4/6i administered in a phased fashion, could potentially alleviate ICI resistance in some melanoma patients, consistently with a recent observation (Schaer et al., 2018). More generally, the program's repression in vitro could be a readout to screen for other compounds that sensitize melanoma tumors to ICI.

[0547] The program may be relevant in other tumor types. It is lower in some of the more ICI-responsive tumors (kidney, skin, lung) and higher in tumor types that are less responsive and/or arise from immune-privileged tissues (eye, testis) (Figures 75G,H) Synovial sarcoma, which is driven by a single genomic aberration in the BAF complex, has the highest resistance scores. The BAF complex plays a key role in ICI resistance (Pan et al., 2018), and one of its subunits (SMARCA4) is up-regulated in the resistance program.

[0548] While Applicants focused on malignant cell-intrinsic mechanisms, Applicants also tested for association of T cell abundance with the state of macrophages and B cells (Table 27C). Applicants found a significant association only with macrophages: In cold niches/tumors, macrophages underexpress PD-L2, MHC class II genes (P < 1 * 10 ^"17 , hypergeometric test), and IFN-γ response genes (P = 9.76* 10 ^"10 ), and up-regulate immunosuppressants, such as hypoxia genes (P = 4.55* 10 ^"6 ) and IL-8. Unlike the malignant cell program, the macrophage program was not associated with ICI resistance. Hence, it may represent the response of macrophages to T cell abundance, rather than a cause of T cell exclusion.

[0549] Overall, the work sheds light on the interplay between cells and their microenvironment in tumors, uncovers improved biomarkers for patient selection, and reveals principles for new therapeutics.

[0550] Table 24. Clinical characteristics of the patients and samples in (A) the scRNA- seq cohort, and in (B-C) the validation cohorts; related to Figure 62.

Table 24A

Discovery cohort; SC NA-seq

Treatment Lesion

Cohort Sample Patient Age Sex Treatment Site group type

Subcutaneous

Mel53 Mel53 77 F None Untreated metastasis

back lesion

Post-ICI Subcutaneous

Mel58 Mel58 83 M Ipilimumab metastasis

(resistant) leg lesion

Trametinib, Post-ICI

Mel60 Mel60 60 M metastasis Spleen ipilimumab (resistant)

Tirosh et Transverse

Mel71 Mel71 79 M None Untreated metastasis al. 2016 colon

IL-2, nivolumab,

Post-ICI External iliac

Mel72 Mel72 57 F ipilimumab + anti- metastasis

(resistant) lymph node KIR-Ab

Post-ICI Terminal

Mel74 Mel74 63 M Nivolumab metastasis

(resistant) Ileum

Mel75 Mel75 80 M Ipilimumab + Post-ICI metastasis Subcutaneous nivolumab, WDVAX (resistant) leg lesion

WDVAX,

Post-ICI

Mel78 Mel78 73 M ipilimumab + metastasis Small bowel

(resistant)

nivolumab

Axillary lymph

Mel79 Mel79 74 M None Untreated metastasis

node

Axillary lymph

Mel80 Mel80 86 F None Untreated metastasis

node

Axillary lymph

Mel81 Mel81 43 F None Untreated metastasis

node

Axillary lymph

Mel82 Mel82 73 F None Untreated metastasis

node primary

Mel84 Mel84 67 M None Untreated Acral primary tumor

Tremelimumab + Post-ICI Cutanoues

Mel88 Mel88 54 F metastasis

MEDI3617 (resistant) met

Axillary lymph

Mel89 Mel89 67 M None Untreated metastasis

node

IFN, ipilimumab + Post-ICI Iliac lymph

Mel94 Mel94 54 F metastasis

nivolumab (resistant) node

Ipilimumab, Post-ICI

Mell26 Mell26 63 M metastasis Soft tissue nivolumab (resistant)

Mel04.3 Mel04.3 81 M Ipilimumab OR metastasis Skin ipilimumab +

angiopoietin 2

Post-ICI R adrenal

MelllO MelllO 74 M inhibitor, metastasis

(resistant) metastasis Temezlolamide,

Pembrolizumab

Post-ICI

Mell21.1 Meim.l 74 M S/p Pembrolizumab metastasis Skin

(resistant)

Prior treatment: Necrotic L

Post-ICI

Mell06 Mell06 67 M nivolumab + metastasis axillary lymph

(resistant)

ipilimumab nodes

Ipilimumab +

nivolumab, Post-ICI

Mel75.1 Mel75 81 M metastasis Soft tissue

WDVAX, (resistant)

Pembrolizumab

L thigh soft

S/p IFN, s/p Post-ICI

Mel98 Mel98 47 F metastasis tissue ipilimumab+GMCSF (resistant)

Additional metastasis

Fragmented

S/p nivolumab + Post-ICI pieces of (R)

Mell02 Mell02 72 F metastasis

ipilimumab (resistant) adrenal gland metastasis primary

Mell29PA Mell29 63 M None Untreated Skin tumor

primary

Mell29PB Mell29 63 M None Untreated Skin tumor

Melll6 Melll6 85 M None Untreated metastasis Lymph node

Mell03 Mell03 58 M None Untreated metastasis Lymph node primary

Mell05 Mell05 77 M None Untreated Skin tumor

Bulky (L)

Melll2 Melll2 76 M None Untreated metastasis axillary metastasis

Nivolumab +

L anterior lirilumab (anti-kit), Post-ICI

Mell94 Mell94 68 M metastasis shoulder

Nivolumab, (resistant)

subcutaneous Ipilimumab, Pan- RAF-inhibitor,

Pembrolizumab

Transanal

Mel478 Mel478 54 F None Untreated metastasis

rectal mass

Mell28 Mell28 37 M None Untreated metastasis Lymph node

Table 24B. Clinical characteristics of the patients and samples Validation Cohort 1

Patl6 Patl6_s44 FALSE FALSE FALSE FALSE FALSE FALSE

Patl6 Patl6 s45 1 TRU£ FALSE FALSE FALSE FALSE FALSE

Patl6 Patl6_s46 FALSE i FALSE FALSE FALSE FALSE

Patl6 Patl6_s47 FALS E UK FALSE FALSE FALSE FALSE r d LID D r dtL 1l PD. cA'+So r f-. rHLjt rMLJt rHLjt r Ljt

Patl6 Patl6 s49 ¾ ; R; s- FALSE FALSE FALSE FALSE

Patl7 Patl7_s50 FALSE FALSE FALSE FALSE FALSE FALSE

Patl7 Patl7_s51 FALSE FALSE FALSE V Uh FALSE FALSE

Patl7 Patl7_s52 FALSE FALSE FALSE T UK FALSE FALSE

Patl7 Patl7_s53 FALSE ^■ :> . · FALSE TRU:- FALSE FALSE

Patl8 Patl8_s54 FALSE FALSE FALSE FALSE FALSE FALSE

Patl8 Patl8_s55 FALSE ^■■ i : ^■ FALSE FALSE FALSE FALSE

Patl8 Patl8_s56 FALSE TRUE FALSE FALSE FALSE FALSE

Patl8 Patl8_s57 FALSE FALSE FALSE FALSE FALSE

Patl9 Patl9_s58 FALSE FALSE FALSE FALSE FALSE i?

Patl9 Patl9_s59 FALSE FALSE Illllillll FALSE FALSE IE

Patl9 Patl9 SbO FALSE FALSE FALSE 'K Pat20 Pat20_s61 FALSE FALSE FALSE FALSE FALSE FAL 5E

Pat20 Pat20_s62 FALSE FALSE T RUE FALSE T RUE

Pat21 Pat21_s63 FALSE FALSE FALSE FALSE FALSE FALSE

Pat21 Pat21_s64 FALSE FALSE wm mm m FALSE wmmmmmm FALSE

Pat22 Pat22_s65 FALSE FALSE FALSE FALSE FALSE FALSE

Pat22 Pat22_s66 FALSE FALSE Illllillll FALSE FALSE

Pat23 Pat23_s67 FALSE FALSE FALSE FALSE FALSE FALSE

Pat23 Pat23_s68 FALSE FALSE FALSE FALSE FALSE FALSE

Pat23 Pat23_s69 FALSE FALSE w FALSE FALSE

Pat24 Pat24_s70 |j i : ε FALSE FALSE FALSE TR1 'K

Pat24 Pat24 s71 I i ε FALSE FALSE FALSE ?

Pat24 Pat24 s72 I ε- i FALSE FALSE

Pat24 Pat24 s73 I Ϊ < Ti- UK FALSE FALSE T i

Pat24 Pat24_s74 | T TP iiiiii FALSE FALSE T i f- ^'

Pat24 Pat24 s75 I i ^■ ; ε FALSE FALSE T

Pat24 Pat24 s76 I i <U ε FALSE FALSE ·< ⁽ . ίί:

Pat25 Pat25_s77 FALSE FALSE FALSE FALSE FALSE r ^•

Pat25 Pat25_s78 FALSE FALSE iiiiiiiiii FALSE FALSE T s i

Pat25 Pat25 s79 1 TRU£ FALSE Illllillll FALSE FALSE

Pat25 Pat25_s80 FALSE i FALSE FALSE ί".

Pat25 Pat25_s81 FALSE Th UK Tb UK FALSE T i

Pat25 Pat25_s82 FALSE ; ; ;· TP Ι - ^" FALSE T ^■ Γ- ^'

Pat25 Pat25_s83 FALSE FALSE T

Pat25 Pat25_s84 FALSE FALSE FALSE ·< ⁽ . it:

Pat26 Pat26_s85 FALSE FALSE FALSE FALSE FALSE FALSE

Pat26 Pat26_s86 FALSE FALSE FALSE FALSE FALSE FALSE

Pat26 Pat26_s87 FALSE FALSE i FALSE FALSE

Pat26 Pat26 s88 ¾ ; R; FALSE , FALSE FALSE

Pat26 Pat26_s89 FALSE FALSE it: FALSE FALSE

Pat26 Pat26_s90 FALSE ^■ i. ^■ : FALSE FALSE FALSE

Table 24C. Clinical characteristics of the patients and samples Validation Cohort 2

PFS

Sample RECIST PFS (years) (status, 1 = progression, 0 = no progression)

Patientl85_T NA NA NA Patientl68_T PR 0.539726027 0

Patientl02_T_P MR 0.482191781 1

Patientl69_T PR 1.487671233 0

Patientl56_T PD 0.219178082 1

Patient48_T_M PD 0.136986301 1

Patientl50_T NA NA NA

Patient63_T_P PD 0.243835616 1

Patientl55_T PD 0.309589041 1

Patientl25_T_P CR 1.326027397 0

Patientl35_T CR 0.909589041 0

Patientl48_T PR 1.589041096 0

Patientl5_T_M PR 0.287671233 1

Patientl52_T PD 0.123287671 1

Patient21_T_M PR 1.443835616 0

Patientl33_T PD 0.17260274 1

Patientl63_T PD 0.131506849 1

Patient8_T_M SD 2.616438356 1

Patient4_T_M CR 1.57260274 1

Patient99_T_P PR 0.873972603 1

Patientl05_T_P MR 1.035616438 0

Patientl65_T PD 0.035616438 1

Patient38_T_M PD 0.268493151 1

Patientl26_T_P PR 1.145205479 0

PatientlO_T_M PR 0.463013699 1

Patient22_T_M PD 0.249315068 1

Patientl6_T_M PD 0.126027397 1

Patient72_T_P PD 0.183561644 1

Patient6_T_M SD 0.339726027 1

Patient23_T_M PD 0.210958904 1

Patientl34_T PD 0.17260274 1

Patient83_T_P PD 0.194520548 1

Patientl21_T_P PR 2.112328767 0

Patientl8_T_M PD 0.235616438 1

Patientl32_T CR 1.065753425 1

Patientl84_T NA NA NA

Patient77_T_P PD 0.260273973 1

Patientl31_T PR 1.526027397 0

Patient9_T_M PD 0.057534247 1

Patient79_T_P PD 0.230136986 1

Patient74_T_P NA NA NA

Patientl41_T PR 0.221917808 0

Patient34_T_M PR 0.657534247 1

Patientl87_T CR 0.887671233 0

Patientl46_T CR 0.890410959 0

Patientll6_T_P PD 0.175342466 1

Patient82_T_P PD 0.243835616 1

Patient94_T_P PD 0.109589041 1

Patientl83_T NA NA NA

Patientl66_T PR 0.364383562 0

Patientl70_T SD 0.950684932 0

Patientl73_T PD 0.043835616 1

Patient7_T_M SD 0.594520548 1

Patientll_T_M PD 0.232876712 1

Patientl51_T CR 1.153424658 0

Patient31_T_M PD 0.232876712 1

Patient67_T_P PD 0.257534247 1

Patient36_T_M PD 0.17260274 1

Patientl7_T_M SD 0.553424658 1 Patientl54_T SD 0.687671233 1

Patient87_T_P PR 3.128767123 1

Patientl_T_M PD 0.246575342 1

PatientlOO_T_P PR 1.449315068 0

Patientl53_T PR 0.567123288 1

Patient75_T_P PR 1.232876712 0

Patient61_T_P SD 1.879452055 0

Patient35_T_M SD 0.791780822 1

Patient32_T_M PD 0.134246575 1

Patient25_T_M PR 2.060273973 1

Patient98_T_P PD 0.2 1

Patientll7_T_P PD 0.273972603 1

Patientl4_T_M PD 0.208219178 1

Patient58_T_M PD 0.210958904 1

Patientl08_T_P PD 0.210958904 1

Patientl47_T CR 1.693150685 0

Patient24_T_M PD 0.084931507 1

Patient47_T_M PD 0.202739726 1

Patientl79_T PR 0.920547945 1

Patient45_T_M PR 3.350684932 0

Patientl40_T PD 0.183561644 1

Patientll2_T_P PD 0.249315068 1

Patient96_T_P CR 1.545205479 0

Patient62_T_P PR 1.898630137 0

Patientl44_T PR 1.120547945 0

Patientl88_T PD 0.063013699 1

Patientl30_T_P PD 0.301369863 1

Patient27_T_M PD 0.257534247 1

Patientl62_T PD 0.145205479 1

Patientl42_T SD 0.515068493 1

Patientl27_T_P CR 1.24109589 0

Patient33_T_M PR 3.506849315 0

Patient20_T_M PD 0.230136986 1

Patient30_T_M SD 0.364383562 1

Patientl3_T_M PD 0.120547945 1

Patient78_T_P PD 0.235616438 1

Patient44_T_M PR 1.317808219 0

Patientl72_T SD 0.745205479 1

Patientl9_T_M na NA 0

Patient40_T_M PD 0.17260274 1

Patient42_T_M CR 0.821917808 0

Patient73_T_P PD 0.232876712 1

Patient86_T_P SD 2.753424658 0

Patientl37_T CR 1.323287671 0

Patient37_T_M PD 0.210958904 1

Patientl59_T SD 0.591780822 1

Patientl58_T PR 0.443835616 1

Patientl81_T NA NA NA

Patient76_T_P na 0.123287671 1

Patientl45_T CR 1.375342466 0

Patientl67_T PD 0.156164384 1

Patientl06_T_P CR 1.005479452 0

Patientl49_T NA NA NA

[0551] Table 25. Quality measures of scRNA-seq experiments; related to Figure 62.

CtaSkt data

Cell type Median no. of detected Median no. of aligned No. of TN No. of ICR Total no. of genes reads cells cells cells

B cell 3774 164400 355 463 818

CAF 5518 357423 45 61 106

Endothelial cell 5057 304326 17 87 104

Macrophage 5670 654482 259 161 420

Malignant cells 5482 335563 825 1193 2018

NK 3909 147376 48 44 92

CD4 T cell 4036 220614 436 420 856

CD8 T cell 4064 264494 1039 720 1759

T cell 3827 234410 408 298 706

Low quality cell 732 24991 1551 1386 2937

UD 3433 221421 124 183 307

All cells 3655 176595 5107 5016 10123

Exjs&f iro»!itt¾t c ata {to vitro)

Median

Median no. of no. of Total no.

Type Cell line and condition

detected genes aligned of cells

reads

A2058 Abemaciclib 4270 19144 2769

A2058 DMSO 3510 12945 2607

Human melanoma cell UACC257 Abemaciclib 4044 25271 2939

lines UACC257 DMSO 3286 14174 4401

IGR37 Abemaciclib 4259 26184 1570

IGR37 DMSO 3990 16972 2454

Monoculture Abemaciclib 4492 34414 2064

Patient-derived co- Monoculture DMSO 3708 20337 3865

culture TIL coculture Abemaciclib 5719 65130 102

TIL coculture DMSO 4824 40700 124

B16 2044 5254 3031

Mouse cell lines CT26 2369 7365 3208

MC38 2406 6865 3424

[0552] Table 26. (A) Cell type signatures and markers used for cell classification; (B) cell type signatures derived from the analysis of scRNA-seq data; related to Figure 62; (C) Alternative cell type signatures and markers used for cell classification.

Table 26A.

MYELOI

MA D

ENDOTHE STROM BASOP EOSINO ERYTHRO MEGAKARO

CAF B CELL ST MDSC DENDRI LIAL CELL AL CELL HILE PHIL CYTE CYTE CELL TIC CELL

COLl ENP

CD34 ICAM1 Al ANPEP BLK C3AR1 CD24 P3 CCR7 CD9 CCR7

COLl

CDH5 ICAM2 A2 CCR3 CD19 C5AR1 GYPA KIT CD1A GP1BA CD1A

COL6

ENG ICAM3 Al CD44 CD2 CCR1 PTPRC CD1B ITGA2B CD1B

COL6

FLT4 ITGA4 A2 CD63 CD22 CCR3 CD1C ITGAV CD1C

COL6

ICAM1 ITGB1 A3 CD69 CD40 CD244 CD207 ITGB3 CD207

ITGB3 KIT DCN ENPP3 CD5 CD52 CD209 PECAM1 CD209

KDR MADCA FAP ICAM1 CD69 CD53 CD4 SELP CD4 Ml

MCAM MME THY1 IL3RA CD70 CXCR3 CD40 CD40

PECAM1 MMP1 LAMP1 CD79A FCER2 CD80 CD80

PROCR MMP2 TLR4 CD79B FUT4 CD83 CD83

SELE MMP9 CD80 IL9R CD86 CD86

PDGFR CMKLR CMKLR

TEK A CD86 ITGA4 1 1

PDGFR HLA-

VCAM1 B CD93 LAIR1 DOA DCX

PECAM H LA-

VWF 1 FCER2 PTGDR2 DOB ITGA4

HLA-

THY1 MS4A1 S100A9 DRA ITGAM

SIGLECl HLA-

TIMP1 PAX5 0 DRB1 ITGAX

HLA-

TIMP2 PDCDl SIGLEC8 DRB5 LY75

HLA-

TLR1 SDC1 DRB6 NRP1

TNFRSF PDCDIL

TLR2 13B ITGA4 G2

TNFRSF

TLR3 13C ITGAM

TNFRSF

TLR4 9 ITGAX

VCAM1 TNFSF4 LY75

NRP1

PDCDl

LG2

NAIV

PLASMACYTOI T E CD4 NEUTROPHI NK PLATELE

D DENDRITIC FOLLICULA TH1 TH2 TH9 TH17

T L CELL T CELL R HELPER CELL

B3GAT

CCR7 ANPEP 1 CCR7 BSG BCL6 CCR1 CCR3 CD3D CCR4

CD3D C5AR1 CD244 CD1A CCL5 CD3D CCR5 CCR4 CD3E CCR6

CD3E CD14 CD69 CD1B CCR3 CD3E CD4 CCR7 CD3G CD38

CD3G CD33 IL2RB CD1C CD109 CD3G CSF2 CCR8 CD4 CD3D

GAT A

CD4 CEACAM8 ITGA2 CD4 CD151 CD4 CXCR3 CD4 3 CD3E

SELL CSF3R ITGAM CD40 CD226 CD40LG DPP4 CSF2 IRF4 CD3G

CXCR1 ITGAX CD80 CD36 CD84 HAVCR2 CXCR4 STAT6 CD4

CXCR2 KLRA1 CD83 CD46 CXCR5 IFNA1 GAT A3 IL17A

HAVCR

FCGR1A KLRB1 CD86 CD47 ICOS IFNGR1 1 IL17F

FUT4 KLRD1 CD8A CD48 IL6R IL2 ICOS IL1R1

ITGAM KLRK1 CLEC4C CD63 PDCDl KLRD1 IL10 IL21

ITGAX NCAM1 CMKLR1 CD69 SLAMF1 TNF IL13 IL22

TNFSF1

MME NCR1 IL3RA CD84 STAT3 1 IL1R1 KLRB1

LINC-

PECAM1 NKG2 ITGA4 CD9 TNFSF4 IL4 ROR

SIGLEC

SELL 7 ITGAM CNGB1 IL5 STAT3

SLAMF

TLR2 6 ITGAX CSF3R IL6

SLAMF PTGDR

7 NRP1 FCGR2A 2 PDCD1LG2 FCGR2B

TLR9 GP1BA

ICAM2

ITGA2

ITGA2B

ITGA6

ITGAV

ITGB1

ITGB3

JAM3

LAMP2

LRRC32

LYN

PECAM1

SELP

SPN

TNFSF14

VEGFA

PI

RFC2 HMMR

RPA2 HN1

RRM1 KIF11

RRM2 KIF20B

SLBP KIF23

TIPIN KIF2C

TYMS LBR

UBR7 MKI67

UHRF1 NCAPD2

UNG NDC80

USP1 NEK2

WDR76 NUF2

NUSAP1

PSRC1

RANGAP

1

SMC4

TACC3

TMPO

T0P2A

TPX2

TTK

TUBB4B

UBE2C

Table 26B.

B CELL CAF ENDOTHELIAL MACROPHAGE MALIGNANT NK

ADAM19 ABCA6 A2M ABCA1 KYNU AASDHPPT NAV2 ALOX5AP

ADAM28 ABCA8 ABCD4 ABI1 LAIR1 AATF NDUFA4 APMAP

AFF3 ABI3BP ADAM15 ACAA1 LAP3 ACN9 NDUFAF3 CALM1

ATF7IP ACTA2 ADAMTS9 ACER3 LGALS2 ACOT7 NDUFB9 CD160

BACH2 ACVR1 ADCY4 ACP2 LGALS9 ACSL3 NDUFS2 CD244

BANK1 ADAM12 ADM5 ACP5 LGMN ADIPOR1 NEDD4L CD247

BCL11A ADAMTS12 AFAP1L1 ACSL1 LILRA1 ADSL NELFCD CLIC3

BLK ADAMTS2 APLNR ADAMDEC1 LILRA2 AHCY NFYA CTSW

BLNK ANTXR1 AQP1 ADAP2 LILRA3 AIF1L NGRN FCRL6

BTLA A0X1 ARHGAP29 ADORA3 LILRA4 AK2 NHP2 FGFBP2

CCR6 ARMCX2 ARHGAP31 ADPGK LILRA5 ALDOA NME1 GNLY

CD19 ASPN ARHGEF15 AIF1 LILRA6 ALX1 NOP58 GZMB

CD1C BACE1 ASAP1 AKR1A1 LILRB1 AMZ2 NPM1 GZMM

CD22 BAG2 BCAM ALDH2 LILRB2 ANAPC11 NSG1 HOPX

CD24 BGN BCL6B ALDH3B1 LILRB3 ANKRD54 NT5DC3 ID2

CD37 C1R BCR AMICA1 LILRB4 ANP32A NUP93 IL18RAP

CD52 CIS BMPR2 AMPD3 LILRB5 AP1S2 OCA2 IL2RB

CD79A CALD1 BMX ANKRD22 LIPA APEH PACSIN2 KIR2DL3

CD79B CCDC80 CALCRL AP1B1 LOC338758 APOA1BP PAFAH1B3 KIR3DL2

CHMP7 CD248 CARDIO APOC1 LOC729737 APOC2 PAGE5 KLRB1

CIITA CDH11 CASKIN2 AQP9 LRRC25 APOD PAICS KLRC1

CLEC17A CDR1 CCL14 ARAP1 LST1 APOO PAX3 KLRD1

CNR2 CERCAM CD200 ARHGAP18 LTA4H ARPC1A PEBP1 KLRF1

C0L19A1 CILP CD34 ARHGAP27 LYN ATIC PEGIO MATK

COL4A3 CKAP4 CD93 ARHGEFIOL LYZ ATP1A1 PEX19 MYBL1

CR2 CLEC11A CDH5 ARPC1B M6PR ATP5C1 PFDN2 NCAM1

CXCR5 CLIP3 CFI ARRB2 MAFB ATP5G1 PHACTR1 NCR1

CYBASC3 CNN1 CLDN15 ASAH1 MAN2B1 ATP5G2 PHB NCR3

EEF1B2 C0L11A1 CLDN5 ATF5 MAPKAPK3 ATP5G3 PHF5A NKG7 EEF1G C0L12A1 CLEC14A ATG3 MARCO ATP6V1C1 PHLDA1 NMUR1

EIF2S3 C0L14A1 CLEC1A ATG7 MERTK ATP6V1E1 PIGY PRF1

ELK2AP C0L16A1 CNTNAP3B ATP6AP1 MFSD1 ATP6V1G1 PIR PTGDR

FAIM3 C0L1A1 C0L15A1 ATP6V0B MGAT1 BAIAP2 PLEKHB1 PTPN4

FAM129C C0L1A2 C0L4A1 ATP6V0D1 MIF4GD BANCR PLP1 SAMD3

FAM65B C0L3A1 COL4A2 ATP6V1B2 MIIP BCAN PMEL SH2D1B

FCER2 C0L5A1 CRIP2 ATP6V1F MILR1 BCAS3 P0LD2 TXK

FCRL1 COL5A2 CXorf36 BACH1 MKNK1 BCL2L13 P0LR2F XCL1

FCRL2 C0L6A1 CYYR1 BCKDHA MNDA BIRC7 P0MGNT1 XCL2

FCRL5 COL6A2 DARC BCL2A1 M0B1A BZW2 PPIL1

FCRLA COL6A3 DCHS1 BID MPEG1 C10orf90 PRAME

GGA2 C0L8A1 DLL4 BL0C1S1 MPP1 Cllorf31 PRDX6

GNB2L1 COMP D0CK6 BLVRA MRC1 C17orf89 PSMB4

HLA-DOB CPE D0CK9 BLVRB MS4A4A Clorf43 PSMB7

HLA-DQA2 CPXM1 DYSF C10orf54 MS4A6A Clorf85 PSMD4

HVCN1 CPZ ECE1 Cllorf75 MS4A7 C1QBP PTTGl

IGJ CRABP2 ECSCR C15orf48 MSR1 C22orf32 PUF60

IGLL1 CREB3L1 EFNA1 C19orf38 MTHFD2 C4orf48 PYGB

IGLL3P CRISPLD2 EFNB2 Clorfl62 MTMR14 CA14 PYURF

IGLL5 CTSK EGFL7 C1QA MX1 CA8 QDPR

IRF8 CXCL12 ELK3 C1QB MX2 CACYBP QPCT

KBTBD8 CXCL14 ELTD1 C1QC MXD1 CAPN3 RAB17

KIAA0125 CYBRD1 EMCN C2 MYD88 CBX3 RAB38

KIAA0226L CYGB ENG C3AR1 N4BP2L1 CCND1 RABGGTB

LOC283663 CYP1B1 EPAS1 C5AR1 NAAA CCT2 RAD51C

LRMP DCN EPB41L4A C9orf72 NADK CCT3 RAE1

MS4A1 DDAH1 EPHB4 CAPG NAGA CCT4 RAN

NAPSB DDR2 ERG CAPZA2 NAGK CCT6A RAP1GAP

NCF1C DEPTOR ESAM CARD9 NAIP CCT8 RGS20

NC0A3 DKK3 EX0C3L1 CASP1 NCF2 CDH19 R0PN1

P2RX5 DPT F11R CAT NCF4 CDH3 R0PN1B

PAX5 EBF2 FABP4 CCDC88A NCKAP1L CDK2 RRS1

PLEKHF2 ECM2 FAM107A CCR1 NC0A4 CDK4 RSL1D1

PNOC EDNRA FAM65A CCR2 NFAM1 CEP170 RTKN

P0LD4 EFEMP2 FAT 4 CCRL2 NFKBID CHCHD6 RUVBL2

P0U2AF1 EGFLAM FGD5 CD14 NINJ1 CHD1L S100A1

POU2F2 EGFR FKBP1A CD163 NLRC4 CLCN7 SIOOB

PRKCB EMILIN1 FLU CD1D NLRP3 CLNS1A SAMM50

QRSL1 FAT1 FLT4 CD274 NMI CMC2 SCD

RALGPS2 FBLN1 FZD6 CD300C N0D2 C0A3 SDC3

RHOH FBLN2 GALNT18 CD300E NPC2 C0A4 SDCBP

SEL1L3 FBLN5 GATA2 CD300LB NPL C0A6 SDHC

SELL FGF7 GIPC2 CD300LF NR1H3 C0X5B SEC11C

SMIM14 FIBIN GNG11 CD302 0AS1 C0X6A1 SF3A1

SNX29 FMOD GPR116 CD33 0AZ1 COX7A2 SGCD

SNX29P1 FN1 GPR146 CD68 0LR1 COX7A2L SHC4

SP110 FNDC1 GRB10 CD80 OSCAR C0X7C SKP1

SP140 FRMD6 GUK1 CD86 P2RX4 C0X8A SLC19A1

SPIB FST HECW2 CECR1 P2RY12 CSAG1 SLC19A2

ST6GAL1 FSTL1 HERC2P2 CFD P2RY13 CSAG2 SLC24A5

STAG3 GEM HID1 CFP P2RY14 CSAG3 SLC25A13

STAP1 GFPT2 HSPG2 CLECIOA P2RY6 CSPG4 SLC25A4

STRBP GFRA1 HYAL2 CLEC12A PAK1 CYC1 SLC39A4

TCL1A GLT8D2 ICA1 CLEC4A PCK2 CYP27A1 SLC45A2

TLR10 GPC1 ID1 CLEC4E PFKFB3 DAAM2 SLC5A3

TLR9 GPC4 ID3 CLEC5A PGD DANCR SLC6A15

TMEM154 GPC6 IFITM3 CLEC7A PILRA DAP3 SLC7A5

TNFRSF13B GPR133 IGFBP7 CMKLR1 PLA2G15 DCT SLM02 TP53INP1 GPR176 IL33 CMTM6 PLA2G7 DCXR SMS

VPREB3 GPX8 IL3RA CNDP2 PLAUR DDIT3 SNCA

WDFY4 HSPB2 IP011-LRRC70 CNPY3 PLBD1 DDT SNHG16

ZCCHC7 HSPB6 ITGA5 C0R07 PLEK DLL3 SNHG6

HSPB7 ITGA6 CPVL PLEKH01 DNAH14 SNRPC

HTRA3 ITGB4 CREG1 PLEKH02 DNAJA4 SNRPD1

IGFBP6 JAG2 CSF1R PLIN2 DRG1 SNRPE

INHBA JAM2 CSF2RA PLXDC2 EDNRB S0D1

ISLR JUP CSF3R PPM1M EIF3C SORD

ITGA11 KANK3 CST3 PPT1 EIF3D S0RT1

ITGB5 KDR CSTA PRAM1 EIF3E SOX10

ITGBL1 KLHL3 CTSA PRKCD EIF3H SPCS1

KDELR2 LAMA5 CTSB PSAP EIF3L SRP9

KDELR3 LDB2 CTSC PSME2 EIF3M ST13

LARP6 LOC100505495 CTSD PTAFR EN01 ST3GAL4

LEPREL2 LRRC70 CTSH PTPRE EN02 ST3GAL6

LM07 LUZP1 CTSL1 PYCARD ENTPD6 ST6GALNAC2

LM0D1 LYVE1 CTSS RAB20 EPB41L4A-AS1 STAM

LOX MALL CXCL10 RAB4B ERBB3 STIP1

10X11 MANSC1 CXCL16 RAB8A ESRP1 STK32A

LPAR1 MECOM CXCL9 RASGEF1B ETV4 STMN1

LTBP2 ME0X1 CXCR2P1 RASSF4 ETV5 ST0ML2

LUM MKL2 CYB5R4 RBM47 EX0SC4 STRA13

LURAP1L MMRN1 CYBA RBPJ FAH STRADB

MAP1A MMRN2 CYBB REEP4 FAHD2B STX7

MEG3 MPZL2 CYP2S1 RELT FAM103A1 STXBP1

MFAP4 MTUS1 DAPK1 RGS10 FAM162A SUPT4H1

MGST1 MYCT1 DBNL RGS18 FAM178B SYNGR1

MIR100HG MY015B DENND1A RGS19 FARP2 TBC1D10A

MMP2 N0S3 DHRS9 RGS2 FASN TBC1D16

M0XD1 NOSTRIN DMXL2 RHBDF2 FBX032 TBC1D7

MRC2 N0TCH4 DNAJC5B RHOG FBX07 TBCA

MRGPRF NPDC1 D0K1 RILPL2 FDFT1 TBRG4

MSC NPR1 D0K3 RIPK2 FKBP4 TEX2

MT1M NR5A2 DPYD RNASE6 FMN1 TFAP2A

MXRA5 PALD1 EBI3 RNASEK FXYD3 TIMM50

MXRA8 PALMD EMR2 RNASET2 GALE TMED10

MYL9 PCDH1 EPSTI1 RNF13 GAPDH TMEM147

NEXN PCDH12 ETV6 RNF130 GAPDHS TMEM177

NID2 PCDH17 EVI2A RNF144B GAS2L3 TMEM255A

N0TCH3 PDE2A F13A1 RNF149 GAS5 TMX4

NTM PDLIM1 FAM105A RTN1 GAS7 T0M1L1

NTRK2 PECAM1 FAM157B S100A11 GCSH TOMM20

NUPR1 PGM5 FAM26F S100A8 GDF15 TOMM22

OGN PIEZ01 FAM49A S100A9 GJB1 T0MM6

0LFML1 PIK3R3 FAM96A SAMHD1 GMNN T0MM7

0LFML2B PKP4 FBP1 SAT1 GMPR T0P1MT

0LFML3 PLEKHA7 FCER1G SCAMP2 GPATCH4 TRIM2

OMD PLVAP FCGR1A SCIMP GPM6B TRIM63

0SR2 PLXNA2 FCGR1B SC02 GPR137B TRMT112

PALLD PLXND1 FCGR1C SCPEP1 GPR143 TSNAX

PAMR1 PODXL FCGR2A SDS GPS1 TTLL4

PAPSS2 PPM IF FCGR2C SECTM1 GSTP1 TUBB2A

PCDH18 PPP1R13B FCGR3B SEMA4A GTF2F2 TUBB2B

PCOLCE PRCP FCGRT SERPINA1 GYG2 TUBB4A

PC0LCE2 PREX2 FCN1 SERPINB1 H2AFZ TYR

PDGFRA PTPRB FERMT3 SFT2D1 HAX1 TYRP1

PDGFRB PVRL2 FES SGPL1 HDDC2 UBA2 PDGFRL PXN FGL2 SH3BGRL HIST1H2AC UBL3

PDLIM2 RALGAPA2 FKBP15 SHKBP1 HIST1H2BD UCHL5

PLA2G2A RAMP2 FLVCR2 SIGLECl HIST3H2A UQCRH

PLAC9 RAMP3 F0LR2 SIGLEC14 HMG20B UTP18

PLOD2 RAPGEF3 FPR1 SIGLEC5 HMGA1 VAT1

PODN RAPGEF4 FPR2 SIGLEC7 HPS4 VDAC1

POSTN RASIP1 FPR3 SIGLEC9 HPS5 WBP11

PPIB RBP7 FT HI SIRPA HSBP1 WBP2

PRR16 RGL2 FTL SIRPB1 HSP90AA1 WBSCR22

PRR24 RHOJ FUCA1 SIRPB2 HSP90AB1 WDFY1

PRRX1 R0B04 FUOM SKAP2 HSPA4 WDR43

PRRX2 S1PR1 GAA SLAMF8 HSPA9 XAGE1A

PTN SCARF1 GABARAP SLC11A1 HSPD1 XAGE1B

RARRES2 SDPR GALC SLC15A3 HSPE1 XAGE1C

RCN3 SELE GATM SLC16A3 HSPH1 XAGE1D

R0R2 SELP GBP1 SLC1A3 IGSF11 XAGE1E

SCUBE3 SH3BGRL2 GCA SLC25A19 IGSF3 XYLB

SDC1 SHR00M4 GGTA1P SLC29A3 IGSF8 ZCCHC17

SDC2 SLC29A1 GK SLC2A5 ILF2 ZFAS1

SEC24D SLC9A3R2 GLA SLC2A8 IMMP2L ZFP106

SEMA5A SLC02A1 GLB1 SLC2A9 INPP5F ZNF280B

SERPINF1 SMAD1 GLRX SLC31A2 IRF4

SFRP2 SNCG GLUL SLC43A2 ISYNA1

SFRP4 S0CS2 GM2A SLC46A3 KCNJ13

SH2D4A S0X18 GNA13 SLC7A7 LAGE3

SH3D19 SPNS2 GNA15 SLC9A9 LDHB

SH3PXD2A STOM GPBAR1 SLC02B1 LHFPL3-AS1

SLIT2 SULF2 GPR34 SMPDL3A LINC00473

SLIT3 SYNPO GPR84 SNX10 LINC00518

SM0C2 TACR1 GPX1 SNX6 LINC00673

S0D3 TA0K2 GRN S0D2 LOC100126784

SPARC TEAD4 GST01 SPI1 LOC100127888

SP0CK1 TEK H2AFY SPINT2 LOC100130370

SP0N1 TENC1 HCAR2 SQRDL LOC100133445

SRPX2 TFF3 HCAR3 SRC LOC100505865

STEAP1 TGFBR2 HCK STX11 L0C146481

SULF1 TGM2 HEIH STXBP2 LOC340357

SUSD2 THBD HERPUD1 TALD01 10X14

SVEP1 THSD1 HIST2H2BF TBXAS1 LSM2

TAGLN TIE1 HK2 TFRC LZTS1

TBX15 TLL1 HK3 TGFBI MAD2L1BP

TCEAL7 TM4SF1 HLA-DMA THEMIS2 MAGEA12

TGFB3 TM4SF18 HLA-DMB TIFAB MAGEA2

THBS2 TMEM204 HLA-DPA1 TLR1 MAGEA2B

THY1 TMEM255B HLA-DPB1 TLR2 MAGEA3

TIMP1 TNFAIP1 HLA-DPB2 TLR4 MAGEA4

TMEM119 TNFRSF10B HLA-DQA1 TLR5 MAGEA6

TMEM45A TSPAN12 HLA-DQB1 TLR8 MAGEC1

TPM1 TSPAN15 HLA-DRA TMEM106A MAGED2

TPM2 TSPAN18 HLA-DRB1 TMEM144 MDH1

TWIST1 TSPAN7 HLA-DRB5 TMEM176A MDH2

TWIST2 USHBP1 HLA-DRB6 TMEM176B METTL23

UCHL1 VWA1 HM0X1 TMEM37 METTL9

VASN VWF HN1 TMEM51 MFI2

VCAN ZNF366 HPS1 TMEM86A MIA

WISP2 ZNF385D HSPA6 TNFAIP2 MIF

WNT2 HSPA7 TNFAIP8L2 MITF

HSPBAP1 TNFSF13 MKI67IP IDH1 TNFSF13B MLANA

IFI30 TPP1 MLPH

IFI35 TRAFD1 MOK

IFIT2 TREM1 M0RN2

IFNGR1 TREM2 MRPL12

IFNGR2 TRPM2 MRPL21

IGFLR1 TTYH3 MRPL23

IGSF6 TWF2 MRPL24

IL10RB TYMP MRPL38

IL18 TYROBP MRPL40

IL1B UBE2D1 MRPS21

IL1RN UBXN11 MRPS23

IL4I1 UNC93B1 MRPS25

IL8 VAMP8 MRPS26

IRF5 VM01 MRPS6

IRF7 VSIG4 MSI2

ITGAX WDFY2 MTHFS

JAK2 ZEB2 MXI1

KCNMA1 ZNF267 MY010

KCNMB1 ZNF385A NARS2

T CD4

T CD4 T CD8 T CELL STROMA IMMUNE

EXHAUSTED

AIM1 AD0RA2A ARHGEF1 A4GALT ACAP1 C9orfl6

AQP3 ASB2 ASB2 ADAMTS1 AKNA CDK5R1

BCL11B ASXL2 ATHL1 ADAMTSL1 ALOX5AP CTLA4

CAMK4 CBLB BCL11B ADIRF ANKRD44 DDX5

CCR4 CCDC141 C16orf54 ANGPTL2 APOBEC3G HLA-J

CCR8 CCDC64 CASP8 APP ARHGAP15 ICA1

CD28 CD27 CCDC64 ARHGAP29 ARHGAP25 IGFLR1

CD4 CD3E CCND2 BGN ARHGAP30 IL21

CD40LG CD84 CD2 BMP1 ARHGAP4 ITGB2-AS1

CD5 CD8A CD247 C1R ARHGAP9 ITM2A

CD6 CD8B CD27 CCDC80 ARHGDIB KCNK5

DGKA CLEC2D CD28 CFH ATP2A3 KIAA0247

DUSP16 CRTAM CD3D CLU BIN2 LIMS1

EML4 CXCL13 CD3E COL15A1 C16orf54 LY6G5C

F5 DNAJB1 CD3G COL18A1 CCDC88B MAF

FAAH2 GPR171 CD5 COL4A1 CD37 METTL8

FAM102A GZMK CD6 COL4A2 CD48 MRP63

FBLN7 IFNG CD7 COL6A2 CD52 NFATC1

FLT3LG ITGA4 CD96 COX7A1 CD53 NR3C1

F0XP3 ITGAE CDC42SE2 CTGF CD69 PDCD1

FYB ITM2A CELF2 CYB5R3 CD84 PTPN11

ICOS JAKMIP1 CN0T6L CYR61 CDC42SE2 PTPRC

IL6R KLHL28 C0R01A DCHS1 CELF2 RNF19A

IL7R LAG3 CST7 DPYSL3 CNTRL SARDH

ITGB2-AS1 LYST CTLA4 EFEMP1 COR01A SLA

ITK MAP4K1 CXCR3 EHD2 CSK SRGN

LAT MC0LN2 CXCR6 ELN CXCR4 TBC1D4

LEPR0TL1 MIAT CYTIP EPAS1 CYTH4 THADA

LOC100128420 MIR155HG DEF6 FAM171A1 CYTIP TIGIT

LOC285740 NELL2 DENND2D FAP DEF6 TSPYL2

MAF PAG1 EMB FAT 4 DENND1C ZNF211

MAL PCED1B EVL FBN1 DOCK2

PASK PDCD1 FYB FLRT2 DOCK8

PBX4 PRDM1 FYN FSCN1 DUSP2

PBXIP1 PTPN7 GATA3 FSTL1 EVI2B PIK3IP1 RAB27A GNG2 GJA1 FERMT3

PIM2 RNF19A GPR171 GNG11 FGD3

SEPT6 SIRPG GPR174 HSPG2 FNBP1

SLAMF1 SIT1 GPRIN3 HTRA1 GBP5

SPOCK2 SNAP47 GRAP2 IFITM3 GPR65

SUSD3 THEMIS GZMA IGF2 GPSM3

TBC1D4 TIGIT GZMM IGFBP4 HCLS1

TCF7 TIMD4 HNRNPAIPIO IGFBP7 HMHA1

TESPA1 TMEM155 ICOS JAG1 IKZF1

TIAM1 TNFRSF9 IL12RB1 KIAA1217 IL10RA

TMEM66 TNIP3 IL21R IAMBI 1116

TNFAIP3 TOX IL2RB LAMB2 IL2RG

TNFSF8 TTC24 IL2RG LAMC1 INPP5D

TNIK TTN IL32 LEPROT ITGA4

TPT1 ZBED2 INPP4B LHFP ITGAL

IPCEF1 LIMCH1 ITGB2

ITGAL LIMS2 LAIR1

ITK LMCD1 LAPTM5

JAK3 10X12 LCP1

KCNA3 LPHN2 LILRB3

LAT LRRC32 LIMD2

LCK MAP1B LPXN

LIME1 ME0X2 LSP1

LOC100130231 MGP LY9

MB0AT1 MMP2 MAP4K1

MIAT NFIB MY01G

NLRC5 NIDI NCKAP1L

PAG1 NNMT NR4A2

PARP8 NPDC1 PARP8

PCED1B NR2F2 PARVG

PCED1B-AS1 NT5E PIK3CD

PDCD1 NUAK1 PIM2

PIP4K2A PEAR1 PLCB2

PRDM1 PHLDB2 PLEKHA2

PRF1 PLSCR4 PRKCB

PRKCQ PPAP2A PSD4

PTPN22 PPAP2B PSTPIP2

PTPN7 PPIC PTK2B

PTPRC PRKCDBP PTPN22

PYHIN1 PROCR PTPN6

RASAL3 PRSS23 PTPN7

RASGRP1 PTRF PTPRC

RGS1 PXDN RAC2

RHOF RAB11FIP5 RASSF5

RNF213 RABAC1 RCSD1

SCML4 RBPMS RGS1

SEPT1 RUNX1T1 RHOH

SH2D1A S100A16 RPS6KA1

SH2D2A SERPINH1 SAMSN1

SH3KBP1 SPARC SASH3

SIRPG SPARCL1 SLA

SIT1 STC2 SNX20

SKAP1 TFPI SP140

SLC9A3R1 TGFB1I1 STK17B

SPATA13 THBS1 TAGAP

SPN THY1 TBC1D10C

SP0CK2 TMEM204 TMC6

STAT4 TNKS1BP1 TMC8 SYTL3 TNXB TMSB4X

TBC1D10C TPBG TRAF3IP3

TC2N UNC5B TSC22D3

TESPA1 VCL TSTD1

THEMIS ZEB1 UCP2

TIGIT ZNF423 VAV1

TMEM66 ZNF521 WIPF1

TNFAIP3

TOX

TRAF1

TRAT1

TTC39C

TUBA4A

UBASH3A

WIPF1

ZAP70

ZC3HAV1

T CD4 NAIVE T CD4 TREG T CD8 CYTOTOXIC T CD8 EXHAUSTED T CD8 NAIVE

ABLIM1 ARID3B APOBEC3C ABCC9 ATM

ATM CARD16 B2M AKAP5 ATXN7

CAMK4 CCR4 CCL3 ANKLE1 CAMK4

CCR7 CCR8 CCL4 AP4B1-AS1 CCR7

EEF1A1 CD177 CCL5 APOBEC3A EEF1A1

EEF1B2 DDX60 CSF1 ARHGEF26-AS1 FAM102A

EEF1G ERI1 CST7 ASXL2 FKBP5

FAM65B EZH2 FASLG ATHL1 GPR155

FHIT FAS GZMB ATXN1 IL7R

GIMAP5 F0XP3 GZMH CBLB LEF1

IL7R GAT A3 HLA-C CD3E NELL2

LDHB GBP5 IFNG CD8A PIK3IP1

LDLRAP1 GCHFR PRF1 CDKN1B PPP1R2

LEF1 HNRNPC CLEC2D PRKCQ-AS1

LOC100130231 HPRT1 CNOT6L SELL

NAP1L1 IL10RA CTLA4 SORL1

NOSIP IL1R2 CXCL13 TCF7

PABPC1 IL2RA DENND2D TSC22D3

PIK3IP1 IL2RG DFNB31 UBA52

SELL IL32 DGKH

SERINC5 LAIR2 DOCK8

SF1 LAYN DTHD1

TCF7 L0C541471 DUSP4

TMEM66 LTB ELF1

TPT1 PARK7 ENTPD1

TRABD2A PIM2 FAM122C

TSC22D3 PMAIP1 FAM3C

TXNIP PPP2CA FAM73A

UBA52 RASGRP1 FBXL18

RORA FCRL3

RTKN2 GBP2

S100A4 GDPD1

SAMD9 GLUD1P7

STAM HAVCR2

SUM02 HINT3

TNFRSF18 HNRPLL

USP15 IFNLR1

WDR1 ILIO

ZBTB32 INPP4B INPP5F

ITGA4

ITM2A

ITPKB

KIAA1324

LAG3

LINC00294

LOC100131257

LOC100190986

LOC100271836

LOC286186

LOC440354

LOC728558

LYST

MAPK13

MCL1

MTX3

NFATC1

NXNL2

0DF2L

0SBPL3

PCED1B

PCGF5

PDCD1

PDE4D

PER2

PLEKHG2

PRICKLE2-AS3

PTPRC

RAB27A

RAMP2-AS1

RGS1

RNF19A

SCD5

SF3B3

SH2D2A

SMG1P1

STAT1

STAT3

TANG02

TATDN3

TBXA2R

TIGIT

TMEM136

TMEM212

TNFRSF1B

TNFRSF9

TP53INP1

TRAF5

TTN

TXNDC11

USP33

VSIG1

VSTM4

ZNF620

ZNF79

o

O

ΙΛ O

PTGDR2

PDCDILG

2

( (

PDCDILG

2

HLA- HLA- PDCDILG

DRB5 DRB6 2

ΙrΛ- TNFRSF1 TNFRSF1

o 3B 3C

r- o

o

o

[

a

B

C

C

G

IS

P

R

R

R

R

R

R

S

U

A

C

C

C

C

CHCHD2 2 1 0 0 1 0

CTPS1 2 1 0 1 0 0

NACA 2 1 0 1 0 0

NCL 2 1 0 1 0 0

NME1 2 1 1 0 0 1

NOLC1 2 1 0 1 0 0

NONO 2 0 0 1 1 0

PABPCl 2 1 0 1 0 1

PAICS 2 1 1 0 0 0

PFN1 2 1 0 1 0 0

P0LD2 2 1 1 0 0 0

PPA1 2 1 0 1 0 0

PTMA 2 1 0 1 0 1

PUF60 2 1 1 0 0 0

RPL10A 2 1 0 1 0 1

RPL11 2 1 0 1 0 0

RPL12 2 1 0 1 0 0

RPL13 2 1 0 1 0 1

RPL13A 2 1 0 1 0 0

RPL13AP5 2 1 0 1 0 0

RPL17 2 1 0 1 0 0

RPL18 2 1 0 1 0 0

RPL18A 2 1 0 1 0 0

RPL21 2 1 0 1 0 0

RPL26 2 1 0 1 0 0

RPL27 2 1 0 0 1 0

RPL28 2 1 0 1 0 1

RPL29 2 1 0 1 0 1

RPL3 2 1 0 1 0 1

RPL36 2 1 0 0 1 1

RPL36A 2 1 0 1 0 0

RPL37 2 1 0 1 0 0

RPL4 2 1 0 1 0 0

RPL5 2 1 0 1 0 1

RPL6 2 1 0 1 0 0

RPL8 2 1 0 1 0 0

RPLPO 2 1 0 1 0 1

RPLP1 2 1 0 1 0 1

RPS10 2 1 0 1 0 0

RPS11 2 1 0 1 0 1

RPS13 2 1 0 0 1 0

RPS14 2 1 0 0 1 0

RPS15 2 1 0 0 1 1

RPS15A 2 1 0 1 0 1

RPS16 2 1 0 1 0 0

RPS17 2 1 0 1 0 0

RPS17L 2 1 0 1 0 0

RPS18 2 1 0 1 0 0

RPS19 2 1 0 1 0 0

RPS23 2 1 0 1 0 0

RPS24 2 1 0 1 0 0

RPS27 2 1 0 1 0 1

RPS28 2 1 0 0 1 1

RPS3 2 1 0 1 0 1

RPS4X 2 1 0 1 0 0 RPS5 2 1 0 1 0 1

RPS6 2 1 0 1 0 1

RPS7 2 1 0 1 0 1

RPS8 2 1 0 1 0 1

RPS9 2 1 0 1 0 1

RPSA 2 1 0 1 0 0

RRS1 2 1 1 0 0 0

SERPINF1 2 1 0 1 0 0

SET 2 1 0 1 0 0

SHMT2 2 1 0 1 0 0

SLC19A1 2 1 1 0 0 0

SLC25A13 2 1 1 0 0 0

SNHG6 2 1 0 1 0 0

SNRPE 2 1 0 1 0 1

S0X4 2 1 0 1 0 1

SSR2 2 1 0 1 0 0

TIMM50 2 1 0 1 0 0

T0P1MT 2 1 1 0 0 0

TUBB 2 1 0 1 0 0

UQCRFS1 2 1 0 1 0 0

UQCRH 2 1 0 1 0 0

VDAC2 2 1 0 1 0 0

ACTB 1 0 0 1 0 1

AEN 1 0 0 1 0 0

ANP32E 1 0 0 1 0 1

APP 1 1 0 0 0 0

ARMC6 1 0 0 0 1 0

ATP5A1 1 0 0 1 0 0

ATP5D 1 1 0 0 0 0

ATP5G2 1 0 0 1 0 0

ATP5G3 1 1 0 0 0 0

B0LA2 1 0 0 0 1 0

B0LA2B 1 0 0 0 1 0

B0P1 1 1 0 0 0 0

BTF3 1 1 0 0 0 0

C20orfll2 1 0 0 1 0 0

C6orf48 1 1 0 0 0 1

CAM 1 0 0 1 0 0

CACYBP 1 1 0 0 0 0

CBX5 1 0 0 1 0 0

CCT2 1 0 0 1 0 0

CCT4 1 1 0 0 0 1

CCT7 1 1 0 0 0 0

CDC123 1 0 0 0 1 0

CDCA7 1 1 0 0 0 0

CFL1 1 0 0 1 0 0

CKS1B 1 0 0 0 1 0

CMSS1 1 0 0 0 1 0

CNRIP1 1 0 0 1 0 0

CS 1 0 0 1 0 0

DARS 1 1 0 0 0 0

DCAF13 1 0 0 1 0 0

OCT 1 0 0 1 0 0 DCTPP1 1 1 0 0 0 0

DDX21 1 1 0 0 0 0

DDX39A 1 0 0 0 1 0

DDX39B 1 0 0 1 0 1

DLL3 1 0 0 1 0 0

DNAJC9 1 0 0 0 1 0

EEF1B2 1 1 0 0 0 0

EEF1D 1 1 0 0 0 0

EEF2 1 1 0 0 0 0

EIF3E 1 1 0 0 0 0

EIF3F 1 1 0 0 0 0

EIF3G 1 1 0 0 0 1

EIF3M 1 1 0 0 0 0

EIF4EBP2 1 0 0 1 0 0

ENOl 1 1 0 0 0 0

EXOSC5 1 1 0 0 0 0

FAM174B 1 0 0 1 0 0

FAM60A 1 0 0 0 1 0

FAM92A1 1 1 0 0 0 0

FBLN1 1 0 0 1 0 0

F0XRED2 1 0 0 1 0 0

FTL 1 0 0 1 0 1

FUS 1 0 0 1 0 0

GABARAP 1 0 0 1 0 0

GGH 1 1 0 0 0 0

GNL3 1 1 0 0 0 0

GRWD1 1 0 0 1 0 0

H3F3A 1 0 0 1 0 0

H3F3AP4 1 0 0 1 0 0

HMGA1 1 0 0 1 0 0

HMGB1 1 1 0 0 0 0

HN1 1 0 0 0 1 0

HNRNPAIPIO 1 0 0 1 0 0

HNRNPH1 1 1 0 0 0 1

HNRNPM 1 1 0 0 0 0

HSP90AB1 1 0 1 0 0 1

HSPA8 1 0 0 1 0 1

HSPD1 1 1 0 0 0 0

IFRD2 1 1 0 0 0 0

ILF3 1 1 0 0 0 0

IMPDH2 1 1 0 0 0 1

ITM2C 1 0 0 1 0 0

KIAA0101 1 0 0 1 0 0

LDHB 1 1 0 0 0 0

LSM4 1 1 0 0 0 0

LSM7 1 1 0 0 0 1

LYPLA1 1 1 0 0 0 0

MAGEA4 1 0 0 1 0 0

MAGEC1 1 1 0 0 0 0

MCM7 1 1 0 0 0 0

METAP2 1 0 0 1 0 0

MIDI 1 0 0 1 0 0

MIR4461 1 0 0 1 0 0 MKI67IP 1 1 0 0 0 0

MLLT11 1 0 0 1 0 0

MPZL1 1 0 0 1 0 0

MRPL15 1 1 0 0 0 1

MRPL37 1 1 0 0 0 0

MRPL4 1 1 0 0 0 0

MRPL47 1 0 0 0 1 1

MRPS12 1 1 0 0 0 0

MRPS21 1 0 0 1 0 0

NDUFA11 1 1 0 0 0 0

NDUFA13 1 0 0 0 1 0

NDUFS2 1 0 0 1 0 1

NME2 1 1 0 0 0 0

NOP 16 1 1 0 0 0 0

NPM1 1 1 0 0 0 1

NREP 1 1 0 0 0 0

PA2G4 1 0 0 1 0 0

PAFAH1B3 1 0 0 1 0 0

PET 100 1 0 0 0 1 0

PFDN2 1 0 0 1 0 0

PFDN4 1 0 0 0 1 0

PGAM1 1 0 0 1 0 0

PIH1D1 1 0 0 1 0 0

PLEKHJ1 1 1 0 0 0 0

P0LR1D 1 1 0 0 0 0

P0LR2E 1 1 0 0 0 0

PPP2R1A 1 0 0 1 0 0

PRMT1 1 1 0 0 0 0

PSMA7 1 0 0 0 1 0

PSMD4 1 0 0 1 0 0

RAN 1 0 0 1 0 0

RBM34 1 0 0 1 0 0

RNASEH2A 1 0 0 0 1 0

RNF2 1 0 0 1 0 0

R0M01 1 0 0 0 1 0

RPAIN 1 0 0 1 0 0

RPL10 1 1 0 0 0 1

RPL14 1 1 0 0 0 0

RPL15 1 1 0 0 0 0

RPL19 1 1 0 0 0 0

RPL22 1 1 0 0 0 0

RPL27A 1 1 0 0 0 0

RPL30 1 1 0 0 0 0

RPL32 1 1 0 0 0 0

RPL35 1 1 0 0 0 0

RPL35A 1 0 0 0 1 0

RPL39 1 1 0 0 0 0

RPL7 1 1 0 0 0 0

RPL7A 1 1 0 0 0 1

RPL9 1 1 0 0 0 0

RPLP2 1 1 0 0 0 0

RPS12 1 0 0 1 0 1

RPS2 1 1 0 0 0 1 RPS20 1 1 0 0 0 1

RPS25 1 1 0 0 0 0

RPS3A 1 1 0 0 0 1

RQCD1 1 1 0 0 0 0

RSL1D1 1 1 0 0 0 1

RTKN 1 0 1 0 0 0

SCD 1 0 0 1 0 0

SCNM1 1 0 0 1 0 1

SERBP1 1 1 0 0 0 0

SF3B4 1 0 0 1 0 0

SKP2 1 0 0 1 0 0

SLC25A3 1 0 0 1 0 0

SLC25A6 1 1 0 0 0 0

SLIRP 1 0 0 0 1 0

SLM02 1 0 0 0 1 0

SMARCA4 1 1 0 0 0 0

SMIM15 1 1 0 0 0 0

SMS 1 0 0 1 0 0

SNAI2 1 0 0 1 0 0

SNHG15 1 1 0 0 0 0

SNRPB 1 1 0 0 0 0

SNRPC 1 1 0 0 0 1

SNRPD1 1 1 0 0 0 0

SNRPD2 1 1 0 0 0 0

SNRPF 1 0 0 0 1 0

SNRPG 1 0 0 0 1 0

SRM 1 1 0 0 0 0

SRP14 1 0 0 1 0 0

SSB 1 1 0 0 0 0

TIMM13 1 1 0 0 0 0

TIMM44 1 1 0 0 0 0

TMC6 1 0 0 1 0 0

TP53 1 0 0 1 0 0

TPI1 1 1 0 0 0 1

TPRKB 1 0 0 0 1 0

TRAP1 1 1 0 0 0 0

TRIM28 1 1 0 0 0 1

TRPM1 1 0 0 1 0 0

TSR1 1 0 0 1 0 0

TUBA1B 1 0 0 1 0 1

TULP4 1 0 0 1 0 0

TXNDC17 1 0 0 0 1 0

TYMS 1 1 0 0 0 0

UBL5 1 0 0 0 1 0

UCK2 1 1 0 0 0 0

UHRF1 1 1 0 0 0 0

USMG5 1 0 0 0 1 0

USP22 1 0 0 1 0 0

VCY1B 1 0 0 1 0 0

VPS72 1 0 0 1 0 0

XIST 1 1 0 0 0 0

YWHAE 1 0 0 1 0 1

ZFAS1 1 1 0 0 0 0 ZNF286A

Repri sssed

Number of Functional supporting Exclusion Exclusion seed Post-treatment immune

GENE (down)

evidences (down) (down) (down) resistance (down) (down)

AHNAK 3 1 0 1 1

APOD 3 1 0 1 1

ATP1A1 3 1 0 1 1

B2M 3 1 0 1 1

CD44 3 1 0 1 1

CD63 3 1 0 1 1

CTSB 3 1 0 1 1

CTSD 3 1 0 1 1

FOS 3 1 0 1 1

GRN 3 1 0 1 1

HLA-A 3 1 0 1 1

HLA-B 3 1 0 1 1

HLA-C 3 1 0 1 1

HLA-E 3 1 0 1 1

HLA-H 3 1 0 1 1

LAMP2 3 1 0 1 1

LGALS3 3 1 0 1 1

LGALS3BP 3 1 0 1 1

NPC2 3 1 0 1 1

PSAP 3 1 0 1 1

SERPINE2 3 1 0 1 1

TAPBP 3 1 0 1 1

TIMP2 3 1 0 1 1

A2M 2 1 0 1 0

ACSL3 2 1 0 1 0

AEBP1 2 1 0 1 0

AGA 2 1 0 1 0

APOC2 2 1 1 0 0

APOE 2 1 0 1 0

ATP1B1 2 1 0 1 0

CD151 2 1 0 1 0

CD47 2 1 0 1 0

CD58 2 1 0 1 0

CD59 2 1 0 1 0

CDH19 2 1 0 1 0

CSPG4 2 1 0 1 0

CST3 2 1 0 1 0

CTSA 2 1 0 1 0

CTSL1 2 1 0 1 0

CTSO 2 1 0 0 1

CYP27A1 2 1 1 0 0

DAG1 2 1 0 1 0

DDR1 2 1 0 1 0

EEA1 2 1 0 1 0

EMP1 2 1 0 1 0

EVA1A 2 1 0 1 0 FBX032 2 1 0 1 0

FGFR1 2 1 0 1 0

GAA 2 1 0 1 0

GPNMB 2 1 0 1 0

GSN 2 1 0 1 0

HLA-F 2 1 0 1 0

HSPA1A 2 1 0 1 0

IRF4 2 1 1 0 0

ITGA3 2 1 0 1 0

KCNN4 2 1 0 1 0

KLF4 2 0 0 1 1

LEF1-AS1 2 1 0 0 1

LRPAP1 2 1 0 1 0

MFGE8 2 1 0 1 0

MIA 2 1 0 1 0

MT2A 2 1 0 1 0

NEAT1 2 1 0 1 0

NPC1 2 1 0 1 0

NSG1 2 1 0 1 0

PR0S1 2 1 0 1 0

S100A6 2 1 0 1 0

SIOOB 2 1 0 1 0

SAT1 2 1 0 1 0

SCARB2 2 1 0 1 0

SDC3 2 1 0 1 0

SEC IIC 2 1 1 0 0

SERPINA3 2 1 0 1 0

SGK1 2 1 0 1 0

SLC26A2 2 1 0 1 0

SLC5A3 2 1 0 1 0

STOM 2 0 0 1 1

STX7 2 1 1 0 0

TAPBPL 2 0 0 1 1

TIMP1 2 1 0 1 0

TIMP3 2 1 0 1 0

TM4SF1 2 1 0 1 0

7 ^' MEDIO 2 1 0 1 0

TPP1 2 1 0 1 0

TSC22D3 2 1 0 1 0

TYR 2 1 0 1 0

UBC 2 1 0 1 0

VAT1 2 1 0 0 1

WBP2 2 1 1 0 0

XAGE1D 2 1 1 0 0

ACSL4 1 0 0 1 0

ACTA2 1 0 0 0 1

ADM 1 0 0 1 0

ANGPTL4 1 0 0 1 0

ANXA1 1 0 0 1 0

ANXA2 1 0 0 1 0

APLP2 1 0 0 1 0

AP0L1 1 1 0 0 0

ARL6IP5 1 0 0 1 0 ARSA 1 1 0 0 0

ATF3 1 0 0 1 0

ATP1B3 1 0 0 1 0

ATP6V0C 1 1 0 0 0

BACE2 1 0 0 1 0

BBX 1 0 0 1 0

BCL6 1 0 0 1 0

C4A 1 1 0 0 0

C6orf226 1 0 0 0 1

CALU 1 0 0 1 0

CARD16 1 1 0 0 0

CASP1 1 0 0 1 0

CAST 1 0 0 1 0

CAV1 1 0 0 1 0

CAS/2 1 1 0 0 0

CCND3 1 0 0 1 0

CCR10 1 0 0 0 1

CD9 1 0 0 1 0

CDH1 1 1 0 0 0

CHI3L1 1 0 0 1 0

CITEDl 1 0 0 0 1

CLIC4 1 0 0 1 0

C0R01A 1 0 0 0 1

CRELD1 1 0 0 1 0

CRYAB 1 0 0 1 0

CSGALNACTl 1 0 0 1 0

CXCR4 1 0 0 0 1

CYP4V2 1 1 0 0 0

DCBLD2 1 0 0 1 0

DDX17 1 0 0 0 1

DDX5 1 0 0 1 0

DPYSL2 1 0 0 1 0

DUSP4 1 0 0 1 0

DUSP6 1 0 0 1 0

ECM1 1 0 0 1 0

EGR1 1 0 0 1 0

EPHX2 1 0 0 1 0

ERBB3 1 0 0 1 0

EZH1 1 0 0 1 0

FAM3C 1 0 0 1 0

FCGR2C 1 0 0 1 0

FCRLA 1 0 0 1 0

FLJ39051 1 0 0 0 1

FLJ43663 1 0 0 1 0

FLNA 1 1 0 0 0

FMN1 1 0 0 0 1

FRZB 1 0 0 0 1

FSTL3 1 0 0 0 1

FTH1 1 0 0 0 1

GADD45B 1 0 0 1 0

GATSL3 1 1 0 0 0

GEM 1 0 0 1 0

GJB1 1 1 0 0 0 GOLGB1 1 0 0 1 0

GPR155 1 1 0 0 0

GPR56 1 1 0 0 0

HLA-DRB5 1 0 0 0 1

HLA-G 1 1 0 0 0

HPCAL1 1 0 0 1 0

HTATIP2 1 0 0 1 0

IDI2-AS1 1 0 0 0 1

IFI27 1 1 0 0 0

IFI27L2 1 1 0 0 0

IFI35 1 0 0 1 0

IFI6 1 1 0 0 0

IGF1R 1 0 0 1 0

IGFBP7 1 1 0 0 0

IGSF8 1 1 0 0 0

IL1RAP 1 0 0 1 0

IL6ST 1 0 0 1 0

ITGA6 1 0 0 1 0

ITGA7 1 1 0 0 0

ITGB1 1 0 0 1 0

ITGB3 1 0 0 1 0

ITM2B 1 0 0 1 0

JMJD7 1 0 0 0 1

JUN 1 0 0 1 0

KLF6 1 0 0 1 0

LAMB2 1 1 0 0 0

LCP1 1 0 0 0 1

LEPROT 1 0 0 1 0

LGALS1 1 0 0 1 0

LGMN 1 1 0 0 0

LINC00518 1 0 0 0 1

LOC100126784 1 1 0 0 0

LOC100506190 1 1 0 0 0

LOC100506714 1 0 0 0 1

LOC100507463 1 0 0 0 1

LPL 1 0 0 1 0

LY6E 1 1 0 0 0

LY96 1 0 0 0 1

LYRM9 1 1 0 0 0

MAGEC2 1 0 0 1 0

MALAT1 1 1 0 0 0

MATN2 1 1 0 0 0

MCAM 1 1 0 0 0

MFI2 1 0 0 1 0

MMP14 1 1 0 0 0

MPZ 1 1 0 0 0

MT1E 1 0 0 1 0

MT1M 1 0 0 1 0

MT1X 1 0 0 1 0

MTRNR2L1 1 1 0 0 0

MTRNR2L10 1 1 0 0 0

MTRNR2L2 1 1 0 0 0

MTRNR2L3 1 1 0 0 0 MTRNR2L4 1 1 0 0 0

MTRNR2L5 1 1 0 0 0

MTRNR2L6 1 1 0 0 0

MTRNR2L7 1 1 0 0 0

MTRNR2L8 1 1 0 0 0

MYOID 1 1 0 0 0

NAV2 1 1 0 0 0

NFE2L1 1 1 0 0 0

NFKBIA 1 0 0 1 0

NFKBIZ 1 0 0 1 0

NMRK1 1 0 0 0 1

NNMT 1 0 0 1 0

NR4A1 1 0 0 1 0

P2RX4 1 0 0 0 1

PAGE5 1 0 1 0 0

PDE4DIP 1 1 0 0 0

PDK4 1 0 0 1 0

PERP 1 1 0 0 0

PIK3IP1 1 0 0 0 1

PLP2 1 0 0 1 0

PRKCDBP 1 0 0 1 0

PRNP 1 0 0 1 0

PRSS23 1 0 0 1 0

PSMB9 1 0 0 1 0

PTRF 1 0 0 1 0

PYGB 1 0 0 0 1

QPCT 1 1 0 0 0

RAB27A 1 0 0 0 1

RBP7 1 0 0 0 1

RDH5 1 1 0 0 0

RNF145 1 0 0 1 0

RNF213 1 0 0 0 1

RPS4Y1 1 0 0 1 0

RTP4 1 0 0 0 1

S100A1 1 1 0 0 0

S100A13 1 1 0 0 0

SCCPDH 1 0 0 1 0

SDCBP 1 0 0 0 1

SEL1L 1 0 0 1 0

SEMA3B 1 0 0 1 0

SERINC1 1 1 0 0 0

SERPINA1 1 1 0 0 0

SGCE 1 0 0 1 0

SHC4 1 1 0 0 0

SLC20A1 1 0 0 1 0

SLC22A18 1 0 0 0 1

SLC39A14 1 0 0 1 0

SLC7A5P1 1 0 0 0 1

SLC7A8 1 1 0 0 0

SNX9 1 1 0 0 0

S0D1 1 0 0 1 0

S0RT1 1 1 0 0 0

SP100 1 0 0 0 1 SPESP1 1 0 0 0 1

SPINT1 1 0 0 0 1

SPON2 1 1 0 0 0

SPP1 1 1 0 0 0

SPRY 2 1 0 0 1 0

SQSTM1 1 0 0 1 0

SRPX 1 0 0 1 0

ST3GAL6-AS1 1 0 0 0 1

ST6GALNAC2 1 0 0 0 1

STRIP2 1 1 0 0 0

SYNE2 1 1 0 0 0

SYNGR2 1 0 0 1 0

SYPL1 1 0 0 1 0

TF 1 0 0 1 0

TFAP2A 1 0 0 0 1

TG0LN2 1 0 0 1 0

THBD 1 1 0 0 0

TMBIM6 1 1 0 0 0

TMED9 1 0 0 1 0

TMEM255A 1 1 0 0 0

TMEM66 1 0 0 1 0

TMX4 1 0 0 1 0

TNC 1 0 0 1 0

TNFSF4 1 1 0 0 0

TRIM22 1 0 0 0 1

TRIML2 1 1 0 0 0

TSPYL2 1 1 0 0 0

TTLL1 1 0 0 0 1

TXNIP 1 1 0 0 0

UCN2 1 0 0 0 1

UPP1 1 0 0 1 0

WDFY1 1 0 1 0 0

ZBTB20 1 0 0 1 0

ZBTB38 1 0 0 1 0

Table 27B. Alternative T cell exclusion and post-treatment signatures

Table 27B.1

CELL CYCLE FILTERED

POST

POST T CD8 EXC. RELATIVE T CD8 RELATIVE T CD8

TREATMENT T CD8 EXC. (UP)

TREATMENT (DOWN) EXC. (UP) EXC. (DOWN)

DOWN

ABR A2M AASDHPPT A2M ATIC APOD

ANXA13 ACSL3 AHCY AEBP1 BTF3 APOE

ATP5A1 AEBP1 APP AGA CHCHD2 ATP1A1

BCAN AHNAK ATP5D AHNAK EEF1G B2M

BZW2 ANXA1 BTF3 APOC2 EIF3G CAPN3

C17orf76-ASl ANXA2 BZW2 APOD EIF3M CD63

C1QBP APLP2 C17orf76-ASl APOE EIF4A1 CDH1

C20orfll2 APOC2 C1QBP APOL1 ENOl CTSD

CD68 APOD C6orf48 ARSA EXOSC4 DAAM2

CDH3 APOE CCT3 ATP1A1 FARSA GPNMB

CHP1 ARL6IP5 CCT6A ATP1B1 GAPDH GPR56 cs ATP1A1 DAP3 ATP6V0B H19 HLA-A

DCT ATP1B1 DARS ATP6V0C HNRNPA1 HLA-B

DDX39B ATP1B3 DDX21 B2M LSM7 HLA-C

EEF1A1 B2M EEF1B2 C4A MAGEA4 HLA-F

EEF1G BBX EEF1G CAV2 MAGEC1 HLA-H

EGFL8 CALU EEF2 CCND3 MDH2 HPS5

EIF2S3 CAV1 EIF2S3 CD151 MKI67IP HSP90AA1

EIF3K CCND3 EIF3G CD47 MLLT11 IFI27

EIF4A1 CD151 EIF3I CD58 MRPS24 IRF4

EIF4EBP2 CD44 EIF3M CD59 NACA LGALS3

FAM174B CD47 EIF4A1 CD63 NDUFB9 LGALS3BP

F0XRED2 CD58 FARSA CDH1 NME1 MCAM

FTL CD59 FBL CDH19 NREP MTRNR2L1

GABARAP CD63 FKBP4 CSPG4 RPL13AP5 MTRNR2L10

GAS5 CD9 GAS5 CTSA RPL18A MTRNR2L2

GNB2L1 CDH19 GNB2L1 CTSB RPL19 MTRNR2L3

GPI CLIC4 GPATCH4 CTSD RPL26 MTRNR2L4

H3F3A CRYAB GPI CTSL1 RPL27A MTRNR2L6

HHATL CSPG4 HNRNPA1 DAG1 RPL31 MTRNR2L8

HMGA1 CST3 HNRNPC DDR1 RPL32 NSG1

HNRNPC CTSB ILF2 DDX5 RPL35A PLXNC1

IDH2 CTSD IMPDH2 EEA1 RPL36 PSAP

ILF2 CTSL1 ISYNA1 EMP1 RPL37 QPCT

ISYNA1 DAG1 LSM7 EVA1A RPL37A RAB5B

ITM2C DCBLD2 MDH2 EZR RPL39 S100A1

KCNAB2 DDR1 MKI67IP FBX032 RPL6 SIOOB

KLHDC8B DDX5 MRPL4 FGFR1 RPL7 SAT1

LHFPL3-AS1 DPYSL2 NAPRT1 FOS RPLP2 SEC11C

MAGEA4 DUSP4 NME1 GAA RPS11 SLC7A8

MIDI DUSP6 N0LC1 GATSL3 RPS13 ST3GAL6

MIR4461 EEA1 NPM1 GJB1 RPS14 TMED10

MPZL1 EGR1 PABPC1 GPR155 RPS15 TMEM255A

NACA EMP1 PAICS GRN RPS16 TYR

NDUFS2 FAM114A1 PFN1 GSN RPS17 VAT1

NENF FAM3C PLEKHJ1 HLA-A RPS17L

NONO FCRLA PLTP HLA-B RPS18

PABPC1 FGFR1 P0LD2 HLA-C RPS20

PFDN2 FOS P0LR1D HLA-E RPS21

PFN1 FXYD3 P0LR2E HLA-F RPS23

PLTP GAA QTRT1 HLA-G RPS25

PPP2R1A GRN RPL10 HLA-H RPS27A

PRAME GSN RPL10A HSPA1A RPS28

PTMA HLA-A RPL11 ID2 RPS4X

RAB38 HLA-B RPL12 IFI27 RPS5

RBM34 HLA-C RPL13 IFI27L2 RPS6

RPL10A HLA-E RPL13A IGFBP7 SMARCA4

RPL11 HLA-F RPL13AP5 IGSF8 SNRPD2

RPL13 HLA-H RPL14 IRF4 ST0ML2

RPL13AP5 HPCAL1 RPL15 ITGA3 TIMM13

RPL17 HSPA1A RPL17 ITGA7 TPI1

RPL18 IGF1R RPL18 LAMP2 UBA52

RPL18A IGFBP7 RPL18A LEF1-AS1 WBSCR22

RPL26 IL6ST RPL21 LGALS3

RPL28 ITGA3 RPL23 LGMN

RPL29 ITGB1 RPL26 LOC100126784

RPL31 ITGB3 RPL27 LOC100506190

RPL36A ITM2B RPL27A LRPAP1

RPL37A JUN RPL28 LYRM9 RPL4 LAMP2 RPL29 MALAT1

RPL41 LGALS3 RPL31 MATN2

RPL5 L0XL3 RPL32 MFGE8

RPL6 LPL RPL35 MIA

RPL8 LRPAP1 RPL36 MPZ

RPLPO MAGEC2 RPL36A MT2A

RPLP1 MCL1 RPL37 MTRNR2L1

RPS10 MFGE8 RPL37A MTRNR2L10

RPS11 MFI2 RPL39 MTRNR2L2

RPS12 MIA RPL4 MTRNR2L3

RPS15 MRPS6 RPL41 MTRNR2L4

RPS15A MT2A RPL5 MTRNR2L5

RPS16 NFKBIA RPL6 MTRNR2L6

RPS17 NFKBIZ RPL7 MTRNR2L8

RPS17L NNMT RPL7A MYH9

RPS18 NPC1 RPL8 MY01D

RPS19 NPC2 RPL9 NAV2

RPS23 NR4A1 RPLPO NEAT1

RPS24 NSG1 RPLP2 NFE2L1

RPS27 PERP RPS10 NPC1

RPS27A PKM RPS11 NPC2

RPS3 PRKCDBP RPS13 NSG1

RPS4X PR0S1 RPS14 PDE4DIP

RPS5 PRSS23 RPS15 PERP

RPS6 PSAP RPS15A PR0S1

RPS7 PTRF RPS16 PSAP

RPS8 RPS4Y1 RPS17 RDH5

RPS9 S100A6 RPS17L S100A1

RPSA SIOOB RPS18 S100A6

SAE1 SCCPDH RPS19 SDC3

SCD SDC3 RPS21 SEC11C

SCIN SEMA3B RPS23 SERINC1

SERPINF1 SERPINA3 RPS24 SERPINA1

SERPINH1 SERPINE2 RPS25 SERPINA3

SHMT2 SGCE RPS27 SERPINE2

SLC25A3 SGK1 RPS27A SGK1

SLC45A2 SLC20A1 RPS28 SLC26A2

SNAI2 SLC26A2 RPS3 SLC5A3

SNHG6 SLC39A14 RPS3A SNX9

S0X4 SLC5A3 RPS4X SP0N2

SRP14 SYPL1 RPS5 SPP1

SSR2 TAPBP RPS6 STRIP2

TIMM50 TIMP1 RPS7 SVIP

TMC6 TIMP2 RPS8 THBD

TP53 TIMP3 RPS9 TIMP2

TRIB2 TM4SF1 RPSA TM4SF1

TRPM1 TNC RRS1 TMBIM6

TUBB4A T0B1 RSL1D1 TMEM255A

TULP4 TPP1 RUVBL2 TNFSF4

UBA52 TSC22D3 SAE1 TPP1

USP22 UBC SERBP1 TRIML2

ZFP36L1 ZBTB38 SERPINF1 TSC22D3

SHMT2 TSPYL2

SLC19A1 TXNIP

SLC25A6 TYR

SMARCA4 UBC

SMIM15 VAT1

SNHG16 XAGE1D SNHG6 ZNF331

SRM

SSR2

TIMM13

TIMM44

TOP1MT

TPI1

TRIM28

UBA52

UQCRFS1

WDR12

XIST

ZFAS1

Table 27B.2

DIFFERENT T CELL SIGNATURES

RELATIV

RELATIVE T E T CD8 T CD4 EXC. T CD4 EXC. T CD8 EXC. T CD8 EXC. T CELL EXC. T CELL EXC.

CD8 EXC.

EXC. (UP) (DOWN) (UP) (DOWN) (UP) (DOWN) (DOWN)

(UP)

BTF3 APOD AHCY A2M AHCY A2M AHCY A2M

CHCHD2 APOE APP AGA APP ACSL3 ALDH18A1 AEBP1

CYC1 ATP1A1 BANCR AHNAK ATP5D AEBP1 APP AGA

EEF1B2 ATP6V0C BZW2 ANXA1 ATP5G3 AGA ASAP1 AHNAK

C17orf76-

EEF1G B2M AS1 AP0C2 B0P1 AHNAK ATP5D ANXA1

EIF3G CAPN3 C1QBP APOD BTF3 AP0C2 ATP5G2 AP0C2

EIF3M CD59 C6orf48 APOE BZW2 APOD BANCR APOD

C17orf76-

EIF4A1 CD63 CCT3 ARSA AS1 APOE BCAN APOE

EN01 CDH1 CCT6A ATP1A1 C19orf48 AP0L1 B0P1 ARSA

FARSA CTSD CDCA7 ATP1B1 C1QBP ARSA BTF3 ATP1A1

GAPDH DAAM2 CYC1 ATP6V0C C6orf48 ATP1A1 BZW2 ATP1B1

C17orf76-

H19 GPNMB DAP3 B2M CACYBP ATP1B1 AS1 ATP6V0C

HNRNPA

1 GPR56 EEF1A1 C4A CCT3 ATP6V0C C19orf48 B2M

HSPE1 HLA-A EEF1B2 CAPN3 CCT4 B2M C1QBP C4A

LDHB HLA-B EE FID CARD16 CCT6A C4A C6orf48 CAPG

LSM4 HLA-C EEF1G CD151 CCT7 CARD16 CACYBP CARD16

LSM7 HLA-E EEF2 CD47 CDCA7 CAV2 CCT3 CAV1

MAGEA4 HLA-F EIF2S3 CD58 CDK4 CD151 CCT6A CAV2

MAGEC1 HLA-G EIF3E CD59 CHCHD2 CD44 CCT7 CCND3

MDH2 HLA-H EIF3G CD63 CTPS1 CD47 CDCA7 CD151

MKI67IP HPS5 EIF3K CDH1 DARS CD58 CPXM1 CD47

MLLT11 HSP90AA1 EIF3L CDH19 DCTPP1 CD59 CTPS1 CD58

MRPS24 IFI27 EIF4A1 CREB3L2 DDX21 CD63 CYC1 CD59

NACA IFI6 FBL CSPG4 EEF1B2 CDH1 CYP51A1 CD63

NDUFB9 IGSF8 FKBP4 CST3 EE FID CDH19 DARS CDH19

NHP2 IRF4 GAS5 CTSB EEF1G CSPG4 DCAF13 CREB3L2

NME1 LAMP2 GCSH CTSD EEF2 CST3 DCT CSPG4

NREP LGALS3 GNB2L1 CTSL1 EIF2S3 CTSA DDX21 CST3

PPIA LGALS3BP GNL3 DAG1 EIF3E CTSB EEF1A1 CTSA

RPL13AP

5 L0NP2 GPATCH4 DDR1 EIF3F CTSD EEF1B2 CTSB

RPL18A MCAM GPI EEA1 EIF3G CTSL1 EE FID CTSD

RPL19 MLPH HMGB1 EMP1 EIF3K CTSO EEF1G CTSL1 RPL26 MTRNR2L1 HNRNPA1 EVA1A EIF3M CYP27A1 EEF2 DAG1

MTRNR2L1

RPL27A 0 HNRNPC FBX032 EIF4A1 CYP4V2 EIF2S3 DDR1

RPL31 MTRNR2L2 HNRNPH1 FGFR1 EN01 DAG1 EIF3E DUSP4

RPL32 MTRNR2L3 HNRNPM GAA EX0SC5 DDR1 EIF3G EEA1

RPL36 MTRNR2L4 HSPD1 GATSL3 FAM92A1 EEA1 EIF3H EMP1

RPL37 MTRNR2L6 IDH2 GJB1 FARSA EMP1 EIF3I EVA1A

RPL37A MTRNR2L8 IFRD2 GPR56 FBL EVA1A EIF3K EZR

RPL39 NSG1 ILF2 GRN FKBP4 FBX032 EIF3L FBX032

RPL6 PLXNC1 IMPDH2 GSN GAS5 FGFR1 EIF3M FGFR1

RPL7 PSAP LSM7 HCP5 GGH FLNA EIF4A1 GAA

RPLPO QPCT LYPLA1 HLA-A GNB2L1 FOS EN01 GATSL3

RPLP2 RAB5B MDH2 HLA-B GNL3 GAA FAM92A1 GJB1

RPS10 S100A1 MRPL15 HLA-C GPATCH4 GATSL3 FBL GPR155

RPS11 SIOOB MRPL4 HLA-F GPI GJB1 FKBP4 GRN

RPS13 SAT1 NCL HLA-G HMGB1 GPNMB GAS5 GSN

RPS14 SEC11C NDUFA11 HLA-H HNRNPA1 GPR155 GCSH HCP5

RPS15 SHC4 NDUFS7 IFI27 HNRNPC GPR56 GNB2L1 HLA-A

RPS16 SLC7A8 NME1 IFI27L2 HNRNPH1 GRN GNL3 HLA-B

RPS17 S0RT1 N0P16 IGFBP7 HNRNPM GSN GPATCH4 HLA-C

RPS17L ST3GAL6 NPM1 IRF4 HSPD1 HLA-A GPI HLA-E

RPS18 STX7 PABPC1 ITGA3 IDH2 HLA-B GPM6B HLA-F

RPS20 TMED10 PAICS ITGA7 IFRD2 HLA-C HMGB1 HLA-G

TMEM255

RPS21 A PFN1 ITGB3 ILF2 HLA-E HNRNPA1 HLA-H

RPS23 TYR PLEKHJ1 KCNN4 ILF3 HLA-F HNRNPC HSPA1A

RPS25 P0LD2 LAMP2 IMPDH2 HLA-G HNRNPH1 IFI27

RPS27A P0LR1D LEF1-AS1 ISYNA1 HLA-H HNRNPM IFI27L2

RPS28 P0LR2E LGALS3 LDHB HSPA1A HNRPDL IFI35

LOC10012678

RPS5 RPL10 4 LSM4 IFI27 HSPD1 IFI6

LOC10050619

RPS6 RPL10A 0 LSM7 IFI27L2 IDH2 IGFBP7

RPS7 RPL11 LRPAP1 LYPLA1 IFI6 ILF2 IRF4

RPSA RPL12 LYRM9 MAGEC1 IGFBP7 ILF3 ITGA3

RUVBL2 RPL13 MATN2 MCM7 IGSF8 IMPDH2 ITGA7

SMARCA

4 RPL13A MFGE8 MDH2 IRF4 LDHB ITGB3

SNRPD2 RPL13AP5 MIA MKI67IP ITGA3 LIMD2 KCNN4

SNRPE RPL14 MPZ MRPL15 ITGA7 LSM7 LAMP2

ST0ML2 RPL15 MT2A MRPL37 KCNN4 LYPLA1 LEF1-AS1

TIMM13 RPL17 MTRNR2L1 MRPL4 LAMB2 MAGEA4 LGALS1

TPI1 RPL18 MTRNR2L10 MRPS12 LAMP2 MARCKS LGALS3

LOC10012678

UBA52 RPL18A MTRNR2L2 NACA LEF1-AS1 MARCKSL1 4

LOC10050619

UHRF1 RPL21 MTRNR2L3 NCL LGALS3 MDH2 0

UQCRH RPL22 MTRNR2L4 NDUFA11 LGALS3BP MEST LRP10

WBSCR2

2 RPL26 MTRNR2L5 NME1 LGMN MIDI LRPAP1

LOC10012678

RPL27A MTRNR2L6 NME2 4 MKI67IP LY6E

LOC10050619

RPL28 MTRNR2L7 N0LC1 0 MPZL1 LYRM9

RPL29 MTRNR2L8 N0P16 LRPAP1 MRPL15 MATN2

RPL3 MY01D NPM1 LY6E MRPL4 MFGE8

RPL30 NEAT1 NREP LYRM9 NACA MFI2

RPL31 NFKBIA PABPC1 MALAT1 NAP1L1 MIA

RPL32 NPC1 PAICS MATN2 NCL MMP14 RPL35 NPC2 PFN1 MCAM NHP2 MPZ

RPL36 NSG1 PLEKHJ1 MFGE8 NME2 MT2A

RPL36A PDE4DIP P0LD2 MIA N0LC1 MTRNR2L1

RPL37 PERP P0LR1D MMP14 NONO MTRNR2L10

RPL37A PR0S1 P0LR2E MPZ N0P58 MTRNR2L2

RPL39 PSAP PPA1 MT2A NPM1 MTRNR2L3

RPL4 RDH5 PPIA MTRNR2L1 NREP MTRNR2L4

RPL41 S100A1 PRMT1 MTRNR2L10 PABPC1 MTRNR2L5

RPL5 S100A13 PTMA MTRNR2L2 PAICS MTRNR2L6

RPL6 S100A6 PUF60 MTRNR2L3 PFDN2 MTRNR2L7

RPL7 SAT1 RPL10 MTRNR2L4 PFN1 MTRNR2L8

RPL7A SDC3 RPL10A MTRNR2L5 PHB2 MY01D

RPL8 SERINC1 RPL11 MTRNR2L6 PLTP NEAT1

RPL9 SERPINA1 RPL12 MTRNR2L7 P0LD2 NFKBIA

RPLPO SERPINA3 RPL13 MTRNR2L8 P0LR1D NPC1

RPLP1 SERPINE2 RPL13A MY01D P0LR2E NPC2

RPLP2 SGCE RPL13AP5 NAV2 PPIA NSG1

RPS10 SGK1 RPL14 NEAT1 PTMA PAGE5

RPS11 SLC26A2 RPL15 NFE2L1 PTP4A3 PDE4DIP

RPS13 SLC5A3 RPL17 NPC1 RPL10 PERP

RPS14 SP0N2 RPL18 NPC2 RPL10A PKM

RPS15 SPP1 RPL18A NSG1 RPL11 PR0S1

RPS15A STRIP2 RPL19 PDE4DIP RPL12 PSAP

RPS16 SYNE2 RPL21 PERP RPL13 RDH5

RPS17 THBD RPL22 PR0S1 RPL13A RTP4

RPS17L TIMP1 RPL26 PSAP RPL13AP5 S100A1

RPS18 TIMP2 RPL27 QPCT RPL14 S100A13

RPS19 TM4SF1 RPL27A RDH5 RPL15 S100A6

RPS20 TMBIM6 RPL28 S100A1 RPL17 SIOOB

RPS21 TMEM255A RPL29 S100A13 RPL18 SAT1

RPS23 TNFRSF12A RPL3 S100A6 RPL18A SCARB2

RPS24 TNFSF4 RPL30 SIOOB RPL19 SCCPDH

RPS25 TPP1 RPL31 SAT1 RPL21 SDC3

RPS27 TRIML2 RPL32 SCARB2 RPL22 SERINC1

RPS27A TSC22D3 RPL35 SDC3 RPL26 SERPINA1

RPS28 TSPYL2 RPL36 SEC11C RPL27 SERPINA3

RPS3 TXNIP RPL36A SERINC1 RPL27A SERPINE2

RPS3A TYR RPL37 SERPINA1 RPL28 SGCE

RPS4X UBC RPL37A SERPINA3 RPL29 SGK1

RPS5 WBP2 RPL39 SERPINE2 RPL3 SLC26A2

RPS6 WSB1 RPL4 SGK1 RPL30 SLC5A3

RPS7 RPL41 SHC4 RPL31 SNX9

RPS8 RPL5 SLC26A2 RPL32 SP0N2

RPS9 RPL6 SLC5A3 RPL35 SPP1

RPSA RPL7 SLC7A8 RPL36 SQSTM1

RQCD1 RPL7A SNX9 RPL36A STRIP2

RRS1 RPL8 S0RT1 RPL37 SYNE2

RSL1D1 RPL9 SP0N2 RPL37A THBD

SAE1 RPLPO SPP1 RPL38 TIMP1

SERBP1 RPLP1 STRIP2 RPL39 TIMP3

SERPINF1 RPLP2 STX7 RPL4 TM4SF1

SET RPS10 SYNE2 RPL41 TMBIM6

SHMT2 RPS11 TAPBP RPL5 TMEM255A

SLC25A13 RPS13 THBD RPL6 TNFRSF12A

SLC25A5 RPS14 TIMP1 RPL7 TNFSF4

SLC25A6 RPS15 TIMP2 RPL7A TPP1

SMARCA4 RPS15A TIMP3 RPL8 TRIML2

SMIM15 RPS16 TM4SF1 RPL9 TSC22D3 SNHG15 RPS17 TMBIM6 RPLPO TSPYL2

SNHG16 RPS17L TMED10 RPLP1 TXNIP

SNHG6 RPS18 TMEM255A RPLP2 UBC

SNRPE RPS19 TNFSF4 RPS10 WBP2

SORD RPS2 TPP1 RPS11 ZBTB38

SOX4 RPS20 TRIML2 RPS12

SRM RPS21 TSC22D3 RPS13

TIMM13 RPS23 TSPYL2 RPS14

TIMM44 RPS24 TXNIP RPS15

TIMM50 RPS25 TYR RPS15A

TOMM20 RPS27 UBC RPS16

TOP1MT RPS27A VAT1 RPS17

TUFM RPS28 WBP2 RPS17L

UBA52 RPS3 XAGE1D RPS18

UCK2 RPS3A RPS19

UQCR11 RPS4X RPS2

UQCRFS1 RPS5 RPS20

ZFAS1 RPS6 RPS21

RPS7 RPS23

RPS8 RPS24

RPS9 RPS25

RPSA RPS27

RQCD1 RPS27A

RRS1 RPS28

RSL1D1 RPS3

RUVBL2 RPS3A

SAE1 RPS4X

SERBP1 RPS5

SERPINF1 RPS6

SET RPS7

SHMT2 RPS8

SLC19A1 RPS9

SLC25A13 RPSA

SLC25A6 RQCD1

SMARCA4 RRP15

SMIM15 RRS1

SNHG15 RSL1D1

SNHG6 RUVBL2

SNRPB SAE1

SNRPC SERBP1

SNRPD1 SERPINF1

SNRPD2 SET

SNRPE SHMT2

S0X4 SLC19A1

SRM SLC25A13

SSB SLC25A5

SSR2 SLC25A6

TIMM13 SMARCA4

TIMM44 SMIM15

TIMM50 SNAI2

T0P1MT SNHG15

TPI1 SNHG6

TRAP1 SNRPD1

TRIM28 SNRPD2

TUBB SNRPE

TYMS SORD

UBA52 S0X4

UCK2 SRM UHRF1 SSR2

UQCRFS1 ST0ML2

UQCRH STRAP

VDAC2 TIMM13

XIST TIMM44

ZFAS1 TIMM50

TOMM20

T0P1MT

TP53

TRAP1

TUBB

TUFM

TYMS

TYRP1

UBA52

UCK2

UQCRFS1

UQCRH

USP22

XIST

YWHAE

ZFAS1

DIFFERENT T CELL SIGNATURES

T CD4

T CD4 T CD4 T CD8 T CD8 T CD8

EXHAUSTE T CD4 TREG T CD8 NAIVE EXHAUSTED TREG EXC. CYTOTOXIC CYTOTOXIC NAIVE EXC.

D EXC. EXC. (UP) EXC. (DOWN) EXC. (UP) (DOWN) EXC. (UP) EXC. (DOWN) (UP)

(DOWN)

ACP5 A2M ABR A2M ADCK3 A2M ADSL A2M

ACTG1 AKAP12 ACP5 AGA ADSL AEBP1 AHCY ACSL3

AK2 ANGPTL4 ACTG1 AHNAK AHCY AGA APEX1 AEBP1

AP1S2 ANXA1 AHCY ANXA1 APEX1 AHNAK ATP5D AGA

AP0A1BP APLP2 ANKRD10 APLP2 APP ANXA1 BANCR AHNAK

ASAH1 AP0C2 APP AP0C2 ATP5D APOC2 BTF3 ANXA1

C17orf76-

ASAP1 APOD ASAP1 APOD ATP5G2 APOD AS1 APOC2

ATP5D ATP1B1 ATP5D ATP1A1 BANCR APOE C19orf48 APOD

BAIAP2 ATP6V0E2 BANCR ATP1B1 BTF3 ARSA C1QBP APOE

BCAN ATRAID BCAN ATP6V0E2 BZW2 ATP1A1 C6orf48 ATP1A1

C17orf76-

Cllorf24 C16orf45 BZW2 ATRAID AS1 ATP6V0C CACYBP ATP1B1

C17orf76-ASl C4A C17orf76-ASl B2M C19orf48 ATP6V1E1 CCT2 B2M

Clorf43 CALM2 C6orf48 C4A C1QBP B2M CCT3 C4A

CA14 CBLB CA14 CBLB C6orf48 C4A CCT4 CALU

CCT3 CCND3 CCNG1 CCND3 CACYBP CALU CCT7 CARD16

CDC16 CD151 CCT3 CD151 CCNB1IP1 CAPG CDCA7 CAV1

CDH3 CD47 CDH3 CD47 CCT2 CARD16 CDK4 CAV2

CDK2 CD58 CDR1 CD58 CCT3 CAV1 CPXM1 CCPG1

CEP170 CD59 CEP170 CD59 CCT4 CAV2 CYC1 CD151

CERS4 CDH19 CHP1 CD63 CCT5 CD151 DAP3 CD47

CHCHD6 CFI CPXM1 CDH19 CCT6A CD47 DDX21 CD58

CTSK CHI3L1 CRISPLD1 CHI3L1 CCT7 CD58 EEF1A1 CD59

DAP3 CHN1 CYP51A1 CHN1 CDCA7 CD59 EEF1B2 CD63

DCT CHRM3 DAP3 CLU CDR1 CD63 EE FID CDH1

DPP7 CLU DCT COX 17 CPXM1 CDH1 EEF1G CDH19

EDNRB CPVL EDNRB CPVL CYC1 CDH19 EEF2 CLU

EE FID CRELD1 EEF1A1 CREB3L2 DARS CREB3L2 EIF2S3 CREB3L2

EEF2 CRYAB EEF1B2 CRELD1 DCAF13 CSPG4 EIF3E CSPG4 EIF2S3 CSPG4 EE FID CSPG4 DDX21 CST3 EIF3F CST3

EIF3D CST3 EEF1G CST3 EEF1A1 CTSA EIF3G CTSA

EIF3I CTSB EEF2 CTHRC1 EEF1B2 CTSB EIF3H CTSB

EIF3L DDR1 EIF2S3 CTSB EE FID CTSD EIF3I CTSD

EPS15 DPYSL2 EIF3E CTSD EEF1G CYP27A1 EIF3K DAG1

ESRP1 DSCR8 EIF3H DAG1 EEF2 CYSTM1 EIF3L DDR1

FAM167B DUSP6 EIF3K DDR1 EIF2S3 DAG1 EIF3M DUSP4

FAM174B DYNLRB1 EIF3L DPYSL2 EIF3E DDR1 EIF4A1 DUSP6

FAM178B EFNA5 EIF4A1 DSCR8 EIF3F ECM1 EN01 ECM1

FMN1 EGR1 ESRP1 DUSP6 EIF3G EEA1 ESRP1 EEA1

FTL ERRFI1 FAM174B DYNLRB1 EIF3H EMP1 EX0SC4 EGR1

FXYD5 FAM3C FAM178B EEA1 EIF3K END0D1 EX0SC5 ERBB3

GAS5 FAM46A FAM92A1 EMP1 EIF3L EVA1A FAM178B EVA1A

GCNT2 FCGR2A FBL ETV4 EIF3M FBX032 FAM92A1 FAM3C

GGA1 FGFR1 FKBP4 EVA1A EIF4A1 FLNA FARSA FBX032

GMPR GAA F0XRED2 EZR EIF4B GAA FBL FGFR1

GNB2L1 GAGE12G FTL FAM3C EN01 GATSL3 FKBP4 FLNA

EPB41L4A-

GPI GAGE4 GAS5 FCGR2A AS1 GJB1 FRZB FXYD3

GPM6B GAGE6 GNB2L1 FGFR1 FARSA GNPTG GAS5 GAA

GPR143 GATSL3 GNL3 GAA FBL GPR155 GGH GATSL3

GRSF1 GBP2 GPATCH4 GATSL3 FKBP4 GPR56 GNB2L1 GJB1

GST01 H3F3B GPI GJB1 GAS5 GRN GNL3 GNPTG

GSTP1 HSPA1A GPM6B GRN GCSH GSN GPI GPR155

HAGHL HSPA1B GPR143 GSN GNB2L1 HLA-A H19 GPR56

HAS2 IER3 HAS2 H3F3B GNL3 HLA-B HMGA1 GRN

HMG20B IGF1R HMCN1 HCP5 GPATCH4 HLA-C HMGB1 GSN

HNRNPC ISCU HNRNPA1 HLA-F GPI HLA-F HNRNPA1 HLA-B

HPS4 ITGA10 HNRNPC HSPA1A HMGB1 HLA-G HNRNPC HLA-C

HSPA2 ITGA3 IFI16 IFI35 HNRNPA1 HLA-H HNRNPH1 HLA-F

HNRNPA1P1

IFI16 ITGA7 IGSF11 ISCU 0 IFI27 HNRNPM HLA-H

ILVBL ITGB3 ILF2 ITGA3 HNRNPC IFI27L2 HSP90AB1 HSPA1A

IMPDH2 KCNN4 ILVBL ITGA7 HNRNPH1 IFI35 HSPD1 IFI27

INPP4B KRT18 IMPDH2 ITGB3 HNRNPM IFI6 IDH2 IFI35

IS0C2 LEF1-AS1 ISYNA1 KCNN4 HNRPDL IGFBP7 ILF2 IFI6

ITPKB LIF ITM2C LEF1-AS1 HSP90AB1 IGSF8 ILF3 IGFBP7

KCNAB2 LINC00623 KCNJ13 LGALS3 HSPD1 IRF4 IMPDH2 IGSF8

KIT L0XL3 LHFPL3-AS1 LIF ILF2 ITGA3 ISYNA1 ITGA3

LHFPL3-AS1 10X14 LIMD2 LINC00116 ILF3 ITGA7 LDHB ITGA7

LOC1001334

LINC00518 LRPAP1 45 LRPAP1 IMPDH2 ITGB3 LIMD2 ITGB3

LOC1001909

LMNA LTBP3 86 LTBP3 LDHB LAMP2 LSM4 KCNN4

LOC1001334

45 LYRM9 LYPLA1 LYRM9 LIMD2 LEF1-AS1 LSM7 LAMP2

MARCKS MAEL MARCKS MAEL LSM7 LGALS1 LYPLA1 LEF1-AS1

MAZ MAGEA10 MCC MAP1B LYPLA1 LGALS3 MAGEA4 LGALS3

MC1R MAGEA3 MEST MATN2 MAGEA4 LGALS3BP MDH2 LGALS3BP

LOC1001267 LOC1001267

MCC MAGEA4 MITF METTL7B MARCKS 84 MEST 84

LOC1005061

METTL9 MAP1B MPZL1 MFGE8 MARCKSL1 LRPAP1 MIDI 90

MITF MATN2 MYC MFI2 MDH2 LY6E MRPL15 L0XL4

MLANA MDK MY05A MIA MEST LYRM9 MRPL37 LRPAP1

MLPH METTL7B NAP1L1 MPZ MKI67IP MATN2 MRPS12 LY6E

MRPL24 MFGE8 NAPRT1 MT2A MPZL1 MFGE8 NACA LYRM9

MRPL44 MFI2 NCL MTRNR2L1 MRPL15 MIA NCL MATN2

MXI1 MIA NIDI MTRNR2L1 NACA MMP14 NDUFB9 MCAM 0

MYC MPZ N0A1 MTRNR2L2 NAP1L1 MPZ NME1 MFGE8

MYO10 MRPS6 NPIPL3 MTRNR2L3 NFYA MT2A NME2 MIA

MY05A MT2A NPM1 MTRNR2L5 NHP2 MTRNR2L1 N0LC1 MMP14

NAPRT1 MTRNR2L6 P2RX7 MTRNR2L6 NME1 MTRNR2L10 NONO MPZ

NCL NDRG1 PABPC1 MTRNR2L7 NME2 MTRNR2L2 NPM1 MT2A

NDUFS2 NNMT PAICS MTRNR2L8 N0LC1 MTRNR2L3 NREP MTRNR2L1

OAT 0CIAD2 PAX3 NDRG1 NONO MTRNR2L4 PABPC1 MTRNR2L10

P2RX7 PAGE2 PEX19 NDUFB2 NPM1 MTRNR2L5 PAICS MTRNR2L2

PABPC1 PAGE2B PI4KB NNMT NREP MTRNR2L6 PFN1 MTRNR2L3

PAICS PAGE5 PIR NPC1 PABPC1 MTRNR2L7 PHB2 MTRNR2L4

PAX3 PDK4 PLP1 NSG1 PAICS MTRNR2L8 P0LD2 MTRNR2L5

PHACTR1 PERP PLTP 0CIAD2 PAN3 MY01D P0LR1D MTRNR2L6

PI4KB PLEKHB1 P0LR1D PAGE5 PFN1 NDUFAF3 P0LR2E MTRNR2L7

PIR PRR4 PRRC2C PERP PHB2 NPC1 PPIA MTRNR2L8

PLP1 PSMB1 RAB38 PKM PLEKHJ1 NPC2 PTMA MY01D

PLTP RAB34 RAP1GAP PR0S1 P0LR1D NSG1 PTP4A3 NPC1

PMEL RDH5 RPL10 PRSS23 P0LR2E PAGE5 PUF60 NPC2

P0LD2 S100A16 RPL10A RDH5 PPA1 PDE4DIP RAN NSG1

PSMB4 S100A6 RPL11 S100A1 PPIA PERP RPL10 PERP

PTTGIIP SAA1 RPL12 S100A13 PRMT1 PKM RPL10A PR0S1

PYCARD SEMA3B RPL13 S100A16 PTMA PR0S1 RPL11 PRSS23

RAB32 SEPP1 RPL13A S100A6 PTP4A3 PRSS23 RPL12 PSAP

RAB38 SERPINA1 RPL13AP5 SDC3 RBMX PSAP RPL13 QPCT

RAP1GAP SERPINA3 RPL14 SEC11C RNF2 RDH5 RPL13A RDH5

RAP2B SERPINE2 RPL15 SERPINA1 RPL10 R0PN1 RPL13AP5 S100A1

RPL10 SERPINI1 RPL17 SERPINA3 RPL10A S100A1 RPL14 S100A13

RPL10A SFRP1 RPL18 SERPINE2 RPL11 S100A13 RPL15 S100A6

RPL11 SGCE RPL18A SGCE RPL12 S100A6 RPL17 SIOOB

RPL12 SLC26A2 RPL21 SLC26A2 RPL13 SIOOB RPL18 SAT1

RPL13 SLC39A14 RPL22 SLC39A14 RPL13A SAT1 RPL18A SCARB2

RPL13A SLC5A3 RPL26 SLC5A3 RPL13AP5 SCARB2 RPL19 SCCPDH

RPL13AP5 SNX9 RPL27A SNX9 RPL14 SCCPDH RPL21 SDC3

RPL14 SP0N2 RPL28 SP0N2 RPL15 SDC3 RPL21P28 SEMA3B

RPL17 SPP1 RPL29 SPP1 RPL17 SEC11C RPL22 SERPINA1

RPL18 SSBP1 RPL3 SVIP RPL18 SEMA3B RPL26 SERPINA3

RPL18A SSBP2 RPL30 TAPBPL RPL18A SERPINA1 RPL27 SERPINE2

RPL28 TCN1 RPL31 TCN1 RPL19 SERPINA3 RPL27A SGCE

RPL29 THBD RPL32 THBD RPL21 SERPINE2 RPL28 SGK1

RPL3 TIMP1 RPL35 TIMP1 RPL21P28 SGK1 RPL29 SHC4

RPL35 TJP1 RPL36 TJP1 RPL22 SHC4 RPL3 SLC26A2

RPL5 TM4SF1 RPL36A TM4SF1 RPL23 SLC26A2 RPL30 SLC5A3

TNFRSF12

RPL7A TMBIM4 RPL37 A RPL23A SLC5A3 RPL31 SNX9

RPL8 TMX4 RPL37A TNFSF4 RPL26 SLC7A8 RPL32 SP0N2

RPLPO TNFSF4 RPL39 TPP1 RPL27 SNX9 RPL35 SPP1

RPS10 TRIML2 RPL4 TRIML2 RPL27A SP0N2 RPL36 THBD

RPS11 TSC22D3 RPL5 TSC22D3 RPL28 SPP1 RPL36A TIMP1

RPS16 TSPAN13 RPL6 UBC RPL29 SQSTM1 RPL37 TIMP2

RPS18 TXNIP RPL7 WBP2 RPL3 SYNE2 RPL37A TIMP3

RPS19 UBC RPL7A WEE1 RPL30 THBD RPL39 TM4SF1

RPS24 WSB1 RPL8 XAGE1A RPL31 TIMP1 RPL4 TMEM255A

RPS3 XAGE1A RPL9 XAGE1B RPL32 TIMP2 RPL41 TMX4

RPS3A XAGE1B RPLPO XAGE1C RPL34 TIMP3 RPL5 TNFSF4

RPS5 XAGE1C RPLP1 XAGE1D RPL35 TM4SF1 RPL6 TPP1

RPS7 XAGE1D RPLP2 XAGE1E RPL35A TMED10 RPL7 TRIML2

RPS8 XAGE1E RPS10 RPL36 TMEM255A RPL7A TSC22D3

RPS9 ZBTB20 RPS11 RPL36A TMEM59 RPL8 TXNIP RPSA ZMYND8 RPS15 RPL37 TMX4 RPL9 TYR

RUVBL2 RPS15A RPL37A TNFSF4 RPLPO UBC

SAMM50 RPS16 RPL38 TPP1 RPLP1 ZBTB20

SCARB1 RPS17 RPL39 TRIML2 RPLP2 ZBTB38

SCD RPS17L RPL4 TSC22D3 RPS10

SCIN RPS18 RPL41 TXNIP RPS11

SDCBP RPS19 RPL5 TYR RPS12

SEMA6A RPS20 RPL6 UBC RPS13

SLC19A1 RPS23 RPL7 WBP2 RPS14

SLC25A5 RPS24 RPL7A ZBTB38 RPS15

SLC25A6 RPS25 RPL8 RPS15A

SLC45A2 RPS27 RPL9 RPS16

SLC7A5P1 RPS27A RPLPO RPS17

SNAI2 RPS28 RPLP1 RPS17L

SNHG16 RPS3 RPLP2 RPS18

S0AT1 RPS3A RPS10 RPS19

ST3GAL4 RPS4X RPS11 RPS2

STXBP1 RPS5 RPS12 RPS20

TBC1D16 RPS6 RPS13 RPS21

TDRD3 RPS7 RPS14 RPS23

TFAP2A RPS8 RPS15 RPS24

TIMM50 RPS9 RPS15A RPS25

TNFRSF14 RPSA RPS16 RPS27

TPCN2 RSL1D1 RPS17 RPS27A

TRAK2 SAE1 RPS17L RPS28

TRIB2 SCD RPS18 RPS3

TRIM63 SDCBP RPS19 RPS3A

TRPM1 SERBP1 RPS2 RPS4X

TTC39A SERPINF1 RPS20 RPS5

TTYH2 SET RPS21 RPS6

TTYH3 SLC19A1 RPS23 RPS7

TUBB4A SLC25A5 RPS24 RPS8

TXLNA SLC25A6 RPS25 RPS9

TYRP1 SNAI2 RPS27 RPSA

UBL3 SNHG16 RPS27A RRS1

UGCG SNHG6 RPS28 RSL1D1

UQCRFS1 S0X4 RPS3 RUVBL2

VAT1 SSR2 RPS3A SAE1

VIM TFAP2A RPS4X SERBP1

WDFY1 TIMM13 RPS5 SERPINF1

TIMM50 RPS6 SET

TMEM204 RPS7 SHMT2

TNFRSF14 RPS8 SLC19A1

TOMM20 RPS9 SLC25A6

T0P1MT RPSA SMARCA4

TPCN2 RQCD1 SMIM15

TPT1 RRP15 SNAI2

TRIB2 RSL1D1 SNHG6

TRPM1 RUVBL2 SNRPB

TUBB4A SAE1 SNRPD1

TYRP1 SERBP1 SNRPD2

UBA52 SERPINF1 SNRPE

UQCRFS1 SET S0X4

WDFY1 SHMT2 SSR2

XIST SLC25A6 ST0ML2

ZEB2 SMARCA4 STRAP

ZFAS1 SMIM15 TIMM13

SNAI2 TIMM44 SNHG15 TIMM50

SNHG6 TOMM22

SNRPD1 T0P1MT

SNRPD2 TP53

SNRPE TPI1

SOX4 TPM2

SSB TRIM28

SSR2 TUBB

ST0ML2 TYRP1

STRAP UBA52

TIMM13 UHRF1

TIMM44 UQCRFS1

TOMM20 UQCRH

T0P1MT ZFAS1

TP53 ZNF146

TRIM28

TUBB

TUFM

TYRP1

UBA2

UBA52

UCK2

UQCRH

USP22

VDAC2

XIST

YWHAE

ZFAS1

ZNF146

Table 27C. T cell exclusion and post-treatment signatures identified in macrophages

Macrophages in cold tumors Post-treatment macrophages

Up-regulated Down-regulated Up-regulated Down-regulated

ADAM 8 AKR1A1 CSTB ADORA3

ALDOA ALDH1A1 HLA-DQA1 ASPH

ANGPTL4 APOC1 HSD11B1 C3AR1

C19orf59 APOE HSP90AA1 CD200R1

CD300E APOL3 IL18BP CD28

CD55 AXL LGALS2 CD99

CD82 B2M NR1H3 COMT

CDA Clorf54 PPA1 CREM

CYTIP C1QA SLAMF7 CRTAP

DDIT4 C1QB TMSB4X DDOST

DUSP6 C1QC UBD EGFL7

EIF1 C2 EIF1AY

EMP3 CD38 FCGR2A

EN02 CD4 FCGRT

FLNA CD74 GATM

FXYD5 CIITA GNG2

GAPDH CLIC2 GSTTl

GPI CMKLR1 GYPC

IL8 CTSC HIST1H1E

LGALS1 CXCL9 HPGDS

LSP1 EBI3 IFI44

MTHFS ENPP2 LRP1

MYADM EPB41L2 MEF2C

MYOIG FAM26F MS4A4A PGAM1 FGD2 MS4A7

S100A10 GBP4 MTSS1

S100A12 GIMAP5 NAIP

S100A4 GM2A NQ02

S100A6 HAPLN3 0LFML3

S100A8 HLA-DMA PMP22

S100A9 HLA-DMB PRDX2

SLC11A1 HLA-DOA RNASE1

STK10 HLA-DPA1 RPS4Y1

STK17B HLA-DPB1 SEPP1

TREM1 HLA-DPB2 SLC18B1

VCAN HLA-DQA1 SLC40A1

VIM HLA-DQB1 SPP1

HLA-DQB2 STAB1

HLA-DRA TGFBI

HLA-DRB1 TMEM106C

HLA-DRB5 TMEM9

LGALS3BP TPD52L2

LILRB4 ULK3

MS4A6A

NAGK

NR1H3

P2RY12

P2RY6

PDCD1LG2

PLA2G2D

PLEKH01

PPA1

PRDX1

PSME2

RARRES3

SDC3

SERPING1

SLAMF7

SLAMF8

TIFAB

TMSB4X

TRAFD1

UBD

V0PP1

[0554] Table 28. Differentially expressed gene sets in the malignant cells from post- treatment vs. untreated tumors; related to Fig

Gene set

- - 36.5 4.05

GO_CELLULAR_COPPER_ION_HOMEOSTASIS 44.3 4.04 13 9 0.69

215.

GO CELLULAR RESPONSE TO ZINC ION 8 -4 16 7 0.44

ENDOPLASMIC RETICULUM MEMBRANE 42.6 3.93 85 55 0.65

GO REGULATION OF ENDOTHELIAL CELL APOPTOTIC PROCESS 52.4 3.79 42 14 0.33

208.

METALLOTHIONEINS 1 3.72 13 6 0.46

GO INTRAMOLECULAR OXIDOREDUCTASE ACTIVITY TRANSPOSING S S BONDS 40.5 3.64 22 14 0.64

NUCLEAR ENVELOPE ENDOPLASMIC RETICULUM NETWORK 38.4 3.59 94 62 0.66

GO CELLULAR RESPONSE TO VITAMIN D 78.7 3.56 14 4 0.29

KEGG SNARE INTERACTIONS IN VESICULAR TRANSPORT 17.6 3.43 38 23 0.61

ENDOPLASMIC RETICULUM PART 44.4 3.43 97 65 0.67

GO_COPPER_ION_HOMEOSTASIS 38.1 3.38 16 12 0.75

163.

KEGG ECM RECEPTOR INTERACTION 9 3.35 84 35 0.42

GO ENDOPLASMIC RETICULUM GOLGI INTERMEDIATE COMPARTMENT 40.3 -3.3 105 64 0.61

153.

GO BLOOD VESSEL MORPHOGENESIS 3 -3.3 364 117 0.32

GO PLATELET DERIVED GROWTH FACTOR RECEPTOR BINDING 62.3 3.24 15 5 0.33

148.

GO ANGIOGENESIS 4 3.23 293 102 0.35

GO RESPONSE TO ZINC ION 76.2 3.22 55 21 0.38

172.

PID INTEGRIN CS PATHWAY 6 3.19 26 9 0.35

GOLGI MEMBRANE 53.1 3.13 45 26 0.58

GO_TRANSITION_METAL_ION_TRANSMEMBRANE_TRANSPORTER_ACTIVIT Y 61.3 3.12 39 19 0.49

POSITIVE REGULATION OF CELL PROLIFERATION 31.5 3.11 149 48 0.32

164.

GO MUSCLE CELL MIGRATION 4 3.11 18 10 0.56

NUCLEAR ORPHAN RECEPTOR 83.4 3.09 3 2 0.67

GO_POSITIVE_REGULATION_OF_EXTRINSIC_APOPTOTIC_SIGNALING_P ATHWAY_VIA_DEATH_DOMAIN_R

ECEPTORS 75.4 3.08 17 11 0.65

GO_PHOSPHOTRANSFERASE_ACTIVITY_FOR_OTHER_SUBSTITUTED_PHOS PHATE_G ROUPS 32.3 3.07 19 11 0.58

ST INTERLEUKIN 13 PATHWAY -2.4 3.03 7 2 0.29

148.

WOUND_HEALING 0 3.02 54 13 0.24

C/EBP 38.9 -3 10 3 0.3

GO INSULIN LIKE GROWTH FACTOR BINDING 62.7 2.98 25 11 0.44

122.

MUSCLE DEVELOPMENT 5 2.98 93 29 0.31

GO PLATELET ALPHA GRANU LE MEMBRANE 105. 2.96 13 7 0.54 0

G 0_M A N N OS 1 D AS E_ACTI V ΙΤΥ 28.5 2.95 15 5 0.33

GO POSITIVE REGULATION OF ADHERENS JUNCTION ORGANIZATION 61.4 2.95 21 9 0.43

GO NEGATIVE REGULATION OF EPITHELIAL CELL APOPTOTIC PROCESS 70.5 2.95 35 8 0.23

ENDOPLASMIC RETICULUM 50.0 2.94 294 180 0.61

CELL FATE COMMITMENT 72.6 2.94 13 3 0.23

GO ENDOPLASMIC RETICULUM GOLGI INTERMEDIATE COMPARTMENT MEMBRANE 65.4 2.93 63 38 0.6

126.

GO NEGATIVE REGULATION OF INTERLEU IN 8 PRODUCTION 6 2.93 15 5 0.33

PID TNF PATHWAY 73.0 2.92 46 22 0.48

GO RECEPTOR REGULATOR ACTIVITY 93.0 2.92 45 10 0.22

107.

GO EXTRACELLULAR STRUCTURE ORGANIZATION 3 2.92 304 111 0.37

ER_GOLGI_INTERMEDIATE_COMPARTMENT 12.4 2.91 24 20 0.83

124.

GO RESPONSE TO CADMIUM ION 5 -2.9 40 25 0.62

GO HEPARAN SULFATE PROTEOGLYCAN BIOSYNTHETIC PROCESS 32.0 2.89 23 8 0.35

144.

GO AXON REGENERATION 4 2.88 24 9 0.38

ENDOMEMBRANE SYSTEM 22.0 2.87 220 137 0.62

170.

HALLMARK IL6 JAK STAT3 SIGNALING 2 2.87 87 40 0.46

GO HEPARAN SULFATE PROTEOGLYCAN METABOLIC PROCESS 30.7 2.86 28 8 0.29

GO POSITIVE REGULATION OF CELL JUNCTION ASSEMBLY 88.3 2.85 24 11 0.46

143.

GO VASCULATURE DEVELOPMENT 8 2.84 469 153 0.33

CELLULAR_CATION_HOMEOSTASIS 96.8 2.83 106 32 0.3

GO CELL SUBSTRATE JUNCTION ASSEMBLY 79.6 2.82 41 19 0.46

PID FRA PATHWAY 55.9 2.81 37 17 0.46

GO REGULATION OF ADHERENS JUNCTION ORGANIZATION 63.4 2.81 50 22 0.44

GO CELL ADHESION MEDIATED BY INTEGRIN 81.8 2.81 12 8 0.67

216.

GO_SARCOLEMMA 6 2.81 125 37 0.3

GO NEGATIVE REGULATION OF ENDOTHELIAL CELL APOPTOTIC PROCESS 38.2 -2.8 27 7 0.26

GO CORECEPTOR ACTIVITY 68.2 2.79 38 11 0.29

GO REGULATION OF INTERLEUKIN 8 BIOSYNTHETIC PROCESS 12.9 2.78 12 3 0.25

REACTOME EXTRINSIC PATHWAY FOR APOPTOSIS 55.4 2.78 13 8 0.62

112.

HALLMARK_HYPOXIA 2 2.78 200 116 0.58

GO ER NUCLEUS SIGNALING PATHWAY 28.3 2.75 34 25 0.74

HOMOPHILIC CELL ADHESION - - 16 4 0.25 55.0 2.74

G 0_S N A P_R EC E PTO R_ACTI V ΙΤΥ 20.2 2.73 38 22 0.58

128.

HALLMARK EPITHELIAL MESENCHYMAL TRANSITION 6 2.73 200 110 0.55

155.

GO_CELLULAR_RESPONSE_TO_CADMIUM_ION 1 2.73 15 9 0.6

GO BASAL LAMINA 27.9 2.72 21 6 0.29

CELL CELL ADHESION 40.3 2.72 86 19 0.22

POSITIVE REGULATION OF MULTICELLULAR ORGANISMAL PROCESS 45.5 2.71 66 18 0.27

FIBROBLAST 73.9 2.71 6 3 0.5

GO ATPASE COMPLEX 80.5 -2.7 24 7 0.29

GO INTRINSIC COMPONENT OF EXTERNAL SIDE OF PLASMA MEMBRANE 68.1 2.69 27 7 0.26

PID INTEGRIN3 PATHWAY 78.1 2.68 43 22 0.51

CATION_HOMEOSTASIS 93.1 2.68 109 32 0.29

162.

GO CELL SUBSTRATE ADHESION 0 2.68 164 58 0.35

GO_INTRINSIC_APOPTOTIC_SIGNALING_PATHWAY_IN_RESPONSE_TO_E NDOPLASMIC_RETICULUM_STRE

SS 37.6 2.67 32 18 0.56

GO POSITIVE REGULATION OF CELL MATRIX ADHESION 57.1 2.66 40 15 0.38

GO NEGATIVE REGULATION OF GLYCOPROTEIN METABOLIC PROCESS 60.2 2.66 15 10 0.67

162.

GO NEGATIVE REGULATION OF TYPE 2 IMMUNE RESPONSE 5 2.66 11 4 0.36

REACTOME ACTIVATION OF CHAPERONES BY ATF6 ALPHA 22.9 2.64 13 8 0.62

GO_NEGATIVE_REGULATION_OF_DNA_RECOMBI NATION 13.6 2.63 16 8 0.5

GO CELLULAR RESPONSE TO TOPOLOGICALLY INCORRECT PROTEIN 22.7 2.63 122 81 0.66

GO CELLULAR RESPONSE TO CALCIUM ION 69.5 2.63 49 18 0.37

133.

GO SECRETORY GRANULE MEMBRANE 4 2.63 78 28 0.36

GOLGI VESICLE TRANSPORT 13.7 2.62 48 37 0.77

REACTOME_DIABETES_PATHWAYS 20.3 2.62 133 80 0.6

GO NEGATIVE REGULATION OF GLYCOPROTEIN BIOSYNTHETIC PROCESS 24.0 2.61 12 9 0.75

197.

CAHOY ASTROGLIAL 1 2.61 100 37 0.37

GO HEMIDESMOSOME ASSEMBLY 95.2 -2.6 12 5 0.42

GO FIBRINOLYSIS 98.5 -2.6 21 6 0.29

171.

GO PROTEIN COMPLEX INVOLVED IN CELL ADHESION 7 -2.6 30 10 0.33

ST IL 13 PATHWAY -1.6 2.59 7 2 0.29

POSITIVE REGULATION OF PROTEIN MODIFICATION PROCESS 37.4 2.58 29 9 0.31

HALLMARK UV RESPONSE UP 67.1 2.57 158 93 0.59

CELL MIGRATION 87.0 2.57 96 34 0.35 ATPASE_ACTIVITY_COUPLED_TO_TRANSMEMBRANE_MOVEMENT_OF_IONS_PH OSPHORYLATIVE_M ECHA 130.

NISM 2 2.57 20 5 0.25

GO INTEGRIN BINDING 95.0 2.56 105 48 0.46

154.

HALLMARK TNFA SIGNALING VIA NFKB 1 2.56 200 108 0.54

164.

GO PLATELET ALPHA GRANU LE 1 2.56 75 35 0.47

PID INTEGRIN1 PATHWAY 89.7 2.55 66 34 0.52

119.

GO CATION TRANSPORTING ATPASE COMPLEX 7 2.55 16 4 0.25

PROTEIN AMINO ACID LI PIDATION 35.6 2.54 24 19 0.79

GO_NEGATIVE_REGU LATI ON_OF_LIPID_STORAGE 92.0 2.54 17 6 0.35

GO BASEMENT MEMBRANE ORGANIZATION 26.2 2.53 11 7 0.64

POSITIVE REGULATION OF CYTOKINE PRODUCTION 41.7 2.53 15 5 0.33

BIOCARTA SODD PATHWAY 37.4 2.52 10 8 0.8

GO PERK MEDIATED UNFOLDED PROTEI N RESPONSE 39.2 2.52 12 10 0.83

PHOSPHOLIPID METABOLIC PROCESS 44.8 2.52 74 42 0.57

Targets of NFAT_Q6 53.2 2.52 246 80 0.33

BIOCARTA STRESS PATHWAY 71.8 2.52 25 10 0.4

CYTOPLASM_ORGANIZATION_AND_BIOGENESIS 68.0 2.51 15 7 0.47

Targets of FREAC3_01 23.3 -2.5 251 65 0.26

GO COLLAGEN BINDING 84.5 -2.5 65 27 0.42

PID INTEGRIN4 PATHWAY 35.8 2.49 11 4 0.36

CELL SURFACE 42.6 2.49 79 27 0.34

GO PHOSPHATE TRANSMEMBRANE TRANSPORTER ACTIVITY 14.3 2.48 30 16 0.53

NAIVE VS ACTIVATED CD8 TCELL DN 38.5 2.48 200 81 0.4

MEMBRANE LIPID BIOSYNTHETIC PROCESS 20.4 2.47 49 29 0.59

GO_GLYCEROPHOSPHOLIPID_CATABOLIC_PROCESS 28.0 2.47 13 7 0.54

GO INTERSTITIAL MATRIX 82.0 2.47 14 3 0.21

103.

GO REGULATION OF EXTRINSIC APOPTOTIC SIGNALING PATHWAY VIA DEATH DOMAIN RECEPTORS 8 2.47 55 32 0.58

151.

INORGANIC ANION TRANSPORT 9 2.47 18 4 0.22

REACTOME CLASS B 2 SECRETIN FAMILY RECEPTORS 62.6 2.46 88 19 0.22

GO DECIDUALIZATION 99.4 2.46 21 7 0.33

129.

GO MULTI MULTICELLULAR ORGANISM PROCESS 0 2.46 213 62 0.29

NABA_BASEM ENT_M EM BRAN ES 19.2 2.45 40 12 0.3

GO PROTEINACEOUS EXTRACELLULAR MATRIX 60.9 2.45 356 86 0.24

GO EXTRACELLULAR MATRIX - - 426 116 0.27 121. 2.45

2

129.

GO INTEGRIN MEDIATED SIGNALING PATHWAY 1 2.45 82 36 0.44

SECRETION 34.2 2.44 178 68 0.38

GO_CARBOHYDRATE_DERIVATIVE_CATABOLIC_PROCESS 62.7 2.44 174 76 0.44

184.

HALLMARK APOPTOSIS 4 2.44 161 111 0.69

LIPOPROTEIN METABOLIC PROCESS 34.8 2.43 33 21 0.64

LIPOPROTEIN BIOSYNTHETIC PROCESS 36.5 2.43 26 19 0.73

GO BASEMENT MEMBRANE 54.6 2.43 93 32 0.34

REACTOME_UNFOLDED_PROTEIN_RESPONSE 13.9 2.42 80 58 0.72

GO LIPOPROTEIN BIOSYNTHETIC PROCESS 63.0 2.42 85 40 0.47

GO HYDROLASE ACTIVITY ACTING ON G LYCOSYL BONDS 65.4 2.42 122 44 0.36

GO REGULATION OF VIRAL ENTRY INTO HOST CELL 72.1 2.42 28 12 0.43

BIOCARTA IL1R PATHWAY 72.2 2.41 33 12 0.36

199.

HALLM ARKJ L2_STAT5_SIG NALI NG 1 2.41 200 91 0.46

GO NEGATIVE REGULATION OF SMALL GTPASE MEDIATED SIGNAL TRANSDUCTION 72.3 -2.4 40 14 0.35

107.

G 0_G RO WTH_FACTO R_BI N Dl NG 5 2.39 123 46 0.37

118.

GO METALLOENDOPEPTIDASE INHIBITOR ACTIVITY 8 2.39 14 5 0.36

133.

TTAYRTAA_Targets of E4BP4_01 2 2.39 265 74 0.28

200.

GO REGULATION OF T HELPER 2 CELL DIFFERENTIATION 2 2.39 11 3 0.27

CELL ACTIVATION 24.5 2.38 77 17 0.22

GO EXTRACELLULAR MATRIX COMPONENT 46.2 2.38 125 47 0.38

138.

GO RESPONSE TO AXON INJURY 0 2.38 48 19 0.4

GO FORMATION OF PRIMARY GERM LAYER 93.4 2.37 110 33 0.3

HYDROLASE_ACTIVITY_ACTING_ON_ACID_ANHYDRIDESCATALYZING_TR ANSMEMBRANE_MOVEMENT_OF 126.

SUBSTANCES 7 2.37 39 14 0.36

GO CELLULAR RESPONSE TO PROSTAGLANDIN STIMULUS 41.8 2.36 24 10 0.42

GO NEGATIVE REGULATION OF MULTICELLU LAR ORGANISMAL METABOLIC PROCESS 55.1 2.36 12 6 0.5

GO NEGATIVE REGULATION OF GROWTH 96.4 2.36 236 85 0.36

121.

GO REGULATION OF ERK1 AND ERK2 CASCADE 1 2.36 238 74 0.31

156.

GO CELL MATRIX ADHESION 5 2.36 119 42 0.35

PID P38 MKK3 6PATHWAY 11.8 2.35 26 9 0.35

GO ACROSOMAL MEMBRANE - - 22 8 0.36 98.5 2.35

133.

BLOOD COAGULATION 9 2.35 43 12 0.28

134.

GO REGULATION OF INTERLEU IN 2 PRODUCTION 5 2.35 48 19 0.4

GO_IREl_MEDIATED_UNFOLDED_PROTEIN_RESPONSE 17.4 2.34 56 44 0.79

GO PROTEIN HETEROOLIGOMERIZATION 31.5 2.34 113 44 0.39

110.

GO NEGATIVE REGULATION OF SODIUM ION TRANSPORT 1 2.34 11 4 0.36

MEMBRANE FUSION 27.6 2.33 28 15 0.54

KEGG GLYCOSPHINGOLIPID BIOSYNTHESIS GANGLIO SERIES 46.3 2.33 15 6 0.4

GO_REGULATION_OF_CELL_SUBSTRATE_ADHESION 62.1 2.33 173 67 0.39

GO REGULATION OF PROTEIN GLYCOSYLATION 18.5 2.32 14 5 0.36

GO PLASMA MEMBRANE FUSION 40.8 2.32 26 8 0.31

GO COMPACT MYELIN 55.0 2.31 15 8 0.53

Targets of CDPCR1_01 74.8 2.31 130 33 0.25

AMINO ACID DERIVATIVE BIOSYNTHETIC PROCESS 10.4 -2.3 10 4 0.4

KEGG GLYCOSAMI NOGLYCAN BIOSYNTHESIS CHONDROITIN SULFATE 61.3 -2.3 22 6 0.27

GO REGULATION OF CELL MATRIX ADHESION 63.6 -2.3 90 34 0.38

GO_ANTIMICROBIAL_HUMORAL_RESPONSE 81.3 -2.3 52 14 0.27

GO NEGATIVE REGULATION OF PROTEIN KINASE B SIGNALING 47.7 2.29 36 16 0.44

GO RESPONSE TO OXYGEN LEVELS 69.2 2.29 311 127 0.41

GO RESPONSE TO TRANSITION METAL NANOPARTICLE 89.8 2.29 148 63 0.43

106.

GO FIBRONECTIN BINDING 4 2.29 28 16 0.57

147.

GO POSITIVE REGULATION OF INTERLEUKIN 2 PRODUCTION 4 2.29 31 12 0.39

GO ENDOPLASMIC RETICULUM LUMEN 32.2 2.28 201 84 0.42

GO_POSITIVE_REGULATION_OF_EXTRINSIC_APOPTOTIC_SIGNALING_P ATHWAY 52.9 2.28 53 35 0.66

GO CELLULAR RESPONSE TO OXYGEN LEVELS 58.7 2.28 143 55 0.38

REACTOME INTEGRIN CELL SURFACE INTERACTIONS 89.7 2.28 79 37 0.47

125.

EXTRACELLULAR REGION PART 7 2.28 338 88 0.26

157.

GO SECRETORY GRANULE LUMEN 3 2.28 85 31 0.36

GO SNARE COMPLEX 17.4 2.27 53 28 0.53

KEGG GLYCOSAMI NOGLYCAN DEGRADATION 47.0 2.27 21 9 0.43

133.

ATPASE_ACTIVITY_COUPLED_TO_TRANSMEMBRANE_MOVEMENT_OF_IONS 4 2.27 24 9 0.38

196.

GO NEGATIVE REGULATION OF COAGULATION 2 2.27 48 13 0.27 REACTOME TRANSPORT OF VITAMINS NUCLEOSIDES AND RELATED MOLECULES 10.1 2.26 31 9 0.29

GO IRON ION BINDING 18.2 2.26 163 42 0.26

GO ACETYLG LUCOSAM 1 NYLTRANSFERASE ACTIVITY 39.0 2.26 49 19 0.39

GO POSITIVE REGULATION OF RECEPTOR MEDIATED ENDOCYTOSIS 75.5 2.26 47 13 0.28

HALLMARK UV RESPONSE DN 95.4 2.26 144 64 0.44

113.

GO CELL ADHESION MOLECULE BINDING 3 2.26 186 74 0.4

148.

REACTOME CELL SURFACE INTERACTIONS AT THE VASCULAR WALL 4 2.26 91 38 0.42

GO UBIQUITIN UBIQUITIN LIGASE ACTIVITY 10.5 2.25 13 7 0.54

GO_N_GLYCAN_PROCESSING 37.7 2.25 20 5 0.25

GO BRANCH ELONGATION OF AN EPITHELIUM 38.5 2.25 17 4 0.24

REACTOME_TRANSPORT_OF_GLUCOSE_AND_OTHER_SUGARS_BILE_SALTS _AND_ORGANIC_ACIDS_META

L IONS AND AMINE COMPOUNDS 70.9 2.25 89 18 0.2

102.

GO BASAL PLASMA MEMBRANE 3 2.25 33 9 0.27

156.

GO PLATELET DEG RANU LATION 8 2.25 107 51 0.48

PDZ DOMAIN BINDING 29.5 2.24 14 4 0.29

BIOCARTA GATA3 PATHWAY 52.3 2.24 16 4 0.25

GO_NEGATIVE_REGULATION_OF_CELL_SUBSTRATE_ADHESION 81.8 2.24 53 25 0.47

AMINE BIOSYNTHETIC PROCESS 12.3 2.23 15 7 0.47

GO REGULATION OF RECEPTOR ACTIVITY 13.6 2.23 117 30 0.26

GO PYRIMIDINE NUCLEOSIDE CATABOLIC PROCESS 79.6 2.23 21 8 0.38

132.

GO CIRCULATORY SYSTEM DEVELOPMENT 2 2.23 788 233 0.3

GO_MATURE_B_CELL_DI FFERENTIATION 21.5 2.22 17 7 0.41

GO OLIGOSACCHARIDE CATABOLIC PROCESS 24.1 2.22 12 7 0.58

GO RESPONSE TO PROSTAGLANDIN 38.5 2.22 34 11 0.32

GO_OXIDOREDUCTASE_ACTIVITY_ACTING_ON_THE_CH_NH2_GROUP_OF_ DONORS_OXYGEN_AS_ACCEP

TOR 60.9 2.22 15 5 0.33

ST TUMOR NECROSIS FACTOR PATHWAY 96.7 2.22 29 17 0.59

101.

GO_REGULATION_OF_INTERLEUKIN_8_SECRETION 5 2.22 19 8 0.42

157.

GO REGULATION OF MEMBRANE PROTEIN ECTODOMAIN PROTEOLYSIS 9 2.22 21 9 0.43

ER_TO_GOLGI_VESICLE_MEDIATED_TRANSPORT -4.8 2.21 18 15 0.83

PID TCR JNK PATHWAY 26.5 2.21 14 6 0.43

REACTOME IL1 SIGNALING 34.9 2.21 39 16 0.41

GO_POSITIVE_REGULATION_OF_IMMUNOGLOBULIN_SECRETION 97.2 2.21 11 4 0.36

129.

PID API PATHWAY 8 -2.2 70 31 0.44 Targets of LMO2COM_01 20.1 2.19 264 72 0.27

GO RESPONSE TO STARVATION 41.8 2.19 154 70 0.45

114.

GO MEMBRANE RAFT ORGANIZATION 2 2.19 17 12 0.71

131.

COAGULATION 3 2.19 44 12 0.27

GO SULFATE TRANSPORT 73.2 2.18 14 3 0.21

Targets of STAT5A_02 73.8 2.18 141 42 0.3

145.

GO SECRETORY GRANULE 5 2.18 352 114 0.32

149.

G 0_REG U LATI 0 N_0 F_CO AG U LATI 0 N 1 2.18 88 26 0.3

169.

GO CELL SURFACE 9 2.18 757 217 0.29

GO NUCLEOTIDE TRANSMEMBRANE TRANSPORT -6.9 2.17 12 7 0.58

PROTEIN TRANSPORTER ACTIVITY -7.7 2.17 14 7 0.5

ENDOPLASMIC RETICULUM LUMEN 16.1 2.17 14 12 0.86

GO_REGULATION_OF_PEPTIDYL_SERINE_PHOSPHORYLATION 34.4 2.17 118 37 0.31

LIPID RAFT 83.2 2.17 29 16 0.55

GO CELLULAR RESPONSE TO EXTERNAL STIMULUS 74.8 2.16 264 114 0.43

GO REGULATION OF EXTRINSIC APOPTOTIC SIGNALING PATHWAY 97.6 2.16 153 77 0.5

144.

GO RESPONSE TO DRUG 6 2.16 431 159 0.37

147.

GO REGULATION OF EXTRACELLULAR MATRIX DISASSEMBLY 7 2.16 14 4 0.29

REACTOME ACTIVATION OF CHAPERONE GENES BY XBP1S 15.4 2.15 46 35 0.76

GO DENDRITE MORPHOGENESIS 17.1 2.15 42 12 0.29

GO MATURE B CELL DI FFERENTIATION INVOLVED IN IMMUNE RESPONSE 27.9 2.15 13 6 0.46

133.

GO CELLULAR RESPONSE TO MECHANICAL STIMULUS 1 2.15 80 32 0.4

138.

GO HETEROTYPIC CELL CELL ADHESION 7 2.15 27 9 0.33

BIOCARTA LYM PATHWAY 59.0 2.14 11 7 0.64

HINATA NF B MATRIX 78.2 2.14 10 7 0.7

GO NEGATIVE REGULATION OF RHO PROTEIN SIGNAL TRANSDUCTION 83.8 2.14 14 8 0.57

GO TELOMERE LOCALIZATION -8.5 2.13 11 4 0.36

INTRINSIC TO ENDOPLASMIC RETICULUM MEMBRANE 11.4 2.13 24 14 0.58

CELLULAR HOMEOSTASIS 62.0 2.13 147 45 0.31

GO_CELL_MIGRATION_INVOLVED_IN_SPROUTING_ANGIOGENESIS 87.1 2.13 15 4 0.27

GO GASTRULATION 36.6 2.12 155 46 0.3

PID IL1 PATHWAY - - 34 15 0.44 68.3 2.12

GO_ENDOPEPTIDASE_ACTIVITY 81.6 2.12 448 135 0.3

INTEGRAL TO ENDOPLASMIC RETICULUM MEMBRANE -9.6 2.11 24 14 0.58

REACTOME ACTIVATION OF CHAPERONE GENES BY ATF6 ALPHA 16.4 2.11 11 7 0.64

GO ZINC II ION TRANSPORT 38.1 2.11 26 13 0.5

RYAAA NNNNNNTTGW UNKNOWN 51.3 2.11 84 22 0.26

GGARNTKYCCA UNKNOWN 56.6 2.11 78 24 0.31

GO MEMBRANE HYPERPOLARIZATION 86.7 2.11 11 3 0.27

PID INTEGRIN A9B1 PATHWAY 88.1 2.11 25 11 0.44

113.

GO MEMBRANE ASSEMBLY 4 2.11 25 10 0.4

135.

GO ALCOHOL TRANSMEMBRANE TRANSPORTER ACTIVITY 7 2.11 24 5 0.21

LEUKOCYTE_ACTIVATION 21.6 -2.1 69 16 0.23

GO POSITIVE REGULATION OF PEPTIDYL SERINE PHOSPHORYLATION 60.5 -2.1 88 29 0.33

GO OXALATE TRANSPORT 81.4 2.09 12 3 0.25

GO MEMBRANE BIOGENESIS 92.9 2.09 30 12 0.4

133.

GO SECRETORY VESICLE 0 2.09 461 143 0.31

REACTOME_EXTRACELLU LAR_MATRIX_ORGANIZATION 29.2 2.08 87 25 0.29

Targets of ATargets of 01 45.9 2.08 259 109 0.42

130.

ATPASE_ACTIVITY_COUPLED_TO_MOVEMENT_OF_SUBSTANCES 1 2.08 40 14 0.35

GO ENDOPLASMIC RETICULUM CHAPERONE COMPLEX -3.3 2.07 11 8 0.73

GO CIS GOLGI NETWORK 26.0 2.07 40 23 0.57

GO RESPONSE TO OXIDATIVE STRESS 58.4 2.07 352 165 0.47

Targets of FOXD3_01 77.7 2.07 199 45 0.23

HYDROLASE ACTIVITY HYDROLYZING 0 GLYCOSYL COMPOUNDS 37.8 2.06 37 13 0.35

Targets of CEBP_Q2_01 52.0 2.06 267 76 0.28

GO REGULATION OF CELL JUNCTION ASSEMBLY 53.5 2.06 68 27 0.4

GO_PEPTIDASE_ACTIVITY 53.9 2.06 663 202 0.3

GO REGULATION OF EPITHELIAL CELL APOPTOTIC PROCESS 88.5 2.06 59 20 0.34

ACTIVE TRANSMEMBRANE TRANSPORTER ACTIVITY 98.3 2.06 122 31 0.25

127.

GO REGULATION OF PEPTIDASE ACTIVITY 3 2.06 392 176 0.45

GO RESPONSE TO FOOD 15.0 2.05 19 5 0.26

GO_PROTEIN_DEGLYCOSYLATION 22.0 2.05 21 13 0.62

GO AMINOGLYCAN CATABOLIC PROCESS 66.4 2.05 68 27 0.4

INTEGRAL TO ORGANELLE MEMBRANE 12.4 2.04 50 27 0.54 LYMPHOCYTE ACTIVATION 16.2 2.04 61 15 0.25

BIOCARTA VITCB PATHWAY 23.6 2.04 11 6 0.55

NEGATIVE REGULATION OF SECRETION 25.6 2.04 13 5 0.38

MEMBRANE LIPID METABOLIC PROCESS 61.4 2.04 101 55 0.54

GO CELL CELL CONTACT ZONE 91.7 2.04 64 21 0.33

112.

KEGG COMPLEMENT AND COAGULATION CASCADES 2 2.04 69 28 0.41

182.

GO NEGATIVE REGULATION OF WOUND HEALING 9 2.04 58 13 0.22

NUCLEOTIDE KINASE ACTIVITY -0.4 2.03 13 5 0.38

GO_ENDODERM_FORMATION 52.7 2.03 50 20 0.4

GO GLYCOLIPID BIOSYNTHETIC PROCESS 58.1 2.03 62 33 0.53

Ml MACROPHAGES 77.2 2.03 54 25 0.46

137.

RESPONSE TO WOUNDING 2 2.03 190 58 0.31

149.

GO REGULATION OF ASTROCYTE DIFFERENTIATION 9 2.03 27 7 0.26

GO HOST -4.3 2.02 12 8 0.67

GO REGULATION OF CHOLESTEROL HOMEOSTASIS 29.2 2.02 11 4 0.36

GO_REGULATION_OF_SODIUM_ION_TRANSMEMBRANE_TRANSPORT 67.2 2.02 48 14 0.29

TIL HCC C9 CD4 GZMK 75.2 2.02 10 5 0.5

SUGAR BINDING 98.2 2.02 34 7 0.21

139.

GO APICAL PLASMA MEMBRANE 4 2.02 292 74 0.25

143.

GO REGULATION OF SODIUM ION TRANSPORT 0 2.02 77 22 0.29

GO UDP GLYCOSYLTRANSFERASE ACTIVITY 33.4 2.01 139 38 0.27

GO OXIDOREDUCTASE ACTIVITY ACTING ON THE CH NH2 GROUP OF DONORS 37.8 2.01 19 6 0.32

GO ENDODERM DEVELOPMENT 49.7 2.01 71 21 0.3

GO CARBOHYDRATE BINDING 65.6 2.01 277 72 0.26

Targets of OCT1_Q5_01 69.3 2.01 273 64 0.23

GO_MATERNAL_PROCESS_INVOLVED_l N_FEMALE_PREG NANCY 72.7 2.01 60 21 0.35

141.

GO SODIUM POTASSIUM EXCHANGING ATPASE COMPLEX 2 2.01 11 3 0.27

166.

HALLMARK COAGULATION 9 2.01 138 64 0.46

SULFURIC ESTER HYDROLASE ACTIVITY 49.6 -2 16 4 0.25

GO RESPONSE TO UV 39.8 2 126 60 0.48

FATTY ACID OXIDATION 17.5 2 18 12 0.67

GO PROTEIN SUMOYLATION 74.6 2.01 115 68 0.59

GO POSITIVE REGULATION OF DNA REPAIR 59.9 2.01 38 17 0.45

GO CHROMOSOMAL REGION 54.3 2.01 330 159 0.48 GO NEGATIVE REGULATION OF DEFENSE RESPONSE TO VIRUS 42.6 2.01 18 8 0.44 EGG LIMONENE AND PI NENE DEGRADATION 40.9 2.01 10 7 0.7

NUCLEAR_HORMONE_RECEPTOR_BINDING 39.1 2.01 28 15 0.54

CELLULAR PROTEIN COMPLEX DISASSEMBLY 35.6 2.01 13 7 0.54

BIOCARTA VEGF PATHWAY 21.9 2.01 29 15 0.52

GO FILAMENTOUS ACTIN 8.3 2.01 20 6 0.3

G 0_DN A_M ETHYLATI 0 N_0 R_DEM ETHYLATI 0 N 2.5 2.01 59 22 0.37

GO REGULATION OF TELOMERASE ACTIVITY 68.3 2.02 43 17 0.4

GO HORMONE RECEPTOR BINDING 23.8 2.02 168 73 0.43

GO_REGULATION_OF_MITOCHONDRIAL_OUTER_MEMBRANE_PERMEABILIZ ATION_INVOLVED_IN_APOPT

OTIC SIGNALING PATHWAY 17.7 2.02 43 23 0.53

GO_DNA_HELICASE_COMPLEX 50.8 2.03 14 9 0.64

GO VIRAL GENOME REPLICATION 28.4 2.03 21 13 0.62

GO REGULATION OF SPINDLE ASSEMBLY 8.3 2.03 15 11 0.73

TAAYNRNNTCC UNKNOWN 3.8 2.03 172 44 0.26

108.

GO REGULATION OF TELOMERE MAINTENANCE VIA TELOMERE LENGTHENI NG 6 2.04 50 26 0.52

BIOCARTA EIF2 PATHWAY 19.9 2.04 11 7 0.64

GO REGULATION OF CHROMATIN SILENCING 70.9 2.05 21 9 0.43

GO MICROTUBULE 70.7 2.05 405 173 0.43

GO_POSITIVE_REGULATION_OF_PROTEIN_LOCALIZATION_TO_NUCLEUS 61.0 2.05 129 53 0.41

GO NEGATIVE REGULATION OF TELOMERE MAINTENANCE VIA TELOMERE LENGTHENING 59.2 2.05 17 12 0.71

Targets of E2F_Q6_01 44.6 2.05 240 111 0.46

PROTEIN COMPLEX DISASSEMBLY 33.0 2.05 14 7 0.5

GO_PEROXISOME_PROLIFERATOR_ACTIVATED_RECEPTOR_BINDI NG 23.0 2.05 15 4 0.27

GO FEMALE MEIOTIC DIVISION 19.4 2.05 26 10 0.38

GO POSITIVE REGULATION OF MRNA PROCESSING 7.8 2.05 32 20 0.62

GO MICROTUBULE CYTOSKELETON ORGANIZATION 7.8 2.05 348 134 0.39

Targets of AP4_Q6_01 21.6 2.06 255 71 0.28

REACTOME TRANSPORT OF MATURE MRNA DERIVED FROM AN INTRONLESS TRANSCRIPT 36.8 2.07 33 26 0.79

AUXILIARY TRANSPORT PROTEIN ACTIVITY 9.0 2.07 26 6 0.23

GO POSITIVE REGULATION OF TELOMERE MAINTENANCE VIA TELOMERE LENGTHENING 97.0 2.08 33 14 0.42

GO NEGATIVE REGULATION OF CHROMOSOME ORGANIZATION 77.3 2.08 96 49 0.51

RNA_DEPENDENT_ATPASE_ACTIVITY 48.5 2.08 18 14 0.78

GO MIRNA BINDING 31.2 2.08 16 5 0.31

GO Gl DNA DAMAGE CHECKPOINT 31.2 2.08 73 44 0.6

GO TELOMERE ORGANIZATION 47.0 2.09 104 49 0.47

DNAJ NTEGRITY_CHECKPOINT 25.9 2.09 24 11 0.46

GO CYTOPLASMIC MICROTUBULE 33.9 2.1 57 27 0.47

GO UBIQUITIN LIKE PROTEIN LIGASE BINDING 27.1 2.1 264 154 0.58

GO POSITIVE REGULATION OF ERYTHROCYTE DIFFERENTIATION 12.0 2.1 23 7 0.3

GO REGULATION OF HISTONE H3 K9 ACETYLATION 28.0 2.11 14 4 0.29

GO DNA BINDING BENDING 19.1 2.11 20 6 0.3

GO MACROPHAGE ACTIVATION INVOLVED IN IMMUNE RESPONSE 10.2 2.11 11 3 0.27

NEGATIVE REGULATION OF IMMUNE SYSTEM PROCESS 8.8 2.11 14 3 0.21

GO DNA INTEGRITY CHECKPOINT 37.4 2.12 146 72 0.49

GO_REGULATION_OF_SPINDLE_ORGANIZATION 15.4 2.12 20 14 0.7

GO CHROMATIN BINDING 78.1 2.13 435 148 0.34

GO VIRAL LATENCY 68.8 2.13 11 9 0.82

DNA HELICASE ACTIVITY 52.6 2.13 25 15 0.6

GO NUCLEAR CHROMOSOME TELOMERIC REGION 62.3 2.14 132 66 0.5

GO POSITIVE REGULATION OF GLUCOSE IMPORT IN RESPONSE TO INSULIN STIMULUS 13.8 2.14 12 4 0.33

GO CELL CELL RECOGNITION 92.1 2.15 60 13 0.22

GO RIBONUCLEOPROTEIN GRANULE 90.5 2.15 148 87 0.59

CONTRACTILE FIBER PART 82.7 2.15 23 8 0.35

GO MITOTIC NUCLEAR DIVISION 44.5 2.15 361 187 0.52

GO CELL CYCLE PHASE TRANSITION 35.9 2.16 255 127 0.5

Targets of OCT1_02 29.3 2.16 214 50 0.23

GO BINDING OF SPERM TO ZONA PELLUCIDA 99.0 2.17 33 9 0.27

GO_POSITIVE_REGULATION_OF_DNA_BIOSYNTHETIC_PROCESS 81.2 2.17 59 23 0.39

TRANSLATION FACTOR ACTIVITY NUCLEIC ACID BINDING 69.0 2.17 39 29 0.74

REACTOME CELL DEATH SIGNALLING VIA NRAGE NRIF AND NADE 32.1 2.17 60 22 0.37

GO EMBRYONIC HEMOPOIESIS 17.2 2.17 20 6 0.3

GO POSITIVE REGULATION OF TELOMERE MAINTENANCE 98.3 2.18 47 24 0.51

151

GO ADENYL NUCLEOTIDE BINDING 83.7 2.19 4 548 0.36

GO DAMAGED DNA BINDING 66.2 2.19 63 38 0.6

GO SPINDLE POLE 31.4 2.19 126 54 0.43

GO_CENTROSOME_CYCLE 7.5 2.19 45 18 0.4

CONTRACTILE FIBER 88.8 2.2 25 8 0.32 AEROBIC RESPIRATION 53.2 2.2 15 13 0.87

RESPONSE TO RADIATION 39.0 2.2 60 16 0.27

PID_IL3_PATHWAY 9.7 2.2 27 10 0.37

GO TRANSCRIPTION EXPORT COMPLEX 52.6 2.21 13 12 0.92

GO POSITIVE REGULATION OF DNA TEMPLATED TRANSCRIPTION ELONGATION 47.8 2.21 23 16 0.7

PID INSULIN GLUCOSE PATHWAY 18.1 2.22 26 11 0.42

GO_POSITIVE_REGULATION_OF_MRNA_METABOLIC_PROCESS 17.2 2.22 45 27 0.6

ZF-MIZ 11.8 2.22 7 4 0.57

GO MRNA 3 UTR BINDING 52.2 2.23 48 26 0.54

REACTOME PURINE METABOLISM 48.0 2.23 33 22 0.67

DNA REPLICATION INITIATION 9.2 2.23 16 7 0.44

GO REGULATION OF CHROMATIN ORGANIZATION 70.9 2.24 152 61 0.4

GO NEGATIVE REGULATION OF GENE SILENCING 42.6 2.24 19 5 0.26

BIOCARTA Gl PATHWAY 41.8 2.24 28 10 0.36

GO CELL CYCLE CHECKPOINT 54.9 2.25 194 93 0.48

GO_PROTEI N_N_TERM 1 NUS_BI NDI NG 25.9 2.25 103 64 0.62

GO ENDODEOXYRIBONUCLEASE ACTIVITY 48.6 2.26 51 21 0.41

GO ASPARTATE METABOLIC PROCESS 31.4 2.26 11 5 0.45

GO POSITIVE REGULATION OF CELLULAR RESPONSE TO INSULIN STIMULUS 17.0 2.26 23 6 0.26

GO_RESPONSE_TO_ACIDIC_PH 16.8 2.26 21 5 0.24

GO ENDOLYSOSOME MEMBRANE 16.3 2.27 11 5 0.45

GO MYOFILAMENT 82.7 2.28 24 6 0.25

GO REGULATION OF SIGNAL TRANSDUCTION BY P53 CLASS MEDIATOR 54.0 2.28 162 73 0.45

MACROMOLECULAR COMPLEX DISASSEMBLY 38.2 2.28 15 8 0.53

PID P73PATHWAY 18.0 2.28 79 41 0.52

186

GO RIBONUCLEOTIDE BINDING 81.2 2.29 0 694 0.37

GO REGULATION OF PROTEIN ACETYLATION 48.6 2.29 64 27 0.42

GO_NEGATIVE_REGULATION_OF_CELL_CYCLE_PROCESS 44.5 2.29 214 104 0.49

GO MEIOTIC CELL CYCLE 22.0 2.3 186 58 0.31

GO ALDEHYDE CATABOLIC PROCESS 17.8 2.3 13 9 0.69

M PHASE OF MITOTIC CELL CYCLE 46.5 2.31 85 47 0.55

PID CMYB PATHWAY 41.7 2.31 84 36 0.43

REACTOME DOUBLE STRAND BREAK REPAIR 40.3 2.31 24 9 0.38

REGULATION OF MITOSIS 40.4 2.32 41 20 0.49

GO CELL CYCLE G2 M PHASE TRANSITION 28.4 2.32 138 77 0.56

TCCCRNNRTGC UNKNOWN 23.5 2.32 213 111 0.52

GO_NUCLEAR_CHROMOSOME 70.8 2.33 523 222 0.42

GO CHROMATIN DNA BINDING 69.1 2.33 80 35 0.44

Targets of COUP_DRl_Q6 66.3 2.33 247 94 0.38

ATP DEPENDENT DNA HELICASE ACTIVITY 62.6 2.33 11 8 0.73

GO_M ITOTIC_DNA_l NTEG RITY_CHECKPOI NT 39.4 2.33 100 56 0.56

GO PROTEIN C TERMINUS BINDI NG 25.2 2.33 186 81 0.44

GO P53 BINDING 85.6 2.34 67 23 0.34

M PHASE 45.0 2.35 114 55 0.48

GO CORONARY VASCULATURE DEVELOPMENT 30.3 2.35 37 9 0.24

GO NEGATIVE REGULATION OF DNA DEPENDENT DNA REPLICATION 9.5 2.35 16 5 0.31

Targets of E2F1_Q4_01 60.4 2.36 228 90 0.39

MICROTUBULE CYTOSKELETON ORGANIZATION AND BIOGENESIS 50.9 2.36 35 18 0.51

GO NEGATIVE REGULATION OF VIRAL RELEASE FROM HOST CELL 21.8 2.37 16 9 0.56

R E ACTO M E_A PO PTOSIS_INDUCED_DNA_FRAGME NTATI 0 N 13.7 2.37 13 8 0.62

GO CHROMOSOME 75.3 2.38 880 390 0.44

DNA DEPENDENT ATPASE ACTIVITY 64.9 2.38 22 13 0.59

GO NUCLEOSOMAL DNA BI NDING 79.3 2.39 30 22 0.73

GO_DNA_DOUBLE_STRAND_BREAK_PROCESSING 21.7 2.39 20 9 0.45

GO MICROTUBULE ORGANIZING CENTER ORGANIZATION 15.4 2.39 84 40 0.48

Targets of E2F_Q4_01 69.2 2.4 237 100 0.42

GO ORGANELLE ASSEMBLY 55.9 2.4 495 214 0.43

GO_REGULATION_OF_PROTEIN_INSERTION_INTO_MITOCHONDRIAL_MEM BRANE_INVOLVED_IN_APOPT

OTIC_SIGNALING_PATHWAY 13.8 2.4 29 15 0.52

PID PI3KCI AKT PATHWAY 5.4 2.41 35 16 0.46

REACTOME DESTABILIZATION OF MRNA BY BRF1 57.4 2.42 17 13 0.76

GO POSITIVE REGULATION OF CHROMATIN MODIFICATION 52.4 2.42 85 35 0.41

HISTONE METHYLTRANSFERASE ACTIVITY 26.7 2.42 11 4 0.36

REACTOME PLATELET SENSITIZATION BY LDL 22.8 2.42 16 6 0.38

PROTEIN AMINO ACID ADP RIBOSYLATION 20.9 2.42 10 3 0.3

PROTEIN PHOSPHATASE TYPE 2A REGULATOR ACTIVITY 37.6 2.43 14 7 0.5

CONDENSED CHROMOSOME 47.3 2.44 34 16 0.47

GTTRYCATRRJJNKNOWN 16.7 2.44 172 45 0.26

MITOCHONDRIAL TRANSPORT 44.9 2.45 21 19 0.9 REACTOME INTEGRATION OF PROVIRUS 80.2 2.46 16 6 0.38

GO POSITIVE REGULATION OF MRNA SPLICING VIA SPLICEOSOME 46.8 2.46 14 6 0.43

GO_NEGATIVE_REGULATION_OF_MITOTIC_CELL_CYCLE 36.3 2.46 199 100 0.5

ST FAS SIGNALING PATHWAY 29.5 2.46 65 31 0.48

GO POSITIVE REGULATION OF DNA REPLICATION 68.6 2.47 86 31 0.36

GO NEGATIVE REGULATION OF DNA REPLICATION 64.4 2.47 55 25 0.45

RRCCGTTAJJNKNOWN 36.8 2.47 87 52 0.6

GO CHROMATIN 66.6 2.48 441 168 0.38

GO RESPONSE TO FUNGICIDE 17.5 2.48 11 4 0.36

GO GLOBAL GENOME NUCLEOTIDE EXCISION REPAIR 16.2 2.49 32 25 0.78

GO DNA CATABOLIC PROCESS 16.4 2.5 27 13 0.48

GO ATP DEPENDENT DNA HELICASE ACTIVITY 54.8 2.51 34 19 0.56

MRNA BINDING 91.0 2.52 23 17 0.74

PID AURORA B PATHWAY 31.5 2.52 39 19 0.49

CELL CYCLE PHASE 53.0 2.53 170 78 0.46

GO_AU_RICH_ELEMENT_BINDING 29.4 2.54 23 12 0.52

GO REGULATION OF MICROTUBULE POLYMERIZATION OR DEPOLYMERIZATION 19.1 2.54 178 88 0.49

GO SUMO BINDING 13.8 2.54 14 5 0.36

Targets of CEBPGAMMA_Q6 46.5 2.55 257 78 0.3

HMG 13.1 2.55 51 17 0.33

GO REGULATION OF PROTEIN PHOSPHATASE TYPE 2A ACTIVITY 33.5 2.57 24 11 0.46 EGG BETA ALANINE METABOLISM 64.3 2.58 22 11 0.5

GO RNA POLYMERASE II DISTAL ENHANCER SEQUENCE SPECIFIC DNA BINDING 55.6 2.59 65 28 0.43

GO PEPTIDYL AMINO ACID MODIFICATION 43.8 2.59 841 340 0.4

GO NEGATIVE REGULATION OF TELOMERASE ACTIVITY 29.1 2.59 15 7 0.47

Targets of AP2REP_01 27.2 2.61 178 57 0.32

GO MITOTIC SPINDLE ORGANIZATION 21.8 2.61 69 32 0.46

KEGG GLYOXYLATE AND DICARBOXYLATE METABOLISM 60.4 2.62 16 10 0.62

GO_MITOTIC_CELL_CYCLE_CHECKPOINT 53.4 2.62 139 75 0.54

GO REGULATION OF CELL CYCLE ARREST 50.4 2.62 108 52 0.48

GO REGULATION OF DNA TEMPLATED TRANSCRIPTION ELONGATION 46.4 2.62 44 25 0.57

GO RESPONSE TO AMMONIUM ION 32.2 2.62 51 11 0.22

GO_REGULATION_OF_THYMOCYTE_APOPTOTIC_PROCESS 49.2 2.63 12 4 0.33

GO_POSITIVE_REGULATION_OF_MITOCHONDRIAL_OUTER_MEMBRANE_PE RM EABILIZATION_INVOLVED_

IN APOPTOTIC SIGNALING PATHWAY 19.5 2.63 36 19 0.53

GO NEGATIVE REGULATION OF TELOMERE MAINTENANCE 62.1 2.64 26 17 0.65

GO CHROMOSOME TELOMERIC REGION 64.3 2.65 162 79 0.49

GO_REGULATION_OF_GENE_SILENCING 48.6 2.65 52 16 0.31

PID ATM PATHWAY 33.3 2.66 34 12 0.35

REACTOME E2F ENABLED INHIBITION OF PRE REPLICATION COMPLEX FORMATION 17.8 2.66 10 6 0.6

GO REGULATION OF EXECUTION PHASE OF APOPTOSIS 88.6 2.67 24 11 0.46

MICROTUBULE 51.6 2.67 32 22 0.69

BIOCARTA ATRBRCA PATHWAY 37.5 2.67 21 8 0.38

GO NEGATIVE REGULATION OF RESPONSE TO BIOTIC STIMULUS 20.9 2.68 30 14 0.47

GO POSITIVE REGULATION OF PROTEIN IMPORT INTO NUCLEUS TRANSLOCATION 7.8 2.69 13 5 0.38

GO NEGATIVE REGULATION OF EPITHELIAL CELL MIGRATION 6.2 2.7 53 21 0.4

Targets of E2F1_Q6_01 71.5 2.71 238 98 0.41

GO ORGANIC ACID BINDING 25.8 2.71 209 68 0.33

GO AMINO ACID BINDING 78.2 2.73 108 36 0.33

MITOTIC SPINDLE ORGANIZATION AND BIOGENESIS 41.3 2.73 10 5 0.5

CHROMOSOMEPERICENTRIC_REGION 29.5 2.74 31 14 0.45

GO REGULATION OF DNA REPLICATION 86.8 2.75 161 66 0.41

YAATNRNNNYNATT UNKNOWN 70.5 2.75 104 27 0.26

GO LYMPHOID PROGENITOR CELL DIFFERENTIATION 77.6 2.78 11 3 0.27

Targets of E2F_Q3_01 60.7 2.79 235 89 0.38

PID P38 MK2 PATHWAY 31.2 2.82 21 12 0.57

REACTOME RECRUITMENT OF NUMA TO MITOTIC CENTROSOMES 26.6 2.82 10 7 0.7

DNA RECOMBINATION 70.6 2.85 47 18 0.38

GO GLYOXYLATE METABOLIC PROCESS 55.4 2.86 28 14 0.5

MITOTIC CELL CYCLE CHECKPOINT 22.0 2.86 21 10 0.48

Targets of EFC_Q6 17.6 2.86 268 84 0.31

Targets of E2F_Q3 45.1 2.87 227 91 0.4

REACTOME E2F MEDIATED REGULATION OF DNA REPLICATION 40.9 2.87 35 13 0.37

Targets of ER_Q6_02 15.5 2.87 252 79 0.31

GO POSITIVE REGULATION OF PROTEIN ACETYLATION 43.8 2.88 36 12 0.33

CELL CYCLE PROCESS 52.7 2.89 193 87 0.45

Targets of E2F1_Q6 63.7 2.9 232 101 0.44

GO MODULATION BY SYMBIONT OF HOST CELLULAR PROCESS 8.5 2.92 28 11 0.39

REACTOME EARLY PHASE OF HIV LIFE CYCLE 76.1 2.94 21 10 0.48

SPINDLE POLE 22.6 2.94 18 9 0.5 GO POSITIVE REGULATION OF PROTEIN EXPORT FROM NUCLEUS 44.1 2.95 19 7 0.37

GO GTPASE ACTIVATING PROTEIN BINDING 21.6 2.95 14 7 0.5

TRANSCRIPTION_ELONGATION_REGULATOR_ACTIVITY 23.1 2.99 12 7 0.58

102.

GO POSITIVE REGULATION OF DNA METABOLIC PROCESS 4 3.01 185 76 0.41 EGG BUTANOATE METABOLISM 29.2 3.01 34 17 0.5

GO NUCLEAR CHROMATIN 52.3 3.03 291 111 0.38

GO REGULATION OF MICROTUBULE BASED PROCESS 24.0 3.04 243 106 0.44

GO FOLIC ACID BINDING 53.4 3.06 14 3 0.21

Targets of E2F1DP1RB_01 65.7 3.1 231 96 0.42

Targets of E2F4DP1_01 60.9 3.1 239 100 0.42

BIOCARTA_RB_PATHWAY 33.7 3.1 13 7 0.54

GO POSITIVE REGULATION OF PROTEIN IMPORT 26.6 3.11 104 35 0.34

SG CG SS A A A_Ta rge ts of E2F1DP2_01 57.9 3.12 168 77 0.46

SPINDLE ORGANIZATION AND BIOGENESIS 51.5 3.13 11 6 0.55

Targets of E2F1DP1_01 71.2 3.17 235 97 0.41

GO POSITIVE REGULATION OF NUCLEOCYTOPLASMIC TRANSPORT 29.3 3.19 121 40 0.33

REACTOME TGF BETA RECEPTOR SIGNALING IN EMT EPITHELIAL TO MESENCHYMAL TRANSITION 66.6 3.2 16 6 0.38

BIOCARTA TEL PATHWAY 35.5 3.21 18 10 0.56

Targets of E2F1DP2_01 71.9 3.22 235 97 0.41

DNA DAMAGE RESPONSESIGNAL TRANSDUCTION 42.9 3.24 35 13 0.37

Targets of E2F_02 70.2 3.28 235 98 0.42

BIOCARTA CHREBP2 PATHWAY 19.8 3.28 42 17 0.4

PID BARD1 PATHWAY 57.0 3.32 29 15 0.52

GO_NEGATIVE_REGULATION_OF_ORGANELLE_ORGANIZATION 54.3 3.34 387 184 0.48

REACTOME MITOTIC G2 G2 M PHASES 45.2 3.36 81 47 0.58

Targets of E2F4DP2_01 72.2 3.4 235 97 0.41

DNA DAMAGE RESPONSESIGNAL TRANSDUCTION BY P53 CLASS MEDIATOR 39.3 3.44 13 7 0.54

REACTOME_TGF_BETA_RECEPTOR_SIGNALING_ACTIVATES_SMADS 40.8 3.46 26 12 0.46

Targets of E2F1_Q3 80.0 3.47 244 97 0.4

108.

NEGATIVE REGULATION OF ANGIOGENESIS 0 3.51 13 3 0.23

Targets of CMYB_01 41.1 3.52 249 106 0.43

GO_RNA_CAP_BINDING_COMPLEX 25.1 3.54 14 6 0.43

PROTEIN N TERMINUS BINDING 65.4 3.56 38 22 0.58

GO PRONUCLEUS 49.7 3.57 15 9 0.6

PID DNA P PATHWAY 69.4 3.63 16 9 0.56

GO_RESPONSE_TO_COBALT_ION 77.2 3.64 13 7 0.54

108.

GGAMTNNNNNTCCY UNKNOWN 7 3.67 117 41 0.35

Targets of SMAD3_Q6 25.7 3.74 239 56 0.23

Targets of E2F_Q4 70.6 3.77 234 99 0.42

REACTOME_LOSS_OF_NLP_FROM_MITOTIC_CENTROSOMES 64.6 3.84 59 34 0.58

REACTOME RECRUITMENT OF MITOTIC CENTROSOME PROTEINS AND COMPLEXES 67.7 3.9 66 39 0.59

Targets of E2F_Q6 72.9 3.99 232 97 0.42

138.

Targets of MYCMAX_B (Myc and MAX targets) 8 4.02 268 108 0.4

GO_NEGATIVE_REGULATION_OF_ENDOTHELIAL_CELL_MIG RATION 13.3 4.42 39 16 0.41

GO RESPONSE TO ARSENIC CONTAINING SUBSTANCE 68.6 4.46 29 18 0.62

GO REGULATION OF ORCADIAN RHYTHM 93.0 5.08 103 29 0.28

GO ENDODEOXYRI BONUCLEASE ACTIVITY PRODUCING 5 PHOSPHOMONOESTERS 26.7 5.36 12 4 0.33

[0555] Table 29. ICI predictors: Forty-seven signatures used as alternative ICI response predictors; related to Figure 66.

Descri jtion

Reference Name

AXL (Tirosh)

Melanoma cell cycle (Tirosh)

G1 S (Tirosh)

Tirosh et al Science 2016

G2 M (Tirosh)

Melanoma cells (Tirosh)

MITF (Tirosh)

TME: Current study TME B cell TME CAF

TME Endo

TME Macrophage

TME Mai

TME NK

TME T CD4

TME T CD8

TME T cell

TME stroma

TME immune

TME T CD4 exhausted

TME T CD4 naive

TME T CD4 Treg

TME T CD8 cytotoxic

TME T CD8 exhausted

TME T CD8 naive

https://www.fluidigm.com/applications/advanta-immuno- Fluidgm Panel A

oncology-gene-expression-assay Fluidgm Panel B

in-vivo screen GVAXPDl vs TCRaKO depleted in-vivo screen GVAX vs TCRaKO depleted in-vivo screen TCRaKO vs invitro depleted

Manguso et al. Cell 2017

in-vivo screen GVAXPDl vs TCRaKO enriched in-vivo screen GVAX vs TCRaKO enriched in-vivo screen TCRaKO vs invitro enriched co-culture screen hitslO

Patel et al. Nature 2017

co-culture screen hits50

Ayers IFNg sig

Ayers et al. JCI 2017

Ayers immune sig

Nivolumab (molecular) resistant melanoma up

Nivolumab (molecular) resistant melanoma down

Nivolumab resistant melanoma up

Nivolumab resistant melanoma down

Riaz et al. Cell 2017

On Nivolumab up

On Nivolumab down

Responders on Nivolumab up

Responders on Nivolumab down

Anti-PD-1 resistant melanoma .up

Hugo et al. Cell 2016

Anti-PD-1 resistant melanoma .down

MAPKi resistant melanoma up

Hugo et al. Cell 2015

MAPKi resistant melanoma down

2

CCR6 ARMCX2 ARHGAP31 ADPGK ALDOA GNLY CD6 CD8B CD27

CD19 ASPN ARHGEF15 AIF1 ALX1 GZMB DGKA CLEC2D CD28

CD1C BACE1 ASAP1 AKR1A1 AMZ2 GZMM DUSP16 CRTAM CD3D

CD22 BAG2 BCAM ALDH2 ANAPC11 HOPX EML4 CXCL13 CD3E

CD24 BGN BCL6B ALDH3B1 ANKRD54 ID2 F5 DNAJB1 CD3G

IL18RA

CD37 C1R BCR AMICA1 ANP32A P FAAH2 GPR171 CD5

CD52 CIS BMPR2 AMPD3 AP1S2 IL2RB FAM102A GZMK CD6

KIR2DL

CD79A CALD1 BMX ANKRD22 APEH 3 FBLN7 IFNG CD7

KIR3DL

CD79B CCDC80 CALCRL AP1B1 AP0A1BP 2 FLT3LG ITGA4 CD96

CHMP7 CD248 CARD10 AP0C1 AP0C2 KLRB1 F0XP3 ITGAE CDC42SE2

CIITA CDH11 CASKIN2 AQP9 APOD KLRC1 FYB ITM2A CELF2

CLEC17A CDR1 CCL14 ARAP1 APOO KLRD1 ICOS JAKMIP1 CN0T6L

CNR2 CERCAM CD200 ARHGAP18 ARPC1A KLRF1 IL6R KLHL28 C0R01A

COL19A1 CILP CD34 ARHGAP27 ATIC MATK IL7R LAG3 CST7

COL4A3 CKAP4 CD93 ARHGEFIOL ATP1A1 MYBL1 ITGB2-AS1 LYST CTLA4

NCAM

CR2 CLEC11A CDH5 ARPC1B ATP5C1 1 ITK MAP4K1 CXCR3

CXCR5 CLIP3 CFI ARRB2 ATP5G1 NCR1 LAT MC0LN2 CXCR6

CYBASC3 CNN1 CLDN15 ASAH1 ATP5G2 NCR3 LEPR0TL1 MIAT CYTIP

LOC100128 MIR155

EEF1B2 C0L11A1 CLDN5 ATF5 ATP5G3 NKG7 420 HG DEF6

NMUR

EEF1G C0L12A1 CLEC14A ATG3 ATP6V1C1 1 LOC285740 NELL2 DENND2D

EIF2S3 C0L14A1 CLEC1A ATG7 ATP6V1E1 PRF1 MAF PAG1 EMB

ELK2AP C0L16A1 CNTNAP3B ATP6AP1 ATP6V1G1 PTGDR MAL PCED1B EVL

FAIM3 C0L1A1 C0L15A1 ATP6V0B BAIAP2 PTPN4 PASK PDCD1 FYB

FAM129

C C0L1A2 C0L4A1 ATP6V0D1 BANCR SAMD3 PBX4 PRDM1 FYN

SH2D1

FAM65B C0L3A1 COL4A2 ATP6V1B2 BCAN B PBXIP1 PTPN7 GATA3

FCER2 C0L5A1 CRIP2 ATP6V1F BCAS3 TXK PIK3IP1 RAB27A GNG2

FCRL1 COL5A2 CXorf36 BACH1 BCL2L13 XCL1 PIM2 RNF19A GPR171

FCRL2 C0L6A1 CYYR1 BCKDHA BIRC7 XCL2 SEPT6 SIRPG GPR174

FCRL5 COL6A2 DARC BCL2A1 BZW2 SLAMF1 SIT1 GPRIN3

FCRLA COL6A3 DCHS1 BID C10orf90 SP0CK2 SNAP47 GRAP2

GGA2 C0L8A1 DLL4 BL0C1S1 Cllorf31 SUSD3 THEMIS GZMA

GNB2L1 COMP D0CK6 BLVRA C17orf89 TBC1D4 TIGIT GZMM

HNRNPA1P

HLA-DOB CPE D0CK9 BLVRB Clorf43 TCF7 TIMD4 10

HLA- TMEM1

DQA2 CPXM1 DYSF C10orf54 Clorf85 TESPA1 55 ICOS

HVCN1 CPZ ECE1 Cllorf75 C1QBP TIAM1 TNFRSF9 IL12RB1

IGJ CRABP2 ECSCR C15orf48 C22orf32 TMEM66 TNIP3 IL21R

IGLL1 CREB3L1 EFNA1 C19orf38 C4orf48 TNFAIP3 TOX IL2RB

CRISPLD

IGLL3P 2 EFNB2 Clorfl62 CA14 TNFSF8 TTC24 IL2RG

IGLL5 CTSK EGFL7 C1QA CA8 TNIK TTN 1132

IRF8 CXCL12 ELK3 C1QB CACYBP TPT1 ZBED2 INPP4B

KBTBD8 CXCL14 ELTD1 C1QC CAPN3 IPCEF1

KIAA012

5 CYBRD1 EMCN C2 CBX3 ITGAL

KIAA022

61 CYGB ENG C3AR1 CCND1 ITK

LOC2836

63 CYP1B1 EPAS1 C5AR1 CCT2 JAK3 LRMP DCN EPB41L4A C9orf72 CCT3 KCNA3

MS4A1 DDAH1 EPHB4 CAPG CCT4 LAT

NAPSB DDR2 ERG CAPZA2 CCT6A LCK

NCF1C DEPTOR ESAM CARD9 CCT8 LIME1

LOC100130

NCOA3 DKK3 EX0C3L1 CASP1 CDH19 231

P2RX5 DPT F11R CAT CDH3 MB0AT1

PAX5 EBF2 FABP4 CCDC88A CDK2 MIAT

PLEKHF2 ECM2 FAM107A CCR1 CDK4 NLRC5

PNOC EDNRA FAM65A CCR2 CEP170 PAG1

POLD4 EFEMP2 FAT 4 CCRL2 CHCHD6 PARP8

POU2AF

1 EGFLAM FGD5 CD14 CHD1L PCED1B

POU2F2 EGFR FKBP1A CD163 CLCN7 PCEDIB-ASI

PRKCB EMILIN1 FLU CD1D CLNS1A PDCD1

QRSL1 FAT1 FLT4 CD274 CMC2 PIP4K2A

RALGPS2 FBLN1 FZD6 CD300C C0A3 PRDM1

RHOH FBLN2 GALNT18 CD300E C0A4 PRF1

SEL1L3 FBLN5 GATA2 CD300LB C0A6 PRKCQ

SELL FGF7 GIPC2 CD300LF C0X5B PTPN22

SMIM14 FIBIN GNG11 CD302 C0X6A1 PTPN7

SNX29 FMOD GPR116 CD33 COX7A2 PTPRC

SNX29P1 FN1 GPR146 CD68 COX7A2L PYHIN1

SP110 FNDC1 GRB10 CD80 C0X7C RASAL3

SP140 FRMD6 GUK1 CD86 C0X8A RASGRP1

SPIB FST HECW2 CECR1 CSAG1 RGS1

ST6GAL1 FSTL1 HERC2P2 CFD CSAG2 RHOF

STAG3 GEM HID1 CFP CSAG3 RNF213

STAP1 GFPT2 HSPG2 CLECIOA CSPG4 SCML4

STRBP GFRA1 HYAL2 CLEC12A CYC1 1-Sep

TCL1A GLT8D2 ICA1 CLEC4A CYP27A1 SH2D1A

TLR10 GPC1 ID1 CLEC4E DAAM2 SH2D2A

TLR9 GPC4 ID3 CLEC5A DANCR SH3KBP1

TMEM15

4 GPC6 IFITM3 CLEC7A DAP3 SIRPG

TNFRSF1

3B GPR133 IGFBP7 CMKLR1 DCT SIT1

TP53INP

1 GPR176 IL33 CMTM6 DCXR SKAP1

VPREB3 GPX8 IL3RA CNDP2 DDIT3 SLC9A3R1

IP011-

WDFY4 HSPB2 LRRC70 CNPY3 DDT SPATA13

ZCCHC7 HSPB6 ITGA5 C0R07 DLL3 SPN

HSPB7 ITGA6 CPVL DNAH14 SP0CK2

HTRA3 ITGB4 CREG1 DNAJA4 STAT4

IGFBP6 JAG2 CSF1R DRG1 SYTL3

INHBA JAM2 CSF2RA EDNRB TBC1D10C

ISLR JUP CSF3R EIF3C TC2N

ITGA11 KANK3 CST3 EIF3D TESPA1

ITGB5 KDR CSTA EIF3E THEMIS

ITGBL1 KLHL3 CTSA EIF3H TIGIT

KDELR2 LAMA5 CTSB EIF3L TMEM66

KDELR3 LDB2 CTSC EIF3M TNFAIP3

LOC100505

LARP6 495 CTSD EN01 TOX

LEPREL2 LRRC70 CTSH EN02 TRAF1

LM07 LUZP1 CTSL1 ENTPD6 TRAT1

EPB41L4A-

LM0D1 LYVE1 CTSS AS1 TTC39C LOX MALL CXCL10 ERBB3 TUBA4A

10X11 MANSC1 CXCL16 ESRP1 UBASH3A

LPAR1 MECOM CXCL9 ETV4 WIPF1

LTBP2 ME0X1 CXCR2P1 ETV5 ZAP70

LUM MKL2 CYB5R4 EX0SC4 ZC3HAV1

LURAP1L MMRN1 CYBA FAH

MAP1A MMRN2 CYBB FAHD2B

MEG3 MPZL2 CYP2S1 FAM103A1

MFAP4 MTUS1 DAPK1 FAM162A

MGST1 MYCT1 DBNL FAM178B

MIR100

HG MY015B DENND1A FARP2

MMP2 N0S3 DHRS9 FASN

M0XD1 NOSTRIN DMXL2 FBX032

MRC2 N0TCH4 DNAJC5B FBX07

MRGPRF NPDC1 D0K1 FDFT1

MSC NPR1 D0K3 FKBP4

MT1M NR5A2 DPYD FMN1

MXRA5 PALD1 EBI3 FXYD3

MXRA8 PALMD EMR2 GALE

MYL9 PCDH1 EPSTI1 GAPDH

NEXN PCDH12 ETV6 GAPDHS

NID2 PCDH17 EVI2A GAS2L3

NOTCH3 PDE2A F13A1 GAS5

NTM PDLIM1 FAM105A GAS7

NTRK2 PECAM1 FAM157B GCSH

NUPR1 PGM5 FAM26F GDF15

OGN PIEZ01 FAM49A GJB1

OLFML1 PIK3R3 FAM96A GMNN

OLFML2

B PKP4 FBP1 GMPR

OLFML3 PLEKHA7 FCER1G GPATCH4

OMD PLVAP FCGR1A GPM6B

OSR2 PLXNA2 FCGR1B GPR137B

PALLD PLXND1 FCGR1C GPR143

PAMR1 PODXL FCGR2A GPS1

PAPSS2 PPM IF FCGR2C GSTP1

PCDH18 PPP1R13B FCGR3B GTF2F2

PCOLCE PRCP FCGRT GYG2

PCOLCE2 PREX2 FCN1 H2AFZ

PDGFRA PTPRB FERMT3 HAX1

PDGFRB PVRL2 FES HDDC2

PDGFRL PXN FGL2 HIST1H2AC

PDLIM2 RALGAPA2 FKBP15 HIST1H2BD

PLA2G2A RAMP2 FLVCR2 HIST3H2A

PLAC9 RAMP3 F0LR2 HMG20B

PL0D2 RAPGEF3 FPR1 HMGA1

PODN RAPGEF4 FPR2 HPS4

POSTN RASIP1 FPR3 HPS5

PPIB RBP7 FT HI HSBP1

PRR16 RGL2 FTL HSP90AA1

PRR24 RHOJ FUCA1 HSP90AB1

PRRX1 R0B04 FUOM HSPA4

PRRX2 S1PR1 GAA HSPA9

PTN SCARF1 GABARAP HSPD1

RARRES2 SDPR GALC HSPE1

RCN3 SELE GATM HSPH1

R0R2 SELP GBP1 IGSF11 SCUBE3 SH3BGRL2 GCA IGSF3

SDC1 SHR00M4 GGTA1P IGSF8

SDC2 SLC29A1 GK ILF2

SEC24D SLC9A3R2 GLA IMMP2L

SEMA5A SLC02A1 GLB1 INPP5F

SERPINF

1 SMAD1 GLRX IRF4

SFRP2 SNCG GLUL ISYNA1

SFRP4 S0CS2 GM2A KCNJ13

SH2D4A S0X18 GNA13 LAGE3

SH3D19 SPNS2 GNA15 LDHB

SH3PXD2

A STOM GPBAR1 LHFPL3-AS1

SLIT2 SULF2 GPR34 LINC00473

SLIT3 SYNPO GPR84 LINC00518

SMOC2 TACR1 GPX1 LINC00673

LOC100126

SOD3 TA0K2 GRN 784

LOC100127

SPARC TEAD4 GST01 888

LOC100130

SP0CK1 TEK H2AFY 370

LOC100133

SP0N1 TENC1 HCAR2 445

LOC100505

SRPX2 TFF3 HCAR3 865

STEAP1 TGFBR2 HCK L0C146481

SULF1 TGM2 HEIH LOC340357

SUSD2 THBD HERPUD1 10X14

SVEP1 THSD1 HIST2H2BF LSM2

TAGLN TIE1 HK2 LZTS1

TBX15 TLL1 HK3 MAD2L1BP

TCEAL7 TM4SF1 HLA-DMA MAGEA12

TGFB3 TM4SF18 HLA-DMB MAGEA2

THBS2 TMEM204 HLA-DPA1 MAGEA2B

THY1 TMEM255B HLA-DPB1 MAGEA3

TIMP1 TNFAIP1 HLA-DPB2 MAGEA4

TMEM11

9 TNFRSF10B HLA-DQA1 MAGEA6

TMEM45

A TSPAN12 HLA-DQB1 MAGEC1

TPM1 TSPAN15 HLA-DRA MAGED2

TPM2 TSPAN18 HLA-DRB1 MDH1

TWIST1 TSPAN7 HLA-DRB5 MDH2

TWIST2 USHBP1 HLA-DRB6 METTL23

UCHL1 VWA1 HM0X1 METTL9

VASN VWF HN1 MFI2

VCAN ZNF366 HPS1 MIA

WISP2 ZNF385D HSPA6 MIF

WNT2 HSPA7 MITF

HSPBAP1 MKI67IP

IDH1 MLANA

IFI30 MLPH

IFI35 MOK

IFIT2 M0RN2

IFNGR1 MRPL12

IFNGR2 MRPL21

IGFLR1 MRPL23

IGSF6 MRPL24 IL10RB MRPL38

IL18 MRPL40

IL1B MRPS21

IL1RN MRPS23

IL4I1 MRPS25

IL8 MRPS26

IRF5 MRPS6

IRF7 MSI2

ITGAX MTHFS

JAK2 MXI1

KCNMA1 MY010

KCNMB1 NARS2

KYNU NAV2

LAIR1 NDUFA4

LAP3 NDUFAF3

LGALS2 NDUFB9

LGALS9 NDUFS2

LGMN NEDD4L

LILRA1 NELFCD

LILRA2 NFYA

LILRA3 NGRN

LILRA4 NHP2

LILRA5 NME1

LILRA6 N0P58

LILRB1 NPM1

LILRB2 NSG1

LILRB3 NT5DC3

LILRB4 NUP93

LILRB5 0CA2

LIPA PACSIN2

LOC338758 PAFAH1B3

LOC729737 PAGE5

LRRC25 PAICS

LST1 PAX3

LTA4H PEBP1

LYN PEG10

LYZ PEX19

M6PR PFDN2

MAFB PHACTR1

MAN2B1 PHB

MAPKAPK3 PHF5A

MARCO PHLDA1

MERTK PIGY

MFSD1 PIR

MGAT1 PLEKHB1

MIF4GD PLP1

MIIP PMEL

MILR1 P0LD2

MKNK1 P0LR2F

MNDA P0MGNT1

M0B1A PPIL1

MPEG1 PRAME

MPP1 PRDX6

MRC1 PSMB4

MS4A4A PSMB7

MS4A6A PSMD4

MS4A7 PTTG1

MSR1 PUF60 MTHFD2 PYGB

MTMR14 PYURF

MX1 QDPR

MX2 QPCT

MXD1 RAB17

MYD88 RAB38

N4BP2L1 RABGGTB

NAAA RAD51C

NADK RAE1

NAGA RAN

NAGK RAP1GAP

NAIP RGS20

NCF2 R0PN1

NCF4 R0PN1B

NCKAP1L RRS1

NCOA4 RSL1D1

NFAM1 RTKN

NFKBID RUVBL2

NINJ1 S100A1

NLRC4 SIOOB

NLRP3 SAMM50

NMI SCD

NOD2 SDC3

NPC2 SDCBP

NPL SDHC

NR1H3 SEC11C

OAS1 SF3A1

OAZ1 SGCD

OLR1 SHC4

OSCAR SKP1

P2RX4 SLC19A1

P2RY12 SLC19A2

P2RY13 SLC24A5

P2RY14 SLC25A13

P2RY6 SLC25A4

PAK1 SLC39A4

PCK2 SLC45A2

PFKFB3 SLC5A3

PGD SLC6A15

PILRA SLC7A5

PLA2G15 SLM02

PLA2G7 SMS

PLAUR SNCA

PLBD1 SNHG16

PLEK SNHG6

PLEKH01 SNRPC

PLEKH02 SNRPD1

PLIN2 SNRPE

PLXDC2 S0D1

PPM1M SORD

PPT1 S0RT1

PRAM1 SOX10

PRKCD SPCS1

PSAP SRP9

PSME2 ST13

PTAFR ST3GAL4

PTPRE ST3GAL6

PYCARD ST6GALNAC 2

RAB20 STAM

RAB4B STIP1

RAB8A STK32A

RASGEF1B STMN1

RASSF4 ST0ML2

RBM47 STRA13

RBPJ STRADB

REEP4 STX7

RELT STXBP1

RGS10 SUPT4H1

RGS18 SYNGR1

RGS19 TBC1D10A

RGS2 TBC1D16

RHBDF2 TBC1D7

RHOG TBCA

RILPL2 TBRG4

RIPK2 TEX2

RNASE6 TFAP2A

RNASEK TIMM50

RNASET2 TMED10

RNF13 TMEM147

RNF130 TMEM177

RNF144B TMEM255A

RNF149 TMX4

RTN1 T0M1L1

S100A11 TOMM20

S100A8 TOMM22

S100A9 T0MM6

SAMHD1 T0MM7

SAT1 T0P1MT

SCAMP2 TRIM2

SCIMP TRIM63

SC02 TRMT112

SCPEP1 TSNAX

SDS TTLL4

SECTM1 TUBB2A

SEMA4A TUBB2B

SERPINA1 TUBB4A

SERPINB1 TYR

SFT2D1 TYRP1

SGPL1 UBA2

SH3BGRL UBL3

SHKBP1 UCHL5

SIGLECl UQCRH

SIGLEC14 UTP18

SIGLEC5 VAT1

SIGLEC7 VDAC1

SIGLEC9 WBP11

SIRPA WBP2

SIRPB1 WBSCR22

SIRPB2 WDFY1

SKAP2 WDR43

SLAMF8 XAGE1A

SLC11A1 XAGE1B

SLC15A3 XAGE1C

SLC16A3 XAGE1D

SLC1A3 XAGE1E SLC25A19 XYLB

SLC29A3 ZCCHC17

SLC2A5 ZFAS1

SLC2A8 ZFP106

SLC2A9 ZNF280B

SLC31A2

SLC43A2

SLC46A3

SLC7A7

SLC9A9

SLC02B1

SMPDL3A

SNX10

SNX6

SOD2

SPI1

SPINT2

SQRDL

SRC

STX11

STXBP2

TALD01

TBXAS1

TFRC

TGFBI

THEMIS2

TIFAB

TLR1

TLR2

TLR4

TLR5

TLR8

TMEM106A

TMEM144

TMEM176A

TMEM176B

TMEM37

TMEM51

TMEM86A

TNFAIP2

TNFAIP8L2

TNFSF13

TNFSF13B

TPP1

TRAFD1

TREM1

TREM2

TRPM2

TTYH3

TWF2

TYMP

TYROBP

UBE2D1

UBXN11

UNC93B1

VAMP8

VM01

VSIG4

S gnatures

TME TME TME T CD4 TME T CD4 TME T CD4 TME T CD8 TME T CD8 TME T CD8 stroma immune exhausted naive Treg cytotoxic exhausted naive

A4GALT ACAP1 C9orfl6 ABLIM1 ARID3B APOBEC3C ABCC9 ATM

ADAMTS

1 AKNA CDK5R1 ATM CARD16 B2M AKAP5 ATXN7

ADAMTS LI ALOX5AP CTLA4 CAMK4 CCR4 CCL3 ANKLE1 CAMK4

ADIRF ANKRD44 DDX5 CCR7 CCR8 CCL4 AP4B1-AS1 CCR7

ANGPTL APOBEC3

2 G HLA-J EEF1A1 CD177 CCL5 APOBEC3A EEF1A1

ARHGAP1

APP 5 ICA1 EEF1B2 DDX60 CSF1 ARHGEF26-AS1 FAM102A

ARHGAP ARHGAP2

29 5 IGFLR1 EEF1G ERI1 CST7 ASXL2 FKBP5

ARHGAP3

BGN 0 IL21 FAM65B EZH2 FASLG ATHL1 GPR155

BMP1 ARHGAP4 ITGB2-AS1 FHIT FAS GZMB ATXN1 IL7R

C1R ARHGAP9 ITM2A GIMAP5 FOXP3 GZMH CBLB LEF1

CCDC80 ARHGDIB KCNK5 IL7R GAT A3 HLA-C CD3E NELL2

CFH ATP2A3 KIAA0247 LDHB GBP5 IFNG CD8A PIK3IP1

CLU BIN2 LIMS1 LDLRAP1 GCHFR PRF1 CDKN1B PPP1R2

COL15A

1 C16orf54 LY6G5C LEF1 HNRNPC CLEC2D PRKCQ-AS1

COL18A LOC100130

1 CCDC88B MAF 231 HPRT1 CNOT6L SELL

COL4A1 CD37 METTL8 NAP1L1 IL10RA CTLA4 SORL1

COL4A2 CD48 MRP63 NOSIP IL1R2 CXCL13 TCF7

COL6A2 CD52 NFATC1 PABPC1 IL2RA DENND2D TSC22D3

COX7A1 CD53 NR3C1 PIK3IP1 IL2RG DFNB31 UBA52

CTGF CD69 PDCD1 SELL IL32 DGKH

CYB5R3 CD84 PTPN11 SERINC5 LAIR2 DOCK8

CDC42SE

CYR61 2 PTPRC SF1 LAYN DTHD1

DCHS1 CELF2 RNF19A TCF7 LOC541471 DUSP4

DPYSL3 CNTRL SARDH TMEM66 LTB ELF1

EFEMP1 COROIA SLA TPT1 PARK7 ENTPD1

EHD2 CSK SRGN TRABD2A PIM2 FAM122C

ELN CXCR4 TBC1D4 TSC22D3 PMAIP1 FAM3C

EPAS1 CYTH4 THADA TXNIP PPP2CA FAM73A

FAM171

Al CYTIP TIGIT UBA52 RASGRP1 FBXL18

FAP DEF6 TSPYL2 RORA FCRL3

DENND1

FAT 4 C ZNF211 RTKN2 GBP2

FBN1 DOCK2 S100A4 GDPD1

FLRT2 DOCK8 SAMD9 GLUD1P7

FSCN1 DUSP2 STAM HAVCR2

FSTL1 EVI2B SUM02 HINT3

GJA1 FERMT3 TNFRSF18 HNRPLL

GNG11 FGD3 USP15 IFNLR1

HSPG2 FNBP1 WDR1 IL10

HTRA1 GBP5 ZBTB32 INPP4B

IFITM3 GPR65 INPP5F IGF2 GPSM3 ITGA4

IGFBP4 HCLS1 ITM2A

IGFBP7 HMHA1 ITPKB

JAG1 IKZF1 KIAA1324

KIAA121

7 IL10RA LAG3

IAMBI IL16 LINC00294

LAMB2 IL2RG LOC100131257

LAMC1 INPP5D LOC100190986

LEPROT ITGA4 LOC100271836

LHFP ITGAL LOC286186

LIMCH1 ITGB2 LOC440354

LIMS2 LAIR1 L0C728558

LMCD1 LAPTM5 LYST

10X12 LCP1 MAPK13

LPHN2 LILRB3 MCL1

LRRC32 LIMD2 MTX3

MAP1B LPXN NFATC1

ME0X2 LSP1 NXNL2

MGP LY9 0DF2L

MMP2 MAP4K1 0SBPL3

NFIB MY01G PCED1B

NIDI NCKAP1L PCGF5

NNMT NR4A2 PDCD1

NPDC1 PARP8 PDE4D

NR2F2 PARVG PER2

NT5E PIK3CD PLEKHG2

NUAK1 PIM2 PRICKLE2-AS3

PEAR1 PLCB2 PTPRC

PHLDB2 PLEKHA2 RAB27A

PLSCR4 PRKCB RAMP2-AS1

PPAP2A PSD4 RGS1

PPAP2B PSTPIP2 RNF19A

PPIC PTK2B SCD5

PRKCDB P PTPN22 SF3B3

PROCR PTPN6 SH2D2A

PRSS23 PTPN7 SMG1P1

PTRF PTPRC STAT1

PXDN RAC2 STAT3

RAB11FI

P5 RASSF5 TANG02

RABAC1 RCSD1 TATDN3

RBPMS RGS1 TBXA2R

RUNX1T

1 RHOH TIGIT

S100A16 RPS6KA1 TMEM136

SERPINH

1 SAMSN1 TMEM212

SPARC SASH3 TNFRSF1B

SPARCL1 SLA TNFRSF9

STC2 SNX20 TP53INP1

TFPI SP140 TRAF5

TGFB1I1 STK17B TTN

THBS1 TAGAP TXNDC11

TBC1D10

THY1 C USP33

TMEM2

04 TMC6 VSIG1 TNKS1B

PI TMC8 VSTM4

TNXB TMSB4X ZNF620

TPBG TRAF3IP3 ZNF79

UNC5B TSC22D3

VCL TSTD1

ZEB1 UCP2

ZNF423 VAV1

ZNF521 WIPF1

[0556] Table 30. (A) Overall Expression of the resistance program across CCLE melanoma cell lines; (B) measurements of 40 cytokines and chemokines in the conditioned media of DMSO and abemaciclib treated cancer cells; related to Figure 67.

Table 30A. Overall Expression of the resistance program across CCLE melanoma cell lines

Immi ne resistance O i erall expressioi i (OE)

Cell line Final Down

Final Up Down Up (refined)

(refined} (refined)

HMCB 1.036 0.357 -0.68 2.307 0.81 -1.497

LOXI MVI 1.021 0.318 -0.703 2.083 0.654 -1.428

A375 0.983 0.352 -0.631 2.221 0.89 -1.331

G RM 0.972 0.296 -0.675 2.218 0.842 -1.376

CHL1 0.841 0.341 -0.5 1.876 0.694 -1.183

A2058 0.596 0.299 -0.297 1.219 0.37 -0.85

IGR39 0.493 -0.014 -0.507 1.1 0.25 -0.85

UACC62 0.383 0.27 -0.114 0.854 0.413 -0.441

G361 0.38 0.276 -0.104 0.81 0.385 -0.424

CJM 0.361 -0.219 -0.58 0.66 -0.047 -0.706

RPMI7951 0.354 -0.17 -0.525 0.626 -0.124 -0.749

M DAM B435S 0.346 -0.115 -0.461 0.775 0.143 -0.632

M EWO 0.316 0.09 -0.226 0.552 0.104 -0.448

COL0679 0.254 0.239 -0.015 0.646 0.335 -0.311

A101D 0.248 0.075 -0.173 0.612 0.158 -0.454

M EUUSO 0.229 0.176 -0.053 0.439 0.327 -0.112

COL0741 0.215 0.214 -0.001 0.255 0.282 0.027

HT144 0.212 0.112 -0.1 0.499 0.263 -0.237

WM793 0.16 -0.089 -0.249 0.318 -0.268 -0.587

IGR1 0.144 0.096 -0.048 0.376 0.143 -0.233

UACC257 0.142 0.335 0.193 0.124 0.522 0.398

HS294T 0.115 0.123 0.007 0.236 0.223 -0.013

HS944T 0.088 0.162 0.074 0.213 0.371 0.158

WM88 0.038 0.037 -0.001 -0.07 -0.056 0.014

HS695T 0.037 0.031 -0.006 0.412 0.137 -0.276

HS895T 0.035 -0.417 -0.451 0.32 -0.41 -0.731

IGR37 0.006 0.269 0.263 0.188 0.442 0.254

COL0849 -0.002 0.137 0.139 -0.179 0.165 0.344

SKM EL3 -0.019 0.196 0.214 -0.084 0.384 0.469

SKM EL30 -0.043 0.102 0.145 0.146 0.203 0.057

SKM EL1 -0.049 0.114 0.163 -0.035 0.313 0.348

M ELHO -0.05 0.153 0.203 -0.236 0.207 0.443

COL0783 -0.062 -0.001 0.061 -0.269 -0.134 0.136 K029AX -0.065 0.129 0.194 -0.21 0.133 0.343

SKMEL2 -0.081 0.074 0.155 0.101 0.322 0.221

IPC298 -0.103 0.101 0.204 -0.104 0.296 0.399

WM983B -0.112 -0.157 -0.045 -0.253 -0.286 -0.032

SKMEL5 -0.12 0.185 0.305 -0.317 0.188 0.506

HS936T -0.144 -0.03 0.114 -0.495 -0.079 0.416

HS839T -0.181 -0.48 -0.299 -0.39 -0.808 -0.418

HS934T -0.196 -0.421 -0.225 -0.369 -0.684 -0.314

WM1799 -0.234 -0.061 0.173 -0.554 -0.374 0.18

WM115 -0.244 -0.227 0.018 -0.676 -0.428 0.247

HS940T -0.253 -0.391 -0.139 -0.697 -0.755 -0.058

HS688AT -0.303 -0.496 -0.192 -0.677 -0.889 -0.212

RVH421 -0.327 -0.056 0.271 -0.615 -0.144 0.472

SH4 -0.328 -0.05 0.277 -0.77 -0.174 0.596

WM2664 -0.335 0.043 0.378 -0.756 0.075 0.831

HS852T -0.352 -0.234 0.118 -0.951 -0.571 0.38

HS600T -0.401 -0.562 -0.161 -0.842 -0.97 -0.129

COLO800 -0.404 -0.111 0.293 -0.67 -0.214 0.456

COL0818 -0.406 -0.209 0.198 -0.768 -0.561 0.207

COL0792 -0.407 0.018 0.426 -0.965 -0.116 0.849

HS939T -0.445 -0.136 0.309 -1.223 -0.437 0.786

C32 -0.5 -0.087 0.413 -1.167 -0.446 0.721

COL0829 -0.526 -0.067 0.459 -1.321 -0.23 1.091

SKMEL31 -0.726 -0.37 0.356 -1.63 -0.809 0.821

SKMEL28 -0.814 -0.183 0.631 -1.259 -0.221 1.039

SKMEL24 -0.833 -0.298 0.535 -1.567 -0.512 1.055

MALME3M -0.941 -0.068 0.872 -2.067 -0.298 1.769

Table 30B. Measurements of 40 cytokines and chemokines in the conditioned media of DMSO and abemaciclib treated cancer cells

Analyte Fold change (abemaciclib vs. DMSO treatment)

Hu MIF 2.9587

Hu IL-8 0.7253

Hu IL-6 0.3788

Hu MCP-1/CCL2 0.7175

Hu ENA-78/CXCL5 1.0188

Hu Gro-a/CXCLl 0.9135

Hu SDFla+b/CXCL12 0.8885

Hu TECK/CCL25 1.5510

Hu GM-CSF 1.0191

Hu Gro-b/CXCL2 0.7471

Hu Fractalkine/CX3CL1 2.1863

Hu SCYB16/CXCL16 1.1278

Hu 6Ckine/CCL21 0.9700

Hu IL-10 1.0079

Hu IP-10/CXCLlO 0.9103

Hu MIP-3a/CCL20 3.4000

Hu IL-16 0.8482

Hu MIP-3b/CCL19 0.8717

Hu l-309/CCLl 1.0389 Hu MCP-3/CCL7 1.0422

Hu MI P-ld/CCL15 1.0809

Hu Eotaxin/CCLll 0.9599

Hu MCP-4/CCL13 0.8887

Hu TNF-a 0.7465

Hu IL-lb 1.0719

Hu IL-4 1.6605

Hu TARC/CCL17 1.0104

Hu IL-2 0.5882

Hu M DC/CCL22 1.1142

Hu Eotaxin-3/CCL26 3.0279

Hu GCP-2/CXCL6 0.6386

Hu CTACK/CCL27 1.0834

Hu MI P-la/CCL3 1.0350

Hu MCP-2/CCL8 1.0388

Hu l-TAC/CXCLll 0.9524

Hu I FN-g Below the detection threshold

Hu BCA-1/CXCL13 Below the detection threshold

Hu MIG/CXCL9 Below the detection threshold

Hu MPI F-1/CCL23 Below the detection threshold

Hu Eotaxin-2/CCL24 Below the detection threshold

Example 11 - Clinical Trial Design

[0557] Applicants have designed an exemplary clinical trial based on the present disclosure. The study design includes a Phase I/II clinical trial combining abemaciclib plus LY3300054 for patients with melanoma with ICB resistance. LY3300054 is a monoclonal antibody that has been shown in vitro to target the PD-L1 expressed on tumor cells and tumor-infiltrating immune cells, preventing its binding to PD-1 and CD80 (B7-1) receptors on the T cells.

[0558] The patients to be recruited include patients that are post-PD-1 and/or post-

CTLA-4 treatment with advanced/metastatic cutaneous melanoma. Phase I will include up to

24 patients. Phase I patients will be administered Anti-PD-Ll therapy plus oral abemaciclib.

Abemaciclib will be administered according to the present disclosure in doses of 75, 100,

150, and 200 mg BID (i.e., twice daily). The primary goals of the phase I trial are safety and recommended phase 2 dose (RP2D). The secondary goal of the phase I trial is clinical benefit. The trial also includes a single-arm Phase II trial. The phase II trial will include n=30 patients and be two stage. The phase II trial will administer Anti-PD-Ll therapy plus oral abemaciclib at the RP2D. The primary goal of the phase II trial is clinical benefit. The secondary goal of the phase II trial is measuring immune phenotypes. Pre-treatment and on- treatment biopsy samples will be analyzed as described herein. Samples will be analyzed by one or more of scRNA-sequencing, immune resistance biomarker score, multiplexed immune profiling, immuno-phenotyping (e.g., flow-cytometry) and/or tumor infiltrating lymphocytes activity (e.g., flow cytometry). The Trial will use a statistical plan.

[0559] Table 31. Statistical Plan

[0560] Part 1 is a single arm, Phase I study with 3+3 design to identify the RP2D of abemaciclib. The total number of patients to be enrolled in the Part 1 is dependent upon the observed safety profile. The expected enrollment is between 3 and 24 patients for evaluating 4 dose levels. If 1 patient experiences a DLT in the first 3 patients, then 3 more patients will be recruited for a total of six in a dose cohort. The following table summarizes the probability of stopping accrual after the first 3 patients in a dose cohort (2 or more patients experience a DLT) for various true DLT rates.

[0561] Table 32 [0562] In addition, the exact 90% confidence interval for toxicity (or any other binomial parameter) will be no wider than 36% among 24 patients.

[0563] Sample size calculations for Part 2 take into consideration patients treated at the RP2D in Part 1.

[0564] For Part 2, abemaciclib plus anti -PD-Ll therapy will be considered worthy of further investigation in advanced/metastatic melanoma patients with resistance to PD-Ll if a clinical benefit rate (CBR) of at least 20% is observed. To achieve this, the study will employ a Simon two-stage design with a total sample of 30 patients to compare a null CBR of 5% against the alternative of 22%.

[0565] Including patients treated at the RP2D in Parti, thirteen patients in total will be enrolled in the first stage. If 1 or more patients achieve the primary endpoint of CBR, then 17 additional patients will be enrolled. If 4 or more of the total of 30 patients achieve the primary endpoint, then abemaciclib plus anti-PD-Ll therapy will be considered promising. This design has at least 90% power and a 6% one-sided type 1 error (target 10%). If the null hypothesis is true, the probability is 0.51 that the trial will stop at the end of stage 1.

[0566] In stage 1, the probability of observing one or more toxicity events given a true toxicity rate as low as 12%, with 13 patients, is at least 80%. If the Part 2 portion of the study is expanded to stage 2, the probability of observing one or more toxicity events given a true toxicity rate as low as 6%, with 30 patients, is at least 80%.

[0567] Correlative and biomarker objectives will be considered exploratory. Assuming the study moves to the second stage, the maximal width of a 90% confidence interval for any binomial parameter will be no wider than 32%, hence estimation of binomial quantities will be fairly accurate. Estimation of continuous biomarker measures will be via mean or median as appropriate and standard deviation. There will be limited power to correlate clinical measures with biomarker endpoints with this limited phase II sample size, hence those analyses will be considered exploratory.

Example 12 - In vivo and ex vivo studies

[0568] As described herein, Applicants can study the gene signatures in vivo and ex vivo.

The studies can provide for information regarding how different treatment regimens can modulate the resistance signatures, tumor lymphocyte infiltration, and/or immune phenotypes. The studies can also provide for key genes required for resistance to the adaptive immune response (e.g., TILs). Figure 76 shows tS E analysis after scRNA-seq of B16 cells implanted subcutaneously into B6 animals followed by treatment with either vehicle, abemaciclib alone, immune checkpoint inhibitors (ICI) alone or ICI plus abema. The cells were "perturbed" in vivo after implantation. Using the data obtained, Applicants can analyze the expression of the resistance signature, tumor infiltration and immune states of the in vivo tumor under each condition.

[0569] Figure 77 shows ex vivo melanoma cells obtained from a single human patient perturbed with barcoded guide sequences targeting the indicated genes. The barcodes from this experiment were isolated and sequenced. The result shows that Applicants have successfully introduced a perturb-seq library that targets genes of resistance in human cells, and that the perturb-seq barcodes could be isolated and sequenced from this experiment. The names are the different channels that were loaded for sequencing. Applicants can perform a co-culture experiment with the patient's own (autologous) tumor-infiltrating lymphocytes after confirming that single-cell transcriptomes can be obtained from the same experiment in addition to the barcodes.

Example 13 - Materials and Methods

Human tumor specimens

[0570] For the discovery scRNA-seq cohort, tissue was procured under Institutional Review Board (IRB) approved protocols at Brigham and Women's Hospital and Dana-Farber Cancer Institute, Boston, MA. Patients were consented to these protocols (11-104) in clinic visits prior to surgery/biopsy. Patients included in the earlier study (Tirosh et al., 2016), and those specimens newly collected here are annotated in Tables 1 and 24A.

[0571] For validation cohorts (bulk-RNA-Seq), patient tissue was collected under IRB protocols of the University Hospital Essen, Germany and Massachusetts General Hospital, Boston, MA (protocol 11-181) and The Wistar Institute, Philadelphia, PA (Human subjects protocol 2802240). Validation Cohort 1 included 90 samples from 26 patients, with multiple biopsies per patient, taken before, during, and/or after various treatment regimens, including both targeted therapies and immunotherapies (see, e.g., Table 24B). Validation Cohort 2 included 112 samples collected before treatment with pembrolizumab (clinical information is provided in Tables 24C).

Single-cell cohort: Tissue handling and tumor disaggregation

[0572] Resected tumors were transported in DMEM (ThermoFisher Scientific, Waltham,

MA) on ice immediately after surgical procurement. Tumors were rinsed with PBS (Life

Technologies, Carlsbad, CA). A small fragment was stored in RNA-Protect (Qiagen, Hilden, Germany) for bulk RNA and DNA isolation. Using scalpels, the remainder of the tumor was minced into tiny cubes <1 mm ³ and transferred into a 50 ml conical tube (BD Falcon, Franklin Lakes, NJ) containing 10 ml pre-warmed M199-media (ThermoFisher Scientific), 2 mg/ml collagenase P (Roche, Basel, Switzerland) and lOU/μΙ DNase I (Roche). Tumor pieces were digested in this media for 10 minutes at 37°C, then vortexed for 10 seconds and pipetted up and down for 1 minute using pipettes of descending sizes (25 ml, 10 ml and 5 ml). As needed, this was repeated twice more until a single-cell suspension was obtained. This suspension was then filtered using a 70μπι nylon mesh (ThermoFisher Scientific) and residual cell clumps were discarded. The suspension was supplemented with 30 ml PBS (Life Technologies) with 2% fetal calf serum (FCS) (Gemini Bioproducts, West Sacramento, CA) and immediately placed on ice. After centrifuging at 580g at 4°C for 6 minutes, the supernatant was discarded and the cell pellet was re-suspended in PBS with 1% FCS and placed on ice prior to staining for FACS.

Single-cell cohort: FACS

[0573] Single-cell suspensions were stained with CD45-FITC (VWR, Radnor, PA) and live/dead stain using Zombie Aqua (BioLegend, San Diego, CA) per manufacturer recommendations. First, doublets were excluded based on forward and sideward scatter, then Applicants gated on viable cells (Aqua ^low ) and sorted single cells (CD45 ⁺ or CD45 ^" ) into 96- well plates chilled to 4°C, pre-prepared with ΙΟμΙ TCL buffer (Qiagen) supplemented with 1% beta- mercaptoethanol (lysis buffer). Single-cell lysates were sealed, vortexed, spun down at 3,700 rpm at 4°C for 2 minutes, placed on dry ice and transferred for storage at -80°C. scRNA-seq

[0574] For plate-based scRNA-seq, whole Transcriptome Amplification (WTA) was performed with a modified SMART-Seq2 protocol, as described previously (Trombetta et al., 2014) with Maxima Reverse Transcriptase (Life Technologies) instead of Superscript II. Next, WTA products were cleaned with Agencourt XP DNA beads and 70% ethanol (Beckman Coulter, Brea, CA) and Illumina sequencing libraries were prepared using Nextera XT (Illumina, San Diego, CA), as previously described (Trombetta et al., 2014). The 96 samples of a multiwell plates were pooled, and cleaned with two 0.8X DNA SPRIs (Beckman Coulter). Library quality was assessed with a high sensitivity DNA chip (Agilent) and quantified with a high sensitivity dsDNA Quant Kit (Life Technologies). [0575] For droplet-based scRNA-seq, experiments were performed on the lOx Genomics Chromium platform, with the Chromium Single Cell 3 ' Library & Gel Bead Kit v2 and Chromium Single Cell 3 ' Chip kit v2 according to the manufacturer' s instructions in the Chromium Single Cell 3 ⁷ Reagents Kits V2 User Guide. Briefly, -6,000 cells were re- suspended in PBS supplemented with 0.04% BSA and loaded to each channel. The cells were then partitioned into Gel Beads in Emulsion in the GemCode instrument, where cell lysis and barcoded reverse transcription of RNA occurred, followed by amplification, shearing and 5 ⁷ adaptor and sample index attachment.

[0576] Barcoded single cell transcriptome libraries were sequenced with 38bp paired end reads on an Illumina NextSeq 500 Instrument.

Validation cohorts: RNA-capture and bulk RNA-Seq

[0577] RNA extraction from formalin-fixed, paraffin-embedded (FFPE) tissue slides was performed by the Genomics Platform of the Broad Institute (Cambridge, MA). For cDNA library construction total RNA was assessed for quality using the Caliper LabChip GX2 (Perkin Elmer). The percentage of fragments with a size greater than 200nt (DV200) was calculated and an aliquot of 200ng of RNA was used as the input for first strand cDNA synthesis using Illumina' s TruSeq RNA Access Library Prep Kit. Synthesis of the second strand of cDNA was followed by indexed adapter ligation. Subsequent PCR amplification enriched for adapted fragments. The amplified libraries were quantified using an automated PicoGreen assay (Thermo Fisher Scientific, Cambridge, MA). 200ng of each cDNA library, not including controls, were combined into 4-plex pools. Capture probes that target the exome were added, and hybridized for the recommended time. Following hybridization, streptavidin magnetic beads were used to capture the library-bound probes from the previous step. Two wash steps effectively remove any nonspecifically bound products. These same hybridization, capture and wash steps are repeated to assure high specificity. A second round of amplification enriches the captured libraries. After enrichment, the libraries were quantified with qPCR using the KAPA Library Quantification Kit for Illumina Sequencing Platforms (Illumina) and then pooled equimolarly. The entire process was performed in 96- well format and all pipetting was done by either Agilent Bravo or Hamilton Starlet. Pooled libraries were normalized to 2nM and denatured using 0.1 N NaOH prior to sequencing. Flowcell cluster amplification and sequencing were performed according to the manufacturer's protocols using Illumina HiSeq 2000 or 2500 (Illumina). Each run was a 76bp paired-end with an eight-base index barcode read. Data was analyzed using the Broad Picard Pipeline (broadinstitute.github.io/picard/), which includes de-multiplexing and data aggregation.

scRNA-seq data pre-processing

[0578] BAM files were converted to merged, demultiplexed FASTQ files. The paired- end reads obtained with the SMART-Seq2 protocol were mapped to the UCSC hgl9 human transcriptome using Bowtie (Langmead et al., 2009), and transcript-per-million (TPM) values were calculated with RSEM vl .2.8 in paired-end mode (Li and Dewey, 2011). The paired- end reads obtained with the lOx Genomics platform were mapped to the UCSC hgl9 human transcriptome using STAR (Dobin et al., 2013), and gene counts/TPM values were obtained using the lOx Genomics computational pipeline (cellranger-2.1.0).

[0579] For bulk RNA-Seq data, expression levels of genes were quantified as Eij=log2(TPMij+l), where TPM,j denotes the TPM value of gene i in sample j. For scRNA- seq data, expression levels were quantified as where TPM,j denotes the TPM value of gene i in cell j. TPM values were divided by 10 because the complexity of the single-cell libraries is estimated to be within the order of 100,000 transcripts. The 10 ^"1 factoring prevents counting each transcript -10 times, which would have resulted in overestimating the differences between positive and zero TPM values. The average expression of a gene i across a population of N cells, denoted here as P, was defined as

[0580] For each cell, Applicants quantified the number of genes with at least one mapped read, and the average expression level of a curated list of housekeeping genes (Tirosh et al., 2016a). Applicants excluded all cells with either fewer than 1,700 detected genes or an average housekeeping expression (E, as defined above) below 3 (see, e.g., Tables 2 and 25). For the remaining cells, Applicants calculated the average expression of each gene (E _p ), and excluded genes with an average expression below 4, which defined a different set of genes in different analyses depending on the subset of cells included. In cases where Applicants analyzed different cell types together, Applicants removed genes only if they had an average Ep below 4 in each of the different cell types that were included in the analysis. When analyzing CD45 ⁺ cells, Applicants excluded genes as described above only after the assignment of cells to cell types in order to prevent the filtering of genes that were expressed by less abundant cell types.

Data imputation and normalization

[0581] In all differential expression analyses of SMART-Seq2, Applicants first modeled the read counts as a mixture of a negative binomial ( B) and Poisson components to estimate the expression levels, using SCDE (Fan et al., 2016) with the code provided in github.com/hms-dbmi/scde. The resulting normalized and imputed expression matrix, denoted as E was used in the differential expression analyses. Analysis of droplet-based scRNA-seq data (10X Genomics Chromium, above) was performed with the Seurat package (www.satijalab.org/seurat), using the likelihood-ratio test for differential gene expression analyses (McDavid et al., 2013).

Identifying cell states associated with specific tumor compositions

[0582] Applicants combined scRNA-seq and bulk RNA-Seq data to characterize the state of a specific cell type in tumors with a specific cellular composition (See, e.g. Figures 44B and 62B). The method takes as input scRNA-seq data and a cohort of bulk RNA-Seq data, both collected from tumors of the same cancer type. The implementation of the approach is provided via GitHub (github.com/livnatje/ImmuneResistance/wiki/Mapping-immune- resistance-in-melanoma; ImmResl immuneResistanceProgram.R), and can be applied to regenerate the results reported here and facilitate new discoveries. For clarity Applicants describe the approach for malignant cells and T cells as applied here, although it can be applied to any pair of cell types, depending on data availability.

[0583] STEP 1. Analyses of the input scRNA-seq data: (a) assign cells to cell types (see sections: Classification of malignant and stromal cells and Classification of immune cells); and (b) define a signature of malignant cells and a signature of T cells, consisting of genes which are primarily (specifically) expressed by malignant cells or T cells, respectively (see section: Data-driven signatures of specific cell types).

[0584] STEP 2. Analyses of the input bulk RNA-Seq data: (a) estimate the T cell infiltration level in each tumor by computing the overall expression (OE, see section: Computing the OE of gene signatures) of the T cell signature in each bulk sample; (b) compute the Pearson correlation coefficient between the expression of the genes in the malignant signature and the OE of the T cell signature across the bulk tumors; and (c) define the seed exclusion-up (down) signature as the top 20 malignant genes that are significantly negatively (positively) correlated in (b) (adjusted P < 0.1, using Benjamini-Hochberg correction for multiple hypotheses testing (Benjamini and Hochberg, 1995)).

[0585] If confounding factors in the bulk RNA-Seq data should be controlled for, partial Pearson correlation is used in (2.b).

[0586] STEP 3. Analyses of the input scRNA-seq data of the malignant cells, (a) compute the OE of the seed exclusion signatures in each of the malignant cells; (b) compute the partial Spearman correlation coefficient between the expression of each gene and the OE of the seed exclusion signatures across the single malignant cells, while controlling for technical quality (the number of reads and genes that were detected in the cells). Other confounding factors, besides technical variation, can also be controlled for, for example, cell cycle (see below).

[0587] Of note, to examine whether the seed signatures capture the two opposing transcriptional components of a malignant cell state, Applicants test whether their OE across the malignant cells is negatively correlated.

[0588] STEP 4. Derive the final genome-scale exclusion signatures, defined as: (i) exclusion-up: genes which were significantly positively correlated with the seed exclusion- up signature and significantly negatively correlated with the seed exclusion-down signature in the analysis described in (STEP 3); and (ii) exclusion-down: genes which were significantly positively correlated with the seed exclusion-down signature and significantly negatively correlated with the seed exclusion-up signature in the analysis described in (STEP 3). In this analysis, a gene is defined as significantly correlated with a signature if it was among the 200 topmost correlated genes, with Spearman correlation coefficient |p| > 0.1 and adjusted p-value < 10 ^"10 (Benjamini-Hochberg correction for multiple hypotheses testing (Benjamini and Hochberg, 1995)).

[0589] To generate the exclusion program reported in the manuscript, Applicants applied the approach to the clinical scRNA-seq melanoma data and bulk RNA-Seq data of 473 Skin Cutaneous Melanoma (SKCM) tumors from TCGA (as provided in xenabrowser.net/datapages/). In (STEP 2) Applicants used the CD8 ⁺ T cell signature Applicants generated (Table 26B).

[0590] Applicants also performed several additional analyses. First, for comparison, Applicants also applied the approach to other T cell populations, by using other T cell signatures (Table 26B) in (STEP 2): pan-T cells (CD3 ⁺ ), CD4 ⁺ T cells; naive, cytotoxic, and exhausted CD8 ⁺ T cell subsets; and naive, exhausted, and regulatory CD4 ⁺ T cell subsets. Second, to compute the relative abundance of CD8 ⁺ T cells among the non-malignant cells Applicants used the CD8 ⁺ T cell signature and tumor purity that was previously assessed by genetic variations with ABSULOTE (Akbani et al., 2015; Carter et al., 2012). Of note, in this setting the resulting "up" and "down" seed signatures were less anti -correlated with each other across the single malignant cells (Pearson r = -0.22, P = 1.40* 10 ^"24 , compared to r = - 0.58, P = 6.19*10 ^~183 , in the original setting). These findings indicate that the association between the state of the malignant cells and the relative proportion of T cells out of the non- malignant compartment may be more complex than the connection between malignant cells states and the proportion of T cells in the overall tumor. Tumor purity was provided in (STEP 2) as a confounding factor. Third, Applicants applied the approach when controlling for tumor and cellular proliferation. To do so, Applicants computed the OE of two cell cycle signatures (Gl/S and G2/M, Table 26A (Tirosh et al., 2016)) across the bulk tumors and single malignant cells. Applicants then provided these values as confounding factors in (STEP 2) and (STEP 3), to control for the tumor proliferation rate and cell cycling, respectively.

[0591] In cases where the approach is applied to two cell types whose abundance in the tumor is highly correlated, for example macrophages and T cells, the seed exclusion-up signature can be identified in a more permissive manner. Otherwise, it may include very few genes. In the case of macrophages and T cells, the (more permissive) seed exclusion-up signature includes macrophage specific genes that fulfill the following requirements: (1) in comparison to other macrophage specific genes, their expression across bulk tumors has a low correlation to T cell abundance (conditional probability < 0.1); and (2) their expression across macrophages in the scRNA-seq data is negatively correlated to the OE of the exclusion-down seed signature. The analysis then proceeds in the same manner as described above.

Computing the OE of gene signatures

[0592] Gene modules are more robust to noise and provide more coherent signals than the expression of single genes (Shalek et al., 2013, 2014; Wagner et al., 2016). To compute the OE of a gene module or signature Applicants used a scheme that filters technical variation and highlights biologically meaningful patterns. The procedure is based on the notion that the measured expression of a specific gene is correlated with its true expression

(signal), but also contains a technical (noise) component. The latter may be due to various stochastic processes in the capture and amplification of the gene's transcripts, sample quality, as well as variation in sequencing depth (Wagner et al., 2016). The signal-to-noise ratio varies, depending, among other variables, on gene transcript abundance.

[0593] Applicants therefore computed the OE of gene signatures in a way that accounts for the variation in the signal-to-noise ratio across genes and cells. Given a gene signature and a gene expression matrix E (as defined above), Applicants first binned the genes into 50 expression bins according to their average expression across the cells or samples. The average expression of a gene across a set of cells within a sample is E _p (see: RNA-Seq data pre-processing) and the average expression of a gene across a set of N tumor samples was defined as: E _j Given a gene signature S that consists of K genes, with genes

in bin b, Applicants sample random S-compatible signatures for normalization. A random signature is S-compatible with signature S if it consists of overall K genes, such that in each bin (b) it has exactly genes. The OE of signature S in cell or sample j is then defined as:

[0594] Where S is a random S-compatible signature, and C _y is the centered expression of gene i in cell or sample j, defined as = Ej _j — Ε[£^·] . Because the computation is based on the centered gene expression matrix C, genes that generally have a higher expression compared to other genes will not skew or dominate the signal.

[0595] Applicants found that 1,000 random S-compatible signatures are sufficient to yield a robust estimate of the expected value E_?[∑i _e s £*_ ]. The distribution of the OE values was normal or a mixture of normal distributions, and, unlike the expression of a single gene, fulfilled the assumptions of the mixed effects models or hierarchal linear models that Applicants applied to study the differential expression of gene signatures (as described in the Identifying differentially expressed gene sets section).

[0596] In cases where the OE of a given signature has a bimodal distribution across the cell population, it can be used to naturally separate the cells into two subsets. To this end, Applicants applied the Expectation Maximization (EM) algorithm for mixtures of normal distributions to define the two underlying normal distributions. Applicants then assigned cells to the two subsets, depending on the distribution (high or low) that they were assigned to.

[0597] Applicants use the term a transcriptional program (e.g., the immune resistant program) to characterize cell states which are defined by a pair of signatures, such that one (S-up) is overexpressed and the other (S-down) is underexpressed. Applicants define the OE of such cell states as the OE of S-up minus the OE of S-down.

[0598] To compute the OE of gene signatures in bulk tumors or single cell data one can apply the R code Applicants provide via GitHub (github.com/livnatje/ImmuneResistance; ImmRes OE.R).

Classification of malignant and stromal cells

[0599] In the non-immune compartment (CD45 ^" cells), Applicants distinguished malignant and nonmalignant cells according to three criteria: (1) their inferred CNV profiles (Tirosh et al., 2016); (2) under-expression of different nonmalignant cell type signatures; and (3) higher similarity to melanoma tumors than to adjacent normal tissue, based on the comparison to bulk RNA-Seq profiles. Specifically: (1) to infer CNVs from the scRNA-seq data Applicants used the approach described in (Tirosh et al., 2016) as implemented in the R code provided in github.com/broadinstitute/inferCNV with the default parameters. Cells with an average absolute CNV level that was below the 0.1 quantile of the entire CD45 ^" cell population were considered as potentially nonmalignant according to this criterion. (2) Applicants used signatures of endothelial cells, stromal cells, and Cancer Associated Fibroblasts (CAFs), as provided in Table 26A and C. The signatures combine well- established markers from two sources (www.biolegend.com/cell_markers and (Tirosh et al., 2016)). Applicants computed the OE of these three signatures in each of the CD45 ^" cells, while controlling for the impact of technical cell quality (as described in section Computing the OE of gene signatures). CD45 ^" cells that expressed any one of these three signatures above the 0.95 quantile were considered as potentially nonmalignant according to this criterion. (3) Applicants downloaded the pan-cancer TCGA RNA-Seq V2 expression data from xena.ucsc.edu, and log ² -transformed the RSEM-based gene quantifications. For each cell, Applicants computed the correlation (e.g., Spearman correlation) between its profile (in TPM) and each bulk profile (in TPM) of 473 skin cutaneous melanoma samples and 727 normal solid tissues. Applicants then tested, for each cell, if it was more similar to the melanoma tumors compared to the normal tissues, by applying a one-sided Wilcoxon ranksum test on the correlation coefficients that were obtained for that cell. Cells that were more similar to the normal tissues (P < 0.05, Wilcoxon ranksum test) were considered as potentially nonmalignant according to this criterion.

[0600] The cell assignments that were obtained by these three different criteria were highly consistent (see, e.g., Figures 69A,B, hypergeometric p-value < 10 ^"17 ). Cells that were identified as potentially nonmalignant according to one or more of these three criteria were defined as nonmalignant, and were omitted from further analyses of the malignant cells. The nonmalignant CD45 ^" cells were further classified into CAFs and endothelial cells, if they overexpressed only one of the corresponding gene signatures, and as unresolved cells otherwise.

Classification of immune cells

[0601] To classify immune cells, Applicants first filtered CD45 ⁺ cells that were potentially malignant or doublets of immune and malignant cells based on their inferred CNV profiles. To this end, Applicants defined the overall CNV level of a given cell as the sum of the absolute CNV estimates across all genomic windows. For each tumor, Applicants generated its CNV profile by averaging the CNV profiles of its malignant cells, when considering only those with the highest overall CNV level (top 10%). Applicants then evaluated each cell by two values: (1) its overall CNV level, and (2) its CNV-R-score, that is, the Spearman correlation coefficient obtained when comparing its CNV profile to the CNV profile of its tumor. These two values were used to classify cells as malignant, nonmalignant, and unresolved cells that were excluded from further analysis (see, e.g., Figures 69C-E).

[0602] Next, Applicants applied two different clustering approaches to assign immune (CD45 ⁺ ) cells into cell types. In the first approach, Applicants clustered the CD45 ⁺ cells according to 194 well-established markers of 22 immune cell subtypes (Table 26A; assembled from www.biolegend.com/cell_markers and (Tirosh et al., 2016)). The clustering was performed in three steps: (1) Applicants computed the Principal Components (PCs) of the scRNA-seq profiles, while restricting the analysis to the 194 biomarker genes. Applicants used the top PCs that captured more than 50% of the cell-cell variation. In the presented analyses, 10 PCs were used, but the results were robust and stable when using the first 5-15 PCs. (2) Applicants applied t-SNE (t-Distributed Stochastic Neighbor Embedding) (van der Maaten and Hinton, 2008) to transform these first PCs to a two-dimensional embedding, using the R implementation of the t-SNE method with the default parameters, as provided in lvdmaaten.github.io/tsne/. (3) Applicants applied a density clustering method, DBscan (Ester et al., 1996), on the two-dimensional t-SNE embedding that was obtained in (2). This process resulted in four clusters for which the top preferentially expressed genes included multiple known markers of particular cell types (see, e.g., Figures 69F,G). Alternatively, this process resulted in six clusters for which the top preferentially expressed genes included multiple known markers of particular cell types. [0603] To map between clusters and cell types Applicants compared each cluster to the other clusters according to the OE of the different cell type signatures (one sided t-test, Table 26A). The cell type signature that was most significantly (t-test p-value <10 ^"10 ) overexpressed in the cluster compared to all other clusters was used to define the cluster identity. In this manner, Applicants annotated the clusters as CD8 ⁺ and CD4 ⁺ T cells, B cells, and macrophages (see, e.g., Figure 62D). Alternatively, Applicants annotated the clusters as CD8 and CD4 T cells, B cells, macrophages, and neutrophils (Fig. 1C). Cells that clustered with the CD8 ⁺ T cells and did not express CD8A or CD8B were labeled as NK cells if they overexpressed NK markers, otherwise they were considered as unresolved T cells. T cells that were clustered together with the CD4 T cells and expressed CD8A or CD8B were also considered as unresolved T cells. Unresolved T cells were not used in further analyses.

[0604] To assess the robustness of the assignments, Applicants applied another approach, and determined the concordance between the two assignments. In the second approach, Applicants first made initial cell assignments based on the OE of well-established cell type markers: T cells (CD2, CD3D, CD3E, CD3G), B cells (CD19, CD79A, CD79B, BLK), and macrophages (CD163, CD14, CSF1R). Across all the CD45 ⁺ cells, the OE levels of these signatures had bimodal distributions. Applicants used the bimodal OE of each signature to assign cells to cell types (see Computing OE of gene signatures). Cells that were assigned to more than one cell type at this point were considered as unresolved. Cells that were defined as T cells according to this measure were further classified as CD8 ⁺ or CD4 ⁺ T cells if they expressed CD 8 (CD8A or CD8B) or CD4, respectively. T cells that expressed both CD4 and CD8 were considered as unresolved. As a result, 67.3% of the cells had an initial cell type assignment.

[0605] Next, Applicants clustered the cells with the Infomap algorithm (Rosvall and

Bergstrom, 2008). Infomap decomposes an input graph into modules by deriving a compressive description of random walks on the graph. The input to the algorithm was an unweighted &-NN graph (k = 50) that Applicants generated based on the expression of the

194 biomarker genes across the CD45 ⁺ cells. Infomap produced 22 clusters, separating the different CD45 ⁺ cells not only according to cell types but also according to various cell states.

For each cluster, Applicants examined if it was enriched with cells of a specific cell type, according to the initial assignments. Nineteen clusters were enriched with only one cell type.

The cells within these clusters were assigned to the cell type of their cluster, unless their initial assignment was different, and in this case, they were considered as unresolved. [0606] The cell type assignments that were obtained by the two approaches were highly concordant: 97% of the cells had the same assignment with both approaches.

[0607] Interactive visualization of the immune cells' tS E plots are provided in portals.broadinstitute.org/single_cell/study/melanoma-immuno therapy-resistance.

Data-driven signatures of specific cell types

[0608] To identify cell type signatures Applicants performed pairwise comparisons between the eight cell types that Applicants identified: malignant cells, CAFs, endothelial cells, NK cells, B cells, macrophages, and CD8 ⁺ and CD4 ⁺ T cells. Applicants performed these comparisons via one-sided Wilcoxon ranksum-tests on the normalized data E. Genes were considered as cell type specific if they were overexpressed in a particular cell type compared to all other cell types (Wilcoxon ranksum-test p-value <10 ^"5 ). For T cell types (CD8 ⁺ and CD4 ⁺ ) Applicants used more permissive cutoffs, as the transcriptional differences between these cell types are more subtle. To ensure that the genes are significantly higher in the specific T cell type across all pairwise comparisons, for each T cell type Applicants: (1) computed the least significant (maximal) p-value for each gene, when comparing its expression in the T cell type (CD8 ⁺ or CD4 ⁺ ) to its expression in each of the other cell types, (2) used the genes with the lowest maximal p-values to construct the signature (at most 50 genes with maximal P <2* 10 ^"3 ). To derive a Pan-T cell signature that characterizes both CD8 ⁺ and CD4 ⁺ T cells, Applicants used genes that were overexpressed in CD8 ⁺ and CD4 ⁺ T cells (P <10 ^"5 ) compared to all other cell types, when disregarding T cells and NK cells.

[0609] To derive CD8 ⁺ T cell state signatures Applicants: (1) classified CD8 ⁺ T cells as cytotoxic, exhausted, naive, or 'undetermined' based on well-established markers of these cell states (Table 26A); (2) performed pairwise comparisons between the different CD8 ⁺ T cell subsets to derive initial CD8 ⁺ T cell state signatures; (3) compared each CD8 ⁺ T cell subset to all other cell types {e.g., B cells, macrophages, etc.), and (4) filtered non-specific genes from the initial CD8 ⁺ T cell state signatures. Applicants performed the same analysis with CD4 ⁺ T cells to derive signatures of cytotoxic, exhausted, naive, and regulatory CD4 ⁺ T cells. The cytotoxic CD4 ⁺ T cells signature included only four genes and thus was not used in subsequent analyses.

[0610] Applicants also identified signatures of three broader cell type categories: immune cells, lymphocytes, and stromal cells. The immune cell signature includes genes that are overexpressed by all the immune cell types compared to all other non-immune cells, and likewise for the other two cell categories. The lymphocyte signature included only five genes and thus was not used in subsequent analyses.

[0611] The lists of cell subtype specific genes, which were identified as described above, are provided in Table 26B. The implementation of these analyses is provided via GitHub (github.com/livnatje/ImmuneResistance/wiki/Mapping-immune-re sistance-in-melanoma; see ImmResl denovoCellTypeSig.R), and can be applied to reproduce the cell subtype signatures and generate cell subtype signatures based on other scRNA-seq cohorts.

[0612] Alternatively, to identify cell-type signatures Applicants performed pairwise comparisons between the nine different cell types that Applicants identified: malignant cells, CD8 and CD4 T-cells, NK cells, B-cells, macrophages, neutrophils, CAFs, and endothelial cells. Applicants then performed pairwise comparisons between the different cell types via one-sided Wilcoxon ranksum-tests on the imputed and normalized data E '. Genes that were overexpressed in a particular cell subtype compared to all other cell subtypes (Wilcoxon ranksum-test p-value <10 ^"5 ) were considered as cell-type specific. For cell types with less than 1,000 cells Applicants also ranked the genes based on the maximal p-value that was obtained when comparing the cell type to each of the other cell types; the bottom 100 genes that also passed the first filter were considered as cell type specific. As CD8 T-cells and NK cells had similar expression patterns, Applicants excluded NK cells from the analysis when identifying T-cell specific genes. In the analyses described above Applicants considered the CD4 and CD8 as one entity of T-cells, but also derived CD4 and CD8 specific signatures, by considering as separated entities. The lists of cell-type specific genes are provided in table 3. Identifying the post-treatment program

[0613] To identify potential signatures of resistance, Applicants searched for transcriptional features that distinguish between the cells of TN (i.e., treatment naive, or untreated) and ICR patients (i.e., post-treatment), for each cell category separately. In certain examples, Applicants analyzed each cell type that had a sufficient number (>100) of cells: malignant cells, macrophages, B cells, CD8 and CD4 T cells.

[0614] Applicants identified genes differentially expressed between the malignant cells of untreated and post-treatment tumors by using a sub sampling approach that mitigates the effects of outliers and prevents tumors with a particularly large number of sequenced malignant cells from dominating the results. In each subsample, Applicants selected a subset of the tumors, subsampled at most 30 malignant cells from each tumor, and identified differentially expressed genes between the post-treatment and untreated cells. Differentially expressed genes were identified by applying SCDE (Kharchenko et al., 2014), a Bayesian method that was developed specifically to detect single-cell differential expression. As input to SCDE Applicants used the normalized and imputed expression matrix E ' (see Data imputation and normalization).

[0615] Applicants repeated the subsampling procedure 500 times, and computed for each gene g the fraction of subsamples in which it was found to be significantly under (Fdown, _g ) or over (F _U p,g) expressed in the post-treatment population compared to the untreated population (|z-score| > 1.96). Genes with Fdown.g values larger than the 0.9 quantile of the Fdown distribution were considered as potentially down-regulated in the post-treatment malignant cells. Likewise, genes with F _up , _g values larger than the 0.9 quantile were considered as potentially up-regulated in the respective post-treatment malignant cells.

[0616] Applicants further filtered the signatures with two additional statistical tests that Applicants applied on the full scRNA-seq data (Ε ') of the malignant cells. The first test was SCDE followed by multiple hypotheses correction (Holm-Bonferroni (Holm, 1979)). The second was a non-parametric empirical test, where Applicants performed a Wilcoxon ranksum test to examine if a given gene is differentially expressed in the post-treatment vs. untreated cells, based on E '. Applicants corrected for multiple hypotheses testing using the Benjamini-Hochberg False Discovery Rate (FDR) (Benjamini and Hochberg, 1995), and obtained empirical p-values to ensure the differences in expression were not merely reflecting differences in cell quality (i.e., the number of aligned reads per cell). To this end, Applicants generated 1,000 random permutations of the gene expression matrix E ', such that each permutation preserves the overall distribution of each gene, as well as the association between the expression of each gene and cell quality. Applicants performed the Wilcoxon ranksum test on the permuted E ' matrixes to compute empirical p-values.

[0617] To assemble the final post-treatment signatures, Applicants selected genes that fulfilled the subsampling criteria described above and were most significantly differentially expressed according to both the SCDE and empirical tests (top 200 genes with corrected P <0.05).

[0618] The implementation of these analyses is provided via GitHub (github.com/livnatje/ImmuneResistance/wiki/Mapping-immune-re sistance-in-melanoma; ImmResl immuneResistanceProgram.R), and can be applied to regenerate the post-treatment signatures from the data.

Identifying differentially expressed gene sets [0619] To test the ability of a given gene signature to distinguish between the malignant cells collected from post-treatment vs. untreated patients Applicants modeled the data with a mixed-effects model that accounts for the dependencies and structure of the data. The model had overall five covariates and two levels: (1) a cell-level, and (2) a sample-level. Level-1 covariates controlled for cell quality by providing the number of reads (log-transformed) and the number of genes that were detected in each malignant cell, and denoted which cells were cycling, based on the bimodal OE of the cell cycle signatures defined in (Tirosh et al., 2016). Level -2 covariates were the patient's gender, age, and treatment group, and a binary covariate that denotes if the sample was a metastatic or a primary lesion. The sample-level controlled for the dependency between the scRNA-seq profiles of malignant cells that were obtained from the same patient, having a sample-specific intercept. Using this model Applicants quantified the significance of the association between the treatment covariate and the OE of a given signature across the malignant cells. Applicants implemented the mixed-effects model in R, using the lme4 and ImerTest packages (CRAN.R-project.org/package=lme4, CRAN.R- project.org/package=lmerTest).

[0620] Applicants applied this approach to test the post-treatment and exclusion programs defined here, as well as annotated pre-defined gene sets downloaded from MSigDB v6.0 (Subramanian et al., 2005). The results are provided in Tables 4, 8 and Figures 2C and 63D

Cross validation analysis

[0621] To examine the generalizability of the post-treatment signatures Applicants performed a cross-validation procedure. In each cross-validation round the test set consisted of all the cells of one patient, and the training set consisted of the data from all the other patients in the cohort. In each round, Applicants used only the training data to generate post- treatment signatures (as described in Identifying the post-treatment program), and computed the OE of the resulting post-treatment program. To center the expression matrix for the computation of the OE values, Applicants used all the malignant cells in the data, such that the OE scores of one patient were relative to those of the other patients. Finally, Applicants computed Receiver Operating Characteristic (ROC) curves based on the resulting post- treatment OE scores, obtained for the test set. In an example, Applicants computed the OE of the resulting mICR (post-treatment) signatures in the cells of the test patient to obtain their resistance scores (mICR-up minus mICR-down).

Integrating the exclusion and post-treatment programs [0622] Applicants combined the post-treatment and exclusion programs with a simple union of the matching signatures, into the immune resistance program (Table 27A and Table 28). To give more weight to genes that are included in both signatures Applicants compute the OE of the resistance program by averaging the OE of the exclusion and post-treatment programs.

[0623] Applicants further refined the immune resistance program by integrating the scRNA-seq data with the results of a genome-scale CRISPR screen that identified gene KOs which sensitize malignant melanoma cells to T cell killing (Patel et al., 2017). Applicants defined the single malignant cells as putatively "resistant" if they underexpressed (lowest 1%) one of the top hits of the screen: B2M, CD58, HLA-A, MLANA, SOX10, SRP54, TAP2, TAPBP. This underexpression did not reflect low cell quality, because these "resistant" cells had a higher number of genes and reads. These cells had significantly higher immune resistance scores (P = 2.24* 10 ^"18 and 1.59* 10 ^"3 , t-test and mixed-effects, respectively), and were enriched with cycling cells (P = 1.74* 10 ^"13 , hypergeometric test). Applicants derived a functional resistance program that consists of differentially expressed genes when comparing the "resistant" cells to other malignant cells (Table 27A). Applicants then refined the resistance score by adding to it also the OE of this functional program (note that this purposely increases the contribution to the score of genes that are both in the original resistance program and are identified by this additional comparison). In another example, Applicants identified the topmost differentially expressed genes by comparing the "resistant" cells to other malignant cells, and included in the refined immune resistance-up (down) signature only 25 immune resistance-up (down) genes that pass this additional differential expression test.

[0624] Applicants report the performances of all the resistance program subsets: exclusion, post-treatment, and their (weighted) union, with and without the functional refinement (Figures 73 and 74 and Tables 27-28). As comparators, Applicants used the hits of the co-culture screen along with other potentially prognostic signatures, to generate competing predictors of patient survival and response (Figures 66G,H _? 4E,H and 5E,H? and

Tables 29A, 30 and 9 see section Competing ICI response predictors).

Exploring the association between the immune resistance program and cell cycle

[0625] Applicants applied two approaches to examine the association between the immune resistance program and cell cycle: (1) Applicants detected immune resistance genes when using only non-cycling malignant cells, and (2) Applicants used all the data after filtering cell cycle effects. Applicants start by computing the OE of two cell cycle signatures (Gl/S and G2/M, Table 26A) (Tirosh et al., 2016) across the malignant cells and bulk melanoma TCGA tumors.

[0626] In the first approach Applicants classified malignant cell as cycling or non- cycling, and confirmed that the immune resistance program can be recovered also when excluding all cycling cells from consideration. More specifically, when analyzing only the non-cycling malignant cells, all but two of the genes in the post-treatment signatures were still significantly differentially expressed between the untreated and post-treatment tumors, and all genes from the exclusion program were still significantly associated with T cell exclusion.

[0627] In the second approach Applicants re-generated the program based on all the data while controlling for cell cycle as a potential confounder. In the case of the exclusion signatures, Applicants provided these cell cycle scores as confounding factors in the partial correlation analyses (see steps 2 and 3 in Identifying cell states associated with specific tumor compositions). In the case of the post-treatment signatures, Applicants filtered out the cell cycle features from the data using PAGODA (Fan et al., 2016) (using pagoda.subtract.aspect) and regenerated the post-treatment signature. This regression successfully masked the differences between cycling and non-cycling cells, for example, when considering cell cycle genes (Figure 70F). However, it did not mask the association between cycling cells and the expression of the immune resistance genes (Figures 70G-H).

[0628] The resistance program that Applicants generated after filtering cell cycle effects (Table 27B) was very similar to the original one (P < 1 * 10 ^"17 , hypergeometric test, Jaccard index = 0.56 and 0.66, induced and repressed signatures, respectively; Figure 70D). Lastly, the OE of the two programs was highly correlated across the malignant cells (r = 0.99, P < 1 * 10 ^"17 ), such that cycling cells overexpressed both programs (P < 3.48* 10 ^"7 , mixed-effects; Figure 70E)

[0629] In another example, Applicants performed the following analysis to identify gene modules that characterize cycling cells specifically in CD8 T-cells (table 7). First, Applicants identified cycling cells in the CD8 T-cells and in the malignant cells based on the bimodal

OE of a cell-cycle signature (the GO gene set cell cycle process, as defined in the Overall

Expression (OE) of gene signatures section). Applicants then identified differentially expressed genes (with SCDE {13)) between the cycling and non-cycling cells, separately in the CD8 T-cells and in the malignant cells. Lastly, Applicants filtered from the resulting CD8 T-cell cycling signatures the genes that were also included in the corresponding malignant signatures.

Cell-cell interaction network

[0630] Applicants generated genome-scale cell-cell interactions networks by integrating (1) protein-protein interactions that were previously assembled by (Ramilowski et al., 2015) as cognate ligand-receptor pairs, with (2) cell subtype specific signatures from the single-cell profiles, identified as described above in Data-driven signatures of specific cell types. The resulting network maps the physical interactions between the different cell subtypes that Applicants characterized. Each cell subtype and protein are represented by a node in the network. An edge between a cell subtype node and a ligand or receptor node denotes that this protein is included in the cell-subtype signatures. An edge between two proteins denotes that they can physically bind to each other and mediate cell-cell interactions. A path from one cell subtype to another represents a potential route by which the cells can interact. For each cell subtype, Applicants defined a 'communication signature', which includes all the surface proteins that can bind to this cell subtype signature proteins. To examine if the immune resistant malignant cells suppress their interactions with other cell subtypes Applicants examined if the different immune resistance signatures were enriched (hypergeometric test) with genes from the different immune and stroma 'communication signatures' (see, e.g., Figure 3E and 64B). An interactive map of the cell-cell interaction network is provided in portals. broadinstitute. org/single_cell/study/melanoma-immunotherapy -resistance#study- download, and can be explored with Cytoscape www.cytoscape.org.

Clinical longitudinal analysis (validation cohort 1)

[0631] Applicants used a mixed-effects model to represent the longitudinal treatment data

(Figure 62A, validation cohort 1) and examine the association between the expression of various gene signatures and different treatment categories. The model included two levels: a sample-level and a patient-level. The sample-level had overall 8 covariates: three treatment covariates and five tumor microenvironment covariates. The sample-level treatment covariates denote in this case whether the sample was exposed to: (1) targeted therapy

(on/post RAF/MEK-inhibitors), (2) ICI (on/post), or (3) non-ICI immunotherapy (NK antibodies, IL2, IFN, or GM CSF) without ICI. The five sample-level tumor microenvironment covariates control for potential changes in the tumor composition by providing the OE of the different nonmalignant cell type signatures that Applicants identified

(Table 26B). The patient-level controlled for the dependency between the scRNA-seq profiles of samples that were obtained from the same patient, having a patient-specific intercept. The dependent variable was the OE of a given signature, which enabled us to quantify the association between the immune resistance program (or any other signature) and the exposure to ICI or targeted therapy (the second and first sample-level covariates, respectively). The implementation of this model is provided via GitHub (github.com/livnatje/ImmuneResistance/wiki/Predicting-immuno therapy-resistance;

ImmRe s 3 longitudinal. R) .

[0632] In another example, Applicants used a mixed-effects model to represent the data and examine the association between the expression of various gene signatures and different treatment categories. The model included two levels. The first, sample-level, had 12 covariates, the first three denote whether the sample was exposed to: (1) targeted therapy (on/post RAF/MEK-inhibitors), (2) ICI (on/post), with or without an additional immunotherapy, (3) non-ICI immunotherapy (NK antibodies, IL2, IFN, or GM CSF) without ICI. The other 9 sample-level covariates control for potential changes in the tumor microenvironment by providing the OE of the different non-malignant cell subtype signatures that Applicants identified (table 3). The second, patient-level, controlled for the dependency between the scRNA-seq profiles of samples that were obtained from the same patient, having a patient-specific intercept that provided the baseline level for each patient.

[0633] Applicants used the mixed effects model to quantify the association between the different ICR signatures and the exposure to ICI or targeted therapy (the second and first sample-level covariates, respectively). When testing the association between the tumor composition and the treatments Applicants used the model described above without the 9 TME covariates.

[0634] Applicants implemented the HLM model in R, using the lme4 and lmerTest packages (CRAN.R-project.org/package=lme4, CRAN.R-project.org/package=lmerTest).

[0635] For each resistance signature, Applicants applied ANOVA to test if the inter- patient variation in the OE values was significantly greater than the intra-patient variation, and reported the least significant ANOVA p-value that was obtained.

The immune resistance program vs. resistance to MAPK inhibitors

[0636] To test if the immune resistance program is related to resistance to MAPK inhibitors Applicants analyzed a published clinical cohort of patient-matched melanoma tumors biopsied before MAPK inhibitor therapy and during disease progression (Hugo et al.,

2015). Applicants used the same mixed-effects model described above (Clinical longitudinal analysis (validation cohort 1)), except that instead of three treatment covariates Applicants had only one, denoting if the sample was pre or post MAPKi treatment. The implementation of this analysis and its application to this published cohort is provided via GitHub (github.com/livnatje/ImmuneResistance/wiki/Predicting-immuno therapy-resistance;

ImmRes3 1 ongitudinal . R) .

Multiplexed, tissue cyclic immunofluorescence (t-CyCIF) of FFPE tissue slides

[0637] Formalin-fixed, paraffin-embedded (FFPE) tissue slides, 5 μπι in thickness, were generated at the Brigham and Women's Hospital Pathology Core Facility from tissue blocks collected from patients under IRB-approved protocols (DFCI 11-104). Multiplexed, tissue cyclic immunofluorescence (t-CyCIF) was performed as described recently (Lin et al., 2018). For direct immunofluorescence, Applicants used the following antibodies: CEP 170 (Abeam, ab84545), LAMP2 (R&D technologies, AF6228), MITF (Abeam, ab3201), DLL3 (Abeam, abl03102, Rab), MITF (Abeam, ab3201, Ms), S100a-488 (Abeam, ab207367), CD3-555 (Abeam, ab208514), CD8a-660 (eBioscience, 50-0008-80), cJUN-488 (Abeam, abl93780), cMyc-555 (Abeam, ab201780), HLAA-647 (Abeam, abl99837), TP53-488 (Cell Signaling, 5429), SQSTM1-555 (Abeam, ab203430). Stained slides from each round of CycIF were imaged with a CyteFinder slide scanning fluorescence microscope (RareCyte Inc. Seattle WA) using either a 10X (NA=0.3) or 40X long-working distance objective (NA = 0.6). Imager5 software (RareCyte Inc.) was used to sequentially scan the region of interest in 4 fluorescence channels. Image processing, background subtraction, image registration, single- cell segmentation and quantification were performed as previously described (Lin et al., 2018).

Mapping cell-cell interactions based on in situ imaging data

[0638] Given the processed imaging data, Applicants assigned cells into cell types by discretizing the log-transformed expression levels of the cell type markers (S100, MITF, CD3, and CD8). Applicants applied the EM algorithm for mixtures of normal distributions to characterize the two normal distributions for each of these cell type marker intensities. S100 ⁺ /MITF ⁺ /CD37CD8- cells were defined as malignant cells; S1007MITF7CD3 ⁺ /CD8- cells were defined as T cells, and S100 /MITF 7CD3 ⁺ /CD8 ⁺ cells were defined as CD8 ⁺ T cells; other cells were defined as uncharacterized.

[0639] For each image Applicants constructed a Delaunay (Gabriel) graph, where two cells are connected to each other if there is no other cell between them. Following the approach presented in (Goltsev et al., 2017), Applicants examined if cells of certain types were less/more likely to be connected to each other in the graph. To this end, Applicants computed the odds ratio of cell-cell interactions of cell type A and cell type B by computing the observed frequency of interactions divided by the expected theoretical frequency

(calculated as the total frequency of edges incident to type A multiplied by the total frequency of edges incident to type B). Two cell types are less or more likely to interact than expected by chance if the log-transformed odds ratio is less or more than 0, respectively. The significance of the deviation from zero was tested using the binomial distribution test.

[0640] For each malignant cell, Applicants computed an immune resistance score based on the in situ protein levels of the immune resistance markers. First, Applicants centered and scaled the log-transformed expression of each protein across the malignant cells from all images (to have a zero average and a standard deviation of 1). Using this normalized data,

Applicants computed the resistance-up score as the sum expression of p53, DLL3, and Myc, the resistance-down score as the sum of HLA-A, Jun, LAMP2, and SQSTM1, and the final resistance score by subtracting the resistance-down score from the resistance-up score. The average resistance score of the malignant cells in each image was used as the in situ resistance score of the corresponding tumor. Applicants then compared these tumor resistance scores to those computed based on the scRNA-seq data from the same patient.

[0641] Next, Applicants examined the association between the expression of the individual markers and the overall resistance score in the malignant cells and the level of T cell infiltration. Each image in the data was composed of a few hundred frames (119-648 frames/image), where each frame consists of 1,502 cells on average. In each frame,

Applicants computed: (1) the fraction of T cells, (2) the average expression of the individual markers in the malignant cells, and (3) the average immune resistance (as above) across the malignant cells. Applicants used a hierarchical logistic regression model to quantify the associations between the expression of the individual markers (or overall resistance score) in the malignant cells (2-3) and the fraction of T cells (1). The independent variables included the average expression of the marker (or the average immune resistance score) in the malignant cells of the frame (level-1), the average expression of normalization markers in the malignant cells of the frame (level-1), and the image the frame was sampled from (level-2).

The dependent variable was the discretized T cell infiltration level of the frame, defining frames with high/low lymphocyte-fraction as "hot"/" cold", respectively. Applicants used different cutoffs to define hot/cold frames, such that a frame with a T cell fraction below the

Q quantile was defined as cold, and a T cell fraction above the 1-Q quantile was defined as hot. Applicants report only markers that showed a consistent association with the "hot" or "cold" niche, when starting with a cutoff of Q = median (0.5), and then using increasingly more stringent cutoffs (0.4, 0.3, 0.2 and 0.1). Applicants provide the p-values obtained with 2 = 0.2.

Integrating scRNA-seq and spatial data

[0642] Applicants integrated the scRNA-seq and multiplexed immunofluorescence (t- CyCIF) data via a variant of Canonical Correlation Analysis (CCA), using the code provided in the R toolkit Seurat (Butler and Satija, 2017). CCA aims to identify shared correlation structures across datasets, such that each dataset provides multiple measurements of a gene- gene covariance structure, and patterns which are common to both datasets are identified. Cells from both sources are then represented in an aligned-CCA space (Butler and Satija, 2017).

[0643] In the application, each cell in the t-CyCIF data was represented by the log- transformed intensities of 14 markers. Each cell in the scRNA-seq data was represented by the imputed expression of the genes encoding the same 14 proteins. To impute the scRNA- seq data Applicants identified a signature for each marker, consisting of the top 50 genes which were mostly correlated with the marker expression across the cell population in the scRNA-seq data. Applicants then used the OE of the marker signature as a measure of its activity in the scRNA-seq data.

[0644] The cells from both sources were represented in the resulting aligned-CCA space. Next, Applicants used the first five aligned-CCA dimensions to cluster the cells and represented them in a 2D t-SNE embedding (van der Maaten and Hinton, 2008). Clustering was preformed using a shared nearest neighbor (SNN) modularity optimization based clustering algorithm, which calculates k-nearest neighbors, constructs an SNN graph, and optimizes the modularity function to determine clusters (Waltman and van Eck, 2013).

[0645] To examine if cells clustered according to cell type or according to source Applicants computed the expected number of cells from each two categories to be assigned to the same cluster by chance, assuming a random distribution of cells into clusters. Applicants then used the observed vs. expected co-clustering ratio to quantify the deviation from the random distribution, and used the binomial test to compute the statistical significance of this deviation from random.

Survival and ICI-response predictions [0646] To test if a given signature predicts survival or progression free-survival (PFS) Applicants first computed the OE of the signature in each tumor based on the bulk RNA-Seq data. Next, Applicants used a Cox regression model with censored data to compute the significance of the association between the OE values and prognosis. To examine if the signature's predictive value was significant beyond T cell infiltration levels Applicants computed for each sample the OE of the CD8 ⁺ T cell signature (above), used this as another covariate in the Cox regression model, and computed another p-value for each signature, based on its association with survival or PFS in this two-covariate model.

[0647] To visualize the predictions of a specific signature in a Kaplan Meier (KM) plot, Applicants stratified the patients into three groups according to the OE of the signature: high or low expression correspond to the top or bottom 25% of the population, respectively, and intermediate otherwise. Applicants used a one-sided log-rank test to examine if there was a significant difference between these three patient groups in terms of their survival or PFS rates.

[0648] OR (or CB) was defined according to RESICT criteria, such that patients with a complete or partial response were defined as OR patients. Patients with progressive disease were defined as PD, and patients with more ill-defined response, such as stable disease or marginal responses, were excluded from this analysis. Applicants further stratified the OR patients according to the duration of the response: (1) less than 6 months, (2) more than 6 months and less than a year, and (3) more than a year (long-term OR). Applicants applied one-sided t-tests to examine if the OE of the different signatures were differentially expressed in the OR vs. PD patients, or in the long-term OR patients compared to the PD patients. Finally, Applicants tested the ability of the different signatures to predict complete response by comparing (t-test) between the complete responders and all other patients with a RECIST annotation (n = 101, see, e.g., Figures 4H, 14, 48H and 66H), and computing the Area Under the Curve (AUC) of the resulting ROC curve.

[0649] To reproduce this analysis and results see ImmRes valCohort2.R provided in github . com/livnatj e/ImmuneResi stance/wiki/Predi cting-immunotherapy-resi stance (relevant functions are included in ImmRes5 valCohort2.R).

Controlling for cell cycle effects in the immune resistance OE scores

[0650] The single-cell data demonstrated that cycling cells have higher expression of the immune resistant program. Since the tumor proliferation rate may be a dynamic and context- dependent property, it might be advisable to compare between tumors based on their basal resistance level, namely, after controlling for the cell cycle effect. To this end, Applicants compute for each tumor the OE of two cell cycle signatures (Gl/S and G2/M signatures in Table 26A and 9). Applicants then fitted a linear model to estimate the expected OE of the resistance signature, when using the OE of the two cell cycle signatures as covariates. The residuals of this linear model, which quantify the deviation from the expected resistance OE values, were considered as the basal resistance level. In an example, Applicants preformed this analysis with different resistance signatures (e.g., uICR, exclusion, etc.).

Alternative ICI response predictors

[0651] To compare the predictive value of the resistance signatures to that of other signatures, Applicants repeated the prediction process, as describe in Survival and ICI response predictions, for each of the following gene signatures (Table 29 and 9): (1) cell type specific signatures identified from the scRNA-seq data (as described in the Data-driven signatures of specific cell types section); (2) signatures that characterize melanoma cell states (the AXL-high, MITF-high, and cell cycle states from (Tirosh et al., 2016)); (3) six sets of genes whose CRISPR knockout in melanoma cells conferred resistance or sensitivity (FDR < 0.05) to different types of immune killing according to a genome-scale in vivo screen (Manguso et al., 2017); (4) genes whose CRISPR knockout in melanoma cells conferred resistance to T cell killing (top 10 and top 50) in a genome-scale co-culture screen (Patel et al., 2017); (5) immune-related signatures that were identified based on the analysis of multiple pembrolizumab clinical datasets, and were shown to predict the response to pembrolizumab in an independent cohort (Ayers et al., 2017); (6) the Fluidigm Advanta™ Immuno-Oncology Gene Expression signatures (www.fluidigm.com/applications/advanta- immuno-oncology-gene-expression-assay); (7) immunotherapy resistance signatures identified in a clinical cohort of pre and post nivolumab treated melanomas (Riaz et al., 2017); (8) immune related signatures identified in a clinical melanoma cohort (Hugo et al., 2015) (9) immunotherapy resistance signatures identified in a clinical cohort of pre-anti-PDl melanoma tumors (Hugo et al., 2016) and (10) PD-L1 expression.

[0652] Applicants summarize in table 9 the predictive value of each of these signatures when applied to predict melanoma (TCGA) patient survival, and the PFS, clinical benefit (CB), and complete response in the melanoma patients of the aPDl cohort.

Searching for immune sensitizing drugs

[0653] Applicants performed the following analysis to identify drugs that could selectively eradicate malignant cells with a high expression of the resistance program, using efficacy measures of 131 drugs across 639 human cancer cell lines (Garnett et al., 2012). For each drug, Applicants defined sensitive cell lines as those with the lowest (bottom 25%, however, the bottom 10% were previously used to define sensitive cell lines) IC50 values. Applicants then used the gene expression provided in (Garnett et al., 2012), computed the OE of the resistance program in each of the 639 cells, and defined "resistant" cell lines as those with the highest OE values (top 25%, or previously, top 10%). Next, for each drug Applicants built a hierarchical logistic regression model, where the dependent variable is the cell line's (drug-specific) binary sensitivity assignment, and the independent variables are the cell lines' "resistance" assignments (level-1) and cancer types (level-2). Drugs then were ranked based on the one-tailed p-values that quantify the significance of the positive association between the drug sensitivity (dependent) variable and the immune resistance (independent) variable.

[0654] To reproduce this analysis and results see github.com/livnatje/ImmuneResistance/wiki/Repressing-the-imm une-resistance-program. Abemaciclib treatment of melanoma cell lines

[0655] Established melanoma cell lines IGR39, UACC62 and A2058 were acquired from the Cancer Cell Line Encyplopedia (CCLE) from the Broad Institute. Cells were treated every 3 days with 500 nM abemacilib (LY2835219, MedChemExpress) or DMSO control. The doubling time of each cell line was established and lines were seeded such that cells collected for scRNA-seq were derived from culture dishes with -50-60% confluency on day 7 of treatment. Cells were lifted off culture dishes using Versene solution (Life Technologies), washed twice in lx PBS, counted and resuspended in PBS supplemented with 0.04%) BSA for loading for scRNA-seq with the 10X Genomics platform.

Melanoma- TIL co-culture

[0656] An autologous pair of melanoma and TIL culture was provided by MD Anderson Cancer Center and were established using previously described protocols (Peng et al., 2016). Melanoma cells were pre-treated with 500 nM abemaciclib or DMSO control for 7 days followed by co-culture with autologous TILs (with an effector to target ratio of 5: 1) for 48 hours. TILs were removed by pipetting of the supernatant, and the remaining melanoma cells were washed twice with PBS, lifted off the culture dish, and resuspended in PBS supplemented with 0.04% BSA for loading for scRNA-seq with the 10X Genomics platform. Mouse experiments [0657] All experiments were performed in accordance with the Dana-Farber Cancer Institute (DFCI) IACUC guidelines at the DFCI Longwood Center Animal Resource Facility per protocol 08-049. 5.0 * 10 ⁵ B16F10 cells were subcutaneously injected into 6 weeks old female C57BL/6 mice (The Jackson Laboratory). Four or seven days after injection, animals were treated with either (1) isotype control antibody injected intraperitoneally (2A3 and polyclonal Syrian hamster IgG, 200μg/mouse and 100μg/mouse, respectively) every 3 days for a total of 4 doses; (2) abemaciclib 90 mg/kg daily administered by oral gavage (LY2835219, MedChemExpress) for a total of 10 doses; (3) combination immune checkpoint blockade (ICI) with aPD-1 (clone 29F.1A12, 200μg/mouse) plus aCTLA-4 (clone 9H10, #BP0131, 100μg/mouse) every 3 days for a total of 4 doses; (4) abemaciclib (90mg/kg) daily for 4 days followed by ICI every 3 days for a total of 4 doses; (5) ICI for one initial dose followed 3 days later by abemaciclib (90mg/kg) daily combined with ICI every 3 days for an additional 3 doses; or (6) upfront combination of ICI and abemaciclib (75mg/kg) every 3 days for a total of 4 doses. CD8 ⁺ T cell depletion was achieved using CD8b mAb (clone53- 5.8, #BE0223, 100μg/mouse) that was administered on day-1, day 0 once a week until the end of the experiment. Tumor size was measured using digital calipers every 3 days. Tumor volume was determined by calculating (length x width ² )/2. Growth curves and survival curves were generated using GraphPad Prism v8.

Abemaciclib doubling time and cytostatic effect

[0658] 5 x 10 ⁴ human melanoma cells (Melanoma cell line 2686, provided by MDACC) were seeded and treated with either DMSO or 500 nM abemaciclib (LY2835219, MedChemExpress) daily for a total of 6 days. Cell number and viability were determined using the Countess™ II FL Automated Cell Counter (Therm oFisher) on days 2, 4 and 6. All experiments were performed in triplicates. Cell doubling per 24 hours was determined based on cell numbers comparing cells seeded and on day 6 using the following formula: duration (in days) x log(2)/log(final cell number) - log(initial cell number).

Mouse melanoma cell line culture and profiling

[0659] B16F10, MC38 and CT26 cell line were obtained from American Type Culture

Collection (ATCC). B16F10 cells were maintained in complete DMEM media (10% FBS and 50U/ml of Penicillin-Streptomycin). MC38 and CT26 were maintained in RPMI-1640

(10%) FBS and 50U/ml of Penicillin-Streptomycin). For scRNA-seq, cells were washed twice with PBS, incubated with trypsin 0.05%> for 2 minutes at 37°C, quenched with complete media, and resuspended in PBS supplemented with 0.04%> BSA prior to loading onto the Chromium 10X platform and processed as described above. All cell lines were tested for Mycoplasma.

Data and code availability

[0660] Processed scRNA-seq data generated for this study, and the Overall Expression of the different signatures that were used in the analysis of the two clinical validation cohorts, are provided through the Single Cell Portal along with interactive plots at the following URL: portals.broadinstitute.org/single_cell/study/melanoma-immuno therapy-resistance. The processed scRNA-seq data is also provided via the Gene Expression Omnibus (GEO), accession number GSE115978. The raw scRNA-seq data is being deposited in dbGAP.

[0661] All the relevant code, with instructions is provided via GitHub github.com/livnatje/ImmuneResistance. The code enables one to repeat the analyses that were performed, reproduce the results, figures, and tables, and apply the computational approaches to other datasets.

T cell cytotoxicity and exhaustion signature analysis

[0662] The analysis of T-cell exhaustion vs. T-cell cytotoxicity was performed as previously described (Hugo et al., 2016), with six different exhaustion signatures, as provided in (Sharma, et al., 2015) and (Li et al., 2017). First, Applicants computed the cytotoxicity and exhaustion scores of each CD8 T cell. Next, to control for the association between the expression of exhaustion and cytotoxicity markers, Applicants estimated the relationship between the cytotoxicity and exhaustion scores using locally-weighted polynomial regression (LOWESS, black line in Fig. IE and 8B). Based on these values, Applicants defined T cells as functional if they fulfilled two criteria: (1) their cytotoxicity score was at the top 20% of the CD8 T cell population (across all patients), and (2) their exhaustion scores were lower than expected given their cytotoxicity scores (below the dashed line in Fig. IE and 8B). Applicants then applied a hypergeometric test to examine if the CD8 T cells of a given patient were enriched with functional cells.

Identifying T cell clones and estimating the fraction of clonally expanded T-cells

[0663] Applicants reconstructed the T-cell Receptors (TCRs) using TraCeR (Eisenhauer et al., 2009), with the Python package provided in github.com/Teichlab/tracer. TCR reconstruction significantly improved in the new cohort compared to previously analyzed patients (table 1): 92% CD8 T-cells had reconstructed TCRs, compared to only 50% such cells in the previously published cohort (fig. 9A). This is likely due to shorter read length and lower sequencing depth in the previous study (Sharma, et al., 2015). Applicants assigned T cells to the clones defined in the TraCeR output. Reassuringly, cells from different patients were never falsely assigned to the same clone, and CD8 and CD4 T-cells were always assigned to different clones, even when they were obtained from the same tumor. In the CD8 T-cells Applicants detected 137 clones (Fig. IF). In the CD4 T-cells Applicants detected only 29 clones, with at most 3 cells per clone.

[0664] The size and number of clones that Applicants identified in each tumor is affected by the number of T-cells that were sequenced from that tumor, and the success rate of TCR reconstruction. To estimate the fraction of clonally expanded T-cells in a given tumor Applicants therefore sampled its T-cells as follows. First, Applicants restricted the analysis to tumors with at least 20 CD8 T-cells with a full-length reconstructed TCR. Next, Applicants repeatedly sampled 20 cells from each tumor, such that, in each iteration, Applicants computed for every tumor the fraction of clonally expanded cells, namely, the fraction of sampled cells that shared their TCR with another cell within the sampled population. The average fraction of clonally expanded cells was used as an estimate of the T-cell clonal expansion level (fig. 9B).

References

Akbani, R., Akdemir, K.C., Aksoy, B.A., Albert, M., Ally, A., Amin, S.B., Arachchi, H., Arora, A., Auman, J.T., Ayala, B., et al. (2015). Genomic Classification of Cutaneous Melanoma. Cell 161, 1681-1696.

Algazi, A.P., Tsai, K.K., Shoushtari, A.N., Munhoz, R.R, Eroglu, Z., Piulats, J.M., Ott, P. A., Johnson, D.B., Hwang, J., Daud, A.I., et al. (2016). Clinical outcomes in metastatic uveal melanoma treated with PD-1 and PD-L1 antibodies. Cancer 722, 3344-3353.

Ayers, M., Lunceford, J., Nebozhyn, M., Murphy, E., Loboda, A., Kaufman, D.R., Albright, A., Cheng, J.D., Kang, S.P., Shankaran, V., et al. (2017). IFN- y -related mRNA profile predicts clinical response to PD-1 blockade. J. Clin. Invest. 727, 2930-2940.

F. Azimi et al., Tumor-Infiltrating Lymphocyte Grade Is an Independent Predictor of Sentinel Lymph Node Status and Survival in Patients With Cutaneous Melanoma. J. Clin. Oncol. 30, 2678-2683 (2012).

Barretina, J., Caponigro, G., Stransky, N., Venkatesan, K., Margolin, A.A., Kim, S., Wilson, C.J., Lehar, J., Kryukov, G.V., Sonkin, D., et benjal. (2012). The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity. Nature 483, 603- 607.

Benjamini, Y., and Hochberg, Y. (1995). Controlling the False Discovery Rate: A Practical and Powerful Approach to Multiple Testing. J. R. Stat. Soc. Ser. B Methodol. 57, 289-300.

D. Bogunovic et al., Immune profile and mitotic index of metastatic melanoma lesions enhance clinical staging in predicting patient survival. Proc. Natl. Acad. Sci. U. S. A. 106, 20429-20434 (2009).

Butler, A., and Satija, R. (2017). Integrated analysis of single cell transcriptomic data across conditions, technologies, and species. BioRxiv 164889.

Carter, S.L., Cibulskis, K., Helman, E., McKenna, A., Shen, H., Zack, T., Laird, P.W., Onofrio, R.C., Winckler, W., Weir, B.A., et al. (2012). Absolute quantification of somatic DNA alterations in human cancer. Nat. Biotechnol. 30, 413-421.

M. Challa-Malladi et al., Combined genetic inactivation of p2-Microglobulin and CD58 reveals frequent escape from immune recognition in diffuse large B cell lymphoma. Cancer Cell. 20, 728-740 (2011).

Curran, M.A., Montalvo, W., Yagita, H., and Allison, J.P. (2010). PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors. Proc. Natl. Acad. Sci. U. S. A. 107, 4275-4280.

Deng, J., Wang, E.S., Jenkins, R.W., Li, S., Dries, R., Yates, K., Chhabra, S., Huang, W., Liu, H., Aref, A.R., et al. (2018). CDK4/6 Inhibition Augments Antitumor Immunity by Enhancing T-cell Activation. Cancer Discov. 8, 216-233.

Dobin, A., Davis, C.A., Schlesinger, F., Drenkow, J., Zaleski, C, Jha, S., Batut, P., Chaisson, M., and Gingeras, T.R. (2013). STAR: ultrafast universal RNA-seq aligner. Bioinforma. Oxf. Engl. 29, 15-21.

E. A. Eisenhauer et al., New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur. J. Cancer Oxf. Engl. 1990. 45, 228-247 (2009).

Ester, M., Kriegel, H.-P., Sander, J., and Xu, X. (1996). A density-based algorithm for discovering clusters a density-based algorithm for discovering clusters in large spatial databases with noise. In Proceedings of the Second International Conference on Knowledge Discovery and Data Mining, (Portland, Oregon: AAAI Press), pp. 226-231. Fan, J., Salathia, N., Liu, R, Kaeser, G.E., Yung, Y.C., Herman, J.L., Kaper, F., Fan, J.-B., Zhang, K., Chun, J., et al. (2016). Characterizing transcriptional heterogeneity through pathway and gene set overdispersion analysis. Nat. Methods 13, 241-244.

Feng, Y., Yao, Z., and Klionsky, D.J. (2015). How to control self-digestion: transcriptional, post-transcriptional, and post-translational regulation of autophagy. Trends Cell Biol. 25, 354-363.

Fridman, W.H., Pages, F., Sautes-Fridman, C, and Galon, J. (2012). The immune contexture in human tumours: impact on clinical outcome. Nat. Rev. Cancer 12, 298-306.

J. Gao et al., Loss of IFN-γ Pathway Genes in Tumor Cells as a Mechanism of Resistance to Anti-CTLA-4 Therapy. Cell. 167, 397-404.e9 (2016).

Garnett, M.J., Edelman, E.J., Heidorn, S.J., Greenman, CD., Dastur, A., Lau, K.W., Greninger, P., Thompson, I.R., Luo, X., Soares, J., et al. (2012). Systematic identification of genomic markers of drug sensitivity in cancer cells. Nature 483, 570-575.

G. T. Gibney, L. M. Weiner, M. B. Atkins, Predictive biomarkers for checkpoint inhibitor based immunotherapy. Lancet Oncol. 17, e542-e551 (2016).

Goel, S., DeCristo, M.J., Watt, A.C., BrinJones, H., Sceneay, J., Li, B.B., Khan, N., Ubellacker, J.M., Xie, S., Metzger-Filho, O., et al. (2017). CDK4/6 inhibition triggers anti- tumour immunity. Nature 548, 471-475.

Goltsev, Y., Samusik, N., Kennedy-Darling, J., Bhate, S., Hale, M., Vasquez, G., and Nolan, G. (2017). Deep profiling of mouse splenic architecture with CODEX multiplexed imaging. BioRxiv 203166.

Gong, X., Litchfield, L.M., Webster, Y., Chio, L.-C, Wong, S.S., Stewart, T.R., Dowless, M., Dempsey, J., Zeng, Y., Torres, R, et al. (2017). Genomic Aberrations that Activate D-type Cyclins Are Associated with Enhanced Sensitivity to the CDK4 and CDK6 Inhibitor Abemaciclib. Cancer Cell 32, 761-776. e6.

Gordy, J.T., Luo, K., Zhang, H., Biragyn, A., and Markham, R.B. (2016). Fusion of the dendritic cell-targeting chemokine MIP3 to melanoma antigen GplOO in a therapeutic DNA vaccine significantly enhances immunogenicity and survival in a mouse melanoma model. J. Immunother. Cancer 4, 96. Hangauer, M.J., Viswanathan, V.S., Ryan, M.J., Bole, D., Eaton, J.K., Matov, A., Galeas, J., Dhruv, H.D., Berens, M.E., Schreiber, S.L., et al. (2017). Drug-tolerant persister cancer cells are vulnerable to GPX4 inhibition. Nature 551, 247.

Herbst, R.S., Soria, J.-C, Kowanetz, M., Fine, G.D., Hamid, O., Gordon, M.S., Sosman, J.A., McDermott, D.F., Powderly, J.D., Gettinger, S.N., et al. (2014). Predictive correlates of response to the anti-PD-Ll antibody MPDL3280A in cancer patients. Nature 575, 563-567.

Hodi, F.S., O'Day, S.J., McDermott, D.F., Weber, R.W., Sosman, J. A., Haanen, J.B., Gonzalez, R., Robert, C, Schadendorf, D., Hassel, J.C., et al. (2010). Improved survival with ipilimumab in patients with metastatic melanoma. N. Engl. J. Med. 363, 711-723.

F. S. Hodi, Kluger HM, Sznol M, Durable, long-term survival in previously treated patients with advanced melanoma who received nivolumab monotherapy in a phase I trial. 2016 AACR Annu. Meet. Abstr. CTOOl Present. April 17 2016.

Holm, S. (1979). A Simple Sequentially Rejective Multiple Test Procedure. Scand. J. Stat. 6, 65-70.

Hugo, W., Shi, H., Sun, L., Piva, M., Song, C, Kong, X., Moriceau, G., Hong, A., Dahlman, K.B., Johnson, D.B., et al. (2015). Non-genomic and Immune Evolution of Melanoma Acquiring MAPKi Resistance. Cell 162, 1271-1285.

Hugo, W., Zaretsky, J.M., Sun, L., Song, C, Moreno, B.H., Hu-Lieskovan, S., Berent-Maoz, B., Pang, J., Chmielowski, B., Cherry, G, et al. (2016). Genomic and Transcriptomic Features of Response to Anti-PD-1 Therapy in Metastatic Melanoma. Cell 165, 35-44.

Kharchenko, P.V., Silberstein, L., and Scadden, D.T. (2014). Bayesian approach to single-cell differential expression analysis. Nat. Methods 11, 740-742.

Kress, T.R., Sabo, A., and Amati, B. (2015). MYC: connecting selective transcriptional control to global RNA production. Nat. Rev. Cancer 15, 593-607.

J. Lamb et al., The Connectivity Map: using gene-expression signatures to connect small molecules, genes, and disease. Science. 313, 1929-1935 (2006).

J. Landsberg et al., Melanomas resist T-cell therapy through inflammation-induced reversible dedifferentiation. Nature. 490, 412-416 (2012).

Langmead, B., Trapnell, C, Pop, M., and Salzberg, S.L. (2009). Ultrafast and memory-efficient alignment of short DNA sequences to the human genome. Genome Biol. 10, R25. Larkin, J., Chiarion-Sileni, V., Gonzalez, R., Grob, J.J., Cowey, C.L., Lao, CD., Schadendorf, D., Dummer, R., Smylie, M., Rutkowski, P., et al. (2015). Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma. N. Engl. J. Med. 373, 23-34.

Laurens Maaten (2009). Learning a Parametric Embedding by Preserving Local Structure. In Proceedings of the Twelth International Conference on Artificial Intelligence and Statistics, David van Dyk, and Max Welling, eds. (PMLR), pp. 384-391.

Lesterhuis, W.J., Rinaldi, C, Jones, A., Rozali, E.N., Dick, I.M., Khong, A., Boon, L., Robinson, B.W., Nowak, A.K., Bosco, A., et al. (2015). Network analysis of immunotherapy-induced regressing tumours identifies novel synergistic drug combinations. Sci. Rep. 5, srepl2298.

Li, B., and Dewey, C.N. (2011). RSEM: accurate transcript quantification from RNA- Seq data with or without a reference genome. BMC Bioinformatics 12, 323.

H. Li et al., Reference component analysis of single-cell transcriptomes elucidates cellular heterogeneity in human colorectal tumors. Nat. Genet. 49, 708-718 (2017).

Lin, J.-R., Izar, B., Mei, S., Wang, S., Shah, P., and Sorger, P. (2017). A simple open- source method for highly multiplexed imaging of single cells in tissues and tumours. BioRxiv 151738.

Lin, J.-R., Izar, B., Wang, S., Yapp, C, Mei, S., Shah, P.M., Santagata, S., and Sorger, P.K. (2018). Highly multiplexed immunofluorescence imaging of human tissues and tumors using t-CyCIF and conventional optical microscopes. ELife 7.

van der Maaten, L., and Hinton, G. (2008). Visualizing Data using t-SNE. 9, 2579-

2605.

Manguso, R.T., Pope, H.W., Zimmer, M.D., Brown, F.D., Yates, K B., Miller, B.C., Collins, N.B., Bi, K., LaFleur, M.W., Juneja, V.R, et al. (2017). In vivo CRISPR screening identifies Ptpn2 as a cancer immunotherapy target. Nature 547, 413-418.

Mariathasan, S., Turley, S.J., Nickles, D., Castiglioni, A., Yuen, K., Wang, Y., Kadel Iii, E.E., Koeppen, H., Astarita, J.L., Cubas, R., et al. (2018). TGFp attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells. Nature 554, 544-548.

McDavid, A., Finak, G, Chattopadyay, P.K., Dominguez, M., Lamoreaux, L., Ma, S.S., Roederer, M., and Gottardo, R. (2013). Data exploration, quality control and testing in single-cell qPCR-based gene expression experiments. Bioinforma. Oxf. Engl. 29, 461-467. Miao, D., Margolis, C.A., Gao, W., Voss, M.H., Li, W., Martini, D.J., Norton, C, Bosse, D., Wankowicz, S.M., Cullen, D., et al. (2018). Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma. Science 359, 801-806.

R. Muthuswamy et al., NF-κΒ hyperactivation in tumor tissues allows tumor-selective reprogramming of the chemokine microenvironment to enhance the recruitment of cytolytic T effector cells. Cancer Res. 72, 3735-3743 (2012).

Nelson, P. J., and Muenchmeier, N. (2013). Membrane-anchored chemokine fusion proteins: A novel class of adjuvants for immunotherapy. Oncoimmunology 2, e26619.

Newman, A.M., Liu, C.L., Green, M.R., Gentles, A.J., Feng, W., Xu, Y., Hoang, CD., Diehn, M., and Alizadeh, A.A. (2015). Robust enumeration of cell subsets from tissue expression profiles. Nat. Methods 12, 453-457.

Oki, S., Ohta, T., Shioi, G, Hatanaka, H., Ogasawara, O., Okuda, Y., Kawaji, H., Nakaki, R., Sese, J., and Meno, C. (2018). Integrative analysis of transcription factor occupancy at enhancers and disease risk loci in noncoding genomic regions.

Pan, D., Kobayashi, A., Jiang, P., Ferrari de Andrade, L., Tay, R.E., Luoma, A.M., Tsoucas, D., Qiu, X., Lim, K., Rao, P., et al. (2018). A major chromatin regulator determines resistance of tumor cells to T cell-mediated killing. Science 359, 770-775.

A. P. Patel et al., Single-cell RNA-seq highlights intratumoral heterogeneity in primary glioblastoma. Science. 344, 1396-1401 (2014).

Patel, S.J., Sanjana, N.E., Kishton, R.J., Eidizadeh, A., Vodnala, S.K., Cam, M., Gartner, J.J., Jia, L., Steinberg, S.M., Yamamoto, T.N., et al. (2017). Identification of essential genes for cancer immunotherapy. Nature 548, 537-542.

Peng, W., Chen, J.Q., Liu, C, Malu, S., Creasy, C, Tetzlaff, M.T., Xu, C, McKenzie, J.A., Zhang, C, Liang, X., et al. (2016). Loss of PTEN Promotes Resistance to T Cell- Mediated Immunotherapy. Cancer Discov. 6, 202-216.

S. Picelli et al., Smart-seq2 for sensitive full-length transcriptome profiling in single cells.

E. Pikarsky et al., NF-kappaB functions as a tumour promoter in inflammation- associated cancer. Nature. 431, 461-466 (2004).

Postow, M.A., Chesney, J., Pavlick, A.C., Robert, C, Grossmann, K., McDermott, D., Linette, G.P., Meyer, N., Giguere, J.K., Agarwala, S.S., et al. (2015). Nivolumab and ipilimumab versus ipilimumab in untreated melanoma. N. Engl. J. Med. 372, 2006-2017. Puram, S.V., Tirosh, I, Parikh, A.S., Patel, A.P., Yizhak, K., Gillespie, S., Rodman, C, Luo, C.L., Mroz, E.A., Emerick, K.S., et al. (2017). Single-Cell Transcriptomic Analysis of Primary and Metastatic Tumor Ecosystems in Head and Neck Cancer. Cell 777, 1611- 1624.e24.

Ramilowski, J.A., Goldberg, T., Harshbarger, J., Kloppmann, E., Lizio, M., Satagopam, V.P., Itoh, M., Kawaji, H., Carninci, P., Rost, B., et al. (2015). A draft network of ligand-receptor-mediated multicellular signalling in human. Nat. Commun. 6, 7866.

Ribas, A., Puzanov, T, Dummer, R., Schadendorf, D., Hamid, O., Robert, C, Hodi, F.S., Schachter, J., Pavlick, A.C., Lewis, K.D., et al. (2015). Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial. Lancet Oncol. 16, 908-918.

Riaz, N., Havel, J. J., Makarov, V., Desrichard, A., Urba, W.J., Sims, J.S., Hodi, F.S., Martin-Algarra, S., Mandal, R., Sharfman, W.H., et al. (2017). Tumor and Microenvironment Evolution during Immunotherapy with Nivolumab. Cell 777.

Rosvall, M., and Bergstrom, C.T. (2008). Maps of random walks on complex networks reveal community structure. Proc. Natl. Acad. Sci. U. S. A. 105, 1118-1123.

Schaer, D.A., Beckmann, R.P., Dempsey, J.A., Huber, L., Forest, A., Amaladas, N., Li, Y., Wang, Y.C., Rasmussen, E.R., Chin, D., et al. (2018). The CDK4/6 Inhibitor Abemaciclib Induces a T Cell Inflamed Tumor Microenvironment and Enhances the Efficacy of PD-L1 Checkpoint Blockade. Cell Rep. 22, 2978-2994.

Shaffer, S.M., Dunagin, M.C., Torborg, S.R., Torre, E.A., Emert, B., Krepler, C, Beqiri, M., Sproesser, K., Brafford, P. A., Xiao, M., et al. (2017). Rare cell variability and drug-induced reprogramming as a mode of cancer drug resistance. Nature 546, 431-435.

Shalek, A.K., Satija, R., Adiconis, X., Gertner, R.S., Gaublomme, J.T., Raychowdhury, R., Schwartz, S., Yosef, N., Malboeuf, C, Lu, D., et al. (2013). Single-cell transcriptomics reveals bimodality in expression and splicing in immune cells. Nature 498, 236-240.

Shalek, A.K., Satija, R., Shuga, J., Trombetta, J.J., Gennert, D., Lu, D., Chen, P., Gertner, R.S., Gaublomme, J.T., Yosef, N., et al. (2014). Single-cell RNA-seq reveals dynamic paracrine control of cellular variation. Nature 510, 363-369.

Shannon, P., Markiel, A., Ozier, O., Baliga, N.S., Wang, J.T., Ramage, D., Amin, N.,

Schwikowski, B., and Ideker, T. (2003). Cytoscape: a software environment for integrated models of biomolecular interaction networks. Genome Res. 13, 2498-2504. Sharma, P., and Allison, J.P. (2015). The future of immune checkpoint therapy. Science 348, 56-61.

Sharma, P., Hu-Lieskovan, S., Wargo, J.A., and Ribas, A. (2017). Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy. Cell 168, 707-723.

M. Singer et al., A Distinct Gene Module for Dysfunction Uncoupled from Activation in Tumor-Infiltrating T Cells. Cell. 166, 1500-1511. e9 (2016).

S. Spranger, R. Bao, T. F. Gajewski, Melanoma-intrinsic β-catenin signalling prevents antitumour immunity. Nature. 523, 231-235 (2015).

M. J. T. Stubbington et al., T cell fate and clonality inference from single-cell transcriptomes. Nat. Methods. 13, 329-332 (2016).

Subramanian, A., Tamayo, P., Mootha, V.K., Mukherjee, S., Ebert, B.L., Gillette, M.A., Paulovich, A., Pomeroy, S.L., Golub, T.R., Lander, E.S., et al. (2005). Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc. Natl. Acad. Sci. U. S. A. 102, 15545-15550.

Subramanian, A., Narayan, R., Corsello, S.M., Peck, D.D., Natoli, T.E., Lu, X., Gould, J., Davis, J.F., Tubelli, A.A., Asiedu, J.K., et al. (2017). A Next Generation Connectivity Map: L1000 Platform and the First 1,000,000 Profiles. Cell 171, 31- 1452.el7.

J. M. Taube et al., Sci. Transl. Med., in press, doi: 10.1126/scitranslmed.3003689.

Tirosh, L, Izar, B., Prakadan, S.M., Wadsworth, M.H., Treacy, D., Trombetta, J.J., Rotem, A., Rodman, C, Lian, C, Murphy, G., et al. (2016a). Dissecting the multicellular ecosystem of metastatic melanoma by single-cell RNA-seq. Science 352, 189-196.

I. Tirosh et al., Single-cell RNA-seq supports a developmental hierarchy in human oligodendroglioma. Nature. 539, 309-313 (2016b).

Trombetta, J.J., Gennert, D., Lu, D., Satija, R., Shalek, A.K., and Regev, A. (2014). Preparation of Single-Cell RNA-Seq Libraries for Next Generation Sequencing. Curr. Protoc. Mol. Biol. Ed. Frederick M Ausubel Al 107, 4.22.1-4.22.17.

P. C. Tumeh et al., PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature. 515, 568-571 (2014).

Van Allen, E.M., Miao, D., Schilling, B., Shukla, S.A., Blank, C, Zimmer, L., Sucker, A., Hillen, U., Foppen, M.H.G, Goldinger, S.M., et al. (2015). Genomic correlates of response to CTLA-4 blockade in metastatic melanoma. Science 350, 207-211. A. S. Venteicher et al., Decoupling genetics, lineages, and microenvironment in IDH mutant gliomas by single-cell RNA-seq. Science. 355 (2017), doi: 10.1126/science.aai8478.

Viswanathan, V.S., Ryan, M.J., Dhruv, H.D., Gill, S., Eichhoff, O.M., Seashore- Ludlow, B., Kaffenberger, S.D., Eaton, J.K., Shimada, K., Aguirre, A.J., et al. (2017). Dependency of a therapy -resistant state of cancer cells on a lipid peroxidase pathway. Nature 547, 453.

Wagner, A., Regev, A., and Yosef, N. (2016). Revealing the vectors of cellular identity with single-cell genomics. Nat. Biotechnol. 34, 1145-1160.

Waltman, L., and van Eck, N.J. (2013). A smart local moving algorithm for large- scale modularity-based community detection. Eur. Phys. J. B 86.

J. M. Zaretsky et al., Mutations Associated with Acquired Resistance to PD-1 Blockade in Melanoma. N. Engl. J. Med. 375, 819-829 (2016).

C. Zheng et al., Landscape of Infiltrating T Cells in Liver Cancer Revealed by Single- Cell Sequencing. Cell. 169, 1342-1356.el6 (2017).

L. Zimmer et al., Phase II DeCOG-study of ipilimumab in pretreated and treatment- naive patients with metastatic uveal melanoma. PloS One. 10, eOl 18564 (2015).

P. Zhou et al., In vivo discovery of immunotherapy targets in the tumour microenvironment. Nature. 506, 52-57 (2014).

* * *

[0665] Various modifications and variations of the described methods, pharmaceutical compositions, and kits of the invention will be apparent to those skilled in the art without departing from the scope and spirit of the invention. Although the invention has been described in connection with specific embodiments, it will be understood that it is capable of further modifications and that the invention as claimed should not be unduly limited to such specific embodiments. Indeed, various modifications of the described modes for carrying out the invention that are obvious to those skilled in the art are intended to be within the scope of the invention. This application is intended to cover any variations, uses, or adaptations of the invention following, in general, the principles of the invention and including such departures from the present disclosure come within known customary practice within the art to which the invention pertains and may be applied to the essential features herein before set forth.